Patent Publication Number: US-2004048798-A1

Title: Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS  
     [0001] This application is a continuation-in-part of pending United States patent application U.S. Ser. No. 10/407,484, filed Apr. 4, 2003; and claims priority from United States patent application U.S. Ser. No. 10/236,878, filed Sep. 6, 2002; and claims priority from United States patent application U.S. Ser. No. 09/455,486, filed Dec. 6, 1999, and claims priority from United States patent application U.S. Ser. No. 09/323,873, now U.S. Pat. No. 6,329,503 filed Jun. 1, 1999, and this application claims priority from U.S. provisional application U.S. S No. 60/435,480, filed Dec. 20, 2002 and United States provisional patent application No. 60/317,840, filed Sep. 6, 2001 and U.S. provisional patent application No. 60/370,387 filed Apr. 5, 2002. This application relates to U.S. provisional patent application No. 60/087,520, filed Jun. 1, 1998 and U.S. provisional patent application No. 60/091,183, filed Jun. 30, 1998 and U.S. patent application Ser. No. 10/011,095, filed Dec. 6, 2001 and U.S. patent application Ser. No. 10/010,667, filed Dec. 6, 2001 and U.S. provisional patent application No. 60/296,656, filed Jun. 6, 2001, and U.S. patent application Ser. No. 10/165,044, filed Jun. 6, 2002. The contents of the applications listed in this paragraph are fully incorporated by reference herein. 
    
    
     
       STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH  
       [0002] Not applicable.  
       FIELD OF THE INVENTION  
       [0003] The invention described herein relates to genes and their encoded proteins, termed 98P4B6 or STEAP-2, expressed in certain cancers, and to diagnostic and therapeutic methods and compositions useful in the management of cancers that express 98P4B6.  
       BACKGROUND OF THE INVENTION  
       [0004] Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.  
       [0005] Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.  
       [0006] Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 30,000 men die annually of this disease—second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, surgical castration and chemotherapy continue to be the main treatment modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.  
       [0007] On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease. Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.  
       [0008] Progress in identifying additional specific markers for prostate cancer has been improved by the generation of prostate cancer xenografts that can recapitulate different stages of the disease in mice. The LAPC (Los Angeles Prostate Cancer) xenografts are prostate cancer xenografts that have survived passage in severe combined immune deficient (SCID) mice and have exhibited the capacity to mimic the transition from androgen dependence to androgen independence (Klein et al., 1997, Nat. Med. 3:402). More recently identified prostate cancer markers include PCTA-1 (Su et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7252), prostate-specific membrane (PSM) antigen (Pinto et al., Clin Cancer Res Sep. 2, 1996 (9): 1445-51), STEAP (Hubert, et al., Proc Natl Acad Sci USA. Dec. 7, 1999; 96(25): 14523-8) and prostate stem cell antigen (PSCA) (Reiter et al., 1998, Proc. Natl. Acad. Sci. USA 95: 1735).  
       [0009] While previously identified markers such as PSA, PSM, PCTA and PSCA have facilitated efforts to diagnose and treat prostate cancer, there is need for the identification of additional markers and therapeutic targets for prostate and related cancers in order to further improve diagnosis and therapy.  
       [0010] Renal cell carcinoma (RCC) accounts for approximately 3 percent of adult malignancies. Once adenomas reach a diameter of 2 to 3 cm, malignant potential exists. In the adult, the two principal malignant renal tumors are renal cell adenocarcinoma and transitional cell carcinoma of the renal pelvis or ureter. The incidence of renal cell adenocarcinoma is estimated at more than 29,000 cases in the United States, and more than 11,600 patients died of this disease in 1998. Transitional cell carcinoma is less frequent, with an incidence of approximately 500 cases per year in the United States.  
       [0011] Surgery has been the primary therapy for renal cell adenocarcinoma for many decades. Until recently, metastatic disease has been refractory to any systemic therapy. With recent developments in systemic therapies, particularly immunotherapies, metastatic renal cell carcinoma may be approached aggressively in appropriate patients with a possibility of durable responses. Nevertheless, there is a remaining need for effective therapies for these patients.  
       [0012] Of all new cases of cancer in the United States, bladder cancer represents approximately 5 percent in men (fifth most common neoplasm) and 3 percent in women (eighth most common neoplasm). The incidence is increasing slowly, concurrent with an increasing older population. In 1998, there was an estimated 54,500 cases, including 39,500 in men and 15,000 in women. The age-adjusted incidence in the United States is 32 per 100,000 for men and eight per 100,000 in women. The historic male/female ratio of 3:1 may be decreasing related to smoking patterns in women. There were an estimated 11,000 deaths from bladder cancer in 1998 (7,800 in men and 3,900 in women). Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.  
       [0013] Most bladder cancers recur in the bladder. Bladder cancer is managed with a combination of transurethral resection of the bladder (TUR) and intravesical chemotherapy or immunotherapy. The multifocal and recurrent nature of bladder cancer points out the limitations of TUR. Most muscle-invasive cancers are not cured by TUR alone. Radical cystectomy and urinary diversion is the most effective means to eliminate the cancer but carry an undeniable impact on urinary and sexual function. There continues to be a significant need for treatment modalities that are beneficial for bladder cancer patients.  
       [0014] An estimated 130,200 cases of colorectal cancer occurred in 2000 in the United States, including 93,800 cases of colon cancer and 36,400 of rectal cancer. Colorectal cancers are the third most common cancers in men and women. Incidence rates declined significantly during 1992-1996 (−2.1% per year). Research suggests that these declines have been due to increased screening and polyp removal, preventing progression of polyps to invasive cancers. There were an estimated 56,300 deaths (47,700 from colon cancer, 8,600 from rectal cancer) in 2000, accounting for about 11% of all U.S. cancer deaths.  
       [0015] At present, surgery is the most common form of therapy for colorectal cancer, and for cancers that have not spread, it is frequently curative. Chemotherapy, or chemotherapy plus radiation, is given before or after surgery to most patients whose cancer has deeply perforated the bowel wall or has spread to the lymph nodes. A permanent colostomy (creation of an abdominal opening for elimination of body wastes) is occasionally needed for colon cancer and is infrequently required for rectal cancer. There continues to be a need for effective diagnostic and treatment modalities for colorectal cancer.  
       [0016] There were an estimated 164,100 new cases of lung and bronchial cancer in 2000, accounting for 14% of all U.S. cancer diagnoses. The incidence rate of lung and bronchial cancer is declining significantly in men, from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s, the rate of increase among women began to slow. In 1996, the incidence rate in women was 42.3 per 100,000.  
       [0017] Lung and bronchial cancer caused an estimated 156,900 deaths in 2000, accounting for 28% of all cancer deaths. During 1992-1996, mortality from lung cancer declined significantly among men (-1.7% per year) while rates for women were still significantly increasing (0.9% per year). Since 1987, more women have died each year of lung cancer than breast cancer, which, for over 40 years, was the major cause of cancer death in women. Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men. Of concern, although the declines in adult tobacco use have slowed, tobacco use in youth is increasing again.  
       [0018] Treatment options for lung and bronchial cancer are determined by the type and stage of the cancer and include surgery, radiation therapy, and chemotherapy. For many localized cancers, surgery is usually the treatment of choice. Because the disease has usually spread by the time it is discovered, radiation therapy and chemotherapy are often needed in combination with surgery. Chemotherapy alone or combined with radiation is the treatment of choice for small cell lung cancer; on this regimen, a large percentage of patients experience remission, which in some cases is long lasting. There is however, an ongoing need for effective treatment and diagnostic approaches for lung and bronchial cancers.  
       [0019] An estimated 182,800 new invasive cases of breast cancer were expected to occur among women in the United States during 2000. Additionally, about 1,400 new cases of breast cancer were expected to be diagnosed in men in 2000. After increasing about 4% per year in the 1980s, breast cancer incidence rates in women have leveled off in the 1990s to about 110.6 cases per 100,000.  
       [0020] In the U.S. alone, there were an estimated 41,200 deaths (40,800 women, 400 men) in 2000 due to breast cancer. Breast cancer ranks second among cancer deaths in women. According to the most recent data, mortality rates declined significantly during 1992-1996 with the largest decreases in younger women, both white and black. These decreases were probably the result of earlier detection and improved treatment.  
       [0021] Taking into account the medical circumstances and the patient&#39;s preferences, treatment of breast cancer may involve lumpectomy (local removal of the tumor) and removal of the lymph nodes under the arm; mastectomy (surgical removal of the breast) and removal of the lymph nodes under the arm; radiation therapy; chemotherapy; or hormone therapy. Often, two or more methods are used in combination. Numerous studies have shown that, for early stage disease, long-term survival rates after lumpectomy plus radiotherapy are similar to survival rates after modified radical mastectomy. Significant advances in reconstruction techniques provide several options for breast reconstruction after mastectomy. Recently, such reconstruction has been done at the same time as the mastectomy.  
       [0022] Local excision of ductal carcinoma in situ (DCIS) with adequate amounts of surrounding normal breast tissue may prevent the local recurrence of the DCIS. Radiation to the breast and/or tamoxifen may reduce the chance of DCIS occurring in the remaining breast tissue. This is important because DCIS, if left untreated, may develop into invasive breast cancer. Nevertheless, there are serious side effects or sequelae to these treatments. There is, therefore, a need for efficacious breast cancer treatments.  
       [0023] There were an estimated 23,100 new cases of ovarian cancer in the United States in 2000. It accounts for 4% of all cancers among women and ranks second among gynecologic cancers. During 1992-1996, ovarian cancer incidence rates were significantly declining. Consequent to ovarian cancer, there were an estimated 14,000 deaths in 2000. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.  
       [0024] Surgery, radiation therapy, and chemotherapy are treatment options for ovarian cancer. Surgery usually includes the removal of one or both ovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus (hysterectomy). In some very early tumors, only the involved ovary will be removed, especially in young women who wish to have children. In advanced disease, an attempt is made to remove all intra-abdominal disease to enhance the effect of chemotherapy. There continues to be an important need for effective treatment options for ovarian cancer.  
       [0025] There were an estimated 28,300 new cases of pancreatic cancer in the United States in 2000. Over the past 20 years, rates of pancreatic cancer have declined in men. Rates among women have remained approximately constant but may be beginning to decline. Pancreatic cancer caused an estimated 28,200 deaths in 2000 in the United States. Over the past 20 years, there has been a slight but significant decrease in mortality rates among men (about −0.9% per year) while rates have increased slightly among women.  
       [0026] Surgery, radiation therapy, and chemotherapy are treatment options for pancreatic cancer. These treatment options can extend survival and/or relieve symptoms in many patients but are not likely to produce a cure for most. There is a significant need for additional therapeutic and diagnostic options for pancreatic cancer.  
       SUMMARY OF THE INVENTION  
       [0027] The present invention relates to a gene, designated 98P4B6, that has now been found to be over-expressed in the cancer(s) listed in Table I. Northern blot expression analysis of 98P4B6 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide (FIG. 2) and amino acid (FIG. 2, and FIG. 3) sequences of 98P4B6 are provided. The tissue-related profile of 98P4B6 in normal adult tissues, combined with the over-expression observed in the tissues listed in Table I, shows that 98P4B6 is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic, prophylactic, prognostic, and/or therapeutic target for cancers of the tissue(s) such as those listed in Table I.  
       [0028] The invention provides polynucleotides corresponding or complementary to all or part of the 98P4B6 genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding 98P4B6-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 contiguous amino acids of a 98P4B6-related protein, as well as the peptides/proteins themselves; DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides or oligonucleotides complementary or having at least a 90% homology to the 98P4B6 genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides that hybridize to the 98P4B6 genes, mRNAs, or to 98P4B6-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding 98P4B6. Recombinant DNA molecules containing 98P4B6 polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of 98P4B6 gene products are also provided. The invention further provides antibodies that bind to 98P4B6 proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker or therapeutic agent. In certain embodiments, there is a proviso that the entire nucleic acid sequence of FIG. 2 is not encoded and/or the entire amino acid sequence of FIG. 2 is not prepared. In certain embodiments, the entire nucleic acid sequence of FIG. 2 is encoded and/or the entire amino acid sequence of FIG. 2 is prepared, either of which are in respective human unit dose forms.  
       [0029] The invention further provides methods for detecting the presence and status of 98P4B6 polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express 98P4B6. A typical embodiment of this invention provides methods for monitoring 98P4B6 gene products in a tissue or hematology sample having or suspected of having some form of growth dysregulation such as cancer.  
       [0030] The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 98P4B6 such as cancers of tissues listed in Table I, including therapies aimed at inhibiting the transcription, translation, processing or function of 98P4B6 as well as cancer vaccines. In one aspect, the invention provides compositions, and methods comprising them, for treating a cancer that expresses 98P4B6 in a human subject wherein the composition comprises a carrier suitable for human use and a human unit dose of one or more than one agent that inhibits the production or function of 98P4B6. Preferably, the carrier is a uniquely human carrier. In another aspect of the invention, the agent is a moiety that is immunoreactive with 98P4B6 protein. Non-limiting examples of such moieties include, but are not limited to, antibodies (such as single chain, monoclonal, polyclonal, humanized, chimeric, or human antibodies), functional equivalents thereof (whether naturally occurring or synthetics, and combinations thereof. The antibodies can be conjugated to a diagnostic or therapeutic moiety. In another aspect, the agent is a small molecule as defined herein.  
       [0031] In another aspect, the agent comprises one or more than one peptide which comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLA class I molecule in a human to elicit a CTL response to 98P4B6 and/or one or more than one peptide which comprises a helper T lymphocyte (HTL) epitope which binds an HLA class II molecule in a human to elicit an HTL response. The peptides of the invention may be on the same or on one or more separate polypeptide molecules. In a further aspect of the invention, the agent comprises one or more than one nucleic acid molecule that expresses one or more than one of the CTL or HTL response stimulating peptides as described above. In yet another aspect of the invention, the one or more than one nucleic acid molecule may express a moiety that is immunologically reactive with 98P4B6 as described above. The one or more than one nucleic acid molecule may also be, or encodes, a molecule that inhibits production of 98P4B6. Non-limiting examples of such molecules include, but are not limited to, those complementary to a nucleotide sequence essential for production of 98P4B6 (e.g. antisense sequences or molecules that form a triple helix with a nucleotide double helix essential for 98P4B6 production) or a ribozyme effective to lyse 98P4B6 mRNA.  
       [0032] Note that to determine the starting position of any peptide set forth in Tables VIII-XXI and XXII to XLIX (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides in Table VII. Generally, a unique Search Peptide is used to obtain HLA peptides of a particular for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table VII. Accordingly, if a Search Peptide begins at position “X”, one must add the value “X−1” to each position in Tables VIII-XXI and XXII to XLIX to obtain the actual position of the HLA peptides in their parental molecule. For example, if a particular Search Peptide begins at position 150 of its parental molecule, one must add 150−1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.  
       [0033] One embodiment of the invention comprises an HLA peptide, that occurs at least twice in Tables VIII-XXI and XXII to XLIX collectively, or an oligonucleotide that encodes the HLA peptide. Another embodiment of the invention comprises an HLA peptide that occurs at least once in Tables VIII-XXI and at least once in tables XXII to XLIX, or an oligonucleotide that encodes the HLA peptide.  
       [0034] Another embodiment of the invention is antibody epitopes, which comprise a peptide regions, or an oligonucleotide encoding the peptide region, that has one two, three, four, or five of the following characteristics:  
       [0035] i) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of FIG. 5;  
       [0036] ii) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of FIG. 6;  
       [0037] iii) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of FIG. 7;  
       [0038] iv) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of FIG. 8; or  
       [0039] v) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of FIG. 9. 
     
    
    
     BRIEF DESCRIPTION OF THE FIGURES  
     [0040]FIG. 1. The 98P4B6 SSH sequence of 183 nucleotides.  
     [0041]FIG. 2. A) The cDNA and amino acid sequence of 98P4B6 variant 1 (also called “98P4B6 v.1 or “98P4B6 variant 1”) is shown in FIG. 2A. The start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0042] B) The cDNA and amino acid sequence of 98P4B6 variant 2 (also called “98P4B6 v.2”) is shown in FIG. 2B. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 4-138 including the stop codon.  
     [0043] C) The cDNA and amino acid sequence of 98P4B6 variant 3 (also called “98P4B6 v.3”) is shown in FIG. 2C. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 188-1552 including the stop codon.  
     [0044] D) The cDNA and amino acid sequence of 98P4B6 variant 4 (also called “98P4B6 v.4”) is shown in FIG. 2D. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 318-1682 including the stop codon.  
     [0045] E) The cDNA and amino acid sequence of 98P4B6 variant 5 (also called “98P4B6 v.5”) is shown in FIG. 2E. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 318-1577 including the stop codon.  
     [0046] F) The cDNA and amino acid sequence of 98P4B6 variant 6 (also called “98P4B6 v.6”) is shown in FIG. 2F. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 318-1790 including the stop codon.  
     [0047] G) The cDNA and amino acid sequence of 98P4B6 variant 7 (also called “98P4B6 v.7”) is shown in FIG. 2G. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0048] H) The cDNA and amino acid sequence of 98P4B6 variant 8 (also called “98P4B6 v.8”) is shown in FIG. 2H. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0049] I) The cDNA and amino acid sequence of 98P4B6 variant 9 (also called “98P4B6 v.9”) is shown in FIG. 2I. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0050] J) The cDNA and amino acid sequence of 98P4B6 variant 10 (also called “98P4B6 v.10”) is shown in FIG. 2J. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0051] K) The cDNA and amino acid sequence of 98P4B6 variant 11 (also called “98P4B6 v.11”) is shown in FIG. 2K. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0052] L) The cDNA and amino acid sequence of 98P4B6 variant 12 (also called “98P4B6 v.12”) is shown in FIG. 2L. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0053] M) The cDNA and amino acid sequence of 98P4B6 variant 13 (also called “98P4B6 v.13”) is shown in FIG. 2M. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 3551719 including the stop codon.  
     [0054] N) The cDNA and amino acid sequence of 98P4B6 variant 14 (also called “98P4B6 v.14”) is shown in FIG. 2N. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0055] O) The cDNA and amino acid sequence of 98P4B6 variant 15 (also called “98P4B6 v.15”) is shown in FIG. 2O. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0056] P) The cDNA and amino acid sequence of 98P4B6 variant 16 (also called “98P4B6 v.16”) is shown in FIG. 2P. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0057] Q) The cDNA and amino acid sequence of 98P4B6 variant 17 (also called “98P4B6 v.17”) is shown in FIG. 2Q. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0058] R) The cDNA and amino acid sequence of 98P4B6 variant 18 (also called “98P4B6 v.18) is shown in FIG. 2R. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0059] S) The cDNA and amino acid sequence of 98P4B6 variant 19 (also called “98P4B6 v.19”) is shown in FIG. 2S. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 355-1719 including the stop codon.  
     [0060] T) The cDNA and amino acid sequence of 98P4B6 variant 20 (also called “98P4B6 v.20”) is shown in FIG. 2T. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0061] U) The cDNA and amino acid sequence of 98P4B6 variant 21 (also called “98P4B6 v.21”) is shown in FIG. 2U. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0062] V) The cDNA and amino acid sequence of 98P4B6 variant 22 (also called “98P4B6 v.22”) is shown in FIG. 2V. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0063] W) The cDNA and amino acid sequence of 98P4B6 variant 23 (also called “98P4B6 v.23”) is shown in FIG. 2W. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0064] X) The cDNA and amino acid sequence of 98P4B6 variant 24 (also called “98P4B6 v.24”) is shown in FIG. 2X. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 295-2025 including the stop codon.  
     [0065] Y) The cDNA and amino acid sequence of 98P4B6 variant 25 (also called “98P4B6 v.25”) is shown in FIG. 2Y. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0066] Z) The cDNA and amino acid sequence of 98P4B6 variant 26 (also called “98P4B6 v.26”) is shown in FIG. 2Z. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0067] AA) The cDNA and amino acid sequence of 98P4B6 variant 27 (also called “98P4B6 v.27”) is shown in FIG. 2AA. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0068] AB) The cDNA and amino acid sequence of 98P4B6 variant 28 (also called “98P4B6 v.28”) is shown in FIG. 2AB. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0069] AC) The cDNA and amino acid sequence of 98P4B6 variant 29 (also called “98P4B6 v.29”) is shown in FIG. 2AC. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0070] AD) The cDNA and amino acid sequence of 98P4B6 variant 30 (also called “98P4B6 v.30”) is shown in FIG. 2AD. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0071] AE) The cDNA and amino acid sequence of 98P4B6 variant 31 (also called “98P4B6 v.31”) is shown in FIG. 2AE. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0072] AF) The cDNA and amino acid sequence of 98P4B6 variant 32 (also called “98P4B6 v.32”) is shown in FIG. 2AF. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0073] AG) The cDNA and amino acid sequence of 98P4B6 variant 33 (also called “98P4B6 v.33”) is shown in FIG. 2AG. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0074] AH) The cDNA and amino acid sequence of 98P4B6 variant 34 (also called “98P4B6 v.34”) is shown in FIG. 2AH. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0075] AI) The cDNA and amino acid sequence of 98P4B6 variant 35 (also called “98P4B6 v.35”) is shown in FIG. 2AI. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0076] AJ) The cDNA and amino acid sequence of 98P4B6 variant 36 (also called “98P4B6 v.36”) is shown in FIG. 2AJ. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0077] AK) The cDNA and amino acid sequence of 98P4B6 variant 37 (also called “98P4B6 v.37”) is shown in FIG. 2AK. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0078] AL) The cDNA and amino acid sequence of 98P4B6 variant 38 (also called “98P4B6 v.38”) is shown in FIG. 2AL. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 394-1866 including the stop codon.  
     [0079]FIG. 3.  
     [0080] A) The amino acid sequence of 98P4B6 v.1 is shown in FIG. 3A; it has 454 amino acids.  
     [0081] B) The amino acid sequence of 98P4B6 v.2 is shown in FIG. 3B; it has 45 amino acids.  
     [0082] C) The amino acid sequence of 98P4B6 v.5 is shown in FIG. 3C; it has 419 amino acids.  
     [0083] D) The amino acid sequence of 98P4B6 v.6 is shown in FIG. 3D; it has 490 amino acids.  
     [0084] E) The amino acid sequence of 98P4B6 v.7 is shown in FIG. 3E; it has 576 amino acids.  
     [0085] F) The amino acid sequence of 98P4B6 v.8 is shown in FIG. 3F; it has 490 amino acids.  
     [0086] G) The amino acid sequence of 98P4B6 v.13 is shown in FIG. 3G; it has 454 amino acids.  
     [0087] H) The amino acid sequence of 98P4B6 v.14 is shown in FIG. 3H; it has 454 amino acids.  
     [0088] I) The amino acid sequence of 98P4B6 v.21 is shown in FIG. 3I; it has 576 amino acids.  
     [0089] J) The amino acid sequence of 98P4B6 v.25 is shown in FIG. 3J; it has 490 amino acids.  
     [0090] As used herein, a reference to 98P4B6 includes all variants thereof, including those shown in FIGS. 2, 3,  10 , and  11 , unless the context clearly indicates otherwise.  
     [0091]FIG. 4. Comparison of 98P4B6 with known genes: Human STAMP1, human six transmembrane epithelial antigen of prostate 2 and mouse six transmembrane epithelial antigen of prostate 2. FIG. 4(A) Alignment of 98P4B6 variant 1 to human STAMP1 (gi 15418732). FIG. 4(B) Alignment of 98P4B6 variant 1 with human STEAP2 (gi: 23308593). FIG. 4(C) Alignment of 98P4B6 variant 1 with mouse STEAP2 (gi 28501136). FIG. 4(D): Clustal Alignment of the three 98P4B6 variants, depicting that 98P4B6 V1B contains an additional 62 aa at its N-terminus relative to V1, and that 98P4B6 V2 carries a I to T point mutation at aa 225 relative to V1.  
     [0092]FIG. 5. Hydrophilicity amino acid profile of 98P4B6v.1, v.2, v.5, v.6, and v.7 determined by computer algorithm sequence analysis using the method of Hopp and Woods (Hopp T. P., Woods K. R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on the Protscale website located on the World Wide Web at (expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.  
     [0093]FIG. 6. Hydropathicity amino acid profile of 98P4B6v.1, v.2, v.5, v.6, and v.7 determined by computer algorithm sequence analysis using the method of Kyte and Doolittle (Kyte J., Doolittle R. F., 1982. J. Mol. Biol. 157:105-132) accessed on the ProtScale website located on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.  
     [0094]FIG. 7. Percent accessible residues amino acid profile of 98P4B6v.1, v.2, v.5, v.6, and v.7 determined by computer algorithm sequence analysis using the method of Janin (Janin J., 1979 Nature 277:491-492) accessed on the ProtScale website located on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.  
     [0095]FIG. 8. Average flexibility amino acid profile of 98P4B6v.1, v.2, v.5, v.6, and v.7 determined by computer algorithm sequence analysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., and Ponnuswamy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255) accessed on the ProtScale website located on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.  
     [0096]FIG. 9. Beta-turn amino acid profile of 98P4B6v.1, v.2, v.5, v.6, and v.7 determined by computer algorithm sequence analysis using the method of Deleage and Roux (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294) accessed on the ProtScale website located on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.  
     [0097]FIG. 10. FIG. 10( a ): Schematic alignment of SNP variants of 98P4B6 v.1. Variants 98P4B6 v.9 through v.19 were variants with single nucleotide difference from v.1. Though these SNP variants were shown separately, they could also occur in any combinations and in any transcript variants, as shown in FIG. 12, that contains the bases. SNP in regions of other transcript variants, such as v.2, v.6 and v.8, not common with v.1 were not shown here. Numbers correspond to those, of 98P4B6 v.1. Black box shows the same sequence as 98P4B6 v.1. SNPs are indicated above the box. FIG. 10( b ): Schematic alignment of SNP variants of 98P4B6 v.7. Variants 98P4B6 v.20 through v.24 were variants with single nucleotide difference from v.7. Though these SNP variants were shown separately, they could also occur in any combinations and in any transcript variants, as shown in FIG. 12, that contains the bases. Those SNP in regions common with v.1 were not shown here. Numbers correspond to those of 98P4B6 v.7. Black box shows the same sequence as 98P4B6 v.7. SNPs are indicated above the box. FIG. 10( c ): Schematic alignment of SNP variants of 98P4B6 v.8. Variants 98P4B6 v.25 through v.38 were variants with single nucleotide difference from v.8. Though these SNP variants were shown separately, they could also occur in any combinations and in any transcript variants, as shown in FIG. 12, that contains the bases. Those SNP in regions of common with v.1 were not shown here. Numbers correspond to those of 98P4B6 v.8. Black box shows the same sequence as 98P4B6 v.8. SNPs are indicated above the box.  
     [0098]FIG. 11. Schematic alignment of protein variants of 98P4B6. Protein variants corresponded to nucleotide variants. Nucleotide variants 98P4B6 v.3, v.4, v.9 through v.12, and v.15 through v.19 coded for the same protein as v.1. Nucleotide variants 98P4B6 v.6 and v.8 coded the same protein except for single amino acid at 475, which is an “M” in v.8. Variants v.25 was translated from v.25, a SNP variant of v.8, with one amino acid difference at 565. Similarly, v.21 differed from v.7 by one amino acid at 565. Single amino acid differences were indicated above the boxes. Black boxes represent the same sequence as 98P4B6 v.1. Numbers underneath the box correspond to 98P4B6 v.1.  
     [0099]FIG. 12. Structure of transcript variants of 98P4B6. Variant 98P4B6 v.2 through v.8 were transcript variants of v.1. Variant v.2 was a single exon transcript whose 3′ portion was the same as the last exon of v.1. The first two exons of v.3 were in intron 1 of v. 1. Variants v.4, v.5 and v.6 spliced out 224-334 in the first exon of v.1. In addition, v.5 spliced out exon 5 while v.6 spliced out exon 6 but extended exon 5 of v.1. Variant v.7 used alternative transcription start and different 3′ exons. Variant v.8 extended 5′ end and kept the whole intron 5 of v.1. The first 35 bases of v.1 were not in the nearby 5′ region of v.1 on the current assembly of the human genome. Ends of exons in the transcripts are marked above the boxes. Potential exons of this gene are shown in order as on the human genome. Poly A tails and single nucleotide differences are not shown in the figure. Numbers in ( )” underneath the boxes correspond to those of 98P4B6 v.1. Lengths of introns and exons are not proportional.  
     [0100]FIG. 13. Secondary structure and transmembrane domains prediction for 98P4B6 protein variants.  13 (A),  13 (B),  13 (C),  13 (D),  13 (E): The secondary structure of 98P4B6 protein variant 1 (SEQ ID. NO: 193), Variant 2 (SEQ ID NO: 194), Variant 5 (SEQ ID NO: 195), Variant 6 (SEQ ID NO: 196), and Variant 7 (SEQ ID NO: 197) were predicted using the HNN—Hierarchical Neural Network method (Guermeur, 1997, located on the World Wide Web at.pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html, accessed from the ExPasy molecular biology server located on the World Wide Web at .expasy.ch/tools. This method predicts the presence and location of alpha helices, extended strands, and random coils from the primary protein sequence. The percent of the protein in a given secondary structure is also listed.  
     [0101] 13 (F),  13 (H),  13 (J),  13 (L), and  13 (N): Schematic representations of the probability of existence of transmembrane regions and orientation of 98P4B6 variants 1, 2, 5-7, respectively, based on the TMpred algorithm of Hofmann and Stoffel which utilizes TMBASE (K. Hofmann, W. Stoffel. TMBASE—A database of membrane spanning protein segments Biol. Chem. Hoppe-Seyler 374:166, 1993).  13 (G),  13 (I),  13 (K),  13 (M), and  13 (O): Schematic representations of the probability of the existence of transmembrane regions and the extracellular and intracellular orientation of 98P4B6 variants 1, 2, 5-7, respectively, based on the TMHMM algorithm of Sonnhammer, von Heijne, and Krogh (Erik L. L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Liltlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, Calif.: AAAI Press, 1998). The TMpred and TMHMM algorithms are accessed from the ExPasy molecular biology server located on the World Wide Web at .expasy.ch/tools/.  
     [0102]FIG. 14. 98P4B6 Expression in Human Normal and Patient Cancer Tissues. First strand cDNA was generated from normal stomach, normal brain, normal heart, normal liver, normal skeletal muscle, normal testis, normal prostate, normal bladder, normal kidney, normal colon, normal lung, normal pancreas, and a pool of cancer specimens from prostate cancer patients, bladder cancer patients, kidney cancer patients, colon cancer patients, lung cancer patients, pancreas cancer patients, and a pool of 2 patient prostate metastasis to lymph node. Normalization was performed by PCR using primers to actin. Semi-quantitative PCR, using primers directed to 98P4B6 v.1, v.13, and v.14 (A), or directed specifically to the splice variants 98P4B6 v.6 and v.8 (B), was performed at 26 and 30 cycles of amplification. Samples were run on an agarose gel, and PCR products were quantitated using the Alphalmager software. Results show strong expression of 98P4B6 v.1, v.13, and v.14 and its splice variants v.6 and v.8 in normal prostate and in prostate cancer. Expression was also detected in bladder cancer, kidney cancer, colon cancer, lung cancer, pancreas cancer, breast cancer, cancer metastasis as well as in the prostate cancer metastasis to lymph node specimens, compared to all normal tissues tested.  
     [0103]FIG. 15. 98P4B6 Expression in lung, ovary, prostate, bladder, cervix, uterus and pancreas patient cancer specimens. First strand cDNA was prepared from a panel of patient cancer specimens. Normalization was performed by PCR using primers to actin. Semi-quantitative PCR, using primers to 98P4B6 v.1, v.13, and v.14, was performed at 26 and 30 cycles of amplification. Samples were run on an agarose gel, and PCR products were quantitated using the Alphalmager software. Expression was recorded as absent, low, medium or strong. Results show expression of 98P4B6 in the majority of all patient cancer specimens tested.  
     [0104]FIG. 16. Expression of 98P4B6 in stomach cancer patient specimens. (A) RNA was extracted from normal stomach (N) and from 10 different stomach cancer patient specimens (T). Northern blot with 10 μg of total RNA/lane was probed with 98P4B6 sequence. Results show strong expression of 98P4B6 in the stomach tumor tissues and lower expression in normal stomach. The lower panel represents ethidium bromide staining of the blot showing quality of the RNA samples. (B) Expression of 98P4B6 was assayed in a panel of human stomach cancers (T) and their respective matched normal tissues (N) on RNA dot blots. 98P4B6 was detected in 7 out of 8 stomach tumors but not in the matched normal tissue.  
     [0105]FIG. 17. Detection of 98P4B6 expression with polyclonal antibody. 293T cells were transfected with 98P4B6.GFP.pcDNA3.1/mychis construct clone A12 or clone B12. STEAP1.GFP vector was used as a positive control. And as a negative control an empty vector was used. Forty hours later, cell lysates were collected. Samples were run on an SDS-PAGE acrylamide gel, blotted and stained with either anti-GFP antibody (A), anti-98P4B6 antibody generated against amino acids 198-389 (B), or anti-98P4B6 antibody generated against amino acids 153-165. The blot was developed using the ECL chemiluminescence kit and visualized by autoradiography. Results show expression of the expected 98P4B6.GFP fusion protein as detected by the anfi-GFP antibody. Also, we were able to raise 2 different polyclonal antibodies that recognized the 98P4B6.GFP fusion proteins as shown in B and C.  
     [0106]FIG. 18. Detection of 98P4B6 expression with polyclonal antibody. 293T cells were transfected with 98P4B6.GFP.pcDNA3.1/mychis construct clone A12 or clone B12. Expression of the 98P4B6.GFP fusion protein was detected by flow cytometry (A) and by flurorescent microscopy (B). Results show strong green fluorescence in the majority of the cells. The fusion protein localized to the perinuclear area and to the cell membrane.  
     [0107]FIG. 19. STEAP-2 Characteristics. The expression of STEAP-2 in normal tissues is predominantly restricted to the prostate. STEAP-2 is expressed in several cancerous tissues. In patient-derived prostate, colon, and lung cancer specimens; and Multiple cancer cell lines, including prostate, colon, Ewing&#39;s sarcoma, lung, kidney, pancreas and testis. By ISH, STEAP-2 expression appears to be primarily limited to ductal epithelial cells.  
     [0108]FIG. 20. STEAP-2 Induces Tyrosine Phosphorylation in PC3 Cells. STEAP-2 induces the tyrosine phosphorylation of proteins at 140-150, 120, 75-80, 62 and 40 kDa.  
     [0109]FIG. 21. STEAP-2 Enhances Tyrosine Phosphorylation in NIH 3T3 Cells. STEAP-2 enhances the phosphorylation of p135-140, p78-75 by STEAP-2 in NIH 3T3 cells. STEAP-2 C-Flag enhances the phosphorylation of p180, and induces the de-phosphorylation of p132, p82 and p75.  
     [0110]FIG. 22. STEAP-2 Induces ERK Phosphorylation. STEAP-2 Induces ERK phosphorylation in PC3 and 3T3 cells in 0.5 and 10% FBS. Lack or ERK phosphorylation in 3T3-STEAP-2-cflag cells. Potential role as dominant negative.  
     [0111]FIG. 23. STEAP Enhances Calcium Flux in PC3 cells. PC-STEAP-1 and PC3-STEAP-2 exhibit enhanced calcium flux in response to LPA. PC3-STEAP-1 demonstrates susceptibility to the L type calcium channel inhibitor, conotoxin. PC3-STEAP-2 shown susceptibility to the PQ type calcium channel inhibitor, agatoxin. NDGA and TEA had no effect on the proliferation of PC3-STEAP-2 cells.  
     [0112]FIG. 24. STEAP-2 Alters the Effect of Paclitaxel on PC3 Cells. Other Chemotherapeutics Tested without yielding a differential response between STEAP-expressing and control cells were Flutamide, Genistein, Rapamycin. STEAP-2 confers partial resistance to Paclitaxel in PC3 cells. Over 8 fold increase in percent survival of PC3-STEAP-2 relative to PC3-Neo cells.  
     [0113]FIG. 25. Inhibition of Apoptosis by STEAP-2. PC3 cells were treated with paclitaxel for 60 hours and analyzed for apoptosis by annexin V-PI staining. Expression of STEAP-2 partially inhibits apoptosis by paclitaxel.  
     [0114]FIG. 26. STEAP-2 Attenuates Paclitaxel Mediated Apoptosis. PC3 cells were treated with paclitaxel for 68 hours and analyzed for apoptosis. Expression of STEAP-2, but not STEAP-2CFlag, partially inhibits apoptosis by paclitaxel. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION  
     [0115] Outline of Sections  
     [0116] I.) Definitions  
     [0117] II.) 98P4B6 Polynucleotides  
     [0118] II.A.) Uses of 98P4B6 Polynucleotides  
     [0119] II.A.1.) Monitoring of Genetic Abnormalities  
     [0120] II.A.2.) Antisense Embodiments  
     [0121] II.A.3.) Primers and Primer Pairs  
     [0122] II.A.4.) Isolation of 98P4B6-Encoding Nucleic Acid Molecules  
     [0123] II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems  
     [0124] III.) 98P4B6-related Proteins  
     [0125] III.A.) Motif-bearing Protein Embodiments  
     [0126] III.B.) Expression of 98P4B6-related Proteins  
     [0127] III.C.) Modifications of 98P4B6-related Proteins  
     [0128] III.D.) Uses of 98P4B6-related Proteins  
     [0129] IV.) 98P4B6 Antibodies  
     [0130] V.) 98P4B6 Cellular Immune Responses  
     [0131] VI.) 98P4B6 Transgenic Animals  
     [0132] VII.) Methods for the Detection of 98P4B6  
     [0133] VIII.) Methods for Monitoring the Status of 98P4B6-related Genes and Their Products  
     [0134] IX.) Identification of Molecules That Interact With 98P4B6  
     [0135] X.) Therapeutic Methods and Compositions  
     [0136] X.A.) Anti-Cancer Vaccines  
     [0137] X.B.) 98P4B6 as a Target for Antibody-Based Therapy  
     [0138] X.C.) 98P4B6 as a Target for Cellular Immune Responses  
     [0139] X.C.1. Minigene Vaccines  
     [0140] X.C.2. Combinations of CTL Peptides with Helper Peptides  
     [0141] X.C.3. Combinations of CTL Peptides with T Cell Priming Agents  
     [0142] X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides  
     [0143] X.D.) Adoptive Immunotherapy  
     [0144] X.E.) Administration of Vaccines for Therapeutic or Prophylactic Purposes  
     [0145] XI.) Diagnostic and Prognostic Embodiments of 98P4B6.  
     [0146] XII.) Inhibition of 98P4B6 Protein Function  
     [0147] XII.A.) Inhibition of 98P4B6 With Intracellular Antibodies  
     [0148] XII.B.) Inhibition of 98P4B6 with Recombinant Proteins  
     [0149] XII.C.) Inhibition of 98P4B6 Transcription or Translation  
     [0150] XII.D.) General Considerations for Therapeutic Strategies  
     [0151] XIII.) Identification, Characterization and Use of Modulators of 98P4B6  
     [0152] XIV.) KITS/Articles of Manufacture  
     [0153] I.) Definitions:  
     [0154] Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.  
     [0155] The terms “advanced prostate cancer”, “locally advanced prostate cancer”, “advanced disease” and “locally advanced disease” mean prostate cancers that have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1-C2 disease under the Whitmore-Jewelt system, and stage T3-T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.  
     [0156] “Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence 98P4B6 (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence 98P4B6. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.  
     [0157] The term analog” refers to a molecule which is structurally similar or shares similar or corresponding attributes with another molecule (e.g. a 98P4B6-related protein). For example, an analog of a 98P4B6 protein can be specifically bound by an 3 antibody or T cell that specifically binds to 98P4B6.  
     [0158] The term “antibody” is used in the broadest sense. Therefore, an “antibody” can be naturally occurring or man-made such as monoclonal antibodies produced by conventional hybridoma technology. Anti-98P4B6 antibodies comprise monoclonal and polyclonal antibodies as well as fragments containing the antigen-binding domain and/or one or more complementarity determining regions of these antibodies.  
     [0159] An “antibody fragment” is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. In one embodiment it specifically covers single anti-98P4B6 antibodies and clones thereof (including agonist, antagonist and neutralizing antibodies) and anti-98P4B6 antibody compositions with polyepitopic specificity.  
     [0160] The term “codon optimized sequences” refers to nucleotide sequences that have been optimized for a particular host species by replacing any codons having a usage frequency of less than about 20%. Nucleotide sequences that have been optimized for expression in a given host species by elimination of spurious polyadenylation sequences, elimination of exon/intron splicing signals, elimination of transposon-like repeats and/or optimization of GC content in addition to codon optimization are referred to herein as an “expression enhanced sequences.” 
     [0161] A “combinatorial library” is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Numerous chemical compounds are synthesized through such combinatorial mixing of chemical building blocks (Gallop et al., J. Med. Chem. 37(9): 1233-1251 (1994)).  
     [0162] Preparation and screening of combinatorial libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbarnates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Stratagene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3): 309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Pat. No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&amp;EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506, 337; benzodiazepines, U.S. Pat. No. 5,288,514; and the like).  
     [0163] Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 NIPS, 390 NIPS, Advanced Chem Tech, Louisville Ky.; Symphony, Rainin, Woburn, Mass.; 433A, Applied Biosystems, Foster City, Calif.; 9050, Plus, Millipore, Bedford, NIA). A number of well-known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations such as the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate H, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J.; Asinex, Moscow, RU; Tripos, Inc., St: Louis, Mo.; ChemStar, Ltd, Moscow, RU; 3D Pharmaceuticals, Exton, Pa.; Martek Biosciences, Columbia, Md.; etc.).  
     [0164] The term “cytotoxic agent” refers to a substance that inhibits or prevents the expression activity of cells, function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Examples of cytotoxic agents include, but are not limited to auristatins, auromycins, maytansinoids, yttrium, bismuth, ricin, ricin A-chain, combrestatin, duocarmycins, dolostatins, doxorubicin, daunorubicin, taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, Sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 or 213 , P 32  and radioactive isotopes of Lu including Lu 177 . Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form.  
     [0165] The “gene product” is sometimes referred to herein as a protein or mRNA. For example, a “gene product of the invention” is sometimes referred to herein as a “cancer amino acid sequence”, “cancer protein”, “protein of a cancer listed in Table I”, a “cancer mRNA”, “mRNA of a cancer listed in Table I”, etc. In one embodiment, the cancer protein is encoded by a nucleic acid of FIG. 2. The cancer protein can be a fragment, or alternatively, be the full-length protein to the fragment encoded by the nucleic acids of FIG. 2. In one embodiment, a cancer amino acid sequence is used to determine sequence identity or similarity. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of FIG. 2. In another embodiment, the sequences are sequence variants as further described herein.  
     [0166] “High throughput screening” assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Pat. No. 5,559,410 discloses high throughput screening methods for proteins; U.S. Pat. No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays); while U.S. Pat. Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.  
     [0167] In addition, high throughput screening systems are commercially available (see, e.g., Amersham Biosciences, Piscataway, N.J.; Zymark Corp., Hopkinton, Mass.; Air Technical Industries, Mentor, Ohio; Beckman Instruments, Inc. Fullerton, Calif.; Precision Systems, Inc., Natick, Mass.; etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.  
     [0168] The term “homolog” refers to a molecule which exhibits homology to another molecule, by for example, having sequences of chemical residues that are the same or similar at corresponding positions.  
     [0169] “Human Leukocyte Antigen” or “HLA” is a human class I or class II Major Histocompatibility Complex (MHC) protein (see, e.g., Stites, et al., IMMUNOLOGY, 8 TH  ED., Lange Publishing, Los Altos, Calif. (1994).  
     [0170] The terms “hybridize”, “hybridizing”, “hybridizes” and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6×SSC/0.1% SDS/100 μg/ml ssDNA, in which temperatures for hybridization are above 37 degrees C. and temperatures for washing in 0.1×SSC/0.1% SDS are above 55 degrees C.  
     [0171] The phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their in situ environment. For example, a polynucleotide is said to be “isolated” when it is substantially separated from contaminant polynucleotides that correspond or are complementary to genes other than the 98P4B6 genes or that encode polypeptides other than 98P4B6 gene product or fragments thereof. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated 98P4B6 polynucleotide. A protein is said to be “isolated,” for example, when physical, mechanical or chemical methods are employed to remove the 98P4B6 proteins from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated 98P4B6 protein. Alternatively, an isolated protein can be prepared by chemical means.  
     [0172] The term “mammal” refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.  
     [0173] The terms “metastatic prostate cancer” and “metastatic disease” mean prostate cancers that have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is a preferred treatment modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation. Approximately half of these androgen-refractory patients die within 6 months after developing that status. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases are often osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.  
     [0174] The term “modulator” or “test compound” or “drug candidate” or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the cancer phenotype or the expression of a cancer sequence, e.g., a nucleic acid or protein sequences, or effects of cancer sequences (e.g., signaling, gene expression, protein interaction, etc.) In one aspect, a modulator will neutralize the effect of a cancer protein of the invention. By “neutralize” is meant that an activity of a protein is inhibited or blocked, along with the consequent effect on the cell. In another aspect, a modulator will neutralize the effect of a gene, and its corresponding protein, of the invention by normalizing levels of said protein. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein, or downstream effector pathways. In one embodiment, the modulator suppresses a cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a cancer phenotype. Generally, a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.  
     [0175] Modulators, drug candidates or test compounds encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 Daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Modulators also comprise biomolecules such as peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides. One class of modulators are peptides, for example of from about five to about 35 amino acids, with from about five to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. Preferably, the cancer modulatory protein is soluble, includes a non-transmembrane region, and/or, has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine. In one embodiment, a cancer protein of the invention is conjugated to an immunogenic agent as discussed herein. In one embodiment, the cancer protein is conjugated to BSA. The peptides of the invention, e.g., of preferred lengths, can be linked to each other or to other amino acids to create a longer peptide/protein. The modulatory peptides can be digests of naturally occurring proteins as is outlined above, random peptides, or “biased” random peptides. In a preferred embodiment, peptide/protein-based modulators are antibodies, and fragments thereof, as defined herein.  
     [0176] Modulators of cancer can also be nucleic acids. Nucleic acid modulating agents can be naturally occurring nucleic acids, random nucleic acids, or “biased” random nucleic acids. For example, digests of prokaryotic or eukaryotic genomes can be used in an approach analogous to that outlined above for proteins.  
     [0177] The term “monoclonal anbbody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.  
     [0178] A “motif”, as in biological motif of a 98P4B6-related protein, refers to any pattern of amino acids forming part of the primary sequence of a protein, that is associated with a particular function (e.g. protein-protein interaction, protein-DNA interaction, etc) or modification (e.g. that is phosphorylated, glycosylated or amidated), or localization (e.g. secretory sequence, nuclear localization sequence, etc.) or a sequence that is correlated with being immunogenic, either humorally or cellularly. A motif can be either contiguous or capable of being aligned to certain positions that are generally correlated with a certain function or property. In the context of HLA motifs, “motif” refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs for HLA binding are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.  
     [0179] A “pharmaceutical excipient” comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.  
     [0180] “Pharmaceutically acceptable” refers to a non-toxic, inert, and/or composition that is physiologically compatible with humans or other mammals.  
     [0181] The term “polynucleotide” means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term if often used interchangeably with “oligonucleotide”. A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T), as shown for example in FIG. 2, can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA, in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).  
     [0182] The term “polypeptide” means a polymer of at least about 4, 5, 6, 7, or 8 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably with “peptide” or “protein”.  
     [0183] An HLA “primary anchor residue” is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a “motif” for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding groove of an HLA molecule, with their side chains buried in specific pockets of the binding groove. In one embodiment, for example, the primary anchor residues for an HLA class I molecule are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 8, 9, 10, 11, or 12 residue peptide epitope in accordance with the invention. Alternatively, in another embodiment, the primary anchor residues of a peptide binds an HLA class II molecule are spaced relative to each other, rather than to the termini of a peptide, where the peptide is generally of at least 9 amino acids in length. The primary anchor positions for each motif and supermotif are set forth in Table IV. For example, analog peptides can be created by altering the presence or absence of particular residues in the primary and/or secondary anchor positions shown in Table IV. Such analogs are used to modulate the binding affinity and/or population coverage of a peptide comprising a particular HLA motif or supermotif.  
     [0184] “Radioisotopes” include, but are not limited to the following (non-limiting exemplary uses are also set forth):  
     [0185] Examples of Medical Isotopes:  
     [0186] Isotope  
     [0187] Description of use  
     [0188] Actinium-225  
     [0189] (AC-225)  
     [0190] See Thorium-229 (Th-229)  
     [0191] Actinium-227  
     [0192] (AC-227)  
     [0193] Parent of Radium-223 (Ra-223) which is an alpha emitter used to treat metastases in the skeleton resulting from cancer (i.e., breast and prostate cancers), and cancer radioimmunotherapy  
     [0194] Bismuth-212  
     [0195] (Bi-212)  
     [0196] See Thorium-228 (Th-228)  
     [0197] Bismuth-213  
     [0198] (Bi-213)  
     [0199] See Thorium-229 (Th-229)  
     [0200] Cadmium-109  
     [0201] (Cd-109)  
     [0202] Cancer detection  
     [0203] Cobalt-60  
     [0204] (Co-60)  
     [0205] Radiation source for radiotherapy of cancer, for food irradiators, and for sterilization of medical supplies  
     [0206] Copper-64  
     [0207] (Cu-64)  
     [0208] A positron emitter used for cancer therapy and SPECT imaging  
     [0209] Copper-67  
     [0210] (Cu-67)  
     [0211] Beta/gamma emitter used in cancer radioimmunotherapy and diagnostic studies (i.e., breast and colon cancers, and lymphoma)  
     [0212] Dysprosium-166  
     [0213] (Dy-166)  
     [0214] Cancer radioimmunotherapy  
     [0215] Erbium-169  
     [0216] (Er-169)  
     [0217] Rheumatoid arthritis treatment, particularly for the small joints associated with fingers and toes  
     [0218] Europium-152  
     [0219] (Eu-152)  
     [0220] Radiation source for food irradiation and for sterilization of medical supplies  
     [0221] Europium-154  
     [0222] (Eu-154)  
     [0223] Radiation source for food irradiation and for sterilization of medical supplies  
     [0224] Gadolinium-153  
     [0225] (Gd-153)  
     [0226] Osteoporosis detection and nuclear medical quality assurance devices  
     [0227] Gold-198  
     [0228] (Au-198)  
     [0229] Implant and intracavity therapy of ovarian, prostate, and brain cancers  
     [0230] Holmium-166  
     [0231] (Ho-166)  
     [0232] Multiple myeloma treatment in targeted skeletal therapy, cancer radioimmunotherapy, bone marrow ablation, and rheumatoid arthritis treatment  
     [0233] Iodine-125  
     [0234] (I-125)  
     [0235] Osteoporosis detection, diagnostic imaging, tracer drugs, brain cancer treatment, radiolabeling, tumor imaging, mapping of receptors in the brain, interstitial radiation therapy, brachytherapy for treatment of prostate cancer, determination of glomerular filtration rate (GFR), determination of plasma volume, detection of deep vein thrombosis of the legs  
     [0236] Iodine-131  
     [0237] (I-131)  
     [0238] Thyroid function evaluation, thyroid disease detection, treatment of thyroid cancer as well as other non-malignant thyroid diseases (i.e., Graves disease, goiters, and hyperthyroidism), treatment of leukemia, lymphoma, and other forms of cancer (e.g., breast cancer) using radioimmunotherapy  
     [0239] Iridium-192  
     [0240] (Ir-192)  
     [0241] Brachytherapy, brain and spinal cord tumor treatment, treatment of blocked arteries (i.e., arteriosclerosis and restenosis), and implants for breast and prostate tumors  
     [0242] Lutetium-177  
     [0243] (Lu-177)  
     [0244] Cancer radioimmunotherapy and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)  
     [0245] Molybdenum-99  
     [0246] (Mo-99)  
     [0247] Parent of Technetium-99m (Tc-99m) which is used for imaging the brain, liver, lungs, heart, and other organs. Currently, Tc-99m is the most widely used radioisotope used for diagnostic imaging of various cancers and diseases involving the brain, heart, liver, lungs; also used in detection of deep vein thrombosis of the legs  
     [0248] Osmium-194  
     [0249] (Os-194)  
     [0250] Cancer radioimmunotherapy  
     [0251] Palladium-103  
     [0252] (Pd-103)  
     [0253] Prostate cancer treatment  
     [0254] Platinum-195m  
     [0255] (Pt-195m)  
     [0256] Studies on biodistribution and metabolism of cisplatin, a chemotherapeutic drug  
     [0257] Phosphorus-32  
     [0258] (P-32)  
     [0259] Polycythemia rubra vera (blood cell disease) and leukemia treatment, bone cancer diagnosis/treatment; colon, pancreatic, and liver cancer treatment; radiolabeling nucleic acids for in vitro research, diagnosis of superficial tumors, treatment of blocked arteries (i.e., arteriosclerosis and restenosis), and intracavity therapy  
     [0260] Phosphorus-33  
     [0261] (P-33)  
     [0262] Leukemia treatment, bone disease diagnosis/treatment, radiolabeling, and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)  
     [0263] Radium-223  
     [0264] (Ra-223)  
     [0265] See Actinium-227 (Ac-227)  
     [0266] Rhenium-186  
     [0267] (Re-186)  
     [0268] Bone cancer pain relief, rheumatoid arthritis treatment, and diagnosis and treatment of lymphoma and bone, breast, colon, and liver cancers using radioimmunotherapy  
     [0269] Rhenium-188  
     [0270] (Re-188)  
     [0271] Cancer diagnosis and treatment using radioimmunotherapy, bone cancer pain relief, treatment of rheumatoid arthritis, and treatment of prostate cancer  
     [0272] Rhodium-105  
     [0273] (Rh-105)  
     [0274] Cancer radioimmunotherapy  
     [0275] Samarium-145  
     [0276] (Sm-145)  
     [0277] Ocular cancer treatment  
     [0278] Samarium-153  
     [0279] (Sm-153)  
     [0280] Cancer radioimmunotherapy and bone cancer pain relief  
     [0281] Scandium-47  
     [0282] (Sc-47)  
     [0283] Cancer radioimmunotherapy and bone cancer pain relief  
     [0284] Selenium-75  
     [0285] (Se-75)  
     [0286] Radiotracer used in brain studies, imaging of adrenal cortex by gamma-scintigraphy, lateral locations of steroid secreting tumors, pancreatic scanning, detection of hyperactive parathyroid glands, measure rate of bile acid loss from the endogenous pool  
     [0287] Strontium-85  
     [0288] (Sr-85)  
     [0289] Bone cancer detection and brain scans  
     [0290] Strontium-89  
     [0291] (Sr-89)  
     [0292] Bone cancer pain relief, multiple myeloma treatment, and osteoblastic therapy  
     [0293] Technetium-99m  
     [0294] (Tc-99m)  
     [0295] See Molybdenum-99 (Mo-99)  
     [0296] Thorium-228  
     [0297] (Th-228)  
     [0298] Parent of Bismuth-212 (Bi-212) which is an alpha emitter used in cancer radioimmunotherapy  
     [0299] Thorium-229  
     [0300] (Th-229)  
     [0301] Parent of Actinium-225 (Ac-225) and grandparent of Bismuth-213 (Bi-213) which are alpha emitters used in cancer radioimmunotherapy  
     [0302] Thulium-170  
     [0303] (Tm-170)  
     [0304] Gamma source for blood irradiators, energy source for implanted medical devices  
     [0305] Tin-117m  
     [0306] (Sn-117m)  
     [0307] Cancer immunotherapy and bone cancer pain relief  
     [0308] Tungsten-188  
     [0309] (W-188)  
     [0310] Parent for Rhenium-188 (Re-188) which is used for cancer diagnostics/treatment, bone cancer pain relief, rheumatoid arthritis treatment, and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)  
     [0311] Xenon-127  
     [0312] (Xe-127)  
     [0313] Neuroimaging of brain disorders, high resolution SPECT studies, pulmonary function tests, and cerebral blood flow studies  
     [0314] Ytterbium-175  
     [0315] (Yb-175)  
     [0316] Cancer radioimmunotherapy  
     [0317] Yttrium-90  
     [0318] (Y-90)  
     [0319] Microseeds obtained from irradiating Yttrium-89 (Y-89) for liver cancer treatment  
     [0320] Yttrium-91  
     [0321] (Y-91)  
     [0322] A gamma-emitting label for Yttrium-90 (Y-90) which is used for cancer radioimmunotherapy (i.e., lymphoma, breast, colon, kidney, lung, ovarian, prostate, pancreatic, and inoperable liver cancers)  
     [0323] By “randomized” or grammatical equivalents as herein applied to nucleic acids and proteins is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. These random peptides (or nucleic acids, discussed herein) can incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.  
     [0324] In one embodiment, a library is “fully randomized,” with no sequence preferences or constants at any position. In another embodiment, the library is a “biased random” library. That is, some positions within the sequence either are held constant, or are selected from a limited number of possibilities. For example, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.  
     [0325] A “recombinant” DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation in vitro.  
     [0326] Non-limiting examples of small molecules include compounds that bind or interact with 98P4B6, ligands including hormones, neuropeptides, chemokines, odorants, phospholipids, and functional equivalents thereof that bind and preferably inhibit 98P4B6 protein function. Such non-limiting small molecules preferably have a molecular weight of less than about 10 kDa, more preferably below about 9, about 8, about 7, about 6, about 5 or about 4 kDa. In certain embodiments, small molecules physically associate with, or bind, 98P4B6 protein; are not found in naturally occurring metabolic pathways; and/or are more soluble in aqueous than non-aqueous solutions  
     [0327] “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).  
     [0328] “Stringent conditions” or “high stringency conditions”, as defined herein, are identified by, but not limited to, those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt&#39;s solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C. “Moderately stringent conditions” are described by, but not limited to, those in Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt&#39;s solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.  
     [0329] An HLA “supermotif” is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles. Overall phenotypic frequencies of HLA-supertypes in different ethnic populations are set forth in Table IV (F). The non-limiting constituents of various supetypes are as follows:  
     [0330] A2: A*0201, A*0202, A*0203, A*0204, A* 0205, A*0206, A*6802, A*6901, A*0207  
     [0331] A3: A3, A11, A31, A*3301, A*6801, A*0301, A*1101, A*3101  
     [0332] B7: B7, B*3501-03, B*51, B*5301, B*5401, B*5501, B*5502, B*5601, B*6701, B*7801, B*0702, B*5101, B*5602  
     [0333] B44: B*3701, B*4402, B*4403, B*60 (B*4001), B61 (B*4006)  
     [0334] A1: A*0102, A*2604, A*3601, A*4301, A*8001  
     [0335] A24: A*24, A*30, A*2403, A*2404, A*3002, A*3003  
     [0336] B27: B*1401-02, B*1503, B*1509, B*1510, B*1518, B*3801-02, B*3901, B*3902, B*3903-04, B*4801-02, B*7301, B*2701-08  
     [0337] B58: B*1516,.B*1517, B*5701, B*5702, B58  
     [0338] B62: B*4601, B52, B*1501 (B62), B*1502 (B75), B*1513 (B77)  
     [0339] Calculated population coverage afforded by different HLA-supertype combinations are set forth in Table IV (G).  
     [0340] As used herein “to treat” or “therapeutic” and grammatically related terms, refer to any improvement of any consequence of disease, such as prolonged survival, less morbidity, and/or a lessening of side effects which are the byproducts of an alternative therapeutic modality; full eradication of disease is not required.  
     [0341] A “transgenic animal” (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A “transgene” is a DNA that is integrated into the genome of a cell from which a transgenic animal develops.  
     [0342] As used herein, an HLA or cellular immune response “vaccine” is a composition that contains or encodes one or more peptides of the invention. There are numerous embodiments of such vaccines, such as a cocktail of one or more individual peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such individual peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The “one or more peptides” can include any whole unit integer from 1-150 or more, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I peptides of the invention can be admixed with, or linked to, HLA class II peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. HLA vaccines can also comprise peptide-pulsed antigen presenting cells, e.g., dendritic cells.  
     [0343] The term “variant” refers to a molecule that exhibits a variation from a described type or norm, such as a protein that has one or more different amino acid residues in the corresponding position(s) of a specifically described protein (e.g. the 98P4B6 protein shown in FIG. 2 or FIG. 3. An analog is an example of a variant protein. Splice isoforms and single nucleotides polymorphisms (SNPs) are further examples of variants.  
     [0344] The “98P4B6-related proteins” of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants, analogs and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined herein or readily available in the art. Fusion proteins that combine parts of different 98P4B6 proteins or fragments thereof, as well as fusion proteins of a 98P4B6 protein and a heterologous polypeptide are also included. Such 98P4B6 proteins are collectively referred to as the 98P4B6-related proteins, the proteins of the invention, or 98P4B6. The term “98P4B6-related protein” refers to a polypeptide fragment or a 98P4B6 protein sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 amino acids; or, at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, or 576 or more amino acids.  
     [0345] II.) 98P4B6 Polynucleotides  
     [0346] One aspect of the invention provides polynucleotides corresponding or complementary to all or part of a 98P4B6 gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding a 98P4B6-related protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to a 98P4B6 gene or mRNA sequence or a part thereof, and polynucleotides or oligonucleotides that hybridize to a 98P4B6 gene, mRNA, or to a 98P4B6 encoding polynucleotide (collectively, “98P4B6 polynucleotides”. In all instances when referred to in this section, T can also be U in FIG. 2.  
     [0347] Embodiments of a 98P4B6 polynucleotide include: a 98P4B6 polynucleotide having the sequence shown in FIG. 2, the nucleotide sequence of 98P4B6 as shown in FIG. 2 wherein T is U; at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2 where T is U. For example, embodiments of 98P4B6 nucleotides comprise, without limitation:  
     [0348] (I) a polynucleotide comprising, consisting essentially of, or consisting of a sequence as shown in FIG. 2, wherein T can also be U;  
     [0349] (II) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2A, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0350] (III) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2B, from nucleotide residue number 4 through nucleotide residue number 138, including the stop codon, wherein T can also be U;  
     [0351] (IV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2C, from nucleotide residue number 188 through nucleotide residue number 1552, including the a stop codon, wherein T can also be U;  
     [0352] (V) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2D, from nucleotide residue number 318 through nucleotide residue number 1682, including the stop codon, wherein T can also be U;  
     [0353] (VI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2E, from nucleotide residue number 318 through nucleotide residue number 1577, including the stop codon, wherein T can also be U;  
     [0354] (VII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2F, from nucleotide residue number 318 through nucleotide residue number 1790, including the stop codon, wherein T can also be U;  
     [0355] (VIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2G, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0356] (IX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2H, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0357] (X) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 21, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0358] (XI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2J, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0359] (XII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2K, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0360] (XIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2L, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0361] (XIV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2M, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0362] (XV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2N, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0363] (XVI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 20, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0364] (XVII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2P, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0365] (XVIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2Q, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0366] (XIX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2R, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0367] (XX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2S, from nucleotide residue number 355 through nucleotide residue number 1719, including the stop codon, wherein T can also be U;  
     [0368] (XXI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2T, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0369] (XXII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2U, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0370] (XXIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2V, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0371] (XXIV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2W, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0372] (XXV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2X, from nucleotide residue number 295 through nucleotide residue number 2025, including the stop codon, wherein T can also be U;  
     [0373] (XXVI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2Y, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0374] (XXVII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2Z, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0375] (XXVIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2M, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0376] (XXIX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AB, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0377] (XXX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AC, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0378] (XXXI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AD, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0379] (XXXII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AE, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0380] (XXXIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AF, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0381] (XXIV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AG, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0382] (XXXV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AH, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0383] (XXXVI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AI, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0384] (XXXVII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AJ, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0385] (XXXVIII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AK, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0386] (XXXIX) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2AL, from nucleotide residue number 394 through nucleotide residue number 1866, including the stop codon, wherein T can also be U;  
     [0387] (XL) a polynucleotide that encodes a 98P4B6-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% homologous to an entire amino acid sequence shown in FIGS.  2 A-AL;  
     [0388] (XLI) a polynucleotide that encodes a 98P4B6-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical to an entire amino acid sequence shown in FIG. 2A-AL;  
     [0389] (XLII) a polynucleotide that encodes at least one peptide set forth in Tables VIII-XXI and XXII-XLIX;  
     [0390] (XLIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3A, 3G, and  3 H in any whole number increment up to 454 that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0391] (XLIV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3A, 3G, and  3 H in any whole number increment up to 454 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0392] (XLV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3A, 3G, and  3 H in any whole number increment up to 454 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0393] (XLVI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3A, 3G, and  3 H in any whole number increment up to 454 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;  
     [0394] (XLVII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3A, 3G, and  3 H in any whole number increment up to 454 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9;  
     [0395] (XLVIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3B in any whole number increment up to 45 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0396] (XLIX) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3B in any whole number increment up to 45 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0397] (L) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3B in any whole number increment up to 45 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0398] (LI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3B in any whole number increment up to 45 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;  
     [0399] (LII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3B in any whole number increment up to 45 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9  
     [0400] (LIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3C in any whole number increment up to 419 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0401] (LIV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3C in any whole number increment up to 419 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0402] (LV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3C in any whole number increment up to 419 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0403] (LVI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3C in any whole number increment up to 419 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;  
     [0404] (LVII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG. 3C in any whole number increment up to 419 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9  
     [0405] (LVIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3D, 3F, and  3 J in any whole number increment up to 490 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0406] (LIX) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3D, 3F, and  3 J in any whole number increment up to 490 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0407] (LX) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3D, 3F, and  3 J in any whole number increment up to 490 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0408] (LXI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3D, 3F, and  3 J in any whole number increment up to 490 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8; (LXII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3D, 3F, and  3 J in any whole number increment up to 490 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9  
     [0409] (LXIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3E and 31 in any whole number increment up to 576 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0410] (LXIV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3E and 31 in any whole number increment up to 576 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0411] (LXV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3E and 3I in any whole number increment up to 576 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0412] (LXVI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3E and 31 in any whole number increment up to 576 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;  
     [0413] (LXVII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS. 3E and 3I in any whole number increment up to 576 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9  
     [0414] (LXVIII) a polynucleotide that is fully complementary to a polynucleotide of any one of (I)-(LXVII).  
     [0415] (LXIX) a peptide that is encoded by any of (I) to (LXVIII); and  
     [0416] (LXX) a composition comprising a polynucleotide of any of (I)-(LXVIII) or peptide of (LXIX) together with a pharmaceutical excipient and/or in a human unit dose form.  
     [0417] (LXXI) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to modulate a cell expressing 98P4B6,  
     [0418] (LXXII) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 98P4B6  
     [0419] (LXXIII) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 98P4B6, said cell from a cancer of a tissue listed in Table I;  
     [0420] (LXXIV) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to diagnose, prophylax, prognose, or treat a a cancer;  
     [0421] (LXXV) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to diagnose, prophylax, prognose, or treat a a cancer of a tissue listed in Table I; and,  
     [0422] (LXXVI) a method of using a polynucleotide of any (I)-(LXVIII) or peptide of (LXIX) or a composition of (LXX) in a method to identify or characterize a modulator of a cell expressing 98P4B6.  
     [0423] As used herein, a range is understood to disclose specifically all whole unit positions thereof.  
     [0424] Typical embodiments of the invention disclosed herein include 98P4B6 polynucleotides that encode specific portions of 98P4B6 mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:  
     [0425] (a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 410, 420, 430, 440, 450 or 454 or more contiguous amino acids of 98P4B6 variant 1; the maximal lengths relevant for other variants are: variant 2, 44 amino acids; variant 5, 419 amino acids, variant 6, 490 amino acids, variant 7, 576 amino acids, variant 8, 490 amino acids, variant 13, 454 amino acids, variant 14, 454 amino acids, variant 21, 576 amino acids, and variant 25, 490 amino acids.  
     [0426] For example, representative embodiments of the invention disclosed herein include: polynucleotides and their encoded peptides themselves encoding about amino acid 1 to about amino acid 10 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 10 to about amino acid 20 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 20 to about amino acid 30 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 30 to about amino acid 40 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 40 to about amino acid 50 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 50 to about amino acid 60 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 60 to about amino acid 70 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 70 to about amino acid 80 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 80 to about amino acid 90 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 90 to about amino acid 100 of the 98P4B6 protein shown in FIG. 2 or FIG. 3, in increments of about 10 amino acids, ending at the carboxyl terminal amino acid set forth in FIG. 2 or FIG. 3. Accordingly, polynucleotides encoding portions of the amino acid sequence (of about 10 amino acids), of amino acids, 100 through the carboxyl terminal amino acid of the 98P4B6 protein are embodiments of the invention. Wherein it is understood that each particular amino acid position discloses that position plus or minus five amino acid residues.  
     [0427] Polynucleotides encoding relatively long portions of a 98P4B6 protein are also within the scope of the invention. For example, polynucleotides encoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 30, or 40 or 50 etc.) of the 98P4B6 protein “or variant” shown in FIG. 2 or FIG. 3 can be generated by a variety of techniques well known in the art. These polynucleotide fragments can include any portion of the 98P4B6 sequence as shown in FIG. 2.  
     [0428] Additional illustrative embodiments of the invention disclosed herein include 98P4B6 polynucleotide fragments encoding one or more of the biological motifs contained within a 98P4B6 protein “or variant” sequence, including one or more of the motif-bearing subsequences of a 98P4B6 protein “or variant” set forth in Tables VIII-XXI and XXII-XLIX. In another embodiment, typical polynucleotide fragments of the invention encode one or more of the regions of 98P4B6 protein or variant that exhibit homology to a known molecule. In another embodiment of the invention, typical polynucleotide fragments can encode one or more of the 98P4B6 protein or variant N-glycosylation sites, cAMP and cGMP-dependent protein kinase phosphorylation sites, casein kinase II phosphorylation sites or N-myristoylation site and amidation sites.  
     [0429] Note that to determine the starting position of any peptide set forth in Tables VIII-XXI and Tables XXII to XLIX (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides listed in Table VII. Generally, a unique Search Peptide is used to obtain HLA peptides for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table VII. Accordingly, if a Search Peptide begins at position “X”, one must add the value a “X minus 1” to each position in Tables VIII-XXI and Tables XXII-IL to obtain the actual position of the HLA peptides in their parental molecule. For example if a particular Search Peptide begins at position 150 of its parental molecule, one must add 150−1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.  
     [0430] II.A.) Uses of 98P4B6 Polynucleotides  
     [0431] II.A.1.) Monitoring of Genetic Abnormalities  
     [0432] The polynucleotides of the preceding paragraphs have a number of different specific uses. The human 98P4B6 gene maps to the chromosomal location set forth in the Example entitled “Chromosomal Mapping of 98P4B6.” For example; because the 98P4B6 gene maps to this chromosome, polynucleotides that encode different regions of the 98P4B6 proteins are used to characterize cytogenetic abnormalities of this chromosomal locale, such as abnormalities that are identified as being associated with various cancers. In certain genes, a variety of chromosomal abnormalities including rearrangements have been identified as frequent cytogenetic abnormalities in a number of different cancers (see e.g. Krajinovic et al., Mutat. Res. 382(3-4): 81-83 (1998); Johansson et al., Blood 86(10): 3905-3914 (1995) and Finger et al., P.N.A.S. 85(23): 9158-9162 (1988)). Thus, polynucleotides encoding specific regions of the 98P4B6 proteins provide new tools that can be used to delineate, with greater precision than previously possible, cytogenetic abnormalities in the chromosomal region that encodes 98P4B6 that may contribute to the malignant phenotype. In this context, these polynucleotides satisfy a need in the art for expanding the sensitivity of chromosomal screening in order to identify more subtle and less common chromosomal abnormalities (see e.g. Evans et al., Am. J. Obstet. Gynecol 171(4): 1055-1057 (1994)).  
     [0433] Furthermore, as 98P4B6 was shown to be highly expressed in prostate and other cancers, 98P4B6 polynucleotides are used in methods assessing the status of 98P4B6 gene products in normal versus cancerous tissues. Typically, polynucleotides that encode specific regions of the 98P4B6 proteins are used to assess the presence of perturbations (such as deletions, insertions, point mutations, or alterations resulting in a loss of an antigen etc.) in specific regions of the 98P4B6 gene, such as regions containing one or more motifs. Exemplary assays include both RT-PCR assays as well as single-strand conformation polymorphism (SSCP) analysis (see, e.g., Marrogi et al., J. Cutan. Pathol. 26(8): 369-378 (1999), both of which utilize polynucleotides encoding specific regions of a protein to examine these regions within the protein.  
     [0434] II.A.2.) Antisense Embodiments  
     [0435] Other specifically contemplated nucleic acid related embodiments of the invention disclosed herein are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone, or including alternative bases, whether derived from natural sources or synthesized, and include molecules capable of inhibiting the RNA or protein expression of 98P4B6. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives that specifically bind DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the 98P4B6 polynucleotides and polynucleotide sequences disclosed herein.  
     [0436] Antisense technology entails the administration of exogenous oligonucleotides that bind to a target polynucleotide located within the cells. The term “antisense” refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., 98P4B6. See for example, Jack Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The 98P4B6 antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, supra), which exhibit enhanced cancer cell growth inhibitory action. S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention can be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transfer reagent. See, e.g., Iyer, R. P. et al., J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. et al., J. Am. Chem. Soc. 112:1253-1254 (1990). Additional 98P4B6 antisense oligonucleotides of the present invention include morpholino antisense oligonucleotides known in the art (see, e.g., Partridge et al., 1996, Antisense &amp; Nucleic Acid Drug Development 6:169-175).  
     [0437] The 98P4B6 antisense oligonucleotides of the present invention typically can be RNA or DNA that is complementary to and stably hybridizes with the first 100 5′ codons or last 100 3′ codons of a 98P4B6 genomic sequence or the corresponding mRNA. Absolute complementarity is not required, although high degrees of complementarity are preferred. Use of an oligonucleotide complementary to this region allows for the selective hybridization to 98P4B6 mRNA and not to mRNA specifying other regulatory subunits of protein kinase. In one embodiment, 98P4B6 antisense oligonucleotides of the present invention are 15 to 30-mer fragments of the antisense DNA molecule that have a sequence that hybridizes to 98P4B6 mRNA. Optionally, 98P4B6 antisense oligonucleotide is a 30-mer oligonucleotide that is complementary to a region in the first 10 5′ codons or last 10 3′ codons of 98P4B6. Alternatively, the antisense molecules are modified to employ ribozymes in the inhibition of 98P4B6 expression, see, e.g., L. A. Couture &amp; D. T. Stinchcomb;  Trends Genet  12: 510-515 (1996).  
     [0438] II.A.3.) Primers and Primer Pairs  
     [0439] Further specific embodiments of these nucleotides of the invention include primers and primer pairs, which allow the specific amplification of polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. Such probes and primers are used to detect the presence of a 98P4B6 polynucleotide in a sample and as a means for detecting a cell expressing a 98P4B6 protein.  
     [0440] Examples of such probes include polypeptides comprising all or part of the human 98P4B6 cDNA sequence shown in FIG. 2. Examples of primer pairs capable of specifically amplifying 98P4B6 mRNAs are also described in the Examples. As will be understood by the skilled artisan, a great many different primers and probes can be prepared based on the sequences provided herein and used effectively to amplify and/or detect a 98P4B6 mRNA.  
     [0441] The 98P4B6 polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the 98P4B6 gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of 98P4B6 polypeptides; as tools for modulating or inhibiting the expression of the 98P4B6 gene(s) and/or translation of the 98P4B6 transcript(s); and as therapeutic agents.  
     [0442] The present invention includes the use of any probe as described herein to identify and isolate a 98P4B6 or 98P4B6 related nucleic acid sequence from a naturally occurring source, such as humans or other mammals, as well as the isolated nucleic acid sequence per se, which would comprise all or most of the sequences found in the probe used.  
     [0443] II.A.4.) Isolation of 98P4B6-Encoding Nucleic Acid Molecules  
     [0444] The 98P4B6 cDNA sequences described herein enable the isolation of other polynucleotides encoding 98P4B6 gene product(s), as well as the isolation of polynucleotides encoding 98P4B6 gene product homologs, alternatively spliced isoforms, allelic variants, and mutant forms of a 98P4B6 gene product as well as polynucleotides that encode analogs of 98P4B6-related proteins. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding a 98P4B6 gene are well known (see, for example, Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press, New York, 1989; Current Protocols in Molecular Biology. Ausubel et al., Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies can be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing 98P4B6 gene cDNAs can be identified by probing with a labeled 98P4B6 cDNA or a fragment thereof. For example, in one embodiment, a 98P4B6 cDNA (e.g., FIG. 2) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full-length cDNAs corresponding to a 98P4B6 gene. A 98P4B6 gene itself can be isolated by screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with 98P4B6 DNA probes or primers.  
     [0445] II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems  
     [0446] The invention also provides recombinant DNA or RNA molecules containing a 98P4B6 polynucleotide, a fragment, analog or homologue thereof, including but not limited to phages, plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. Methods for generating such molecules are well known (see, for example, Sambrook et al., 1989, supra).  
     [0447] The invention further provides a host-vector system comprising a recombinant DNA molecule containing a 98P4B6 polynucleotide, fragment, analog or homologue thereof within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell). Examples of suitable mammalian cells include various prostate cancer cell lines such as DU145 and TsuPr1, other transfectable or transducible prostate cancer cell lines, primary cells (PrEC), as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of 98P4B6 or a fragment, analog or homolog thereof can be used to generate 98P4B6 proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.  
     [0448] A wide range of host-vector systems suitable for the expression of 98P4B6 proteins or fragments thereof are available, see for example, Sambrook et al., 1989, supra; Current Protocols in Molecular Biology, 1995, supra). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSRαtkneo (Muller et al., 1991, MCB 11:1785). Using these expression vectors, 98P4B6 can be expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, NIH 3T3 and TsuPr1. The host-vector systems of the invention are useful for the production of a 98P4B6 protein or fragment thereof. Such host-vector systems can be employed to study the functional properties of 98P4B6 and 98P4B6 mutations or analogs.  
     [0449] Recombinant human 98P4B6 protein or an analog or homolog or fragment thereof can be produced by mammalian cells transfected with a construct encoding a 98P4B6-related nucleotide. For example, 293T cells can be transfected with an expression plasmid encoding 98P4B6 or fragment, analog or homolog thereof, a 98P4B6-related protein is expressed in the 293T cells, and the recombinant 98P4B6 protein is isolated using standard purification methods (e.g., affinity purification using anti-98P4B6 antibodies). In another embodiment, a 98P4B6 coding sequence is subcloned into the retroviral vector pSRαMSVtkneo and used to infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 and rat-1 in order to establish 98P4B6 expressing cell lines. Various other expression systems well known in the art can also be employed. Expression constructs encoding a leader peptide joined in frame to a 98P4B6 coding sequence can be used for the generation of a secreted form of recombinant 98P4B6 protein.  
     [0450] As discussed herein, redundancy in the genetic code permits variation in 98P4B6 gene sequences. In particular, it is known in the art that specific host species often have specific codon preferences, and thus one can adapt the disclosed sequence as preferred for a desired host. For example, preferred analog codon sequences typically have rare codons (i.e., codons having a usage frequency of less than about 20% in known sequences of the desired host) replaced with higher frequency codons. Codon preferences for a specific species are calculated, for example, by utilizing codon usage tables available on the INTERNET such as at URL dna.affrc.go.jp/˜nakamura/codon.html.  
     [0451] Additional sequence modifications are known to enhance protein expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon/intron splice site signals, transposon-like repeats, and/or other such well-characterized sequences that are deleterious to gene expression. The GC content of the sequence is adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Where possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Other useful modifications include the addition of a translational initiation consensus sequence at the start of the open reading frame, as described in Kozak,  Mol. Cell Biol.,  9:5073-5080 (1989). Skilled artisans understand that the general rule that eukaryotic ribosomes initiate translation exclusively at the 5′ proximal AUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS 92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).  
     [0452] III.) 98P4B6-Related Proteins  
     [0453] Another aspect of the present invention provides 98P4B6-related proteins. Specific embodiments of 98P4B6 proteins comprise a polypeptide having all or part of the amino acid sequence of human 98P4B6 as shown in FIG. 2 or FIG. 3. Alternatively, embodiments of 98P4B6 proteins comprise variant, homolog or analog polypeptides that have alterations in the amino acid sequence of 98P4B6 shown in FIG. 2 or FIG. 3.  
     [0454] Embodiments of a 98P4B6 polypeptide include: a 98P4B6 polypeptide having a sequence shown in FIG. 2, a peptide sequence of a 98P4B6 as shown in FIG. 2 wherein T is U; at least 10 contiguous nucleotides of a polypeptide having the sequence as shown in FIG. 2; or, at least 10 contiguous peptides of a polypeptide having the sequence as shown in FIG. 2 where T is U. For example, embodiments of 98P4B6 peptides comprise, without limitation:  
     [0455] (I) a protein comprising, consisting essentially of, or consisting of an amino acid sequence as shown in FIG. 2A-AL or FIGS.  3 A-J;  
     [0456] (II) a 98P4B6-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% homologous to an entire amino acid sequence shown in FIGS.  2 A-AL;  
     [0457] (III) a 98P4B6-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical to an entire amino acid sequence shown in FIG. 2A-AL or 3A-J;  
     [0458] (IV) a protein that comprises at least one peptide set forth in Tables VIII to XLIX, optionally with a proviso that it is not an entire protein of FIG. 2;  
     [0459] (V) a protein that comprises at least one peptide set forth in Tables VIII-XXI, collectively, which peptide is also set forth in Tables XXII to XLIX, collectively, optionally with a proviso that it is not an entire protein of FIG. 2;  
     [0460] (VI) a protein that comprises at least two peptides selected from the peptides set forth in Tables VIII-XLIX, optionally with a proviso that it is not an entire protein of FIG. 2;  
     [0461] (VII) a protein that comprises at least two peptides selected from the peptides set forth in Tables VIII to XLIX collectively, with a proviso that the protein is not a contiguous sequence from an amino acid sequence of FIG. 2;  
     [0462] (VIII) a protein that comprises at least one peptide selected from the peptides set forth in Tables VIII-XXI; and at least one peptide selected from the peptides set forth in Tables XXII to XLIX, with a proviso that the protein is not a contiguous sequence from an amino acid sequence of FIG. 2;  
     [0463] (IX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of FIGS. 3A, 3B,  3 C,  3 D,  3 E,  3 F,  3 G,  3 H,  3 I or  3 J in any whole number increment up to 454, 45, 419, 490, 576, 490, 454, 454, 576, or 490 respectively that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;  
     [0464] (X) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of FIGS. 3A, 3B,  3 C,  3 D,  3 E,  3 F,  3 G,  3 H,  3 I or  3 J in any whole number increment up to 454, 45, 419, 490, 576, 490, 454, 454, 576, or 490 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of FIG. 6;  
     [0465] (XI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of FIGS. 3A, 3B,  3 C,  3 D,  3 E,  3 F,  3 G,  3 H,  3 I or  3 J in any whole number increment up to 454, 45, 419, 490, 576, 490, 454, 454, 576, or 490 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27; 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;  
     [0466] (XII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of FIGS. 3A, 3B,  3 C,  3 D,  3 E,  3 F,  3 G,  3 H,  3 I or  3 J in any whole number increment up to 454, 45, 419, 490, 576, 490, 454, 454, 576, or 490 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;  
     [0467] (XIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, amino acids of a protein of FIGS. 3A, 3B,  3 C,  3 D,  3 E,  3 F,  3 G,  3 H,  3 I or  3 J in any whole number increment up to 454, 45, 419, 490, 576, 490, 454, 454, 576, or 490 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of FIG. 9;  
     [0468] (XIV) a peptide that occurs at least twice in Tables VIII-XXI and XXII to XLIX, collectively;  
     [0469] (XV) a peptide that occurs at least three times in Tables VIII-XXI and XXII to XLIX, collectively;  
     [0470] (XVI) a peptide that occurs at least four times in Tables VIII-XXI and XXII to XLIX, collectively;  
     [0471] (XVII) a peptide that occurs at least five times in Tables VIII-XXI and XXII to XLIX, collectively;  
     [0472] (XVIII) a peptide that occurs at least once in Tables VIII-XXI, and at least once in tables XXII to XLIX;  
     [0473] (XIX) a peptide that occurs at least once in Tables VIII-XXI, and at least twice in tables XXII to XLIX;  
     [0474] (XX) a peptide that occurs at least twice in Tables VIII-XXI, and at least once in tables XXII to XLIX;  
     [0475] (XXI) a peptide that occurs at least twice in Tables VIII-XXI, and at least twice in tables XXII to XLIX;  
     [0476] (XXII) a peptide which comprises one two, three, four, or five of the following characteristics, or an oligonucleotide encoding such peptide:  
     [0477] i) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of FIG. 5;  
     [0478] ii) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of FIG. 6;  
     [0479] iii) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of FIG. 7;  
     [0480] iv) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of FIG. 8; or,  
     [0481] v) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of FIG. 9;  
     [0482] (XXIII) a composition comprising a peptide of (I)-(XXII) or an antibody or binding region thereof together with a pharmaceutical excipient and/or in a human unit dose form.  
     [0483] (XXIV) a method of using a peptide of (I)-(XXII), or an antibody or binding region thereof or a composition of (XXIII) in a method to modulate a cell expressing 98P4B6,  
     [0484] (XXV) a method of using a peptide of (I)-(XXII) or an antibody or binding region thereof or a composition of (XXIII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 98P4B6  
     [0485] (XXVI) a method of using a peptide of (I)-(XXII) or an antibody or binding region thereof or a composition (XXIII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 98P4B6, said cell from a cancer of a tissue listed in Table I;  
     [0486] (XXVII) a method of using a peptide of (I)-(XXII) or an antibody or binding region thereof or a composition of (XXIII) in a method to diagnose, prophylax, prognose, or treat a a cancer;  
     [0487] (XXVIII) a method of using a peptide of (I)-(XXII) or an antibody or binding region thereof or a composition of (XXIII) in a method to diagnose, prophylax, prognose, or treat a a cancer of a tissue listed in Table I; and,  
     [0488] (XXIX) a method of using a a peptide of (I)-(XXII) or an antibody or binding region thereof or a composition (XXIII) in a method to identify or characterize a modulator of a cell expressing 98P4B6.  
     [0489] As used herein, a range is understood to specifically disclose all whole unit positions thereof.  
     [0490] Typical embodiments of the invention disclosed herein include 98P4B6 polynucleotides that encode specific portions of 98P4B6 mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:  
     [0491] (a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115 ,120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 410, 420, 430, 440, 450, or 454 more contiguous amino acids of 98P4B6 variant 1; the maximal lengths relevant for other variants are: variant 52, 45 amino acids; variant 5, 419 amino acids, variant 6, 490, variant 7, 576 amino acids, variant 8, 490 amino acids, variant 13, 454, variant 14, 454 amino acids, variant 21, 576 amino acids, and variant 25, 490 amino acids.  
     [0492] In general, naturally occurring allelic variants of human 98P4B6 share a high degree of structural identity and homology (e.g., 90% or more homology). Typically, allelic variants of a 98P4B6 protein contain conservative amino acid substitutions within the 98P4B6 sequences described herein or contain a substitution of an amino acid from a corresponding position in a homologue of 98P4B6. One class of 98P4B6 allelic variants are proteins that share a high degree of homology with at least a small region of a particular 98P4B6 amino acid sequence, but further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. In comparisons of protein sequences, the terms, similarity, identity, and homology each have a distinct meaning as appreciated in the field of genetics. Moreover, orthology and paralogy can be important concepts describing the relationship of members of a given protein family in one organism to the members of the same family in other organisms.  
     [0493] Amino acid abbreviations are provided in Table II. Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Proteins of the invention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 conservative substitutions. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (O) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK&#39;s of these two amino acid residues are not significant. Still other changes can be considered “conservative” in particular environments (see, e.g. Table III herein; pages 13-15 ““Biochemistry” 2 nd  ED. Lubert Stryer ed (Stanford University); Henikoff et al., PNAS 1992 Vol 89 10915-10919; Lei et al., J Biol Chem May 19, 1995; 270(20):11882-6).  
     [0494] Embodiments of the invention disclosed herein include a wide variety of art-accepted variants or analogs of 98P4B6 proteins such as polypeptides having amino acid insertions, deletions and substitutions. 98P4B6 variants can be made using methods known in the art such as site-directed mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter et al.,  Nucl. Acids Res.,  13:4331 (1986); Zoller et al.,  Nucl. Acids Res.,  10:6487 (1987)), cassette mutagenesis (Wells et al., Gene, 34:315 (1985)), restriction selection mutagenesis (Wells et al.,  Philos. Trans. R. Soc. London SerA,  317:415 (1986)) or other known techniques can be performed on the cloned DNA to produce the 98P4B6 variant DNA.  
     [0495] Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence that is involved in a specific biological activity such as a protein-protein interaction. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions (Creighton,  The Proteins,  (W. H. Freeman &amp; Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)). If alanine substitution does not yield adequate amounts of variant, an isosteric amino acid can be used.  
     [0496] As defined herein, 98P4B6 variants, analogs or homologs, have the distinguishing attribute of having at least one epitope that is “cross reactive” with a 98P4B6 protein having an amino acid sequence of FIG. 3. As used in this sentence, cross reactive” means that an antibody or T cell that specifically binds to a 98P4B6 variant also specifically binds to a 98P4B6 protein having an amino acid sequence set forth in FIG. 3. A polypeptide ceases to be a variant of a protein shown in FIG. 3, when it no longer contains any epitope capable of being recognized by an antibody or T cell that specifically binds to the starting 98P4B6 protein. Those skilled in the art understand that antibodies that recognize proteins bind to epitopes of varying size, and a grouping of the order of about four or five amino acids, contiguous or not, is regarded as a typical number of amino acids in a minimal epitope. See, e.g., Nair et al., J. Immunol 2000 165(12): 6949-6955; Hebbes et al., Mol Immunol (1989) 26(9):865-73; Schwartz et al., J Immunol (1985) 135(4):2598-608.  
     [0497] Other classes of 98P4B6-related protein variants share 70%, 75%, 80%, 85% or 90% or more similarity with an amino acid sequence of FIG. 3, or a fragment thereof. Another specific class of 98P4B6 protein variants or analogs comprises one or more of the 98P4B6 biological motifs described herein or presently known in the art. Thus, encompassed by the present invention are analogs of 98P4B6 fragments (nucleic or amino acid) that have altered functional (e.g. immunogenic) properties relative to the starting fragment. It is to be appreciated that motifs now or which become part of the art are to be applied to the nucleic or amino acid sequences of FIG. 2 or FIG. 3.  
     [0498] As discussed herein, embodiments of the claimed invention include polypeptides containing less than the full amino acid sequence of a 98P4B6 protein shown in FIG. 2 or FIG. 3. For example, representative embodiments of the invention comprise peptides/proteins having any 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of a 98P4B6 protein shown in FIG. 2 or FIG. 3.  
     [0499] Moreover, representative embodiments of the invention disclosed herein include polypeptides consisting of about amino acid 1 to about amino acid 10 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 10 to about amino acid 20 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 20 to about amino acid 30 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 30 to about amino acid 40 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 40 to about amino acid 50 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 50 to about amino acid 60 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 60 to about amino acid 70 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 70 to about amino acid 80 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 80 to about amino acid 90 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 90 to about amino acid 100 of a 98P4B6 protein shown in FIG. 2 or FIG. 3, etc. throughout the entirety of a 98P4B6 amino acid sequence. Moreover, polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 130, or 140 or 150 etc.) of a 98P4B6 protein shown in FIG. 2 or FIG. 3 are embodiments of the invention. It is to be appreciated that the starting and stopping positions in this paragraph refer to the specified position as well as that position plus or minus 5 residues.  
     [0500] 98P4B6-related proteins are generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a 98P4B6-related protein. In one embodiment, nucleic acid molecules provide a means to generate defined fragments of a 98P4B6 protein (or variants, homologs or analogs thereof).  
     [0501] III.A.) Motif-Bearing Protein Embodiments  
     [0502] Additional illustrative embodiments of the invention disclosed herein include 98P4B6 polypeptides comprising the amino acid residues of one or more of the biological motifs contained within a 98P4B6 polypeptide sequence set forth in FIG. 2 or FIG. 3. Various motifs are known in the art, and a protein can be evaluated for the presence of such motifs by a number of publicly available Internet sites (see, e.g., URL addresses: pfam.wustl.edu/; searchlauncher.bcm.tmc.edu/seq-search/struc-predict.html; psort.ims.u-tokyo.ac.jp/; cbs.dtu.dk/; ebi.ac.uk/interpro/scan.html; expasy.ch/tools/scnpsitl.html; Epimatrix™ and Epimer™, Brown University, brown.edu/ResearchfTB-HIVLablepimatrix/epimatrix.html; and BIMAS, bimas.dcrt.nih.gov/.).  
     [0503] Motif bearing subsequences of all 98P4B6 variant proteins are set forth and identified in Tables VIII-XXI and XXII-XLIX.  
     [0504] Table V sets forth several frequently occurring motifs based on pfam searches (see URL address pfam.wustl.edu/). The columns of Table V list (1) motif name abbreviation, (2) percent identity found amongst the different member of the motif family, (3) motif name or description and (4) most common function; location information is included if the motif is relevant for location.  
     [0505] Polypeptides comprising one or more of the 98P4B6 motifs discussed above are useful in elucidating the specific characteristics of a malignant phenotype in view of the observation that the 98P4B6 motifs discussed above are associated with growth dysregulation and because 98P4B6 is overexpressed in certain cancers (See, e.g., Table I). Casein kinase II, cAMP and camp-dependent protein kinase, and Protein Kinase C, for example, are enzymes known to be associated with the development of the malignant phenotype (see e.g. Chen et al., Lab Invest., 78(2): 165-174 (1998); Gaiddon et al., Endocrinology 136(10): 4331-4338 (1995); Hall et al., Nucleic Acids Research 24(6): 1119-1126 (1996); Peterziel et al., Oncogene 18(46): 6322-6329 (1999) and O&#39;Brian, Oncol. Rep. 5(2): 305-309 (1998)). Moreover, both glycosylation and myristoylation are protein modifications also associated with cancer and cancer progression (see e.g. Dennis et al., Biochem. Biophys. Acta 1473(1):21-34 (1999); Raju et al., Exp. Cell Res. 235(1): 145-154 (1997)). Amidation is another protein modification also associated with cancer and cancer progression (see e.g. Treston et al., J. Natl. Cancer Inst. Monogr. (13): 169-175 (1992)).  
     [0506] In another embodiment, proteins of the invention comprise one or more of the immunoreactive epitopes identified in accordance with art-accepted methods, such as the peptides set forth in Tables VIII-XXI and XXII-XLIX. CTL epitopes can be determined using specific algorithms to identify peptides within a 98P4B6 protein that are capable of optimally binding to specified HLA alleles (e.g., Table IV; Epimatrix™ and Epimer™, Brown University, URL brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html; and BIMAS, URL bimas.dcrt.nih.gov/.) Moreover, processes for identifying peptides that have sufficient binding affinity for HLA molecules and which are correlated with being immunogenic epitopes, are well known in the art, and are carried out without undue experimentation. In addition, processes for identifying peptides that are immunogenic epitopes, are well known in the art, and are carried out without undue experimentation either in vitro or in vivo.  
     [0507] Also known in the art are principles for creating analogs of such epitopes in order to modulate immunogenicity. For example, one begins with an epitope that bears a CTL or HTL motif (see, e.g., the HLA Class I and HLA Class II motifs/supermotifs of Table IV). The epitope is analoged by substituting out an amino acid at one of the specified positions, and replacing it with another amino acid specified for that position. For example, on the basis of residues defined in Table IV, one can substitute out a deleterious residue in favor of any other residue, such as a preferred residue; substitute a less-preferred residue with a preferred residue; or substitute an originally-occurring preferred residue with another preferred residue. Substitutions can occur at primary anchor positions or at other positions in a peptide; see, e.g., Table IV.  
     [0508] A variety of references reflect the art regarding the identification and generation of epitopes in a protein of interest as well as analogs thereof. See, for example, WO 97/33602 to Chesnut et al.; Sette, Immunogenetics 1999 50(3-4): 201-212; Sette et al., J. Immunol. 2001 166(2): 1389-1397; Sidney et al., Hum. Immunol. 1997 58(1): 12-20; Kondo et al., Immunogenetics 1997 45(4): 249-258; Sidney et al., J. Immunol. 1996 157(8): 3480-90; and Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et at., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)); Kast et al., 1994 152(8): 3904-12; Borras-Cuesta et at., Hum. Immunol. 2000 61(3): 266-278; Alexander et al., J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander et al., PMID: 7895164, UI: 95202582; O&#39;Sullivan et al, J. Immunol. 1991 147(8): 2663-2669; Alexander et al., Immunity 1994 1(9): 751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92.  
     [0509] Related embodiments of the invention include polypeptides comprising combinations of the different motifs set forth in Table VI, and/or, one or more of the predicted CTL epitopes of Tables VIII-XXI and XXII-XLIX, and/or, one or more of the predicted HTL epitopes of Tables XLVI-XLIX, and/or, one or more of the T cell binding motifs known in the art. Preferred embodiments contain no insertions, deletions or substitutions either within the motifs or within the intervening sequences of the polypeptides. In addition, embodiments which include a number of either N-terminal and/or C-terminal amino acid residues on either side of these motifs may be desirable (to, for example, include a greater portion of the polypeptide architecture in which the motif is located). Typically, the number of N-terminal and/or C-terminal amino acid residues on either side of a motif is between about 1 to about 100 amino acid residues, preferably 5 to about 50 amino acid residues.  
     [0510] 98P4B6-related proteins are embodied in many forms, preferably in isolated form. A purified 98P4B6 protein molecule will be substantially free of other proteins or molecules that impair the binding of 98P4B6 to antibody, T cell or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a 98P4B6-related proteins include purified 98P4B6-related proteins and functional, soluble 98P4B6-related proteins. In one embodiment, a functional, soluble 98P4B6 protein or fragment thereof retains the ability to be bound by antibody, T cell or other ligand.  
     [0511] The invention also provides 98P4B6 proteins comprising biologically active fragments of a 98P4B6 amino acid sequence shown in FIG. 2 or FIG. 3. Such proteins exhibit properties of the starting 98P4B6 protein, such as the ability to elicit the generation of antibodies that specifically bind an epitope associated with the starting 98P4B6 protein; to be bound by such antibodies; to elicit the activation of HTL or CTL; and/or, to be recognized by HTL or CTL that also specifically bind to the starting protein.  
     [0512] 98P4B6-related polypeptides that contain particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Gamier-Robson, Kyte-Doolitle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or based on immunogenicity. Fragments that contain such structures are particularly useful in generating subunit-specific anti-98P4B6 antibodies or T cells or in identifying cellular factors that bind to 98P4B6. For example, hydrophilicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Hopp, T. P. and Woods, K. R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Kyte, J. and Doolittle, R. F., 1982, J. Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can be generated, and immunogenic peptide fragments identified, using the method of Janin J., 1979, Nature 277:491-492. Average Flexibility profiles can be generated, and immunogenic peptide fragments identified, using the method of Bhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. Protein Res. 32:242-255. Beta-turn profiles can be generated, and immunogenic peptide fragments identified, using the method of Deleage, G., Roux B., 1987, Protein Engineering 1:289-294.  
     [0513] CTL epitopes can be determined using specific algorithms to identify peptides within a 98P4B6 protein that are capable of optimally binding to specified HLA alleles (e.g., by using the SYFPEITHI site at World Wide Web URL syfpeithi.bmi-heidelberg.com/; the listings in Table IV(A)-(E); Epimatrix™ and Epimer™, Brown University, URL (brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html); and BIMAS, URL bimas.dcrt.nih.gov/). Illustrating this, peptide epitopes from 98P4B6 that are presented in the context of human MHC Class I molecules, e.g., HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted (see, e.g., Tables VIII-XXI, XXII-XLIX). Specifically, the complete amino acid sequence of the 98P4B6 protein and relevant portions of other variants, i.e., for HLA Class I predictions 9 flanking residues on either side of a point mutation or exon juction, and for HLA Class II predictions 14 flanking residues on either side of a point mutation or exon junction corresponding to that variant, were entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) web site listed above; in addition to the site SYFPEITHI, at URL syfpeithi.bmi-heidelberg.com/.  
     [0514] The HLA peptide motif search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules, in particular HLA-A2 (see, e.g., Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as numerous other HLA Class I molecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers. For example, for Class I HLA-A2, the epitopes preferably contain a leucine (L) or methionine (M) at position 2 and a valine (V) or leucine (L) at the C-terminus (see, e.g., Parker et al., J. Immunol. 149:3580-7 (1992)). Selected results of 98P4B6 predicted binding peptides are shown in Tables VIII-XXI and XXII-XLIX herein. In Tables VIII-XXI and XXII-XLVII, selected candidates, 9-mers and 10-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. In Tables XLVI-XLIX, selected candidates, 15-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half time of dissociation of complexes containing the peptide at 37° C. at pH 6.5. Peptides with the highest binding score are predicted to be the most tightly bound to HLA Class I on the cell surface for the greatest period of time and thus represent the best immunogenic targets for T-cell recognition.  
     [0515] Actual binding of peptides to an HLA allele can be evaluated by stabilization of HLA expression on the antigen-processing defective cell line T2 (see, e.g., Xue et al., Prostate 30:73-8 (1997) and Peshwa et al., Prostate 36:129-38 (1998)). Immunogenicity of specific peptides can be evaluated in vitro by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of antigen presenting cells such as dendritic cells.  
     [0516] It is to be appreciated that every epitope predicted by the BIMAS site, Epimer™ and Epimatrix™ sites, or specified by the HLA class I or class II motifs available in the art or which become part of the art such as set forth in Table IV (or determined using World Wide Web site URL syfpeithi.bmi-heidelberg.com/, or BIMAS, bimas.dcrt.nih.gov/) are to be “applied” to a 98P4B6 protein in accordance with the invention. As used in this context “applied” means that a 98P4B6 protein is evaluated, e.g., visually or by computer-based patterns finding methods, as appreciated by those of skill in the relevant art. Every subsequence of a 98P4B6 protein of 8, 9, 10, or 11 amino acid residues that bears an HLA Class I motif, or a subsequence of 9 or more amino acid residues that bear an HLA Class II motif are within the scope of the invention.  
     [0517] III.B.) Expression of 98P4B6-Related Proteins  
     [0518] In an embodiment described in the examples that follow, 98P4B6 can be conveniently expressed in cells (such as 293T cells) transfected with a commercially available expression vector such as a CMV-driven expression vector encoding 98P4B6 with a C-terminal 6×His and MYC tag (pcDNA3.1/mycHIS, Invitrogen or Tag5, GenHunter Corporation, Nashville Tenn.). The Tag5 vector provides an IgGK secretion signal that can be used to facilitate the production of a secreted 98P4B6 protein in transfected cells. The secreted HIS-tagged 98P4B6 in the culture media can be purified, e.g., using a nickel column using standard techniques.  
     [0519] III.C.) Modifications of 98P4B6-Related Proteins  
     [0520] Modifications of 98P4B6-related proteins such as covalent modifications are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a 98P4B6 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of a 98P4B6 protein. Another type of covalent modification of a 98P4B6 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of a protein of the invention. Another type of covalent modification of 98P4B6 comprises linking a 98P4B6 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.  
     [0521] The 98P4B6-related proteins of the present invention can also be modified to form a chimeric molecule comprising 98P4B6 fused to another, heterologous polypeptide or amino acid sequence. Such a chimeric molecule can be synthesized chemically or recombinantly. A chimeric molecule can have a protein of the invention fused to another tumor-associated antigen or fragment thereof. Alternatively, a protein in accordance with the invention can comprise a fusion of fragments of a 98P4B6 sequence (amino or nucleic acid) such that a molecule is created that is not, through its length, directly homologous to the amino or nucleic acid sequences shown in FIG. 2 or FIG. 3. Such a chimeric molecule can comprise multiples of the same subsequence of 98P4B6. A chimeric molecule can comprise a fusion of a 98P4B6-related protein with a polyhistidine epitope tag, which provides an epitope to which immobilized nickel can selectively bind, with cytokines or with growth factors. The epitope tag is generally placed at the amino- or carboxyl-terminus of a 98P4B6 protein. In an alternative embodiment, the chimeric molecule can comprise a fusion of a 98P4B6-related protein with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an “immunoadhesin”), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a 98P4B6 polypeptide in place of at least one variable region within an Ig molecule. In a preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see, e.g., U.S. Pat. No. 5,428,130 issued Jun. 27, 1995.  
     [0522] III.D.) Uses of 98P4B6-Related Proteins  
     [0523] The proteins of the invention have a number of different specific uses. As 98P4B6 is highly expressed in prostate and other cancers, 98P4B6-related proteins are used in methods that assess the status of 98P4B6 gene products in normal versus cancerous tissues, thereby elucidating the malignant phenotype. Typically, polypeptides from specific regions of a 98P4B6 protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations etc.) in those regions (such as regions containing one or more motifs). Exemplary assays utilize antibodies or T cells targeting 98P4B6-related proteins comprising the amino acid residues of one or more of the biological motifs contained within a 98P4B6 polypeptide sequence in order to evaluate the characteristics of this region in normal versus cancerous tissues or to elicit an immune response to the epitope. Alternatively, 98P4B6-related proteins that contain the amino acid residues of one or more of the biological motifs in a 98P4B6 protein are used to screen for factors that interact with that region of 98P4B6.  
     [0524] 98P4B6 protein fragments/subsequences are particularly useful in generating and characterizing domain-specific antibodies (e.g., antibodies recognizing an extracellular or intracellular epitope of a 98P4B6 protein), for identifying agents or cellular factors that bind to 98P4B6 or a particular structural domain thereof, and in various therapeutic and diagnostic contexts, including but not limited to diagnostic assays, cancer vaccines and methods of preparing such vaccines.  
     [0525] Proteins encoded by the 98P4B6 genes, or by analogs, homologs or fragments thereof, have a variety of uses, including but not limited to generating antibodies and in methods for identifying ligands and other agents and cellular constituents that bind to a 98P4B6 gene product. Antibodies raised against a 98P4B6 protein or fragment thereof are useful in diagnostic and prognostic assays, and imaging methodologies in the management of human cancers characterized by expression of 98P4B6 protein, such as those listed in Table I. Such antibodies can be expressed intracellularly and used in methods of treating patients with such cancers. 98P4B6-related nucleic acids or proteins are also used in generating HTL or CTL responses.  
     [0526] Various immunological assays useful for the detection of 98P4B6 proteins are used, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), immunocytochemical methods, and the like. Antibodies can be labeled and used as immunological imaging reagents capable of detecting 98P4B6-expressing cells (e.g., in radioscintigraphic imaging methods). 98P4B6 proteins are also particularly useful in generating cancer vaccines, as further described herein.  
     [0527] IV.) 98P4B6 Antibodies  
     [0528] Another aspect of the invention provides antibodies that bind to 98P4B6-related proteins. Preferred antibodies specifically bind to a 98P4B6-related protein and do not bind (or bind weakly) to peptides or proteins that are not 98P4B6-related proteins under physiological conditions. In this context, examples of physiological conditions include: 1) phosphate buffered saline; 2) Tris-buffered saline containing 25 mM Tris and 150 mM NaCl; or normal saline (0.9% NaCl); 4) animal serum such as human serum; or, 5) a combination of any of 1) through 4); these reactions preferably taking place at pH 7.5, alternatively in a range of pH 7.0 to 8.0, or alternatively in a range of pH 6.5 to 8.5; also, these reactions taking place at a temperature between 4° C. to 37° C. For example, antibodies that bind 98P4B6 can bind 98P4B6-related proteins such as the homologs or analogs thereof.  
     [0529] 98P4B6 antibodies of the invention are particularly useful in cancer (see, e.g., Table I) diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibodies are useful in the treatment, diagnosis, and/or prognosis of other cancers, to the extent 98P4B6 is also expressed or overexpressed in these other cancers. Moreover, intracellularly expressed antibodies (e.g., single chain antibodies) are therapeutically useful in treating cancers in which the expression of 98P4B6 is involved, such as advanced or metastatic prostate cancers.  
     [0530] The invention also provides various immunological assays useful for the detection and quantification of 98P4B6 and mutant 98P4B6-related proteins. Such assays can comprise one or more 98P4B6 antibodies capable of recognizing and binding a 98P4B6-related protein, as appropriate. These assays are performed within various immunological assay formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like.  
     [0531] Immunological non-antibody assays of the invention also comprise T cell immunogenicity assays (inhibitory or stimulatory) as well as major histocompatibility complex (MHC) binding assays.  
     [0532] In addition, immunological imaging methods capable of detecting prostate cancer and other cancers expressing 98P4B6 are also provided by the invention, including but not limited to radioscintigraphic imaging methods using labeled 98P4B6 antibodies. Such assays are clinically useful in the detection, monitoring, and prognosis of 98P4B6 expressing cancers such as prostate cancer.  
     [0533] 98P4B6 antibodies are also used in methods for purifying a 98P4B6-related protein and for isolating 98P4B6 homologues and related molecules. For example, a method of purifying a 98P4B6-related protein comprises incubating a 98P4B6 antibody, which has been coupled to a solid matrix, with a lysate or other solution containing a 98P4B6-related protein under conditions that permit the 98P4B6 antibody to bind to the 98P4B6-related protein; washing the solid matrix to eliminate impurities; and eluting the 98P4B6-related protein from the coupled antibody. Other uses of 98P4B6 antibodies in accordance with the invention include generating anti-idiotypic antibodies that mimic a 98P4B6 protein.  
     [0534] Various methods for the preparation of antibodies are well known in the art. For example, antibodies can be prepared by immunizing a suitable mammalian host using a 98P4B6-related protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)). In addition, fusion proteins of 98P4B6 can also be used, such as a 98P4B6 GST-fusion protein. In a particular embodiment, a GST fusion protein comprising all or most of the amino acid sequence of FIG. 2 or FIG. 3 is produced, then used as an immunogen to generate appropriate antibodies. In another embodiment, a 98P4B6-related protein is synthesized and used as an immunogen.  
     [0535] In addition, naked DNA immunization techniques known in the art are used (with or without purified 98P4B6-related protein or 98P4B6 expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).  
     [0536] The amino acid sequence of a 98P4B6 protein as shown in FIG. 2 or FIG. 3 can be analyzed to select specific regions of the 98P4B6 protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of a 98P4B6 amino acid sequence are used to identify hydrophilic regions in the 98P4B6 structure. Regions of a 98P4B6 protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolitle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Hydrophilicity profiles can be generated using the method of Hopp, T. P. and Woods, K. R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can be generated using the method of Kyte, J. and Doolittle, R. F., 1982, J. Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can be generated using the method of Janin J., 1979, Nature 277:491-492. Average Flexibility profiles can be generated using the method of Bhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. Protein Res. 32:242-255. Beta-turn profiles can be generated using the method of Deleage, G., Roux B., 1987, Protein Engineering 1:289-294. Thus, each region identified by any of these programs or methods is within the scope of the present invention. Methods for the generation of 98P4B6 antibodies are further illustrated by way of the examples provided herein. Methods for preparing a protein or polypeptide for use as an immunogen are well known in the art. Also well known in the art are methods for preparing immunogenic conjugates of a protein with a carrier, such as BSA, KLH or other carrier protein. In some circumstances, direct conjugation using, for example, carbodiimide reagents are used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, Ill., are effective. Administration of a 98P4B6 immunogen is often conducted by injection over a suitable time period and with use of a suitable adjuvant, as is understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.  
     [0537] 98P4B6 monoclonal antibodies can be produced by various means well known in the art. For example, immortalized cell lines that secrete a desired monoclonal antibody are prepared using the standard hybridoma technology of Kohler and Milstein or modifications that immortalize antibody-producing B cells, as is generally known. Immortalized cell lines that secrete the desired antibodies are screened by immunoassay in which the antigen is a 98P4B6-related protein. When the appropriate immortalized cell culture is identified, the cells can be expanded and antibodies produced either from in vitro cultures or from ascites fluid.  
     [0538] The antibodies or fragments of the invention can also be produced, by recombinant means. Regions that bind specifically to the desired regions of a 98P4B6 protein can also be produced in the context of chimeric or complementarity-determining region (CDR) grafted antibodies of multiple species origin. Humanized or human 98P4B6 antibodies can also be produced, and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies, by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences, are well known (see for example, Jones et al, 1986, Nature 321: 522-525; Riechmann et at, 1988, Nature 332: 323-327; Verhoeyen et at., 1988, Science 239: 15341536). See also, Carter et at, 1993, Proc. Natl. Acad. Sci. USA 89: 4285 and Sims et at, 1993, J. Immunol. 151: 2296.  
     [0539] Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan et al., 1998, Nature Biotechnology 16: 535-539). Fully human 98P4B6 monoclonal antibodies can be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an in vitro immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from combinatorial libraries. Id., pp 65-82). Fully human 98P4B6 monoclonal antibodies can also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucherdapati and Jakobovits et al., published Dec. 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614; U.S. Pat. No. 6,162,963 issued Dec. 19, 2000; U.S. Pat. No. 6,150,584 issued Nov. 12, 2000; and, U.S. Pat. No. 6,114,598 issued Sep. 5, 2000). This method avoids the in vet manipulation required with phage display technology and efficiency produces high affinity authentic human antibodies.  
     [0540] Reactivity of 98P4B6 antibodies with a 98P4B6-related protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, 98P4B6-related proteins, 98P4B6-expressing cells or extracts thereof. A 98P4B6 antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more 98P4B6 epitopes are generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res. 53: 2560-2565).  
     [0541] V.) 98P4B6 Cellular Immune Responses  
     [0542] The mechanism by which T cells recognize antigens has been delineated. Efficacious peptide epitope vaccine compositions of the invention induce a therapeutic or prophylactic immune responses in very broad segments of the world-wide population. For an understanding of the value and efficacy of compositions of the invention that induce cellular immune responses, a brief review of immunology-related technology is provided.  
     [0543] A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al.,  Cell  47:1071, 1986; Babbitt, B. P. et al.,  Nature  317:359, 1985; Townsend, A. and Bodmer, H.,  Annu. Rev. Immunol.  7:601, 1989; Germain, R. N.,  Annu. Rev. Immunol.  11:403,1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are set forth in Table IV (see also, e.g., Southwood, et al.,  J. Immunol.  160:3363, 1998; Rammensee, et al,  Immunogenetics  41:178, 1995; Rammensee et at, SYFPEITHI, access via World Wide Web at URL (134.2.96.221/scripts.hlaserver.dll/home.htm); Selle, A. and Sidney,  J. Curr. Opin. Immunol.  10:478,1998; Engelhard, V. H.,  Curr. Opin. Immunol.  6:13,1994; Selte, A. and Grey, H. M.,  Curr. Opin. Immunol.  4:79,1992; Sinigaglia, F. and Hammer, J.  Curr. Biol.  6:52,1994; Ruppert et al.,  Cell  74:929-937, 1993; Kondo et al.,  J. Immunol.  155:4307-4312,1995; Sidney et al.,  J. Immunol.  157:3480-3490,1996; Sidney et al.,  Human Immunol.  45:79-93,1996; Sette, A. and Sidney, J.  Immunogenetics  November 1999; 50(3-4):201-12, Review).  
     [0544] Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft/groove of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D. R.  Annu. Rev. Immunol  13:587,1995; Smith, et al.,  Immunity  4:203, 1996; Fremont et al.,  Immunity  8:305,1998; Stern et al.,  Structure  2:245, 1994; Jones, E. Y.  Curr. Opin. Immunol.  9:75, 1997; Brown, J. H. et al.,  Nature  364:33, 1993; Guo, H. C. et al.,  Proc. Natl. Acad. Sci. USA  90:8053, 1993; Guo, H. C. et al.,  Nature  360:364, 1992; Silver, M. L. et al.,  Nature  360:367, 1992; Matsumura, M. et al.,  Science  257:927, 1992; Madden et al.,  Cell  70:1035, 1992; Fremont, D. H. et al.,  Science  257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D. C.,  J. Mol. Biol.  219:277, 1991.)  
     [0545] Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that are correlated with binding to particular HLA antigen(s).  
     [0546] Thus, by a process of HLA motif identification, candidates for epitope-based vaccines have been identified; such candidates can be further evaluated by HLA-peptide binding assays to determine binding affinity and/or the time period of association of the epitope and its corresponding HLA molecule. Additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, and/or immunogenicity.  
     [0547] Various strategies can be utilized to evaluate cellular immunogenicity, including:  
     [0548] 1) Evaluation of primary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. et al,  Mol. Immunol.  32:603, 1995; Celis, E. et al.,  Proc. Natl. Acad. Sci. USA  91:2105, 1994; Tsai, V. et al.,  J. Immunol.  158:1796, 1997; Kawashima, I. et al.,  Human Immunol.  59:1, 1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a lymphokine- or  51 Cr-release assay involving peptide sensitized target cells.  
     [0549] 2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. et al.,  J. Immunol.  26:97,1996; Wentworth, P. A. et al.,  Int. Immunol.  8:651, 1996; Alexander, J. et al.,  J. Immunol.  159:4753, 1997). For example, in such methods peptides in incomplete Freund&#39;s adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a  51 Cr-release assay involving peptide sensitized target cells and target, cells expressing endogenously generated antigen.  
     [0550] 3) Demonstration of recall T cell responses from immune individuals who have been either effectively vaccinated and/or from chronically ill patients (see, e.g., Rehermann, B. et al.,  J. Exp. Med.  181:1047, 1995; Doolan, D. L. et al.,  Immunity  7:97, 1997; Bertoni, R. et al.,  J. Clin. Invest  100:503, 1997; Threlkeld, S. C. et al.,  J. Immunol.  159:1648,1997; Diepolder, H. M. et al.,  J. Virol.  71:6011, 1997). Accordingly, recall responses are detected by culturing PBL from subjects that have been exposed to the antigen due to disease and thus have generated an immune response “naturally”, or from patients who were vaccinated against the antigen. PBL from subjects are cultured in vitro for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of “memory” T cells, as compared to “naive” T cells. At the end of the culture period, T cell activity is detected using assays including  51 Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.  
     [0551] VI.) 98P4B6 Transgenic Animals  
     [0552] Nucleic acids that encode a 98P4B6-related protein can also be used to generate either transgenic animals or “knock out” animals that, in turn, are useful in the development and screening of therapeutically useful reagents. In accordance with established techniques, cDNA encoding 98P4B6 can be used to clone genomic DNA that encodes 98P4B6. The cloned genomic sequences can then be used to generate transgenic animals containing cells that express DNA that encode 98P4B6. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Pat. No. 4,736,866 issued Apr. 12, 1988, and U.S. Pat. No. 4,870,009 issued Sep. 26, 1989. Typically, particular cells would be targeted for 98P4B6 transgene incorporation with tissue-specific enhancers.  
     [0553] Transgenic animals that include a copy of a transgene encoding 98P4B6 can be used to examine the effect of increased expression of DNA that encodes 98P4B6. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this aspect of the invention, an animal is treated with a reagent and a reduced incidence of a pathological condition, compared to untreated animals that bear the transgene, would indicate a potential therapeutic intervention for the pathological condition.  
     [0554] Alternatively, non-human homologues of 98P4B6 can be used to construct a 98P4B6 “knock out” animal that has a defective or altered gene encoding 98P4B6 as a result of homologous recombination between the endogenous gene encoding 98P4B6 and altered genomic DNA encoding 98P4B6 introduced into an embryonic cell of the animal. For example, cDNA that encodes 98P4B6 can be used to clone genomic DNA encoding 98P4B6 in accordance with established techniques. A portion of the genomic DNA encoding 98P4B6 can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see, e.g., Thomas and Capecchi,  Cell,  51:503 (1987) for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (see, e.g., Li et al.,  Cell,  69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras (see, e.g., Bradley, in  Teratocarcinomas and Embryonic Stem Cells: A Practical Approach,  E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal, and the embryo brought to term to create a “knock out” animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock out animals can be characterized, for example, for their ability to defend against certain pathological conditions or for their development of pathological conditions due to absence of a 98P4B6 polypeptide.  
     [0555] VII.) Methods for the Detection of 98P4B6  
     [0556] Another aspect of the present invention relates to methods for detecting 98P4B6 polynucleotides and 98P4B6-related proteins, as well as methods for identifying a cell that expresses 98P4B6. The expression profile of 98P4B6 makes it a diagnostic marker for metastasized disease. Accordingly, the status of 98P4B6 gene products provides information useful for predicting a variety of factors including susceptibility to advanced stage disease, rate of progression, and/or tumor aggressiveness. As discussed in detail herein, the status of 98P4B6 gene products in patient samples can be analyzed by a variety protocols that are well known in the art including immunohistochemical analysis, the variety of Northern blotting techniques including in situ hybridization, RT-PCR analysis (for example on laser capture micro-dissected samples), Western blot analysis and tissue array analysis.  
     [0557] More particularly, the invention provides assays for the detection of 98P4B6 polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable 98P4B6 polynucleotides include, for example, a 98P4B6 gene or fragment thereof, 98P4B6 mRNA, alternative splice variant 98P4B6 mRNAs, and recombinant DNA or RNA molecules that contain a 98P4B6 polynucleotide. A number of methods for amplifying and/or detecting the presence of 98P4B6 polynucleotides are well known in the art and can be employed in the practice of this aspect of the invention.  
     [0558] In one embodiment, a method for detecting a 98P4B6 mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using a 98P4B6 polynucleotides as sense and antisense primers to amplify 98P4B6 cDNAs therein; and detecting the presence of the amplified 98P4B6 cDNA. Optionally, the sequence of the amplified 98P4B6 cDNA can be determined.  
     [0559] In another embodiment, a method of detecting a 98P4B6 gene in a biological sample comprises first isolating genomic DNA from the sample; amplifying the isolated genomic DNA using 98P4B6 polynucleotides as sense and antisense primers; and detecting the presence of the amplified 98P4B6 gene. Any number of appropriate sense and antisense probe combinations can be designed from a 98P4B6 nucleotide sequence (see, e.g., FIG. 2) and used for this purpose.  
     [0560] The invention also provides assays for detecting the presence of a 98P4B6 protein in a tissue or other biological sample such as serum, semen, bone, prostate, urine, cell preparations, and the like. Methods for detecting a 98P4B6-related protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like. For example, a method of detecting the presence of a 98P4B6-related protein in a biological sample comprises first contacting the sample with a 98P4B6 antibody, a 98P4B6-reactive fragment thereof, or a recombinant protein containing an antigen-binding region of a 98P4B6 antibody; and then detecting the binding of 98P4B6-related protein in the sample.  
     [0561] Methods for identifying a cell that expresses 98P4B6 are also within the scope of the invention. In one embodiment, an assay for identifying a cell that expresses a 98P4B6 gene comprises detecting the presence of 98P4B6 mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays&#39; using complementary DNA probes (such as in situ hybridization using labeled 98P4B6 riboprobes, Northern blot and related techniques) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for 98P4B6, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell that expresses a 98P4B6 gene comprises detecting the presence of 98P4B6-related protein in the cell or secreted by the cell. Various methods for the detection of proteins are well known in the art and are employed for the detection of 98P4B6-related proteins and cells that express 98P4B6-related proteins.  
     [0562] 98P4B6 expression analysis is also useful as a tool for identifying and evaluating agents that modulate 98P4B6 gene expression. For example, 98P4B6 expression is significantly upregulated in prostate cancer, and is expressed in cancers of the tissues listed in Table I. Identification of a molecule or biological agent that inhibits 98P4B6 expression or over-expression in cancer cells is of therapeutic value. For example, such an agent can be identified by using a screen that quantifies 98P4B6 expression by RT-PCR, nucleic acid hybridization or antibody binding.  
     [0563] VII.) Methods for Monitoring the Status of 98P4B6-Related Genes and Their Products  
     [0564] Oncogenesis is known to be a multistep process where cellular growth becomes progressively dysregulated and cells progress from a normal physiological state to precancerous and then cancerous states (see, e.g., Alers et al., Lab Invest. 77(5): 437-438 (1997) and Isaacs et al., Cancer Surv. 23: 19-32 (1995)). In this context, examining a biological sample for evidence of dysregulated cell growth (such as aberrant 98P4B6 expression in cancers) allows for early detection of such aberrant physiology, before a pathologic state such as cancer has progressed to a stage that therapeutic options are more limited and or the prognosis is worse. In such examinations, the status of 98P4B6 in a biological sample of interest can be compared, for example, to the status of 98P4B6 in a corresponding normal sample (e.g. a sample from that individual or alternatively another individual that is not affected by a pathology). An alteration in the status of 98P4B6 in the biological sample (as compared to the normal sample) provides evidence of dysregulated cellular growth. In addition to using a biological sample that is not affected by a pathology as a normal sample, one can also use a predetermined normative value such as a predetermined normal level of mRNA expression (see, e.g., Grever et al., J. Comp. Neurol. Dec. 9, 1996; 376(2): 306-14 and U.S. Pat. No. 5,837,501) to compare 98P4B6 status in a sample.  
     [0565] The term “status” in this context is used according to its art accepted meaning and refers to the condition or state of a gene and its products. Typically, skilled artisans use a number of parameters to evaluate the condition or state of a gene and its products. These include, but are not limited to the location of expressed gene products (including the location of 98P4B6 expressing cells) as well as the level, and biological activity of expressed gene products (such as 98P4B6 mRNA, polynucleotides and polypeptides). Typically, an alteration in the status of 98P4B6 comprises a change in the location of 98P4B6 and/or 98P4B6 expressing cells and/or an increase in 98P4B6 mRNA and/or protein expression.  
     [0566] 98P4B6 status in a sample can be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, in situ hybridization, RT-PCR analysis on laser capture micro-dissected samples, Western blot analysis, and tissue array analysis. Typical protocols for evaluating the status of a 98P4B6 gene and gene products are found, for example in Ausubel et al. eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus, the status of 98P4B6 in a biological sample is evaluated by various methods utilized by skilled artisans including, but not limited to genomic Southern analysis (to examine, for example perturbations in a 98P4B6 gene), Northern analysis and/or PCR analysis of 98P4B6 mRNA (to examine, for example alterations in the polynucleotide sequences or expression levels of 98P4B6 mRNAs), and, Western and/or immunohistochemical analysis (to examine, for example alterations in polypeptide sequences, alterations in polypeptide localization within a sample, alterations in expression levels of 98P4B6 proteins and/or associations of 98P4B6 proteins with polypeptide binding partners). Detectable 98P4B6 polynucleotides include, for example, a 98P4B6 gene or fragment thereof, 98P4B6 mRNA, alternative splice variants, 98P4B6 mRNAs, and recombinant DNA or RNA molecules containing a 98P4B6 polynucleotide.  
     [0567] The expression profile of 98P4B6 makes it a diagnostic marker for local and/or metastasized disease, and provides information on the growth or oncogenic potential of a biological sample. In particular, the status of 98P4B6 provides information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining 98P4B6 status and diagnosing cancers that express 98P4B6, such as cancers of the tissues listed in Table I. For example, because 98P4B6 mRNA is so highly expressed in prostate and other cancers relative to normal prostate tissue, assays that evaluate the levels of 98P4B6 mRNA transcripts or proteins in a biological sample can be used to diagnose a disease associated with 98P4B6 dysregulation, and can provide prognostic information useful in defining appropriate therapeutic options.  
     [0568] The expression status of 98P4B6 provides information including the presence, stage and location of dysplastic, precancerous and cancerous cells, predicting susceptibility to various stages of disease, and/or for gauging tumor aggressiveness. Moreover, the expression profile makes it useful as an imaging reagent for metastasized disease. Consequently, an aspect of the invention is directed to the various molecular prognostic and diagnostic methods for examining the status of 98P4B6 in biological samples such as those from individuals suffering from, or suspected of suffering from a pathology characterized by dysregulated cellular growth, such as cancer.  
     [0569] As described above, the status of 98P4B6 in a biological sample can be examined by a number of well-known procedures in the art. For example, the status of 98P4B6 in a biological sample taken from a specific location in the body can be examined by evaluating the sample for the presence or absence of 98P4B6 expressing cells (e.g. those that express: 98P4B6 mRNAs or proteins). This examination can provide evidence of dysregulated cellular growth, for example, when 98P4B6-expressing cells are found in a biological sample that does not normally contain such cells (such as a lymph node), because such alterations in the status of 98P4B6 in a biological sample are often associated with dysregulated cellular growth. Specifically, one indicator of dysregulated cellular growth is the metastases of cancer cells from an organ of origin (such as the prostate) to a different area of the body (such as a lymph node). In this context, evidence of dysregulated cellular growth is important for example because occult lymph node metastases can be detected in a substantial proportion of patients with prostate cancer, and such metastases are associated with known predictors of disease progression (see, e.g., Murphy et al., Prostate 42(4): 315-317 (2000);Su et al., Semin. Surg. Oncol. 18(1): 17-28 (2000) and Freeman et al., J Urol August 1995 154(2 Pt 1):474-8).  
     [0570] In one aspect, the invention provides methods for monitoring 98P4B6 gene products by determining the status of 98P4B6 gene products expressed by cells from an individual suspected of having a disease associated with dysregulated cell growth (such as hyperplasia or cancer) and then comparing the status so determined to the status of 98P4B6 gene products in a corresponding normal sample. The presence of aberrant 98P4B6 gene products in the test sample relative to the normal sample provides an indication of the presence of dysregulated cell growth within the cells of the individual.  
     [0571] In another aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in 98P4B6 mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. The presence of 98P4B6 mRNA can, for example, be evaluated in tissues including but not limited to those listed in Table I. The presence of significant 98P4B6 expression in any of these tissues is useful to indicate the emergence, presence and/or severity of a cancer, since the corresponding normal tissues do not express 98P4B6 mRNA or express it at lower levels.  
     [0572] In a related embodiment, 98P4B6 status is determined at the protein level rather than at the nucleic acid level. For example, such a method comprises determining the level of 98P4B6 protein expressed by cells in a test tissue sample and comparing the level so determined to the level of 98P4B6 expressed in a corresponding normal sample. In one embodiment, the presence of 98P4B6 protein is evaluated, for example, using immunohistochemical methods. 98P4B6 antibodies or binding partners capable of detecting 98P4B6 protein expression are used in a variety of assay formats well known in the art for this purpose.  
     [0573] In a further embodiment, one can evaluate the status of 98P4B6 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules. These perturbations can include insertions, deletions, substitutions and the like. Such evaluations are useful because perturbations in the nucleotide and amino acid sequences are observed in a large number of proteins associated with a growth dysregulated phenotype (see, e.g., Marrogi et al., 1999, J. Cutan. Pathol. 26(8):369-378). For example, a mutation in the sequence of 98P4B6 may be indicative of the presence or promotion of a tumor. Such assays therefore have diagnostic and predictive value where a mutation in 98P4B6 indicates a potential loss of function or increase in tumor growth.  
     [0574] A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are well known in the art. For example, the size and structure of nucleic acid or amino acid sequences of 98P4B6 gene products are observed by the Northern, Southern, Western, PCR and DNA sequencing protocols discussed herein. In addition, other methods for observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Pat. No. 5,382,510 issued Sep. 7, 1999, and U.S. Pat. No. 5,952,170 issued Jan. 17, 1995).  
     [0575] Additionally, one can examine the methylation status of a 98P4B6 gene in a biological sample. Aberrant demethylation and/or hypermethylabon of CpG islands in gene 5′ regulatory regions frequently occurs in immortalized and transformed cells, and can result in altered expression of various genes. For example, promoter hypermethylation of the pi-class glutathione S-transferase (a protein expressed in normal prostate but not expressed in &gt;90% of prostate carcinomas) appears to permanently silence transcription of this gene and is the most frequently detected genomic alteration in prostate carcinomas (De Marzo et al., Am. J. Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration is present in at least 70% of cases of high-grade prostatic intraepithelial neoplasia (PIN) (Brooks et al., Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536). In another example, expression of the LAGE-I tumor specific gene (which is not expressed in normal prostate but is expressed in 25-50% of prostate cancers) is induced by deoxy-azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation (Lethe et al., Int. J. Cancer 76(6): 903-908 (1998)). A variety of assays for examining methylation status of a gene are well known in the art. For example, one can utilize, in Southern hybridization approaches, methylation-sensitive restriction enzymes that cannot cleave sequences that contain methylated CpG sites to assess the methylation status of CpG islands. In addition, MSP (methylation specific PCR) can rapidly profile the methylation status of all the CpG sites present in a CpG island of a given gene. This procedure involves initial modification of DNA by sodium bisulfite (which will convert all unmethylated cytosines to uracil) followed by amplification using primers specific for methylated versus unmethylated DNA. Protocols involving methylation interference can also be found for example in Current Protocols In Molecular Biology, Unit 12, Frederick M. Ausubel et al. eds., 1995.  
     [0576] Gene amplification is an additional method for assessing the status of 98P4B6. Gene amplification is measured in a sample directly, for example, by conventional Southern blotting or Northern blotting to quantitate the transcription of mRNA (Thomas, 1980, Proc. Natl. Acad. Sci. USA, 77:5201-5205), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies are employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn are labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.  
     [0577] Biopsied tissue or peripheral blood can be conveniently assayed for the presence of cancer cells using for example, Northern, dot blot or RT-PCR analysis to detect 98P4B6 expression. The presence of RT-PCR amplifiable 98P4B6 mRNA provides an indication of the presence of cancer. RT-PCR assays are well known in the art. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol. Res. 25:373-384; Ghossein et al., 1995, J. Clin. Oncol. 13:1195-2000; Heston et al., 1995, Clin. Chem. 41:1687-1688).  
     [0578] A further aspect of the invention is an assessment of the susceptibility that an individual has for developing cancer. In one embodiment, a method for predicting susceptibility to cancer comprises detecting 98P4B6 mRNA or 98P4B6 protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of 98P4B6 mRNA expression correlates to the degree of susceptibility. In a specific embodiment, the presence of 98P4B6 in prostate or other tissue is examined, with the presence of 98P4B6 in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor). Similarly, one can evaluate the integrity 98P4B6 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations in 98P4B6 gene products in the sample is an indication of cancer susceptibility (or the emergence or existence of a tumor).  
     [0579] The invention also comprises methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of 98P4B6 mRNA or 98P4B6 protein expressed by tumor cells, comparing the level so determined to the level of 98P4B6 mRNA or 98P4B6 protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of 98P4B6 mRNA or 98P4B6 protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness. In a specific embodiment, aggressiveness of a tumor is evaluated by determining the extent to which 98P4B6 is expressed in the tumor cells, with higher expression levels indicating more aggressive tumors. Another embodiment is the evaluation of the integrity of 98P4B6 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations indicates more aggressive tumors.  
     [0580] Another embodiment of the invention is directed to methods for observing the progression of a malignancy in an individual over time. In one embodiment, methods for observing the progression of a malignancy in an individual over time comprise determining the level of 98P4B6 mRNA or 98P4B6 protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of 98P4B6 mRNA or 98P4B6 protein expressed in an equivalent tissue sample taken from the same individual at a different time, wherein the degree of 98P4B6 mRNA or 98P4B6 protein expression in the tumor sample over time provides information on the progression of the cancer. In a specific embodiment, the progression of a cancer is evaluated by determining 98P4B6 expression in the tumor cells over time, where increased expression over time indicates a progression of the cancer. Also, one can evaluate the integrity 98P4B6 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like, where the presence of one or more perturbations indicates a progression of the cancer.  
     [0581] The above diagnostic approaches can be combined with any one of a wide variety of prognostic and diagnostic protocols known in the art. For example, another embodiment of the invention is directed to methods for observing a coincidence between the expression of 98P4B6 gene and 98P4B6 gene products (or perturbations in 98P4B6 gene and 98P4B6 gene products) and a factor that is associated with malignancy, as a means for diagnosing and prognosticating the status of a tissue sample. A wide variety of factors associated with malignancy can be utilized, such as the expression of genes associated with malignancy (e.g. PSA, PSCA and PSM expression for prostate cancer etc.) as well as gross cytological observations (see, e.g., Bocking et al., 1984, Anal. Quant. Cytol. 6(2):74-88; Epstein, 1995, Hum. Pathol. 26(2):223-9; Thorson et al., 1998, Mod. Pathol. 11 (6):543-51; Baisden et al., 1999, Am. J. Surg. Pathol. 23(8):918-24). Methods for observing a coincidence between the expression of 98P4B6 gene and 98P4B6 gene products (or perturbations in 98P4B6 gene and 98P4B6 gene products) and another factor that is associated with malignancy are useful, for example, because the presence of a set of specific factors that coincide with disease provides information crucial for diagnosing and prognosticating the status of a tissue sample.  
     [0582] In one embodiment, methods for observing a coincidence between the expression of 98P4B6 gene and 98P4B6 gene products (or perturbations in 98P4B6 gene and 98P4B6 gene products) and another factor associated with malignancy entails detecting the overexpression of 98P4B6 mRNA or protein in a tissue sample, detecting the overexpression of PSA mRNA or protein in a tissue sample (or PSCA or PSM expression), and observing a coincidence of 98P4B6 mRNA or protein and PSA mRNA or protein overexpression (or PSCA or PSM expression). In a specific embodiment, the expression of 98P4B6 and PSA mRNA in prostate tissue is examined, where the coincidence of 98P4B6 and PSA mRNA overexpression in the sample indicates the existence of prostate cancer, prostate cancer susceptibility or the emergence or status of a prostate tumor.  
     [0583] Methods for detecting and quantifying the expression of 98P4B6 mRNA or protein are described herein, and standard nucleic acid and protein detection and quantification technologies are well known in the art. Standard methods for the detection and quantification of 98P4B6 mRNA include in situ hybridization using labeled 98P4B6 riboprobes, Northern blot and related techniques using 98P4B6 polynucleotide probes, RT-PCR analysis using primers specific for 98P4B6, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR is used to detect and quantify 98P4B6 mRNA expression. Any number of primers capable of amplifying 98P4B6 can be used for this purpose, including but not limited to the various primer sets specifically described herein. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type 98P4B6 protein can be used in an immunohistochemical assay of biopsied tissue.  
     [0584] IX.) Identification of Molecules that Interact with 98P4B6  
     [0585] The 98P4B6 protein and nucleic acid sequences disclosed herein allow a skilled artisan to identify proteins, small molecules and other agents that interact with 98P4B6, as well as pathways activated by 98P4B6 via any one of a variety, of art accepted protocols. For example, one can utilize one of the so-called interaction trap systems (also referred to as the “two-hybrid assay”). In such systems, molecules interact and reconstitute a transcription factor which directs expression of a reporter gene, whereupon the expression of the reporter gene is assayed. Other systems identify protein-protein interactions in vivo through reconstitution of a eukaryotic transcriptional activator, see, e.g., U.S. Pat. No. 5,955,280 issued Sep. 21, 1999, U.S. Pat. No. 5,925,523 issued Jul. 20, 1999, U.S. Pat. No. 5,846,722 issued Dec. 8, 1998 and U.S. Pat. No. 6,004,746 issued Dec. 21, 1999. Algorithms are also available in the art for genome-based predictions of protein function (see, e.g., Marcotte, et al., Nature 402: 4 November 1999, 83-86).  
     [0586] Alternatively one can screen peptide libraries to identify molecules that interact with 98P4B6 protein sequences. In such methods, peptides that bind to 98P4B6 are identified by screening libraries that encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, the bacteriophage particles are then screened against the 98P4B6 protein(s).  
     [0587] Accordingly, peptides having a wide variety of uses, such as therapeutic, prognostic or diagnostic reagents, are thus identified without any prior information on the structure of the expected ligand or receptor molecule. Typical peptide libraries and screening methods that can be used to identify molecules that interact with 98P4B6 protein sequences are disclosed for example in U.S. Pat. No. 5,723,286 issued Mar. 3, 1998 and U.S. Pat. No. 5,733,731 issued Mar. 31, 1998.  
     [0588] Alternatively, cell lines that express 98P4B6 are used to identify protein-protein interactions mediated by 98P4B6. Such interactions can be examined using immunoprecipitation techniques (see, e.g., Hamilton B. J., et al. Biochem. Biophys. Res. Commun. 1999, 261:646-51). 98P4B6 protein can be immunoprecipitated from 98P4B6-expressing cell lines using anti-98P4B6 antibodies. Alternatively, antibodies against His-tag can be used in a cell line engineered to express fusions of 98P4B6 and a His-tag (vectors mentioned above). The immunoprecipitated complex can be examined for protein association by procedures such as Western blotting,  35 S-methionine labeling of proteins, protein microsequencing, silver staining and two-dimensional gel electrophoresis.  
     [0589] Small molecules and ligands that interact with 98P4B6 can be identified through related embodiments of such screening assays. For example, small molecules can be identified that interfere with protein function, including molecules that interfere with 98P4B6&#39;s ability to mediate phosphorylation and de-phosphorylation, interaction with DNA or RNA molecules as an indication of regulation of cell cycles, second messenger signaling or tumorigenesis. Similarly, small molecules that modulate 98P4B6-related ion channel, protein pump, or cell communication functions are identified and used to treat patients that have a cancer that expresses 98P4B6 (see, e.g., Hille, B., Ionic Channels of Excitable Membranes 2 nd  Ed., Sinauer Assoc., Sunderland, Mass., 1992). Moreover, ligands that regulate 98P4B6 function can be identified based on their ability to bind 98P4B6 and activate a reporter construct. Typical methods are discussed for example in U.S. Pat. No. 5,928,868 issued Jul. 27, 1999, and include methods for forming hybrid ligands in which at least one ligand is a small molecule. In an illustrative embodiment, cells engineered to express a fusion protein of 98P4B6 and a DNA-binding protein are used to co-express a fusion protein of a hybrid ligand/small molecule and a cDNA library transcriptional activator protein. The cells further contain a reporter gene, the expression of which is conditioned on the proximity of the first and second fusion proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cells that express the reporter gene are selected and the unknown small molecule or the unknown ligand is identified. This method provides a means of identifying modulators, which activate or inhibit 98P4B6.  
     [0590] An embodiment of this invention comprises a method of screening for a molecule that interacts with a 98P4B6 amino acid sequence shown in FIG. 2 or FIG. 3, comprising the steps of contacting a population of molecules with a 98P4B6 amino acid sequence, allowing the population of molecules and the 98P4B6 amino acid sequence to interact under conditions that facilitate an interaction, determining the presence of a molecule that interacts with the 98P4B6 amino acid sequence, and then separating molecules that do not interact with the 98P4B6 amino acid sequence from molecules that do. In a specific embodiment, the method further comprises purifying, characterizing and identifying a molecule that interacts with the 98P4B6 amino acid sequence. The identified molecule can be used to modulate a function performed by 98P4B6. In a preferred embodiment, the 98P4B6 amino acid sequence is contacted with a library of peptides.  
     [0591] X.) Therapeutic Methods and Compositions  
     [0592] The identification of 98P4B6 as a protein that is normally expressed in a restricted set of tissues, but which is also expressed in prostate and other cancers, opens a number of therapeutic approaches to the treatment of such cancers. As contemplated herein, 98P4B6 functions as a transcription factor involved in activating tumor-promoting genes or repressing genes that block tumorigenesis.  
     [0593] Accordingly, therapeutic approaches that inhibit the activity of a 98P4B6 protein are useful for patients suffering from a cancer that expresses 98P4B6. These therapeutic approaches generally fall into two classes. One class comprises various methods for inhibiting the binding or association of a 98P4B6 protein with its binding partner or with other proteins. Another class comprises a variety of methods for inhibiting the transcription of a 98P4B6 gene or translation of 98P4B6 mRNA.  
     [0594] X.A.) Anti-Cancer Vaccines  
     [0595] The invention provides cancer vaccines comprising a 98P4B6-related protein or 98P4B6-related nucleic acid. In view of the expression of 98P4B6, cancer vaccines prevent and/or treat 98P4B6-expressing cancers with minimal or no effects on non-target tissues. The use of a tumor antigen in a vaccine that generates humoral and/or cell-mediated immune responses as anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63:231-237; Fong et al., 1997, J. Immunol. 159:3113-3117).  
     [0596] Such methods can be readily practiced by employing a 98P4B6-related protein, or a 98P4B6-encoding nucleic acid molecule and recombinant vectors capable of expressing and presenting the 98P4B6 immunogen (which typically comprises a number of antibody or T cell epitopes). Skilled artisans understand that a wide variety of vaccine systems for delivery of immunoreactive epitopes are known in the art (see, e.g., Heryln et al., Ann Med February 1999 31(1):66-78; Maruyama et al., Cancer Immunol Immunother June 2000 49(3):123-32) Briefly, such methods of generating an immune response (e.g. humoral and/or cell-mediated) in a mammal, comprise the steps of: exposing the mammal&#39;s immune system to an immunoreactive epitope (e.g. an epitope present in a 98P4B6 protein shown in FIG. 3 or analog or homolog thereof) so that the mammal generates an immune response that is specific for that epitope (e.g. generates antibodies that specifically recognize that epitope). In a preferred method, a 98P4B6 immunogen contains a biological motif, see e.g., Tables VIII-XXI and XXII-XLIX, or a peptide of a size range from 98P4B6 indicated in FIG. 5, FIG. 6, FIG. 7, FIG. 8, and FIG. 9.  
     [0597] The entire 98P4B6 protein, immunogenic regions or epitopes thereof can be combined and delivered by various means. Such vaccine compositions can include, for example, lipopeptides (e.g., Vitiello, A. et al.,  J. Clin. Invest.  95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) (“PLG”) microspheres (see, e.g., Eldridge, et al.,  Molec. Immunol.  28:287-294, 1991: Alonso et al.,  Vaccine  12:299-306, 1994; Jones et al.,  Vaccine  13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al.,  Nature  344:873-875,1990; Hu et al.,  Clin Exp Immunol.  113:235-243,1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P.,  Proc. Natl. Acad. Sci. U.S.A.  85:5409-5413, 1988; Tam, J. P.,  J. Immunol. Methods  196:17-32,1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. et al., In:  Concepts in vaccine development,  Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. et al.,  Nature  320:535, 1986; Hu, S. L. et al.,  Nature  320:537, 1986; Kieny, M.-P. et al.,  AIDS Bio/Technology  4:790, 1986; Top, F. H. et al.,  J. Infect Dis.  124:148, 1971; Chanda, P. K. et al.,  Virology  175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. et al.,  J. Immunol. Methods.  192:25, 1996; Eldridge, J. H. et al.,  Sem. Hematol.  30:16, 1993; Falo, L. D., Jr. et al.,  Nature Med.  7:649,1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A.  Annu. Rev. Immunol.  4:369,1986; Gupta, R. K. et al.,  Vaccine  11:293, 1993), liposomes (Reddy, R. et al.,  J. Immunol.  148:1585, 1992; Rock, K. L.,  Immunol. Today  17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al.,  Science  259:1745,1993; Robinson, H. L., Hunt, L. A., and Webster, R. G.,  Vaccine  11:957, 1993; Shiver, J. W. et al., In:  Concepts in vaccine development,  Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A.,  Annu. Rev. Immunol.  12:923, 1994 and Eldridge, J. H. et al.,  Sem. Hematol.  30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Mass.) may also be used.  
     [0598] In patients with 98P4B6-associated cancer, the vaccine compositions of the invention can also be used in conjunction with other treatments used for cancer, e.g., surgery, chemotherapy, drug therapies, radiation therapies, etc. including use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and the like.  
     [0599] Cellular Vaccines:  
     [0600] CTL epitopes can be determined using specific algorithms to identify peptides within 98P4B6 protein that bind corresponding HLA alleles (see e.g., Table IV; Epimer™ and Epimatrix™, Brown University (URL brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html); and, BIMAS, (URL bimas.dcrt.nih.gov/; SYFPEITHI at URL syfpeithi.bmi-heidelberg.com/). In a preferred embodiment, a 98P4B6 immunogen contains one or more amino acid sequences identified using techniques well known in the art, such as the sequences shown in Tables VIII-XXI and XXII-XLIX or a peptide of 8, 9, 10 or 11 amino acids specified by an HLA Class I motif/supermotif (e.g., Table IV (A), Table IV (D), or Table IV (E)) and/or a peptide of at least 9 amino acids that comprises an HLA Class II motif/supermotif (e.g., Table IV (B) or Table IV (C)). As is appreciated in the art, the HLA Class I binding groove is essentially closed ended so that peptides of only a particular size range can fit into the groove and be bound, generally HLA Class I epitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLA Class II binding groove is essentially open ended; therefore a peptide of about 9 or more amino acids can be bound by an HLA Class II molecule. Due to the binding groove differences between HLA Class I and II, HLA Class I motifs are length specific, i.e., position two of a Class I motif is the second amino acid in an amino to carboxyl direction of the peptide. The amino acid positions in a Class II motif are relative only to each other, not the overall peptide, i.e., additional amino acids can be attached to the amino and/or carboxyl termini of a motif-bearing sequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than 25 amino acids.  
     [0601] Antibody-Based Vaccines  
     [0602] A wide variety of methods for generating an immune response in a mammal are known in the art (for example as the first step in the generation of hybridomas). Methods of generating an immune response in a mammal comprise exposing the mammal&#39;s immune system to an immunogenic epitope on a protein (e.g. a 98P4B6 protein) so that an immune response is generated. A typical embodiment consists of a method for generating an immune response to 98P4B6 in a host, by contacting the host with a sufficient amount of at least one 98P4B6 B cell or cytotoxic T-cell epitope or analog thereof; and at least one periodic interval thereafter re-contacting the host with the 98P4B6 B cell or cytotoxic T-cell epitope or analog thereof. A specific embodiment consists of a method of generating an immune response against a 98P4B6-related protein or a man-made multiepitopic peptide comprising: administering 98P4B6 immunogen (e.g. a 98P4B6 protein or a peptide fragment thereof, a 98P4B6 fusion protein or analog etc.) in a vaccine preparation to a human or another mammal. Typically, such vaccine preparations further contain a suitable adjuvant (see, e.g., U.S. Pat. No. 6,146,635) or a universal helper epitope such as a PADRE™ peptide (Epimmune Inc., San Diego, Calif.; see, e.g., Alexander et al., J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander et al., Immunity 1994 1(9): 751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92). An alternative method comprises generating an immune response in an individual against a 98P4B6 immunogen by: administering in vivo to muscle or skin of the individual&#39;s body a DNA molecule that comprises a DNA sequence that encodes a 98P4B6 immunogen, the DNA sequence operatively linked to regulatory sequences which control the expression of the DNA sequence; wherein the DNA molecule is taken up by cells, the DNA sequence is expressed in the cells and an immune response is generated against the immunogen (see, e.g., U.S. Pat. No. 5,962,428). Optionally a genetic vaccine facilitator such as anionic lipids; saponins; lectins; estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; and urea is also administered. In addition, an antiidiotypic antibody can be administered that mimics 98P4B6, in order to generate a response to the target antigen.  
     [0603] Nucleic Acid Vaccines:  
     [0604] Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA that encode protein(s) of the invention can be administered to a patient. Genetic immunization methods can be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing 98P4B6. Constructs comprising DNA encoding a 98P4B6-related protein/immunogen and appropriate regulatory sequences can be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded 98P4B6 protein/immunogen. Alternatively, a vaccine comprises a 98P4B6-related protein. Expression of the 98P4B6-related protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against cells that bear a 98P4B6 protein. Various prophylactic and therapeutic genetic immunization techniques known in the art can be used (for review, see information and references published at Internet address genweb.com). Nucleic acid-based delivery is described, for instance, in Wolff et. al.,  Science  247:1465 (1990) as well as U.S. Pat. Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720. Examples of DNA-based delivery technologies include “naked DNA”, facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated (“gene gun”) or pressure-mediated delivery (see, e.g., U.S. Pat. No. 5,922,687).  
     [0605] For therapeutic or prophylactic immunization purposes, proteins of the invention can be expressed via viral or bacterial vectors. Various viral gene delivery systems that can be used in the practice of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lent virus, and sindbis virus (see, e.g., Restifo, 1996, Curr. Opin. Immunol. 8:658-663; Tsang et al.  J. Natl. Cancer Inst.  87:982-990 (1995)). Non-viral delivery systems can also be employed by introducing naked DNA encoding a 98P4B6-related protein into the patient (e.g., intramuscularly or intradermally) to induce an anti-tumor response.  
     [0606] Vaccinia virus is used, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the protein immunogenic peptide, and thereby elicits a host immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al.,  Nature  351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, retroviral vectors,  Salmonella typhi  vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.  
     [0607] Thus, gene delivery systems are used to deliver a 98P4B6-related nucleic acid molecule. In one embodiment, the full-length human 98P4B6 cDNA is employed. In another embodiment, 98P4B6 nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopes are employed.  
     [0608] Ex Vivo Vaccines  
     [0609] Various ex vivo strategies can also be employed to generate an immune response. One approach involves the use of antigen presenting cells (APCs) such as dendritic cells (DC) to present 98P4B6 antigen to a patient&#39;s immune system. Dendritic cells express MHC class I and II molecules, B7 co-stimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients&#39; immune systems (Tjoa et al., 1996, Prostate 28:65-69; Murphy et al, 1996, Prostate 29:371-380). Thus, dendritic cells can be used to present 98P4B6 peptides to T cells in the context of MHC class I or II molecules. In one embodiment, autologous dendritic cells are pulsed with 98P4B6 peptides capable of binding to MHC class I and/or class II molecules. In another embodiment, dendritic cells are pulsed with the complete 98P4B6 protein. Yet another embodiment involves engineering the overexpression of a 98P4B6 gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur et al., 1997, Cancer Gene Ther. 4:17-25), retrovirus (Henderson et al., 1996, Cancer Res. 56:3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas et al., 1997, Cancer Res. 57:2865-2869), or tumor-derived RNA transfection (Ashley et al, 1997, J. Exp. Med. 186:1177-1182). Cells that express 98P4B6 can also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.  
     [0610] X.B.) 98P4B6 as a Target for Antibody-Based Therapy  
     [0611] 98P4B6 is an attractive target for antibody-based therapeutic strategies. A number of antibody strategies are known in the art for targeting both extracellular and intracellular molecules (see, e.g., complement and ADCC mediated killing as well as the use of intrabodies). Because 98P4B6 is expressed by cancer cells of various lineages relative to corresponding normal cells, systemic administration of 98P4B6-immunoreactive compositions are prepared that exhibit excellent sensitivity without toxic, non-specific and/or non-target effects caused by binding of the immunoreactive composition to non-target organs and tissues. Antibodies specifically reactive with domains of 98P4B6 are useful to treat 98P4B6-expressing cancers systemically, either as conjugates with a toxin or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.  
     [0612] 98P4B6 antibodies can be introduced into a patient such that the antibody binds to 98P4B6 and modulates a function, such as an interaction with a binding partner, and consequently mediates destruction of the tumor cells and/or inhibits the growth of the tumor cells. Mechanisms by which such antibodies exert a therapeutic effect can include: complement-mediated cytolysis, antibody-dependent cellular cytotoxicity, modulation of the physiological function of 98P4B6, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/or apoptosis.  
     [0613] Those skilled in the art understand that antibodies can be used to specifically target and bind immunogenic molecules such as an immunogenic region of a 98P4B6 sequence shown in FIG. 2 or FIG. 3. In addition, skilled artisans understand that it is routine to conjugate antibodies to cytotoxic agents (see, e.g., Slevers et al.  Blood  93:11 3678-3684: (Jun. 1, 1999)). When cytotoxic and/or therapeutic agents are delivered directly to cells, such as by conjugating them to antibodies specific for a molecule expressed by that cell (e.g. 98P4B6), the cytotoxic agent will exert its known biological effect (i.e. cytotoxicity) on those cells.  
     [0614] A wide variety of compositions and methods for using antibody-cytotoxic agent conjugates to kill cells are known in the art. In the context of cancers, typical methods entail administering to an animal having a tumor a biologically effective amount of a conjugate comprising a selected cytotoxic and/or therapeutic agent linked to a targeting agent (e.g. an anti-98P4B6 antibody) that binds to a marker (e.g. 98P4B6) expressed, accessible to binding or localized on the cell surfaces. A typical embodiment is a method of delivering a cytotoxic and/or therapeutic agent to a cell expressing 98P4B6, comprising conjugating the cytotoxic agent to an antibody that immunospecifically binds to a 98P4B6 epitope, and, exposing the cell to the antibody-agent conjugate. Another illustrative embodiment is a method of treating an individual suspected of suffering from metastasized cancer, comprising a step of administering parenterally to said individual a pharmaceutical composition comprising a therapeutically effective amount of an antibody conjugated to a cytotoxic and/or therapeutic agent.  
     [0615] Cancer immunotherapy using anti-98P4B6 antibodies can be done in accordance with various approaches that have been successfully employed in the treatment of other types of cancer, including but not limited to colon cancer (Arlen et al., 1998, Crit. Rev. Immunol. 18:133-138), multiple myeloma (Ozaki et al., 1997, Blood 90:3179-3186, Tsunenari et al., 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong et al., 1996, Leuk. Res. 20:581-589), colorectal cancer (Moun et al., 1994, Cancer Res. 54:6160-6166; Velders et al., 1995, Cancer Res. 55:4398-4403), and breast cancer (Shepard et al., 1991, J. Clin. Immunol. 11:117-127). Some therapeutic approaches involve conjugation of naked antibody to a toxin or radioisotope, such as the conjugation of Y 91  or I 131  to anti-CD20 antibodies (e.g., Zevalin™, IDEG Pharmaceuticals Corp. or Bexxar™, Coulter Pharmaceuticals), while others involve co-administration of antibodies and other therapeutic agents, such as Herceptin™ (trastuzumab) with paclitaxel (Genentech, Inc.). The antibodies can be conjugated to a therapeutic agent. To treat prostate cancer, for example, 98P4B6 antibodies can be administered in conjunction with radiation, chemotherapy or hormone ablation. Also, antibodies can be conjugated to a toxin such as calicheamicin (e.g., Mylotarg™, Wyeth-Ayerst, Madison, N.J., a recombinant humanized IgG4 kappa antibody conjugated to antitumor antibiotic calicheamicin) or a maytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platform, ImmunoGen, Cambridge, Mass., also see e.g., U.S. Pat. No. 5,416,064).  
     [0616] Although 98P4B6 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well. Fan et al. (Cancer Res. 53:4637-4642, 1993), Prewett et al. (International J. of Onco. 9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991) describe the use of various antibodies together with chemotherapeutic agents.  
     [0617] Although 98P4B6 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well.  
     [0618] Cancer patients can be evaluated for the presence and level of 98P4B6 expression, preferably using immunohistochemical assessments of tumor tissue, quantitative 98P4B6 imaging, or other techniques that reliably indicate the presence and degree of 98P4B6 expression. Immunohistochemical analysis of tumor biopsies or surgical specimens is preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.  
     [0619] Anti-98P4B6 monoclonal antibodies that treat prostate and other cancers include those that initiate a potent immune response against the tumor or those that are directly cytotoxic. In this regard, anti-98P4B6 monoclonal antibodies (mAbs) can elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites on complement proteins. In addition, anti-98P4B6 mAbs that exert a direct biological effect on tumor growth are useful to treat cancers that express 98P4B6. Mechanisms by which directly cytotoxic mAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism(s) by which a particular anti-98P4B6 mAb exerts an anti-tumor effect is evaluated using any number of in vitro assays that evaluate cell death such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.  
     [0620] In some patients, the use of murine or other non-human monoclonal antibodies, or human/mouse chimeric mAbs can induce moderate to strong immune responses against the non-human antibody. This can result in clearance of the antibody from circulation and reduced efficacy. In the most severe cases, such an immune response can lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the therapeutic methods of the invention are those that are either fully human or humanized and that bind specifically to the target 98P4B6 antigen with high affinity but exhibit low or no antigenicity in the patient.  
     [0621] Therapeutic methods of the invention contemplate the administration of single anti-98P4B6 mAbs as well as combinations, or cocktails, of different mAbs. Such mAb cocktails can have certain advantages inasmuch as they contain mAbs that target different epitopes, exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination can exhibit synergistic therapeutic effects. In addition, anti-98P4B6 mAbs can be administered concomitantly with other therapeutic modalities, including but not limited to various chemotherapeutic agents, androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery or radiation. The anti-98P4B6 mAbs are administered in their “naked” or unconjugated form, or can have a therapeutic agent(s) conjugated to them.  
     [0622] Anti-98P4B6 antibody formulations are administered via any route capable of delivering the antibodies to a tumor cell. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Treatment generally involves repeated administration of the anti-98P4B6 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of 10-1000 mg mAb per week are effective and well tolerated.  
     [0623] Based on clinical experience with the Herceptin™ mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-98P4B6 mAb preparation represents an acceptable dosing regimen. Preferably, the initial loading dose is administered as a 90-minute or longer infusion. The periodic maintenance dose is administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. As appreciated by those of skill in the art, various factors can influence the ideal dose regimen in a particular case. Such factors include, for example, the binding affinity and half life of the Ab or mAbs used, the degree of 98P4B6 expression in the patient, the extent of circulating shed 98P4B6 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient.  
     [0624] Optionally, patients should be evaluated for the levels of 98P4B6 in a given sample (e.g. the levels of circulating 98P4B6 antigen and/or 98P4B6 expressing cells) in order to assist in the determination of the most effective dosing regimen, etc. Such evaluations are also used for monitoring purposes throughout therapy, and are useful to gauge therapeutic success in combination with the evaluation of other parameters (for example, urine cytology and/or ImmunoCyt levels in bladder cancer therapy, or by analogy, serum PSA levels in prostate cancer therapy).  
     [0625] Anti-idiotypic anti-98P4B6 antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a 98P4B6-related protein. In particular, the generation of anti-idiotypic antibodies is well known in the art; this methodology can readily be adapted to generate anti-idiotypic anti-98P4B6 antibodies that mimic an epitope on a 98P4B6-related protein (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J. Clin. Invest. 96:334-342; Herlyn et al., 1996, Cancer Immunol. Immunother. 43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccine strategies.  
     [0626] X.C.) 98P4B6 as a Target for Cellular Immune Responses  
     [0627] Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more HLA-binding peptides as described herein are further embodiments of the invention. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptides. A peptide can be present in a vaccine individually. Alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, e.g., recombinantly or by chemical synthesis.  
     [0628] Carriers that can be used with vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (i.e., acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund&#39;s adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P 3 CSS). Moreover, an adjuvant such as a synthetic cytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotides has been found to increase CTL responses 10- to 100-fold. (see, e.g. Davila and Celis, J. Immunol. 165:539-547 (2000))  
     [0629] Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later development of cells that express or overexpress 98P4B6 antigen, or derives at least some therapeutic benefit when the antigen was tumor-associated.  
     [0630] In some embodiments, it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody and or helper T cell responses directed to the target antigen. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the invention, along with a cross reactive HTL epitope such as PADRE™ (Epimmune, San Diego, Calif.) molecule (described e.g., in U.S. Pat. No. 5,736,142).  
     [0631] A vaccine of the invention can also include antigen-presenting cells (APC), such as dendritic cells (DC), as a vehicle to present peptides of the invention. Vaccine compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro. For example, dendritic cells are transfected, e.g., with a minigene in accordance with the invention, or are pulsed with peptides. The dendritic cell can then be administered to a patient to elicit immune responses in vivo. Vaccine compositions, either DNA- or peptide-based; can also be administered in vivo in combination with dendritic cell mobilization whereby loading of dendritic cells occurs in vivo.  
     [0632] Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polyepitopic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles be balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.  
     [0633] 1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For HLA Class I this includes 3-4 epitopes that come from at least one tumor associated antigen (TM). For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one TM (see, e.g., Rosenberg et al., Science 278:1447-1450). Epitopes from one TM may be used in combination with epitopes from one or more additional TMs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TMs.  
     [0634] 2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC 50  of 500 nM or less, often 200 nM or less; and for Class II an IC 50  of 1000 nM or less.  
     [0635] 3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage.  
     [0636] 4.) When selecting epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope.  
     [0637] 5.) Of particular relevance are epitopes referred to as “nested epitopes.” Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise B cell, HLA class I and/or HLA class II epitopes. When providing nested epitopes, a general objective is to provide the greatest number of epitopes per sequence. Thus, an aspect is to avoid providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a multi-epitopic sequence, such as a sequence comprising nested epitopes, it is generally important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties.  
     [0638] 6.) If a polyepitopic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed when selecting a peptide comprising nested epitopes. However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopesy, or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a “dominant epitope.” A dominant epitope may lead to such a zealous response that immune responses to other epitopes are: diminished or suppressed.  
     [0639] 7.) Where the sequences of multiple variants of the same target protein are present, potential peptide epitopes can also be selected on the basis of their conservancy. For example, a criterion for conservancy may define that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide be conserved in a designated percentage of the sequences evaluated for a specific protein antigen.  
     [0640] X.C.1. Minigene Vaccines  
     [0641] A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention.  
     [0642] The use of multi-epitope minigenes is described below and in, Ishioka et al.,  J. Immunol.  162:3915-3925, 1999; An, L. and Whitton, J. L.,  J. Virol.  71:2292, 1997; Thomson, S. A. et al.,  J. Immunol.  157:822, 1996; Whitton, J. L. et al.,  J. Virol.  67:348, 1993; Hanke, R. et al.,  Vaccine  16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing epitopes derived 98P4B6, the PADRES universal helper T cell epitope or multiple HTL epitopes from 98P4B6 (see e.g., Tables VIII-XXI and XXII to XLIX), and an endoplasmic reticulum-translocating signal sequence can be engineered. A vaccine may also comprise epitopes that are derived from other TAAs.  
     [0643] The immunogenicity of a multi-epitopic minigene can be confirmed in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes in vivo can be correlated with the in vitro responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes.  
     [0644] For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, antibody epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences. adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention.  
     [0645] The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.  
     [0646] Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an  E. coli  origin of replication; and an  E. coli  selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Pat. Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.  
     [0647] Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.  
     [0648] Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate  E. coli  strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.  
     [0649] In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity.  
     [0650] In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LeIF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego, Calif.). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF-β) may be beneficial in certain diseases.  
     [0651] Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in  E. coli , followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well-known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, Calif.). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.  
     [0652] Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as “naked DNA,” is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino &amp; Gould-Fogerite,  BioTechniques  6(7): 682 (1988); U.S. Pat. No. 5,279,833; WO 91/06309; and Felgner, et al.,  Proc. Natl. Acad. Sci. USA  84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.  
     [0653] Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for “naked” DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 ( 51 Cr) labeled and used as target cells for epitope-specific CTL lines; cytolysis, detected by  51 Cr release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.  
     [0654] In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded,  51 Cr-labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for in vivo induction of CTLs. Immunogenicity of HTL epitopes is confirmed in transgenic mice in an analogous manner.  
     [0655] Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Pat. No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles.  
     [0656] Minigenes can also be delivered using other bacterial or viral delivery systems well known in the art, e.g., an expression construct encoding epitopes of the invention can be incorporated into a viral vector such as vaccinia.  
     [0657] X.C.2. Combinations of CTL Peptides with Helper Peptides  
     [0658] Vaccine compositions comprising CTL peptides of the invention can be modified, e.g., analoged, to provide desired attributes, such as improved serum half life, broadened population coverage or enhanced immunogenicity.  
     [0659] For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.  
     [0660] In certain-embodiments, the T helper peptide is one that is recognized by T helper cells present in a majority of a genetically diverse population. This can be accomplished by selecting peptides that bind to many, most, or all of the HLA class II molecules. Examples of such amino acid bind many HLA Class II molecules include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO: 97),  Plasmodium falciparum  circumsporozoite (CS) protein at positions 378-398 (DIEKKIAKMEKASSVFNVVNS; SEQ ID NO: 98), and Streptococcus 18 kD protein at positions 116-131 (GAVDSILGGVATYGAA; SEQ ID NO: 99). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.  
     [0661] Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (see, e.g., PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (e.g., PADRE™M, Epimmune, Inc., San Diego, Calif.) are designed, most preferably, to bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: XKXVAAWTLKAAX (SEQ ID NO: 100), where “X” is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all “L” natural amino acids and can be provided in the form of nucleic acids that encode the epitope.  
     [0662] HTL peptide epitopes can also be modified to alter their biological properties. For example, they can be modified to include D-amino acids to increase their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, proteins, carbohydrates, and the like to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini.  
     [0663] X.C.3. Combinations of CTL Peptides with T Cell Priming Agents  
     [0664] In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes B lymphocytes or T lymphocytes. Lipids have been identified as agents capable of priming CTL in vivo. For example, palmitic acid residues can be attached to the ε- and α-amino groups of a lysine residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund&#39;s adjuvant. In a preferred embodiment, a particularly effective immunogenic composition comprises palmitic acid attached to ε- and α-amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.  
     [0665] As another example of lipid priming of CTL responses,  E. coli  lipoproteins, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P 3 CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide (see, e.g., Deres, et al.,  Nature  342:561, 1989). Peptides of the invention can be coupled to P 3 CSS, for example, and the lipopeptide administered to an individual to prime specifically an immune response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P 3 CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses.  
     [0666] X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides  
     [0667] An embodiment of a vaccine composition in accordance with the invention comprises ex vivo administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient&#39;s blood. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Pharmacia-Monsanto, St. Louis, Mo.) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces.  
     [0668] The DC can be pulsed ex vivo with a cocktail of peptides, some of which stimulate CTL responses to 98P4B6. Optionally, a helper T cell (HTL) peptide, such as a natural or artificial loosely restricted HLA Class II peptide, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention is used to treat a cancer which expresses or overexpresses 98P4B6.  
     [0669] X.D. Adoptive Immunotherapy  
     [0670] Antigenic 98P4B6-related peptides are used to elicit a CTL and/or HTL response ex vivo, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. Ex vivo CTL or HTL responses to a particular antigen are induced by incubating in tissue culture the patient&#39;s, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (e.g., a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.  
     [0671] X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes  
     [0672] Pharmaceutical and vaccine compositions of the invention are typically used to treat and/or prevent a cancer that expresses or overexpresses 98P4B6. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective B cell, CTL and/or HTL response to the antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.  
     [0673] For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already bearing a tumor that expresses 98P4B6. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Patients can be treated with the immunogenic peptides separately or in conjunction with other treatments, such as surgery, as appropriate.  
     [0674] For therapeutic use, administration should generally begin at the first diagnosis of 98P4B6-associated cancer. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. The embodiment of the vaccine composition (i.e., including, but not limited to embodiments such as peptide cocktails, polyepitopic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary according to the stage of the disease or the patient&#39;s health status. For example, in a patient with a tumor that expresses 98P4B6, a vaccine comprising 98P4B6-specific CTL may be more efficacious in killing tumor cells in patient with advanced disease than alternative embodiments.  
     [0675] It is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to stimulate effectively a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention.  
     [0676] The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0 μg to about 50,000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient&#39;s response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient&#39;s blood. Administration should continue until at least clinical symptoms or laboratory tests indicate that the neoplasia, has been eliminated or reduced and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.  
     [0677] In certain embodiments, the peptides and compositions of the present invention are employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.  
     [0678] The vaccine compositions of the invention can also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. This is followed by boosting dosages of between about, 1.0 μg to about 50,000 μg of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient&#39;s blood.  
     [0679] The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, nasal, intrathecal, or local (e.g. as a cream or topical ointment) administration. Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.  
     [0680] A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.  
     [0681] The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.  
     [0682] The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.  
     [0683] A human unit dose form of a composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable carrier, in one embodiment an aqueous carrier, and is administered in a volume/quantity that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington&#39;s Pharmaceutical Sciences, 17 th  Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pa., 1985). For example a peptide dose for initial immunization can be from about 1 to about 50,000 μg, generally 100-5,000 μg, for a 70 kg patient. For example, for nucleic acids an initial immunization may be performed using an expression vector in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of 5-10 7  to 5×10 9  pfu.  
     [0684] For antibodies, a treatment generally involves repeated administration of the anti-98P4B6 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. In general, doses in the range of 10-500 mg mAb per week are effective and well tolerated. Moreover, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-98P4B6 mAb preparation represents an acceptable dosing regimen. As appreciated by those of skill in the art, various factors can influence the ideal dose in a particular case. Such factors include, for example, half life of a composition, the binding affinity of an Ab, the immunogenicity of a substance, the degree of 98P4B6 expression in the patient, the extent of circulating shed 98P4B6 antigen, the desired steady-state concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient. Non-limiting preferred human unit doses are, for example, 500 μg-1 mg, 1 mg-50 mg, 50 mg-100 mg, 100 mg-200 mg, 200 mg-300 mg, 400 mg-500 mg, 500 mg-600 mg, 600 mg-700 mg, 700 mg-800 mg, 800 mg-900 mg, 900 mg-1 g, or 1 mg-700 mg. In certain embodiments, the dose is in a range of 2-5 mg/kg body weight, e.g., with follow on weekly doses of 1-3 mg/kg; 0.5 mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg/kg body weight followed, e.g., in two, three or four weeks by weekly doses; 0.5-10 mg/kg body weight, e.g., followed in two, three or four weeks by weekly doses; 225, 250, 275, 300, 325, 350, 375, 400 mg m 2  of body area weekly; 1-600 mg m 2  of body area weekly; 225-400 mg m 2  of body area weekly; these does can be followed by weekly doses for 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12 or more weeks.  
     [0685] In one embodiment, human unit dose forms of polynucleotides comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art a therapeutic effect depends on a number of factors, including the sequence of the polynucleotide, molecular weight of the polynucleotide and route of administration. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. Generally, for a polynucleotide of about 20 bases, a dosage range may be selected from, for example, an independently selected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 500 mg/kg up to an independently selected upper limit, greater than the lower limit, of about 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dose may be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200 to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to 500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg. Generally, parenteral routes of administration may require higher doses of polynucleotide compared to more direct application to the nucleotide to diseased tissue, as do polynucleotides of increasing length.  
     [0686] In one embodiment, human unit dose forms of T-cells comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art, a therapeutic effect depends on a number of factors. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. A dose may be about 10 4  cells to about 10 6  cells, about 10 6  cells to about 10 8  cells, about 10 8  to about 10 11  cells, or about 10 8  to about 5×10 10  cells. A dose may also about 10 6  cells/m 2  to about 10 10  cells/m 2 , or about 10 6  cells/m 2  to about 10 8  cells/m 2 .  
     [0687] Proteins(s) of the invention, and/or nucleic acids encoding the protein(s), can also be administered via liposomes, which may also serve to: 1) target the proteins(s) to a particular tissue, such as lymphoid tissue; 2) to target selectively to diseases cells; or, 3) to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al.,  Ann. Rev. Biophys. Bioeng.  9:467 (1980), and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.  
     [0688] For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.  
     [0689] For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.  
     [0690] For aerosol administration, immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are about 0.01%-20% by weight, preferably about 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from about 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute about 0.1%-20% by weight of the composition, preferably about 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.  
     [0691] XI.) Diagnostic and Prognostic Embodiments of 98P4B6.  
     [0692] As disclosed herein, 98P4B6 polynucleotides, polypeptides, reactive cytotoxic T cells (CTL), reactive helper T cells (HTL) and anti-polypeptide antibodies are used in well known diagnostic, prognostic and therapeutic assays that examine conditions associated with dysregulated cell growth such as cancer, in particular the cancers listed in Table I (see, e.g., both its specific pattern of tissue expression as well as its overexpression in certain cancers as described for example in the Example entitled “Expression analysis of 98P4B6 in normal tissues, and patient specimens”).  
     [0693] 98P4B6 can be analogized to a prostate associated antigen PSA, the archetypal marker that has been used by medical practitioners for years to identify and monitor the presence of prostate cancer (see, e.g., Merrill et al., J. Urol. 163(2): 503-5120 (2000); Polascik et al., J. Urol. Aug; 162(2):293-306 (1999) and Fortier et al., J. Nat. Cancer Inst. 91(19): 1635-1640(1999)). A variety of other diagnostic markers are also used in similar contexts including p53 and K-ras (see, e.g., Tulchinsky et al., Int J Mol Med July 1999 4(1):99-102 and Minimoto et al., Cancer Detect Prev 2000;24(1):1-12). Therefore, this disclosure of 98P4B6 polynucleotides and polypeptides (as well as 98P4B6 polynucleotide probes and anti-98P4B6 antibodies used to identify the presence of these molecules) and their properties allows skilled artisans to utilize these molecules in methods that are analogous to those used, for example, in a variety of diagnostic assays directed to examining conditions associated with cancer.  
     [0694] Typical embodiments of diagnostic methods which utilize the 98P4B6 polynucleotides, polypeptides, reactive T cells and antibodies are analogous to those methods from well-established diagnostic assays, which employ, e.g., PSA polynucleotides, polypeptides, reactive T cells and antibodies. For example, just as PSA polynucleotides are used as probes (for example in Northern analysis, see, e.g., Sharief et al., Biochem. Mol. Biol. Int. 33(3):567-74(1994)) and primers (for example in PCR analysis, see, e.g., Okegawa et al., J. Urol. 163(4): 1189-1190(2000)) to observe the presence and/or the level of PSA mRNAs in methods of monitoring PSA overexpression or the metastasis of prostate cancers, the 98P4B6 polynucleotides described herein can be utilized in the same way to detect 98P4B6 overexpression or the metastasis of prostate and other cancers expressing this gene. Alternatively, just as PSA polypeptides are used to generate antibodies specific for PSA which can then be used to observe the presence and/or the level of PSA proteins in methods to monitor PSA protein overexpression (see, e.g., Stephan et al., Urology 55(4):560-3 (2000)) or the metastasis of prostate cells (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3):233-7 (1996)), the 98P4B6 polypeptides described herein can be utilized to generate antibodies for use in detecting 98P4B6 overexpression or the metastasis of prostate cells and cells of other cancers expressing this gene.  
     [0695] Specifically, because metastases involves the movement of cancer cells from an organ of origin (such as the lung or prostate gland etc.) to a different area of the body (such as a lymph node), assays which examine a biological sample for the presence of cells expressing 98P4B6 polynucleotides and/or polypeptides can be used to provide evidence of metastasis. For example, when a biological sample from tissue that does not normally contain 98P4B6-expressing cells (lymph node) is found to contain 98P4B6-expressing cells such as the 98P4B6 expression seen in LAPC4 and LAPC9, xenografts isolated from lymph node and bone metastasis, respectively, this finding is indicative of metastasis.  
     [0696] Alternatively 98P4B6 polynucleotides and/or polypeptides can be used to provide evidence of cancer, for example, when cells in a biological sample that do not normally express 98P4B6 or express 98P4B6 at a different level are found to express 98P4B6 or have an increased expression of 98P4B6 (see, e.g., the 98P4B6 expression in the cancers listed in Table I and in patient samples etc. shown in the accompanying Figures). In such assays, artisans may further wish to generate supplementary evidence of metastasis by testing the biological sample for the presence of a second tissue restricted marker (in addition to 98P4B6) such as PSA, PSCA etc. (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3): 233-237 (1996)).  
     [0697] Just as PSA polynucleotide fragments and polynucleotide variants are employed by skilled artisans for use in methods of monitoring PSA, 98P4B6 polynucleotide fragments and polynucleotide variants are used in an analogous manner. In particular, typical PSA polynucleotides used in methods of monitoring PSA are probes or primers which consist of fragments of the PSA cDNA sequence. Illustrating this, primers used to PCR amplify a PSA polynucleotide must include less than the whole PSA sequence to function in the polymerase chain reaction. In the context of such PCR reactions, skilled artisans generally create a variety of different polynucleotide fragments that can be used as primers in order to amplify different portions of a polynucleotide of interest or to optimize amplification reactions (see, e.g., Caetano-Anolles, G. Biotechniques 25(3): 472-476, 478-480 (1998); Robertson et al., Methods Mol. Biol. 98:121-154 (1998)). An additional illustration of the use of such fragments is provided in the Example entitled “Expression analysis of 98P4B6 in normal tissues, and patient specimens,” where a 98P4B6 polynucleotide fragment is used as a probe to show the expression of 98P4B6 RNAs in cancer cells. In addition, variant polynucleotide sequences are typically used as primers and probes for the corresponding mRNAs in PCR and Northern analyses (see, e.g., Sawai et al., Fetal Diagn. Ther. November-December 1996 11 (6):407-13 and Current Protocols In Molecular Biology, Volume 2, Unit 2, Frederick M. Ausubel et al. eds., 1995)). Polynucleotide fragments and variants are useful in this context where they are capable of binding to a target polynucleotide sequence (e.g., a 98P4B6 polynucleotide shown in FIG. 2 or variant thereof) under conditions of high stringency.  
     [0698] Furthermore, PSA polypeptides which contain an epitope that can be recognized by an antibody or T cell that specifically binds to that epitope are used in methods of monitoring PSA. 98P4B6 polypeptide fragments and polypeptide analogs or variants can also be used in an analogous manner. This practice of using polypeptide fragments or polypeptide variants to generate antibodies (such as anti-PSA antibodies or T cells) is typical in the art with a wide variety of systems such as fusion proteins being used by practitioners (see, e.g., Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubel et al. eds., 1995). In this context, each epitope(s) functions to provide the architecture with which an antibody or T cell is reactive. Typically, skilled artisans create a variety of different polypeptide fragments that can be used in order to generate immune responses specific for different portions of a polypeptide of interest (see, e.g., U.S. Pat. No. 5,840,501 and U.S. Pat. No. 5,939,533). For example it may be preferable to utilize a polypeptide comprising one of the 98P4B6 biological motifs discussed herein or a motif-bearing subsequence which is readily identified by one of skill in the art based on motifs available in the art. Polypeptide fragments, variants or analogs are typically useful in this context as long as they comprise an epitope capable of generating an antibody or T cell specific for a target polypeptide sequence (e.g. a 98P4B6 polypeptide shown in FIG. 3).  
     [0699] As shown herein, the 98P4B6 polynucleotides and polypeptides (as well as the 98P4B6 polynucleotide probes and anti-98P4B6 antibodies or T cells used to identify the presence of these molecules) exhibit specific properties that make them useful in diagnosing cancers such as those listed in Table I. Diagnostic assays that measure the presence of 98P4B6 gene products, in order to evaluate the presence or onset of a disease condition described herein, such as prostate cancer, are used to identify patients for preventive measures or further monitoring, as has been done so successfully with PSA. Moreover, these materials satisfy a need in the art for molecules having similar or complementary characteristics to PSA in situations where, for example, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of a test for PSA alone (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3): 233-237 (1996)), and consequently, materials such as 98P4B6 polynucleotides and polypeptides (as well as the 98P4B6 polynucleotide probes and anti-98P4B6 antibodies used to identify the presence of these molecules) need to be employed to confirm a metastases of prostatic origin.  
     [0700] Finally, in addition to their use in diagnostic assays, the 98P4B6 polynucleotides disclosed herein have a number of other utilities such as their use in the identification of oncogenetic associated chromosomal abnormalities in the chromosomal region to which the 98P4B6 gene maps (see the Example entitled “Chromosomal Mapping of 98P4B6” below). Moreover, in addition to their use in diagnostic assays, the 98P4B6-related proteins and polynucleotides disclosed herein have other utilities such as their use in the forensic analysis of tissues of unknown origin (see, e.g., Takahama K Forensic Sci Int Jun. 28, 1996;80(1-2): 63-9).  
     [0701] Additionally, 98P4B6-related proteins or polynucleotides of the invention can be used to treat a pathologic condition characterized by the over-expression of 98P4B6. For example, the amino acid or nucleic acid sequence of FIG. 2 or FIG. 3, or fragments of either, can be used to generate an immune response to a 98P4B6 antigen. Antibodies or other molecules that react with 98P4B6 can be used to modulate the function of this molecule, and thereby provide a therapeutic benefit.  
     [0702] XII.) Inhibition of 98P4B6 Protein Function  
     [0703] The invention includes various methods and compositions for inhibiting the binding of 98P4B6 to its binding partner or its association with other protein(s) as well as methods for inhibiting 98P4B6 function.  
     [0704] XII.A.) Inhibition of 98P4B6 with Intracellular Antibodies  
     [0705] In one approach, a recombinant vector that encodes single chain antibodies that specifically bind to 98P4B6 are introduced into 98P4B6 expressing cells via gene transfer technologies. Accordingly, the encoded single chain anti-98P4B6 antibody is expressed intracellularly, binds to 98P4B6 protein, and thereby inhibits its function. Methods for engineering such intracellular single chain antibodies are well known. Such intracellular antibodies, also known as “intrabodies”, are specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment is focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors (see, e.g., Richardson et al., 1995, Proc. Natl. Acad. Sci. USA 92: 3137-3141; Beerli et al., 1994, J. Biol. Chem. 289: 23931-23936; Deshane et al., 1994, Gene Ther. 1: 332-337).  
     [0706] Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide. Optionally, single chain antibodies are expressed as a single chain variable region fragment joined to the light chain constant region. Well-known intracellular trafficking signals are engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to target precisely the intrabody to the desired intracellular compartment. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif. Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.  
     [0707] In one embodiment, intrabodies are used to capture 98P4B6 in the nucleus, thereby preventing its activity within the nucleus. Nuclear targeting signals are engineered into such 98P4B6 intrabodies in order to achieve the desired targeting. Such 98P4B6 intrabodies are designed to bind specifically to a particular 98P4B6 domain. In another embodiment, cytosolic intrabodies that specifically bind to a 98P4B6 protein are used to prevent 98P4B6 from gaining access to the nucleus, thereby preventing it from exerting any biological activity within the nucleus (e.g., preventing 98P4B6 from forming transcription complexes with other factors).  
     [0708] In order to specifically direct the expression of such intrabodies to particular cells, the transcription of the intrabody is placed under the regulatory control of an appropriate tumor-specific promoter and/or enhancer. In order to target intrabody expression specifically to prostate, for example, the PSA promoter and/or promoter/enhancer can be utilized (See, for example, U.S. Pat. No. 5,919,652 issued Jul. 6, 1999).  
     [0709] XII.B.) Inhibition of 98P4B6 with Recombinant Proteins  
     [0710] In another approach, recombinant molecules bind to 98P4B6 and thereby inhibit 98P4B6 function. For example, these recombinant molecules prevent or inhibit 98P4B6 from accessing/binding to its binding partner(s) or associating with other protein(s). Such recombinant molecules can, for example, contain the reactive part(s) of a 98P4B6 specific antibody molecule. In a particular embodiment, the 98P4B6 binding domain of a 98P4B6 binding partner is engineered into a dimeric fusion protein, whereby the fusion protein comprises two 98P4B6 ligand binding domains linked to the Fc portion of a human IgG, such as human IgG1. Such IgG portion can contain, for example, the CH2 and CH3 domains and the hinge region, but not the CH1 domain. Such dimeric fusion proteins are administered in soluble form to patients suffering from a cancer associated with the expression of 98P4B6, whereby the dimeric fusion protein specifically binds to 98P4B6 and blocks 98P4B6 interaction with a binding partner. Such dimeric fusion proteins are further combined into multimeric proteins using known antibody linking technologies.  
     [0711] XII.C.) Inhibition of 98P4B6 Transcription or Translation  
     [0712] The present invention also comprises various methods and compositions for inhibiting the transcription of the 98P4B6 gene. Similarly, the invention also provides methods and compositions for inhibiting the translation of 98P4B6 mRNA into protein.  
     [0713] In one approach, a method of inhibiting the transcription of the 98P4B6 gene comprises contacting the 98P4B6 gene with a 98P4B6 antisense polynucleotide. In another approach, a method of inhibiting 98P4B6 mRNA translation comprises contacting a 98P4B6 mRNA with an antisense polynucleotide. In another approach, a 98P4B6 specific ribozyme is used to cleave a 98P4B6 message, thereby inhibiting translation. Such antisense and ribozyme based methods can also be directed to the regulatory regions of the 98P4B6 gene, such as 98P4B6 promoter and/or enhancer elements. Similarly, proteins capable of inhibiting a 98P4B6 gene transcription factor are used to inhibit 98P4B6 mRNA transcription: The; various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.  
     [0714] Other factors that inhibit the transcription of 98P4B6 by interfering with 98P4B6 transcriptional activation are also useful to treat cancers expressing 98P4B6. Similarly, factors that interfere with 98P4B6 processing are useful to treat cancers that express 98P4B6. Cancer treatment methods utilizing such factors are also within the scope of the invention.  
     [0715] XII.D.) General Considerations for Therapeutic Strategies  
     [0716] Gene transfer and gene therapy technologies can be used to deliver therapeutic polynucleotide molecules to tumor cells synthesizing 98P4B6 (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other 98P4B6 inhibitory molecules). A number of gene therapy approaches are known in the ark Recombinant vectors encoding 98P4B6 antisense polynucleotides, ribozymes, factors capable of interfering with 98P4B6 transcription, and so forth, can be delivered to target tumor cells using such gene therapy approaches.  
     [0717] The above therapeutic approaches can be combined with any one of a wide variety of surgical, chemotherapy or radiation therapy regimens. The therapeutic approaches of the invention can enable the use of reduced dosages of chemotherapy (or other therapies) and/or less frequent administration, an advantage for all patients and particularly for those that do not tolerate the toxicity of the chemotherapeutic agent well.  
     [0718] The anti-tumor activity of a particular composition (e.g., antisense, ribozyme, intrabody), or a combination of such compositions, can be evaluated using various in vitro and in vivo assay systems. In vitro assays that evaluate therapeutic activity include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of 98P4B6 to a binding partner, etc.  
     [0719] In vivo, the effect of a 98P4B6 therapeutic composition can be evaluated in a suitable animal model. For example, xenogenic prostate cancer models can be used, wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice (Klein et al., 1997, Nature Medicine 3: 402-408)., For example, PCT Patent Application WO98/16628 and U.S. Pat. No. 6,107,540 describe various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy can be predicted using assays that measure inhibition of tumor formation, tumor regression or metastasis, and the like.  
     [0720] In vivo assays that evaluate the promotion of apoptosis are useful in evaluating therapeutic compositions. In one embodiment, xenografts from tumor bearing mice treated with the therapeutic composition can be examined for the presence of apoptotic foci and compared to untreated control xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.  
     [0721] The therapeutic compositions used in the practice of the foregoing methods can be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material that when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is generally non-reactive with the patient&#39;s immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington&#39;s Pharmaceutical Sciences 16 th  Edition, A. Osal., Ed., 1980).  
     [0722] Therapeutic formulations can be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site; Potentially effective routes of administration include, but are not limited to, intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like. A preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. Therapeutic protein preparations can be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water (containing for example, benzyl alcohol preservative) or in sterile water prior to injection.  
     [0723] Dosages and administration protocols for the treatment of cancers using the foregoing methods will vary with the method and the target cancer, and will generally depend on a number of other factors appreciated in the art.  
     [0724] XIII.) Identification, Characterization and Use of Modulators of 98P4B6  
     [0725] Methods to Identify and Use Modulators  
     [0726] In one embodiment, screening is performed to identify modulators that induce or suppress a particular expression profile, suppress or induce specific pathways, preferably generating the associated phenotype thereby. In another embodiment, having identified differentially expressed genes important in a particular state; screens are performed to identify modulators that alter expression of individual genes, either increase or decrease. In another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.  
     [0727] In addition, screens are done for genes that are induced in response to a candidate agent. After identifying a modulator (one that suppresses a cancer expression pattern leading to a normal expression pattern, or a modulator of a cancer gene that leads to expression of the gene as in normal tissue) a screen is performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent-treated cancer tissue reveals genes that are not expressed in normal tissue or cancer tissue, but are expressed in agent treated tissue, and vice versa. These agent-specific sequences are identified and used by methods described herein for cancer genes or proteins. In particular these sequences and the proteins they encode are used in marking or identifying agent-treated cells. In addition, antibodies are raised against the agent-induced proteins and used to target novel therapeutics to the treated cancer tissue sample.  
     [0728] Modulator-Related Identification and Screening Assays:  
     [0729] Gene Expression-Related Assays  
     [0730] Proteins, nucleic acids, and antibodies of the invention are used in screening assays. The cancer-associated proteins, antibodies, nucleic acids, modified proteins and cells containing these sequences are used in screening assays, such as evaluating the effect of drug candidates on a “gene expression profile,” expression profile of polypeptides or alteration of biological function. In one embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Davis, G F, et al, J Biol Screen 7:69 (2002); Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94,1996).  
     [0731] The cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified cancer proteins or genes are used in screening assays. That is, the present invention comprises methods for screening for compositions which modulate the cancer phenotype or a physiological function of a cancer protein of the invention. This is done on a gene itself or by evaluating the effect of drug candidates on a “gene expression profile” or biological function. In one embodiment, expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring after treatment with a candidate agent, see Zlokarnik, supra.  
     [0732] A variety of assays are executed directed to the genes and proteins of the invention. Assays are run on an individual nucleic acid or protein level. That is, having identified a particular gene as up regulated in cancer, test compounds are screened for the ability to modulate gene expression or for binding to the cancer protein of the invention. “Modulation” in this context includes an increase or a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing cancer, with changes of at least 10%, preferably; 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in cancer tissue compared to normal tissue a target value of a 10-fold increase in expression by the test compound is often desired. Modulators that exacerbate the type of gene expression seen in cancer are also useful, e.g., as an upregulated target in further analyses.  
     [0733] The amount of gene expression is monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, a gene product itself is monitored, e.g., through the use of antibodies to the cancer protein and standard immunoassays. Proteomics and separation techniques also allow for quantification of expression.  
     [0734] Expression Monitoring to Identify Compounds that Modify Gene Expression  
     [0735] In one embodiment, gene expression monitoring, i.e., an expression profile, is monitored simultaneously for a number of entities. Such profiles will typically involve one or more of the genes of FIG. 2. In this embodiment, e.g., cancer nucleic acid probes are attached to biochips to detect and quantify cancer sequences in a particular cell. Alternatively, PCR can be used. Thus, a series, e.g., wells of a microtiter plate, can be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.  
     [0736] Expression monitoring is performed to identify compounds that modify the expression of one or more cancer-associated sequences, e.g., a polynucleotide sequence set out in FIG. 2. Generally, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate cancer, modulate cancer proteins of the invention, bind to a cancer protein of the invention, or interfere with the binding of a cancer protein of the invention and an antibody or other binding partner.  
     [0737] In one embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such “combinatorial chemical libraries” are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds,” as compounds for screening, or as therapeutics.  
     [0738] In certain embodiments, combinatorial libraries of potential modulators are screened for an ability to bind to a cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.  
     [0739] As noted above, gene expression monitoring is conveniently used to test candidate modulators (e.g., protein, nucleic acid or small molecule). After the candidate agent has been added and the cells allowed to incubate for a period, the sample containing a target sequence to be analyzed is, e.g., added to a biochip.  
     [0740] If required, the target sequence is prepared using known techniques. For example, a sample is treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.  
     [0741] The target sequence can be labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence&#39;s specific binding to a probe. The label also can be an enzyme, such as alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that is detected. Alternatively, the label is a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.  
     [0742] As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise “sandwich assays”, which include the use of multiple probes, as is generally outlined in U.S. Pat. Nos. 5, 681,702; 5,597,909; 5,545,730; 5,594,117; 5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352; 5,594,118; 5,359,100; 5,124, 246; and 5,681,697. In this embodiment; in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.  
     [0743] A variety of hybridization conditions are used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allow formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc. These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Pat. No. 5,681,697. Thus, it can be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.  
     [0744] The reactions outlined herein can be accomplished in a variety of ways. Components of the reaction can be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which can be used to facilitate optimal hybridization and detection, and/or reduce nonspecific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target. The assay data are analyzed to determine the expression levels of individual genes, and changes in expression levels as between states, forming a gene expression profile.  
     [0745] Biological Activity-Related Assays  
     [0746] The invention provides methods identify or screen for a compound that modulates the activity of a cancer-related gene or protein of the invention. The methods comprise adding a test compound, as defined above, to a cell comprising a cancer protein of the invention. The cells contain a recombinant nucleic acid that encodes a cancer protein of the invention. In another embodiment, a library of candidate agents is tested on a plurality of cells.  
     [0747] In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e., cell-cell contacts). In another example, the determinations are made at different stages of the cell cycle process. In this way, compounds that modulate genes or proteins of the invention are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the cancer protein of the invention. Once identified, similar structures are evaluated to identify critical structural features of the compound.  
     [0748] In one embodiment, a method of modulating (e.g., inhibiting) cancer cell division is provided; the method comprises administration of a cancer modulator. In another embodiment, a method of modulating (e.g., inhibiting) cancer is provided; the method comprises administration of a cancer modulator. In a further embodiment, methods of treating cells or individuals with cancer are provided; the method comprises administration of a cancer modulator.  
     [0749] In one embodiment, a method for modulating the status of a cell that expresses a gene of the invention is provided. As used herein status comprises such art-accepted parameters such as growth, proliferation, survival, function, apoptosis, senescence, location, enzymatic activity, signal transduction, etc. of a cell. In one embodiment, a cancer inhibitor is an antibody as discussed above. In another embodiment, the cancer inhibitor is an antisense molecule. A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described herein.  
     [0750] High Throughput Screening to Identify Modulators  
     [0751] The assays to identify suitable modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.  
     [0752] In one embodiment, modulators evaluated in high throughput screening methods are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, are used. In this way, libraries of proteins are made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes, or ligands and receptors.  
     [0753] Use of Soft Agar Growth and Colony Formation to Identify and Characterize Modulators  
     [0754] Normal cells require a solid substrate to attach and grow. When cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, can regenerate normal phenotype and once again require a solid substrate to attach to and grow. Soft agar growth or colony formation in assays are used to identify modulators of cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A modulator reduces or eliminates the host cells&#39; ability to grow suspended in solid or semisolid media, such as agar.  
     [0755] Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed., 1994). See also, the methods section of Garkavtsev et al. (1996), supra.  
     [0756] Evaluation of Contact Inhibition and Growth Density Limitation to Identify and Characterize Modulators  
     [0757] Normal cells typically grow in a flat and organized pattern in cell culture until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. Transformed cells, however, are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, transformed cells grow to a higher saturation density than corresponding normal cells. This is detected morphologically by the formation of a disoriented monolayer of cells or cells in foci. Alternatively, labeling index with (3H)-thymidine at saturation density is used to measure density limitation of growth, similarly an MTT or Alamar blue assay will reveal proliferation capacity of cells and the the ability of modulators to affect same. See Freshney (1994), supra. Transformed cells, when transfected with tumor suppressor genes, can regenerate a normal phenotype and become contact inhibited and would grow to a lower density.  
     [0758] In this assay, labeling index with  3 H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with ( 3 H)-thymidine is determined by incorporated cpm.  
     [0759] Contact independent growth is used to identify modulators of cancer sequences, which had led to abnormal cellular proliferation and transformation. A modulator reduces or eliminates contact independent growth, and returns the cells to a normal phenotype.  
     [0760] Evaluation of Growth Factor or Serum Dependence to Identify and Characterize Modulators  
     [0761] Transformed cells have lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Inst. 37:167-175 (1966); Eagle et al., J. Exp. Med 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. The degree of growth factor or serum dependence of transformed host cells can be compared with that of control. For example, growth factor or serum dependence of a cell is monitored in methods to identify and characterize compounds that modulate cancer-associated sequences of the invention.  
     [0762] Use of Tumor-Specific Marker Levels to Identify and Characterize Modulators  
     [0763] Tumor cells release an increased amount of certain factors (hereinafter “tumor specific markers”) than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, Tumor Vascularization, and Potential Interference with Tumor Growth, in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor Angiogenesis Factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)), while bFGF is released from endothelial tumors (Ensoli, B et al).  
     [0764] Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland &amp; Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305 312 (1980); Gullino, Angiogenesis, Tumor Vascularization, and Potential Interference with Tumor Growth, in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney, Anticancer Res. 5:111-130 (1985). For example, tumor specific marker levels are monitored in methods to identify and characterize compounds that modulate cancer-associated sequences of the invention.  
     [0765] Invasiveness into Matrigel to Identify, and Characterize Modulators  
     [0766] The degree of invasiveness into Matrigel or an extracellular matrix constituent can be used as an assay to identify and characterize compounds that modulate cancer associated sequences. Tumor cells exhibit a positive correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells. Techniques described in Cancer Res. 1999; 59:6010; Freshney (1994), supra, can be used. Briefly, the level of invasion of host cells is measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with  125 I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra.  
     [0767] Evaluation of Tumor Growth In Vivo to Identify and Characterize Modulators  
     [0768] Effects of cancer-associated sequences on cell growth are tested in transgenic or immune-suppressed organisms. Transgenic organisms are prepared in a variety of art-accepted ways. For example, knock-out transgenic organisms, e.g., mammals such as mice, are made, in which a cancer gene is disrupted or in which a cancer gene is inserted. Knock-out transgenic mice are made by insertion of a marker gene or other heterologous gene into the endogenous cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous cancer gene with a mutated version of the cancer gene, or by mutating the endogenous cancer gene, e.g., by exposure to carcinogens.  
     [0769] To prepare transgenic chimeric animals, e.g., mice, a DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells some of which are derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric mice can be derived according to U.S. Pat. No. 6,365,797, issued Apr. 2, 2002; U.S. Pat. No. 6,107,540 issued Aug. 22, 2000; Hogan et al., Manipulating the Mouse Embryo: A laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).  
     [0770] Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, a genetically athymic “nude” mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectornized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10 6  cells) injected into isogenic hosts produce invasive tumors in a high proportion of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing cancer-associated sequences are injected subcutaneously or orthotopically. Mice are then separated into groups, including control groups and treated experimental groups) e.g. treated with a modulator). After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions, or weight) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student&#39;s T test) are said to have inhibited growth.  
     [0771] In Vitro Assays to Identify and Characterize Modulators  
     [0772] Assays to identify compounds with modulating activity can be performed in vitro. For example, a cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as Western blotting, ELISA and the like with an antibody that selectively binds to the cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., Northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.  
     [0773] Alternatively, a reporter gene system can be devised using a cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or P-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art (Davis G F, supra; Gonzalez, J. &amp; Negulescu, P. Curr. Opin. Biotechnol. 1998: 9:624).  
     [0774] As outlined above, in vitro screens are done on individual genes and gene products. That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself is performed.  
     [0775] In one embodiment, screening for modulators of expression of specific gene(s) is performed. Typically, the expression of only one or a few genes is evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.  
     [0776] Binding Assays to Identify and Characterize Modulators  
     [0777] In binding assays in accordance with the invention, a purified or isolated gene product of the invention is generally used. For example, antibodies are generated to a protein of the invention, and immunoassays are run to determine the amount and/or location of protein. Alternatively, cells comprising the cancer proteins are used in the assays.  
     [0778] Thus, the methods comprise combining a cancer protein of the invention and a candidate compound such as a ligand, and determining the binding of the compound to the cancer protein of the invention. Preferred embodiments utilize the human cancer protein; animal models of human disease of can also be developed and used. Also, other analogous mammalian proteins also can be used as appreciated by those of skill in the art. Moreover, in some embodiments variant or derivative cancer proteins are used.  
     [0779] Generally, the cancer protein of the invention, or the ligand, is non-diffusibly bound to an insoluble support. The support can, e.g., be one having isolated sample receiving areas (a microtiter plate, an array, etc.). The insoluble supports can be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports can be solid or porous and of any convenient shape.  
     [0780] Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharide, nylon, nitrocellulose, or Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition to the support is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies which do not sterically block either the ligand binding site or activation sequence when attaching the protein to the support, direct binding to “sticky” or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or ligand/binding agent to the support, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.  
     [0781] Once a cancer protein of the invention is bound to the support, and a test compound is added to the assay. Alternatively, the candidate binding agent is bound to the support and the cancer protein of the invention is then added. Binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc.  
     [0782] Of particular interest are assays to identify agents that have a low toxicity for human cells. A wide variety of assays can be used for this purpose, including proliferation assays, cAMP assays, labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.  
     [0783] A determination of binding of the test compound (ligand, binding agent, modulator, etc.) to a cancer protein of the invention can be done in a number of ways. The test compound can be labeled, and binding determined directly, e.g., by attaching all or a portion of the cancer protein of the invention to a solid support, adding a labeled candidate compound (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps can be utilized as appropriate.  
     [0784] In certain embodiments, only one of the components is labeled, e.g., a protein of the invention or ligands labeled. Alternatively, more than one component is labeled with different labels, e.g., I 125 , for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.  
     [0785] Competitive Binding to Identify and Characterize Modulators  
     [0786] In one embodiment, the binding of the “test compound” is determined by competitive binding assay with a “competitor.” The competitor is a binding moiety that binds to the target molecule (e.g., a cancer protein of the invention). Competitors include compounds such as antibodies, peptides, binding partners, ligands, etc. Under certain circumstances, the competitive binding between the test compound and the competitor displaces the test compound. In one embodiment, the test compound is labeled. Either the test compound, the competitor, or both, is added to the protein for a time sufficient to allow binding. Incubations are performed at a temperature that facilitates optimal activity, typically between four and 40° C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening; typically between zero and one, hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.  
     [0787] In one embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the cancer protein and thus is capable of binding to, and potentially modulating, the activity of the cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the post-test compound wash solution indicates displacement by the test compound. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.  
     [0788] In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor indicates that the test compound binds to the cancer protein with higher affinity than the competitor. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, indicates that the test compound binds to and thus potentially modulates the cancer protein of the invention.  
     [0789] Accordingly, the competitive binding methods comprise differential screening to identity agents that are capable of modulating the activity of the cancer proteins of the invention. In this embodiment, the methods comprise combining a cancer protein and a competitor in a first sample. A second sample comprises a test compound, the cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the cancer protein.  
     [0790] Alternatively, differential screening is used to identify drug candidates that bind to the native cancer protein, but cannot bind to modified cancer proteins. For example the structure of the cancer protein is modeled and used in rational drug design to synthesize agents that interact with that site, agents which generally do not bind to site-modified proteins. Moreover, such drug candidates that affect the activity of a native cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of such proteins.  
     [0791] Positive controls and negative controls can be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples occurs for a time sufficient to allow for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.  
     [0792] A variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., can be used. The mixture of components is added in an order that provides for the requisite binding.  
     [0793] Use of Polynucleotides to Down-Regulate or Inhibit a Protein of the Invention.  
     [0794] Polynucleotide modulators of cancer can be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand-binding molecule, as described in WO 91/04753. Suitable ligand-binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of cancer can be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of a polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.  
     [0795] Inhibitory and Antisense Nucleotides  
     [0796] In certain embodiments, the activity of a cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide or inhibitory small nuclear RNA (snRNA), i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a cancer protein of the invention, mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.  
     [0797] In the context of this invention, antisense polynucleotides can comprise naturally occurring nucleotides, or synthetic species formed from naturally occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprised by this invention so long as they function effectively to hybridize with nucleotides of the invention. See, e.g., Isis Pharmaceuticals, Carlsbad, Calif.; Sequitor, Inc., Natick, Mass.  
     [0798] Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.  
     [0799] Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for cancer molecules. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 12 nucleotides, preferably from about 12 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein &amp;Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).  
     [0800] Ribozymes  
     [0801] In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P and axhead ribozymes (see, e.g., Castanolto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).  
     [0802] The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0360257; U.S. Pat. No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205:121-126 (1994)).  
     [0803] Use of Modulators in Phenotypic Screening  
     [0804] In one embodiment, a test compound is administered to a population of cancer cells, which have an associated cancer expression profile. By “administration” or “contacting” herein is meant that the modulator is added to the cells in such a manner as to allow the modulator to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, a nucleic acid encoding a proteinaceous agent (i.e., a peptide) is put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used. Once the modulator has been administered to the cells, the cells are washed if desired and are allowed to incubate under preferably physiological conditions for some period. The cells are then harvested and a new gene expression profile is generated. Thus, e.g., cancer tissue is screened for agents that modulate, e.g., induce or suppress, the cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on cancer activity. Similarly, altering a biological function or a signaling pathway is indicative of modulator activity. By defining such a signature for the cancer phenotype, screens for new drugs that alter the phenotype are devised. With this approach, the drug target need not be known and need not be represented in the original gene/protein expression screening platform, nor does the level of transcript for the target protein need to change. The modulator inhibiting function will serve as a surrogate marker  
     [0805] As outlined above, screens are done to assess genes or gene products. That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself is performed.  
     [0806] Use of Modulators to Affect Peptides of the Invention  
     [0807] Measurements of cancer polypeptide activity, or of the cancer phenotype are performed using a variety of assays. For example, the effects of modulators upon the function of a cancer polypeptide(s) are measured by examining parameters described above. A physiological change that affects activity is used to assess the influence of a test compound on the polypeptides of this invention. When the functional outcomes are determined using intact cells or animals, a variety of effects can be assesses such as, in the case of a cancer associated with solid tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., by Northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGNIP.  
     [0808] Methods of Identifying Characterizing Cancer-Associated Sequences  
     [0809] Expression of various gene sequences is correlated with cancer. Accordingly, disorders based on mutant or variant cancer genes are determined. In one embodiment, the invention provides methods for identifying cells containing variant cancer genes, e.g., determining the presence of, all or part, the sequence of at least one endogenous cancer gene in a cell. This is accomplished using any number of sequencing techniques. The invention comprises methods of identifying the cancer genotype of an individual, e.g., determining all or part of the sequence of at least one gene of the invention in the individual. This is generally done in at least one tissue of the individual, e.g., a tissue set forth in Table I, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced gene to a known cancer gene, i.e., a wild-type gene to determine the presence of family members, homologies, mutations or variants. The sequence of all or part of the gene can then be compared to the sequence of a known cancer gene to determine if any differences exist. This is done using any number of known homology programs, such as BLAST, Bestfit, etc. The presence of a difference in the sequence between the cancer gene of the patient and the known cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.  
     [0810] In a preferred embodiment, the cancer genes are used as probes to determine the number of copies of the cancer gene in the genome. The cancer genes are used as probes to determine the chromosomal localization of the cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the cancer gene locus.  
     [0811] XIV.) Kits/Articles of Manufacture  
     [0812] For use in the diagnostic and therapeutic applications described herein, kits are also within the scope of the invention. Such kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method. For example, the container(s) can comprise a probe that is or can be detectably labeled. Such probe can be an antibody or polynucleotide specific for a FIG. 2-related protein or a FIG. 2 gene or message, respectively. Where the method utilizes nucleic acid hybridization to detect the target nucleic acid, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, florescent, or radioisotope label. The kit can include all or part of the amino acid sequences in FIG. 2 or FIG. 3 or analogs thereof, or a nucleic acid molecules that encodes such amino acid sequences.  
     [0813] The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.  
     [0814] A label can be present on the container to indicate that the composition is used for a specific therapy or non-therapeutic application, such as a diagnostic or laboratory application, and can also indicate directions for either in vivo or in vitro use, such as those described herein. Directions and or other information can also be included on an insert(s) or label(s) which is included with or on the kit.  
     [0815] The terms “kit” and “article of manufacture” can be used as synonyms.  
     [0816] In another embodiment of the invention, an article(s) of manufacture containing compositions, such as amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), e.g., materials useful for the diagnosis, prognosis, prophylaxis and/or treatment of neoplasias of tissues such as those set forth in Table I is provided. The article of manufacture typically comprises at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass or plastic. The container can hold amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), in one embodiment the container holds a polynucleotide for use in examining the mRNA expression profile of a cell, together with reagents used for this purpose.  
     [0817] The container can alternatively hold a composition which is effective for treating, diagnosis, prognosing or prophylaxing a condition and can have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agents in the composition can be an antibody capable of specifically binding 98P4B6 and modulating the function of 98P4B6.  
     [0818] The label can be on or associated with the container. A label a can be on a container when letters, numbers or other characters forming the label are molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. The label can indicate that the composition is used for diagnosing, treating, prophylaxing or prognosing a condition, such as a neoplasia of a tissue set forth in Table I. The article of manufacture can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringers solution and/or dextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and/or package inserts with indications and/or instructions for use.  
     EXAMPLES  
     [0819] Various aspects of the invention are further described and illustrated by way of the several examples that follow, none of which are intended to limit the scope of the invention.  
     Example 1  
     SSH-Generated Isolation of cDNA Fragment of the 98P4B6 Gene  
     [0820] To isolate genes that are over-expressed in prostate cancer we used the Suppression Subtractive Hybridization (SSH) procedure using cDNA derived from prostate tissues. The 98P4B6 SSH cDNA sequence was derived from normal prostate minus LAPC-4AD prostate xenograft cDNAs. The 98P4B6 cDNA was identified as highly expressed in prostate cancer.  
     [0821] Materials and Methods  
     [0822] Human Tissues:  
     [0823] The patient cancer and normal tissues were purchased from different sources such as the NDRI (Philadelphia, Pa.). mRNA for some normal tissues were purchased from Clontech, Palo Alto, Calif.  
     [0824] RNA Isolation:  
     [0825] Tissues were homogenized in Trizol reagent (Life Technologies, Gibco BRL) using 10 ml/g tissue isolate total RNA. Poly A RNA was purified from total RNA using Qiagen&#39;s Oligotex mRNA Mini and Midi kits. Total and mRNA were quantified by spectrophotometric analysis (O.D. 260/280 nm) and analyzed by gel electrophoresis.  
     [0826] Oligonucleotides:  
     [0827] The following HPLC purified oligonucleotides were used.  
                                      DPNCDN (cDNA synthesis primer):                         (SEQ ID NO: 101)                                 5′TTTT GATC AAGCTT303′                           Adaptor 1:                     (SEQ ID NO: 102)                                 5′CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAG3′                                     (SEQ ID NO: 103)                                 3′GGCCCGTC CTAG 5′                           Adaptor 2:                     (SEQ ID NO: 104)                                 5′GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAG3′                                     (SEQ ID NO: 105)                                 3′CGGCTC CTAG 5′                           PCR primer 1:                     (SEQ ID NO: 106)                                 5′CTAATACGACTCACTATAGGGC3′                           Nested primer (NP)1:                     (SEQ ID NO: 107)                                 5′TCGAGCGGCCGCCCGGGCAG GA 3′                           Nested primer (NP)2:                     (SEQ ID NO: 108)                                 5′AGCGTGGTCGCGGCCGAG GA 3′              
 
     [0828] Suppression Subtractive Hybridization:  
     [0829] Suppression Subtractive Hybridization (SSH) was used to identify cDNAs corresponding to genes that may be differentially expressed in prostate cancer. The SSH reaction utilized cDNA from prostate cancer xenograft and normal tissues.  
     [0830] The gene 98P4B6 sequence was derived from normal prostate tissue minus prostate cancer xenograft LAPC-4AD cDNA subtraction. The SSH DNA sequence (FIG. 1) was identified.  
     [0831] The cDNA derived from LAPC-4AD was used as the source of the “driver” cDNA, while the cDNA from normal prostate was used as the source of the “tester” cDNA. Double stranded cDNAs corresponding to tester and driver cDNAs were synthesized from 2 μg of poly(A) +  RNA isolated from the relevant tissue, as described above, using CLONTECH&#39;s PCR-Select cDNA Subtraction Kit and 1 ng of oligonucleotide DPNCDN as primer. First- and second-strand synthesis were carried out as described in the Kit&#39;s user manual protocol (CLONTECH Protocol No. PT1117-1, Catalog No. K1804-1). The resulting cDNA was digested with Dpn II for 3 hrs at 37° C. Digested cDNA was extracted with phenol/chloroform (1:1) and ethanol precipitated.  
     [0832] Driver cDNA was generated by combining in a 1:1 ratio Dpn II digested cDNA from the relevant tissue source (see above) with digested cDNAs derived from normal tissue.  
     [0833] Tester cDNA was generated by diluting 1 μl of Dpn II digested cDNA from the relevant tissue source (see above) (400 ng) in 5 μl of water. The diluted cDNA (2 μl, 160 ng) was then ligated to 2 μl of Adaptor 1 and Adaptor 2 (10 μM), in separate ligation reactions, in a total volume of 10 μl at 16° C. overnight, using 400 u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 μl of 0.2 M EDTA and heating at 72° C. for 5 min.  
     [0834] The first hybridization was performed by adding 1.5 μl (600 ng) of driver cDNA to each of two tubes containing 1.5 μl (20 ng) Adaptor 1- and Adaptor 2-ligated tester cDNA. In a final volume of 4 μl, the samples were overlaid with mineral oil, denatured in an MJ Research thermal cycler at 98° C. for 1.5 minutes, and then were allowed to hybridize for 8 hrs at 68° C. The two hybridizations were then mixed together with an additional 1 μl of fresh denatured driver cDNA and were allowed to hybridize overnight at 68° C. The second hybridization was then diluted in 200 μl of 20 mM Hepes, pH 8.3, 50 mM NaCl, 0.2 mM EDTA, heated at 70° C. for 7 min. and stored at −20° C.  
     [0835] PCR Amplification, Cloning and Sequencing of Gene Fragments Generated from SSH:  
     [0836] To amplify gene fragments resulting from SSH reactions, two PCR amplifications were performed. In the primary PCR reaction 1 μl of the diluted final hybridization mix was added to 1 μl of PCR primer 1 (10 μM), 0.5 μl dNTP mix (10 μM), 2.5 μl 10× reaction buffer (CLONTECH) and 0.5 μl 50× Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25 μl. PCR 1 was conducted using the following conditions: 75° C. for 5 min., 94° C. for 25 sec., then 27 cycles of 94° C. for 10 sec, 66° C. for 30 sec, 72° C. for 1.5 min. Five separate primary PCR reactions were performed for each experiment. The products were pooled and diluted 1:10 with water. For the secondary PCR reaction, 1 μl from the pooled and diluted primary PCR reaction was added to the same reaction mix as used for PCR 1, except that primers NP1 and NP2 (10 μM) were used instead of PCR primer 1. PCR 2 was performed using 10-12 cycles of 94° C. for 10 sec, 68° C. for 30 sec, and 72° C. for 1.5 minutes. The PCR products were analyzed using 2% agarose gel electrophoresis.  
     [0837] The PCR products were inserted into pCR2.1 using the T/A vector cloning kit (Invitrogen). Transformed  E. coli  were subjected to blue/white and ampicillin selection. White colonies were picked and arrayed into 96 well plates and were grown in liquid culture overnight. To identify inserts, PCR amplification was performed on 1 μl of bacterial culture using the conditions of PCR1 and NP1 and NP2 as primers. PCR products were analyzed using 2% agarose gel electrophoresis.  
     [0838] Bacterial clones were stored in 20% glycerol in a 96 well format. Plasmid DNA was prepared, sequenced, and subjected to nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP databases.  
     [0839] RT-PCR Expression Analysis:  
     [0840] First strand cDNAs can be generated from 1 μg of mRNA with oligo (dT)12-18 priming using the Gibco-BRL Superscript Preamplification system. The manufacturer&#39;s protocol was used which included an incubation for 50 min at 42° C. with reverse-transcriptase followed by RNAse H treatment at 37° C. for 20 min. After completing the reaction, the volume can be increased to 200 μl with water prior to normalization. First strand cDNAs from 16 different normal human tissues can be obtained from Clontech.  
     [0841] Normalization of the first strand cDNAs from multiple tissues was performed by using the primers 5′atatcgccgcgctcgtcgtcgacaa3′ (SEQ ID NO: 109) and 5′agccacacgcagctcattgtagaagg 3′ (SEQ ID NO: 110) to amplify β-actin. First strand cDNA (5 μl) were amplified in a total volume of 50 μl containing 0.4 μM primers, 0.2 μM each dNTPs, 1×PCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM MgCl 2 , 50 mM KCl, pH 8.3) and 1× Klentaq DNA polymerase (Clontech). Five μl of the PCR reaction can be removed at 18, 20, and 22 cycles and used for agarose gel electrophoresis. PCR was performed using an MJ Research thermal cycler under the following conditions: Initial denaturation can be at 94° C. for 15 sec, followed by a 18, 20, and 22 cycles of 94° C. for 15, 65° C. for 2 min, 72° C. for 5 sec. A final extension at 72° C. was carried out for 2 min. After agarose gel electrophoresis, the band intensities of the 283 bp β-actin bands from multiple tissues were compared by visual inspection. Dilution factors for the first strand cDNAs were calculated to result in equal β-actin band intensities in all tissues after 22 cycles of PCR. Three rounds of normalization can be required to achieve equal band intensities in all tissues after 22 cycles of PCR.  
     [0842] To determine expression levels of the 98P4B6 gene, 5 μl of normalized first strand cDNA were analyzed by PCR using 26, and 30 cycles of amplification. Semi-quantitative expression analysis can be achieved by comparing the PCR products at cycle numbers that give light band intensities. The primers used for RT-PCR were designed using the 98P4B6 SSH sequence and are listed below:  
                              98P4B6.1               5′-GACTGAGCTGGAACTGGAATTTGT-3′   (SEQ ID NO: 111)               98P4B6.2       5′-TTTGAGGAGACTTCATCTCACTGG-3′   (SEQ ID NO: 112)          
 
     Example 2  
     Isolation of Full Length 98P4B6 Encoding cDNA  
     [0843] The 98P4B6 SSH cDNA sequence was derived from a substraction consisting of normal prostate minus prostate cancer xenograft. The SSH cDNA sequence (FIG. 1) was designated 98P4B6.  
     [0844] The 98P4B6 SSH DNA sequence of 183 bp is shown in FIG. 1. Full-length 98P4B6 v.1 (clone GTD3) of 2453 bp was cloned from prostate cDNA library, revealing an ORF of 454 amino acids (FIG. 2 and FIG. 3). 98P4B6 v.6 was also cloned from normal prostate library. Other variants of 98P4B6 were also identified and these are listed in FIGS. 2 and 3.  
     [0845] 98P4B6 v.2, v.3, v.4, v.5, v.6, v.7 and v.8 are splice variants of 98P4B6 v.1. 98P4B6 v.9 through v.19 are SNP variants and differ from v.1 by one amino acid. 98P4B6 v.20 through v.24 are SNP variants of v.7. 98P4B6 v.25 through v.38 are SNP variants of v.8. Though these SNP variants were shown separately, they could also occur in any combinations and in any transcript variants.  
     Example 3  
     Chromosomal Mapping of 98P4B6  
     [0846] Chromosomal localization can implicate genes in disease pathogenesis. Several chromosome mapping approaches are available including fluorescent in situ hybridization (FISH), human/hamster radiation hybrid (RH) panels (Walter et al., 1994; Nature Genetics 7:22; Research Genetics, Huntsville Ala.), human-rodent somatic cell hybrid panels such as is available from the Cornell Institute (Camden, N.J.), and genomic viewers utilizing BLAST homologies to sequenced and mapped genomic clones (NCBI, Bethesda, Md.).  
     [0847] 98P4B6 maps to chromosome 7q21 using 98P4B6 sequence and the NCBI BLAST tool: located on the World Wide Web at .ncbi.nim.nih.gov/genome/seq/page.cgi?F=HsBlast.html&amp;&amp;ORG=Hs).  
     Example 4  
     Expression Analysis of 98P4B6  
     [0848] Expression analysis by. RT-PCR demonstrated that 98P4B6 is strongly expressed in prostate cancer patient specimens (FIG. 14). First strand cDNA was generated from normal stomach, normal brain, normal heart, normal liver, normal skeletal muscle, normal testis, normal prostate, normal bladder, normal kidney, normal colon, normal lung, normal pancreas, and a pool of cancer specimens from prostate cancer patients, bladder cancer patients, kidney cancer patients, colon cancer patients, lung cancer patients, pancreas cancer patients, and a pool of 2 patient prostate metastasis to lymph node. Normalization was performed by PCR using primers to actin. Semi-quantitative PCR, using primers directed to 98P4B6 v.1, v.13, or/and v.14 (A), or directed specifically to the splice variants 98P4B6 v.6 and v.8 (B), was performed at 26 and 30 cycles of amplification. Samples were run on an agarose gel, and PCR products were quantitated using the Alphalmager software. Results show strong expression of 98P4B6 and its splice variants v.6 and v.8 in normal prostate and in prostate cancer. Expression was also detected in bladder cancer, kidney cancer, colon cancer, lung cancer, pancreas cancer, breast cancer, cancer metastasis as well as in the prostate cancer metastasis to lymph node specimens, compared to all normal tissues tested. As noted below, e.g., in Example 6, as 98P4B6 v.1 is in expressed in cancer tissues such as those listed in Table 1, the other protein-encoding 98P4B6 variants are expressed in these tissues as well; this principle is corroborated by data in (FIG. 14) for the proteins herein designated 98P4B6 v.6 or v.8 is found, e.g., in prostate, lung, ovary, bladder, breast, colon, kidney and pancreas, cancers, as well as in the literature (Porkka et al., Lab Invest, 2002 and Korkmaz et al., JBC, 2002) where the protein 98P4B6 v.8 is identified in normal prostate and prostate cancer.  
     [0849] When the genomic region to which a gene maps is modulated in a particular cancer, the alternative transcripts or splice variants of the gene are modulated as well. Disclosed herein is that 98P4B6 has a particular expression profile related to cancer. Alternative transcripts and splice variants of 98P4B6 are also involved in cancers in the same or additional tissues, thus serving as tumor-associated markers/antigens.  
     [0850] Expression of 98P4B6 v.1, v.13, and/or v.14 was detected in prostate, lung, ovary, bladder, cervix, uterus and pancreas cancer patient specimens (FIG. 15). First strand cDNA was prepared from a panel of patient cancer specimens. Normalization was performed by PCR using primers to actin. Semi-quantitative PCR, using primers to 98P4B6, was performed at 26 and 30 cycles of amplification. Samples were run on an agarose gel, and PCR products were quantitated using the Alphalmager software. Expression was recorded as absent, low, medium or strong. Results show expression of 98P4B6 in the majority of all patient cancer specimens tested.  
     [0851]FIG. 16 shows that 98P4B6 is expressed in stomach cancer patient specimens. (A) RNA was extracted from normal stomach (N) and from 10 different stomach cancer patient specimens (T). Northern blot with 10 μg of total RNA/lane was probed with 98P4B6 sequence. Results show strong expression of 98P4B6 in the stomach tumor tissues and lower expression in normal stomach. The lower panel represents ethidium bromide staining of the blot showing quality of the RNA samples. (B) Expression of 98P4B6 was assayed in a panel of human stomach cancers (T) and their respective matched normal tissues (N) on RNA dot blots. 98P4B6 was detected in 7 out of 8 stomach tumors but not in the matched normal tissues.  
     Example 5  
     Transcript Variants of 98P4B6  
     [0852] Transcript variants are variants of mature mRNA from the same gene which arise by alternative transcription or alternative splicing. Alternative transcripts are transcripts from the same gene but start transcription at different points. Splice variants are mRNA variants spliced differently from the same transcript. In eukaryotes, when a multi-exon gene is transcribed from genomic DNA, the initial RNA is spliced to produce functional mRNA, which has only exons and is used for: translation into an amino acid sequence. Accordingly, a given gene can have zero to many alternative transcripts and each transcript can have zero to many splice variants. Each transcript variant has a unique exon makeup, and can have different coding and/or non-coding (5′ or 3′ end) portions, from the original transcript. Transcript variants can code for similar or different proteins with the same or a similar function or can encode proteins with different functions, and can be expressed in the same tissue at the same time or in different tissues at the same time or in the same tissue at different times or in different tissues at different times. Proteins encoded by transcript variants can have similar or different cellular or extracellular localizations, e.g., secreted versus intracellular.  
     [0853] Transcript variants are identified by a variety of art-accepted methods. For example, alternative transcripts and splice variants are identified by full-length cloning experiment, or by use of full-length transcript and EST sequences. First, all human ESTs were grouped into clusters which show direct or indirect identity with each other. Second, ESTs in the same cluster were further grouped into sub-clusters and assembled into a consensus sequence. The original gene sequence is compared to the consensus sequence(s) or other full-length sequences. Each consensus sequence is a potential splice variant for that gene. Even when a variant is identified that is not a full-length clone, that portion of the variant is very useful for antigen generation and for further cloning of the full-length splice variant, using techniques known in the art.  
     [0854] Moreover, computer programs are available in the art that identify transcript variants based on genomic sequences. Genomic-based transcript variant identification programs include FgenesH (A. Salamov and V. Solovyev, “Ab initio gene finding in Drosophila genomic DNA,” Genome Research. April 2000; 10(4):516-22);Grail (URL compbio.ornl.gov/Grail-bin/EmptyGrailForm) and GenScan (URL genes.mit.edu/GENSCAN.html). For a general discussion of splice variant identification protocols see., e.g., Southan, C., A genomic perspective on human proteases, FEBS Lett. Jun. 8, 2001; 498(2-3):214-8; de Souza, S. J., et al., Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags, Proc. Natl. Acad Sci USA. Nov. 7, 2000; 97(23):12690-3.  
     [0855] To further confirm the parameters of a transcript variant, a variety of techniques are available in the art, such as full-length cloning, proteomic validation, PCR-based validation, and 5′ RACE validation, etc. (see e.g., Proteomic Validation: Brennan, S. O., et al., Albumin banks peninsula: a new termination variant characterized by electrospray mass spectrometry, Biochem Biophys Acta. Aug. 17, 1999;1433(1-2):321-6; Ferranti P, et al., Differential splicing of pre-messenger RNA produces multiple forms of mature caprine alpha(s1)-casein, Eur J. Biochem. Oct. 1, 1997;249(1):1-7. For PCR-based Validation: Wellmann S, et al., Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology, Clin Chem. April 2001;47(4):654-60; Jia, H. P., et al., Discovery of new human beta-defensins using a genomics-based approach, Gene. Jan. 24, 2001; 263(1-2):211-8. For PCR-based and 5′ RACE Validation: Brigle, K. E., et al., Organization of the murine reduced folate carrier gene and identification of variant splice forms, Biochem Biophys Acta. Aug. 7, 1997; 1353(2): 191-8).  
     [0856] It is known in the art that genomic regions are modulated in cancers. Recently, Porkka et al. (2002) reported that transcript variants of STEAP2 were expressed and were found in both normal and malignant prostate tissue (Porkka, K. P., et al. Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Laboratory Investigation November 2002; 82(11):1573-1582). Another group of scientists also reported that transcript variants of STEAP2 (98P4B6 v.6 herein) also were expressed significantly higher in prostate cancer than normal prostate (Korkmaz, K. S., et al. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. The Journal of Biological Chemistry. 2002 Sept. 277(39):36689-36696.). When the genomic region to which a gene maps is modulated in a particular cancer, the alternative transcripts or splice variants of the gene are modulated as well. Disclosed herein is that 98P4B6 has a particular expression profile related to cancer. Alternative transcripts and splice variants of 98P4B6 are also involved in cancers in the same or additional tissues, thus serving as tumor-associated markers/antigens.  
     [0857] Using the full-length gene and EST sequences, seven transcript variants were identified, designated as 98P4B6 v.2, v.3, v.4, v.5, v.6, v.7 and v.8, as shown in FIG. 12. The boundaries of exons in the original transcript, 98P4B6 v.1 were shown in Table LI. The first 22 bases of v.1 were not in the nearby 5′ region of v.1 on the current assembly of the human genome. Compared with 98P4B6 v.1, variant v.2 was a single exon transcript whose 3′ portion was the same as the last exon of v.1. The first two exons of v.3 were in intron 1 of v. 1. Variants v.4, v.5, and v.6 spliced out 224-334 in the first exon of v.1. In addition, v.5 spliced out exon 5 while v.6 spliced out exon 6 but extended exon 5 of v.1. Variant v.7 used alternative transcription start and different 3′ exons. Variant v.8 extended 5′ end and kept the whole intron 5 of v.1. Theoretically, each different combination of exons in spatial order, e.g. exons 2 and 3, is a potential splice variant.  
     [0858] Tables LII through LV are set forth on a variant-by-variant basis. Tables LII(a)-(g) show the nucleotide sequence of the transcript variant. Tables LIII(a)-(g) show the alignment of the transcript variant with the nucleic acid sequence of 98P4B6 v.1. Tables LIV(a)-(g) lay out the amino acid translation of the transcript variant for the identified reading frame orientation. Tables LV(a)-(g) display alignments of the amino acid sequence encoded by the splice variant with that of 98P4B6 v.1. Additionally, single nucleotide polymorphisms (SNP) are noted in the alignment.  
     Example 6  
     Single Nucleotide Polymorphisms of 98P4B6  
     [0859] A Single Nucleotide Polymorphism (SNP) is a single base pair variation in a nucleotide sequence at a specific location. At any given point of the genome, there are four possible nucleotide base pairs: A/T, C/G, G/C and T/A. Genotype refers to the specific base pair sequence of one or more locations in the genome of an individual. Haplotype refers to the base pair sequence of more than one location on the same DNA molecule (or the same chromosome in higher organisms), often in the context of one gene or in the context of several tightly linked genes. SNP that occurs on a cDNA is called cSNP. This cSNP may change amino acids of the protein encoded by the gene and thus change the functions of the protein. Some SNP cause inherited diseases; others contribute to quantitative variations in phenotype and reactions to environmental factors including diet and drugs among individuals. Therefore, SNP and/or combinations of alleles (called haplotypes) have many applications, including diagnosis of inherited diseases, determination of drug reactions and dosage, identification of genes responsible for diseases, and analysis of the genetic relationship between individuals (P. Nowotny, J. M. Kwon and A. M. Goate, “SNP analysis to dissect human traits,” Curr. Opin. Neurobiol. October 2001; 11 (5):637-641; M. Pirmohamed and B. K. Park, “Genetic susceptibility to adverse drug reactions,” Trends Pharmacol. Sci. June 2001; 22(6):298-305; J. H. Riley, C. J. Allan, E. Lai and A. Roses, “The use of single nucleotide polymorphisms in the isolation of common disease genes,” Pharmacogenomics. February 2000; 1(1):39-47; R. Judson, J. C. Stephens and A. Windemuth, “The predictive power of haplotypes in clinical response,” Pharmacogenomics. February 2000; 1(1):15-26).  
     [0860] SNP are identified by a variety of art-accepted methods (P. Bean, “The promising voyage of SNP target discovery,” Am. Clin. Lab. October-November 2001; 20(9):18-20; K. M. Weiss, “In search of human variation,” Genome Res. July 1998; 8(7):691-697; M. M. She, “Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies,” Clin. Chem. February 2001; 47(2):164-172). For example, SNP can be identified by sequencing DNA fragments that show polymorphism by gel-based methods such as restriction fragment length polymorphism (RFLP) and denaturing gradient gel electrophoresis (DGGE). They can also be discovered by direct sequencing of DNA samples pooled from different individuals or by comparing sequences from different DNA samples. With the rapid accumulation of sequence data in public and private databases, one can discover SNP by comparing sequences using computer programs (Z. Gu, L. Hillier and P. Y. Kwok, “Single nucleotide polymorphism hunting in cyberspace,” Hum. Mutat. 1998; 12(4):221-225). SNP can be verified and genotype or haplotype of an individual can be determined by a variety of methods including direct sequencing and high throughput microarrays (P. Y. Kwok, “Methods for genotyping single nucleotide polymorphisms,” Annu. Rev. Genomics Hum. Genet. 2001; 2:235-258; M. Kokoris, K. Dix, K. Moynihan, J. Mathis, B. Erwin, P. Grass, B. Hines and A. Duesterhoeft, “High-throughput SNP genotyping with the Masscode system,” Mol. Diagn. December 2000; 5(4):329-340).  
     [0861] Using the methods described above, eleven SNP were identified in the original transcript, 98P4B6 v.1, at positions 46 (A/G), 179 (C/T), 180 (A/G), 269 (A/G), 404 (G/T), 985 (C/T), 1170 (T/C), 1497 (A/G), 1746 (T/G), 2046 (T/G) and 2103 (T/C). The transcripts or proteins with alternative allele were designated as variant 98P4B6 v.9 through v.19, as shown in FIG. 10 a . FIG. 11 shows the schematic alignment of protein variants, corresponding to nucleotide variants. Nucleotide variants that code for the same amino acid sequence as v.1 are not shown in FIG. 11. These alleles of the SNP, though shown separately here, can occur in different combinations (haplotypes) and in any one of the transcript variants (such as 98P4B6 v.5) that contains the site of the SNP. In addition, there were SNP in other transcript variants in regions not shared with v.1. For example, there were fourteen SNP in the fifth intron of v.1, which was part of transcript variants v.2, v.6 and v.8. These SNP are shown in FIG. 10 c  and listed as following (numbers relative v.8): 1760 (G/A), 1818 (G/T), 1870 (C/T), 2612 (T/C), 2926 (T/A), 4241 (T/A), 4337 (A/G), 4338 (A/C), 4501 (NG), 4506 (C/T), 5434 (C/A), 5434 (C/G), 5434 (C/T) and 5589 (C/A). FIG. 10 b  shows the SNP in the unique regions of transcript variant v.7: 1956 (A/C), 1987 (T/A), 2010 (G/C), 2010 (G/T) and 2059 (G/A) (numbers correspond to nucleotide sequence of v.7).  
     Example 7  
     Production of Recombinant 98P4B6 in Prokaryotic Systems  
     [0862] To express recombinant 98P4B6 and 98P4B6 variants in prokaryotic cells, the full or partial length 98P4B6 and 98P4B6 variant cDNA sequences are cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 98P4B6 variants are expressed: the full length sequence presented in FIGS. 2 and 3, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 98P4B6, variants, or analogs thereof.  
     [0863] A. In Vitro Transcription and Translation Constructs:  
     [0864] pCRII: To generate 98P4B6 sense and anti-sense RNA probes for RNA in situ investigations, pCRII constructs (Invitrogen, Carlsbad Calif.) are generated encoding either all or fragments of the 98P4B6 cDNA. The pCRII vector has Sp6 and T7 promoters flanking the insert to drive the transcription of 98P4B6 RNA for use as probes in RNA in situ hybridization experiments. These probes are used to analyze the cell and tissue expression of 98P4B6 at the RNA level. Transcribed 98P4B6 RNA representing the cDNA amino acid coding region of the 98P4B6 gene is used in in vitro translation systems such as the TnT™ Coupled Reticulolysate System (Promega, Corp., Madison, Wis.) to synthesize 98P4B6 protein.  
     [0865] B. Bacterial Constructs:  
     [0866] pGEX Constructs: To generate recombinant 98P4B6 proteins in bacteria that are fused to the Glutathione S-transferase (GST) protein, all or parts of the 98P4B6 cDNA protein coding sequence are cloned into the pGEX family of GST-fusion vectors (Amersham Pharmacia Biotech, Piscataway, N.J.). These constructs allow controlled expression of recombinant 98P4B6 protein sequences with GST fused at the amino-terminus and a six histidine epitope (6×His) at the carboxyl-terminus. The GST and 6×His tags permit purification of the recombinant fusion protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-GST and anti-His antibodies. The 6×His tag is generated by adding 6 histidine codons to the cloning primer at the 3′ end, e.g., of the open reading frame (ORF). A proteolytic cleavage site, such as the PreScission™ recognition site in pGEX-6P-1, may be employed such that it permits cleavage of the GST tag from 98P4B6-related protein. The ampicillin resistance gene and pBR322 origin permits selection and maintenance of the pGEX plasmids in  E. coli . A glutathione-Stransferase (GST) fusion protein encompassing amino acids 2-204 of the STEAP-2 protein sequence was generated in the pGEX vector. The recombinant GST-STEAP-2 fusion protein was purified from induced bacteria by glutathione-sepaharose affinity chromatography and used as immunogen for generation of a polyclonal antibody.  
     [0867] pMAL Constructs: To generate, in bacteria, recombinant 98P4B6 proteins that are fused to maltose-binding protein (MBP), all or parts of the 98P4B6 cDNA protein coding sequence are fused to the MBP gene by cloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs, Beverly, Mass.). These constructs allow controlled expression of recombinant 98P4B6 protein sequences with MBP fused at the amino-terminus and a 6×His epitope tag at the carboxyl-terminus. The MBP and 6×His tags permit purification of the recombinant protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-MBP and anti-His antibodies. The 6×His epitope tag is generated by adding 6 histidine codons to the 3′ cloning primer. A Factor Xa recognition site permits cleavage of the pMAL tag from 98P4B6. The pMAL-c2X and pMAL-p2X vectors are optimized to express the recombinant protein in the cytoplasm or periplasm respectively. Periplasm expression enhances folding of proteins with disulfide bonds.  
     [0868] pET Constructs: To express 98P4B6 in bacterial cells, all or parts of the 98P4B6 cDNA protein coding sequence are cloned into the pET family of vectors (Novagen, Madison, Wis.). These vectors allow tightly controlled expression of recombinant 98P4B6 protein in bacteria with and without fusion to proteins that enhance solubility, such as NusA and thioredoxin (Trx), and epitope tags, such as 6×His and S-Tag™ that aid purification and detection of the recombinant protein. For example, constructs are made utilizing pET NusA fusion system 43.1 such that regions of the 98P4B6 protein are expressed as amino-terminal fusions to NusA.  
     [0869] C. Yeast Constructs:  
     [0870] pESC Constructs: To express 98P4B6 in the yeast species  Saccharomyces cerevisiae  for generation of recombinant protein and functional studies, all or parts of the 98P4B6 cDNA protein coding sequence are cloned into the pESC family of vectors each of which contain 1 of 4 selectable markers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, Calif.). These vectors allow controlled expression from the same plasmid of up to 2 different genes or cloned sequences containing either Flag™ or Myc epitope tags in the same yeast cell. This system is useful to confirm protein-protein interactions of 98P4B6. In addition, expression in yeast yields similar post-translational modifications, such as glycosylations and phosphorylations, that are found when expressed in eukaryotic cells.  
     [0871] pESP Constructs: To express 98P4B6 in the yeast species  Saccharomyces pombe , all or parts of the 98P4B6 cDNA protein coding sequence are cloned into the pESP family of vectors. These vectors allow controlled high level of expression of a 98P4B6 protein sequence that is fused at either the amino terminus or at the carboxyl terminus to GST which aids purification of the recombinant protein. A Flag™ epitope tag allows detection of the recombinant protein with anti-Flag™ antibody.  
     Example 8  
     Production of Recombinant 98P4B6 in Higher Eukaryotic Systems  
     [0872] A. Mammalian Constructs:  
     [0873] To express recombinant 98P4B6 in eukaryotic cells, the full or partial length 98P4B6 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 98P4B6 are expressed in these constructs, amino acids 1 to 255, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 98P4B6 v.1 through v.11; amino acids 1 to 1266, or any 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 98P4B6 v.12 and v.13, variants, or analogs thereof.  
     [0874] The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates can be probed with the anti-98P4B6 polyclonal serum, described herein.  
     [0875] pcDNA4/HisMax Constructs: To express 98P4B6 in mammalian cells, a 98P4B6 ORF, or portions thereof, of 98P4B6 are cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has Xpress™ and six histidine (6×His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in  E. coli.    
     [0876] pcDNA3.1/MycHis Constructs: To express 98P4B6 in mammalian cells, a 98P4B6 ORF, or portions thereof, of 98P4B6 with a consensus Kozak translation initiation site was cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6×His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene can be used, as it allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in  E. coli.    
     [0877] pcDNA3.1/GFP Construct: To express 98P4B6 in mammalian cells and to allow detection of the recombinant proteins using fluorescence, the 98P4B6 ORF sequence was codon optimized according to Mirzabekov et al. (1999), and was cloned into pcDNA3.1/GFP vector to generate 98P4B6.GFP.pcDNA3.1 construct. Protein expression was driven from the cytomegalovirus (CMV) promoter. The recombinant protein had the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, in vivo detection and cell biology studies. The pcDNA3.1/GFP vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in  E. coli.    
     [0878] Transfection of 98P4B6.GFP.pcDNA3.1 into 293T cells was performed as shown in FIGS. 17 and 18. Results show strong expression of the fusion protein by western blot analysis (FIG. 17), flow cytometry (FIG. 18A) and fluorescent microscopy (FIG. 18B).  
     [0879] Additional constructs with an amino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning the entire length of a 98P4B6 protein.  
     [0880] PAPtag: A 98P4B6 ORF, or portions thereof, is cloned into pAPtag-5 (GenHunter Corp. Nashville, Tenn.). This construct generates an alkaline phosphatase fusion at the carboxyl-terminus of a 98P4B6 protein while fusing the IgGκ signal sequence to the amino-terminus. Constructs are also generated in which alkaline phosphatase with an amino-terminal IgGκ signal sequence is fused to the amino-terminus of a 98P4B6 protein. The resulting recombinant 98P4B6 proteins are optimized for secretion into the media of transfected mammalian cells and can be used to identify proteins such as ligands or receptors that interact with 98P4B6 proteins. Protein expression is driven from the CMV promoter and the recombinant proteins also contain myc and 6×His epitopes fused at the carboxyl-terminus that facilitates detection and purification. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the recombinant protein and the ampicillin resistance gene permits selection of the plasmid in  E. coli.    
     [0881] pTag5: A 98P4B6 ORF, or portions thereof, is cloned into pTag-5. This vector is similar to pAPtag but without the alkaline phosphatase fusion. This construct generates 98P4B6 protein with an amino-terminal IgGκ signal sequence and myc and 6×His epitope tags at the carboxyl-terminus that facilitate detection and affinity purification. The resulting recombinant 98P4B6 protein is optimized for secretion into the media of transfected mammalian cells, and is used as immunogen or ligand to identify proteins such as ligands or receptors that interact with the 98P4B6 proteins. Protein expression is driven from the CMV promoter. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in  E. coli.    
     [0882] PsecFc: A 98P4B6 ORF, or portions thereof, is also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 98P4B6 proteins, while fusing the IgGκ signal sequence to N-terminus. 98P4B6 fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 98P4B6 proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with 98P4B6 protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in  E. coli.    
     [0883] pSRα Constructs: To generate mammalian cell lines that express 98P4B6 constitutively, 98P4B6 ORF, or portions thereof, of 98P4B6 were cloned into pSRα constructs. Amphotropic and ecotropic retroviruses were generated by transfection of pSRα constructs into the 293T-10A1 packaging line or co-transfection of pSRα and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus is used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 98P4B6, into the host cell-lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in  E. coli . The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.  
     [0884] Additional pSRα constructs are made that fuse an epitope tag such as the FLAG™ tag to the carboxyl-terminus of 98P4B6 sequences to allow detection using anti-Flag antibodies. For example, the FLAG™ sequence 5′ gat tac aag gat gac gac gat aag 3′ (SEQ ID NO: 113) is added to cloning primer at the 3′ end of the ORF. Additional pSRα constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6×His fusion proteins of the full-length 98P4B6 proteins.  
     [0885] Additional Viral Vectors: Additional constructs are made for viral-mediated delivery and expression of 98P4B6. High virus titer leading to high level expression of 98P4B6 is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. A 98P4B6 coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer&#39;s instructions to generate adenoviral vectors. Alternatively, 98P4B6 coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.  
     [0886] Regulated Expression Systems: To control expression of 98P4B6 in mammalian cells, coding sequences of 98P4B6, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System (Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Sratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 98P4B6. These vectors are thereafter used to control expression of 98P4B6 in various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.  
     [0887] B. Baculovirus Expression Systems  
     [0888] To generate recombinant 98P4B6 proteins in a baculovirus expression system, 98P4B6 ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-98P4B6 is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 ( Spodoptera frugiperda ) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details). Baculovirus is then collected from cell supernatant and purified by plaque assay.  
     [0889] Recombinant 98P4B6 protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 98P4B6 protein can be detected using anti-98P4B6 or anti-His-tag antibody. 98P4B6 protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 98P4B6.  
     Example 9  
     Antigenicity Profiles and Secondary Structure  
     [0890]FIG. 5(A-E), FIG. 6(A-E), FIG. 7(A-E), FIG. 8(A-E), and FIG. 9(A-E) depict graphically five amino acid profiles of 98P4B6 variants 1, 2, 5-7, each assessment available by accessing the ProtScale website located on the World Wide Web at .expasy.ch/cgi-bin/protscale.pl) on the ExPasy molecular biology server.  
     [0891] These profiles: FIG. 5, Hydrophilicity, (Hopp T. P., Woods K. R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); FIG. 6, Hydropathicity, (Kyte J., Doolittle R. F., 1982. J. Mol. Biol. 157:105-132); FIG. 7, Percentage Accessible Residues (Janin J., 1979 Nature 277:491-492); FIG. 8, Average Flexibility, (Bhaskaran R., and Ponnuswarmy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255); FIG. 9, Beta-turn (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294); and optionally others available in the art, such as on the ProtScale website, were used to identify antigenic regions of each of the 98P4B6 variant proteins. Each of the above amino acid profiles of 98P4B6 variants were generated using the following ProtScale parameters for analysis: 1) A window size of 9; 2) 100% weight of the window edges compared to the window center; and, 3) amino acid profile values normalized to lie between 0 and 1.  
     [0892] Hydrophilicity (FIG. 5), Hydropathicity (FIG. 6) and Percentage Accessible Residues (FIG. 7) profiles were used to determine stretches of hydrophilic amino acids (i.e., values greater than 0.5 on the Hydrophilicity and Percentage Accessible Residues profile, and values less than 0.5 on the Hydropathicity profile). Such regions are likely to be exposed to the aqueous environment, be present on the surface of the protein, and thus available for immune recognition, such as by antibodies.  
     [0893] Average Flexibility (FIG. 8) and Beta-turn (FIG. 9) profiles determine stretches of amino acids (i.e., values greater than 0.5 on the Beta-turn profile and the Average Flexibility profile) that are not constrained in secondary structures such as beta sheets and alpha helices. Such regions are also more likely to be exposed on the protein and thus accessible to immune recognition, such as by antibodies.  
     [0894] Antigenic sequences of the 98P4B6 variant proteins indicated, e.g., by the profiles set forth in FIG. 5(A-E), FIG. 6(A-E), FIG. 7(A-E), FIG. 8(A-E), and/or FIG. 9(A-E) are used to prepare immunogens, either peptides or nucleic acids that encode them, to generate therapeutic and diagnostic anti-98P4B6 antibodies. The immunogen can be any 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more than 50 contiguous amino acids, or the corresponding nucleic acids that encode them, from the 98P4B6 protein variants 1, 2, 5-7 listed in FIGS. 2 and 3. In particular, peptide immunogens of the invention can comprise, a peptide region of at least 5 amino acids of FIGS. 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profiles of FIG. 5; a peptide region of at least 5 amino acids of FIGS. 2 and 3 in any whole number increment that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6; a peptide region of at least 5 amino acids of FIGS. 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profiles of FIG. 7; a peptide region of at least 5 amino acids of FIGS. 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profiles on FIG. 8; and, a peptide region of at least 5 amino acids of FIGS. 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9. Peptide immunogens of the invention can also comprise nucleic acids that encode any of the forgoing.  
     [0895] All immunogens of the invention, peptide or nucleic acid, can be embodied in human unit dose form, or comprised by a composition that includes a pharmaceutical excipient compatible with human physiology.  
     [0896] The secondary structure of 98P4B6 protein variants 1, 2, 5-7, namely the predicted presence and location of alpha helices, extended strands, and random coils, is predicted from the primary amino acid sequence using the HNN—Hierarchical Neural Network method (Guermeur, 1997, http://pbil.ibcp.fr/cgi-bin/npsa automat.pl?page=npsa_nn.html), accessed from the ExPasy molecular biology server (located on the World Wide Web at .expasy.ch/toolsq. The analysis indicates that 98P4B6 variant 1 is composed of 54.41% alpha helix, 12.33% extended strand, and 33.26% random coil (FIG. 13A). Variant 2 is composed of 17.78% alpha helix, 6.67% extended strand, and 75.56% random coil (FIG. 13B). Variant 5 is composed of 51.55% alpha helix, 13.13% extended strand, and 35.32% random coil (FIG. 13C). Variant 6 is composed of 54.49% alpha helix, 11.84% extended strand, and 33.67% random coil (FIG. 13D). Variant 7 is composed of 48.26% alpha helix, 15.28% extended strand, and 36.46% random coil (FIG. 13E).  
     [0897] Analysis for the potential presence of transmembrane domains in the 98P4B6 variant proteins was carried out using a variety of transmembrane prediction algorithms accessed from the ExPasy molecular biology server (located on the World Wide Web at .expasy.ch/toolsI). Shown graphically in FIGS. 13F and 13G are the results of analysis of variant 1 depicting the presence and location of 6 transmembrane domains using the TMpred program (FIG. 13F) and 5 transmembrane domains using the TMHMM program (FIG. 13G). Shown graphically in FIGS. 13H and 13I are the results of analysis of variant 2 depicting the presence and location of 1 transmembrane domains using the TMpred program (FIG. 13H) and no transmembrane domains using the TMHMM program (FIG. 13I). Shown graphically in FIGS. 13J and 13K are the results of analysis of variant 5 depicting the presence and location of 6 transmembrane domains using the TMpred program (FIG. 13J) and 4 transmembrane domains using the TMHMM program (FIG. 13K). Shown graphically in FIGS. 13L and 13M are the results of analysis of variant 6 depicting the presence and location of 6 transmembrane domains using the TMpred program (FIG. 13L) and 6 transmembrane domains using the TMHMM program (FIG. 13M). Shown graphically in FIGS. 13N and 13O are the results of analysis of variant 7 depicting the presence and location of 6 transmembrane domains using the TMpred program (FIG. 13N) and 4 transmembrane domains using the TMHMM program (FIG. 13O). The results of each program, namely the amino acids encoding the transmembrane domains are summarized in Table VI.  
     Example 10  
     Generation of 98P4B6 Polyclonal Antibodies  
     [0898] Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. In addition to immunizing with a full length 98P4B6 protein variant, computer algorithms are employed in design of immunogens that, based on amino acid sequence analysis contain characteristics of being antigenic and available for recognition by the immune system of the immunized host (see Example 9 entitled “Antigenicity Profiles and Secondary Structure”). Such regions would be predicted to be hydrophilic, flexible, in beta-turn conformations, and be exposed on the surface of the protein (see, e.g., FIG. 5(A-E), FIG. 6(A &amp; B), FIG. 7(A-E), FIG. 8(A-E), or FIG. 9(A-E) for amino acid profiles that indicate such regions of 98P4B6 protein variants).  
     [0899] For example, recombinant bacterial fusion proteins or peptides containing hydrophilic, flexible, beta-turn regions of 98P4B6 protein variants are used as antigens to generate polyclonal antibodies in New Zealand White rabbits or monoclonal antibodies as described in Example 11. For example, in 98P4B6 variant 1, such regions include, but are not limited to, amino acids 153-165, amino acids 240-260, and amino acids 345-358. In sequence specific for variant 2, such regions include, but are not limited to, amino acids 26-38. In sequence specific for variant 5, such regions include, but are not limited to, amino acids 400-410. In sequence specific for variant 6, such regions include, but are not limited to, amino acids 455-490. In sequence specific for variant 7, such regions include, but are not limited to, amino acids 451-465 and amino acids 472-498. It is useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. In one embodiment, a peptide encoding amino acids 153-165 of 98P4B6 variant 1 was conjugated to KLH and used to immunize a rabbit. Alternatively the immunizing agent may include all or portions of the 98P4B6 variant proteins, analogs or fusion proteins thereof. For example, the 98P4B6 variant 1 amino acid sequence can be fused using recombinant DNA techniques to any one of a variety of fusion protein partners that are well known in the art, such as glutathione-S-transferase (GST) and HIS tagged fusion proteins. In another embodiment, amino acids 2-204 of 98P4B6 variant 1 was fused to GST using recombinant techniques and the pGEX expression vector, expressed, purified and used to immunize a rabbit. Such fusion proteins are purified from induced bacteria using the appropriate affinity matrix.  
     [0900] Other recombinant bacterial fusion proteins that may be employed include maltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulin constant region (see the section entitled “Production of 98P4B6 in Prokaryotic Systems” and Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubul et al. eds., 1995; Linsley, P. S., Brady, W., Umes, M., Grosmaire, L., Damle, N., and Ledbetter, L.(1991) J. Exp. Med. 174, 561-566).  
     [0901] In addition to bacterial derived fusion proteins, mammalian expressed protein antigens are also used. These antigens are expressed from mammalian expression vectors such as the Tag5 and Fc-fusion vectors (see the section entitled “Production of Recombinant 98P4B6 in Eukaryotic Systems”), and retain post-translational modifications such as glycosylations found in native protein. In one embodiment, amino acids 324-359 of variant 1, encoding an extracellular loop between transmembrane domains, is cloned into the Tag5 mammalian secretion vector. The recombinant protein is purified by metal chelate chromatography from tissue culture supernatants of 293T cells stably expressing the recombinant vector. The purified Tag5 98P4B6 protein is then used as immunogen.  
     [0902] During the immunization protocol, it is useful to mix or emulsify the antigen in adjuvants that enhance the immune response of the host animal. Examples of adjuvants include, but are not limited to, complete Freund&#39;s adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
     [0903] In a typical protocol, rabbits are initially immunized subcutaneously with up to 200 μg, typically 100-200 μg, of fusion protein or peptide conjugated to KLH mixed in complete Freund&#39;s adjuvant (CFA). Rabbits are then injected subcutaneously every two weeks with up to 200 μg, typically 100-200 μg, of the immunogen in incomplete Freund&#39;s adjuvant (IFA). Test bleeds are taken approximately 7-10 days following each immunization and used to monitor the titer of the antiserum by ELISA.  
     [0904] To test reactivity and specificity of immune serum, such as the rabbit serum derived from immunization with the Tag5-98P4B6 variant 1 protein, the full-length 98P4B6 variant 1 cDNA is cloned into pCDNA 3.1 myc-his expression vector (Invitrogen, see the Example entitled “Production of Recombinant 98P4B6 in Eukaryotic Systems”). After transfection of the constructs into 293T cells, cell lysates are probed with the anti-98P4B6 serum and with anti-His antibody (Santa Cruz Biotechnologies, Santa Cruz, Calif.) to determine specific reactivity to denatured 98P4B6 protein using the Western blot technique. Detection of 98P4B6 variant 1 protein expressed in 293T with polyclonal antibodies raised to a GST-fusion protein and peptide is shown in FIGS. 17B and 17C, respectively. In addition, the immune serum is tested by fluorescence microscopy, flow cytometry and immunoprecipitation against 293T and other recombinant 98P4B6-expressing cells to determine specific recognition of native protein. Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometric techniques using cells that endogenously express 98P4B6 are also carried out to test reactivity and specificity.  
     [0905] Anti-serum from rabbits immunized with 98P4B6 variant fusion proteins, such as GST and MBP fusion proteins, are purified by depletion of antibodies reactive to the fusion partner sequence by passage over an affinity column containing the fusion partner either alone or in the context of an irrelevant fusion protein. For example, antiserum derived from a G&amp;T-98P4B6 variant 1 fusion protein was first purified by passage over a column of GST protein covalently coupled to AffiGel matrix (BioRad, Hercules, Calif.). The antiserum is then affinity purified by passage over a column composed of a MBP-98P4B6 fusion protein covalently coupled to Affigel matrix. The serum is then further purified by protein G affinity chromatography to isolate the IgG fraction. Sera from other His-tagged antigens and peptide immunized rabbits as well as fusion partner depleted sera are affinity purified by passage over a column matrix composed of the original protein immunogen or free peptide, such as the anti-peptide polyclonal antibody used in FIG. 17C.  
     Example 11  
     Generation of 98P4B6 Monoclonal Antibodies (mAbs)  
     [0906] In one embodiment, therapeutic mAbs to 98P4B6 variants comprise those that react with epitopes specific for each variant protein or specific to sequences in common between the variants that would disrupt or modulate the biological function of the 98P4B6 variants, for example those that would disrupt the interaction with ligands and binding partners. Immunogens for generation of such mAbs include those designed to encode or contain the entire 98P4B6 protein variant sequence, regions of the 98P4B6 protein variants predicted to be antigenic from computer analysis of the amino acid sequence (see, e.g., FIG. 5(A-E), FIG. 6(A-E), FIG. 7(A-E), FIG. 8(A-E), or FIG. 9(A-E), and Example 9 entitled “Antigenicity Profiles and Secondary Structure”). Immunogens include peptides, recombinant bacterial proteins, and mammalian expressed Tag 5 proteins and human and murine IgG FC fusion proteins. In addition, cells engineered to express high levels of a respective 98P4B6 variant, such as 293T-98P4B6 variant 1 or 300.19-98P4B6 variant 1 murine Pre-B cells, are used to immunize mice.  
     [0907] To generate mAbs to a 98P4B6 variant, mice are first immunized intraperitoneally (IP) with, typically, 10-50 μg of protein immunogen or 10 7  98P4B6-expressing cells mixed in complete Freund&#39;s adjuvant. Mice are then subsequently immunized IP every 2-4 weeks with, typically, 10-50 μg of protein immunogen or 10 7  cells mixed in incomplete Freund&#39;s adjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. In addition to the above protein and cell-based immunization strategies, a DNA-based immunization protocol is employed in which a mammalian expression vector encoding a 98P4B6 variant sequence is used to immunize mice by direct injection of the plasmid DNA. For example, amino acids 324-359 is cloned into the Tag5 mammalian secretion vector and the recombinant vector is used as immunogen. In another example the same amino acids are cloned into an Fc-fusion secretion vector in which the 98P4B6 variant 1 sequence is fused at the amino-terminus to an IgK leader sequence and at the carboxyl-terminus to the coding sequence of the human or murine IgG Fc region. This recombinant vector is then used as immunogen. The plasmid immunization protocols are used in combination with purified proteins expressed from the same vector and with cells expressing the respective 98P4B6 variant.  
     [0908] During the immunization protocol, test bleeds are taken 7-10 days following an injection to monitor titer and specificity of the immune response. Once appropriate reactivity and specificity is obtained as determined by ELISA, Western blotting, immunoprecipitation, fluorescence microscopy, and flow cytometric analyses, fusion and hybridoma generation is then carried out with established procedures well known in the art (see, e.g., Harlow and Lane, 1988).  
     [0909] In one embodiment for generating 98P4B6 monoclonal antibodies, a Tag5-98P4B6 variant 1 antigen encoding amino acids 324-359, is expressed and purified from stably transfected 293T cells. Balb C mice are initially immunized intraperitoneally with 25 μg of the Tag5-98P4B6 variant 1 protein mixed in complete Freund&#39;s adjuvant. Mice are subsequently immunized every two weeks with 25 μg of the antigen mixed in incomplete Freund&#39;s adjuvant for a total of three immunizations. ELISA using the Tag5 antigen determines the titer of serum from immunized mice. Reactivity and specificity of serum to full length 98P4B6 variant 1 protein is monitored by Western blotting, immunoprecipitation and flow cytometry using 293T cells transfected with an expression vector encoding the 98P4B6 variant 1 cDNA (see e.g., the Example entitled “Production of Recombinant 98P4B6 in Eukaryotic Systems” and FIG. 20). Other recombinant 98P4B6. variant 1-expressing cells or cells endogenously expressing 98P4B6 variant 1 are also used. Mice showing the strongest reactivity are rested and given a final injection of Tag5 antigen in PBS and then sacrificed four days later. The spleens of the sacrificed mice are harvested and fused to SPO/2 myeloma cells using standard procedures (Harlow and Lane, 1988). Supernatants from HAT selected growth wells are screened by ELISA, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometry to identify 98P4B6 specific antibody-producing clones.  
     [0910] To generate monoclonal antibodies that are specific for each 98P4B6 variant protein, immunogens are designed to encode sequences unique for each variant. In one embodiment, a Tag5 antigen encoding the full sequence of 98P4B6 variant 2 (AA 1-45) is produced, purified and used as immunogen to derive monoclonal antibodies specific to 98P4B6 variant 2. In another embodiment, an antigenic peptide composed of amino acids 400-410 of 98P4B6 variant 5 is coupled to KLH and used as immunogen. In another embodiment, a GST fusion protein encoding amino acids 455-490 of 98P4B6 of variant 6 is used as immunogen to derive variant 6 specific monoclonal antibodies. In another embodiment, a peptide composed of amino acids 472-498 of variant 7 is coupled to KLH and used as immunogen to generate variant 7 specific monoclonal antibodies. Hybridoma supernatants are then screened on the respective antigen and then further screened on cells expressing the specific variant and cross-screened on cells expressing the other variants to derive variant-specific monoclonal antibodies.  
     [0911] The binding affinity of a 98P4B6 variant monoclonal antibody is determined using standard technologies. Affinity measurements quantify the strength of antibody to epitope binding and are used to help define which 98P4B6 variant monoclonal antibodies preferred for diagnostic or therapeutic use, as appreciated by one of skill in the art. The BIAcore system (Uppsala, Sweden) is a preferred method for determining binding affinity. The BIAcore system uses surface plasmon resonance (SPR, Welford K. 1991, Opt. Quant. Elect. 23:1; Morton and Myszka, 1998, Methods in Enzymology 295: 268) to monitor biomolecular interactions in real time. BIAcore analysis conveniently generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants.  
     Example 12  
     HLA Class I and Class II Binding Assays  
     [0912] HLA class I and class II binding assays using purified HLA molecules are performed in accordance with disclosed protocols (e.g., PCT publications WO 94/20127 and WO 94/03205; Sidney et al.,  Current Protocols in Immunology  18.3.1 (1998); Sidney, et al.,  J. Immunol  154:247 (1995); Sette, et al.,  Mol. Immunol.  31:813 (1994)). Briefly, purified MHC molecules (5 to 500 nM) are incubated with various unlabeled peptide inhibitors and 1-10 nM  125 I-radiolabeled probe peptides as described. Following incubation, MHC-peptide complexes are separated from free peptide by gel filtration and the fraction of peptide bound is determined. Typically, in preliminary experiments, each MHC preparation is titered in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays are performed using these HLA concentrations.  
     [0913] Since under these conditions [label]&lt;[HLA] and IC 50 Δ[HLA], the measured IC 50  values are reasonable approximations of the true K D  values. Peptide inhibitors are typically tested at concentrations ranging from 120 μg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the IC 50  of a positive control for inhibition by the IC 50  for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC 50  nM values by dividing the IC 50  nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation is accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.  
     [0914] Binding assays as outlined above may be used to analyze HLA supermotif and/or HLA motif-bearing peptides (see Table IV).  
     Example 13  
     Identification of HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes  
     [0915] HLA vaccine compositions of the invention can include multiple epitopes. The multiple epitopes can comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification and confirmation of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage is performed using the strategy described below.  
     [0916] Computer Searches and Algorithms for Identification of Supermotif and/or Motif-Bearing Epitopes  
     [0917] The searches performed to identify the motif-bearing peptide sequences in the Example entitled “Antigenicity Profiles” and Tables VIII-XXI and XXII-XLIX employ the protein sequence data from the gene product of 98P4B6 set forth in FIGS. 2 and 3, the specific search peptides used to generate the tables are listed in Table VII.  
     [0918] Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs are performed as follows. All translated 98P4B6 protein sequences are analyzed using a text string search software program to identify potential peptide sequences containing appropriate HLA binding motifs; such programs are readily produced in accordance with information in the art in view of known motif/supermotif disclosures. Furthermore, such calculations can be made mentally.  
     [0919] Identified A2-, A3-, and DR-supermotif sequences are scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms account for the impact of different amino acids at different positions, and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type:  
     “Δ G”=a   1i   ×a   2i   ×a   3i    . . . ×a   ni    
     [0920] where a ji  is a coefficient which represents the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue j occurs at position i in the peptide, it is assumed to contribute a constant amount j i  to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide.  
     [0921] The method of derivation of specific algorithm coefficients has been described in Gulukota et al.,  J. Mol. Biol.  267:1258-126, 1997; (see also Sidney et al.,  Human Immunol.  45:79-93, 1996; and Southwood et al.,  J. Immunol.  160:3363-3373, 1998). Briefly, for all i positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying j is calculated relative to the remainder of the group, and used as the estimate of j i . For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired.  
     [0922] Selection of HLA-A2 Supertype Cross-Reactive Peptides  
     [0923] Protein sequences from 98P4B6 are scanned utilizing motif identification software, to identify 8-, 9-10- and 11-mer sequences containing the HLA-A2-supermotif main anchor specificity. Typically, these sequences are then scored using the protocol described above and the peptides corresponding to the positive-scoring sequences are synthesized and tested for their capacity to bind purified HLA-A*0201 molecules in vitro (HLA-A*0201 is considered a prototype A2 supertype molecule).  
     [0924] These peptides are then tested for the capacity to bind to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). Peptides that bind to at least three of the five A2-supertype alleles tested are typically deemed A2-supertype cross-reactive binders. Preferred peptides bind at an affinity equal to or less than 500 nM to three or more HLA-A2 supertype molecules.  
     [0925] Selection of HLA-A3 Supermotif-Bearing Epitopes  
     [0926] The 98P4B6 protein sequence(s) scanned above is also examined for the presence of peptides with the HLA-A3-supermotif primary anchors. Peptides corresponding to the HLA A3 supermotif-bearing sequences are then synthesized and tested for binding to HLA-A*0301 and HLA-A*1101 molecules, the molecules encoded by the two most prevalent A3-supertype alleles. The peptides that bind at least one of the two alleles with binding affinities of ≦500 nM, often ≦200 nM, are then tested for binding cross-reactivity to the other common A3-supertype alleles (e.g., A*3101, A*3301, and A*6801) to identify those that can bind at least three of the five HLA-A3-supertype molecules tested.  
     [0927] Selection of HLA-B7 Supermotif Bearing Epitopes  
     [0928] The 98P4B6 protein(s) scanned above is also analyzed for the presence of 8-, 9-10-, or 11-mer peptides with the HLA-B7-supermotif. Corresponding peptides are synthesized and tested for binding to HLA-B*0702, the molecule encoded by the most common B7-supertype allele (i.e., the prototype B7 supertype allele). Peptides binding B*0702 with IC 50  of ≦500 nM are identified using standard methods. These peptides are then tested for binding to other common B7-supertype molecules (e.g., B*3501, B*5101, B*5301, and B*5401). Peptides capable of binding to three or more of the five B7-supertype alleles tested are thereby identified.  
     [0929] Selection of A1 and A24 Motif-Bearing Epitopes  
     [0930] To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into vaccine compositions. An analysis of the 98P4B6 protein can also be performed to identify HLA-A1- and A24-motif-containing sequences.  
     [0931] High affinity and/or cross-reactive binding epitopes that bear other motif and/or supermotifs are identified using analogous methodology.  
     Example 14  
     Confirmation of Immunogenicity  
     [0932] Cross-reactive candidate CTL A2-supermotif-bearing peptides that are identified as described herein are selected to confirm in vitro immunogenicity. Confirmation is performed using the following methodology:  
     [0933] Target Cell Lines for Cellular Screening:  
     [0934] The 0.221A2.1 cell line, produced by transferring the HLA-A2.1 gene into the HLA-A, -B, —C null mutant human B-lymphoblastoid cell line 721.221, is used as the peptide-loaded target to measure activity of HLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential amino acids and 10% (v/v) heat inactivated FCS. Cells that express an antigen of interest, or transfectants comprising the gene encoding the antigen of interest, can be used as target cells to confirm the ability of peptide-specific CTLs to recognize endogenous antigen.  
     [0935] Primary CTL Induction Cultures:  
     [0936] Generation of Dendritic Cells (DC): PBMCs are thawed in RPMI with 30 μg/ml DNAse, washed twice and resuspended in complete medium (RPMI-1640 plus 5% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin/streptomycin). The monocytes are purified by plating 10×10 6  PBMC/well in a 6-well plate. After 2 hours at 37° C., the non-adherent cells are removed by gently shaking the plates and aspirating the supernatants. The wells are washed a total of three times with 3 ml RPMI to remove most of the non-adherent and loosely adherent cells. Three ml of complete medium containing 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCs on day 6 at 75 ng/ml and the cells are used for CTL induction cultures on day 7.  
     [0937] Induction of CTL with DC and Peptide: CD8+ T-cells are isolated by positive selection with Dynal immunomagnetic beads (Dynabeads® M-450) and the detacha-bead® reagent. Typically about 200-250×10 6  PBMC are processed to obtain 24×10 6  CD8, T-cells (enough for a 48-well plate culture). Briefly, the PBMCs are thawed in RPMI with 30 μg/ml DNAse, washed once with PBS containing 1% human AB serum and resuspended in PBS/1% AB serum at a concentration of 20×10 6  cells/ml. The magnetic beads are washed 3 times with PBS/AB serum, added to the cells (140 μl beads/20×10 6  cells), and incubated for 1 hour at 4° C. with continuous mixing. The beads and cells are washed 4× with PBS/AB serum to remove the nonadherent cells and resuspended at 100×10 6  cells/ml (based on the original cell number) in PBS/AB serum containing 100 μl/ml detacha-bead® reagent and 30 μg/ml DNAse. The mixture is incubated for 1 hour at room temperature with continuous mixing. The beads are washed again with PBS/ABIDNAse to collect the CD8+ T-cells. The DC are collected and centrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40 μg/ml of peptide at a cell concentration of 1-2×10 6 /ml in the presence of 3 μg/ml 13 microglobulin for 4 hours at 20° C. The DC are then irradiated (4,200 rads), washed 1 time with medium and counted again.  
     [0938] Setting up induction cultures: 0.25 ml cytokine-generated DC (at 1×10 5  cells/ml) are co-cultured with 0.25 ml of CD8+ T-cells (at 2×10 6  cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml of IL-7. Recombinant human IL-10 is added the next day at a final concentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10 IU/ml.  
     [0939] Restimulation of the induction cultures with peptide-pulsed adherent cells: Seven and fourteen days after the primary induction, the cells are restimulated with peptide-pulsed adherent cells. The PBMCs are thawed and washed twice with RPMI and DNAse. The cells are resuspended at 5×10 6  cells/ml and irradiated at −4200 rads. The PBMCs are plated at 2×10 6  in 0.5 ml complete medium per well and incubated for 2 hours at 37° C. The plates are washed twice with RPMI by tapping the plate gently to remove the nonadherent cells and the adherent cells pulsed with 10 μg/ml of peptide in the presence of 3 μg/ml 2 microglobulin in 0.25 ml RPMI/5% AB per well for 2 hours at 37° C. Peptide solution from each well is aspirated and the wells are washed once with RPMI. Most of the media is aspirated from the induction cultures (CD8+ cells) and brought to 0.5 ml with fresh media. The cells are then transferred to the wells containing the peptide-pulsed adherent cells. Twenty four hours later recombinant human IL-10 is added at a final concentration of 10 ng/ml and recombinant human IL2 is added the next day and again 2-3 days later at 50 IU/ml (Tsai et al.,  Critical Reviews in Immunology  18(1-2):65-75, 1998). Seven days later, the cultures are assayed for CTL activity in a  51 Cr release assay. In some experiments the cultures are assayed for peptide-specific recognition in the in situ IFNγ ELISA at the time of the second restimulation followed by assay of endogenous recognition 7 days later. After expansion, activity is measured in both assays for a side-by-side comparison.  
     [0940] Measurement of CTL Lytic Activity by  51 Cr Release.  
     [0941] Seven days after the second restimulation, cytotoxicity is determined in a standard (5 hr)  51 Cr release assay by assaying individual wells at a single E:T. Peptide-pulsed targets are prepared by incubating the cells with 10 μg/ml peptide overnight at 37° C.  
     [0942] Adherent target cells are removed from culture flasks with trypsin-EDTA. Target cells are labeled with 200 μCi of  51 Cr sodium chromate (Dupont, Wilmington, Del.) for 1 hour at 37° C. Labeled target cells are resuspended at 10 6  per ml and diluted 1:10 with K562 cells at a concentration of 3.3×10 6 /ml (an NK-sensitive erythroblastoma cell line used to reduce non-specific lysis). Target cells (100 μl) and effectors (100 μl) are plated in 96 well round-bottom plates and incubated for 5 hours at 37° C. At that time, 100 μl of supernatant are collected from each well and percent lysis is determined according to the formula:  
     [( cpm  of the test sample− cpm  of the spontaneous  51 Cr release sample)/( cpm  of the maximal  51 Cr release sample− cpm  of the spontaneous  51 Cr release sample)]×100.  
     [0943] Maximum and spontaneous release are determined by incubating the labeled targets with 1% Triton X-100 and media alone, respectively. A positive culture is defined as one in which the specific lysis (sample−background) is 10% or higher in the case of individual wells and is 15% or more at the two highest E:T ratios when expanded cultures are assayed.  
     [0944] In Situ Measurement of Human IFNγ Production as an Indicator of Peptide-Specific and Endogenous Recognition  
     [0945] Immulon 2 plates are coated with mouse anti-human IFNγ monoclonal antibody (4 μg/ml 0.1M NaHCO 3 , pH 8.2) overnight at 4° C. The plates are washed with Ca 2+ , Mg 2+  free PBS/0.05% Tween 20 and blocked with PBS/10% FCS for two hours, after which the CTLs (100 μl/well) and targets (100 μl/well) are added to each well, leaving empty wells for the standards and blanks (which received media only). The target cells, either peptide-pulsed or endogenous targets, are used at a concentration of 1×10 6  cells/ml. The plates are incubated for 48 hours at 37° C. with 5% CO 2 .  
     [0946] Recombinant human IFN-gamma is added to the standard wells starting at 400 μg or 1200 μg/100 microliter/well and the plate incubated for two hours at 37° C. The plates are washed and 100 μl of biotinylated mouse anti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3% FCS/0.05% Tween 20) are added and incubated for 2 hours at room temperature. After washing again, 100 microliter HRP-streptavidin (1:4000) are added and the plates incubated for one hour at room temperature. The plates are then washed 6× with wash buffer, 100 microliter/well developing solution (TMB 1:1) are added, and the plates allowed to develop for 5-15 minutes. The reaction is stopped with 50 microliter/well 1 M H 3 PO 4  and read at OD450. A culture is considered positive if it measured at least 50 μg of IFN-gamma/well above background and is twice the background level of expression.  
     [0947] CTL Expansion.  
     [0948] Those cultures that demonstrate specific lytic activity against peptide-pulsed targets and/or tumor targets are expanded over a two week period with anti-CD3. Briefly, 5×10 4  CD8+ cells are added to a T25 flask containing the following: 1×10 6  irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml, 2×10 5  irradiated (8,000 rad) EBV-transformed cells per ml, and OKT3 (anti-CD3) at 30 ng per ml in RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25 μM 2-mercaptoethanol, L-glutamine and penicillin/streptomycin. Recombinant human IL2 is added 24 hours later at a final concentration of 200 IU/ml and every three days thereafter with fresh media at 50 IU/ml. The cells are split if the cell concentration exceeds 1×10 6 /ml and the cultures are assayed between days 13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the  51 Cr release assay or at 1×10 6 /ml in the in situ IFNγ assay using the same targets as before the expansion.  
     [0949] Cultures are expanded in the absence of anti-CD3+ as follows. Those cultures that demonstrate specific lytic activity against peptide and endogenous targets are selected and 5×10 4  CD8+ cells are added to a T25 flask containing the following: 1×10 6  autologous PBMC per ml which have been peptide-pulsed with 10 μg/ml peptide for two hours at 37° C. and irradiated (4,200 rad); 2×10 5  irradiated (8,000 rad) EBV-transformed cells per ml RPMI-1640 containing 10%(v/v) human AB serum, non-essential AA, sodium pyruvate, 25 mM 2-ME, L-glutamine and gentamicin.  
     [0950] Immunogenicity of A2 Supermotif-Bearing Peptides  
     [0951] A2-supermotif cross-reactive binding peptides are tested in the cellular assay for the ability to induce peptide-specific CTL in normal individuals. In this analysis, a peptide is typically considered to be an epitope if it induces peptide-specific CTLs in at least individuals, and preferably, also recognizes the endogenously expressed peptide.  
     [0952] Immunogenicity can also be confirmed using PBMCs isolated from patients bearing a tumor that expresses 98P4B6. Briefly, PBMCs are isolated from patients, re-stimulated with peptide-pulsed monocytes and assayed for the ability to recognize peptide-pulsed target cells as well as transfected cells endogenously expressing the antigen.  
     [0953] Evaluation of A*03/A11 Immunogenicity  
     [0954] HLA-A3 supermotif-bearing cross-reactive binding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA-A2 supermotif peptides.  
     [0955] Evaluation of B7 Immunogenicity  
     [0956] Immunogenicity screening of the B7-supertype cross-reactive binding peptides identified as set forth herein are confirmed in a manner analogous to the confirmation of A2-and A3-supermotif-bearing peptides.  
     [0957] Peptides bearing other supermotifs/motifs, e.g., HLA-A1, HLA-A24 etc. are also confirmed using similar methodology  
     Example 15  
     Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs  
     [0958] HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analoged to confer upon the peptide certain characteristics, e.g. greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analoging peptides to exhibit modulated binding affinity are set forth in this example.  
     [0959] Analoging at Primary Anchor Residues  
     [0960] Peptide engineering strategies are implemented to further increase the cross-reactivity of the epitopes. For example, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus.  
     [0961] To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A*0201, then, if A*0201 binding capacity is maintained, for A2-supertype cross-reactivity.  
     [0962] Alternatively, a peptide is confirmed as binding one or all supertype members and then analoged to modulate binding affinity to any one (or more) of the supertype members to add population coverage.  
     [0963] The selection of analogs for immunogenicity in a cellular screening analysis is typically further restricted by the capacity of the parent wild type (WT) peptide to bind at least weakly, i.e., bind at an IC 50  of 500 nM or less, to three of more A2 supertype alleles. The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant. Analoged peptides have been shown to have increased immunogenicity and cross-reactivity by T cells specific for the parent epitope (see, e.g., Parkhurst et al, J. Immunol. 157:2539, 1996; and Pogue et al., Proc. Natl. Acad. Sci. USA 92:8166,1995).  
     [0964] In the cellular screening of these peptide analogs, it is important to confirm that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, target cells that endogenously express the epitope.  
     [0965] Analoging of HLA-A3 and B7-Supermotif-Bearing Peptides  
     [0966] Analogs of HLA-A3 supermotif-bearing epitopes are generated using strategies similar to those employed in analoging HLA-A2 supermotif-bearing peptides. For example, peptides binding to 3/5 of the A3-supertype molecules are engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2.  
     [0967] The analog peptides are then tested for the ability to bind A*03 and A*11 (prototype A3 supertype alleles). Those peptides that demonstrate ≦500 nM binding capacity are then confirmed as having A3-supertype cross-reactivity.  
     [0968] Similarly to the A2- and A3-motif bearing peptides, peptides binding 3 or more B7-supertype alleles can be improved, where possible, to achieve increased cross-reactive binding or greater binding affinity or binding half life. B7 supermotif-bearing peptides are, for example, engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney et al. (J. Immunol. 157:3480-3490, 1996).  
     [0969] Analoging at primary anchor residues of other motif and/or supermotif-bearing epitopes is performed in a like manner.  
     [0970] The analog peptides are then be confirmed for immunogenicity, typically in a cellular screening assay. Again, it is generally important to demonstrate that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, targets that endogenously express the epitope.  
     [0971] Analoging at Secondary Anchor Residues  
     [0972] Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are associated with such properties. For example, the binding capacity of a B7 supermotif-bearing peptide with an F residue at position 1 is analyzed. The peptide is then analoged to, for example, substitute L for F at position 1. The analoged peptide is evaluated for increased binding affinity, binding half life and/or increased cross-reactivity. Such a procedure identifies analoged peptides with enhanced properties.  
     [0973] Engineered analogs with sufficiently improved binding capacity or cross-reactivity can also be tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. Analoged peptides are additionally tested for the ability to stimulate a recall response using PBMC from patients with 98P4B6-expressing tumors.  
     [0974] Other Analoging Strategies  
     [0975] Another form of peptide analoging, unrelated to anchor positions, involves the substitution of a cysteine with α-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substitution of α-amino butyric acid for cysteine not only alleviates this problem, but has been shown to improve binding and crossbinding capabilities in some instances (see, e.g., the review by Sette et al., In: Persistent Viral Infections, Eds. R. Ahmed and 1. Chen, John Wiley &amp; Sons, England, 1999).  
     [0976] Thus, by the use of single amino acid substitutions, the binding properties and/or cross-reactivity of peptide ligands for HLA supertype molecules can be modulated.  
     Example 16  
     Identification and Confirmation of 98P4B6-Derived Sequences with HLA-DR Binding Motifs  
     [0977] Peptide epitopes bearing an HLA class II supermotif or motif are identified and confirmed as outlined below using methodology similar to that described for HLA Class I peptides.  
     [0978] Selection of HLA-DR-Supermotif-Bearing Epitopes.  
     [0979] To identify 98P4B6-derived, HLA class II HTL epitopes, a 98P4B6 antigen is analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences are selected comprising a DR-supermotif, comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total).  
     [0980] Protocols for predicting peptide binding to DR molecules have been developed (Southwood et al.,  J. Immunol  160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (i.e., at position 1 and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele-specific selection tables (see, e.g., Southwood et al., ibid.), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides.  
     [0981] The 98P4B6-derived peptides identified above are tested for their binding capacity for various common HLA-DR molecules. All peptides are initially tested for binding to the DR molecules in the primary panel: DR1, DR4w4, and DR7: Peptides binding at least two of these three DR molecules are then tested for binding to DR2w2 P1, DR2w202, DR6w19, and DR9 molecules in secondary assays. Finally, peptides binding at least two of the four secondary panel DR molecules, and thus cumulatively at least four of seven different DR molecules, are screened for binding to DR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides binding at least seven of the ten DR molecules comprising the primary, secondary, and tertiary screening assays are considered cross-reactive DR binders. 98P4B6-derived peptides found to bind common HLA-DR alleles are of particular interest.  
     [0982] Selection of DR3 Motif Peptides  
     [0983] Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is a relevant criterion in the selection of HTL epitopes. Thus, peptides shown to be candidates may also be assayed for their DR3 binding capacity. However, in view of the binding specificity of the DR3 motif, peptides binding only to DR3 can also be considered as candidates for inclusion in a vaccine formulation.  
     [0984] To efficiently identify peptides that bind DR3, target 98P4B6 antigens are analyzed for sequences carrying one of the two DR3-specific binding motifs reported by Geluk et al. ( J. Immunol.  152:5742-5748, 1994). The corresponding peptides are then synthesized and confirmed as having the ability to bind DR3 with an affinity of 11M or better, i.e., less than 1 μM. Peptides are found that meet this binding criterion and qualify as HLA class II high affinity binders.  
     [0985] DR3 binding epitopes identified in this manner are included in vaccine compositions with DR supermotif-bearing peptide epitopes.  
     [0986] Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides are analoged to improve affinity or cross-reactivity. For example, aspartic acid at position 4 of the 9-mer core sequence is an optimal residue for DR3 binding, and substitution for that residue often improves DR 3 binding.  
     Example 17  
     Immunogenicity of 98P4B6-Derived HTL Epitopes  
     [0987] This example determines immunogenic DR supermotif- and DR3 motif-bearing epitopes among those identified using the methodology set forth herein.  
     [0988] Immunogenicity of HTL epitopes are confirmed in a manner analogous to the determination of immunogenicity of CTL epitopes, by assessing the ability to stimulate HTL responses and/or by using appropriate transgenic mouse models. Immunogenicity is determined by screening for: 1.) in vitro primary induction using normal PBMC or 2.) recall responses from patients who have 98P4B6-expressing tumors.  
     Example 18  
     Calculation of Phenotypic Frequencies of HLA-Supertypes in Various Ethnic Backgrounds to Determine Breadth of Population Coverage  
     [0989] This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs.  
     [0990] In order to analyze population coverage, gene frequencies of HLA alleles are determined. Gene frequencies for each HLA allele are calculated from antigen or allele frequencies utilizing the binomial distribution formulae gf=1−(SQRT(1−af)) (see, e.g., Sidney et al.,  Human Immunol.  45:79-93, 1996). To obtain overall phenotypic frequencies, cumulative gene frequencies are calculated, and the cumulative antigen frequencies derived by the use of the inverse formula [af=1−(1−Cgf) 2 )].  
     [0991] Where frequency data is not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies is assumed. To obtain total potential supertype population coverage no linkage disequilibrium is assumed, and only alleles confirmed to belong to each of the supertypes are included (minimal estimates). Estimates of total potential coverage achieved by inter-loci combinations are made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g., total=A+B*(1−A)). Confirmed members of the A3-like supertype are A3, A11, A31, A*3301, and A*6801. Although the A3-like supertype may also include A34, A66, and A*7401, these alleles were not included in overall frequency calculations. Likewise, confirmed members of the A2-like supertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802, and A*6901. Finally, the B7-like supertype-confirmed alleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601, B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, and B*5602).  
     [0992] Population coverage achieved by combining the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups. Coverage may be extended by including peptides bearing the A1 and A24 motifs. On average, A1 is present in 12% and A24 in 29% of the population across five different major ethnic groups (Caucasian, North American Black, Chinese, Japanese, and Hispanic). Together, these alleles are represented with an average frequency of 39% in these same ethnic populations. The total coverage across the major ethnicities when A1 and A24 are combined with the coverage of the A2-, A3- and B7-supertype alleles is &gt;95%, see, e.g., Table IV (G). An analogous approach can be used to estimate population coverage achieved with combinations of class II motif-bearing epitopes.  
     [0993] Immunogenicity studies in humans (e.g., Bertoni et al.,  J. Clin. Invest.  100:503, 1997; Doolan et al.,  Immunity  7:97, 1997; and Threlkeld et al.,  J. Immunol.  159:1648, 1997) have shown that highly cross-reactive binding peptides are almost always recognized as epitopes. The use of highly cross-reactive binding peptides is an important selection criterion in identifying candidate epitopes for inclusion in a vaccine that is immunogenic in a diverse population.  
     [0994] With a sufficient number of epitopes (as disclosed herein and from the art), an average population coverage is predicted to be greater than 95% in each of five major ethnic populations. The game theory Monte Carlo simulation analysis, which is known in the art (see e.g., Osborne, M. J. and Rubinstein, A. “A course in game theory” MIT Press, 1994), can be used to estimate what percentage of the individuals in a population comprised of the Caucasian, North American Black, Japanese, Chinese, and Hispanic ethnic groups would recognize the vaccine epitopes described herein. A preferred percentage is 90%. A more preferred percentage is 95%.  
     Example 19  
     CTL Recognition Of Endogenously Processed Antigens After Priming  
     [0995] This example confirms that CTL induced by native or analoged peptide epitopes identified and selected as described herein recognize endogenously synthesized, i.e., native antigens.  
     [0996] Effector cells isolated from transgenic mice that are immunized with peptide epitopes, for example HLA-A2 supermotif-bearing epitopes, are re-stimulated in vitro using peptide-coated stimulator cells. Six days later, effector cells are assayed for cytotoxicity and the cell lines that contain peptide-specific cytotoxic activity are further re-stimulated. An additional six days later, these cell lines are tested for cytotoxic activity on  51 Cr labeled Jurkat-A2.1/K b  target cells in the absence or presence of peptide, and also tested on  51 Cr labeled target cells bearing the endogenously synthesized antigen, i.e. cells that are stably transfected with 98P4B6 expression vectors.  
     [0997] The results demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized 98P4B6 antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that are being evaluated. In addition to HLA-A*0201/K b  transgenic mice, several other transgenic mouse models including mice with human A11, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes.  
     Example 20  
     Activity of CTL-HTL Conjugated Epitopes in Transgenic Mice  
     [0998] This example illustrates the induction of CTLs and HTLs in transgenic mice, by use of a 98P4B6-derived CTL and HTL peptide vaccine compositions. The vaccine composition used herein comprise peptides to be administered to a patient with a 98P4B6-expressing tumor. The peptide composition can comprise multiple CTL and/or HTL epitopes. The epitopes are identified using methodology as described herein. This example also illustrates that enhanced immunogenicity can be achieved by inclusion of one or more HTL epitopes in a CTL vaccine composition; such a peptide composition can comprise an HTL epitope conjugated to a CTL epitope. The CTL epitope can be one that binds to multiple HLA family members at an affinity of 500 nM or less, or analogs of that epitope. The peptides may be lipidated, if desired.  
     [0999] Immunization procedures: Immunization of transgenic mice is performed as described (Alexander et al.,  J. Immunol.  159:4753-4761, 1997). For example, A2/K b  mice, which are transgenic for the human HLA A2.1 allele and are used to confirm the immunogenicity of HLA-A*0201 motif- or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously (base of the tail) with a 0.1 ml of peptide in Incomplete Freund&#39;s Adjuvant, or if the peptide composition is a lipidated CTL/HTL conjugate, in DMSO/saline, or if the peptide composition is a polypeptide, in PBS or Incomplete Freund&#39;s Adjuvant. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS-activated lymphoblasts coated with peptide.  
     [1000] Cell lines: Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/K b -chimeric gene (e.g., Vitiello et al.,  J. Exp. Med.  173:1007,1991)  
     [1001] In vitro CTL activation: One week after priming, spleen cells (30×10 6  cells/flask) are co-cultured at 37° C. with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10×10 6  cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity.  
     [1002] Assay for cytotoxic activity: Target cells (1.0 to 1.5×10 6 ) are incubated at 37° C. in the presence of 200 μl of  51 Cr. After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of 1 μg/ml. For the assay, 10 4    51 Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 μl) in U-bottom 96-well plates. After a six hour incubation period at 37° C., a 0.1 ml aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the formula: percent specific release=100×(experimental release−spontaneous release)/(maximum release−spontaneous release). To facilitate comparison between separate CTL assays run under the same conditions, %  51 Cr release data is expressed as lytic units/10 6  cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a six hour  51 Cr release assay. To obtain specific lytic units/10 6 , the lytic units/10 6  obtained in the absence of peptide is subtracted from the lytic units/10 6  obtained in the presence of peptide. For example, if 30%  51 Cr release is obtained at the effector (E): target (T) ratio of 50:1 (i.e., 5×10 5  effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5×10 4  effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be: [(1/50,000)−(1/500,000)]×10 6=18  LU.  
     [1003] The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using, for example, CTL epitopes as outlined above in the Example entitled “Confirmation of Immunogenicity.” Analyses similar to this may be performed to confirm the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures, it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions.  
     Example 21  
     Selection of CTL and HTL Epitopes for Inclusion in a 98P4B6-Specific Vaccine  
     [1004] This example illustrates a procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or can be single and/or polyepitopic peptides.  
     [1005] The following principles are utilized when selecting a plurality of epitopes for inclusion in a vaccine composition. Each of the following principles is balanced in order to make the selection.  
     [1006] Epitopes are selected which, upon administration, mimic immune responses that are correlated with 98P4B6 clearance. The number of epitopes used depends on observations of patients who spontaneously clear 98P4B6. For example, if it has been observed that patients who spontaneously clear 98P4B6-expressing cells generate an immune response to at least three (3) epitopes from 98P4B6 antigen, then at least three epitopes should be included for HLA class I. A similar rationale is used to determine HLA class II epitopes.  
     [1007] Epitopes are often selected that have a binding affinity of an IC 50  of 500 nM or less for an HLA class I molecule, or for class II, an IC 50  of 1000 nM or less; or HLA Class I peptides with high binding scores from the BIMAS web site, at URL bimas.dcrt.nih.gov/.  
     [1008] In order to achieve broad coverage of the vaccine through out a diverse population, sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. In one embodiment, epitopes are selected to provide at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage.  
     [1009] When creating polyepitopic compositions, or a minigene that encodes same, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. For example, a protein sequence for the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high concentration of epitopes. Epitopes may be nested or overlapping (i.e., frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. A multi-epitopic, peptide can be generated synthetically, recombinantly, or via cleavage from the native source. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. This embodiment provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent the creating of any analogs) directs the immune response to multiple peptide sequences that are actually present in 98P4B6, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length.  
     [1010] A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude to an immune response that controls or clears cells that bear or overexpress 98P4B6.  
     Example 22  
     Construction of “Minigene” Multi-Epitope DNA Plasmids  
     [1011] This example discusses the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of B cell, CTL and/or HTL epitopes or epitope analogs as described herein.  
     [1012] A minigene expression plasmid typically includes multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearing peptide epitopes derived 98P4B6, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from 98P4B6 to provide broad population coverage, i.e. both HLA DR-1-4-7 supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector.  
     [1013] Such a construct may additionally include sequences that direct the HTL epitopes to the endoplasmic reticulum. For example, the li protein may be fused to one or more HTL epitopes as described in the art, wherein the CLIP sequence of the li protein is removed and replaced with an HLA class II epitope sequence so that HLA class II epitope is directed to the endoplasmic reticulum, where the epitope binds to an HLA class II molecules.  
     [1014] This example illustrates the methods to be used for construction of a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art.  
     [1015] The minigene DNA plasmid of this example contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector.  
     [1016] Overlapping oligonucleotides that can, for example, average about 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed using the following conditions: 95° C. for 15 sec, annealing temperature (50 below the lowest calculated Tm of each primer pair) for 30 sec, and 72° C. for 1 min.  
     [1017] For example, a minigene is prepared as follows. For a first PCR reaction, 5 μg of each of two oligonucleotides are annealed and extended: In an example using eight oligonucleotides, i.e., four pairs of primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 μl reactions containing Pfu polymerase buffer (1×=10 mM KCL, 10 mM (NH4) 2 SO 4 , 20 mM Tris-chloride, pH 8.75, 2 mM MgSO 4 , 0.1% Triton X-100, 100 μg/ml BSA), 0.25 mM each dNTP, and 2.5 U. of Pfu polymerase. The full-length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing.  
     Example 23  
     The Plasmid Construct and the Degree to which it Induces Immunogenicity  
     [1018] The degree to which a plasmid construct, for example a plasmid constructed in accordance with the previous Example, is able to induce immunogenicity is confirmed in vitro by determining epitope presentation by APC following transduction or transfection of the APC with an epitope-expressing nucleic acid construct. Such a study determines “antigenicity” and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e.g., Sijts et al.,  J. Immunol.  156:683-692, 1996; Demotz et al.,  Nature  342:682-684,1989); or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by diseased or transfected target cells, and then determining the concentration of peptide necessary to obtain equivalent levels of lysis or lymphokine release (see, e.g., Kageyama et al.,  J. Immunol.  154:567-576, 1995).  
     [1019] Alternatively, immunogenicity is confirmed through in vivo injections into mice and subsequent in vitro assessment of CTL and HTL activity, which are analyzed using cytotoxicity and proliferation assays, respectively, as detailed e.g., in Alexander et al.,  Immunity  1:751-761, 1994.  
     [1020] For example, to confirm the capacity of a DNA minigene construct containing at least one HLA-A2 supermotif peptide to induce CTLs in vivo, HLA-A2.1/K b  transgenic mice, for example, are immunized intramuscularly with 100 μg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene.  
     [1021] Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a  51 Cr release assay. The results indicate the magnitude of the CTL response directed against the A2-restricted epitope, thus indicating the in vivo immunogenicity of the minigene vaccine and polyepitopic vaccine.  
     [1022] It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is also found that the minigene elicits appropriate immune responses directed toward the provided epitopes.  
     [1023] To confirm the capacity of a class II epitope-encoding minigene to induce HTLs in vivo, DR transgenic mice, or for those epitopes that cross react with the appropriate mouse MHC molecule, I-A b -restricted mice, for example, are immunized intramuscularly with 100 μg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund&#39;s adjuvant. CD4+ T cells, i.e. HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a  3 H-thymidine incorporation proliferation assay, (see, e.g., Alexander et al. Immunity 1:751-761, 1994). The results indicate the magnitude of the HTL response, thus demonstrating the in vivo immunogenicity of the minigene.  
     [1024] DNA minigenes, constructed as described in the previous Example, can also be confirmed as a vaccine in combination with a boosting agent using a prime boost protocol. The boosting agent can consist of recombinant protein (e.g., Barnett et al.,  Aids Res. and Human Retroviruses  14, Supplement 3:S299-S309, 1998) or recombinant vaccinia, for example, expressing a minigene or DNA encoding the complete protein of interest (see, e.g., Hanke et al.,  Vaccine  16:439-445,1998; Sedegah et al.,  Proc. Natl. Acad. Sci USA  95:7648-53,1998; Hanke and McMichael,  Immunol. Letters  66:177-181, 1999; and Robinson et al.,  Nature Med.  5:526-34,1999).  
     [1025] For example, the efficacy of the DNA minigene used in a prime boost protocol is initially evaluated in transgenic mice. In this example, A2.1/K b  transgenic mice are immunized IM with 100 μg of a DNA minigene encoding the immunogenic peptides including at least one HLA-A2 supermotif-bearing peptide. After an incubation period (ranging from 3-9 weeks), the mice are boosted IP with 10 7  pfu/mouse of a recombinant vaccinia virus expressing the same sequence encoded by the DNA minigene. Control mice are immunized with 100 μg of DNA or recombinant vaccinia without the minigene sequence, or with DNA encoding the minigene, but without the vaccinia boost. After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay. Additionally, splenocytes are stimulated in vitro with the A2-restricted peptide epitopes encoded in the minigene and recombinant vaccinia, then assayed for peptide-specific activity in an alpha, beta and/or gamma IFN ELISA.  
     [1026] It is found that the minigene utilized in a prime-boost protocol elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone. Such an analysis can also be performed using HLA-A11 or HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 or HLA-B7 motif or supermotif epitopes. The use of prime boost protocols in humans is described below in the Example entitled “Induction of CTL Responses Using a Prime Boost Protocol.” 
     Example 24  
     Peptide Compositions for Prophylactic Uses  
     [1027] Vaccine compositions of the present invention can be used to prevent 98P4B6 expression in persons who are at risk for tumors that bear this antigen. For example, a polyepitopic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in the above Examples, which are also selected to target greater than 80% of the population, is administered to individuals at risk for a 98P4B6-associated tumor.  
     [1028] For example, a peptide-based composition is provided as a single polypeptide that encompasses multiple epitopes. The vaccine is typically administered in a physiological solution that comprises an adjuvant, such as Incomplete Freunds Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 Vtg, generally 100-5,000 μg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against 98P4B6-associated disease.  
     [1029] Alternatively, a composition typically comprising transfecting agents is used for the administration of a nucleic acid-based vaccine in accordance with methodologies known in the art and disclosed herein.  
     Example 25  
     Polyepitopic Vaccine Compositions Derived from Native 98P4B6 Sequences  
     [1030] A native 98P4B6 polyprotein sequence is analyzed, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify “relatively short” regions of the polyprotein that comprise multiple epitopes. The “relatively short” regions are preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct or overlapping, “nested” epitopes can be used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The “relatively short” peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (i.e., frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes.  
     [1031] The vaccine composition will include, for example, multiple CTL epitopes from 98P4B6 antigen and at least one HTL epitope. This polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide.  
     [1032] The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally, such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup(s) that is presently unknown. Furthermore, this embodiment (excluding an analoged embodiment) directs the immune response to multiple peptide sequences that are actually present in native 98P4B6, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing peptide or nucleic acid vaccine compositions.  
     [1033] Related to this embodiment, computer programs are available in the art which can be used to identify in a target sequence, the greatest number of epitopes per sequence length.  
     Example 26  
     Polyepitopic Vaccine Compositions from Multiple Antigens  
     [1034] The 98P4B6 peptide epitopes of the present invention are used in conjunction with epitopes from other target tumor-associated antigens, to create a vaccine composition that is useful for the prevention or treatment of cancer that expresses 98P4B6 and such other antigens. For example, a vaccine composition can be provided as a single polypeptide that incorporates multiple epitopes from 98P4B6 as well as tumor-associated antigens that are often expressed with a target cancer associated with 98P4B6 expression, or can be administered as a composition comprising a cocktail of one or more discrete epitopes. Alternatively, the vaccine can be administered as a minigene construct or as dendritic cells which have been loaded with the peptide epitopes in vitro.  
     Example 27  
     Use of Peptides to Evaluate an Immune Response  
     [1035] Peptides of the invention may be used to analyze an immune response for the presence of specific antibodies, CTL or HTL directed to 98P4B6. Such an analysis can be performed in a manner described by Ogg et al.,  Science  279:2103-2106, 1998. In this Example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen.  
     [1036] In this example highly sensitive human leukocyte antigen tetrameric complexes (“tetramers”) are used for a cross-sectional analysis of, for example, 98P4B6 HLA-A*0201-specific CTL frequencies from HLA A*0201-positive individuals at different stages of disease or following immunization comprising a 98P4B6 peptide containing an A*0201 motif. Tetrameric complexes are synthesized as described (Musey et al.,  N. Engl. J. Med.  337:1267, 1997). Briefly, purified HLA heavy chain (A*0201 in this example) and β2-microglobulin are synthesized by means of a prokaryotic expression system. The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain, 02-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Mo.), adenosine 5′ triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin.  
     [1037] For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300 g for 5 minutes and resuspended in 50 μl of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain &gt;99.98% of control samples. Controls for the tetramers include both A*0201-negative individuals and A*0201-positive non-diseased donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the 98P4B6 epitope, and thus the status of exposure to 98P4B6, or exposure to a vaccine that elicits a protective or therapeutic response.  
     Example 28  
     Use of Peptide Epitopes to Evaluate Recall Responses  
     [1038] The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from 98P4B6-associated disease or who have been vaccinated with a 98P4B6 vaccine.  
     [1039] For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any 98P4B6 vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type.  
     [1040] PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, Mo.), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L-glutamine (2 mM), penicillin (50U/ml), streptomycin (50 μg/ml), and Hepes (10 mM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10 μg/ml to each well and HBV core 128-140 epitope is added at 1 μg/ml to each well as a source of T cell help during the first week of stimulation.  
     [1041] In the microculture format, 4×10 5  PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100 μl/well of complete RPMI. On days 3 and 10, 100 μl of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 10 5  irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific  51 Cr release, based on comparison with non-diseased control subjects as previously described (Rehermann, et al.,  Nature Med.  2:1104,1108, 1996; Rehermann et al.,  J. Clin. Invest.  97:1655-1665, 1996; and Rehermann et al.  J. Clin. Invest.  98:1432-1440,1996).  
     [1042] Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, Mass.) or established from the pool of patients as described (Guilhot, et al.  J. Virol.  66:2670-2678, 1992).  
     [1043] Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic peptide epitope of the invention at 10 μM, and labeled with 100 μCi of  51 Cr (Amersham Corp., Arlington Heights, Ill.) for 1 hour after which they are washed four times with HBSS.  
     [1044] Cytolytic activity is determined in a standard 4-h, split well  51 Cr release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMG are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula: 100×[(experimental release−spontaneous release)/maximum release−spontaneous release)]. Maximum release is determined by lysis of targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, Mo.). Spontaneous release is &lt;25% of maximum release for all experiments.  
     [1045] The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to 98P4B6 or a 98P4B6 vaccine.  
     [1046] Similarly, Class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of 1.5×10 5  cells/well and are stimulated with 10 μg/ml synthetic peptide of the invention, whole 98P4B6 antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing 10U/ml IL-2. Two days later, 1 μCi  3 H-thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for  3 H-thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of  3 H-thymidine incorporation in the presence of antigen divided by the  3 H-thymidine incorporation in the absence of antigen.  
     Example 29  
     Induction of Specific CTL Response in Humans  
     [1047] A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:  
     [1048] A total of about 27 individuals are enrolled and divided into 3 groups:  
     [1049] Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 μg of peptide composition;  
     [1050] Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 μg peptide composition;  
     [1051] Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 μg of peptide composition.  
     [1052] After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.  
     [1053] The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.  
     [1054] Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.  
     [1055] Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.  
     [1056] The vaccine is found to be both safe and efficacious.  
     Example 30  
     Phase II Trials in Patients Expressing 98P4B6  
     [1057] Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having cancer that expresses 98P4B6. The main objectives of the trial are to determine an effective dose and regimen for inducing CTLs in cancer patients that express 98P4B6, to establish the safety of inducing a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clinical picture of these patients, as manifested, e.g., by the reduction and/or shrinking of lesions. Such a study is designed, for example, as follows:  
     [1058] The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded.  
     [1059] There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65 and represent diverse ethnic backgrounds. All of them have a tumor that expresses 98P4B6.  
     [1060] Clinical manifestations or antigen-specific T-cell responses are monitored to assess the effects of administering the peptide compositions. The vaccine composition is found to be both safe and efficacious in the treatment of 98P4B6-associated disease.  
     Example 31  
     Induction of CTL Responses Using a Prime Boost Protocol  
     [1061] A prime boost protocol similar in its underlying principle to that used to confirm the efficacy of a DNA vaccine in transgenic mice, such as described above in the Example entitled “The Plasmid Construct and the Degree to Which It Induces Immunogenicity,” can also be used for the administration of the vaccine to humans. Such a vaccine regimen can include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant.  
     [1062] For example, the initial immunization may be performed using an expression vector, such as that constructed in the Example entitled “Construction of “Minigene” Multi-Epitope DNA Plasmids” in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of 5-10 7  to 5×10 9  pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples are obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.  
     [1063] Analysis of the results indicates that a magnitude of response sufficient to achieve a therapeutic or protective immunity against 98P4B6 is generated.  
     Example 32  
     Administration of Vaccine Compositions Using Dendritic Cells (DC)  
     [1064] Vaccines comprising peptide epitopes of the invention can be administered using APCs, or “professional” APCs such as DC. In this example, peptide-pulsed DC are administered to a patient to stimulate a CTL response in vivo. In this method, dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses in vivo. The induced CTL and HTL then destroy or facilitate destruction, respectively, of the target cells that bear the 98P4B6 protein from which the epitopes in the vaccine are derived.  
     [1065] For example, a cocktail of epitope-comprising peptides is administered ex vivo to PBMC, or isolated DC therefrom. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Monsanto, St. Louis, Mo.) or GM-CSF/IL-4. After pulsing the DC with peptides, and prior to reinfusion into patients, the DC are washed to remove unbound peptides.  
     [1066] As appreciated clinically, and readily determined by one of skill based on clinical outcomes, the number of DC reinfused into the patient can vary (see, e.g.,  Nature Med.  4:328, 1998 ; Nature Med.  2:52, 1996 and  Prostate  32:272, 1997). Although 2-50×10 6  DC per patient are typically administered, larger number of DC, such as 10 7  or 10 8  can also be provided. Such cell populations typically contain between 50-90% DC.  
     [1067] In some embodiments, peptide-loaded PBMC are injected into patients without purification of the DC. For example, PBMC generated after treatment with an agent such as Progenipoietin™ are injected into patients without purification of the DC. The total number of PBMC that are administered often ranges from 10 8  to 10 10 . Generally, the cell doses injected into patients is based on the percentage of DC in the blood of each patient, as determined, for example, by immunofluorescence analysis with specific anti-DC antibodies. Thus, for example, if Progenipoietin™ mobilizes 2% DC in the peripheral blood of a given patient, and that patient is to receive 5×10 6  DC, then the patient will be injected with a total of 2.5×10 8  peptide-loaded PBMC. The percent DC mobilized by an agent such as Progenipoietin™ is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art.  
     [1068] Ex Vivo Activation of CTL/HTL Responses  
     [1069] Alternatively, ex vivo CTL or HTL responses to 98P4B6 antigens can be induced by incubating, in tissue culture, the patient&#39;s, or genetically compatible, CTL or HTL precursor cells together with a source of APC, such as DC, and immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, i.e., tumor cells.  
     Example 33  
     An Alternative Method of Identifying and Confirming Motif-Bearing Peptides  
     [1070] Another method of identifying and confirming motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can be transfected with nucleic acids that express the antigen of interest, e.g. 98P4B6. Peptides produced by endogenous antigen processing of peptides produced as a result of transfection will then bind to HLA molecules within the cell and be transported and displayed on the cell&#39;s surface. Peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, e.g., by mass spectral analysis (e.g., Kubo et al.,  J. Immunol.  152:3913, 1994). Because the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell.  
     [1071] Alternatively, cell lines that do not express endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells can then be used as described, i.e., they can then be transfected with nucleic acids that encode 98P4B6 to isolate peptides corresponding to 98P4B6 that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell.  
     [1072] As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell.  
     Example 34  
     Complementary Polynucleotides  
     [1073] Sequences complementary to the 98P4B6-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring 98P4B6. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using, e.g., OLIGO 4.06 software (National Biosciences) and the coding sequence of 98P4B6. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to a 98P4B6-encoding transcript.  
     Example 35  
     Purification of Naturally-Occurring or Recombinant 98P4B6 Using 98P4B6-Specific Antibodies  
     [1074] Naturally occurring or recombinant 98P4B6 is substantially purified by immunoaffinity chromatography using antibodies specific for 98P4B6. An immunoaffinity column is constructed by covalently coupling anti-98P4B6 antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer&#39;s instructions.  
     [1075] Media containing 98P4B6 are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of 98P4B6 (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/98P4B6 binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCR.P is collected.  
     Example 36  
     Identification of Molecules which Interact with 98P4B6  
     [1076] 98P4B6, or biologically active fragments thereof, are labeled with 121 1 Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled 98P4B6, washed, and any wells with labeled 98P4B6 complex are assayed. Data obtained using different concentrations of 98P4B6 are used to calculate values for the number, affinity, and association of 98P4B6 with the candidate molecules.  
     Example 37  
     In Vivo Assay for 98P4B6 Tumor Growth Promotion  
     [1077] The effect of the 98P4B6 protein on tumor cell growth is evaluated in vivo by gene overexpression in tumor-bearing mice. For example, prostate (PC3), lung (A427), stomach, ovarian (PA1) and uterus cell lines are engineered to express 98P4B6. SCID mice are injected subcutaneously on each flank with 1×10 6  of PC3, A427, PA1, or NIH-3T3 cells containing tkNeo empty vector or 98P4B6. At least two strategies may be used: (1) Constitutive 98P4B6 expression under regulation of a promoter such as a constitutive promoter obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published Jul. 5, 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, provided such promoters are compatible with the host cell systems, and (2) Regulated expression under control of an inducible vector system, such as ecdysone, tet, etc., provided such promoters are compatible with the host cell systems. Tumor volume is then monitored at the appearance of palpable tumors and followed over time to determine if 98P4B6-expressing cells grow at a faster rate and whether tumors produced by 98P4B6-expressing cells demonstrate characteristics of altered aggressiveness (e.g. enhanced metastasis, vascularization, reduced responsiveness to chemotherapeutic drugs).  
     [1078] Additionally, mice can be implanted with 1×10 5  of the same cells orthotopically to determine if 98P4B6 has an effect on local growth in the prostate or on the ability of the cells to metastasize, specifically to lungs, lymph nodes, and bone marrow.  
     [1079] The assay is also useful to determine the 98P4B6 inhibitory effect of candidate therapeutic compositions, such as for example, 98P4B6 intrabodies, 98P4B6 antisense molecules and ribozymes.  
     Example 38  
     98P4B6 Monoclonal Antibody-Mediated Inhibition of Tumors In Vivo  
     [1080] The significant expression of 98P4B6 in prostate, lung, stomach, ovary, and uterus cancer tissues, its restrictive expression in normal tissues, together with its expected cell surface expression makes 98P4B6 an excellent target for antibody therapy. Similarly, 98P4B6 is a target for T-cell based immunotherapy. Thus, the therapeutic efficacy of anti-98P4B6 mAbs in human prostate cancer xenograft mouse models is evaluated by using androgen-independent LAPC-4 and LAPC-9 xenografts (Craft, N., et al., Cancer Res, 1999. 59(19): p. 5030-6) and the androgen independent recombinant cell line PC3-98P4B6 (see, e.g., Kaighn, M. E., et al., Invest Urol, 1979. 17(1): p. 16-23). Similar approaches using patient derived xenografts or xenograft cell lines are used for cancers listed in Table I.  
     [1081] Antibody efficacy on tumor growth and metastasis formation is studied, e.g., in a mouse orthotopic prostate cancer xenograft models and mouse lung, uterus, or stomach xenograft models. The antibodies can be unconjugated, as discussed in this Example, or can be conjugated to a therapeutic modality, as appreciated in the art. Anti-98P4B6 mAbs inhibit formation of both the androgen-dependent LAPC-9 and androgen-independent PC3-98P4B6 tumor xenografts. Anti-98P4B6 mAbs also retard the growth of established orthotopic tumors and prolonged survival of tumor-bearing mice. These results indicate the utility of anti-98P4B6 mAbs in the treatment of local and advanced stages of cancer. (See, e.g., (Saffran, D., et al., PNAS 10:1073-1078 or URL located on the World Wide Web at .pnas.org/cgi/doi/10.1073/pnas.051624698).  
     [1082] Administration of the anti-98P4B6 mAbs can lead to retardation of established orthotopic tumor growth and inhibition of metastasis to distant sites, resulting in a significant prolongation in the survival of tumor-bearing mice. These studies indicate that 98P4B6 is an attractive target for immunotherapy and demonstrate the therapeutic potential of anti-98P4B6 mAbs for the treatment of local and metastatic cancer. This example demonstrates that unconjugated 98P4B6 monoclonal antibodies are effective to inhibit the growth of human prostate tumor xenografts, as well as lung, uterus, or stomach xenograft grown in SCID mice; accordingly a combination of such efficacious monoclonal antibodies is also effective.  
     [1083] Tumor inhibition Using Multiple Unconjugated 98P4B6 mAbs  
     [1084] Materials and Methods  
     [1085] 98P4B6 Monoclonal Antibodies:  
     [1086] Monoclonal antibodies are raised against 98P4B6 as described in Example 11 entitled “Generation of 98P4B6 Monoclonal Antibodies (mAbs).” The antibodies are characterized by ELISA, Western blot, FACS, and immunoprecipitation for their capacity to bind 98P4B6. Epitope mapping data for the anti-98P4B6 mAbs, as determined by ELISA and Western analysis, recognize epitopes on the 98P4B6 protein. Immunohistochemical analysis of cancer tissues and cells with these antibodies is performed.  
     [1087] The monoclonal antibodies are purified from ascites or hybridoma tissue culture supernatants by Protein-G Sepharose chromatography, dialyzed against PBS, filter sterilized, and stored at −20° C. Protein determinations are performed by a Bradford assay (Bio-Rad, Hercules, Calif.). A therapeutic monoclonal antibody or a cocktail comprising a mixture of individual monoclonal antibodies is prepared and used for the treatment of mice receiving subcutaneous or orthotopic injections of LAPC-9 tumor xenografts.  
     [1088] Cancer Xenografts and Cell Lines  
     [1089] The LAPC-9 xenograft, which expresses a wild-type androgen receptor and produces prostate-specific antigen (PSA), is passaged in 6- to 8-week-old male ICR-severe combined immunodeficient (SCID) mice (Taconic Farms) by s.c. trocar implant (Craft, N., et al., supra). The prostate (PC3), lung (A427), ovarian (PA1) carcinoma cell lines (American Type Culture Collection) are maintained in RPMI or DMEM supplemented with L-glutamine and 10% FBS.  
     [1090] PC3-98P4B6, A427-98P4B6, PA1-98P4B6 and 3T3-98P4B6 cell populations are generated by retroviral gene transfer as described in Hubert, R. S., et al., STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA, 1999. 96(25): p. 14523-8. Anti-98P4B6 staining is detected by using an FITC-conjugated goat anti-mouse antibody (Southern Biotechnology Associates) followed by analysis on a Coulter Epics-XL flow cytometer.  
     [1091] Xenograft Mouse Models.  
     [1092] Subcutaneous (s.c.) tumors are generated by injection of 1×10 6  LAPC-9, PC3, PC3-98P4B6, A427, A427-98P4B6, PA1, PA1-98P4B6, 3T3 or 3T3-98P4B6 cells mixed at a 1:1 dilution with Matrigel (Collaborative Research) in the right flank of male SCID mice. To test antibody efficacy on tumor formation, i.p. antibody injections are started on the same day as tumor-cell injections. As a control, mice are injected with either purified mouse IgG (ICN) or PBS; or a purified monoclonal antibody that recognizes an irrelevant antigen not expressed in human cells. In preliminary studies, no difference is found between mouse IgG or PBS on tumor growth. Tumor sizes are determined by vernier caliper measurements, and the tumor volume is calculated as length×width×height. Mice with s.c. tumors greater than 1.5 cm in diameter are sacrificed. PSA levels are determined by using a PSA ELISA kit (Anogen, Mississauga, Ontario). Circulating levels of anti-98P4B6 mAbs are determined by a capture ELISA kit (Bethyl Laboratories, Montgomery, Tex.). (See, e.g., (Saffran, D., et al., PNAS 10:1073-1078 or URL located on the World Wide Web at .pnas.org/cgi/doi/10.1073/pnas.051624698)  
     [1093] Orthotopic injections are performed under anesthesia by using ketamine/xylazine. For prostate orthotopic studies, an incision is made through the abdominal muscles to expose the bladder and seminal vesicles, which then are delivered through the incision to expose the dorsal prostate. LAPC-9 or PC3 cells (5×10 5 ) mixed with Matrigel are injected into each dorsal lobe in a 10-μl volume. To monitor tumor growth, mice are bled on a weekly basis for determination of PSA levels. The mice are segregated into groups for the appropriate treatments, with anti-98P4B6 or control mAbs being injected i.p.  
     [1094] Anti-98P4B6 mAbs Inhibit Growth of 98P4B6-Expressing Xenograft-Cancer Tumors  
     [1095] The effect of anti-98P4B6 mAbs on tumor formation is tested by using LAPC-9 and PC3-98P4B6 orthotopic models. As compared with the s.c. tumor model, the orthotopic model, which requires injection of tumor cells directly in the mouse prostate, lung, or ovary, respectively, results in a local tumor growth, development of metastasis in distal sites, deterioration of mouse health, and subsequent death (Saffran, D., et al., PNAS supra; Fu, X., et al., Int J Cancer, 1992. 52(6): p. 987-90; Kubota, T., J Cell Biochem, 1994. 56(1): p. 4-8). The features make the orthotopic model more representative of human disease progression and allowed us to follow the therapeutic effect of mAbs on clinically relevant end points.  
     [1096] Accordingly, tumor cells are injected into the mouse prostate, lung, or ovary, and 2 days later, the mice are segregated into two groups and treated with either: a) 200-500 μg, of anti-98P4B6 Ab, or b) PBS three times per week for two to five weeks.  
     [1097] A major advantage of the orthotopic cancer model is the ability to study the development of metastases. Formation of metastasis in mice bearing established orthotopic tumors is studies by IHC analysis on lung sections using an antibody against a prostate-specific cell-surface protein STEAP expressed at high levels in LAPC-9 xenografts (Hubert, R. S., et al., Proc Natl Acad Sci USA, 1999. 96(25): p. 14523-8).  
     [1098] Mice bearing established orthotopic LAPC-9 or PC3-98P4B6 tumors are administered 1000 μg injections of either anti-98P4B6 mAb or PBS over a 4-week period. Mice in both groups are allowed to establish a high tumor burden (PSA levels greater than 300 ng/ml for IAPC-9), to ensure a high frequency of metastasis formation in mouse lungs. Mice then are killed and their prostate and lungs are analyzed for the presence of tumor cells by IHC analysis.  
     [1099] These studies demonstrate a broad anti-tumor efficacy of anti-98P4B6 antibodies on initiation and progression of prostate cancer in xenograft mouse models. Anfi-98P4B6 antibodies inhibit tumor formation of both androgen-dependent and androgen-independent tumors as well as retarding the growth of already established tumors and prolong the survival of treated mice. Moreover, anti-98P4B6 mAbs demonstrate a dramatic inhibitory effect on the spread of local prostate tumor to distal sites, even in the presence of a large tumor burden. Thus, anti-98P4B6 mAbs are efficacious on major clinically relevant end points (tumor growth), prolongation of survival, and health.  
     Example 39  
     Therapeutic and Diagnostic Use of Anti-98P4B6 Antibodies in Humans  
     [1100] Anti-98P4B6 monoclonal antibodies are safely and effectively used for diagnostic, prophylactic, prognostic and/or therapeutic purposes in humans. Western blot and immunohistochemical analysis of cancer tissues and cancer xenografts with anti-98P4B6 mAb show strong extensive staining in carcinoma but significantly lower or undetectable levels in normal tissues. Detection of 98P4B6 in carcinoma and in metastatic disease demonstrates the usefulness of the mAb as a diagnostic and/or prognostic indicator. Anti-98P4B6 antibodies are therefore used in diagnostic applications such as immunohistochemistry of kidney biopsy specimens to detect cancer from suspect patients.  
     [1101] As determined by flow cytometry, anti-98P4B6 mAb specifically binds to carcinoma cells. Thus, anti-98P4B6 antibodies are used in diagnostic whole body imaging applications, such as radioimmunoscintigraphy and radioimmunotherapy, (see, e.g., Potamianos S., et. al. Anticancer Res 20(2A):925-948 (2000)) for the detection of localized and metastatic cancers that exhibit expression of 98P4B6. Shedding or release of an extracellular domain of 98P4B6 into the extracellular milieu, such as that seen for alkaline phosphodiesterase B10 (Meerson, N. R., Hepatology 27:563-568 (1998)), allows diagnostic detection of 98P4B6 by anti-98P4B6 antibodies in serum and/or urine samples from suspect patients.  
     [1102] Anti-98P4B6 antibodies that specifically bind 98P4B6 are used in therapeutic applications for the treatment of cancers that express 98P4B6. Anti-98P4B6 antibodies are used as an unconjugated modality and as conjugated form in which the antibodies are attached to one of various therapeutic or imaging modalities well known in the art, such as a prodrugs, enzymes or radioisotopes. In preclinical studies, unconjugated and conjugated anti-98P4B6 antibodies are tested for efficacy of tumor prevention and growth inhibition in the SCID mouse cancer xenograft models, e.g., kidney cancer models AGS-K3 and AGS-K6, (see, e.g., the Example entitled “98P4B6 Monoclonal Antibody-mediated Inhibition of Bladder and Lung Tumors In Vivo”). Either conjugated and unconjugated anti-98P4B6 antibodies are used as a therapeutic modality in human clinical trials either alone or in combination with other treatments as described in following Examples.  
     Example 40  
     Human Clinical Trials for the Treatment and Diagnosis of Human Carcinomas Through Use of Human Anti-98P4B6 Antibodies In Vivo  
     [1103] Antibodies are used in accordance with the present invention which recognize an epitope on 98P4B6, and are used in the treatment of certain tumors such as those listed in Table I. Based upon a number of factors, including 98P4B6 expression levels, tumors such as those listed in Table I are presently preferred indications. In connection with each of these indications, three clinical approaches are successfully pursued.  
     [1104] I.) Adjunctive therapy: In adjunctive therapy, patients are treated with anti-98P4B6 antibodies in combination with a chemotherapeutic or antineoplastic agent and/or radiation therapy. Primary cancer targets, such as those listed in Table I, are treated under standard protocols by the addition anti-98P4B6 antibodies to standard first and second line therapy. Protocol designs address effectiveness as assessed by reduction in tumor mass as well as the ability to reduce usual doses of standard chemotherapy. These dosage reductions allow additional and/or prolonged therapy by reducing dose-related toxicity of the chemotherapeutic agent. Anti-98P4B6 antibodies are utilized in several adjunctive clinical trials in combination with the chemotherapeutic or antineoplastic agents adriamycin (advanced prostrate carcinoma), cisplatin (advanced head and neck and lung carcinomas), taxol (breast cancer), and doxorubicin (preclinical).  
     [1105] II.) Monotherapy: In connection with the use of the anti-98P4B6 antibodies in monotherapy of tumors, the antibodies are administered to patients without a chemotherapeutic or antineoplastic agent. In one embodiment, monotherapy is conducted clinically in end stage cancer patients with extensive metastatic disease. Patients show some disease stabilization. Trials demonstrate an effect in refractory patients with cancerous tumors.  
     [1106] III.) Imaging Agent: Through binding a radionuclide (e.g., iodine or yttrium (I 131 , Y 90 ) to anti-98P4B6 antibodies, the radiolabeled antibodies are utilized as a diagnostic and/or imaging agent. In such a role, the labeled antibodies localize to both solid tumors, as well as, metastatic lesions of cells expressing 98P4B6. In connection with the use of the anti-98P4B6 antibodies as imaging agents, the antibodies are used as an adjunct to surgical treatment of solid tumors, as both a pre-surgical screen as well as a post-operative follow-up to determine what tumor remains and/or returns. In one embodiment, a ( 111 In)-98P4B6 antibody is used as an imaging agent in a Phase I human clinical trial in patients having a carcinoma that expresses 98P4B6 (by analogy see, e.g., Divgi et al.  J. Natl. Cancer Inst.  83:97-104 (1991)). Patients are followed with standard anterior and posterior gamma camera. The results indicate that primary lesions and metastatic lesions are identified  
     [1107] Dose and Route of Administration  
     [1108] As appreciated by those of ordinary skill in the art, dosing considerations can be determined through comparison with the analogous products that are in the clinic. Thus, anti-98P4B6 antibodies can be administered with doses in the range of 5 to 400 mg/m 2, with the lower doses used, e.g., in connection with safety. studies. The affinity of anti-98P4B6 antibodies relative to the affinity of a known antibody for its target is one parameter used by those of skill in the art for determining analogous dose regimens. Further, anti-98P4B6 antibodies that are fully human antibodies, as compared to the chimeric antibody, have slower clearance; accordingly, dosing in patients with such fully human anti-98P4B6 antibodies can be lower, perhaps in the range of 50 to 300 mg/m 2 , and still remain efficacious. Dosing in mg/m 2 , as opposed to the conventional measurement of dose in mg/kg, is a measurement based on surface area and is a convenient dosing measurement that is designed to include patients of all sizes from infants to adults.  
     [1109] Three distinct delivery approaches are useful for delivery of anti-98P4B6 antibodies. Conventional intravenous delivery is one standard delivery technique for many tumors. However, in connection with tumors in the peritoneal cavity, such as tumors of the ovaries, biliary duct, other ducts, and the like, intraperitoneal administration may prove favorable for obtaining high dose of antibody at the tumor and to also minimize antibody clearance. In a similar manner, certain solid tumors possess vasculature that is appropriate for regional perfusion. Regional perfusion allows for a high dose of antibody at the site of a tumor and minimizes short term clearance of the antibody.  
     [1110] Clinical Development Plan (CDP)  
     [1111] Overview: The CDP follows and develops treatments of anti-98P4B6 antibodies in connection with adjunctive therapy, monotherapy, and as an imaging agent. Trials initially demonstrate safety and thereafter confirm efficacy in repeat doses. Trails are open label comparing standard chemotherapy with standard therapy plus anti-98P4B6 antibodies. As will be appreciated, one criteria that can be utilized in connection with enrollment of patients is 98P4B6 expression levels in their tumors as determined by biopsy.  
     [1112] As with any protein or antibody infusion-based therapeutic, safety concerns are related primarily to (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 98P4B6. Standard tests and follow-up are utilized to monitor each of these safety concerns. Anti-98P4B6 antibodies are found to be safe upon human administration.  
     Example 41  
     Human Clinical Trial Adjunctive Therapy with Human Anti-98P4B6 Antibody and Chemotherapeutic Agent  
     [1113] A phase I human clinical trial is initiated to assess the safety of six intravenous doses of a human anti-98P4B6 antibody in connection with the treatment of a solid tumor, e.g., a cancer of a tissue listed in Table I. In the study, the safety of single doses of anti-98P4B6 antibodies when utilized as an adjunctive therapy to an antineoplastic or chemotherapeutic agent as defined herein, such as, without limitation: cisplatin, topotecan, doxorubicin, adriamycin, taxol, or the like, is assessed. The trial design includes delivery of six single doses of an anti-98P4B6 antibody with dosage of antibody escalating from approximately about 25 mg/m  2  to about 275 mg/m  2  over the course of the treatment in accordance with the following schedule:  
                                                           Day 0   Day 7   Day 14   Day 21   Day 28   Day 35                  mAb Dose   25   75   125   175   225   275           mg/m 2     mg/m 2     mg/m 2     mg/m 2     mg/m 2     mg/m 2         Chemotherapy   +   +   +   +   +   +       (standard dose)                  
 
     [1114] Patients are closely followed for one-week following each administration of antibody and chemotherapy. In particular, patients are assessed for the safety concerns mentioned above: (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the human antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 98P4B6. Standard tests and follow-up are utilized to monitor each of these safety concerns. Patients are also assessed for clinical outcome, and particularly reduction in tumor mass as evidenced by MRI or other imaging.  
     [1115] The anti-98P4B6 antibodies are demonstrated to be safe and efficacious, Phase II trials confirm the efficacy and refine optimum dosing.  
     Example 42  
     Human Clinical Trial: Monotherapy with Human Anti-98P4B6 Antibody  
     [1116] Anti-98P4B6 antibodies are safe in connection with the above-discussed adjunctive trial, a Phase II human clinical trial confirms the efficacy and optimum dosing for monotherapy. Such trial is accomplished, and entails the same safety and outcome analyses, to the above-described adjunctive trial with the exception being that patients do not receive chemotherapy concurrently with the receipt of doses of anti-98P4B6 antibodies.  
     Example 43  
     Human Clinical Trial: Diagnostic Imaging with Anti-98P4B6 Antibody  
     [1117] Once again, as the adjunctive therapy discussed above is safe within the safety criteria discussed above, a human clinical trial is conducted concerning the use of anti-98P4B6 antibodies as a diagnostic imaging agent. The protocol is designed in a substantially similar manner to those described in the art, such as in Divgi et al. J. Natl. Cancer Inst. 83:97-104 (1991). The antibodies are found to be both safe and efficacious when used as a diagnostic modality.  
     Example 44  
     Homology Comparison of 98P4B6 to Known Sequences  
     [1118] The 98P4B6 gene is homologous to a cloned and sequenced gene, namely human STAMP1 (gi 15418732) (Korkmaz, K. S et al, J. Biol. Chem. 2002, 277: 36689), showing 99% identity and 99% homology to that gene (FIG. 4). The 98P4B6 protein also shows 99% identity and 99% homology to another human six transmembrane epithelial antigen of prostate 2 (gi 23308593) (Walker, M. G et al, Genome Res. 1999, 9:1198; Porkka, K. P., Helenius, M. A. and Visakorpi, T, Lab. Invest. 2002, 82: 1573). The closest mouse homolog to 98P4B6 is six transmembrane epithelial antigen of prostate 2 (gi 28501136), with 97% identity and 99% homology. We have identified several variants of the 98P4B6 protein, including 4 splice variants and 3 SNPs (FIG. 11). The 98P4B6 v.1 protein consists of 454 amino acids, with calculated molecular weight of 52 kDa, and μl of 8.7. It is a 6 transmembrane protein that can localize to the cell surface or possibly to the endoplasmic reticulum (Table VI). Several 98P4B6 variants, including v.1, v.5-8, v.13, v.14, v.21, v.25 share similar features, such protein motifs with functional significance, as well as structural commonalities such as multiple transmembrane domains. The 98P4B6 v.2 is a short protein with no known motifs.  
     [1119] Motif analysis revealed the presence of several known motifs, including oxido-reductase, homocysteine hydrolase and dudulin motifs. Variant v.7 and SNPs of this variant also carry an Ets motif, often associated with transcriptional activity.  
     [1120] Several oxidoreductases have been identified in mammalian cells, including the NADH/quinone oxidoreductase. This protein associate with the cell membrane and function as a proton/Na+ pump, which regulates the protein degradation of the tumor suppressor p53, and protects mammalian cells from oxidative stress, cytotoxicity, and mutages (Asher G, et al, Proc Natl Acad Sci USA. 2002, 99:13125; Jaiswal A K, Arch Biochem Biophys 2000, 375:62 Yano T, Mol Aspects Med 2002, 23:345). Homocysteine hydrolase is an enzyme known to catalyze the breakdown of S-adenosylhomocysteine to homocysteine and adenosine, ultimately regulating trans-methylation, therby regulating protein expression, cell cycle and proliferation (Turner MAet al. Cell Biochem Biophys 2000;33:101;Zhang et al, J Biol. Chem. 2001; 276:35867) This information indicates that 98P4B6 plays a role in the cell growth of mammalian cells, regulate gene transcription and transport of electrons and small molecules. Accordingly, when 98P4B6 functions as a regulator of cell growth, tumor formation, or as a modulator of transcription involved in activating genes associated with inflammation, tumorigenesis, or proliferation, 98P4B6 is used for therapeutic, diagnostic, prognostic and/or preventative purposes. In addition, when a molecule, such as a variant or polymorphism of 98P4B6 is expressed in cancerous tissues, it is used for therapeutic, diagnostic, prognostic and/or preventative purposes.  
     Example 45  
     Phenotypic Effects of STEAP-2 Expression  
     [1121] Experiments regarding the expression of STEAP-2 protein having the amino acid sequence shown in FIG. 2 and encoded by a cDNA insert in a plasmid deposited with the American Type Culture Collection on Jul. 2, 1999 and assigned as ATCC Accession No. PTA-311. As deduced from the coding sequence, the open reading frame encodes 454 amino acids with 6 transmembrane domains. A summary of the characteristics associated with STEAP-2 protein is shown on FIG. 19.  
     [1122] The data set forth in the present patent application provide an expression profile of the STEAP-2 protein that is predominantly specific for the prostate among normal tissues, for certain types of prostate tumors as well as other tumors. This evidence is based on detecting messenger RNA using Northern blotting. In keeping with standard practice in this industry, Northern blots are routinely used to assess gene expression, as it does not require the time consuming process of synthesizing the relevant protein, raising antibodies, assuring the specificity of the antibodies, required for Western blotting of proteins and the histological examination of tissues. Northern blotting offers a credible and efficient method of assessing RNA expression and expression levels.  
     [1123] This Example demonstrates that STEAP-2 protein is, indeed, produced. In summary, the experiments show that PC-3 cells and 3T3 cells which were modified to contain an expression system for STEAP-2 showed enhanced levels of tyrosine phosphorylation in general, and of phosphorylation of ERK protein in particular. The data also show that PC-3 cells that contain an expression system for STEAP-2 showed modified calcium flux, a modified response to paclitaxel, and a general inhibition of drug-induced apoptosis. These are effects exhibited at the protein level, thus these data alone are probative that the STEAP-2 protein exists.  
     [1124] Furthermore, although such phenotypic effects are protein-mediated, further evidence indicates that the STEAP-2 protein itself is the mediator of the effects. This evidence is obtained by utilizing a modified STEAP-2 protein. An expression system is stably introduced into PC3 and 3T3 cells which allows the expression of a modified form of STEAP-2, designated STEAP-2CFI, where “FI” stands for flag. STEAP-2CFI is a STEAP-2 protein having a peptide extension, i.e., a Flag epitope that alters the physical conformation of this protein. The Flag epitope is a string 8 amino acids, often introduced at either the amino or carboxy termini of protein as a means of identifying and following a recombinant protein in engineered cells (Slootstra J W et al, Mol Divers 1997, 2:156). In most cases, the introduction of the Flag epitope at either termini of a protein has little effect on the natural function and location of that protein (Molloy S S et al, EMBO J. 1994, 13:18). However, this is dependent on the characteristics of the protein being Flag tagged. Recent studies have shown that a Flag tag affects the function and conformation of select proteins such as the CLN3 protein (see, e.g., Haskell R E, et al. Mol Genet Metab 1999, 66:253). As with CLN3, introducing a Flag epitope tag to the C-terminus of STEAP-2 alters the physical conformation and properties of this protein. Altering the STEAP-2 protein with the C-Flag epitope resulted in a significant decrease in the effects otherwise observed, including phosphorylation of ERK and resistance to drug-induced cell death. The data indicate that it is the STEAP-2 protein that mediated these phenotypic effects. Finally, in vitro translation studies using rabbit reticulocyte lysate, showed that the STEAP-2 protein is translated and exhibits the expected molecular weight.  
     [1125]FIGS. 20 and 21 show the results obtained when PC-3 and 3T3 cells, respectively, were modified to contain the retroviral expression system pSR□ encoding the indicated proteins, including STEAP-1, STEAP-2 and STEAP-2CFI, respectively. Gene-specific protein expression was driven from a long terminal repeat (LTR), and the Neomycin resistance gene was used for selection of mammalian cells that stably express the protein. PC-3 and 3T3 cells were transduced with the retrovirus, selected in the presence of G418 and cultured under conditions which permit expression of the STEAP-2 coding sequence. The cells were grown overnight in low concentrations of FBS (0.5-1% FBS) and were then stimulated with 10% FBS. The cells were lysed in RIPA buffer and quantitated for protein concentration. Whole cell lysates were separated by SDS-PAGE and analyzed by Western blotting using anti-phospho-ERK (Cell Signaling Inc.) or anti-phosphotyrosine (UBI) antibodies (FIGS. 20, 21, and  22 ). As shown on FIG. 20, as compared to untransformed PC-3 cells, cells modified to contain STEAP-2 contain enhanced amounts of phosphorylated tyrosine. Similar results from an analogous experiment on 3T3 cells are shown on page 3. In this latter experiment, the STEAP-2CFI expression system was also transfected into 3T3 cells, which cells were used as a control. As shown on FIG. 21, the enhanced phosphorylation found in the presence of native STEAP-2 was significantly reduced when the conformation of the protein was altered. These results thus show conclusively that the STEAP-2 protein was produced and mediated the above-described phenotypic effects.  
     [1126]FIG. 22 shows similar results, both in PC-3 and 3T3 cells where phosphorylation of ERK, specifically, is detected. The protocol is similar to that set forth in paragraph 5 above, except that rather than probing the gels with antibodies specific for phosphotyrosine the gels were probed both the anti-ERK and anti-phospho-ERK antibodies. As shown on FIG. 22, in the presence of 10% FBS, both PC-3 cells and 3T3 cells modified to express STEAP-2 showed phosphorylation of ERK which was not detectable in cells transformed to contain STEAP-2CFI. In contrast to control PC-3 cells which exhibit no background ERK phosphorylation, control 3T3-neo cells show low levels of endogenous ERK phosphorylation. Treatment with 10% FBS enhanced phosphorylation of ERK protein in cells expressing STEAP-2 relative to 3T3-neo cells, while no increase in ERK phosphorylation was observed in 3T3 cells expressing modified STEAP-2, i.e. STEAP-2 CFI.  
     [1127] Other effects on cellular metabolism in cells modified to contain a STEAP-2 expression system were also shown in our data. FIG. 23 shows that when cells with and without expression systems for STEAP-2 were measured for calcium flux in the presence of LPA, calcium flux was enhanced in the STEAP-2 containing cells. Using FACS analysis and commercially available indicators (Molecular Probes), parental cells and cells expressing STEAP-2 were compared for their ability to transport calcium. PC3-neo and PC3-STEAP-2 cells were loaded with calcium responsive indicators Fluo4 and Fura red, incubated in the presence or absence of calcium and LPA, and analyzed by flow cytometry. PC3 cells expressing a known calcium transporter, PC3-83P3H3 pCaT were used as positive control (Biochem Biophys Res Commun. 2001, 282:729). The table on FIG. 23 shows that STEAP-2 mediates calcium flux in response to LPA, and that the magnitude of calcium flux is comparable to that produced by a known calcium channel.  
     [1128] In addition, STEAP-2 expressing PC3 cells demonstrated increased sensitivity to agatoxin, a calcium channel blocker as compared to PC3-neo cells. These results indicate that STEAP-2 expression renders PC3 cells sensitive to treatment with the Ca++ channel inhibitors. Information derived from the above experiments provides a mechanism by which cancer cells are regulated. This is particularly relevant in the case of calcium, as calcium channel inhibitors have been reported to induce the death of certain cancer cells, including prostate cancer cell lines (see, e.g., Batra S, Popper L D, Hartley-Asp B. Prostate. 1991,19:299).  
     [1129]FIG. 24 shows that cells transfected with a STEAP-2 expression system have enhanced ability to survive exposure to paclitaxel. In order to determine the effect of STEAP-2 on survival, PC3 cells lacking or expressing STEAP-2 were treated with chemotherapeutic agents currently used in the clinic. Effect of treatment was evaluated by measuring cell proliferation using the Alamare blue assay (FIG. 23). While only 5.2% of PC3-neo cells were able to metabolize Alalmare Blue and proliferate in the presence of 5 μM paclitaxel, 44.8% of PC3-STEAP-2 cells survived under the same conditions: These results indicate that expression of STEAP-2 imparts resistance to paclitaxel. These findings have significant in vivo implications, as they indicate that STEAP-2 provides a growth advantage for prostate tumor cells in patients treated with common therapeutic agents.  
     [1130] A more detailed form of these results is shown on FIGS. 25 and 26. Results in these two pages demonstrate the mode of action by which STEAP-2 supports the survival of PC3 cells. In these studies, PC3 cells expressing or lacking STEAP-2 were treated with paclitaxel for 60 hours, and assayed for apoptosis using annexin V conjugated to FITC and propidium iodide staining. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the membrane, thereby exposing PS to the external cellular environment. PS is recognized by and binds to annexin V, providing scientists with a reliable means of identifying cells undergoing programmed cell death. Staining with propidium iodide identifies dead cells. FIG. 25 show that expression of STEAP-2 inhibits paclitaxel-mediated: apoptosis by 45% relative to paclitaxel-treated PC3-neo cells. The protective effect of STEAP-2 is inhibited when STEAP-2 is modified by the presence of Flag at its C-terminus FIG. 26.  
     [1131] The publicly available literature contains several examples of prostate and other cancers that exhibit similar phenotypic characteristics as those observed in PC3 cells that express STEAP-2. In particular, clinical studies have reported transient tumor regression and/or only partial responses in patients treated with paclitaxel. For instance, only around 50% of prostate cancer patients entered in a single agent clinical trial of paclitaxel showed reduced PSA levels when treated with doses of paclitaxel that induced grade 3 and grade 4 toxicity; a much higher level of response would have been expected based on this dose level, thus this data indicates the development of paclitaxel resistance in prostate cancer patients (Beer T M et al, Ann Oncol 2001, 12:1273). A similar phenomenon of reduced responsiveness and progressive tumor recurrence was observed in other studies (see, e.g., Obasaju C, and Hudes G R. Hematol Oncol Clin North Am 2001,15:525). In addition, inhibition of calcium flux in cells that endogenously express STEAP-2, such as LNCaP cells, induces their cell death (Skryma R et al, J. Physiol. 2000, 527:71).  
     [1132] Thus, STEAP-2 protein is produced not only in the cells tested, but also in unmodified tumor cells or unmodified prostate cells where the presence of mRNA has been shown. The Northern blot data in the specification clearly show that the messenger RNA encoding STEAP-2 is produced in certain prostate and tumor cells. The 3T3 and PC-3 cells, which are themselves tumor cell lines, are clearly able to translate the messenger RNA into protein. Because it has been shown that there is no barrier to translation of the message in cells similar to those tumor and prostate cells in which the mRNA has been shown to be produced, it can properly be concluded that the protein itself can be detected in the unmodified tumor or prostate cells, given the fact that it is shown that mRNA is produced. This conclusion is also supported by the patterns of phenotypic changes seen in cells specifically modified to express STEAP-2, these changes comport with changes seen in cancer cells. Based on the above data, it is scientifically concluded that cells and tissues which produce mRNA encoding STEAP-2 also produce the protein itself.  
     Example 46  
     Identification and Confirmation of Potential Signal Transduction Pathways  
     [1133] Many mammalian proteins have been reported to interact with signaling molecules and to participate in regulating signaling pathways (J. Neurochem. 2001; 76:217-223. Using immunoprecipitation and Western blotting techniques, proteins are identified that associate with 98P4B6 and mediate signaling events. Several pathways known to play a role in cancer biology can be regulated by 98P4B6, including phospholipid pathways such as P13K, AKT, etc, adhesion and migration pathways, including FAK, Rho, Rac-1, etc, as well as mitogenic/survival cascades such as ERK, p38, etc (Cell Growth Differ. 2000,11:279; J Biol. Chem. 1999, 274:801; Oncogene. 2000,19:3003, J. Cell Biol. 1997,138:913.).  
     [1134] To confirm that 98P4B6 directly or indirectly activates known signal transduction pathways in cells, luciferase (luc) based transcriptional reporter assays are carried out in cells expressing individual genes. These transcriptional reporters contain consensus-binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways. The reporters and examples of these associated transcription factors, signal transduction pathways, and activation stimuli are listed below.  
     [1135] 1. NFkB-luc, NFkB/Rel; Ik-kinase/SAPK; growth/apoptosis/stress  
     [1136] 2. SRE-luc, SRF/TCF/ELK1; MAPK/SAPK; growth/differentiation  
     [1137] 3. AP-1-luc, FOS/JUN; MAPK/SAPK/PKC; growth/apoptosis/stress  
     [1138] 4. ARE-luc, androgen receptor; steroids/MAPK; growth/differentiation/apoptosis  
     [1139] 5. p53-luc, p53; SAPK; growth/differentiation/apoptosis  
     [1140] 6. CRE-luc, CREB/ATF2; PKA/p38; growth/apoptosis/stress  
     [1141] Gene-mediated effects can be assayed in cells showing mRNA expression. Luciferase reporter plasmids can be introduced by lipid-mediated transfection (TFX-50, Promega). Luciferase activity, an indicator of relative transcriptional activity, is measured by incubation of cell extracts with luciferin substrate and luminescence of the reaction is monitored in a luminometer.  
     [1142] Signaling pathways activated by 98P4B6 are mapped and used for the identification and validation of therapeutic targets. When 98P4B6 is involved in cell signaling, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     Example 47  
     98P4B6 Functions as a Proton or Small Molecule Transporter  
     [1143] Sequence and homology analysis of 98P4B6 indicate that the 98P4B6 may function as a transporter. To confirm that STEAP-1 functions as an ion channel, FACS analysis and fluorescent microscopy techniques are used (Gergely L, et al., Clin Diagn Lab Immunol. 1997; 4:70; Skryma R, et al., J. Physiol. 2000, 527: 71). Using FACS analysis and commercially available indicators (Molecular Probes), parental cells and cells expressing 98P4B6 are compared for their ability to transport electrons, sodium, calcium; as, well as other small molecules in cancer and normal cell lines. For example, PC3 and PC3-98P4B6 cells were loaded with calcium responsive indicators Fluo4 and Fura red, incubated in the presence or absence of calcium and lipophosphatidic acid (LPA), and analyzed by flow cytometry. Ion flux represents an important mechanism by which cancer cells are regulated. This is particularly true in the case of calcium, as calcium channel inhibitors have been reported to induce the death of certain cancer cells, including prostate cancer cell lines (Batra S, Popper L D, Hartley-Asp B. Prostate. 1991, 19: 299). Similar studies are conducted using sodium, potassium, pH, etc indicators.  
     [1144] Due to its homology to an oxidoreductase, 98P4B6 can participate in imparting drug resistance by mobilizing and transporting small molecules. The effect of 98P4B6 on small molecule transport is investigated using a modified MDR assay. Control and 98P4B6 expressing cells are loaded with a fluorescent small molecule such as calcein AM. Extrusion of calcein from the cell is measured by examining the supernatants for fluorescent compound. MDR-like activity is confirmed using MDR inhibitors.  
     [1145] When 98P4B6 functions as a transporter, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     Example 48  
     Involvement in Tumor Progression  
     [1146] The 98P4B6 gene can contribute to the growth of cancer cells. The role of 98P4B6 in tumor growth is confirmed in a variety of primary and transfected cell lines including prostate as well as NIH 3T3 cells engineered to stably express 98P4B6. Parental cells lacking 98P4B6 and cells expressing 98P4B6 are evaluated for cell growth using a well-documented proliferation assay (Fraser S P, Grimes J A, Djamgoz M B. Prostate. 2000;44:61, Johnson D E, Ochieng J, Evans S L. Anticancer Drugs. 1996, 7:288).  
     [1147] To confirm the role of 98P4B6 in the transformation process, its effect in colony forming assays is investigated. Parental NIH-3T3 cells lacking 98P4B6 are compared to NIH-3T3 cells expressing 98P4B6, using a soft agar assay under stringent and more permissive conditions (Song Z. et al. Cancer Res. 2000;60:6730.  
     [1148] To confirm the role of 98P4B6 in invasion and metastasis of cancer cells, a well-established assay is used, e.g., a Transwell Insert System assay (Becton Dickinson) (Cancer Res. 1999; 59:6010). Control cells, including prostate and fibroblast cell lines lacking 98P4B6 are compared to cells expressing 98P4B6. Cells are loaded with the fluorescent dye, calcein, and plated in the top well of the Transwell insert coated with a basement membrane analog. Invasion is determined by fluorescence of cells in the lower chamber relative to the fluorescence of the entire cell population.  
     [1149] 98P4B6 can also play a role in cell cycle and apoptosis. Parental cells and cells expressing 98P4B6 are compared for differences in cell cycle regulation using a well-established BrdU assay (Abdel-Malek Z A. J Cell Physiol. 1988, 136:247). In short, cells are grown under both optimal (full serum) and limiting (low serum) conditions are labeled with BrdU and stained with anti-BrdU Ab and propidium iodide. Cells are analyzed for entry into the G1, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on apoptosis is evaluated in control parental cells and cells expressing 98P4B6, including normal and tumor prostate cells. Engineered and parental cells are treated with various chemotherapeutic agents, such as etoposide, flutamide, etc, and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and cell death is measured by FACS analysis. The modulation of cell death by 98P4B6 can play a critical role in regulating tumor progression and tumor load.  
     [1150] When 98P4B6 plays a role in cell growth, transformation, invasion or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     Example 49  
     Involvement in Angiogenesis  
     [1151] Angiogenesis or new capillary blood vessel formation is necessary for tumor growth (Hanahan D, Folkman J. Cell. 1996, 86:353; Folkman J. Endocrinology. 1998 139:441). Based on the effect of phsophodieseterase inhibitors on endothelial cells, 98P4B6 plays a role in angiogenesis (DeFouw L et al, Microvasc Res 2001, 62:263). Several assays have been developed to measure angiogenesis in vitro and in vivo, such as the tissue culture assays endothelial cell tube formation and endothelial cell proliferation. Using these assays as well as in vitro neo-vascularization, the role of 98P4B6 in angiogenesis, enhancement or inhibition, is confirmed.  
     [1152] For example, endothelial cells engineered to express 98P4B6 are evaluated using tube formation and proliferation assays. The effect of 98P4B6 is also confirmed in animal models in vivo. For example, cells either expressing or lacking 98P4B6 are implanted subcutaneously in immunocompromised mice. Endothelial cell migration and angiogenesis are evaluated 5-15 days later using immunohistochemistry techniques. 98P4B6 affects angiogenesis, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     Example 50  
     Regulation of Transcription  
     [1153] The localization of 98P4B6 and its similarity to hydrolases as well as its Ets motif (v.7) indicate that 98P4B6 is effectively used as a modulator of the transcriptional regulation of eukaryotic genes. Regulation of gene expression is confirmed, e.g., by studying gene expression in cells expressing or lacking 98P4B6. For this purpose, two types of experiments are performed.  
     [1154] In the first set of experiments, RNA from parental and 98P4B6-expressing cells are extracted and hybridized to commercially available gene arrays (Clontech) (Smid-Koopman E et al. Br J Cancer. 2000. 83:246). Resting cells as well as cells treated with FBS or androgen are compared. Differentially expressed genes are identified in accordance with procedures known in the art. The differentially expressed genes are then mapped to biological pathways (Chen K et al. Thyroid. 2001. 11:41.).  
     [1155] In the second set of experiments, specific transcriptional pathway activation is evaluated using commercially available (Stratagene) luciferase reporter constructs including: NFkB-luc, SRE-luc, ELK1-luc, ARE-luc, p53-luc, and CRE-luc. These transcriptional reporters contain consensus binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways, and represent a good tool to ascertain pathway activation and screen for positive and negative modulators of pathway activation.  
     [1156] Thus, 98P4B6 plays a role in gene regulation. When 98P4B6 is involved in gene regulation it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     Example 51  
     Protein—Protein Association  
     [1157] Several 6TM proteins have been shown to interact with other proteins, thereby regulating signal transduction, gene transcription, transformation, and cell adhesion. Using immunoprecipitation techniques as well as two yeast hybrid systems, proteins are identified that associate with 98P4B6. Immunoprecipitates from cells expressing 98P4B6 and cells lacking 98P4B6 are compared for specific protein-protein associations.  
     [1158] Studies are performed to confirm the extent of association of 98P4B6 with effector molecules, such as nuclear proteins, transcription factors, kinases, phsophates etc. Studies comparing 98P4B6 positive and 98P4B6 negative cells as well as studies comparing unstimulated/resting cells and cells treated with epithelial cell activators, such as cytokines, growth factors, androgen and anti-integrin Ab reveal unique interactions.  
     [1159] In addition, protein-protein interactions are confirmed using two yeast hybrid methodology (Curr Opin Chem Biol. 1999, 3:64). A vector carrying a library of proteins fused to the activation domain of a transcription factor is introduced into yeast expressing a 98P4B6-DNA-binding domain fusion protein and a reporter construct. Protein-protein interaction is detected by colorimetric reporter activity. Specific association with effector molecules and transcription factors directs one of skill to the mode of action of 98P4B6, and thus identifies therapeutic, prognostic, preventative and/or diagnostic targets for cancer. This and similar assays are also used to identify and screen for small molecules that interact with 98P4B6.  
     [1160] Thus it is found that 98P4B6 associates with proteins and small molecules. Accordingly, 98P4B6 and these proteins and small molecules are used for diagnostic, prognostic, preventative and/or therapeutic purposes.  
     [1161] Throughout this application, various website data content, publications, patent applications and patents are referenced. (Websites are referenced by their Uniform Resource Locator, or URL, addresses on the World Wide Web.) The disclosures of each of these references are hereby incorporated by reference herein in their entireties.  
     [1162] The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.  
               TABLE I                       Tissues that Express 98P4B6:       a. Malignant Tissues                                        a   Bladder       b.   Breast       c.   Cervix       d.   Colon       e.   Kidney       f.   Lung       g.   Ovary       h.   Pancreas       i.   Prostate       j.   Stomach       k.   Uterus                  
 
     [1163]               TABLE II                          Amino Acid Abbreviations                                 SINGLE LETTER   THREE LETTER   FULL NAME                       F   Phe   phenylalanine           L   Leu   leucine           S   Ser   serine           Y   Tyr   tyrosine           C   Cys   cysteine           W   Trp   tryptophan           P   Pro   proline           H   His   histidine           Q   Gln   glutamine           R   Arg   arginine           I   Ile   isoleucine           M   Met   methionine           T   Thr   threonine           N   Asn   asparagine           K   Lys   lysine           V   Val   valine           A   Ala   alanine           D   Asp   aspartic acid           E   Glu   glutamic acid           G   Gly   glycine                        
     [1164]               TABLE III                          Amino Acid Substitution Matrix       Adapted from the GCG Software 9.0 BLOSUM62 amino acid substitution matrix       (block substitution matrix). The higher the value, the more likely a substitution is       found in related, natural proteins.       (See world wide web URL ikp.unibe.ch/manual/blosum62.html)                                                                                                 A   C   D   E   F   G   H   I   K   L   M   N   P   Q   R   S   T   V   W   Y   .                                                                                                         4   0   −2   −1   −2   0   −2   −1   −1   −1   −1   −2   −1   −1   −1   1   0   0   −3   −2   A           9   −3   −4   −2   −3   −3   −1   −3   −1   −1   −3   −3   −3   −3   −1   −1   −1   −2   −2   C               6   2   −3   −1   −1   −3   −1   −4   −3   1   −1   0   −2   0   −1   −3   −4   −3   D                   5   −3   −2   0   −3   1   −3   −2   0   −1   2   0   0   −1   −2   −3   −2   E                       6   −3   −1   0   −3   0   0   −3   −4   −3   −3   −2   −2   −1   1   3   F                           6   −2   −4   −2   −4   −3   0   −2   −2   −2   0   −2   −3   −2   −3   G                               8   −3   −1   −3   −2   1   −2   0   0   −1   −2   −3   −2   2   H                                   4   −3   2   1   −3   −3   −3   −3   −2   −1   3   −3   −1   I                                       5   −2   −1   0   −1   1   2   0   −1   −2   −3   −2   K                                           4   2   −3   −3   −2   −2   −2   −1   1   −2   −1   L                                               5   −2   −2   0   −1   −1   −1   1   −1   −1   M                                                   6   −2   0   0   1   0   −3   −4   −2   N                                                       7   −1   −2   −1   −1   −2   −4   −3   P                                                           5   1   0   −1   −2   −2   −1   Q                                                               5   −1   −1   −3   −3   −2   R                                                                   4   1   −2   −3   −2   S                                                                       5   0   −2   −2   T                                                                           4   −3   −1   V                                                                               11   2   W                                                                                   7   Y                    
     [1165] Table IV:  
     [1166] HLA Class I/II Motifs/Supermotifs  
               TABLE IV (A)                          HLA Class I Supermotifs/Motifs                                     POSITION   POSITION           POSITION   3 (Primary   C Terminus           2 (Primary Anchor)   Anchor)   (Primary Anchor)               SUPERMOTIF                   A1   ♯TI LVMS         ♯FWY       A2   ♯LIVM ATQ         ♯IV MATL         A3   ♯VSMA TLI         ♯RK       A24   ♯YF WIVLMT         ♯FI YWLM         B7   ♯P       ♯VILF MWYA         B27   ♯RHK       ♯FYL WMIVA         B44   ♯E D         ♯FWYLIMVA       B58   ♯ATS       ♯FWY LIVMA         B62   ♯QL IVMP         ♯FWY MIVLA         MOTIFS                   A1   ♯TSM       ♯Y       A1       ♯DE AS     ♯Y       A2.1   ♯LM VQIAT         ♯V LIMAT         A3   ♯LMVISATF CGD         ♯KYR HFA         A11   ♯VTMLISAGN CDF         ♯K RYH         A24   ♯YFW M         ♯FLIW       A*3101   ♯MVT ALIS         ♯R K         A*3301   ♯MVALF IST         ♯RK       A*6801   ♯AVT MSLI         ♯RK       B*0702   ♯P       ♯LMF WYAIV         B*3501   ♯P       LMFWY IVA         B51   ♯P       ♯LIVF WYAM         B*5301   ♯P       ♯IMFWY ALV         B*5401   ♯P       ♯ATIV LMFWY                            
 
     [1167] Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table.  
               TABLE IV (B)                          HLA Class II Supermotif                         1   6   9               W, F, Y, V, I, L   A, V, I, L, P, C, S, T   A, V, I, L, C, S, T, M, Y                  
 
     [1168]               TABLE IV (C)                       HLA Class II Motifs                                                                            MOTIFS       1° anchor 1   2   3   4   5   1° anchor 6   7   8   9               DR4   preferred   FMY LIVW     M   T       I   VST CPALIM     MH       MH           deleterious               W           R       WDE       DR1   preferred   MF LIVWY             PAMQ       VMAT SPLIC     M       AVM           deleterious       C   CH   FD   CWD       GDE   D       DR7   preferred   MF LIVWY     M   W   A       IVMSA CTPL     M       IV           deleterious       C       G           GRD   N   G                                                     DR3   MOTIFS   1° anchor 1   2   3   1° anchor 4   5   1° anchor 6               Motif a preferred       LIVMFY           D       Motif b preferred       LIVMFAY           DNQEST       KRH       DR Supermotif       MF LIVWY                     VMSTA CPLI                              
     [1169]               TABLE IV (D)                          HLA Class I Supermotifs                             SUPER-       POSITION:                                                             MOTIFS       1   2   3   4   5   6   7   8   C-terminus               A1             1° Anchor                               1° Anchor                     TI LVMS                             FWY       A2           1° Anchor                             1° Anchor                     {overscore (LIVM ATQ )}                           LIVMAT       A3   Preferred         1° Anchor     YFW           YFW   YFW   P     1° Anchor                     VSMA TLI     (4/5)           (3/5)   (4/5)   (4/5)   RK           deleterious   DE(3/5);       DE               P(5/5)       (4/5)       A24           1° Anchor                             1° Anchor                     {overscore (YF WIVLMT )}                           FIY WLM         B7   Preferred   FWY(5/5)     1° Anchor     FWY                   FWY   1° Anchor               LIVM(3/5)   P   (4/5)                   (3/5)   {overscore (VILF MWYA )}           deleterious   DE(3/5);               DE   G   QN   DE               P(5/5);               (3/5)   (4/5)   (4/5)   (4/5)               G(4/5);               A(3/5);               QN(3/5)       B27             1° Anchor                             1° Anchor                   RHK                           {overscore (FYL WMIVA )}       B44             1° Anchor                             1° Anchor                   E D                             {overscore (FWYLIMVA)}       B58             1° Anchor                             1° Anchor                   ATS                           {overscore (FWY LIVMA )}       B62             1° Anchor                             1° Anchor                   QL IVMP                             {overscore (FWY MIVLA )}                            
     [1170]               TABLE IV (E)                       HLA Class I Motifs                                                POSITION                                                                                                         9 or C-   C-               1   2   3   4   5   6   7   8   terminus   terminus               A1   preferred   GFYW     1° Anchor     DEA   YFW       P   DEQN   YFW     1° Anchor         9-mer           STM                           Y           deleterious   DE       RHKLIVMP   A   G   A       A1   preferred   GRHK   ASTCLIVM     1° Anchor     GSTC       ASTC   LIVM   DE     1° Anchor         9-mer               DE AS                         Y           deleterious   A   RHKDEPYFW       DE   PQN   RHK   PG   GP       A1   preferred   YFW     1° Anchor     DEAQN   A   YFWQN       PASTC   GDE   P     1° Anchor         10-mer           STM                               Y           deleterious   GP       RHKGLIVM   DE   RHK   QNA   RHKYFW   RHK   A       A1   preferred   YFW   STCLIVM     1° Anchor     A   YFW       PG   G   YFW     1° Anchor         10-mer               DE AS                             Y           deleterious   RHK   RHKDEPYFW           P   G       PRHK   QN       A2.1   preferred   YFW     1° Anchor     YFW   STC   YFW       A   P     1° Anchor         9-mer           LM IVQAT                             V LIMAT             deleterious   DEP       DERKH           RKH   DERKH                                     POSITION:   C-                                                                     1   2   3   4   5   6   7   8   9   terminus               A2.1   pre-   AYFW     1° Anchor     LVIM   G       G       FYWLVIM         1° Anchor         10-mer   ferred       LM IVQAT                                 V LIMAT             dele-   DEP       DE   RKHA   P       RKH   DERKH   RKH           te-           rious       A3   pre-   RHK   1° Anchor   YFW   PRHKYFW   A   YFW       P     1° Anchor             ferred       {overscore (LMVISATF CGD )}                           KYR HFA             dele-   DEP       DE           te-           rious       A11   pre-   A     1° Anchor     YFW   YFW   A   YFW   YFW   P     1° Anchor             ferred       VTLMISAGN CDF                             K RYH             dele-   DEP                       A   G           te-           rious       A24   pre-   YFWRHK     1° Anchor         STC           YFW   YFW     1° Anchor         9-mer   ferred       YFW M                             FLIW           dele-   DEG       DE   G   QNP   DERHK   G   AQN           te-           rious       A24   Pre-         1° Anchor         P   YFWP       P             1° Anchor         10-mer   ferred       YFW M                                 FLIW           Dele-           GDE   QN   RHK   DE   A   QN   DEA           te-           rious       A3101   Pre-   RHK     1° Anchor     YFW   P       YFW   YFW   AP     1° Anchor             ferred       MVT ALIS                             R K             Dele-   DEP       DE       ADE   DE   DE   DE           te-           rious       A3301   Pre-       1° Anchor   YFW               AYFW         1° Anchor             ferred       {overscore (MVALF IST )}                           RK           Dele-   GP       DE           te-           rious       A6801   Pre-   YFWSTC     1° Anchor             YFW       YFW   P     1° Anchor                 ferred       AVT MSLI             LIVM               RK           Dele-   GP       DEG       RHK           A           te-           rious       B0702   Pre-   RHKFWY     1° Anchor     RHK       RHK   RHK   RHK   PA   1° Anchor           ferred       P                           {overscore (LMF WY )}                                                 AIV             Dele-   DEQNP       DEP   DE   DE   GDE   QN   DE           te-           rious       B3501   Pre-   FWYLIVM     1° Anchor     FWY               FWY       1° Anchor           ferred       P                           {overscore (LMF WYIVA )}           dele-   AGP               G   G           te-           rious                             POSITION:                                                                                                         9 or C-   C-               1   2   3   4   5   6   7   8   terminus   terminus               A1   pre-   GFYW     1° Anchor     DEA   YFW       P   DEQN   YFW     1° Anchor         9-mer   ferred       STM                           Y           dele-   DE       RHKLIVMP   A   G   A           te-           rious       A1   pre-   GRHK   ASTCLIVM     1° Anchor     GSTC       A   LIVM   DE     1° Anchor         9-mer   ferred           DE AS             STC           Y           dele-   A   RHKDEP       DE   PQN   RHK   PG   GP           te-       YFW           rious           dele-   AGP               G   G           te-           rious       B51   Pre-   LIVMFWY     1° Anchor     FWY   STC   FWY       G   FWY   1° Anchor           ferred       P                           {overscore (LIVF WYAM )}           dele-   AGPDERHKSTC               DE   G   DEQN   GDE           te-           rious       B5301   pre-   LIVMFWY     1° Anchor     FWY   STC   FWY       LIVM   FWY   1° Anchor           ferred       P                   FWY       {overscore (IMFW YALV )}           dele-   AGPQN                   G   RHKQN   DE           te-           rious       B5401   pre-   FWY     1° Anchor     FWYLIVM       LIVM       ALIVM   FWYAP   1° Anchor           ferred       P                           {overscore (ATIV LMFWY )}           dele-   GPQNDE       GDESTC       RHKDE   DE   QNDGE   DE           te-           rious                    
     [1171]               TABLE IV (F)                          Summary of HLA-supertypes       Overall phenotypic frequencies of HLA-supertypes in different ethnic populations                     Specificity   Phenotypic frequency                                                 Supertype   Position 2   C-Terminus   Caucasian   N.A. Black   Japanese   Chinese   Hispanic   Average                                                         B7   P   AILMVFWY   43.2   55.1   57.1   43.0   49.3   49.5       A3   AILMVST   RK   37.5   42.1   45.8   52.7   43.1   44.2       A2   AILMVT   AILMVT   45.8   39.0   42.4   45.9   43.0   42.2       A24   YF (WIVLMT)   FI (YWLM)   23.9   38.9   58.6   40.1   38.3   40.0       B44   E (D)   FWYLIMVA   43.0   21.2   42.9   39.1   39.0   37.0       A1   TI (LVMS)   FWY   47.1   16.1   21.8   14.7   26.3   25.2       B27   RHK   FYL (WMI)   28.4   26.1   13.3   13.9   35.3   23.4       B62   QL (IVMP)   FWY (MIV)   12.6   4.8   36.5   25.4   11.1   18.1       B58   ATS   FWY (LIV)   10.0   25.1   1.6   9.0   5.9   10.3                    
     [1172]               TABLE IV (G)                          Calculated population coverage afforded by different HLA-supertype combinations                         Phenotypic frequency                                         HLA-supertypes   Caucasian   N.A Blacks   Japanese   Chinese   Hispanic   Average                                                 A2, A3 and B7   83.0   86.1   87.5   88.4   86.3   86.2       A2, A3, B7, A24, B44   99.5   98.1   100.0   99.5   99.4   99.3       and A1   99.9   99.6   100.0   99.8   99.9   99.8       A2, A3, B7, A24       B44, A1, B27, B62,       and B58                            
     [1173]               TABLE V                          Frequently Occurring Motifs                                 avrg. %               Name   identity   Description   Potential Function               zf-C2H2   34%   Zinc finger, C2H2 type   Nucleic acid-binding protein functions as                   transcription factor, nuclear location                   probable       cytochrome_b_N   68%   Cytochrome b(N-   membrane bound oxidase, generate               terminal)/b6/petB   superoxide       lg   19%   Immunoglobulin domain   domains are one hundred amino acids                   long and include a conserved                   intradomain disulfide bond.       WD40   18%   WD domain, G-beta repeat   tandem repeats of about 40 residues,                   each containing a Trp-Asp motif.                   Function in signal transduction and                   protein interaction       PDZ   23%   PDZ domain   may function in targeting signaling                   molecules to sub-membranous sites       LRR   28%   Leucine Rich Repeat   short sequence motifs involved in                   protein-protein interactions       Pkinase   23%   Protein kinase domain   conserved catalytic core common to                   both serine/threonine and tyrosine                   protein kinases containing an ATP                   binding site and a catalytic site       PH   16%   PH domain   pleckstrin homology involved in                   intracellular signaling or as constituents                   of the cytoskeleton       EGF   34%   EGF-like domain   30-40 amino-acid long found in the                   extracellular domain of membrane-                   bound proteins or in secreted proteins       Rvt   49%   Reverse transcriptase               (RNA-dependent DNA               polymerase)       Ank   25%   Ank repeat   Cytoplasmic protein, associates integral                   membrane proteins to the cytoskeleton       Oxidored_q1   32%   NADH-   membrane associated. Involved in               Ubiquinone/plastoquinone   proton translocation across the               (complex I), various chains   membrane       Efhand   24%   EF hand   calcium-binding domain, consists of a12                   residue loop flanked on both sides by a                   12 residue alpha-helical domain       Rvp   79%   Retroviral aspartyl   Aspartyl or acid proteases, centered on               protease   a catalytic aspartyl residue       Collagen   42%   Collagen triple helix repeat   extracellular structural proteins involved               (20 copies)   in formation of connective tissue. The                   sequence consists of the G-X-Y and the                   polypeptide chains forms a triple helix.       Fn3   20%   Fibronectin type III domain   Located in the extracellular ligand-                   binding region of receptors and is about                   200 amino acid residues long with two                   pairs of cysteines involved in disulfide                   bonds       7tm_1   19%   7 transmembrane receptor   seven hydrophobic transmembrane               (rhodopsin family)   regions, with the N-terminus located                   extracellularly while the C-terminus is                   cytoplasmic. Signal through G proteins                    
     [1174]               TABLE VI                       Motifs and Post-translational Modifications of 98P4B6                  cAMP- and cGMP—dependent protein kinase       phosphorylation site.                         176-179   RKET   (SEQ ID NO: 114)                 Protein kinase C phosphorylation site.                     235-237   SVK                 Casein kinase II phosphorylation site.                          9-12   SATD   (SEQ ID NO: 115)       50-53   TVME   (SEQ ID NO: 116)       130-133   SCTD   (SEQ ID NO: 117)       172-175   SPEE   (SEQ ID NO: 118)                 N-myristoylation site.                         14-19   GLSIST   (SEQ ID NO: 119)                 G-protein coupled receptors family 1 signature.                         52-68   MESSVLLAMAFDRFVAV   (SEQ ID NO: 120)                    
     [1175]               TABLE VII                       Search Peptides                                    v.1 aa1-454       9-mers, 10-mers and 15-mers                 (SEQ ID NO: 121)                 MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS               RNPKFASEFF PHVVDVTHHE DALTKTNIIF VAIBREHYTS LWDLRHLLVG KILTDVSNNM               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFFFLYS FVRDVIHPYA               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ               CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEEVWRIEMY               ISFGIMSLGL LSLLAVTSIP SVSNALNWRE FSFIQSTLGY VALLISTFHV LIYGWKRAFE               EEYYRFYTPP NFVLALVLPS IVILDLLQLC RYPD               v.2 aa1-45       9-mers, 10-mers, 15-mers                 (SEQ ID NO: 122)                 SGSPGLQALSL SLSSGFTPFS CLSLPSSWDY RCPPPCPADF FLYF               v.5, (one aa diff at 211 and different c-terminal)       Part A       9-mers: aa203-219                 (SEQ ID NO: 123)                 NLPLRLFTFWRGPVVVA               10-mers: aa202-220                 (SEQ ID NO: 124)                 ENLPLRLFTFWRGPVVVAI               15-mers: aa197-225                 (SEQ ID NO: 125)                 SAREIENLPLRLFTFWRGPVVVAISLATF               Part B       9-mers: aa388-419                 (SEQ ID NO: 126)                 WREFSFIQIFCSFADTQTELELEFVFLLTLLL               10-mers: aa387-419                 (SEQ ID NO: 127)                 NWREFSFIQIFCSFADTQTELELEFVFLLTLLL               15-mers: aa382-419                 (SEQ ID NO: 128)                 VSNALNWREFSFIQIFCSFADTQTELELEFVFLLTLLL               v.6, (different from our original in 445-490)       9-mers; aa447-490                 (SEQ ID NO: 129)                 VLPSIVILGKIILFLPCISRKLKRIKKGWEKSQFLEEGIGGTIPHVSPERVTVM               10-mers: aa446-490                 (SEQ ID NO: 130)                 LVLPSIVILGKIILFLPCISRKLKRIKKGWEKSQFLEEGIGGTIPHVSPERVTVM               15-mers: aa441-490                 (SEQ ID NO: 131)                 NFVLALVLPSIVILGKIILFLPCISRKLKRIKKGWEKSQFLEEGIGGTIPHVSPERVTVM               v.7, (deleting our original 340-394, 392-576 is different)       Part A       9-mers:       aa334-350                 (SEQ ID NO: 132)                 FLNMAYQQSTLGYVALL               10-mers: aa333-351                 (SEQ ID NO: 133)                 LFLNMAYQQSTLGYVALLI               15-mers: aa328-355                 (SEQ ID NO: 134)                 RSERYLFLNMAYQQSTLGYVALLISTFHV               Part B       9-mers: aa384-576                 (SEQ ID NO: 135)                 PSIVILDLSVEVLASPAAAWKCLGANILRGGLSEIVLPIEWQQDRKIPPLSTPPPPA               MWTEEAGATAEAQESGIRNKSSSSSQIPVVGVVTEDDEAQDSIDPPESPDPALKAANSWRNPV               LPHTNGVGPLWEFLLRLLKSQAASGTLSLAFTSWSLGEFLGSGTWMKLETIILSKLTQEQKSKHCMF SLISGS               10-mers: aa383-576                 (SEQ ID NO: 136)                 LPSIVILDLSVEVLASPAAAWKCLGANILRGGLSEIVLPTEWQQDRKIPPLSTPPPPA               MWTEEAGATAEAQESGIRNKSSSSSQIPVVGVVTEDDEAQDSIDPPESPDRALKAANSWRNPV               LPHTNGVGPLWEFLLRLLKSQAASGTLSLAFTSWSLG EFLGSGTWMK LETIILSKLT QEQKSKHCMF               SLISGS               15-mers: aa378-576                 (SEQ ID NO: 137)                 VLALVLPSIVILDLSVEVLASPAAAWKCLGANILRGGLSETVLPIEWQQDRKIPPLSTPPPPA               MWTEEAGATAEAQESGIRNKSSSSSQIPVVGVVTEDDEAQDSIDPPESPDRALKAANSWRNPV               LPHTNGVGPLWEFLLRLLKSQAASGTLSLAFTSWSLG EFLGSGTWMK LETIILSKLT QEQKSKHCMF               SLISGS               v.8, SNP variant of v.6, one aa different at 475       9-mers: aa466-482                 (SEQ ID NO: 138)                 KSQFLEEGMGGTIPHVS               10-mers: aa465-483                 (SEQ ID NO: 139)                 EKSQFLEEGMGGTIPHVSP               15-mers: aa460-489                 (SEQ ID NO: 140)                 IKKGWEKSQELEEGMGGTIPHVSPERVTV               V13       9-mers: aa9-25                 (SEQ ID NO: 141)                 SPKSLSETFLPNGINGT               10-mers: aa8-26                 (SEQ ID NO: 142)                 GSPKSLSETFLPNGINGIK               15-mers: aa3-31                 (SEQ ID NO: 143)                 SISMMGSPKSLSETFLPNGINGIKDARKV               v.14       9-mers: aa203-219                 (SEQ ID NO: 144)                 NLPLRLFTFWRGPVVVA               10-mers: aa202-220                 (SEQ ID NO: 145)                 ENLPLRLFTFWRGPVVVAI               15-mers: aa197-225                 (SEQ ID NO: 146)                 SAREIENLPLRLFTFWRGPVVVAISLATF               V.21       9-mers 557-572                 (SEQ ID NO: 147)                 SKLTQEQKTKHCMFSLI               10-mers 556-573                 (SEQ ID NO: 148)                 LSKLTQEQKTKHCMFSLIS               15-mers 551-576                 (SEQ ID NO: 149)                 LETIILSKLTQEQKTKHCMFSLISGS               V.25       9-mers aa 447-463                 (SEQ ID NO: 150)                 ILFLPCISQKLKRTKKG               10-mers aa 446-464                 (SEQ ID NO: 151)                 IILFLPCISQKLKRIKKGW       15-mers aa440-468                         (SEQ ID NO: 152)                 VILGKIILFLPCISQKLKRIKKGWEKSQF                    
     [1176] Tables VIII-XXI:  
                       TABLE VIII                       Start   Subsequence   Score                                    V1-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start position plus       eight.                         443   ILDLLQLCR   25.000       129   NAEYLASLF   9.000       294   WLETWLQCR   9.000       113   LIDVSNNMR   5.000       200   EIENLPLRL   4.500       244   QSDFYKIPI   3.750       405   ISTFHVLIY   3.750       13   LSETCLPNG   2.700       221   SLATFFFLY   2.500       263   AITLLSLVY   2.500       276   LAAAYQLYY   2.500       419   FEEEYYRFY   2.250       155   QLGPKDASR   2.000       66   ASEFFPHVV   1.350       272   LAGLLAAAY   1.000       35   VIGSGDFAK   1.000       178   VIELARQLN   0.900       356   RIEMYISFG   0.900       418   AFEEEYYRF   0.900       319   YSLCLPMRR   0.750       43   KSLTIRLIR   0.750       327   RSERYLFLN   0.675       427   YTPPNFVLA   0.500       304   QLGLLSFFF   0.500       257   KTLPIVAIT   0.500       135   SLFPDSLIV   0.500       223   ATFFFLYSF   0.500       275   LLAAAYQLY   0.500       385   ALNWREFSF   0.500       219   AISLATFFF   0.500       16   TCLPNGING   0.500       90   FVAIHREHY   0.500       87   NIIFVAIHR   0.500       249   KIPIEIVNK   0.400       137   FPDSLIVKG   0.250       189   PIDLGSLSS   0.250       241   RNQQSDFYK   0.250       351   EEEVMRIEM   0.225       349   WNEEEVWRI   0.225       125   YPESNAEYL   0.225       420   EEEYYRFYT   0.225       388   WREFSFIQS   0.225       198   AREIENLPL   0.225       57   VIGSRNPKF   0.200       56   VVIGSRNPK   0.200       217   VVAISLATF   0.200       3   SISMMGSPK   0.200       417   RAFEEEYYR   0.200       436   LVLPSIVIL   0.200       377   TSIPSVSNA   0.150       158   PKDASRQVY   0.125       101   LWDLRHLLV   0.125       117   SNNMRINQY   0.125       392   SFIQSTLGY   0.125       202   ENLPLRLFT   0.125       330   RYLFLNMAY   0.125       38   SGDFAKSLT   0.125       98   YTSLWDLRH   0.125       406   STFHVLIYG   0.125       218   VAISLATFF   0.100       167   ICSNNIQAR   0.100       400   YVALLISTF   0.100       235   VIHPYARNQ   0.100       381   SVSNALNWR   0.100       22   INGIKDARK   0.100       21   GINGIKDAR   0.100       281   QLYYGTKYR   0.100       322   CLPMRRSER   0.100       411   LIYGWKRAF   0.100       191   DLGSLSSAR   0.100       409   HVLIYGWKR   0.100       344   NIENSWNEE   0.090       251   PIEIVNKTL   0.090       308   LSFFFAMVH   0.075       195   LSSAREIEN   0.075       116   VSNNMRINQ   0.075       280   YQLYYGTKY   0.075       220   ISLATFFFL   0.075       175   RQQVIELAR   0.075       127   ESNAEYLAS   0.075       432   FVLALVLPS   0.050       12   SLSETCLPN   0.050       106   HLLVGKILI   0.050       311   FFAMVHVAY   0.050       269   LVYLAGLLA   0.050       216   VVVAISLAT   0.050       124   QYPESNAEY   0.050       166   YICSNNIQA   0.050       258   TLPIVAITL   0.050       18   LPNGINGIK   0.050       435   ALVLPSIVI   0.050       25   IKDARKVTV   0.050       73   VVDVTHHED   0.050       222   LATFFFLYS   0.050       184   QLNFIPIDL   0.050       367   SLGLLSLLA   0.050       46   TIRLIRCGY   0.050       306   GLLSFFFAM   0.050       261   IVAITLLSL   0.050       203   NLPLRLFTL   0.050                 V2-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         23   LSLPSSWDY   7.500       33   CPPPCPADF   0.500       36   PCPADFFLY   0.250       9   LSLSLSSGF   0.150       37   CPADFFLYF   0.125       17   FTPFSCLSL   0.125       24   SLPSSWDYR   0.100       12   SLSSGFTPF   0.100       14   SSGFTPFSC   0.075       5   GLQALSLSL   0.050       7   QALSLSLSS   0.050       13   LSSGFTPFS   0.030       2   GSPGLQALS   0.030       20   FSCLSLPSS   0.030       1   SGSPGLQAL   0.025       32   RCPPPCPAD   0.020       35   PPCPADFFL   0.013       3   SPGLQALSL   0.013       21   SCLSLPSSW   0.010       8   ALSLSLSSD   0.010       10   SLSLSSGFT   0.010       11   LSLSSGFTP   0.007       25   LPSSWDYRC   0.005       16   GFTPFSCLS   0.005       28   SWDYRCPPP   0.005       31   YRCPPPCPA   0.005       15   SGFTPFSCL   0.003       34   PPPCPADFF   0.003       6   LQALSLSLS   0.002       22   CLSLPSSWD   0.001       19   PFSCLSLPS   0.000       18   TPFSCLSLP   0.000       4   PGLQALSLS   0.000       27   SSWDYRCPP   0.000       26   PSSWDYRCP   0.000       29   WDYRCPPPC   0.000       30   DYRCPPPCP   0.000                 V5A-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start position plus       eight.                         1   NLPLRLFTF   0.500       7   FTFWRGPVV   0.050       3   PLRLFTFWR   0.005       5   RLFTFWRGP   0.001       6   LFTFWRGPV   0.001       4   LRLFTFWRG   0.001       2   LPLRLFTFW   0.000       9   FWRGPVVVA   0.000       8   TFWRGPVVV   0.000                 V5B-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         21   ELEFVFLLT   4.500       17   QTELELEFV   2.250       19   ELELEFVFL   1.800       1   WREFSIQI   0.225       16   TQTELELEF   0.075       4   FSFIQIFCS   0.075       24   FVFLLTLLL   0.050       13   FADTQTELE   0.050       18   TELELEFVF   0.025       8   QIFCSFADT   0.020       10   FCSFADTQT   0.010       6   FIQIFCSFA   0.010       2   REFSFIQIF   0.005       5   SFIQIFCSF   0.005       15   DTQTELELE   0.003       20   LELEFVFLL   0.003       22   LEFVFLLTL   0.003       14   ADTQTELEL   0.003       3   EFSFIQIFC   0.003       11   CSFADTQTE   0.002       7   IQIFCSFAD   0.001       23   EFVFLLTLL   0.001       12   SFADTQTEL   0.001       9   IFCSFADTQ   0.001                 V6-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         34   FLEEGIGGT   0.900       12   ILFIPCISR   0.500       6   VILGKIILF   0.500       2   LPSIVILGK   0.250       42   TIPHVSPER   0.200       45   HVSPERVTV   0.200       13   LFLPCISRK   0.100       16   PCISRKLKR   0.050       1   VLPSIVILG   0.050       15   LPCISRKLK   0.050       5   IVILGKIIL   0.050       35   LEEGIGGTI   0.045       41   GTIPHVSPE   0.025       38   GIGGTIPHV   0.020       10   KIILFLPCI   0.020       31   KSQFLEEGI   0.015       46   VSPERTVM   0.015       37   EGIGGTIPH   0.013       4   SIVILGKII   0.010       14   FLPCISRKL   0.010       11   IILFLPCIS   0.010       19   SRKLKRIKK   0.005       7   ILGKIILFL   0.005       26   KKGWEKSQF   0.005       18   ISRKLKRIK   0.003       33   QFLEEGIGG   0.005       43   IPHVSPERV   0.003       9   GKIILFLPC   0.003       39   IGGTIPHVS   0.003       28   GWEKSQFLE   0.002       3   PSIVILGKI   0.002       32   SQFLEEGIG   0.002       23   KRIKKGWEK   0.001       17   CISRKLKRI   0.001       40   GGTIPHVSP   0.001       30   EKSQFLEEG   0.001       27   KGWEKSQFL   0.000       8   LGKIILFLP   0.000       24   RIKKGWEKS   0.000       21   KLKRIKKGW   0.000       36   EEGIGGTIP   0.000       44   PHVSPERVT   0.000       20   RKLKRIKKG   0.000       25   IKKGWEKSQ   0.000       29   WEKSQFLEE   0.000       22   LKRIKKGWE   0.000                 V7A-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   LSETFLPNG   2.700       4   SLSETFLPN   0.050       7   ETFLPNGIN   0.025       8   TFLPNGING   0.025       9   FLPNGINGI   0.010       3   KSLSETFLP   0.007       1   SPKSLSETF   0.003       6   SETFLPNGI   0.001       2   PKSLSETFL   0.000                 V7B-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   AYQQSTLGY   0.125       9   STLGYVALL   0.050       8   QSTLGYVAL   0.030       1   FLNMAYQQS   0.010       4   MAYQQSTLG   0.010       3   NMAYQQSTL   0.005       7   QQSTLGYVA   0.003       2   LNMAYQQST   0.003       6   YQQSTLGYV   0.002                 V7C-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         167   KLETIILSK   90.000       59   WTEEAGATA   4.500       13   LASPAAAWK   4.500       69   AQESGIRNK   2.700       38   PIEWQQDRK   1.800       66   TAEAQESGI   0.900       9   SVEVLASPA   0.900       143   ASGTLSLAF   0.750       99   SIDPPESPD   0.500       51   STPPPPAMW   0.500       5   ILDLSVEVL   0.500       21   KCLGANILR   0.500       90   VTEDDEAQD   0.450       50   LSTPPPPAM   0.300       32   LSEIVLPIE   0.270       151   FTSWSLGEF   0.250       156   LGEFLGSGT   0.225       175   KLTQEQKSK   0.200       159   FLGSGTWMK   0.200       177   TQEQKSKHC   0.135       128   GPLWEFLLR   0.125       145   GTLSLAFTS   0.125       52   TPPPPAMWT   0.125       126   GVGPLWEFL   0.100       35   IVLPIEWQQ   0.100       100   IDPPESPDR   0.100       104   ESPDRALKA   0.075       78   SSSSSQIPV   0.075       154   WSLGEFLGS   0.075       131   WEFLLRLLK   0.050       22   CLGANILRG   0.050       68   EAQESGIRN   0.050       184   HCMFSLISG   0.050       7   DLSVEVLAS   0.050       170   TIILSKLTQ   0.050       2   SIVILDLSV   0.050       17   AAAWKCLGA   0.050       141   QAASGTLSL   0.050       123   HTNGVGPLW   0.050       31   GLSEIVLPI   0.050       130   LWEFLLRLL   0.045       173   LSKLTQEQK   0.030       80   SSSQIPVVG   0.030       81   SSQIPVVGV   0.030       79   SSSSQIPVV   0.030       125   NGVGPLWEF   0.025       65   ATAEAQESG   0.025       37   LPIEWQQDR   0.025       92   EDDEAQDSI   0.025       169   ETIILSKLT   0.025       176   LTQEQKSKH   0.025       91   TEDDEAQDS   0.025       102   PPESPDRAL   0.022       103   PESPDRALK   0.020       11   EVLASPAAA   0.020       83   QIPVVGVVT   0.020       4   VILDLSVEV   0.020       12   VLASPAAAW   0.020       42   QQDRKIPPL   0.015       71   ESGIRNKSS   0.015       96   AQDSIDPPE   0.015       14   ASPAAAWKC   0.015       82   SQIPVVGVV   0.015       139   KSQAASGTL   0.015       147   LSLAFTSWS   0.015       29   RGGLSEIVL   0.013       105   SPDRALKAA   0.013       162   SGTWMKLET   0.013       160   LGSGTWMKL   0.013       127   VGPLWEFLL   0.013       146   TLSLAFTSW   0.010       88   GVVTEDDEA   0.010       142   AASGTLSLA   0.010       64   GATAEAQES   0.010       119   PVLPHTNGV   0.010       46   KIPPLSTPP   0.010       62   EAGATAEAQ   0.010       109   ALKAANSWR   0.010       148   SLAFTSWSL   0.010       112   AANSWRNPV   0.010       149   LAFTSWSLG   0.010       34   EIVLPIEWQ   0.010       116   WRNPVLPHT   0.010       24   GANILRGGL   0.010       89   VVTEDDEAQ   0.010       155   SLGEFLGSG   0.010       120   VLPHTNGVG   0.010       181   KSKHCMFSL   0.008       113   ANSWRNPVL   0.005       67   AEAQESGIR   0.005       185   CMFSLISGS   0.005       144   SGTLSLAFT   0.005       93   DDEAQDSID   0.005       60   TEEAGATAE   0.005       8   LSVEVLASP   0.003       183   KHCMFSLIS   0.003       25   ANILRGGLS   0.003       165   WMKLETIIL   0.003       101   DPPESPDRA   0.003       15   SPAAAWKCL   0.003                  
 
     [1177]                       TABLE IX                       Start   Subsequence   Score                                    V1-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         178   VIELARQLNF   45.000       443   ILDLLQLCRY   25.000       294   WLETWLQCRK   18.000       135   SLFPDSLIVK   10.000       200   EIENLPLRLF   9.000       356   RIEMYISFGI   4.500       220   ISLATFFFLY   3.750       391   FSFIQSTLGY   3.750       76   VTHHEDALTK   2.500       404   LISTFHVLIY   2.500       262   VAITLLSLVY   2.500       275   LLAAAYQLYY   2.500       113   LIDVSNNMRI   2.500       351   EEEVWRIEMY   2.250       418   AFEEEYYRFY   2.250       123   NQYPESNAEY   1.500       13   LSETCLPNGI   1.350       137   FPDSLIVKGF   1.250       427   YTPPNFVLAL   1.250       257   KTLPIVAITL   1.250       271   YLAGLLAAAY   1.000       34   GVIGSGDFAK   1.000       321   LCLPMRRSER   1.000       198   AREIENLPLR   0.900       116   VSNNMRINQY   0.750       327   RSERYLFLNM   0.675       38   SGDFAKSLTI   0.625       384   NALNWREFSF   0.500       218   VAISLATFFF   0.500       274   GLLAAAYQLY   0.500       81   DALTKTNIIF   0.500       322   CLPMRRSERY   0.500       73   VVDVTHHEDA   0.500       232   VRDVIHPYAR   0.500       442   VILDLLQLCR   0.500       125   YPESNAEYLA   0.450       129   NAEYLASLFP   0.450       21   GINGIKDARK   0.400       2   ESISMMGSPK   0.300       66   ASEFFPHVVD   0.270       419   FEEEYYRFYT   0.225       350   NEEEVWRIEM   0.225       222   LATFFFLYSF   0.200       56   VVIGSRNPKF   0.200       281   QLYYGTKYRR   0.200       55   HVVIGSRNPK   0.200       278   AAYQLYYGTK   0.200       417   RAFEEEYYRF   0.200       216   VVVAISLATF   0.200       248   YKIPIEIVNK   0.200       317   VAYSLCLPMR   0.200       17   CLPNGINGIK   0.200       244   QSDFYKIPIE   0.150       377   TSIPSVSNAL   0.150       382   VSNALNWREF   0.150       202   ENLPLRLFTL   0.125       101   LWDLRHLLVG   0.125       329   ERYLFLNMAY   0.125       15   ETCLPNGING   0.125       396   STLGYVALLI   0.125       45   LTIRLIRCGY   0.125       86   TNIIFVAIHR   0.125       32   TVGVIGSGDF   0.100       235   VIHPYARNQQ   0.100       410   VLIYGWKRAF   0.100       112   ILIDVSNNMR   0.100       166   YICSNNIQAR   0.100       16   TCLPNGINGI   0.100       217   VVAISLATFF   0.100       155   QLGPKDASRQ   0.100       344   NIENSWNEEE   0.090       139   DSLIVKGFNV   0.075       405   ISTFHVLIYG   0.075       366   MSLGLLSLLA   0.075       11   KSLSETCLPN   0.075       134   ASLFPDSLIV   0.075       43   KSLTIRLIRC   0.075       303   KQLGLLSFFF   0.075       361   ISFGIMSLGL   0.075       304   QLGLLSFFFA   0.050       107   LLVGKILIDV   0.050       60   SRNPKFASEF   0.050       269   LVYLAGLLAA   0.050       434   LALVLPSIVI   0.050       397   TLGYVALLIS   0.050       364   GIMSLGLLSL   0.050       401   VALLISTFHV   0.050       147   NVVSAWALQL   0.050       189   PIDLGSLSSA   0.050       264   ITLLSLVYLA   0.050       307   LLSFFFAMVH   0.050       310   FFFAMVHVAY   0.050       209   FTLWRGPVVV   0.050       194   SLSSAREIEN   0.050       240   ARNQQSDFYK   0.050       298   WLQCRKQLGL   0.050       440   SIVILDLLQL   0.050       221   SLATFFFLYS   0.050       436   LVLPSIVILD   0.050       406   STFHVLIYGW   0.050                 V2-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         32   RCPPPCPADF   2.000       23   LSLPSSWDYR   1.500       35   PPCPADFFLY   0.625       22   CLSLPSSWDY   0.500       33   CPPPCPADFF   0.250       11   LSLSSGFTPF   0.150       8   ALSLSLSSGF   0.100       13   LSSGFTPFSC   0.075       2   GSPGLQALSL   0.075       28   SWDYRCPPPC   0.050       1   SGSPGLQALS   0.050       36   PCPADFFLYF   0.050       16   GFTPFSCLSL   0.025       12   SLSSGFTPFS   0.020       24   SLPSSWDYRC   0.020       20   FSCLSLPSSW   0.015       14   SSGFTPFSCL   0.015       9   LSLSLSSGFT   0.015       18   TPFSCLSLPS   0.013       7   QALSLSLSSG   0.010       5   GLQALSLSLS   0.010       6   LQALSLSLSS   0.007       10   SLSLSSGFTP   0.005       15   SGFTPFSCLS   0.003       3   SPGLQALSLS   0.003       17   FTPFSCLSLP   0.003       34   PPPCPADFFL   0.001       4   PGLQALSLSL   0.001       31   YRCPPPCPAD   0.001       21   SCLSLPSSWD   0.001       27   SSWDYRCPPP   0.000       25   LPSSWDYRCP   0.000       26   PSSWDYRCPP   0.000       19   PFSCLSLPSS   0.000       30   DYRCPPPCPA   0.000       29   WDYRCPPPCP   0.000                 V5A-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         1   ENLPLRLFTF   1.250       8   FTFWRGPVVV   0.050       3   LPLRLFTFWR   0.013       2   NLPLRLFTFW   0.010       6   RLFTFWRGPV   0.010       7   LFTFWRGPVV   0.001       4   PLRLFTFWRG   0.000       10   FWRGPVVVAI   0.000       5   LRLFTFWRGP   0.000       9   TFWRGPVVVA   0.000                 V5B-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         18   QTELELEFVF   112.500       20   ELELEFVFLL   4.500       22   ELEFVFLLTL   4.500       14   FADTQTELEL   2.500       16   DTQTELELEF   1.250       2   WREFSFIQIF   0.450       5   FSFIQIFCSF   0.150       12   CSFADTQTEL   0.015       9   QIFCSFADTQ   0.010       7   FIQIFCSFAD   0.005       8   IQIFCSFADT   0.003       21   LELEFVFLLT   0.003       4   EFSFIQIFCS   0.003       24   EFVFLLTLLL   0.003       3   REFSFIQIFC   0.003       17   TQTELELEFV   0.002       11   FCSFADTQTE   0.001       19   TELELEFVFL   0.001       6   SFIQIFCSFA   0.001       10   IFCSFADTQT   0.001       23   LEFVFLLTLL   0.001       1   NWREFSFIQI   0.000       15   ADTQTELELE   0.000       13   SFADTQTELE   0.000                 V6-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         42   GTIPHVSPER   5.000       2   VLPSIVILGK   1.000       35   FLEEGIGGTI   0.900       1   LVLPSIVILG   0.500       12   IILFLPCISR   0.500       6   IVILGKIILF   0.500       13   ILFLPCISRK   0.200       15   FLPCISRKLK   0.200       16   LPCISRKLKR   0.125       46   HVSPERVTVM   0.100       7   VILGKIILFL   0.050       5   SIVILGKIIL   0.050       18   CISRKLKRIK   0.020       19   ISRKLKRIKK   0.015       32   KSQFLEEGIG   0.015       39   GIGGTIPHVS   0.010       43   TIPHVSPERV   0.010       11   KIILFLPCIS   0.010       33   SQFLEEGIGG   0.007       38   EGIGGTIPHV   0.005       14   LFLPCISRKL   0.005       36   LEEGIGGTIP   0.005       37   EEGIGGTIPH   0.003       3   LPSIVILGKI   0.003       44   IPHVSPERVT   0.003       29   GWEKSQFLEE   0.002       4   PSIVILGKII   0.002       9   LGKIILFLPC   0.001       23   LKRIKKGWEK   0.001       17   PCISRKLKRI   0.001       10   GKIILFLPCI   0.001       26   IKKGWEKSQF   0.001       34   QFLEEGIGGT   0.001       31   EKSQFLEEGI   0.001       27   KKGWEKSQFL   0.001       8   ILGKIILFLP   0.001       40   IGGTIPHVSP   0.001       41   GGTIPHVSPE   0.000       28   KGWEKSQFLE   0.000       25   RIKKGWEKSQ   0.000       45   PHVSPERVTV   0.000       21   RKLKRIKKGW   0.000       20   SRKLKRIKKG   0.000       30   WEKSQFLEEG   0.000       24   KRIKKGWEKS   0.000       22   KLKRIKKGWE   0.000                 V7A-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         6   LSETFLPNGI   1.350       10   FLPNGINGIK   0.200       8   ETFLPNGING   0.125       4   KSLSETFLPN   0.075       5   SLSETFLPNG   0.020       1   GSPKSLSETF   0.015       9   TFLPNGINGI   0.005       7   SETFLPNGIN   0.001       2   SPKSLSETFL   0.000       3   PKSLSETFLP   0.000                 V7B-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         5   MAYQQSTLGY   2.500       10   STLGYVALLI   0.125       9   QSTLGYVALL   0.030       2   FLNMAYQQST   0.010       4   NMAYQQSTLG   0.005       7   YQQSTLGYVA   0.003       8   QQSTLGYVAL   0.003       3   LNMAYQQSTL   0.003       6   AYQQSTLGYV   0.001       1   LFLNMAYQQS   0.001                 V7C-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         100   SIDPPESPDR   100.000       67   TAEAQESGIR   9.000       33   LSEIVLPIEW   6.750       131   LWEFLLRLLK   4.500       91   VTEDDEAQDS   2.250       10   SVEVLASPAA   1.800       52   STPPPPAMWT   1.250       6   ILDLSVEVLA   1.000       168   KLETIILSKL   0.900       103   PPESPDRALK   0.900       127   GVGPLWEFLL   0.500       143   AASGTLSLAF   0.500       13   VLASPAAAWK   0.400       51   LSTPPPPAMW   0.300       60   WTEEAGATAE   0.225       157   LGEFLGSGTW   0.225       69   EAQESGIRNK   0.200       97   AQDSIDPPES   0.150       70   AQESGIRNKS   0.135       178   TQEQKSKHCM   0.135       170   ETIILSKLTQ   0.125       128   VGPLWEFLLR   0.125       37   VLPIEWQQDR   0.100       14   LASPAAAWKC   0.100       61   TEEAGATAEA   0.090       39   PIEWQQDRKI   0.090       162   GSGTWMKLET   0.075       78   KSSSSSQIPV   0.075       160   FLGSGTWMKL   0.050       22   KCLGANILRG   0.050       167   MKLETIILSK   0.050       38   LPIEWQQDRK   0.050       80   SSSSQIPVVG   0.030       79   SSSSSQIPVV   0.030       83   SQIPVVGVVT   0.030       144   ASGTLSLAFT   0.030       81   SSSQIPVVGV   0.030       146   GTLSLAFTSW   0.025       66   ATAEAQESGI   0.025       152   FTSWSLGEFL   0.025       125   TNGVGPLWEF   0.025       92   TEDDEAQDSI   0.025       177   LTQEQKSKHC   0.025       21   WKCLGANILR   0.025       106   SPDRALKAAN   0.025       94   DDEAQDSIDP   0.022       12   EVLASPAAAW   0.020       4   IVILDLSVEV   0.020       173   ILSKLTQEQK   0.020       47   KIPPLSTPPP   0.020       113   AANSWRNPVL   0.020       72   ESGIRNKSSS   0.015       43   QQDRKIPPLS   0.015       15   ASPAAAWKCL   0.015       140   KSQAASGTLS   0.015       9   LSVEVLASPA   0.015       82   SSQIPVVGVV   0.015       155   WSLGEFLGSG   0.015       105   ESPDRALKAA   0.015       148   LSLAFTSWSL   0.015       124   HTNGVGPLWE   0.013       129   GPLWEFLLRL   0.013       31   GGLSEIVLPI   0.013       145   SGTLSLAFTS   0.013       185   HCMFSLISGS   0.010       149   SLAFTSWSLG   0.010       65   GATAEAQESG   0.010       112   KAANSWRNPV   0.010       142   QAASGTLSLA   0.010       25   GANILRGGLS   0.010       159   EFLGSGTWMK   0.010       23   CLGANILRGG   0.010       109   RALKAANSWR   0.010       176   KLTQEQKSKH   0.010       35   EIVLPIEWQQ   0.010       175   SKLTQEQKSK   0.010       18   AAAWKCLGAN   0.010       36   IVLPIEWQQD   0.010       5   VILDLSVEVL   0.010       172   IILSKLTQEQ   0.010       156   SLGEFLGSGT   0.010       120   PVLPHTNGVG   0.010       147   TLSLAFTSWS   0.010       89   GVVTEDDEAQ   0.010       153   TSWSLGEFLG   0.008       2   PSIVILDLSV   0.008       141   SQAASGTLSL   0.007       150   LAFTSWSLGE   0.005       17   PAAAWKCLGA   0.005       101   IDPPESPDRA   0.005       151   AFTSWSLGEF   0.005       117   WRNPVLPHTN   0.005       42   WQQDRKIPPL   0.003       104   PESPDRALKA   0.003       24   LGANILRGGL   0.003       119   NPVLPHTNGV   0.003       118   RNPVLPHTNG   0.003       102   DPPESPDRAL   0.003       53   TPPPPAMWTE   0.003       1   LPSIVILDLS   0.003                    
     [1178]                       TABLE X                       Start   Subsequence   Score                                    V1-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start position plus       eight.                         227   FLYSFVRDV   1789.612       402   ALLISTFHV   1492.586       307   LLSFFFAMV   853.681       306   GLLSFFFAM   769.748       100   SLWDLRHLL   726.962       333   FLNMAYQQV   479.909       140   SLIVKGFNV   403.402       203   NLPLRLFTL   284.974       210   TLWRGPVVV   236.685       65   FASEFFPHV   131.539       135   SLFPDSLIV   105.510       274   GLLAAAYQL   79.041       393   FIQSTLGYV   72.344       48   RLIRCGYHV   69.552       365   IMSLGLLSL   60.325       5   SMMGSPKSL   57.085       220   ISLATFFFL   53.163       271   YLAGLLAAA   52.561       265   TLLSLVYLA   42.278       433   VLALVLPSI   40.792       442   VILDLLQLC   40.518       112   ILIDVSNNM   34.627       360   YISFGIMSL   31.077       403   LLISTFHVL   28.290       369   GLLSLLAVT   26.001       17   CLPNGINGI   23.995       108   LVGKILIDV   23.795       264   ITLLSLVYL   23.608       258   TLPIVAITL   21.362       184   QLNFIPIDL   21.362       313   AMVHVAYSL   15.428       410   VLIYGWKRA   14.358       141   LIVKGFNVV   12.665       305   LGLLSFFFA   12.364       44   SLTIRLIRC   11.426       436   LVLPSIVIL   11.087       397   TLGYVALLI   10.433       386   LNWREFSFI   10.042       180   ELARQLNFI   9.898       254   IVNKTLPIV   9.756       404   LISTFHVLI   9.267       357   IEMYISFGI   7.401       441   IVILDLLQL   7.309       261   IVAITLLSL   7.309       209   FTLWRGPVV   6.741       368   LGLLSLLAV   6.568       367   SLGLLSLLA   4.968       153   ALQLGPKDA   4.968       146   FNVVSAWAL   4.811       389   REFSFIQST   4.686       435   ALVLPSIVI   4.277       187   FIPIDLGSL   4.040       374   LAVTSIPSV   3.777       262   VAITLLSLV   3.777       299   LQCRKQLGL   3.682       335   NMAYQQVHA   3.588       291   FPPWLETWL   3.528       331   YLFLNMAYQ   3.209       148   VVSAWALQL   3.178       166   YICSNNIQA   3.142       353   EVWRIEMYI   3.125       221   SLATFFFLY   3.121       378   SIPSVSNAL   2.937       164   QVYICSNNI   2.921       268   SLVYLAGLL   2.777       396   STLGYVALL   2.525       434   LALVLPSIV   2.491       304   QLGLLSFFF   2.377       269   LVYLAGLLA   2.365       37   GSGDFAKSL   2.173       366   MSLGLLSLL   2.017       267   LSLVYLAGL   2.017       242   NQQSDFYKI   2.010       177   QVIELARQL   1.533       224   TFFFLYSFV   1.474       349   WNEEEVWRI   1.418       128   SNAEYLASL   1.315       106   HLLVGKILI   1.312       257   KTLPIVAIT   1.264       303   KQLGLLSFF   1.238       428   TPPNFVLAL   1.219       34   GVIGSGDFA   1.172       216   VVVAISLAT   1.108       314   MVHVAYSLC   1.108       371   LSLLAVTSI   0.985       91   VAIHREHYT   0.968       85   KTNIIFVAI   0.964       133   LASLFPDSL   0.939       425   RFYTPPNFV   0.850       250   IPIEIVNKT   0.780       49   LIRCGYHVV   0.760       83   LTKTNIIFV   0.727       132   YLASLFPDS   0.651       427   YTPPNFVLA   0.603       171   NIQARQQVI   0.588       259   LPIVAITLL   0.545       438   LPSIVILDL   0.545       278   AAYQLYYGT   0.497       170   NNIQARQQV   0.454       385   ALNWREFSF   0.432                 V2-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   GLQALSLSL   21.362       10   SLSLSSGFT   5.328       17   FTPFSCLSL   1.365       15   SGFTPFSCL   0.980       1   SGSPGLQAL   0.321       14   SSGFTPFSC   0.188       8   ALSLSLSSG   0.171       12   SLSSGFTPF   0.142       3   SPGLQALSL   0.139       29   WDYRCPPPC   0.102       35   PPCPADFFL   0.098       22   CLSLPSSWD   0.082       37   CPADFFLYF   0.079       24   SLPSSWDYR   0.068       25   LPSSWDYRC   0.055       6   LQALSLSLS   0.030       23   LSLPSSWDY   0.023       13   LSSGFTPFS   0.017       20   FSCLSLPSS   0.005       7   QALSLSLSS   0.004       11   LSLSSGFTP   0.004       27   SSWDYRCPP   0.003       31   YRCPPPCPA   0.003       9   LSLSLSSGF   0.003       21   SCLSLPSSW   0.002       18   TPFSCLSLP   0.001       2   GSPGLQALS   0.000       33   CPPPCPADF   0.000       16   GFTPFSCLS   0.000       36   PCPADFFLY   0.000       32   RCPPPCPAD   0.000       4   PGLQALSLS   0.000       34   PPPCPADFF   0.000       19   PFSCLSLPS   0.000       28   SWDYRCPPP   0.000       26   PSSWDYRCP   0.000       30   DYRCPPPCP   0.000                 V5A-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         7   FTFWRGPVV   6.741       1   NLPLRLFTF   0.994       8   TFWRGPVVV   0.164       5   RLFTFWRGP   0.071       2   LPLRLFTFW   0.032       6   LFTFWRGPV   0.011       3   PLRLFTFWR   0.003       4   LRLFTFWRG   0.001       9   FWRGPVVVA   0.000                 V5B-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         20   LELEFVFLL   543.025       6   FIQIFCSFA   65.673       24   FVFLLTLLL   31.814       22   LEFVFLLTL   22.835       8   QIFCSFADT   7.203       19   ELELEFVFL   1.072       17   QTELELEFV   0.383       10   FCSFADTQT   0.224       4   FSFIQIFCS   0.110       21   ELEFVFLLT   0.068       12   SFADTQTEL   0.061       18   TELELEFVF   0.052       16   TQTELELEF   0.031       14   ADTQTELEL   0.030       2   REFSFIQIF   0.019       7   IQIFCSFAD   0.015       23   EFVFLLTLL   0.003       3   EFSFIQIFC   0.001       1   WREFSFIQI   0.001       11   CSFADTQTE   0.000       13   FADTQTELE   0.000       5   SFIQIFCSF   0.000       9   IFCSFADTQ   0.000       15   DTQTELELE   0.000                 V6-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         7   ILGKIILFL   459.398       27   KGWEKSQFL   91.350       10   KIILFLPCI   43.882       38   GIGGTIPHV   21.996       14   FLPCISRKL   19.653       17   CISRKLKRI   3.299       34   FLEEGIGGT   2.689       5   IVILGKIIL   1.303       4   SIVILGKII   0.588       43   IPHVSPERV   0.378       1   VLPSIVILG   0.291       46   VSPERVTVM   0.213       45   HVSPERVTV   0.207       6   VILGKIILF   0.148       31   KSQFLEEGI   0.117       12   ILFLPCISR   0.094       11   IILFLPCIS   0.026       9   GKIILFLPC   0.013       21   KLKRIKKGW   0.009       35   LEEGIGGTI   0.003       42   TIPHVSPER   0.002       32   SQFLEEGIG   0.001       20   RKLKRIKKG   0.001       33   QFLEEGIGG   0.001       41   GTIPHVSPE   0.000       3   PSIVILGKI   0.000       2   LPSIVILGK   0.000       26   KKGWEKSQF   0.000       39   IGGTIPHVS   0.000       24   RIKKGWEKS   0.000       15   LPCISRKLK   0.000       13   LFLPCISRK   0.000       40   GGTIPHVSP   0.000       29   WEKSQFLEE   0.000       8   LGKIILFLP   0.000       23   KRIKKGWEK   0.000       37   EGIGGTIPH   0.000       30   EKSQFLEEG   0.000       44   PHVSPERVT   0.000       36   EEGIGGTIP   0.000       16   PCISRKLKR   0.000       22   LKRIKKGWE   0.000       25   IKKGWEKSQ   0.000       18   ISRKLKRIK   0.000       28   GWEKSQFLE   0.000       19   SRKLKRIKK   0.000                 V7A-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   FLPNGINGI   110.379       4   SLSETFLPN   0.581       6   SETFLPNGI   0.203       3   KSLSETFLP   0.007       2   PKSLSETFL   0.004       5   LSETFLPNG   0.000       8   TFLPNGING   0.000       7   ETFLPNGIN   0.000       1   SPKSLSETF   0.000                 V7B-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         6   YQQSTLGYV   53.345       3   NMAYQQSTL   15.428       9   STLGYVALL   2.525       1   FLNMAYQQS   0.514       2   LNMAYQQST   0.306       8   QSTLGYVAL   0.209       7   QQSTLGYVA   0.207       4   MAYQQSTLG   0.006       5   AYQQSTLGY   0.000                 V7C-HLA-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         4   VILDLSVEV   246.631       148   SLAFTSWSL   160.218       129   PLWEFLLRL   139.780       31   GLSEIVLPI   98.381       57   AMWTEEAGA   29.780       2   SIVILDLSV   9.563       126   GVGPLWEFL   8.564       5   ILDLSVEVL   6.712       152   TSWSLGEFL   3.119       27   ILRGGLSEI   3.100       42   QQDRKIPPL   1.993       168   LETIILSKL   1.624       127   VGPLWEFLL   1.375       163   GTWMKLETI   1.355       81   SSQIPVVGV   1.044       165   WMKLETIIL   1.018       112   AANSWRNPV   0.966       82   SQIPVVGVV   0.864       134   LLRLLKSQA   0.642       144   SGTLSLAFT   0.615       133   FLLRLLKSQ   0.583       39   IEWQQDRKI   0.572       159   FLGSGTWMK   0.514       119   PVLPHTNGV   0.495       185   CMFSLISGS   0.458       78   SSSSSQIPV   0.454       79   SSSSQIPVV   0.428       83   QIPVVGVVT   0.420       160   LGSGTWMKL   0.403       155   SLGEFLGSG   0.347       141   QAASGTLSL   0.297       136   RLLKSQAAS   0.276       52   TPPPPAMWT   0.268       14   ASPAAAWKC   0.243       15   SPAAAWKCL   0.237       181   KSKHCMFSL   0.228       88   GVVTEDDEA   0.213       22   CLGANILRG   0.171       10   VEVLASPAA   0.164       142   AASGTLSLA   0.159       146   TLSLAFTSW   0.142       12   VLASPAAAW   0.127       11   EVLASPAAA   0.121       49   PLSTPPPPA   0.109       178   QEQKSKHCM   0.097       59   WTEEAGATA   0.083       17   AAAWKCLGA   0.069       147   LSLAFTSWS   0.064       139   KSQAASGTL   0.063       35   IVLPIEWQQ   0.062       29   RGGLSEIVL   0.057       113   ANSWRNPVL   0.057       20   WKCLGANIL   0.056       50   LSTPPPPAM   0.055       175   KLTQEQKSK   0.052       162   SGTWKLET   0.049       6   LDLSVEVLA   0.043       36   VLPIEWQQD   0.043       24   GANILRGGL   0.039       177   TQEQKSKHC   0.032       105   SPDRALKAA   0.030       171   IILSKLTQE   0.030       41   WQQDRKIPP   0.028       9   SVEVLASPA   0.028       182   SKHCMFSLI   0.028       172   ILSKLTQEQ   0.025       145   GTLSLAFTS   0.022       138   LKSQAASGT   0.018       154   WSLGEFLGS   0.016       76   NKSSSSSQI   0.014       7   DLSVEVLAS   0.013       149   LAFTSWSLG   0.011       116   WRNPVLPHT   0.011       104   ESPDRALKA   0.010       66   TAEAQESGI   0.009       125   NGVGPLWEF   0.008       169   ETIILSKLT   0.008       167   KLETIILSK   0.008       26   NILRGGLSE   0.008       140   SQAASGTLS   0.008       61   EEAGATAEA   0.007       176   LTQEQKSKH   0.007       46   KIPPLSTPP   0.007       120   VLPHTNGVG   0.007       166   MKLETIILS   0.006       156   LGEFLGSGT   0.005       158   EFLGSGTWM   0.005       131   WEFLLRLLK   0.005       101   DPPESPDRA   0.005       89   VVTEDDEAQ   0.004       137   LLKSQAASG   0.004       135   LRLLKSQAA   0.004       108   RALKAANSW   0.004       28   LRGGLSEIV   0.003       109   ALKAANSWR   0.003       18   AAWKCLGAN   0.003       91   TEDDEAQDS   0.002       164   TWMKLETII   0.002       3   IVILDLSVE   0.002       65   ATAEAQESG   0.002                    
     [1179]                       TABLE XI                       Start   Subsequence   Score                                    V1-HLA-A0201-10mers-98P4B6       Each peptide is portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         100   SLWDLRHLLV   2366.855       306   GLLSFFFAMV   1858.012       82   ALTKTNIIFV   879.833       304   QLGLLSFFFA   301.110       373   LLAVRSIPSV   271.948       107   LLVGKILIDV   271.948       132   YLASLFPDSL   182.973       219   AISLATFFFL   178.032       367   SLGLLSLLAV   159.970       385   ALNWREFSFI   109.023       298   WLQCRKQLGL   98.267       437   VLPSIVILDL   83.527       266   LLSLVYLAGL   83.527       403   LLISTFHVLI   67.396       402   ALLISTFHVL   61.573       365   IMSLGLLSLL   60.325       140   SLIVKGFNVV   54.181       258   TLPIVAITLL   49.134       433   VLALVLPSIV   48.478       48   RLIRCGYHVV   42.774       370   LLSLLAVTSI   40.792       210   TLWRGPVVVA   38.884       263   AITLLSLVYL   37.157       432   FVLALVLPSI   35.735       401   VALLISTFHV   35.242       207   RLFTLWRGPV   33.455       227   FLYSFVRDVI   30.852       223   ATFFFLYSFV   29.487       65   FASEFFPHVV   28.385       364   GIMSLGLLLSL   24.997       261   IVAITLLSLV   23.795       435   ALVLPSIVIL   20.145       90   FVAIHREHYT   16.497       179   IELARQLNFI   16.141       427   YTPPNFVLAL   11.929       67   SEFFPHVVDV   11.509       111   KILIDVSNNM   8.846       305   LGLLSFFFAM   8.542       172   IQARQQVIEL   8.469       249   KIPEIVNKT   8.248       183   RQLNFIPIDL   8.014       95   REHYTSLWDL   7.165       440   SIVIDLLQL   6.756       209   FTLWRGPVVV   6.741       308   LSFFFAMVHV   6.568       57   VIGSRNPKFA   6.387       419   FEEEYYRFYT   5.579       394   IQSTLGYVAL   5.523       269   LVYLAGLLAA   5.439       313   AMVHVAYSLC   5.382       312   FAMVHVAYSL   5.050       268   SLVYLAGLLA   4.968       92   AIHREHYTSL   4.406       243   QQSDFYKIPI   4.337       257   KTLPIVAITL   3.842       231   FVRDVIHPYA   3.427       314   MVHVAYSLCL   3.178       303   KQLGLLSFFF   3.121       221   SLATFFFLYS   2.959       144   KGFNVVSAWA   2.310       286   TKYRRFPPWL   1.984       147   NVVSAWALQL   1.869       199   REIENLPLRL   1.703       441   IVILDLLQLC   1.700       389   REFSFIQSTL   1.537       226   FFLYSFVRDV   1.437       24   GIKDARKVTV   1.372       201   IENLPLRLFT   1.355       393   FIQSTLGYVA   1.288       64   KFASEFFPHV   1.221       152   WALQLGPKDA   1.174       345   IENSWNEEEV   1.127       299   LQCRKQLGLL   1.101       163   RQVYICSNNI   1.058       428   TPPNFVLALV   1.044       264   ITLLSLVYLA   0.998       113   LIDVSNNMRI   0.975       250   IPIEIVNKTL   0.972       43   KSLTIRLIRC   0.966       323   LPMRRSERYL   0.965       424   YRFYTPPNFV   0.904       36   IGSGDFAKSL   0.901       361   ISFGIMSLGL   0.877       4   ISMMGSPKSL   0.877       336   MAYQQVHANI   0.788       139   DSLIVKGFNV   0.731       12   SLSETCLPNG   0.703       275   LLAAAYQLYY   0.697       134   ASLFPDSLIV   0.689       121   RINQYPESNA   0.683       253   EIVNKTLPIV   0.676       98   YTSLWDLRHL   0.628       398   LGYVALLIST   0.609       16   TCLPNGINGI   0.580       396   STLGYVALLI   0.536       356   RIEMYISFGI   0.532       202   ENLPLRLFTL   0.516       99   TSLWDLRHLL   0.516       273   AGLLAAAYQL   0.516       332   LFLNMAYQQV   0.456                 V2-HLA-A0201-10mers-98P4B6       Each peptide is portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         24   SLPSSWDYRC   4.968       12   SLSSGFTPFS   1.557       22   CLSLPSSWDY   0.559       13   LSSGFTPFSC   0.320       14   SSGFTPFSCL   0.265       9   LSLSLSSGFT   0.219       5   GLQALSLSLS   0.171       2   GSPGLQALSL   0.139       34   PPPCPADFFL   0.098       10   SLSLSSGFTP   0.086       8   ALSLSLSSGF   0.075       16   GFTPFSCLSL   0.015       6   LQALSLSLSS   0.013       4   PGLQALSLSL   0.011       7   QALSLSLSSG   0.009       15   SGFTPFSCLS   0.007       11   LSLSSGFTPF   0.006       27   SSWDYRCPPP   0.003       23   LSLPSSWDYR   0.003       20   FSCLSLPSSW   0.002       17   FTPFSCLSLP   0.002       21   SCLSLPSSWD   0.002       18   TPFSCLSLPS   0.002       33   CPPPCPADFF   0.001       3   SPGLQALSLS   0.001       32   RCPPPCPADF   0.000       1   SGSPGLQALS   0.000       36   PCPADFFLYF   0.000       29   WDYRCPPPCP   0.000       28   SWDYRCPPPC   0.000       35   PPCPADFFLY   0.000       25   LPSSWDYRCP   0.000       31   YRCPPPCPAD   0.000       30   DYRCPPPCPA   0.000       19   PFSCLSLPSS   0.000       26   PSSWDYRCPP   0.000                 V5A-HLA-A0201-10mers-98P4B6       Each peptide is portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         6   RLFTFWRGPV   33.455       8   FTFWRGPVVV   6.741       2   NLPLRLFTFW   0.779       3   LPLRLFTFWR   0.074       7   LFTFWRGPVV   0.034       9   TFWRGPVVVA   0.027       1   ENLPLRLFTF   0.002       4   PLRLFTFWRG   0.002       10   FWRGPVVVAI   0.001       5   LRLFTFWRGP   0.000                 V5B-HLA-A0201-10mers-98P4B6       Each peptide is portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         17   TQTELELEFV   179.213       19   TELELEFVFL   65.849       21   LELEFVFLLT   7.100       23   LEFVFLLTLL   6.009       20   ELELEFVFLL   5.198       8   IQIFCSFADT   2.440       3   REFSFIQIFC   1.966       22   ELEFVFLLTL   0.896       14   FADTQTELEL   0.546       12   CSFADTQTEL   0.516       6   SFIQIFCSFA   0.072       7   FIQIFCSFAD   0.055       5   FSFIQIFCSF   0.016       9   QIFCSFADTQ   0.014       10   IFCSFADTQT   0.009       24   EFVFLLTLLL   0.001       1   NWREFSFIQI   0.001       11   FCSFADTQTE   0.000       18   QTELELEFVF   0.000       16   DTQTELELEF   0.000       4   EFSFIQIFCS   0.000       15   ADTQTELELE   0.000       13   SFADTQTELE   0.000       2   WREFSFIQIF   0.000                 V6-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         7   VILGKIILFL   233.719       43   TIPHVSPERV   4.686       35   FLEEGIGGTI   1.637       5   SIVILGKIIL   1.204       27   KKGWEKSQFL   0.571       8   ILGKIILFLP   0.338       13   ILFLPCISRK   0.216       10   GKIILFLPCI   0.127       1   LVLPSIVILG   0.094       38   EGIGGTIPHV   0.078       15   FLPCISRKLK   0.069       28   KGWEKSQFLE   0.067       2   VLPSIVILGK   0.058       3   LPSIVILGKI   0.035       33   SQFLEEGIGG   0.028       6   IVILGKIILF   0.025       34   QFLEEGIGGT   0.023       14   LFLPCISRKL   0.019       11   KIILFLPCIS   0.015       46   HVSPERVTVM   0.014       12   IILFLPCISR   0.013       44   IPHVSPERVT   0.007       39   GIGGTIPHVS   0.004       9   LGKIILFLPC   0.004       17   PCISRKLKRI   0.003       22   KLKRIKKGWE   0.001       45   PHVSPERVTV   0.001       30   WEKSQFLEEG   0.001       4   PSIVILGKII   0.001       31   EKSQFLEEGI   0.001       21   RKLKRIKKGW   0.000       41   GGTIPHVSPE   0.000       42   GTIPHVSPER   0.000       18   CISRKLKRIK   0.000       40   IGGTIPHVSP   0.000       16   LPCISRKLKR   0.000       37   EEGIGGTIPH   0.000       32   KSQFLEEGIG   0.000       25   RIKKGWEKSQ   0.000       24   KRIKKGWEKS   0.000       23   LKRIKKGWEK   0.000       36   LEEGIGGTIP   0.000       19   ISRKLKRIKK   0.000       26   IKKGWEKSQF   0.000       20   SRKLKRIKKG   0.000       29   GWEKSQFLEE   0.000                 V7A-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   SLSETFLPNG   2.670       9   TFLPNGINGI   0.062       2   SPKSLSETFL   0.027       4   KSLSETFLPN   0.012       6   LSETFLPNGI   0.007       10   FLPNGINGIK   0.004       8   ETFLPNGING   0.000       1   GSPKSLSETF   0.000       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V7B-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   FLNMAYQQST   34.279       8   QQSTLGYVAL   3.249       7   YQQSTLGYVA   0.950       3   LNMAYQQSTL   0.877       10   STLGYVALLI   0.536       9   QSTLGYVALL   0.321       4   NMAYQQSTLG   0.054       6   AYQQSTLGYV   0.016       5   MAYQQSTLGY   0.006       1   LFLNMAYQQS   0.000                 V7C-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         160   FLGSGTWMKL   167.054       42   WQQDRKIPPL   93.953       134   FLLRLLKSQA   84.555       5   VILDLSVEVL   35.002       156   SLGEFLGSGT   30.553       27   NILRGGLSEI   12.208       168   KLETIILSKL   11.006       127   GVGPLWEFLL   10.841       4   IVILDLSVEV   10.346       130   PLWEFLLRLL   7.357       148   LSLAFTSWSL   6.579       58   AMWTEEAGAT   5.807       129   GPLWEFLLRL   4.510       152   FTSWSLGEFL   3.678       112   KAANSWRNPV   3.381       6   ILDLSVEVLA   3.378       141   SQAASGTLSL   2.166       158   GEFLGSGTWM   1.966       28   ILRGGLSEIV   1.805       78   KSSSSSQIPV   1.589       147   TLSLAFTSWS   1.557       19   AAWKCLGANI   1.203       81   SSSQIPVVGV   1.044       14   LASPAAAWKC   0.880       135   LLRLLKSQAA   0.642       126   NGVGPLWEFL   0.639       144   ASGTLSLAFT   0.615       66   ATAEAQESGI   0.594       31   GGLSEIVLPI   0.580       52   STPPPPAMWT   0.569       164   GTWMKLETII   0.493       177   LTQEQKSKHC   0.481       119   NPVLPHTNGV   0.454       138   LLKSQAASGT   0.443       79   SSSSSQIPVV   0.428       181   QKSKHCMFSL   0.396       83   SQIPVVGVVT   0.310       137   RLLKSQAASG   0.276       176   KLTQEQKSKH   0.261       169   LETIILSKLT   0.246       15   ASPAAAWKCL   0.237       9   LSVEVLASPA   0.226       11   VEVLASPAAA   0.164       92   TEDDEAQDSI   0.163       142   QAASGTLSLA   0.159       13   VLASPAAAWK   0.139       149   SLAFTSWSLG   0.127       113   AANSWRNPVL   0.122       50   PLSTPPPPAM   0.109       163   SGTWMKLETI   0.077       122   LPHTNGVGPL   0.071       32   GLSEIVLPIE   0.058       132   WEFLLRLLKS   0.057       82   SSQIPVVGVV   0.056       162   GSGTWMKLET   0.049       23   CLGANILRGG   0.034       178   TQEQKSKHCM   0.032       24   LGANILRGGL   0.031       10   SVEVLASPAA   0.028       88   VGVVTEDDEA   0.027       37   VLPIEWQQDR   0.025       121   VLPHTNGVGP   0.025       153   TSWSLGEFLG   0.023       105   ESPDRALKAA   0.023       166   WMKLETIILS   0.020       110   ALKAANSWRN   0.020       182   KSKHCMFSLI   0.016       22   KCLGANILRG   0.014       36   IVLPIEWQQD   0.014       172   IILSKLTQEQ   0.013       173   ILSKLTQEQK   0.012       2   PSIVILDLSV   0.010       155   WSLGEFLGSG   0.009       115   NSWRNPVLPH   0.009       90   VVTEDDEAQD   0.009       102   DPPESPDRAL   0.009       125   TNGVGPLWEF   0.008       146   GTLSLAFTSW   0.007       47   KIPPLSTPPP   0.007       139   LKSQAASGTL   0.007       61   TEEAGATAEA   0.006       101   IDPPESPDRA   0.006       57   PAMWTEEAGA   0.006       59   MWTEEAGATA   0.005       171   TIILSKLTQE   0.005       84   QIPVVGVVTE   0.005       165   TWMKLETIIL   0.005       109   RALKAANSWR   0.004       97   AQDSIDPPES   0.003       43   QQDRKIPPLS   0.003       145   SGTLSLAFTS   0.003       49   PPLSTPPPPA   0.003       8   DLSVEVLASP   0.003       76   RNKSSSSSQI   0.002       104   PESPDRALKA   0.002       29   LRGGLSEIVL   0.002       3   SIVILDLSVE   0.002       12   EVLASPAAAW   0.002       34   SEIVLPIEWQ   0.002       140   KSQAASGTLS   0.002                    
     [1180]                       TABLE XII                       Start   Subsequence   Score                                    V1-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         221   SLATFFFLY   108.000       306   GLLSFFFAM   24.300       294   WLETWLQCR   18.000       281   QLYYGTKYR   10.000       249   KIPIEIVNK   9.000       103   DLRHLLVGK   9.000       274   GLLAAAYQL   8.100       443   ILDLLQLCR   8.000       223   ATFFFLYSF   6.750       304   QLGLLSFFF   6.000       155   QLGPKDASR   6.000       385   ALNWREFSF   6.000       35   VIGSGDFAK   6.000       409   HVLIYGWKR   5.400       56   VVIGSRNPK   4.500       313   AMVHVAYSL   4.050       82   ALTKTNIIF   4.000       322   CLPMRRSER   4.000       275   LLAAAYQLY   4.000       135   SLFPDSLIV   3.000       100   SLWDLRHLL   3.000       21   GINGIKDAR   2.700       403   LLISTFHVL   2.700       265   TLLSLVYLA   2.700       435   ALVLPSIVI   2.700       203   NLPLRLFTL   2.700       205   PLRLFTLWR   2.400       3   SISMMGSPK   2.000       258   TLPIVAITL   1.800       184   QLNFIPIDL   1.800       397   TLGYVALLI   1.800       365   IMSLGLLSL   1.800       307   LLSFFFAMV   1.800       87   NIIFVAIHR   1.800       106   HLLVGKILI   1.800       433   VLALVLPSI   1.350       191   DLGSLSSAR   1.200       210   TLWRGPVVV   1.000       140   SLIVKGFNV   0.900       17   CLPNGINGI   0.900       231   FVRDVIHPY   0.900       48   RLIRCGYHV   0.900       402   ALLISTFHV   0.900       227   FLYSFVRDV   0.900       417   RAFEEEYYR   0.900       263   AITLLSLVY   0.800       5   SMMGSPKSL   0.675       369   GLLSLLAVT   0.675       396   STLGYVALL   0.608       303   KQLGLLSFF   0.608       44   SLTIRLIRC   0.600       381   SVSNALNWR   0.600       46   TIRLIRCGY   0.600       219   AISLATFFF   0.600       280   YQLYYGTKY   0.540       411   LIYGWKRAF   0.450       271   YLAGLLAAA   0.450       112   ILIDVSNNM   0.450       85   KTNIIFVAI   0.405       90   FVAIHREHY   0.400       367   SLGLLSLLA   0.400       113   LIDVSNNMR   0.400       148   VVSAWALQL   0.360       175   RQQVIELAR   0.360       217   VVAISLATF   0.300       164   QVYICSNNI   0.300       400   YVALLISTF   0.300       43   KSLTIRLIR   0.270       441   IVILDLLQL   0.270       268   SLVYLAGLL   0.270       180   ELARQLNFI   0.270       353   EVWRIEMYI   0.270       358   EMYISFGIM   0.270       276   LAAAYQLYY   0.240       436   LVLPSIVIL   0.203       335   NMAYQQVHA   0.200       57   VIGSRNPKF   0.200       269   LVYLAGLLA   0.200       333   FLNMAYQQV   0.200       261   IVAITLLSL   0.180       225   FFFLYSFVR   0.180       360   YISFGIMSL   0.180       437   VLPSIVILD   0.180       404   LISTFHVLI   0.180       242   NQQSDFYKI   0.162       257   KTLPIVAIT   0.152       331   YLFLNMAYQ   0.150       410   VLIYGWKRA   0.150       34   GVIGSGDFA   0.135       18   LPNGINGIK   0.135       107   LLVGKILID   0.135       241   RNQQSDFYK   0.120       405   ISTFHVLIY   0.120       132   YLASLFPDS   0.120       428   TPPNFVLAL   0.108       153   ALQLGPKDA   0.100       108   LVGKILIDV   0.090       378   SIPSVSNAL   0.090       141   LIVKGFNVV   0.090       282   LYYGTKYRR   0.090                 V2-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         12   SLSSGFTPF   6.000       24   SLPSSWDYR   4.000       5   GLQALSLSL   3.600       37   CPADFFLYF   0.360       23   LSLPSSWDY   0.135       17   FTPFSCLSL   0.060       36   PCPADFFLY   0.036       8   ALSLSLSSG   0.030       22   CLSLPSSWD   0.030       10   SLSLSSGFT   0.030       33   CPPPCPADF   0.030       25   LPSSWDYRC   0.018       9   LSLSLSSGF   0.015       15   SGFTPFSCL   0.013       3   SPGLQALSL   0.012       34   PPPCPADFF   0.003       14   SSGFTPFSC   0.003       21   SCLSLPSSW   0.003       35   PPCPADFFL   0.003       6   LQALSLSLS   0.002       18   TPFSCLSLP   0.002       27   SSWDYRCPP   0.002       1   SGSPGLQAL   0.001       7   QALSLSLSS   0.001       29   WDYRCPPPC   0.001       13   LSSGFTPFS   0.001       2   GSPGLQALS   0.001       16   GFTPFSCLS   0.001       31   YRCPPPCPA   0.000       11   LSLSSGFTP   0.000       32   RCPPPCPAD   0.000       20   FSCLSLPSS   0.000       28   SWDYRCPPP   0.000       4   PGLQALSLS   0.000       30   DYRCPPPCP   0.000       19   PFSCLSLPS   0.000       26   PSSWDYRCP   0.000                 V5A-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         1   NLPLRLFTF   9.000       3   PLRLFTFWR   3.600       7   FTFWRGPVV   0.050       5   RLFTFWRGP   0.030       2   LPLRLFTFW   0.009       9   FWRGPVVVA   0.001       8   TFWRGPVVV   0.001       4   LRLFTFWRG   0.000       6   LFTFWRGPV   0.000                 V5B-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         24   FVFLLTLLL   0.600       19   ELELEFVFL   0.540       21   ELEFVFLLT   0.270       16   TQTELELEF   0.180       8   QIFCSFADT   0.150       2   REFSFIQIF   0.135       20   LELEFVFLL   0.109       22   LEFVFLLTL   0.081       6   FIQIFCSFA   0.060       18   TELELEFVF   0.041       17   QTELELEFV   0.015       5   SFIQIFCSF   0.013       4   FSFIQIFCS   0.005       1   WREFSFIQI   0.004       7   IQIFCSFAD   0.003       14   ADTQTELEL   0.001       10   FCSFADTQT   0.001       12   SFADTQTEL   0.001       11   CSFADTQTE   0.001       15   DTQTELELE   0.000       23   EFVFLLTLL   0.000       13   FADTQTELE   0.000       3   EFSFIQIFC   0.000       9   IFCSFADTQ   0.000                 V6-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         12   ILFLPCISR   60.000       7   ILGKIILFL   2.700       6   VILGKIILF   1.350       10   KIILFLPCI   1.215       2   LPSIVILGK   0.900       42   TIPHVSPER   0.600       21   KLKRIKKGW   0.450       23   KRIKKGWEK   0.270       5   IVILGKIIL   0.180       1   VLPSIVILG   0.180       38   GIGGTIPHV   0.135       15   LPCISRKLK   0.100       14   FLPCISRKL   0.090       13   LFLPCISRK   0.068       34   FLEEGIGGT   0.068       17   CISRKLKRI   0.045       4   SIVILGKII   0.045       19   SRKLKRIKK   0.040       45   HVSPERVTV   0.030       41   GTIPHVSPE   0.020       27   KGWEKSQFL   0.014       16   PCISRKLKR   0.012       18   ISRKLKRIK   0.010       31   KSQFLEEGI   0.009       26   KKGWEKSQF   0.006       11   IILFLPCIS   0.006       9   GKIILFLPC   0.005       46   VSPERVTVM   0.005       24   RIKKGWEKS   0.004       43   IPHVSPERV   0.002       35   LEEGIGGTI   0.001       32   SQFLEEGIG   0.001       29   WEKSQFLEE   0.000       3   PSIVILGKI   0.000       37   EGIGGTIPH   0.000       28   GWEKSQFLE   0.000       8   LGKIILFLP   0.000       33   QFLEEGIGG   0.000       40   GGTIPHVSP   0.000       39   IGGTIPHVS   0.000       25   IKKGWEKSQ   0.000       30   EKSQFLEEG   0.000       20   RKLKRIKKG   0.000       36   EEGIGGTIP   0.000       22   LKRIKKGWE   0.000       44   PHVSPERVT   0.000                 V7A-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   FLPNGINGI   0.900       4   SLSETFLPN   0.180       1   SPKSLSETF   0.020       6   SETFLPNGI   0.002       3   KSLSETFLP   0.001       7   ETFLPNGIN   0.001       5   LSETFLPNG   0.000       8   TFLPNGING   0.000       2   PKSLSETFL   0.000                 V7B-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   STLGYVALL   0.608       3   NMAYQQSTL   0.600       1   FLNMAYQQS   0.040       7   QQSTLGYVA   0.018       5   AYQQSTLGY   0.008       8   QSTLGYVAL   0.003       6   YQQSTLGYV   0.003       4   MAYQQSTLG   0.001       2   LNMAYQQST   0.001                 V7C-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         167   KLETIILSK   270.000       159   FLGSGTWMK   60.000       175   KLTQEQKSK   30.000       31   GLSEIVLPI   24.300       129   PLWEFLLRL   4.050       109   ALKAANSWR   4.000       148   SLAFTSWSL   1.800       5   ILDLSVEVL   1.800       27   ILRGGLSEI   1.350       165   WMKLETIIL   1.200       128   GPLWEFLLR   1.080       57   AMWTEEAGA   1.000       163   GTWMKLETI   0.675       146   TLSLAFTSW   0.600       131   WEFLLRLLK   0.600       21   KCLGANILR   0.540       12   VLASPAAAW   0.300       185   CMFSLISGS   0.300       13   LASPAAAWK   0.300       37   LPIEWQQDR   0.270       126   GVGPLWEFL   0.270       38   PIEWQQDRK   0.200       134   LLRLLKSQA   0.200       173   LSKLTQEQK   0.100       88   GVVTEDDEA   0.090       69   AQESGIRNK   0.090       7   DLSVEVLAS   0.072       2   SIVILDLSV   0.060       136   RLLKSQAAS   0.060       22   CLGANILRG   0.060       151   FTSWSLGEF   0.045       155   SLGEFLGSG   0.041       181   KSKHCMFSL   0.041       125   NGVGPLWEF   0.030       49   PLSTPPPPA   0.030       4   VILDLSVEV   0.030       145   GTLSLAFTS   0.027       42   QQDRKIPPL   0.027       123   HTNGVGPLW   0.022       51   STPPPPAMW   0.022       133   FLLRLLKSQ   0.022       35   IVLPIEWQQ   0.020       36   VLPIEWQQD   0.020       172   ILSKLTQEQ   0.020       143   ASGTLSLAF   0.020       9   SVEVLASPA   0.020       137   LLKSQAASG   0.020       82   SQIPVVGVV   0.018       179   EQKSKHCMF   0.018       59   WTEEAGATA   0.015       83   QIPVVGVVT   0.015       152   TSWSLGEFL   0.015       176   LTQEQKSKH   0.015       73   GIRNKSSSS   0.012       141   QAASGTLSL   0.012       46   KIPPLSTPP   0.009       11   EVLASPAAA   0.009       103   PESPDRALK   0.009       100   IDPPESPDR   0.006       112   AANSWRNPV   0.006       170   TIILSKLTQ   0.006       120   VLPHTNGVG   0.006       66   TAEAQESGI   0.006       26   NILRGGLSE   0.006       127   VGPLWEFLL   0.005       24   GANILRGGL   0.005       142   AASGTLSLA   0.005       81   SSQIPVVGV   0.005       52   TPPPPAMWT   0.005       3   IVILDLSVE   0.005       171   IILSKLTQE   0.005       119   PVLPHTNGV   0.005       99   SIDPPESPD   0.005       168   LETIILSKL   0.004       17   AAAWKCLGA   0.004       67   AEAQESGIR   0.004       108   RALKAANSW   0.003       15   SPAAAWKCL   0.003       86   VVGVVTEDD   0.003       177   TQEQKSKHC   0.003       14   ASPAAAWKC   0.003       89   VVTEDDEAQ   0.003       154   WSLGEFLGS   0.003       139   KSQAASGTL   0.003       157   GEFLGSGTW   0.003       50   LSTPPPPAM   0.002       34   EIVLPIEWQ   0.002       85   PVVGVVTED   0.002       78   SSSSSQIPV   0.002       182   SKHCMFSLI   0.002       160   LGSGTWMKL   0.002       115   SWRNPVLPH   0.002       33   SEIVLPIEW   0.002       79   SSSSQIPVV   0.002       105   SPDRALKAA   0.002       65   ATAEAQESG   0.002       64   GATAEAQES   0.001       29   RGGLSEIVL   0.001       113   ANSWRNPVL   0.001       140   SQAASGTLS   0.001                    
     [1181]                       TABLE XIII                       Start   Subsequence   Score                                    V1-HLA-A3-10-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         135   SLFPDSLIVK   450.000       281   QLYYGTKYRR   60.000       34   GVIGSGDFAK   40.500       275   LLAAAYQLYY   24.000       294   WLETWLQCRK   20.000       274   GLLAAAYQLY   18.000       17   CLPNGINGIK   9.000       21   GINGIKDARK   9.000       306   GLLSFFFAMV   8.100       271   YLAGLLAAAY   6.000       112   ILIDVSNNMR   6.000       443   ILDLLQLCRY   6.000       227   FLYSFVRDVI   4.500       210   TLWRGPVVVA   4.500       322   CLPMRRSERY   4.000       55   HVVIGSRNPK   3.000       402   ALLISTFHVL   2.700       266   LLSLVYLAGL   2.700       403   LLISTFHVLI   2.700       437   VLPSIVILDL   2.700       404   LISTFHVLIY   2.400       107   LLVGKILIDV   2.025       100   SLWDLRHLLV   2.000       76   VTHHEDALTK   2.000       370   LLSLLAVTSI   1.800       132   YLASLFPDSL   1.800       304   QLGLLSFFFA   1.800       385   ALNWREFSFI   1.800       435   ALVLPSIVIL   1.350       303   KQLGLLSFFF   1.215       307   LLSFFFAMVH   1.200       442   VILDLLQLCR   1.200       298   WLQCRKQLGL   1.200       365   IMSLGLLSLL   0.900       410   VLIYGWKRAF   0.900       140   SLIVKGFNVV   0.900       207   RLFTLWRGPV   0.900       258   TLPIVAITLL   0.900       123   NQYPESNAEY   0.900       278   AAYQLYYGTK   0.900       364   GIMSLGLLSL   0.810       427   YTPPNFVLAL   0.810       220   ISLATFFFLY   0.810       221   SLATFFFLYS   0.720       257   KTLPIVAITL   0.608       333   FLNMAYQQVH   0.600       268   SLVYLAGLLA   0.600       324   PMRRSERYLF   0.600       82   ALTKTNIIFV   0.600       367   SLGLLSLLAV   0.600       203   NLPLRLFTLW   0.600       166   YICSNNIQAR   0.600       219   AISLATFFFL   0.540       147   NVVSAWALQL   0.540       150   SAWALQLGPK   0.450       56   VVIGSRNPKF   0.450       417   RAFEEEYYRF   0.450       45   LTIRLIRCGY   0.450       216   VVVAISLATF   0.450       178   VIELARQLNF   0.400       204   LPLRLFTLWR   0.360       358   EMYISFGIMS   0.360       314   MVHVAYSLCL   0.360       48   RLIRCGYHVV   0.300       317   VAYSLCLPMR   0.300       331   YLFLNMAYQQ   0.300       313   AMVHVAYSLC   0.300       373   LLAVTSIPSV   0.300       269   LVYLAGLLAA   0.300       440   SIVILDLLQL   0.270       222   LATFFFLYSF   0.270       154   LQLGPKDASR   0.270       85   KTNIIFVAIH   0.270       356   RIEMYISFGI   0.270       406   STFHVLIYGW   0.225       396   STLGYVALLI   0.203       432   FVLALVLPSI   0.203       217   VVAISLATFF   0.200       433   VLALVLPSIV   0.200       391   FSFIQSTLGY   0.200       369   GLLSLLAVTS   0.180       224   TFFFLYSFVR   0.180       49   LIRCGYHVVI   0.180       103   DLRHLLVGKI   0.162       111   KILIDVSNNM   0.135       249   KIPIEIVNKT   0.135       264   ITLLSLVYLA   0.135       5   SMMGSPKSLS   0.135       113   LIDVSNNMRI   0.120       262   VAITLLSLVY   0.120       372   SLLAVTSIPS   0.120       397   TLGYVALLIS   0.120       157   GPKDASRQVY   0.120       172   IQARQQVIEL   0.108       243   QQSDFYKIPI   0.108       347   NSWNEEEVWR   0.100       39   GDFAKSLTIR   0.090       218   VAISLATFFF   0.090       384   NALNWREFSF   0.090       285   GTKYRRFPPW   0.090                 V2-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         22   CLSLPSSWDY   12.000       8   ALSLSLSSGF   2.000       24   SLPSSWDYRC   1.800       5   GLQALSLSLS   0.180       12   SLSSGFTPFS   0.120       10   SLSLSSGFTP   0.060       35   PPCPADFFLY   0.054       11   LSLSSGFTPF   0.045       23   LSLPSSWDYR   0.045       33   CPPPCPADFF   0.045       36   PCPADFFLYF   0.036       32   RCPPPCPADF   0.135       2   GSPGLQALSL   0.027       14   SSGFTPFSCL   0.013       16   GFTPFSCLSL   0.005       13   LSSGFTPFSC   0.005       18   TPFSCLSLPS   0.004       6   LQALSLSLSS   0.002       34   PPPCPADFFL   0.002       17   FTPFSCLSLP   0.002       20   FSCLSLPSSW   0.001       3   SPGLQALSLS   0.001       15   SGFTPFSCLS   0.001       27   SSWDYRCPPP   0.001       21   SCLSLPSSWD   0.000       7   QALSLSLSSG   0.000       9   LSLSLSSGFT   0.000       28   SWDYRCPPPC   0.000       4   PGLQALSLSL   0.000       29   WDYRCPPPCP   0.000       30   DYRCPPPCPA   0.000       1   SGSPGLQALS   0.000       31   YRCPPPCPAD   0.000       26   PSSWDYRCPP   0.000       25   LPSSWDYRCP   0.000       19   PFSCLSLPSS   0.000                 V5A-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         6   RLFTFWRGPV   0.900       2   NLPLRLFTFW   0.600       3   LPLRLFTFWR   0.540       8   FTFWRGPVVV   0.050       4   PLRLFTFWRG   0.018       1   ENLPLRLFTF   0.012       9   TFWRGPVVVA   0.005       10   FWRGPVVVAI   0.004       7   LFTFWRGPVV   0.000       5   LRLFTFWRGP   0.000                 V5B-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         20   ELELEFVFLL   4.860       22   ELEFVFLLTL   1.620       18   QTELELEFVF   0.300       5   FSFIQIFCSF   0.225       16   DTQTELELEF   0.060       9   QIFCSFADTQ   0.030       12   CSFADTQTEL   0.015       8   IQIFCSFADT   0.013       23   LEFVFLLTLL   0.013       17   TQTELELEFV   0.013       19   TELELEFVFL   0.012       14   FADTQTELEL   0.012       2   WREFSFIQIF   0.009       3   REFSFIQIFC   0.009       21   LELEFVFLLT   0.006       7   FIQIFCSFAD   0.006       1   NWREFSFIQI   0.005       6   SFIQIFCSFA   0.001       24   EFVFLLTLLL   0.001       11   FCSFADTQTE   0.000       10   IFCSFADTQT   0.000       4   EFSFIQIFCS   0.000       15   ADTQTELELE   0.000       13   SFADTQTELE   0.000                 V6-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         13   ILFLPCISRK   150.000       2   VLPSIVILGK   90.000       15   FLPCISRKLK   10.000       42   GTIPHVSPER   2.025       12   IILFLPCISR   1.800       6   IVILGKIILF   0.900       7   VILGKIILFL   0.608       35   FLEEGIGGTI   0.405       19   ISRKLKRIKK   0.200       18   CISRKLKRIK   0.200       5   SIVILGKIIL   0.180       8   ILGKIILFLP   0.135       46   HVSPERVTVM   0.090       16   LPCISRKLKR   0.080       23   LKRIKKGWEK   0.060       1   LVLPSIVILG   0.041       39   GIGGTIPHVS   0.027       43   TIPHVSPERV   0.020       22   KLKRIKKGWE   0.018       11   KIILFLPCIS   0.018       10   GKIILFLPCI   0.012       33   SQFLEEGIGG   0.006       3   LPSIVILGKI   0.004       26   IKKGWEKSQF   0.003       25   RIKKGWEKSQ   0.003       27   KKGWEKSQFL   0.002       28   KGWEKSQFLE   0.001       9   LGKIILFLPC   0.001       17   PCISRKLKRI   0.001       29   GWEKSQFLEE   0.000       37   EEGIGGTIPH   0.000       30   WEKSQFLEEG   0.000       21   RKLKRIKKGW   0.000       4   PSIVILGKII   0.000       38   EGIGGTIPHV   0.000       14   LFLPCISRKL   0.000       41   GGTIPHVSPE   0.000       24   KRIKKGWEKS   0.000       31   EKSQFLEEGI   0.000       44   IPHVSPERVT   0.000       34   QFLEEGIGGT   0.000       32   KSQFLEEGIG   0.000       36   LEEGIGGTIP   0.000       45   PHVSPERVTV   0.000       40   IGGTIPHVSP   0.000       20   SRKLKRIKKG   0.000                 V7A-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FLPNGINGIK   9.000       5   SLSETFLPNG   0.135       1   GSPKSLSETF   0.030       2   SPKSLSETFL   0.006       6   LSETFLPNGI   0.003       8   ETFLPNGING   0.003       4   KSLSETFLPN   0.003       9   TFLPNGINGI   0.002       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V7B-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         5   MAYQQSTLGY   0.400       2   FLNMAYQQST   0.300       10   STLGYVALLI   0.203       9   QSTLGYVALL   0.027       4   NMAYQQSTLG   0.020       7   YQQSTLGYVA   0.018       8   QQSTLGYVAL   0.018       3   LNMAYQQSTL   0.002       6   AYQQSTLGYV   0.000       1   LFLNMAYQQS   0.000                 V7C-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         13   VLASPAAAWK   20.000       173   ILSKLTQEQK   20.000       37   VLPIEWQQDR   12.000       168   KLETIILSKL   4.050       127   GVGPLWEFLL   2.430       160   FLGSGTWMKL   1.200       100   SIDPPESPDR   0.600       176   KLTQEQKSKH   0.600       38   LPIEWQQDRK   0.450       164   GTWMKLETII   0.450       134   FLLRLLKSQA   0.300       6   ILDLSVEVLA   0.300       28   ILRGGLSEIV   0.300       5   VILDLSVEVL   0.270       129   GPLWEFLLRL   0.243       167   MKLETIILSK   0.203       32   GLSEIVLPIE   0.203       135   LLRLLKSQAA   0.200       156   SLGEFLGSGT   0.150       58   AMWTEEAGAT   0.150       146   GTLSLAFTSW   0.135       27   NILRGGLSEI   0.135       166   WMKLETIILS   0.120       147   TLSLAFTSWS   0.120       138   LLKSQAASGT   0.100       130   PLWEFLLRLL   0.068       143   AASGTLSLAF   0.060       110   ALKAANSWRN   0.060       109   RALKAANSWR   0.060       66   ATAEAQESGI   0.045       115   NSWRNPVLPH   0.045       159   EFLGSGTWMK   0.041       131   LWEFLLRLLK   0.040       141   SQAASGTLSL   0.036       152   FTSWSLGEFL   0.030       50   PLSTPPPPAM   0.030       137   RLLKSQAASG   0.030       4   IVILDLSVEV   0.030       19   AAWKCLGANI   0.030       125   TNGVGPLWEF   0.027       42   WQQDRKIPPL   0.027       182   KSKHCMFSLI   0.027       31   GGLSEIVLPI   0.024       128   VGPLWEFLLR   0.024       52   STPPPPAMWT   0.022       103   PPESPDRALK   0.020       10   SVEVLASPAA   0.020       149   SLAFTSWSLG   0.020       121   VLPHTNGVGP   0.020       112   KAANSWRNPV   0.018       175   SKLTQEQKSK   0.015       148   LSLAFTSWSL   0.013       12   EVLASPAAAW   0.013       8   DLSVEVLASP   0.013       69   EAQESGIRNK   0.013       74   GIRNKSSSSS   0.012       67   TAEAQESGIR   0.012       83   SQIPVVGVVT   0.010       89   GVVTEDDEAQ   0.009       47   KIPPLSTPPP   0.009       14   LASPAAAWKC   0.009       158   GEFLGSGTWM   0.009       21   WKCLGANILR   0.008       177   LTQEQKSKHC   0.007       179   QEQKSKHCMF   0.006       113   AANSWRNPVL   0.006       84   QIPVVGVVTE   0.006       178   TQEQKSKHCM   0.006       150   LAFTSWSLGE   0.006       78   KSSSSSQIPV   0.006       122   LPHTNGVGPL   0.005       3   SIVILDLSVE   0.005       36   IVLPIEWQQD   0.005       23   CLGANILRGG   0.005       171   TIILSKLTQE   0.005       81   SSSQIPVVGV   0.005       22   KCLGANILRG   0.004       35   EIVLPIEWQQ   0.004       119   NPVLPHTNGV   0.003       162   GSGTWMKLET   0.003       142   QAASGTLSLA   0.003       124   HTNGVGPLWE   0.003       90   VVTEDDEAQD   0.003       172   IILSKLTQEQ   0.003       181   QKSKHCMFSL   0.003       9   LSVEVLASPA   0.002       51   LSTPPPPAMW   0.002       87   VVGVVTEDDE   0.002       33   LSEIVLPIEW   0.002       91   VTEDDEAQDS   0.002       165   TWMKLETIIL   0.002       29   LRGGLSEIVL   0.002       70   AQESGIRNKS   0.002       132   WEFLLRLLKS   0.002       43   QQDRKIPPLS   0.002       92   TEDDEAQDSI   0.002       79   SSSSSQIPVV   0.002       60   WTEEAGATAE   0.002       153   TSWSLGEFLG   0.002       15   ASPAAAWKCL   0.002                    
     [1182]                       TABLE XIV                       Start   Subsequence   Score                                    V1-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         56   VVIGSRNPK   3.000       409   HVLIYGWKR   1.200       249   KIPIEIVNK   1.200       35   VIGSGDFAK   1.200       175   RQQVIELAR   0.720       417   RAFEEEYYR   0.480       3   SISMMGSPK   0.400       279   AYQLYYGTK   0.400       136   LFPDSLIVK   0.400       381   SVSNALNWR   0.400       241   RNQQSDFYK   0.360       282   LYYGTKYRR   0.320       225   FFFLYSFVR   0.240       21   GINGIKDAR   0.240       53   GYHVVIGSR   0.240       87   NIIFVAIHR   0.240       18   LPNGINGIK   0.200       443   ILDLLQLCR   0.160       103   DLRHLLVGK   0.120       34   GVIGSGDFA   0.090       322   CLPMRRSER   0.080       113   LIDVSNNMR   0.080       155   QLGPKDASR   0.080       318   AYSLCLPMR   0.080       269   LVYLAGLLA   0.080       281   QLYYGTKYR   0.080       294   WLETWLQCR   0.080       97   HYTSLWDLR   0.080       295   LETWLQCRK   0.060       441   IVILDLLQL   0.060       306   GLLSFFFAM   0.054       199   REIENLPLR   0.054       22   INGIKDARK   0.040       148   VVSAWALQL   0.040       77   THHEDALTK   0.040       108   LVGKILIDV   0.040       223   ATFFFLYSF   0.040       261   IVAITLLSL   0.040       167   ICSNNIQAR   0.040       164   QVYICSNNI   0.040       43   KSLTIRLIR   0.036       233   RDVIHPYAR   0.036       48   RLIRCGYHV   0.036       274   GLLAAAYQL   0.036       330   RYLFLNMAY   0.036       408   FHVLIYGWK   0.030       85   KTNIIFVAI   0.030       436   LVLPSIVIL   0.030       303   KQLGLLSFF   0.027       353   EVWRIEMYI   0.024       191   DLGSLSSAR   0.024       254   IVNKTLPIV   0.020       90   FVAIHREHY   0.020       151   AWALQLGPK   0.020       83   LTKTNIIFV   0.020       98   YTSLWDLRH   0.020       231   FVRDVIHPY   0.020       400   YVALLISTF   0.020       217   VVAISLATF   0.020       402   ALLISTFHV   0.018       64   KFASEFFPH   0.018       140   SLIVKGFNV   0.018       214   GPVVVAISL   0.018       135   SLFPDSLIV   0.016       205   PLRLFTLWR   0.016       209   FTWRGPVV   0.015       264   ITLLSLVYL   0.015       396   STLGYVALL   0.015       319   YSLCLPMRR   0.012       394   IQSTLGYVA   0.012       30   KVTVGVIGS   0.012       270   VYLAGLLAA   0.012       203   NLPLRLFTL   0.012       425   RFYTPPNFV   0.012       242   NQQSDFYKI   0.012       287   KYRRFPPWL   0.012       435   ALVLPSIVI   0.012       265   TLLSLVYLA   0.012       299   LQCRKQLGL   0.012       313   AMVHVAYSL   0.012       40   DFAKSLTIR   0.012       106   HLLVGKILI   0.012       426   FYTPPNFVL   0.012       385   ALNWREFSF   0.012       219   AISLATFFF   0.012       304   QLGLLSFFF   0.012       221   SLATFFFLY   0.012       427   YTPPNFVLA   0.010       285   GTKYRRFPP   0.009       280   YQLYYGTKY   0.009       397   TLGYVALLI   0.008       367   SLGLLSLLA   0.008       166   YICSNNIQA   0.008       258   TLPIVAITL   0.008       317   VAYSLCLPM   0.008       100   SLWDLRHLL   0.008       210   TLWRGPVVV   0.008       365   IMSLGLLSL   0.008       263   AITLLSLVY   0.008       360   YISFGIMSL   0.008                 V2-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         24   SLPSSWDYR   0.080       5   GLQALSLSL   0.024       17   FTPFSCLSL   0.020       3   SPGLQALSL   0.004       12   SLSSGFTPF   0.004       37   CPADFFLYF   0.004       21   SCLSLPSSW   0.003       33   CPPPCPADF   0.002       23   LSLPSSWDY   0.001       6   LQALSLSLS   0.001       16   GFTPFSCLS   0.001       32   RCPPPCPAD   0.001       36   PCPADFFLY   0.001       35   PPCPADFFL   0.001       7   QALSLSLSS   0.001       10   SLSLSSGFT   0.000       15   SGFTPFSCL   0.000       22   CLSLPSSWD   0.000       8   ALSLSLSSG   0.000       18   TPFSCLSLP   0.000       25   LPSSWDYRC   0.000       9   LSLSLSSGF   0.000       1   SGSPGLQAL   0.000       31   YRCPPPCPA   0.000       34   PPPCPADFF   0.000       30   DYRCPPPCP   0.000       11   LSLSSGFTP   0.000       14   SSGFTPFSC   0.000       2   GSPGLQALS   0.000       19   PFSCLSLPS   0.000       29   WDYRCPPPC   0.000       27   SSWDYRCPP   0.000       13   LSSGFTPFS   0.000       20   FSCLSLPSS   0.000       28   SWDYRCPPP   0.000       4   PGLQALSLS   0.000       26   PSSWDYRCP   0.000                 V5A-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         3   PLRLFTFWR   0.024       7   FTFWRGPVV   0.020       1   NLPLRLFTF   0.012       8   TFWRGPVVV   0.004       2   LPLRLFTFW   0.003       6   LFTFWRGPV   0.002       5   RLFTFWRGP   0.000       9   FWRGPVVVA   0.000       4   LRLFTFWRG   0.000                 V5B-HLA-A11-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         24   FVFLLTLLL   0.080       16   TQTELELEF   0.012       17   QTELELEFV   0.010       6   FIQIFCSFA   0.004       2   REFSFIQIF   0.004       5   SFIQIFCSF   0.003       7   IQIFCSFAD   0.003       18   TELELEFVF   0.003       20   LELEFVFLL   0.003       22   LEFVFLLTL   0.002       12   SFADTQTEL   0.002       19   ELELEFVFL   0.001       23   EFVFLLTLL   0.001       8   QIFCSFADT   0.001       14   ADTQTELEL   0.000       1   WREFSFIQI   0.000       15   DTQTELELE   0.000       21   ELEFVFLLT   0.000       9   IFCSFADTQ   0.000       13   FADTQTELE   0.000       10   FCSFADTQT   0.000       4   FSFIQIFCS   0.000       3   EFSFIQIFC   0.000       11   CSFADTQTE   0.000                 V6-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         2   LPSIVILGK   0.400       12   ILFLPCISR   0.320       13   LFLPCISRK   0.300       23   FRIKKGWEK   0.180       15   LPCISRKLK   0.100       42   TIPHVSPER   0.080       5   IVILGKIIL   0.060       19   SRKLKRIKK   0.040       45   HVSPERVTV   0.020       10   KIILFLPCI   0.018       16   PCISRKLKR   0.012       6   VILGKIILF   0.012       38   GIGGTIPHV   0.012       7   ILGKIILFL   0.008       21   KLKRIKKGW   0.006       41   GTIPHVSPE   0.005       4   SIVILGKII   0.003       18   ISRKLKRIK   0.002       17   CISRKLKRI   0.002       43   IPHVSPERV   0.002       32   SQFLEEGIG   0.001       24   RIKKGWEKS   0.001       27   KGWEKSQFL   0.001       1   VLPSIVILG   0.001       26   KKGWEKSQF   0.001       11   IILFLPCIS   0.001       33   QFLEEGIGG   0.001       31   KSQFLEEGI   0.001       35   LEEGIGGTI   0.001       14   FLPCISRKL   0.000       34   FLEEGIGGT   0.000       46   VSPERVTVM   0.000       9   GKIILFLPC   0.000       28   GWEKSQFLE   0.000       37   EGIGGTIPH   0.000       29   WEKSQFLEE   0.000       8   LGKIILFLP   0.000       40   GGTIPHVSP   0.000       20   RKLKRIKKG   0.000       3   PSIVILGKI   0.000       22   LKRIKKGWE   0.000       39   IGGTIPHVS   0.000       36   EEGIGGTIP   0.000       25   IKKGWEKSQ   0.000       30   EKSQFLEEG   0.000       44   PHVSPERVT   0.000                 V7A-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   FLPNGINGI   0.004       1   SPKSLSETF   0.002       4   SLSETFLPN   0.001       7   ETFLPNGIN   0.001       8   TFLPNGING   0.001       6   SETFLPNGI   0.001       3   KSLSETFLP   0.000       2   PKSLSETFL   0.000       5   LSETFLPNG   0.000                 V7B-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   STLGYVALL   0.015       7   QQSTLGYVA   0.012       5   AYQQSTLGY   0.008       6   YQQSTLGYV   0.006       3   NMAYQQSTL   0.004       4   MAYQQSTLG   0.000       1   FLNMAYQQS   0.000       8   OSTLGYVAL   0.000       2   LNMAYQQST   0.000                 V7C-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         167   KLETIILSK   2.400       159   FLGSGTWMK   0.800       175   KLTQEQKSK   0.600       21   KCLGANILR   0.360       128   GPLWEFLLR   0.360       131   WEFLLRLLK   0.240       13   LASPAAAWK   0.200       88   GVVTEDDEA   0.090       109   ALKAANSWR   0.080       69   AQESGIRNK   0.060       163   GTWMKLETI   0.060       37   LPIEWQQDR   0.060       126   GVGPLWEFL   0.060       38   PIEWQQDRK   0.040       31   GLSEIVLPI   0.024       173   LSKLTQEQK   0.020       9   SVEVLASPA   0.020       145   GTLSLAFTS   0.013       2   SIVILDLSV   0.012       67   AEAQESGIR   0.012       151   FTSWSLGEF   0.010       176   LTQEQKSKH   0.010       51   STPPPPAMW   0.010       59   WTEEAGATA   0.010       123   HTNGVGPLW   0.010       11   EVLASPAAA   0.009       82   SQIPVVGVV   0.009       108   RALKAANSW   0.009       57   AMWTEEAGA   0.008       165   WMKLETIIL   0.008       148   SLAFTSWSL   0.008       4   VILDLSVEV   0.006       103   PESPDRALK   0.006       42   QQDRKIPPL   0.006       24   GANILRGGL   0.006       35   IVLPIEWQQ   0.006       5   ILDLSVEVL   0.004       134   LLRLLKSQA   0.004       100   IDPPESPDR   0.004       141   QAASGTLSL   0.004       27   ILRGGLSEI   0.004       146   TLSLAFTSW   0.004       12   VLASPAAAW   0.004       17   AAAWKCLGA   0.004       157   GEFLGSGTW   0.004       3   IVILDLSVE   0.003       119   PVLPHTNGV   0.003       89   VVTEDDEAQ   0.002       66   TAEAQESGI   0.002       86   VVGVVTEDD   0.002       142   AASGTLSLA   0.002       112   AANSWRNPV   0.002       181   KSKHCMFSL   0.002       136   RLLKSQAAS   0.002       179   EQKSKHCMF   0.002       33   SEIVLPIEW   0.002       129   PLWEFLLRL   0.002       170   TIILSKLTQ   0.001       73   GIRNKSSSS   0.001       29   RGGLSEIVL   0.001       46   KIPPLSTPP   0.001       41   WQQDRKIPP   0.001       26   NILRGGLSE   0.001       105   SPDRALKAA   0.001       65   ATAEAQESG   0.001       15   SPAAAWKCL   0.001       90   VTEDDEAQD   0.001       158   EFLGSGTWM   0.001       10   VEVLASPAA   0.001       22   CLGANILRG   0.001       185   CMFSLISGS   0.001       184   HCMFSLISG   0.001       127   VGPLWEFLL   0.001       139   KSQAASGTL   0.001       125   NGVGPLWEF   0.001       64   GATAEAQES   0.001       140   SQAASGTLS   0.001       171   IILSKLTQE   0.001       96   AQDSIDPPE   0.001       168   LETIILSKL   0.001       178   QEQKSKHCM   0.001       101   DPPESPDRA   0.001       164   TWMKLETII   0.000       49   PLSTPPPPA   0.000       18   AAWKCLGAN   0.000       143   ASGTLSLAF   0.000       150   AFTSWSLGE   0.000       36   VLPIEWQQD   0.000       83   QIPVVGVVT   0.000       160   LGSGTWMKL   0.000       52   TPPPPAMWT   0.000       172   ILSKLTQQE   0.000       115   SWRNPVLPH   0.000       99   SIDPPESPD   0.000       149   LAFTSWSLG   0.000       113   ANSWRNPVL   0.000       155   SLGEFLGSG   0.000       137   LLKSQAASG   0.000       120   VLPHTNGVG   0.000       78   SSSSSQIPV   0.000                    
     [1183]                       TABLE XV                       Start   Subsequence   Score                                    V1-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         34   GVIGSGDFAK   27.000       55   HVVIGSRNPK   3.000       76   VTHHEDALTK   2.000       135   SLFPDSLIVK   1.600       21   GINGIKDARK   1.200       294   WLETWLQCRK   0.400       278   AAYQLYYGTK   0.400       150   SAWALQLGPK   0.400       17   CLPNGINGIK   0.400       281   QLYYGTKYRR   0.320       442   VILDLLQLCR   0.240       224   TFFFLYSFVR   0.240       407   TFHVLIYGWK   0.200       154   LQLGPKDASR   0.180       318   AYSLCLPMRR   0.160       204   LPLRLFTLWR   0.120       112   ILIDVSNNMR   0.120       280   YQLYYGTKYR   0.090       257   KTLPIVAITL   0.090       303   KQLGLLSFFF   0.081       166   YICSNNIQAR   0.080       269   LVYLAGLLAA   0.080       317   VAYSLCLPMR   0.080       240   ARNQQSDFYK   0.060       321   LCLPMRRSER   0.060       147   NVVSAWALQL   0.060       183   RQLNFIPIDL   0.054       364   GIMSLGLLSL   0.048       406   STFHVLIYGW   0.040       254   IVNKTLPIVA   0.040       314   MVHVAYSLCL   0.040       316   HVAYSLCLPM   0.040       356   RIEMYISFGI   0.036       425   RFYTPPNFVL   0.036       102   WDLRHLLVGK   0.030       248   YKIPIEIVNK   0.030       56   VVIGSRNPKF   0.030       285   GTKYRRFPPW   0.030       216   VVVAISLATF   0.030       83   LTKTNIIFVA   0.030       85   KTNIIFVAIH   0.030       396   STLGYVALLI   0.030       432   FVLALVLPSI   0.030       264   ITLLSLVYLA   0.030       163   RQVYICSNNI   0.027       416   KRAFEEEYYR   0.024       86   TNIIFVAIHR   0.024       39   GDFAKSLTIR   0.024       417   RAFEEEYYRF   0.024       207   RLFTLWRGPV   0.024       217   VVAISLATFF   0.020       223   ATFFFLYSFV   0.020       400   YVALLISTFH   0.020       261   IVAITLLSLV   0.020       32   TVGVIGSGDF   0.020       142   IVKGFNVVSA   0.020       231   FVRDVIHPYA   0.020       73   VVDVTHHEDA   0.020       340   QVHANIENSW   0.020       427   YTPPNFVLAL   0.020       399   GYVALLISTF   0.018       111   KILIDVSNNM   0.018       274   GLLAAAYQLY   0.018       48   RLIRCGYHVV   0.018       306   GLLSFFFAMV   0.018       100   SLWDLRHLLV   0.016       45   LTIRLIRCGY   0.015       209   FTLWRGPVVV   0.015       409   HVLIYGWKRA   0.015       408   FHVLIYGWKR   0.012       243   QQSDFYKIPI   0.012       440   SIVILDLLQL   0.012       24   GIKDARKVTV   0.012       304   QLGLLSFFFA   0.012       145   GFNVVSAWAL   0.012       359   MYISFGIMSL   0.012       172   IQARQQVIEL   0.012       121   RINQYPESNA   0.012       123   NQYPESNAEY   0.012       165   VYICSNNIQA   0.012       107   LLVGKILIDV   0.012       219   AISLATFFFL   0.012       268   SLVYLAGLLA   0.012       376   VTSIPSVSNA   0.010       2   ESISMMGSPK   0.009       401   VALLISTFHV   0.009       214   GPVVVAISLA   0.009       218   VAISLATFFF   0.009       384   NALNWREFSF   0.009       367   SLGLLSLLAV   0.008       307   LLSFFFAMVH   0.008       437   VLPSIVILDL   0.008       227   FLYSFVRDVI   0.008       42   AKSLTIRLIR   0.008       113   LIDVSNNMRI   0.008       210   TLWRGPVVVA   0.008       178   VIELARQLNF   0.008       298   WLQCRKQLGL   0.008       404   LISTFHVLIY   0.008       82   ALTKTNIIFV   0.008                 2V-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         16   GFTPFSCLSL   0.012       22   CLSLPSSWDY   0.008       23   LSLPSSWDYR   0.006       32   RCPPPCPADF   0.006       8   ALSLSLSSGF   0.004       33   CPPPCPADFF   0.002       6   LQALSLSLSS   0.001       2   GSPGLQALSL   0.001       5   GLQALSLSLS   0.001       10   SLSLSSGTFP   0.001       30   DYRCPPPCPA   0.001       17   FTPFSCLSLP   0.001       18   TPFSCLSLPS   0.001       24   SLPSSWDYRC   0.001       35   PPCPADFFLY   0.001       34   PPPCPADFFL   0.001       36   PCPADFFLYF   0.000       12   SLSSGFTPFS   0.000       11   LSLSSGFTPF   0.000       21   SCLSLPSSWD   0.000       7   QALSLSLSSG   0.000       3   SPGLQALSLS   0.000       20   FSCLSLPSSW   0.000       14   SSGFTPFSCL   0.000       4   PGLQALSLSL   0.000       13   LSSGFTPFSC   0.000       29   WDYRCPPPCP   0.000       27   SSWDYRCPPP   0.000       15   SGFTPFSCLS   0.000       9   LSLSLSSGFT   0.000       31   YRCPPPCPAD   0.000       19   PFSCLSLPSS   0.000       25   LPSSWDYRCP   0.000       28   SWDYRCPPPC   0.000       1   SGSPGLQALS   0.000       26   PSSWDYRCPP   0.000                 V5A-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11 each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         3   LPLRLFTFWR   0.180       6   RLFTFWRGPV   0.024       8   FTFWRGPVVV   0.020       9   TFWRGPVVVA   0.004       2   NLPLRLFTFW   0.004       7   LFTFWRGPVV   0.002       1   ENLPLRLFTF   0.001       10   FWRGPVVVAI   0.000       4   PLRLFTFWRG   0.000       5   LRLFTFWRGP   0.000                 V5B-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         18   QTELELEFVF   0.030       16   DTQTELELEF   0.006       17   TQTELELEFV   0.006       14   FADTQTELEL   0.004       20   ELELEFVFLL   0.004       6   SFIQIFCSFA   0.003       22   ELEFVFLLTL   0.002       24   EFVFLLTLLL   0.002       7   FIQIFCSFAD   0.001       23   LEFVFLLTLL   0.001       8   IQIFCSFADT   0.001       19   TELELEFVFL   0.001       9   QIFCSFADTQ   0.001       3   REFSFIQIFC   0.001       1   NWREFSFIQI   0.000       12   CSFADTQTEL   0.000       5   FSFIQIFCSF   0.000       13   SFADTQTELE   0.000       2   WREFSFIQIF   0.000       11   FCSFADTQTE   0.000       10   IFCSFADTQT   0.000       4   EFSFIQIFCS   0.000       21   LELEFVFLLT   0.000       15   ADTQTELELE   0.000                 V6-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         42   GTIPHVSPER   0.900       2   VLPSIVILGK   0.800       13   ILFLPCISRK   0.800       12   IILFLPCISR   0.240       15   FLPCISRKLK   0.200       16   LPCISRKLKR   0.080       6   IVILGKIILF   0.060       19   ISRKLKRIKK   0.040       18   CISRKLKRIK   0.040       23   LKRIKKGWEK   0.040       46   HVSPERVTVM   0.020       5   SIVILGKIIL   0.012       7   VILGKIILFL   0.012       1   LVLPSIVILG   0.006       35   FLEEGIGGTI   0.004       43   TIPHVSPERV   0.004       33   SQFLEEGIGG   0.002       3   LPSIVILGKI   0.002       11   KIILFLPCIS   0.002       39   GIGGTIPHVS   0.001       8   ILGKIILFLP   0.001       22   KLKRIKKGWE   0.001       10   GKIILFLPCI   0.001       25   RIKKGWEKSQ   0.001       27   KKGWEKSQFL   0.001       21   RKLKRIKKGW   0.000       28   KGWEKSQFLE   0.000       37   EEGIGGTIPH   0.000       14   LFLPCISRKL   0.000       34   QFLEEGIGGY   0.000       26   IKKGWEKSQF   0.000       17   PCISRKLKRI   0.000       29   GWEKSQFLEE   0.000       24   KRIKKGWEKS   0.000       38   EGIGGTIPHV   0.000       41   GGTIPHVSPE   0.000       32   KSQFLEEGIG   0.000       36   LEEGIGGTIP   0.000       31   EKSQFLEEGI   0.000       30   WEKSQFLEEG   0.000       9   LGKIILFLPC   0.000       45   PHVSPERVTV   0.000       44   IPHVSPERVT   0.000       40   IGGTIPHVSP   0.000       4   PSIVILGKII   0.000       20   SRKLKRIKKG   0.000                 V7A-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO:15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FLPNGINGIK   0.400       9   TFLPNGINGI   0.003       2   SPKSLSETFL   0.002       8   ETFLPNGING   0.001       1   GSPKSLSETF   0.001       5   SLSETFLPNG   0.000       6   LSETFLPNGI   0.000       4   KSLSETFLPN   0.000       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V7B-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO:15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       for each peptide is the start position plus       nine.                         10   STLGYVALLI   0.030       7   YQQSTLGYVA   0.012       5   MAYQQSTLGY   0.008       8   QQSTLGYVAL   0.006       6   AYQQSTLGYV   0.004       3   LNMAYQQSTL   0.001       2   FLNMAYQQST   0.000       4   NMAYQQSTLG   0.000       1   LFLNMAYQQS   0.000       9   QSTLGYVALL   0.000                 V7C-HLA-A1101-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO:15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       for each peptide is the start position plus       nine.                         173   ILSKLTQEQK   0.400       13   VLASPAAAWK   0.400       38   LPIEWQQDRK   0.300       109   RALKAANSWR   0.180       127   GVGPLWEFLL   0.180       159   EFLGSGTWMK   0.180       100   SIDPPESPDR   0.080       37   VLPIEWQQDR   0.080       167   MKLETIILSK   0.060       164   GTWMKLETII   0.060       146   GTLSLAFTSW   0.045       131   LWEFLLRLLK   0.040       67   TAEAQESGIR   0.040       4   IVILDLSVEV   0.030       103   PPESPDRALK   0.020       10   SVEVLASPAA   0.020       129   GPLWEFLLRL   0.018       175   SKLTQEQKSK   0.015       176   KLTQEQKSKH   0.012       141   SQAASGTLSL   0.012       168   KLETIILSKL   0.012       66   ATAEAQESGI   0.012       152   FTSWSLGEFL   0.010       12   EVLASPAAAW   0.010       89   GVVTEDDEAQ   0.009       160   FLGSGTWMKL   0.009       21   WKCLGANILR   0.008       128   VGPLWEFLLR   0.008       5   VILDLSVEVL   0.006       112   KAANSWRNPV   0.006       134   FLLRLLKSQA   0.006       69   EAQESGIRNK   0.006       27   NILRGGLSEI   0.006       178   TQEQKSKHCM   0.006       42   WQQDRKIPPL   0.006       6   ILDLSVEVLA   0.004       135   LLRLLKSQAA   0.004       143   AASGTLSLAF   0.004       19   AAWKCLGANI   0.004       28   ILRGGLSEIV   0.004       158   GEFLGSGTWM   0.004       36   IVLPIEWQQD   0.003       119   NPVLPHTNGV   0.003       124   HTNGVGPLWE   0.002       113   AANSWRNPVL   0.002       122   LPHTNGVGPL   0.002       52   STPPPPAMWT   0.002       90   VVTEDDEAQD   0.002       142   QAASGTLSLA   0.002       87   VVGVVTEDDE   0.002       151   AFTSWSLGEF   0.002       31   GGLSEIVLPI   0.002       137   RLLKSQAASG   0.002       22   KCLGANILRG   0.002       74   GIRNKSSSSS   0.001       47   KIPPLSTPPP   0.001       32   GLSEIVLPIE   0.001       76   RNKSSSSSQI   0.001       78   KSSSSSQIPV   0.001       60   WTEEAGATAE   0.001       91   VTEDDEAQDS   0.001       83   SQIPVVGVVT   0.001       170   ETIILSKLTQ   0.001       11   VEVLASPAAA   0.001       165   TWMKLETIIL   0.001       125   TNGVGPLWEF   0.001       110   ALKAANSWRN   0.001       166   WMKLETIILS   0.001       115   NSWRNPVLPH   0.001       150   LAFTSWSLGE   0.001       58   AMWTEEAGAT   0.001       3   SIVILDLSVE   0.001       182   KSKHCMFSLI   0.001       171   TIILSKLTQE   0.001       70   AQESGIRNKS   0.001       181   QKSKHCMFSL   0.001       172   IILSKLTQEQ   0.001       148   LSLAFTSWSL   0.001       65   GATAEAQESG   0.001       25   GANILRGGLS   0.001       97   AQDSIDPPES   0.001       43   QQDRKIPPLS   0.001       92   TEDDEAQDSI   0.001       61   TEEAGATAEA   0.001       179   QEQKSKHCMF   0.001       177   LTQEQKSKHC   0.001       147   TLSLAFTSWS   0.000       121   VLPHTNGVGP   0.000       17   PAAAWKCLGA   0.000       138   LLKSQAASGT   0.000       29   LRGGLSEIVL   0.000       53   TPPPPAMWTE   0.000       14   LASPAAAWKC   0.000       84   QIPVVGVVTE   0.000       50   PLSTPPPPAM   0.000       185   HCMFSLISGS   0.000       57   PAMWTEEAGA   0.000       149   SLAFTSWSLG   0.000       33   LSEIVLPIEW   0.000       156   SLGEFLGSGT   0.000                    
     [1184]                       TABLE XVI                       Start   Subsequence   Score                                    V1-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         287   KYRRFPPWL   400.000       426   FYTPPNFVL   240.000       337   AYQQVHANI   105.000       283   YYGTKYRRF   100.000       228   LYSFVRDVI   70.000       390   EFSFIQSTL   28.000       362   SFGIMSLGL   20.000       418   AFEEEYYRF   18.000       330   RYLFLNMAY   18.000       378   SIPSVSNAL   10.080       124   QYPESNAEY   9.900       399   GYVALLIST   9.000       177   QVIELARQL   8.640       184   QLNFIPIDL   8.400       258   TLPIVAITL   8.400       313   AMVHVAYSL   8.400       214   GPVVVAISL   8.400       246   DFYKIPIEI   7.700       270   VYLAGLLAA   7.500       359   MYISFGIMS   7.500       268   SLVYLAGLL   7.200       291   FPPWLETWL   7.200       366   MSLGLLSLL   7.200       220   ISLATFFFL   7.200       403   LLISTFHVL   7.200       303   KQLGLLSFF   7.200       436   LVLPSIVIL   7.200       200   EIENLPLRL   7.200       61   RNPKFASEF   6.600       428   TPPNFVLAL   6.000       274   GLLAAAYQL   6.000       125   YPESNAEYL   6.000       363   FGIMSLGLL   6.000       264   ITLLSLVYL   6.000       396   STLGYVALL   6.000       297   TWLQCRKQL   6.000       259   LPIVAITLL   6.000       5   SMMGSPKSL   6.000       203   NLPLRLFTL   6.000       441   IVILDLLQL   6.000       187   FIPIDLGSL   6.000       146   FNVVSAWAL   6.000       267   LSLVYLAGL   6.000       99   TSLWDLRHL   6.000       100   SLWDLRHLL   5.760       438   LPSIVILDL   5.600       85   KTNIIFVAI   5.040       247   FYKIPIEIV   5.000       423   YYRFYTPPN   5.000       128   SNAEYLASL   4.800       41   FAKSLTIRL   4.800       37   GSGDFAKSL   4.800       173   QARQQVIEL   4.400       300   QCRKQLGLL   4.000       75   DVTHHEDAL   4.000       395   QSTLGYVAL   4.000       299   LQCRKQLGL   4.000       133   LASLFPDSL   4.000       365   IMSLGLLSL   4.000       148   VVSAWALQL   4.000       360   YISFGIMSL   4.000       261   IVAITLLSL   4.000       196   SSAREIENL   4.000       129   NAEYLASLF   3.600       218   VAISLATFF   3.600       385   ALNWREFSF   3.000       33   VGVIGSGDF   3.000       400   YVALLISTF   2.400       304   QLGLLSFFF   2.400       383   SNALNWREF   2.200       57   VIGSRNPKF   2.200       223   ATFFFLYSF   2.000       411   LIYGWKRAF   2.000       219   AISLATFFF   2.000       62   NPKFASEFF   2.000       82   ALTKTNIIF   2.000       239   YARNQQSDF   2.000       217   VVAISLATF   2.000       242   NQQSDFYKI   1.980       81   DALTKTNII   1.800       17   CLPNGINGI   1.800       349   WNEEEVWRI   1.800       171   NIQARQQVI   1.800       290   RFPPWLETW   1.800       105   RHLLVGKIL   1.680       193   GSLSSAREI   1.650       112   ILIDVSNNM   1.512       435   ALVLPSIVI   1.500       106   HLLVGKILI   1.500       134   ASLFPDSLI   1.500       253   EIVNKTLPI   1.500       371   LSLLAVTSI   1.500       353   EVWRIEMYI   1.400       397   TLGYVALLI   1.400       433   VLALVLPSI   1.400       186   NFIPIDLGS   1.260       164   QVYICSNNI   1.200       180   ELARQLNFI   1.200       425   RFYTPPNFV   1.200       386   LNWREFSFI   1.200                 V2-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   GLQALSLSL   7.200       17   FTPFSCLSL   6.000       1   SGSPGLQAL   5.760       15   SGFTPFSCL   4.800       3   SPGLQALSL   4.000       33   CPPPCPADF   3.600       9   LSLALSSGF   3.600       37   CPADFFLYF   2.880       12   SLSSGFTPF   2.400       16   GFTPFSCLS   0.600       30   DYRCPPPCP   0.500       35   PPCPADFFL   0.480       34   PPPCPADFF   0.300       23   LSLPSSWDY   0.180       2   GSPGLQALS   0.180       21   SCLSLPSSW   0.180       7   QALSLSLSS   0.180       14   SSGFTPFSC   0.100       10   SLSLSSGFT   0.100       6   LQALSLSLS   0.100       25   LPSSWDYRC   0.100       13   LSSGFTPFS   0.100       20   FSCLSLPSS   0.100       19   PFSCLSLPS   0.060       32   RCPPPCPAD   0.036       36   PCPADFFLY   0.018       24   SLPSSWDYR   0.015       4   PGLQALSLS   0.015       11   LSLSSGFTP   0.015       27   SSWDYRCPP   0.012       31   YRCPPPCPA   0.012       18   TPFSCLSLP   0.010       29   WDYRCPPPC   0.010       8   ALSLSLSSG   0.010       28   SWDYRCPPP   0.010       22   CLSLPSSWD   0.010       26   PSSWDYRCP   0.001                 V5A-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         1   NLPLRLFTF   3.000       8   TFWRGPVVV   0.500       6   LFTFWRGPV   0.500       2   LPLRLFTFW   0.216       7   FTFWRGPVV   0.100       9   FWRGPVVVA   0.100       5   RLFTFWRGP   0.020       4   LRLFTFWRG   0.002       3   PLRLFTFWR   0.001                 V5B-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         23   EFVFLLTLL   36.000       12   SFADTQTEL   26.400       5   SFIQIFCSF   25.200       19   ELELEFVFL   7.200       24   FVFLLTLLL   4.800       16   TQTELELEF   3.168       20   LELEFVFLL   0.720       3   EFSFIQIFC   0.700       2   REFSFIQIF   0.480       14   ADTQTELEL   0.440       18   TELELEFVF   0.432       22   LEFVFLLTL   0.400       21   ELEFVFLLT   0.252       1   WREFSFIQI   0.180       6   FIQIFCSFA   0.150       17   QTELELEFV   0.150       8   QIFCSFADT   0.120       10   FCSFADTQT   0.100       4   FSFIQIFCS   0.100       9   IFCSFADTQ   0.050       7   IQIFCSFAD   0.015       15   DTQTELELE   0.015       11   CSFADTQTE   0.012       13   FADTQTELE   0.010                 V6-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         27   KGWEKSQFL   11.520       14   FLPCISRKL   9.240       5   IVILGKIIL   6.000       7   ILGKIILFL   5.600       31   KSQFLEEGI   3.600       10   KIILFLPCI   3.000       6   VILGKIILF   3.000       4   SIVILGKII   1.800       17   CISRKLKRI   1.000       46   VSPERVTVM   0.900       26   KKGWEKSQF   0.400       21   KLKRIKKGW   0.280       3   PSIVILGKI   0.231       24   RIKKGWEKS   0.220       35   LEEGIGGTI   0.210       34   FLEEGIGGT   0.180       11   IILFLPCIS   0.180       39   IGGTIPHVS   0.140       45   HVSPERVTV   0.120       38   GIGGTIPHV   0.100       43   IPHVSPERV   0.100       33   QFLEEGIGG   0.090       13   LFLPCISRK   0.090       42   TIPHVSPER   0.023       9   GKIILFLPC   0.022       1   VLPSIVILG   0.021       41   GTIPHVSPE   0.018       28   GWEKSQFLE   0.015       37   EGIGGTIPH   0.015       2   LPSIVILGK   0.014       8   LGKIILFLP   0.014       18   ISRKLKRIK   0.012       32   SQFLEEGIG   0.010       40   GGTIPHVSP   0.010       15   LPCISRKLK   0.010       12   ILFLPCISR   0.010       23   KRIKKGWEK   0.003       20   RKLKRIKKG   0.003       16   PCISRKLKR   0.002       44   PHVSPERVT   0.002       29   WEKSQFLEE   0.001       19   SRKLKRIKK   0.001       30   EKSQFLEEG   0.001       22   LKRIKKGWE   0.001       25   IKKGWEKSQ   0.001       36   EEGIGGTIP   0.001                 V7A-HLA-A24-9mers-98P4B6       Each peptide is a portion for SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         1   SPKSLSETF   2.400       9   FLPNGINGI   1.800       4   SLSETFLPN   0.144       6   SETFLPNGI   0.144       7   ETFLPNGIN   0.100       8   TFLPNGING   0.090       2   PKSLSETFL   0.040       3   KSLSETFLP   0.030       5   LSETFLPNG   0.015                 V7B-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   AYQQSTLGY   7.500       9   STLGYVALL   6.000       8   QSTLGYVAL   4.000       3   NMAYQQSTL   4.000       1   FLNMAYQQS   0.180       2   LNMAYQQST   0.180       6   YQQSTLGYV   0.150       7   QQSTLGYVA   0.120       4   MAYQQSTLG   0.010                 V7C-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         139   KSQAASGTL   12.000       29   RGGLSEIVL   8.000       181   KSKHCMFSL   8.000       130   LWEFLLRLL   7.200       24   GANILRGGL   7.200       127   VGPLWEFLL   6.000       126   GVGPLWEFL   5.760       152   TSWSLGEFL   4.800       160   LGSGTWMKL   4.400       148   SLAFTSWSL   4.000       42   QQDRKIPPL   4.000       15   SPAAAWKCL   4.000       141   QAASGTLSL   4.000       5   ILDLSVEVL   4.000       165   WMKLETIIL   4.000       113   ANSWRNPVL   4.000       158   EFLGSGTWM   3.750       125   NGVGPLWEF   3.300       143   ASGTLSLAF   2.400       151   FTSWSLGEF   2.200       179   EQKSKHCMF   2.000       164   TWWKLETII   1.800       31   GLSEIVLPI   1.680       66   TAEAQESGI   1.500       19   AWKCLGANI   1.200       27   ILRGGLSEI   1.100       163   GTWMKLETI   1.000       132   EFLLRLLKS   0.825       168   LETIILSKL   0.616       102   PPESPDRAL   0.600       50   LSTPPPPAM   0.600       129   PLWEFLLRL   0.480       20   WKCLGANIL   0.480       108   RALKAANSW   0.360       117   RNPVLPHTN   0.360       136   RLLKSQAAS   0.300       82   SQIPVVGVV   0.252       4   VILDLSVEV   0.238       123   HTNGVGPLW   0.210       83   QIPVVGVVT   0.210       104   ESPDRALKA   0.198       51   STPPPPAMW   0.180       145   GTLSLAFTS   0.180       154   WSLGEFLGS   0.180       68   EAQESGIRN   0.180       9   SVEVLASPA   0.180       59   WTEEAGATA   0.180       156   LGEFLGSGT   0.180       52   TPPPPAMWT   0.180       112   AANSWRNPV   0.180       101   DPPESPDRA   0.180       2   SIVILDLSV   0.180       169   ETIILSKLT   0.180       88   GVVTEDDEA   0.165       14   ASPAAAWKC   0.165       25   ANILRGGLS   0.150       72   SGIRNKSSS   0.150       11   EVLASPAAA   0.150       81   SSQIPVVGV   0.150       177   TQEQKSKHC   0.150       147   LSLAFTSWS   0.150       64   GATAEAQES   0.132       134   LLRLLKSQA   0.120       146   TSLSAFTSW   0.120       185   CMFSLISGS   0.120       182   SKHCMFSLI   0.120       58   MWTEEAGAT   0.120       92   EDDEAQDSI   0.120       39   IEWQQDRKI   0.110       162   SGTWMKLET   0.110       17   AAAWKCLGA   0.100       79   SSSSQIPVVV   0.100       140   SQAASGTLS   0.100       76   NKSSSSSQI   0.100       142   AASGTLSLA   0.100       105   SPDRALKAA   0.100       57   AMWTEEAGA   0.100       144   SGTLSLAFT   0.100       18   AAWKCLGAN   0.100       7   DLSVEVLAS   0.100       78   SSSSSQIPV   0.100       12   VLASPAAAW   0.100       73   GIRNKSSSS   0.100       71   ESGIRNKSS   0.100       178   QEQKSKHCM   0.075       150   AFTSWSLGE   0.050       46   KIPPLSTPP   0.043       167   KLETIILSK   0.042       122   PHTNGVGPL   0.040       21   KCLGANILR   0.030       116   WRNPVLPHT   0.025       35   IVLPIEWQQ   0.025       8   LSVEVLASP   0.025       77   KSSSSSQIP   0.024       119   PVLPHTNGV   0.022       37   LPIEWQQDR   0.022       1   PSIVILDLS   0.021       6   LDLSVEVLA   0.021       32   LSEIVLPIE   0.021       183   KHCMFSLIS   0.020                    
     [1185]                       TABLE XVII                       Start   Subsequence   Score                                    V1-HLA-A24-10-mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         124   QYPESNAEYL   360.000       359   MYISFGIMSL   300.000       399   GYVALLISTF   180.000       282   LYYGTKYRRF   100.000       423   YYRFYTPPNF   100.000       290   RFPPWLETWL   86.400       425   RFYTPPNFVL   40.000       186   NFIPIDLGSL   36.000       145   GFNVVSAWAL   30.000       40   DFAKSLTIRL   24.000       257   KTLPIVAITL   20.160       362   SFGIMSLGLL   20.000       213   RGPVVVAISL   16.800       183   RQLNFIPIDL   16.800       377   TSIPSVSNAL   12.096       131   EYLASLFPDS   10.800       250   IPIEIVNKTL   10.080       238   PYARNQQSDF   10.000       270   VYLAGLLAAA   9.000       437   VLPSIVILDL   8.400       312   FAMVHVAYSL   8.400       279   AYQLYYGTKY   8.250       165   VYICSNNIQA   7.500       176   QQVIELARQL   7.200       202   ENLPLRLFTL   7.200       99   TSLWDLRHLL   7.200       427   YTPPNFVLAL   7.200       303   KQLGLLSFFF   7.200       267   LSLVYLAGLL   7.200       426   FYTPPNFVLA   7.200       402   ALLISTFHVL   7.200       53   GYHVVIGSRN   7.000       247   FYKIPIEIVN   7.000       364   GIMSLGLLSL   6.000       127   ESNAEYLASL   6.000       61   RNPKFASEFF   6.000       298   WLQCRKQLGL   6.000       4   ISMMGSPKSL   6.000       273   AGLLAAAYQL   6.000       323   LPMRRSERYL   6.000       147   NVVSAWALQL   6.000       435   ALVLPSIVIL   6.000       440   SIVILDLLQL   6.000       258   TLPIVAITLL   6.000       438   LPSIVILDLL   5.600       422   EYYRFYTPPN   5.000       219   AISLATFFFL   4.800       417   RAFEEEYYRF   4.800       365   IMSLGLLSLL   4.800       197   SAREIENLPL   4.800       172   IQARQQVIEL   4.400       356   RIEMYISFGI   4.200       36   IGSGDFAKSL   4.000       98   YTSLWDLRHL   4.000       132   YLASLFPDSL   4.000       296   ETWLQCRKQL   4.000       266   LLSLVYLAGL   4.000       195   LSSAREIENL   4.000       314   MVHVAYSLCL   4.000       263   AITLLSLVYL   4.000       299   LQCRKQLGLL   4.000       92   AIHREHYTSL   4.000       361   ISFGIMSLGL   4.000       9   SPKSLSETCL   4.000       395   QSTLGYVALL   4.000       394   IQSTLGYVAL   4.000       241   RNQQSDFYKI   3.960       163   RQVYICSNNI   3.600       382   VSNALNWREF   3.300       56   VVIGSRNPKF   3.300       384   NALNWREFSF   3.000       410   VLIYGWKRAF   3.000       216   VVVAISLATF   3.000       178   VIELARQLNF   3.000       218   VAISLATFFF   3.000       200   EIENLPLRLF   3.000       81   DALTKTNIIF   3.000       128   SNAEYLASLF   2.880       137   FPDSLIVKGF   2.800       111   KILIDVSNNM   2.520       217   VVAISLATFF   2.400       16   TCLPNGINGI   2.160       327   RSERYLFLNM   2.160       13   LSETCLPNGI   2.160       396   STLGYVALLI   2.100       432   FVLALVLPSI   2.100       354   VWRIEMYISF   2.000       222   LATFFFLYSF   2.000       32   TVGVIGSGDF   2.000       385   ALNWREFSFI   1.800       170   NNIQARQQVI   1.800       348   SWNEEEVWRI   1.800       199   REIENLPLRL   1.728       403   LLISTFHVLI   1.500       330   RYLFLNMAYQ   1.500       434   LALVLPSIVI   1.500       211   LWRGPVVVAI   1.400       336   MAYQQVHANI   1.400       227   FLYSFVRDVI   1.400       103   DLRHLLVGKI   1.320                 V2-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         16   GFTPFSCLSL   24.000       32   RCPPPCPADF   7.200       2   GSPGLQALSL   6.000       30   DYRCPPPCPA   5.000       14   SSGFTPFSCL   4.800       11   LSLSSGFTPF   3.600       33   CPPPCPADFF   3.600       8   ALSLSLSSGF   2.400       4   PGLQALSLSL   0.720       34   PPPCPADFFL   0.600       36   PCPADFFLYF   0.360       9   LSLSLSSGFT   0.150       5   GLQALSLSLS   0.150       24   SLPSSWDYRC   0.150       1   SGSPGLQALS   0.144       6   LQALSLSLSS   0.120       20   FSCLSLPSSW   0.120       18   TPFSCLSLPS   0.120       15   SGFTPFSCLS   0.100       12   SLSSGFTPFS   0.100       28   SWDYRCPPPC   0.100       13   LSSGFTPFSC   0.100       3   SPGLQALSLS   0.100       22   CLSLPSSWDY   0.100       19   PFSCLSLPSS   0.050       23   LSLPSSWDYR   0.018       7   QALSLSLSSG   0.015       17   FTPFSCLSLP   0.015       21   SCLSLPSSWD   0.015       35   PPCPADFFLY   0.014       27   SSWDYRCPPP   0.012       25   LPSSWDYRCP   0.010       10   SLSLSSGFTP   0.001       31   YRCPPPCPAD   0.001       29   WDYRCPPPCP   0.001       26   PSSWDYRCPP   0.001                 V5A-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         1   ENLPLRLFTF   3.600       10   FWRGPVVVAI   1.400       7   LFTFWRGPVV   0.500       9   TFWRGPVVVA   0.500       2   NLPLRLFTFW   0.216       6   RLFTFWRGPV   0.200       8   FTFWRGPVVV   0.100       3   LPLRLFTFWR   0.015       5   LRLFTFWRGP   0.002       4   PLRLFTFWRG   0.001                 V5B-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         24   EFVFLLTLLL   36.000       22   ELEFVFLLTL   6.000       20   ELELEFVFLL   6.000       12   CSFADTQTEL   4.400       14   FADTQTELEL   4.400       16   DTQTELELEF   3.960       18   QTELELEFVF   3.600       5   FSFIQIFCSF   3.360       1   NWREFSFIQI   1.440       19   TELELEFVFL   0.864       6   SFIQIFCSFA   0.750       4   EFSFIQIFCS   0.500       10   IFCSFADTQT   0.500       23   LEFVFLLTLL   0.480       2   WREFSFIQIF   0.360       8   IQIFCSFADT   0.180       17   TQTELELEFV   0.120       13   SFADTQTELE   0.060       21   LELEFVFLLT   0.030       3   REFSFIQIFC   0.028       7   FIQIFCSFAD   0.015       11   FCSFADTQTE   0.012       9   QIFCSFADTQ   0.010       15   ADTQTELELE   0.001                 V6-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         14   LFLPCISRKL   55.440       7   VILGKIILFL   8.400       5   SIVILGKIIL   6.000       6   IVILGKIILF   3.000       35   FLEEGIGGTI   2.520       3   LPSIVILGKI   1.540       27   KKGWEKSQFL   0.960       34   QFLEEGIGGT   0.900       46   HVSPERVTVM   0.600       11   KIILFLPCIS   0.360       26   IKKGWEKSQF   0.200       4   PSIVILGKII   0.180       38   EGIGGTIPHV   0.150       17   PCISRKLKRI   0.150       43   TIPHVSPERV   0.150       10   GKIILFLPCI   0.150       9   LGKIILFLPC   0.144       39   GIGGTIPHVS   0.140       31   EKSQFLEEGI   0.120       44   IPHVSPERVT   0.100       21   RKLKRIKKGW   0.042       24   KRIKKGWEKS   0.033       32   KSQFLEEGIG   0.030       42   GTIPHVSPER   0.028       1   LVLPSIVILG   0.025       28   KGWEKSQFLE   0.024       2   VLPSIVILGK   0.021       25   RIKKGWEKSQ   0.020       22   KLKRIKKGWE   0.020       29   GWEKSQFLEE   0.020       12   IILFLPCISR   0.015       15   FLPCISRKLK   0.015       8   ILGKIILFLP   0.014       18   CISRKLKRIK   0.012       16   LPCISRKLKR   0.011       19   ISRKLKRIKK   0.011       33   SQFLEEGIGG   0.010       41   GGTIPHVSPE   0.010       40   IGGTIPHVSP   0.010       13   ILFLPCISRK   0.010       36   LEEGIGGTIP   0.002       45   PHVSPERVTV   0.002       20   SRKLKRIKKG   0.001       30   WEKSQFLEEG   0.001       23   LKRIKKGWEK   0.001       37   EEGIGGTIPH   0.001                 V7A-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   TFLPNGINGI   10.800       2   SPKSLSETFL   4.000       1   GSPKSLSETF   3.600       6   LSETFLPNGI   2.160       4   KSLSETFLPN   0.360       10   FLPNGINGIK   0.021       5   SLSETFLPNG   0.012       7   SETFLPNGIN   0.010       8   ETFLPNGING   0.010       3   PKSLSETFLP   0.000                 V7B-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         6   AYQQSTLGYV   7.500       3   LNMAYQQSTL   6.000       8   QQSTLGYVAL   4.000       9   QSTLGYVALL   4.000       10   STLGYVALLI   2.100       1   LFLNMAYQQS   0.900       7   YQQSTLGYVA   0.180       2   FLNMAYQQST   0.180       5   MAYQQSTLGY   0.100       4   NMAYQQSTLG   0.010                 V7C-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         168   KLETIILSKL   18.480       151   AFTSWSLGEF   11.000       5   VILDLSVEVL   7.200       42   WQQDRKIPPL   7.200       126   NGVGPLWEFL   7.200       102   DPPESPDRAL   7.200       113   AANSWRNPVL   6.000       129   GPLWEFLLRL   6.000       148   LSLAFTSWSL   6.000       15   ASPAAAWKCL   6.000       165   TWMKLETIIL   6.000       24   LGANILRGGL   4.800       20   AWKCLGANIL   4.800       127   GVGPLWEFLL   4.800       152   FTSWSLGEFL   4.800       160   FLGSGTWMKL   4.400       122   LPHTNGVGPL   4.000       141   SQAASGTLSL   4.000       182   KSKHCMFSLI   2.400       143   AASGTLSLAF   2.400       125   TNGVGPLWEF   2.200       31   GGLSEIVLPI   2.100       76   RNKSSSSSQI   2.000       27   NILRGGLSEI   1.650       164   GTWMKLETII   1.200       19   AAWKCLGANI   1.200       66   ATAEAQESGI   1.200       163   SGTWMKLETI   1.000       178   TQEQKSKHCM   0.750       130   PLWEFLLRLL   0.576       29   LRGGLSEIVL   0.400       181   QKSKHCMFSL   0.400       139   LKSQAASGTL   0.400       179   QEQKSKHCMF   0.300       140   KSQAASGTLS   0.300       70   AQESGIRNKS   0.277       83   SQIPVVGVVT   0.252       112   KAANSWRNPV   0.240       91   VTEDDEAQDS   0.216       9   LSVEVLASPA   0.216       82   SSQIPVVGVV   0.210       78   KSSSSSQIPV   0.200       4   IVILDLSVEV   0.198       33   LSEIVLPIEW   0.198       119   NPVLPHTNGV   0.180       105   ESPDRALKAA   0.180       52   STPPPPAMWT   0.180       177   LTQEQKSKHC   0.180       134   FLLRLLKSQA   0.180       185   HCMFSLISGS   0.180       146   GTLSLAFTSW   0.180       39   PIEWQQDRKI   0.165       88   VGVVTEDDEA   0.165       10   SVEVLASPAA   0.150       73   SGIRNKSSSS   0.150       25   GANILRGGLS   0.150       157   LGEFLGSGTW   0.150       12   EVLASPAAAW   0.150       156   SLGEFLGSGT   0.144       1   LPSIVILDLS   0.140       6   ILDLSVEVLA   0.140       116   SWRNPVLPHT   0.140       43   QQDRKIPPLS   0.140       64   AGATAEAQES   0.132       14   LASPAAAWKC   0.132       174   LSKLTQEQKS   0.132       51   LSTPPPPAMW   0.120       92   TEDDEAQDSI   0.120       135   LLRLLKSQAA   0.120       106   SPDRALKAAN   0.120       59   MWTEEAGATA   0.120       28   ILRGGLSEIV   0.120       154   SWSLGEFLGS   0.120       145   SGTLSLAFTS   0.120       162   GSGTWMKLET   0.110       97   AQDSIDPPES   0.110       147   TLSLAFTSWS   0.100       180   EQKSKHCMFS   0.100       79   SSSSSQIPVV   0.100       142   QAASGTLSLA   0.100       18   AAAWKCLGAN   0.100       138   LLKSQAASGT   0.100       110   ALKAANSWRN   0.100       144   ASGTLSLAFT   0.100       74   GIRNKSSSSS   0.100       81   SSSQIPVVGV   0.100       166   WMKLETIILS   0.100       72   ESGIRNKSSS   0.100       58   AMWTEEAGAT   0.100       133   EFLLRLLKSQ   0.090       159   EFLGSGTWMK   0.075       158   GEFLGSGTWM   0.050       50   PLSTPPPPAM   0.050       47   KIPPLSTPPP   0.036       22   KCLGANILRG   0.030       118   RNPVLPHTNG   0.030       109   RALKAANSWR   0.030       137   RLLKSQAASG   0.030       96   EAQDSIDPPE   0.025       172   IILSKLTQEQ   0.024                    
     [1186]                       TABLE XVIII                       Start   Subsequence   Score                                    V1-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         173   QARQQVIEL   120.000       214   GPVVVAISL   80.000       259   LPIVAITLL   80.000       428   TPPNFVLAL   80.000       438   LPSIVILDL   80.000       291   FPPWLETWL   80.000       300   QCRKQLGLL   40.000       125   YPESNAEYL   24.000       177   QVIELARQL   20.000       148   VVSAWALQL   20.000       261   IVAITLLSL   20.000       75   DVTHHEDAL   20.000       441   IVILDLLQL   20.000       436   LVLPSIVIL   20.000       41   FAKSLTIRL   12.000       313   AMVHVAYSL   12.000       133   LASLFPDSL   12.000       5   SMMGSPKSL   12.000       27   DARKVTVGV   6.000       100   SLWDLRHLL   6.000       146   FNVVSAWAL   4.000       220   ISLATFFFL   4.000       187   FIPIDLGSL   4.000       128   SNAEYLASL   4.000       363   FGIMSLGLL   4.000       274   GLLAAAYQL   4.000       365   IMSLGLLSL   4.000       366   MSLGLLSLL   4.000       184   QLNFIPIDL   4.000       93   IHREHYTSL   4.000       324   PMRRSERYL   4.000       395   QSTLGYVAL   4.000       267   LSLVYLAGL   4.000       268   SLVYLAGLL   4.000       360   YISFGIMSL   4.000       196   SSAREIENL   4.000       378   SIPSVSNAL   4.000       258   TLPIVAITL   4.000       299   LQCRKQLGL   4.000       99   TSLWDLRHL   4.000       403   LLISTFHVL   4.000       37   GSGDFAKSL   4.000       203   NLPLRLFTL   4.000       264   ITLLSLVYL   4.000       396   STLGYVALL   4.000       287   KYRRFPPWL   4.000       157   GPKDASRQV   4.000       317   VAYSLCLPM   3.000       9   SPKSLSETC   2.000       250   IPIEIVNKT   2.000       353   EVWRIEMYI   2.000       49   LIRCGYHVV   2.000       164   QVYICSNNI   2.000       134   ASLFPDSLI   1.800       435   ALVLPSIVI   1.800       200   EIENLPLRL   1.200       81   DALTKTNII   1.200       323   LPMRRSERY   1.200       108   LVGKILIDV   1.000       358   EMYISFGIM   1.000       112   ILIDVSNNM   1.000       254   IVNKTLPIV   1.000       231   FVRDVIHPY   1.000       328   SERYLFLNM   1.000       306   GLLSFFFAM   1.000       278   AAYQLYYGT   0.900       402   ALLISTFHV   0.600       297   TWLQCRKQL   0.600       262   VAITLLSLV   0.600       239   YARNQQSDF   0.600       434   LALVLPSIV   0.600       65   FASEFFPHV   0.600       161   ASRQVYICS   0.600       426   FYTPPNFVL   0.600       374   LAVTSIPSV   0.600       314   MVHVAYSLC   0.500       34   GVIGSGDFA   0.500       216   VVVAISLAT   0.500       269   LVYLAGLLA   0.500       237   HPYARNQQS   0.400       371   LSLLAVTSI   0.400       85   KTNIIFVAI   0.400       390   EFSFIQSTL   0.400       439   PSIVILDLL   0.400       397   TLGYVALLI   0.400       430   PNFVLALVL   0.400       362   SFGIMSLGL   0.400       171   NIQARQQVI   0.400       180   ELARQLNFI   0.400       193   GSLSSAREI   0.400       386   LNWREFSFI   0.400       204   LPLRLFTLW   0.400       429   PPNFVLALV   0.400       188   IPIDLGSLS   0.400       379   IPSVSNALN   0.400       62   NPKFASEFF   0.400       326   RRSERYLFL   0.400       433   VLALVLPSI   0.400       253   EIVNKTLPI   0.400       106   HLLVGKILI   0.400                 V2-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         3   SPGLQALSL   80.000       35   PPCPADFFL   8.000       15   SGFTPFSCL   6.000       1   SGSPGLQAL   4.000       17   FTPFSCLSL   4.000       5   GLQALSLSL   4.000       25   LPSSWDYRC   2.000       37   CPADFFLYF   0.400       33   CPPPCPADF   0.400       18   TPFSCLSLP   0.200       10   SLSLSSGFT   0.100       14   SSGFTPFSC   0.100       7   QALSLSLSS   0.060       34   PPPCPADFF   0.060       8   ALSLSLSSG   0.030       23   LSLPSSWDY   0.020       12   SLSSGFTPF   0.020       21   SCLSLPSSW   0.020       6   LQALSLSLS   0.020       13   LSSGFTPFS   0.020       2   GSPGLQALS   0.020       9   LSLSLSSGF   0.020       20   FSCLSLPSS   0.020       32   RCPPPCPAD   0.015       22   CLSLPSSWD   0.015       31   YRCPPPCPA   0.015       30   DYRCPPPCP   0.015       27   SSWDYRCPP   0.015       29   WDYRCPPPC   0.010       24   SLPSSWDYR   0.010       11   LSLSSGFTP   0.010       36   PCPADFFLY   0.002       16   GFTPFSCLS   0.002       4   PGLQALSLS   0.002       26   PSSWDYRCP   0.001       28   SWDYRCPPP   0.000       19   PFSCLSLPS   0.000                 V5A-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         2   LPLRLFTFW   0.400       7   FTFWRGPVV   0.200       9   FWRGPVVVA   0.150       6   LFTFWRGPV   0.030       8   TFWRGPVVV   0.020       1   NLPLRLFTF   0.020       3   PLRLFTFWR   0.010       5   RLFTFWRGP   0.010       4   LRLFTFWRG   0.001                 V5B-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         24   FVFLLTLLL   20.000       14   ADTQTELEL   1.200       19   ELELEFVFL   1.200       12   SFADTQTEL   0.400       23   EFVFLLTLL   0.400       22   LEFVFLLTL   0.400       20   LELEFVFLL   0.400       10   FCSFADTQT   0.100       8   QIFCSFADT   0.100       6   FIQIFCSFA   0.100       17   QTELELEFV   0.060       21   ELEFVFLLT   0.030       4   FSFIQIFCS   0.020       16   TQTELELEF   0.020       1   WREFSFIQI   0.012       11   CSFADTQTE   0.010       3   EFSFIQIFC   0.010       7   IQIFCSFAD   0.010       15   DTQTELELE   0.010       13   FADTQTELE   0.009       5   SFIQIFCSF   0.002       2   REFSFIQIF   0.002       18   TELELEFVF   0.002       9   IFCSFADTQ   0.001                 V6-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         5   IVILGKIIL   20.000       14   FLPCISRKL   4.000       43   IPHVSPERV   4.000       7   ILGKIILFL   4.000       27   KGWEKSQFL   4.000       45   HVSPERVTV   1.500       46   VSPERVTVM   1.000       31   KSQFLEEGI   0.400       4   SIVILGKII   0.400       17   CISRKLKRI   0.400       10   KIILFLPCI   0.400       15   LPCISRKLK   0.300       38   GIGGTIPHV   0.200       2   LPSIVILGK   0.200       18   ISRKLKRIK   0.100       3   PSIVILGKI   0.040       34   FLEEGIGGT   0.030       11   IILFLPCIS   0.020       39   IGGTIPHVS   0.020       6   VILGKIILF   0.020       24   RIKKGWEKS   0.020       21   KLKRIKKGW   0.020       40   GGTIPHVSP   0.015       12   ILFLPCISR   0.015       35   LEEGIGGTI   0.012       37   EGIGGTIPH   0.010       22   LKRIKKGWE   0.010       8   LGKIILFLP   0.010       32   SQFLEEGIG   0.010       41   GTIPHVSPE   0.010       1   VLPSIVILG   0.010       9   GKIILFLPC   0.010       42   TIPHVSPER   0.010       26   KKGWEKSQF   0.002       19   SRKLKRIKK   0.002       44   PHVSPERVT   0.002       36   EEGIGGTIP   0.001       20   RKLKRIKKG   0.001       29   WEKSQFLEE   0.001       13   LFLPCISRK   0.001       25   IKKGWEKSQ   0.001       30   EKSQFLEEG   0.001       33   QFLEEGIGG   0.001       23   KRIKKGWEK   0.001       16   PCISRKLKR   0.001       28   GWEKSQFLE   0.000                 V7A-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   FLPNGINGI   0.400       1   SPKSLSETF   0.400       6   SETFLPNGI   0.040       2   PKSLSETFL   0.040       7   ETFLPNGIN   0.030       4   SLSETFLPN   0.020       3   KSLSETFLP   0.010       5   LSETFLPNG   0.003       8   TFLPNGING   0.001                 V7B-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         9   STLGYVALL   4.000       8   QSTLGYVAL   4.000       3   NMAYQQSTL   4.000       2   LNMAYQQST   0.300       6   YQQSTLGYV   0.200       7   QQSTLGYVA   0.100       4   MAYQQSTLG   0.030       1   FLNMAYQQS   0.020       5   AYQQSTLGY   0.006                 V7C-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         15   SPAAAWKCL   80.000       126   GVGPLWEFL   20.000       24   GANILRGGL   18.000       113   ANSWRNPVL   12.000       141   QAASGTLSL   12.000       127   VGPLWEFLL   4.000       148   SLAFTSWSL   4.000       181   KSKHCMFSL   4.000       29   RGGLSEIVL   4.000       139   KSQAASGTL   4.000       27   ILRGGLSEI   4.000       165   WMKLETIIL   4.000       152   TSWSLGEFL   4.000       160   LGSGTWMKL   4.000       102   PPESPDRAL   3.600       52   TPPPPAMWT   3.000       112   AANSWRNPV   2.700       101   DPPESPDRA   2.000       50   LSTPPPPAM   1.500       5   ILDLSVEVL   1.200       42   QQDRKIPPL   1.200       134   LLRLLKSQA   1.000       142   AASGTLSLA   0.900       17   AAAWKCLGA   0.900       105   SPDRALKAA   0.600       11   EVLASPAAA   0.500       88   GVVTEDDEA   0.500       31   GLSEIVLPI   0.400       20   WKCLGANIL   0.400       168   LETIILSKL   0.400       163   GTWMKLETI   0.400       129   PLWEFLLRL   0.400       66   TAEAQESGI   0.360       81   SSQIPVVGV   0.300       57   AMWTEEAGA   0.300       14   ASPAAAWKC   0.300       118   NPVLPHTNG   0.300       84   IPVVGVVTE   0.200       79   SSSSQIPVV   0.200       55   PPAMWTEEA   0.200       82   SQIPVVGVV   0.200       37   LPIEWQQDR   0.200       78   SSSSSQIPV   0.200       73   GIRNKSSSS   0.200       4   VILDLSVEV   0.200       2   SIVILDLSV   0.200       47   IPPLSTPPP   0.200       128   GPLWEFLLR   0.200       121   LPHTNGVGP   0.200       18   AAWKCLGAN   0.180       9   SVEVLASPA   0.150       164   TWMKLETII   0.120       19   AWKCLGANI   0.120       130   LWEFLLRLL   0.120       104   ESPDRALKA   0.100       158   EFLGSGTWM   0.100       162   SGTWMKLET   0.100       169   ETIILSKLT   0.100       83   QIPVVGVVT   0.100       178   QEQKSKHCM   0.100       144   SGTLSLAFT   0.100       119   PVLPHTNGV   0.100       143   ASGTLSLAF   0.060       64   GATAEAQES   0.060       68   EAQESGIRN   0.060       25   ANILRGGLS   0.060       108   RALKAANSW   0.060       35   IVLPIEWQQ   0.050       86   VVGVVTEDD   0.050       3   IVILDLSVE   0.050       89   VVTEDDEAQ   0.050       122   PHTNGVGPL   0.040       76   NKSSSSSQI   0.040       182   SKHCMFSLI   0.040       39   IEWQQDRKI   0.040       12   VLASPAAAW   0.030       62   EAGATAEAQ   0.030       125   NGVGPLWEF   0.030       13   LASPAAAWK   0.030       109   ALKAANSWR   0.030       63   AGATAEAQE   0.030       95   EAQDSIDPP   0.030       65   ATAEAQESG   0.030       149   LAFTSWSLG   0.030       111   KAANSWRNP   0.030       51   STPPPPAMW   0.030       184   HCMFSLISG   0.030       59   WTEEAGATA   0.030       156   LGEFLGSGT   0.030       177   TQEQKSKHC   0.030       140   SQAASGTLS   0.020       48   PPLSTPPPP   0.020       71   ESGIRNKSS   0.020       123   HTNGVGPLW   0.020       72   SGIRNKSSS   0.020       179   EQKSKHCMF   0.020       185   CMFSLISGS   0.020       54   PPPAMWTEE   0.020       147   LSLAFTSWS   0.020       28   LRGGLSEIV   0.020                    
     [1187]                       TABLE XIX                       Start   Subsequence   Score                                    V1-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         323   LPMRRSERYL   240.000       197   SAREIENLPL   120.000       438   LPSIVILDLL   80.000       9   SPKSLSETCL   80.000       250   IPIEIVNKTL   80.000       312   FAMVHVAYSL   36.000       147   NVVSAWALQL   20.000       314   MVHVAYSLCL   20.000       364   GIMSLGLLSL   12.000       263   AITLLSLVYL   12.000       219   AISLATFFFL   12.000       402   ALLISTFHVL   12.000       435   ALVLPSIVIL   12.000       273   AGLLAAAYQL   12.000       4   ISMMGSPKSL   12.000       92   AIHREHYTSL   12.000       27   DARKVTVGVI   12.000       181   LARQLNFIPI   12.000       429   PPNFVLALVL   8.000       296   ETWLQCRKQL   6.000       99   TSLWDLRHLL   6.000       316   HVAYSLCLPM   5.000       231   FVRDVIHPYA   5.000       195   LSSAREIENL   4.000       257   KTLPIVAITL   4.000       377   TSIPSVSNAL   4.000       266   LLSLVYLAGL   4.000       202   ENLPLRLFTL   4.000       132   YLASLFPDSL   4.000       299   LQCRKQLGLL   4.000       176   QQVIELARQL   4.000       427   YTPPNFVLAL   4.000       394   IQSTLGYVAL   4.000       213   RGPVVVAISL   4.000       365   IMSLGLLSLL   4.000       49   LIRCGYHVVI   4.000       428   TPPNFVLALV   4.000       103   DLRHLLVGKI   4.000       36   IGSGDFAKSL   4.000       98   YTSLWDLRHL   4.000       298   WLQCRKQLGL   4.000       325   MRRSERYLFL   4.000       361   ISFGIMSLGL   4.000       258   TLPIVAITLL   4.000       172   IQARQQVIEL   4.000       127   ESNAEYLASL   4.000       440   SIVILDLLQL   4.000       183   RQLNFIPIDL   4.000       267   LSLVYLAGLL   4.000       437   VLPSIVILDL   4.000       395   QSTLGYVALL   4.000       173   QARQQVIELA   3.000       432   FVLALVLPSI   2.000       214   GPVVVAISLA   2.000       434   LALVLPSIVI   1.800       133   LASLFPDSLI   1.800       385   ALNWREFSFI   1.200       336   MAYQQVHANI   1.200       41   FAKSLTIRLI   1.200       111   KILIDVSNNM   1.000       261   IVAITLLSLV   1.000       305   LGLLSFFFAM   1.000       277   AAAYQLYYGT   0.900       161   ASRQVYICSN   0.600       239   YARNQQSDFY   0.600       255   VNKTLPIVAI   0.600       401   VALLISTFHV   0.600       125   YPESNAEYLA   0.600       157   GPKDASRQVY   0.600       227   FLYSFVRDVI   0.600       82   ALTKTNIIFV   0.600       425   RFYTPPNFVL   0.600       65   FASEFFPHVV   0.600       134   ASLFPDSLIV   0.600       223   ATFFFLYSFV   0.600       269   LVYLAGLLAA   0.500       142   IVKGFNVVSA   0.500       75   DVTHHEDALT   0.500       441   IVILDLLQLC   0.500       409   HVLIYGWKRA   0.500       254   IVNKTLPIVA   0.500       90   FVAIHREHYT   0.500       375   AVTSIPSVSN   0.450       199   REIENLPLRL   0.400       95   REHYTSLWDL   0.400       379   IPSVSNALNW   0.400       259   LPIVAITLLS   0.400       211   LWRGPVVVAI   0.400       163   RQVYICSNNI   0.400       145   GFNVVSAWAL   0.400       186   NFIPIDLGSL   0.400       188   IPIDLGSLSS   0.400       370   LLSLLAVTSI   0.400       359   MYISFGIMSL   0.400       16   TCLPNGINGI   0.400       124   QYPESNAEYL   0.400       170   NNIQARQQVI   0.400       243   QQSDFYKIPI   0.400       241   RNQQSDFYKI   0.400       74   VDVTHHEDAL   0.400                 V2-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         34   PPPCPADFFL   8.000       14   SSGFTPFSCL   6.000       2   GSPGLQALSL   4.000       33   CPPPCPADFF   0.600       18   TPFSCLSLPS   0.400       16   GFTPFSCLSL   0.400       3   SPGLQALSLS   0.400       4   PGLQALSLSL   0.400       25   LPSSWDYRCP   0.200       30   DYRCPPPCPA   0.150       24   SLPSSWDYRC   0.100       13   LSSGFTPFSC   0.100       9   LSLSLSSGFT   0.100       8   ALSLSLSSGF   0.060       35   PPCPADFFLY   0.040       7   QALSLSLSSG   0.030       15   SGFTPFSCLS   0.020       22   CLSLPSSWDY   0.020       11   LSLSSGFTPF   0.020       6   LQALSLSLSS   0.020       32   RCPPPCPADF   0.020       1   SGSPGLQALS   0.020       20   FSCLSLPSSW   0.020       12   SLSSGFTPFS   0.020       5   GLQALSLSLS   0.020       21   SCLSLPSSWD   0.015       10   SLSLSSGFTP   0.010       17   FTPFSCLSLP   0.010       27   SSWDYRCPPP   0.010       23   LSLPSSWDYR   0.010       28   SWDYRCPPPC   0.003       36   PCPADFFLYF   0.002       26   PSSWDYRCPP   0.002       31   YRCPPPCPAD   0.002       29   WDYRCPPPCP   0.002       19   PFSCLSLPSS   0.000                 V5A-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FWRGPVVVAI   0.400       6   RLFTFWRGPV   0.300       8   FTFWRGPVVV   0.200       3   LPLRLFTFWR   0.200       2   NLPLRLFTFW   0.020       7   LFTFWRGPVV   0.020       1   ENLPLRLFTF   0.020       9   TFWRGPVVVA   0.015       4   PLRLFTFWRG   0.010       5   LRLFTFWRGP   0.001                 V5B-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         12   CSFADTQTEL   4.000       14   FADTQTELEL   3.600       20   ELELEFVFLL   1.200       22   ELEFVFLLTL   1.200       23   LEFVFLLTLL   0.400       1   NWREFSFIQI   0.400       19   TELELEFVFL   0.400       24   EFVFLLTLLL   0.400       17   TQTELELEFV   0.200       8   IQIFCSFADT   0.100       5   FSFIQIFCSF   0.020       16   DTQTELELEF   0.020       10   IFCSFADTQT   0.010       21   LELEFVFLLT   0.010       6   SFIQIFCSFA   0.010       3   REFSFIQIFC   0.010       9   QIFCSFADTQ   0.010       7   FIQIFCSFAD   0.010       11   FCSFADTQTE   0.010       18   QTELELEFVF   0.006       15   ADTQTELELE   0.003       4   EFSFIQIFCS   0.002       13   SFADTQTELE   0.001       2   WREFSFIQIF   0.001                 V6-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         3   LPSIVILGKI   8.000       46   HVSPERVTVM   5.000       5   SIVILGKIIL   4.000       7   VILGKIILFL   4.000       44   IPHVSPERVT   3.000       14   LFLPCISRKL   0.400       27   KKGWEKSQFL   0.400       16   LPCISRKLKR   0.200       43   TIPHVSPERV   0.200       38   EGIGGTIPHV   0.200       19   ISRKLKRIKK   0.150       35   FLEEGIGGTI   0.120       9   LGKIILFLPC   0.100       6   IVILGKIILF   0.100       1   LVLPSIVILG   0.050       10   GKIILFLPCI   0.040       4   PSIVILGKII   0.040       31   EKSQFLEEGI   0.040       17   PCISRKLKRI   0.040       11   KIILFLPCIS   0.020       39   GIGGTIPHVS   0.020       15   FLPCISRKLK   0.015       40   IGGTIPHVSP   0.015       12   IILFLPCISR   0.015       34   QFLEEGIGGT   0.010       2   VLPSIVILGK   0.010       33   SQFLEEGIGG   0.010       25   RIKKGWEKSQ   0.010       32   KSQFLEEGIG   0.010       13   ILFLPCISRK   0.010       22   KLKRIKKGWE   0.010       8   ILGKIILFLP   0.010       41   GGTIPHVSPE   0.010       18   CISRKLKRIK   0.010       28   KGWEKSQFLE   0.010       42   GTIPHVSPER   0.010       23   LKRIKKGWEK   0.010       45   PHVSPERVTV   0.003       24   KRIKKGWEKS   0.002       26   IKKGWEKSQF   0.002       21   RKLKRIKKGW   0.002       20   SRKLKRIKKG   0.001       37   EEGIGGTIPH   0.001       30   WEKSQFLEEG   0.001       29   GWEKSQFLEE   0.000       36   LEEGIGGTIP   0.000                 V7A-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   SPKSLSETFL   80.000       6   LSETFLPNGI   0.120       9   TFLPNGINGI   0.040       1   GSPKSLSETF   0.020       4   KSLSETFLPN   0.020       10   FLPNGINGIK   0.010       5   SLSETFLPNG   0.010       8   ETFLPNGING   0.010       7   SETFLPNGIN   0.003       3   PKSLSETFLP   0.000                 V7B-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         3   LNMAYQQSTL   12.000       8   QQSTLGYVAL   4.000       9   QSTLGYVALL   4.000       10   STLGYVALLI   0.400       7   YQQSTLGYVA   0.100       2   FLNMAYQQST   0.100       6   AYQQSTLGYV   0.060       5   MAYQQSTLGY   0.060       4   NMAYQQSTLG   0.010       1   LFLNMAYQQS   0.002                 V7C-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start position plus       nine.                         102   DPPESPDRAL   120.000       122   LPHTNGVGPL   80.000       129   GPLWEFLLRL   80.000       113   AANSWRNPVL   36.000       127   GVGPLWEFLL   20.000       15   ASPAAAWKCL   12.000       24   LGANILRGGL   6.000       152   FTSWSLGEFL   4.000       42   WQQDRKIPPL   4.000       160   FLGSGTWMKL   4.000       5   VILDLSVEVL   4.000       126   NGVGPLWEFL   4.000       141   SQAASGTLSL   4.000       119   NPVLPHTNGV   4.000       148   LSLAFTSWSL   4.000       19   AAWKCLGANI   3.600       28   ILRGGLSEIV   2.000       168   KLETIILSKL   1.200       20   AWKCLGANIL   1.200       165   TWMKLETIIL   1.200       66   ATAEAQESGI   1.200       4   IVILDLSVEV   1.000       135   LLRLLKSQAA   1.000       112   KAANSWRNPV   0.900       164   GTWMKLETII   0.400       139   LKSQAASGTL   0.400       181   QKSKHCMFSL   0.400       76   RNKSSSSSQI   0.400       29   LRGGLSEIVL   0.400       1   LPSIVILDLS   0.400       130   PLWEFLLRLL   0.400       27   NILRGGLSEI   0.400       31   GGLSEIVLPI   0.400       163   SGTWMKLETI   0.400       182   KSKHCMFSLI   0.400       144   ASGTLSLAFT   0.300       49   PPLSTPPPPA   0.300       81   SSSQIPVVGV   0.300       142   QAASGTLSLA   0.300       14   LASPAAAWKC   0.300       58   AMWTEEAGAT   0.300       178   TQEQKSKHCM   0.300       16   SPAAAWKCLG   0.200       85   IPVVGVVTED   0.200       82   SSQIPVVGVV   0.200       48   IPPLSTPPPP   0.200       55   PPPAMWTEEA   0.200       78   KSSSSSQIPV   0.200       79   SSSSSQIPVV   0.200       74   GIRNKSSSSS   0.200       53   TPPPPAMWTE   0.200       38   LPIEWQQDRK   0.200       18   AAAWKCLGAN   0.180       143   AASGTLSLAF   0.180       50   PLSTPPPPAM   0.150       10   SVEVLASPAA   0.150       52   STPPPPAMWT   0.150       44   QDRKIPPLST   0.150       12   EVLASPAAAW   0.150       106   SPDRALKAAN   0.120       158   GEFLGSGTWM   0.100       156   SLGEFLGSGT   0.100       162   GSGTWMKLET   0.100       88   VGVVTEDDEA   0.100       134   FLLRLLKSQA   0.100       138   LLKSQAASGT   0.100       177   LTQEQKSKHC   0.100       83   SQIPVVGVVT   0.100       105   ESPDRALKAA   0.100       116   SWRNPVLPHT   0.100       9   LSVEVLASPA   0.100       57   PAMWTEEAGA   0.090       185   HCMFSLISGS   0.060       110   ALKAANSWRN   0.060       25   GANILRGGLS   0.060       64   AGATAEAQES   0.060       36   IVLPIEWQQD   0.050       87   VVGVVTEDDE   0.050       90   VVTEDDEAQD   0.050       89   GVVTEDDEAQ   0.050       150   LAFTSWSLGE   0.030       125   TNGVGPLWEF   0.030       109   RALKAANSWR   0.030       96   EAQDSIDPPE   0.030       63   EAGATAEAQE   0.030       26   ANILRGGLSE   0.030       51   LSTPPPPAMW   0.030       69   EAQESGIRNK   0.030       17   PAAAWKCLGA   0.030       65   GATAEAQESG   0.030       114   ANSWRNPVLP   0.030       6   ILDLSVEVLA   0.030       70   AQESGIRNKS   0.027       147   TLSLAFTSWS   0.020       146   GTLSLAFTSW   0.020       140   KSQAASGTLS   0.020       180   EQKSKHCMFS   0.020       56   PPAMWTEEAG   0.020       145   SGTLSLAFTS   0.020       72   ESGIRNKSSS   0.020                    
     [1188]                       TABLE XX                       Start   Subsequence   Score                                    V1-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start position       plus eight.                         62   NPKFASEFF   60.000       323   LPMRRSERY   40.000       157   GPKDASRQV   24.000       259   LPIVAITLL   20.000       428   TPPNFVLAL   20.000       291   FPPWLETWL   20.000       438   LPSIVILDL   20.000       214   GPVVVAISL   20.000       231   FVRDVIHPY   12.000       37   GSGDFAKSL   10.000       405   ISTFHVLIY   10.000       204   LPLRLFTLW   10.000       239   YARNQQSDF   9.000       41   FAKSLTIRL   9.000       173   QARQQVIEL   9.000       99   TSLWDLRHL   7.500       196   SSAREIENL   7.500       9   SPKSLSETC   6.000       317   VAYSLCLPM   6.000       276   LAAAYQLYY   6.000       272   LAGLLAAAY   6.000       125   YPESNAEYL   6.000       46   TIRLIRCGY   6.000       267   LSLVYLAGL   5.000       395   QSTLGYVAL   5.000       366   MSLGLLSLL   5.000       220   ISLATFFFL   5.000       250   IPIEIVNKT   4.000       112   ILIDVSNNM   4.000       188   IPIDLGSLS   4.000       347   NSWNEEEVW   3.750       133   LASLFPDSL   3.000       300   QCRKQLGLL   3.000       218   VAISLATFF   3.000       177   QVIELARQL   2.000       303   KQLGLLSFF   2.000       371   LSLLAVTSI   2.000       128   SNAEYLASL   2.000       275   LLAAAYQLY   2.000       61   RNPKFASEF   2.000       100   SLWDLRHLL   2.000       237   HPYARNQQS   2.000       379   IPSVSNALN   2.000       117   SNNMRINQY   2.000       306   GLLSFFFAM   2.000       134   ASLFPDSLI   2.000       221   SLATFFFLY   2.000       193   GSLSSAREI   2.000       263   AITLLSLVY   2.000       90   FVAIHREHY   2.000       280   YQLYYGTKY   2.000       358   EMYISFGIM   2.000       27   DARKVTVGV   1.800       441   IVILDLLQL   1.500       161   ASRQVYICS   1.500       59   GSRNPKFAS   1.500       187   FIPIDLGSL   1.500       81   DALTKTNII   1.200       65   FASEFFPHV   1.200       365   IMSLGLLSL   1.000       184   QLNFIPIDL   1.000       385   ALNWREFSF   1.000       148   VVSAWALQL   1.000       274   GLLAAAYQL   1.000       144   KGFNVVSAW   1.000       146   FNVVSAWAL   1.000       383   SNALNWREF   1.000       304   QLGLLSFFF   1.000       363   FGIMSLGLL   1.000       217   VVAISLATF   1.000       57   VIGSRNPKF   1.000       313   AMVHVAYSL   1.000       411   LIYGWKRAF   1.000       378   SIPSVSNAL   1.000       264   ITLLSLVYL   1.000       75   DVTHHEDAL   1.000       436   LVLPSIVIL   1.000       82   ALTKTNIIF   1.000       403   LLISTFHVL   1.000       299   LQCRKQLGL   1.000       400   YVALLISTF   1.000       258   TLPIVAITL   1.000       268   SLVYLAGLL   1.000       5   SMMGSPKSL   1.000       223   ATFFFLYSF   1.000       33   VGVIGSGDF   1.000       396   STLGYVALL   1.000       261   IVAITLLSL   1.000       360   YISFGIMSL   1.000       219   AISLATFFF   1.000       203   NLPLRLFTL   1.000       129   NAEYLASLF   0.900       85   KTNIIFVAI   0.800       127   ESNAEYLAS   0.750       386   LNWREFSFI   0.600       434   LALVLPSIV   0.600       416   KRAFEEEYY   0.600       328   SERYLFLNM   0.600       287   KYRRFPPWL   0.600       24   GIKDARKVT   0.600                 V2-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         37   CPADFFLYF   40.000       33   CPPPCPADF   20.000       3   SPGLQALSL   20.000       23   LSLPSSWDY   10.000       9   LSLSLSSGF   5.000       35   PPCPADFFL   2.000       34   PPPCPADFF   2.000       25   LPSSWDYRC   2.000       15   SGFTPFSCL   1.000       1   SGSPGLQAL   1.000       12   SLSSGFTPF   1.000       5   GLQALSLSL   1.000       17   FTPFSCLSL   1.000       20   FSCLSLPSS   0.500       2   GSPGLQALS   0.500       13   LSSGFTPFS   0.500       14   SSGFTPFSC   0.500       21   SCLSLPSSW   0.500       7   QALSLSLSS   0.300       36   PCPADFFLY   0.300       18   TPFSCLSLP   0.200       6   LQALSLSLS   0.100       10   SLSLSSGFT   0.100       27   SSWDYRCPP   0.100       11   LSLSSGFTP   0.050       32   RCPPPCPAD   0.020       8   ALSLSLSSG   0.010       22   CLSLPSSWD   0.010       29   WDYRCPPPC   0.010       24   SLPSSWDYR   0.010       31   YRCPPPCPA   0.010       4   PGLQALSLS   0.010       16   GFTPFSCLS   0.010       26   PSSWDYRCP   0.008       30   DYRCPPPCP   0.003       19   PFSCLSLPS   0.001       28   SWDYRCPPP   0.000                 V5A-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         2   LPLRLFTFW   10.000       1   NLPLRLFTF   1.000       7   FTFWRGPVV   0.200       9   FWRGPVVVA   0.030       6   LFTFWRGPV   0.020       5   RLFTFWRGP   0.020       8   TFWRGPVVV   0.020       3   PLRLFTFWR   0.003       4   LRLFTFWRG   0.001                 V5B-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         16   TQTELELEF   2.000       24   FVFLLTLL   1.000       4   FSFIQIFCS   0.500       19   ELELEFVFL   0.450       12   SFADTQTEL   0.200       18   TELELEFVF   0.200       20   LELEFVFLL   0.200       2   REFSFIQIF   0.200       22   LEFVFLLTL   0.100       10   FCSFADTQT   0.100       8   QIFCSFADT   0.100       23   EFVFLLTLL   0.100       6   FIQIFCSFA   0.100       14   ADTQTELEL   0.100       5   SFIQIFCSF   0.100       17   QTELELEFV   0.090       11   CSFADTQTE   0.075       21   ELEFVFLLT   0.030       15   DTQTELELE   0.015       1   WREFSFIQI   0.012       7   IQIFCSFAD   0.010       3   EFSFIQIFC   0.010       13   FADTQTELE   0.009       9   IFCSFADTQ   0.001                 V6-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         46   VSPERVTVM   20.000       27   KGWEKSQFL   4.000       43   IPHVSPERV   4.000       31   KSQFLEEGI   4.000       21   KLKRIKKGW   3.000       14   FLPCISRKL   1.000       6   VILGKILILF   1.000       5   IVILGKIIL   1.000       7   ILGKIILFL   1.000       10   KIILFLPCI   0.800       24   RIKKGWEKS   0.600       17   CISRKLKRI   0.400       4   SIVILGKII   0.400       45   HVSPERVTV   0.300       26   KKGWEKSQF   0.300       2   LPSIVILGK   0.200       15   LPCISRKLK   0.200       38   GIGGTIPHV   0.200       3   PSIVILGKI   0.200       18   ISRKLKRIK   0.150       39   IGGTIPHVS   0.100       11   IILFLPCIS   0.100       34   FLEEGIGGT   0.060       8   LGKIILFLP   0.030       32   SQFLEEGIG   0.015       35   LEEGIGGTI   0.012       37   EGIGGTIPH   0.010       41   GTIPHVSPE   0.010       40   GGTIPHVSP   0.010       1   VLPSIVILG   0.010       9   GKIILFLPC   0.010       12   ILFLPCISR   0.010       42   TIPHVSPER   0.010       33   QFLEEGIGG   0.003       29   WEKSQFLEE   0.003       25   IKKGWEKSQ   0.003       22   LKRIKKGWE   0.003       19   SRKLKRIKK   0.003       20   RKLKRIKKG   0.002       23   KRIKKGWEK   0.002       44   PHVSPERVT   0.001       13   LFLPCISRK   0.001       30   EKSQFLEEG   0.001       16   PCISRKLKR   0.001       36   EEGIGGTIP   0.010       28   GWEKSQFLE   0.000                 V7A-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         1   SPKSLSETF   60.000       9   FLPNGINGI   0.400       4   SLSETFLPN   0.200       3   KSLSETFLP   0.150       7   ETFLPNGIN   0.100       6   SETFLPNGI   0.040       5   LSETFLPNG   0.015       2   PKSLSETFL   0.010       8   TFLPNGING   0.001                 V7B-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         8   QSTLGYVAL   5.000       9   STLGYVALL   1.000       3   NMAYQQSTL   1.000       6   YQQSTLGYV   0.200       5   AYQQSTLGY   0.200       7   QQSTLGYVA   0.100       1   FLNMAYQQS   0.100       2   LNMAYQQST   0.100       4   MAYQQSTLG   0.030                 V7C-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start position       plus eight.                         181   KSKHCMFSL   30.000       15   SPAAAWKCL   20.000       139   KSQAASGTL   10.000       50   LSTPPPPAM   10.000       152   TSWSLGEFL   5.000       143   ASGTLSLAF   5.000       165   WMKLETIIL   4.500       101   DPPESPDRA   4.000       179   EQKSKHCMF   3.000       24   GANILRGGL   3.000       141   QAASGTLSL   3.000       108   RALKAANSW   3.000       29   RGGLSEIVL   2.000       52   TPPPPAMWT   2.000       27   ILRGGLSEI   1.200       78   SSSSSQIPV   1.000       126   GVGPLWEFL   1.000       113   ANSWRNPVL   1.000       104   ESPDRALKA   1.000       160   LGSGTWMKL   1.000       127   VGPLWEFLL   1.000       79   SSSSQIPVV   1.000       148   SLAFTSWSL   1.000       151   FTSWSLGEF   1.000       125   NGVGPLWEF   1.000       81   SSQIPVVGV   1.000       31   GLSEIVLPI   0.800       154   WSLGEFLGS   0.750       102   PPESPDRAL   0.600       112   AANSWRNPV   0.600       105   SPDRALKAA   0.600       68   EAQESGIRN   0.600       51   STPPPPAMW   0.500       147   LSLAFTSWS   0.500       146   TLSLAFTSW   0.500       12   VLASPAAAW   0.500       71   ESGIRNKSS   0.500       123   HTNGVGPLW   0.500       14   ASPAAAWKC   0.500       64   GATAEAQES   0.450       163   GTWMKLETI   0.400       37   LPIEWQQDR   0.400       4   VILDLSVEV   0.400       66   TAEAQESGI   0.360       134   LLRLLKSQA   0.300       42   QQDRKIPPL   0.300       73   GIRNKSSSS   0.300       17   AAAWKCLGA   0.300       142   AASGTLSLA   0.300       128   GPLWEFLLR   0.300       18   AAWKCLGAN   0.300       5   ILDLSVEVL   0.300       136   RLLKSQAAS   0.200       82   SQIPVVGVV   0.200       47   IPPLSTPPP   0.200       55   PPAMWTEEA   0.200       121   LPHTNGVGP   0.200       129   PLWEFLLRL   0.200       178   QEQKSKHCM   0.200       117   RNPVLPHTN   0.200       2   SIVILDLSV   0.200       158   EFLGSGTWM   0.200       84   IPVVGVVTE   0.200       118   NPVLPHTNG   0.200       57   AMWTEEAGA   0.150       173   LSKLTQEQK   0.150       7   DLSVEVLAS   0.150       88   GVVTEDDEA   0.150       19   AWKCLGANI   0.120       98   DSIDPPESP   0.100       145   GTLSLAFTS   0.100       83   QIPVVGVVT   0.100       8   LSVEVLASP   0.100       168   LETIILSKL   0.100       169   ETIILSKLT   0.100       162   SGTWMKLET   0.100       11   EVLASPAAA   0.100       25   ANILRGGLS   0.100       72   SGIRNKSSS   0.100       144   SGTLSLAFT   0.100       140   SQAASGTLS   0.100       77   KSSSSSQIP   0.100       185   CMFSLISGS   0.100       20   WKCLGANIL   0.100       95   EAQDSIDPP   0.060       111   KAANSWRNP   0.060       75   RNKSSSSSQ   0.060       59   WTEEAGATA   0.060       1   PSIVILDLS   0.050       80   SSSQIPVVG   0.050       157   GEFLGSGTW   0.050       33   SEIVLPIEW   0.050       161   GSGTWMKLE   0.050       114   NKSSSSSQI   0.040       164   TWMKLETII   0.040       182   SKHCMFSLI   0.040       39   IEWQQDRKI   0.040       58   MWTEEAGAT   0.030       89   VVTEDDEAQ   0.030                    
     [1189]                       TABLE XXI                       Start   Subsequence   Score                                    V1-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 3; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start       position plus nine.                         157   GPKDASRQVY   240.000       9   SPKSLSETCL   60.000       250   IPIEIVNKTL   40.000       197   SAREIENLPL   27.000       323   LPMRRSERYL   20.000       438   LPSIVILDLL   20.000       239   YARNQQSDFY   18.000       417   RAFEEEYYRF   18.000       379   IPSVSNALNW   10.000       116   VSNNMRINQY   10.000       391   FSFIQSTLGY   10.000       220   ISLATFFFLY   10.000       195   LSSAREIENL   7.500       137   FPDSLIVKGF   6.000       327   RSERYLFLNM   6.000       262   VAITLLSLVY   6.000       361   ISFGIMSLGL   5.000       395   QSTLGYVALL   5.000       267   LSLVYLAGLL   5.000       99   TSLWDLRHLL   5.000       127   ESNAEYLASL   5.000       4   ISMMGSPKSL   5.000       382   VSNALNWREF   5.000       377   TSIPSVSNAL   5.000       428   TPPNFVLALV   4.000       188   IPIDLGSLSS   4.000       111   KILIDVSNNM   4.000       181   LARQLNFIPI   3.600       27   DARKVTVGVI   3.600       41   FAKSLTIRLI   3.600       384   NALNWREFSF   3.000       312   FAMVHVAYSL   3.000       222   LATFFFLYSF   3.000       81   DALTKTNIIF   3.000       218   VAISLATFFF   3.000       322   CLPMRRSERY   2.000       429   PPNFVLALVL   2.000       316   HVAYSLCLPM   2.000       61   RNPKFASEFF   2.000       257   KTLPIVAITL   2.000       259   LPIVAITLLS   2.000       45   LTIRLIRCGY   2.000       275   LLAAAYQLYY   2.000       274   GLLAAAYQLY   2.000       303   KQLGLLSFFF   2.000       128   SNAEYLASLF   2.000       123   NQYPESNAEY   2.000       305   LGLLSFFFAM   2.000       404   LISTFHVLIY   2.000       213   RGPVVVAISL   2.000       271   YLAGLLAAAY   2.000       183   RQLNFIPIDL   2.000       214   GPVVVAISLA   2.000       134   ASLFPDSLIV   1.500       440   SIVILDLLQL   1.500       98   YTSLWDLRHL   1.500       161   ASRQVYICSN   1.500       285   GTKYRRFPPW   1.500       103   DLRHLLVGKI   1.200       336   MAYQQVHANI   1.200       255   VNKTLPIVAI   1.200       65   FASEFFPHVV   1.200       49   LIRCGYHVVI   1.200       434   LALVLPSIVI   1.200       133   LASLFPDSLI   1.200       24   GIKDARKVTV   1.200       241   RNQQSDFYKI   1.200       32   TVGVIGSGDF   1.000       435   ALVLPSIVIL   1.000       273   AGLLAAAYQL   1.000       36   IGSGDFAKSL   1.000       308   LSFFFAMVHV   1.000       56   VVIGSRNPKF   1.000       176   QQVIELARQL   1.000       296   ETWLQCRKQL   1.000       43   KSLTIRLIRC   1.000       202   ENLPLRLFTL   1.000       147   NVVSAWALQL   1.000       217   VVAISLATFF   1.000       216   VVVAISLATF   1.000       132   YLASLFPDSL   1.000       364   GIMSLGLLSL   1.000       365   IMSLGLLSLL   1.000       92   AIHREHYTSL   1.000       314   MVHVAYSLCL   1.000       410   VLIYGWKRAF   1.000       299   LQCRKQLGLL   1.000       394   IQSTLGYVAL   1.000       11   KSLSETCLPN   1.000       263   AITLLSLVYL   1.000       172   IQARQQVIEL   1.000       219   AISLATFFFL   1.000       298   WLQCRKQLGL   1.000       37   GSGDFAKSLT   1.000       402   ALLISTFHVL   1.000       258   TLPIVAITLL   1.000       427   YTPPNFVLAL   1.000       139   DSLIVKGFNV   1.000       437   VLPSIVILDL   1.000       266   LLSLVYLAGL   1.000                 V2-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         33   CPPPCPADFF   20.000       35   PPCPADFFLY   6.000       14   SSGFTPFSCL   5.000       11   LSLSSGFTPF   5.000       2   GSPGLQALSL   5.000       20   FSCLSLPSSW   2.500       34   PPPCPADFFL   2.000       3   SPGLQALSLS   2.000       22   CLSLPSSWDY   2.000       32   RCPPPCPADF   2.000       18   TPFSCLSLPS   2.000       8   ALSLSLSSGF   1.000       9   LSLSLSSGFT   0.500       13   LSSGFTPFSC   0.500       25   LPSSWDYRCP   0.300       4   PGLQALSLSL   0.100       15   SGFTPFSCLS   0.100       27   SSWDYRCPPP   0.100       16   GFTPFSCLSL   0.100       6   LQALSLSLSS   0.100       1   SGSPGLQALS   0.100       24   SLPSSWDYRC   0.100       36   PCPADFFLYF   0.100       5   GLQALSLSLS   0.100       12   SLSSGFTPFS   0.100       23   LSLPSSWDYR   0.050       7   QALSLSLSSG   0.030       30   DYRCPPPCPA   0.030       17   FTPFSCLSLP   0.010       10   SLSLSSGFTP   0.010       21   SCLSLPSSWD   0.010       26   PSSWDYRCPP   0.005       28   SWDYRCPPPC   0.003       29   WDYRCPPPCP   0.001       19   PFSCLSLPSS   0.001       31   YRCPPPCPAD   0.001                 V5A-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start       position plus nine.                         1   ENLPLRLFTF   1.000       2   NLPLRLFTFW   0.500       6   RLFTFWRGPV   0.400       8   FTFWRGPVVV   0.200       3   LPLRLFTFWR   0.200       10   FWRGPVVVAI   0.120       7   LFTFWRGPVV   0.020       9   TFWRGPVVVA   0.010       4   PLRLFTFWRG   0.003       5   LRLFTFWRGP   0.001                 V5B-HLA-3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         12   CSFADTQTEL   5.000       5   FSFIQIFCSF   5.000       16   DTQTELELEF   1.000       14   FADTQTELEL   0.900       17   TQTELELEFV   0.600       22   ELEFVFLLTL   0.300       18   QTELELEFVF   0.300       20   ELELEFVFLL   0.300       19   TELELEFVFL   0.300       1   NWREFSFIQI   0.240       8   IQIFCSFADT   0.100       23   LEFVFLLTLL   0.100       24   EFVFLLTLLL   0.100       2   WREFSFIQIF   0.030       3   REFSFIQIFC   0.020       21   LELEFVFLLT   0.020       11   FCSFADTQTE   0.015       10   IFCSFADTQT   0.010       7   FIQIFCSFAD   0.010       4   EFSFIQIFCS   0.010       9   QIFCSFADTQ   0.010       6   SFIQIFCSFA   0.010       13   SFADTQTELE   0.002       15   ADTQTELELE   0.002                 V6-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 13; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start       position plus nine.                         3   LPSIVILGKI   8.000       44   IPHVSPERVT   2.000       46   HVSPERVTVM   2.000       6   IVILGKIILF   1.000       7   VILGKIILFL   1.000       5   SIVILGKIIL   1.000       26   IKKGWEKSQF   0.450       9   LGKIILFLPC   0.300       35   FLEEGIGGTI   0.240       43   TIPHVSPERV   0.200       11   KIILFLPCIS   0.200       27   KKGWEKSQFL   0.200       38   EGIGGTIPHV   0.200       16   LPCISRKLKR   0.200       4   PSIVILGKII   0.200       32   KSQFLEEGIG   0.150       19   ISRKLKRIKK   0.150       39   GIGGTIPHVS   0.100       14   LFLPCISRKL   0.100       21   RKLKRIKKGW   0.100       25   RIKKGWEKSQ   0.060       22   KLKRIKKGWE   0.060       10   GKIILFLPCI   0.040       28   KGWEKSQFLE   0.040       17   PCISRKLKRI   0.040       31   EKSQFLEEGI   0.040       24   KRIKKGWEKS   0.020       34   QFLEEGIGGT   0.020       33   SQFLEEGIGG   0.015       13   ILFLPCISRK   0.010       18   CISRKLKRIK   0.010       8   ILGKIILFLP   0.010       2   VLPSIVILGK   0.010       40   IGGTIPHVSP   0.010       15   FLPCISRKLK   0.010       41   GGTIPHVSPE   0.010       1   LVLPSIVILG   0.010       42   GTIPHVSPER   0.010       12   IILFLPCISR   0.010       45   PHVSPERVTV   0.003       20   SRKLKRIKKG   0.003       30   WEKSQFLEEG   0.003       23   LKRIKKGWEK   0.003       37   EEGIGGTIPH   0.001       36   LEEGIGGTIP   0.000       29   GWEKSQFLEE   0.000                 V7A-HLA-3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   SPKSLSETFL   60.000       1   GSPKSLSETF   5.000       4   KSLSETFLPN   1.000       6   LSETFLPNGI   0.600       9   TFLPNGINGI   0.040       5   SLSETFLPNG   0.020       10   FLPNGINGIK   0.010       7   SETFLPNGIN   0.010       8   ETFLPNGING   0.010       3   PKSLSETFLP   0.000                 V7B-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start       position plus nine.                         5   MAYQQSTLGY   6.000       9   QSTLGYVALL   5.000       3   LNMAYQQSTL   1.000       8   QQSTLGYVAL   1.000       10   STLGYVALLI   0.400       7   YQQSTLGYVA   0.100       2   FLNMAYQQST   0.100       6   AYQQSTLGYV   0.020       4   NMAYQQSTLG   0.010       1   LFLNMAYQQS   0.010                 V7C-HLA-B3501-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 10       amino acids, and the end position for       each peptide is the start       position plus nine.                         100   SIDPPESPDR   100.000       67   TAEAQESGIR   9.000       33   LSEIVLPIEW   6.750       131   LWEFLLRLLK   4.500       91   VTEDDEAQDS   2.250       10   SVEVLASPAA   1.800       52   STPPPPAMWT   1.250       6   ILDLSVEVLA   1.000       168   KLETIILSKL   0.900       103   PPESPDRALK   0.900       127   GVGPLWEFLL   0.500       143   AASGTLSLAF   0.500       13   VLASPAAAWK   0.400       51   LSTPPPPAMW   0.300       60   WTEEAGATAE   0.225       157   LGEFLGSGTW   0.225       69   EAQESGIRNK   0.200       97   AQDSIDPPES   0.150       70   AQESGIRNKS   0.135       178   TQEQKSKHCM   0.135       170   ETIILSKLTQ   0.125       128   VGPLWEFLLR   0.125       37   VLPIEWQQDR   0.100       14   LASPAAAWKC   0.100       61   TEEAGATAEA   0.090       39   PIEWQQDRKI   0.090       162   GSGTWMKLET   0.075       78   KSSSSSQIPV   0.075       160   FLGSGTWMKL   0.050       22   KCLGANILRG   0.050       167   MKLETIILSK   0.050       38   LPIEWQQDRK   0.050       80   SSSSQIPVVG   0.030       79   SSSSSQIPVV   0.030       83   SQIPVVGVVT   0.030       144   ASGTLSLAFT   0.030       81   SSSQIPVVGV   0.030       146   GTLSLAFTSW   0.025       66   ATAEAQESGI   0.025       152   FTSWSLGEFL   0.025       125   TNGVGPLWEF   0.025       92   TEDDEAQDSI   0.025       177   LTQEQKSKHC   0.025       21   WKCLGANILR   0.025       106   SPDRALKAAN   0.025       94   DDEAQDSIDP   0.022       12   EVLASPAAAW   0.020       4   IVILDLSVEV   0.020       173   ILSKLTQEQK   0.020       47   KIPPLSTPPP   0.020       113   AANSWRNPVL   0.020       72   ESGIRNKSSS   0.015       43   QQDRKIPPLS   0.015       15   ASPAAAWKCL   0.015       140   KSQAASGTLS   0.015       9   LSVEVLASPA   0.015       82   SSQIPVVGVV   0.015       155   WSLGEFLGSG   0.015       105   ESPDRALKAA   0.015       148   LSLAFTSWSL   0.015       124   HTNGVGPLWE   0.013       129   GPLWEFLLRL   0.013       31   GGLSEIVLPI   0.013       145   SGTLSLAFTS   0.013       185   HCMFSLISGS   0.010       149   SLAFTSWSLG   0.010       65   GATAEAQESG   0.010       112   KAANSWRNPV   0.010       142   QAASGTLSLA   0.010       25   GANILRGGLS   0.010       159   EFLGSGTWMK   0.010       23   CLGANILRGG   0.010       109   RALKAANSWR   0.010       176   KLTQEQKSKH   0.010       35   EIVLPIEWQQ   0.010       175   SKLTQEQKSK   0.010       18   AAAWKCLGAN   0.010       36   IVLPIEWQQD   0.010       5   VILDLSVEVL   0.010       172   IILSKLTQEQ   0.010       156   SLGEFLGSGT   0.010       120   PVLPHTNGVG   0.010       147   TLSLAFTSWS   0.010       89   GVVTEDDEAQ   0.010       153   TSWSLGEFLG   0.008       2   PSIVILDLSV   0.008       141   SQAASGTLSL   0.007       150   LAFTSWSLGE   0.005       17   PAAAWKCLGA   0.005       101   IDPPESPDRA   0.005       151   AFTSWSLGEF   0.005       117   WRNPVLPHTN   0.005       42   WQQDRKIPPL   0.003       104   PESPDRALKA   0.003       24   LGANILRGGL   0.003       119   NPVLPHTNGV   0.003       118   RNPVLPHTNG   0.003       102   DPPESPDRAL   0.003       53   TPPPPAMWTE   0.003       1   LPSIVILDLS   0.003                    
     [1190]                       TABLE VIII                        Start   Subsequence   Score                                    V8-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         4   FLEEGMGGT   0.900       5   LEEGMGGTI   0.045       1   KSQFLEEGM   0.015       7   EGMGGTIPH   0.013       8   GMGGTIPHV   0.010       9   MGGTIPHVS   0.003       3   QFLEEGMGG   0.003       2   SQFLEEGMG   0.002       6   EEGMGGTIP   0.000                 V13-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         5   LSETFLPNG   2.700       4   SLSETFLPN   0.050       7   ETFLPNGIN   0.025       8   TFLPNGING   0.025       9   FLPNGINGI   0.010       3   KSLSETFLP   0.007       1   SPKSLSETF   0.003       6   SETFLPNGI   0.001       2   PKSLSETFL   0.000                 V14-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   0.500       7   FTFWRGPVV   0.050       3   PLRLFTFWR   0.005       5   RLFTFWRGP   0.001       6   LFTFWRGPV   0.001       4   LRLFTFWRG   0.001       2   LPLRLFTFW   0.000       9   FWRGPVVVA   0.000       8   TFWRGPVVV   0.000                 V21-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   KLTQEQKTK   0.200       4   TQEQKTKHC   0.135       3   LTQEQKTKH   0.025       8   KTKHCMFSL   0.013       6   EQKTKHCMF   0.002       9   TKHCMFSLI   0.001       1   SKLTQEQKT   0.001       7   QKTKHCMFS   0.000       5   QEQKTKHCM   0.000                 V25-HLA-A1-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   LFLPCISQK   0.100       1   ILFLPCISQ   0.050       5   PCISQKLKR   0.050       4   LPCISQKLK   0.050       7   ISQKLKRIK   0.030       8   SQKLKRIKK   0.015       3   FLPCISQKL   0.010       6   CISQKLKRI   0.010       9   QKLKRIKKG   0.000                    
     [1191]                       TABLE IX                        Start   Subsequence   Score                                    V8-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   FLEEGMGGTI   0.900       2   KSQFLEEGMG   0.015       3   SQFLEEGMGG   0.007       8   EGMGGTIPHV   0.005       9   GMGGTIPHVS   0.005       6   LEEGMGGTIP   0.005       7   EEGMGGTIPH   0.003       4   QFLEEGMGGT   0.001       10   MGGTIPHVSP   0.001       1   EKSQFLEEGM   0.001                 V13-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         6   LSETFLPNGI   1.350       10   FLPNGINGIK   0.200       8   ETFLPNGING   0.125       4   KSLSETFLPN   0.075       5   SLSETFLPNG   0.020       1   GSPKSLSETF   0.015       9   TFLPNGINGI   0.005       7   SETFLPNGIN   0.001       2   SPKSLSETFL   0.000       3   PKSLSETFLP   0.000                 V14-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         1   ENLPLRLFTF   1.250       8   FTFWRGPVVV   0.050       3   LPLRLFTFWR   0.013       2   NLPLRLFTFW   0.010       6   RLFTFWRGPV   0.010       7   LFTFWRGPVV   0.001       4   PLRLFTFWRG   0.000       10   FWRGPVVVAI   0.000       5   LRLFTFWRGP   0.000       9   TFWRGPVVVA   0.000                 V21-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   TQEQKTKHCM   0.135       4   LTQEQKTKHC   0.025       3   KLTQEQKTKH   0.010       2   SKLTQEQKTK   0.010       9   KTKHCMFSLI   0.003       10   TKHCMFSLIS   0.003       1   LSKLTQEQKT   0.002       7   EQKTKHCMFS   0.001       6   QEQKTKHCMF   0.001       8   QKTKHCMFSL   0.000                 V25-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         7   CISQKLKRIK   0.200       4   FLPCISQKLK   0.200       2   ILFLPCISQK   0.200       8   ISQKLKRIKK   0.150       5   LPCISQKLKR   0.125       1   IILFLPCISQ   0.050       3   LFLPCISQKL   0.005       6   PCISQKLKRI   0.001       9   SQKLKRIKKG   0.000       10   QKLKRIKKGW   0.000                    
     [1192]                       TABLE X                       Start   Subsequence   Score                                    V8-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGTIPHV   115.534       4   FLEEGMGGT   2.689       1   KSQFLEEGM   0.056       2   SQFLEEGMG   0.004       5   LEEGMGGTI   0.003       3   QFLEEGMGG   0.001       9   MGGTIPHVS   0.000       7   EGMGGTIPH   0.000       6   EEGMGGTIP   0.000                 V13-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start       position plus eight.                         9   FLPNGINGI   110.379       4   SLSETFLPN   0.581       6   SETFLPNGI   0.203       3   KSLSETFLP   0.007       2   PKSLSETFL   0.004       5   LSETFLPNG   0.000       8   TFLPNGING   0.000       7   ETFLPNGIN   0.000       1   SPKSLSETF   0.000                 V14-A0201-9mres-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position for       each peptide is the start       position plus eight.                         7   FTFWRGPVV   6.741       1   NLPLRLFTF   0.994       8   TFWRGPVVV   0.164       5   RLFTFWRGP   0.071       2   LPLRLFTFW   0.032       6   LFTFWRGPV   0.011       3   PLRLFTFWR   0.003       4   LRLFTFWRG   0.001       9   FWRGPVVVA   0.000                 V21-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   KTKHCMFSL   0.485       5   QEQKTKHCM   0.097       2   KLTQEQKTK   0.052       1   SKLTQEQKT   0.038       4   TQEQKTKHC   0.032       9   TKHCMFSLI   0.028       3   LTQEQKTKH   0.007       7   QKTKHCMFS   0.001       6   EQKTKHCMF   0.000                 V25-A0201-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   98.267       6   CISQKLKRI   3.299       1   ILFLPCISQ   0.094       9   QKLKRIKKG   0.001       4   LPCISQKLK   0.000       2   LFLPCISQK   0.000       8   SQKLKRIKK   0.000       7   ISQKLKRIK   0.000       5   PCISQKLKR   0.000                 V8-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the lengh of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   FLEEGMGGTI   1.637       8   EGMGGTIPHV   0.290       3   SQFLEEGMGG   0.028       4   QFLEEGMGGT   0.023       9   GMGGTIPHVS   0.022       1   EKSQFLEEGM   0.000       2   KSQFLEEGMG   0.000       10   MGGTIPHVSP   0.000       7   EEGMGGTIPH   0.000       6   LEEGMGGTIP   0.000                 V13-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   SLSETFLPNG   2.670       9   TFLPNGINGI   0.062       2   SPKSLSETFL   0.027       4   KSLSETFLPN   0.012       6   LSETFLPNGI   0.007       10   FLPNGINGIK   0.004       8   ETFLPNGING   0.000       1   GSPKSLSETF   0.000       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V14-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         6   RLFTFWRGPV   33.455       8   FTFWRGPVVV   6.741       2   NLPLRLFTFW   0.779       3   LPLRFTFWR   0.074       7   LFTFWRGPVV   0.034       9   TFWRGPVVVA   0.027       1   ENLPLRLFTF   0.002       4   PLRLFTFWRG   0.002       10   FWRGPVVVAI   0.001       5   LRLFTFWRGP   0.000                 V21-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   TQEQKTKHCM   0.135       4   LTQEQKTKHC   0.025       3   KLTQEQKTKH   0.010       2   SKLTQEQKTK   0.010       9   KTKHCMFSLI   0.003       10   TKHCMFSLIS   0.003       1   LSKLTQEQKT   0.002       7   EQKTKHCMFS   0.001       6   QEQKTKHCMF   0.001       8   QKTKHCMFSL   0.000                 V25-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   ILFLPCISQK   0.216       3   LFLPCISQKL   0.093       4   FLPCISQKLK   0.069       1   IILFLPCISQ   0.013       6   PCISQKLKRI   0.003       9   SQKLKRIKKG   0.001       10   QKLKRIKKGW   0.000       7   CISQKLKRIK   0.000       8   ISQKLKRIKK   0.000       5   LPCISQKLKR   0.000                    
     [1193]                       TABLE XII                       Start   Subsequence   Score                                    V8-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGTIPHV   1.350       4   FLEEGMGGT   0.068       1   KSQFLEEGM   0.003       2   SQFLEEGMG   0.001       5   LEEGMGGTI   0.001       7   EGMGGTIPH   0.000       3   QFLEEGMGG   0.000       9   MGGTIPHVS   0.000       6   EEGMGGTIP   0.000                 V13-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNGINGI   0.900       4   SLSETFLPN   0.180       1   SPKSLSETF   0.020       6   SETFLPNGI   0.002       3   KSLSETFLP   0.001       7   ETFLPNGIN   0.001       5   LSETFLPNG   0.000       8   TFLPNGING   0.000       2   PKSLSETFL   0.000                 V14-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   9.000       3   PLRLFTFWR   3.600       7   FTFWRGPVV   0.050       5   RLFTFWRGP   0.030       2   LPLRLFTFW   0.009       9   FWRGPVVVA   0.001       8   TFWRGPVVV   0.001       4   LRLFTFWRG   0.000       6   LFTFWRGPV   0.000                 V21-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   KLTQEQKTK   30.000       8   KTKHCMFSL   0.405       6   EQKTKHCMF   0.018       3   LTQEQKTKH   0.015       4   TQEQKTKHC   0.003       9   TKHCMFSLI   0.002       5   QEQKTKHCM   0.001       1   SKLTQEQKT   0.000       7   QKTKHCMFS   0.000                 V25-HLA-A3-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   SQKLKRIKK   1.200       3   FLPCISQKL   0.900       1   ILFLPCISQ   0.300       4   LPCISQKLK   0.100       2   LFLPCISQK   0.068       6   CISQKLKRI   0.045       5   PCISQKLKR   0.012       7   ISQKLKRIK   0.010       9   QKLKRIKKG   0.000                    
     [1194]                       TABLE XIII                       Start   Subsequence   Score                                    V8-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   GMGGTIPHVS   0.270       5   FLEEGMGGTI   0.270       3   SQFLEEGMGG   0.006       7   EEGMGGTIPH   0.000       8   EGMGGTIPHV   0.000       4   QFLEEGMGGT   0.000       6   LEEGMGGTIP   0.000       2   KSQFLEEGMG   0.000       1   EKSQFLEEGM   0.000       10   MGGTIPHVSP   0.000                 V13-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FLPNGINGIK   9.000       5   SLSETFLPNG   0.135       1   GSPKSLSETF   0.030       2   SPKSLSETFL   0.006       6   LSETFLPNGI   0.003       8   ETFLPNGING   0.003       4   KSLSETFLPN   0.003       9   TFLPNGINGI   0.002       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V14-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         6   RLFTFWRGPV   0.900       2   NLPLRLFTFW   0.600       3   LPLRLFTFWR   0.540       8   FTFWRGPVVV   0.050       4   PLRLFTFWRG   0.018       1   ENLPLRLFTF   0.012       9   TFWRGPVVVA   0.005       10   FWRGPVVVAI   0.004       7   LFTFWRGPVV   0.000       5   LRLFTFWRGP   0.000                 V21-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         3   KLTQEQKTKH   0.600       9   KTKHCMFSLI   0.270       2   SKLTQEQKTK   0.015       4   LTQEQKTKHC   0.007       6   QEQKTKHCMF   0.006       5   TQEQKTKHCM   0.006       8   QKTKHCMFSL   0.003       7   EQKTKHCMFS   0.001       1   LSKLTQEQKT   0.001       10   TKHCMFSLIS   0.000                 V25-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   ILFLPCISQK   150.000       4   FLPCISQKLK   10.000       8   ISQKLKRIKK   0.200       7   CISQKLKRIK   0.200       5   LPCISQKLKR   0.080       1   IILFLPCISQ   0.009       3   LFLPCISQKL   0.002       6   PCISQKLKRI   0.001       9   SQKLKRIKKG   0.000       10   QKLKRIKKGW   0.000                    
     [1195]                       TABLE XIV                       Start   Subsequence   Score                                    V8-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGTIPHV   1.350       4   FLEEGMGGT   0.068       1   KSQFLEEGM   0.003       2   SQFLEEGMG   0.001       5   LEEGMGGTI   0.001       7   EGMGGTIPH   0.000       3   QFLEEGMGG   0.000       9   MGGTIPHVS   0.000       6   EEGMGGTIP   0.000                 V13-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNGINGI   0.004       1   SPKSLSETF   0.002       4   SLSETFLPN   0.001       7   ETFLPNGIN   0.001       8   TFLPNGING   0.001       6   SETFLPNGI   0.001       3   KSLSETFLP   0.000       2   PKSLSETFL   0.000       5   LSETFLPNG   0.000                 V14-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         3   PLRLFTFWR   0.024       7   FTFWRGPVV   0.020       1   NLPLRLFTF   0.012       8   TFWRGPVVV   0.004       2   LPLRLFTFW   0.003       6   LFTFWRGPV   0.002       5   RLFTFWRGP   0.000       9   FWRGPVVVA   0.000       4   LRLFTFWRG   0.000                 V21-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   KLTQEQKTK   0.600       8   KTKHCMFSL   0.090       3   LTQEQKTKH   0.010       6   EQKTKHCMF   0.002       5   QEQKTKHCM   0.001       4   TQEQKTKHC   0.000       9   TKHCMFSLI   0.000       7   QKTKHCMFS   0.000       1   SKLTQEQKT   0.000                 V25-HLA-A1101-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   SQKLKRIKK   1.200       2   LFLPCISQK   0.300       4   LPCISQKLK   0.100       5   PCISQKLKR   0.012       3   FLPCISQKL   0.004       7   ISQKLKRIK   0.002       6   CISQKLKRI   0.002       1   ILFLPCISQ   0.002       9   QKLKRIKKG   0.000                    
     [1196]                       TABLE XV                       Start   Subsequence   Score                                    V8-HLA-A11-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   FLEEGMGGTI   0.004       3   SQFLEEGMGG   0.002       9   GMGGTIPHVS   0.001       7   EEGMGGTIPH   0.000       4   QFLEEGMGGT   0.000       8   EGMGGTIPHV   0.000       2   KSQFLEEGMG   0.000       6   LEEGMGGTIP   0.000       1   EKSQFLEEGM   0.000       10   MGGTIPHVSP   0.000                 V13-HLA-A11-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FLPNGINGIK   0.400       9   TFLPNGINGI   0.003       2   SPKSLSETFL   0.002       8   ETFLPNGING   0.001       1   GSPKSLSETF   0.001       5   SLSETFLPNG   0.000       6   LSETFLPNGI   0.000       4   KSLSETFLPN   0.000       7   SETFLPNGIN   0.000       3   PKSLSETFLP   0.000                 V14-HLA-A11-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         3   LPLRLFTFWR   0.180       6   RLFTFWRGPV   0.024       8   FTFWRGPVVV   0.020       9   TFWRGPVVVA   0.004       2   NLPLRLFTFW   0.004       7   LFTFWRGPVV   0.002       1   ENLPLRLFTF   0.001       10   FWRGPVVVAI   0.000       4   PLRLFTFWRG   0.000       5   LRLFTFWRGP   0.000                 V21-HLA-A11-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   KTKHCMFSLI   0.030       2   SKLTQEQKTK   0.015       3   KLTQEQKTKH   0.012       5   TQEQKTKHCM   0.006       8   QKTKHCMFSL   0.001       6   QEQKTKHCMF   0.001       4   LTQEQKTKHC   0.001       7   EQKTKHCMFS   0.000       10   TKHCMFSLIS   0.000       1   LSKLTQEQKT   0.000                 V25-HLA-A11-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   ILFLPCISQK   0.800       4   FLPCISQKLK   0.200       5   LPCISQKLKR   0.080       8   ISQKLKRIKK   0.040       7   CISQKLKRIK   0.040       3   LFLPCISQKL   0.003       1   IILFLPCISQ   0.001       9   SQKLKRIKKG   0.000       10   QKLKRIKKGW   0.000       6   PCISQKLKRI   0.000                    
     [1197]                       TABLE XVI                       Start   Subsequence   Score                                    V8-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   KSQFLEEGM   1.800       4   FLEEGMGGT   0.180       5   LEEGMGGTI   0.150       9   MGGTIPHVS   0.140       8   GMGGTIPHV   0.100       3   QFLEEGMGG   0.090       7   EGMGGTIPH   0.15       2   SQFLEEGMG   0.010       6   EEGMGGTIP   0.001                 V13-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   2.400       9   FLPNGINGI   1.800       4   SLSETFLPN   0.144       6   SETFLPNGI   0.144       7   ETFLPNGIN   0.100       8   TFLPNGING   0.090       2   PKSLSETFL   0.040       3   KSLSETFLP   0.030       5   LSETFLPNG   0.015                 V14-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   3.000       8   TFWRGPVVV   0.500       6   LFTFWRGPV   0.500       2   LPLRLFTFW   0.216       7   FTFWRGPVV   0.100       9   FWRGPVVVA   0.100       5   RLFTFWRGP   0.020       4   LRLFTFWRG   0.002       3   PLRLFTFWR   0.001                 V21-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   KTKHCMFSL   8.000       6   EQKTKHCMF   2.000       4   TQEQKTKHC   0.150       9   TKHCMFSLI   0.120       5   QEQKTKHCM   0.075       2   KLTQEQKTK   0.020       1   SKLTQEQKT   0.020       3   LTQEQKTKH   0.020       7   QKTKHCMFS   0.010                 V25-HLA-A24-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   11.088       6   CISQKLKRI   1.000       2   LFLPCISQK   0.090       7   ISQKLKRIK   0.018       8   SQKLKRIKK   0.011       1   ILFLPCISQ   0.010       4   LPCISQKLK   0.010       9   QKLKRIKKG   0.002       5   PCISQKLKR   0.002                    
     [1198]                       TABLE XVII                       Start   Subsequence   Score                                    V8-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   FLEEGMGGTI   1.800       4   QFLEEGMGGT   0.900       8   EGMGGTIPHV   0.150       9   GMGGTIPHVS   0.140       1   EKSQFLEEGM   0.060       2   KSQFLEEGMG   0.030       10   MGGTIPHVSP   0.010       3   SQFLEEGMGG   0.010       6   LEEGMGGTIP   0.002       7   EEGMGGTIPH   0.001                 V13-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   TFLPNGINGI   10.800       2   SPKSLSETFL   4.000       1   GSPKSLSETF   3.600       6   LSETFLPNGI   2.160       4   KSLSETFLPN   0.360       10   FLPNGINGIK   0.021       5   SLSETFLPNG   0.012       7   SETFLPNGIN   0.010       8   ETFLPNGING   0.010       3   PKSLSETFLP   0.000                 V14-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         1   ENLPLRLFTF   3.600       10   FWRGPVVVAI   1.400       7   LFTFWRGPVV   0.500       9   TFWRGPVVVA   0.500       2   NLPLRLFTFW   0.216       6   RLFTFWRGPV   0.200       8   FTFWRGPVVV   0.100       3   LPLRLFTFWR   0.015       5   LRLFTFWRGP   0.002       4   PLRLFTFWRG   0.001                 V21-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   KTKHCMFSLI   2.400       5   TQEQKTKHCM   0.750       8   QKTKHCMFSL   0.400       6   QEQKTKHCMF   0.300       4   LTQEQKTKHC   0.180       1   LSKLTQEQKT   0.132       7   EQKTKHCMFS   0.100       3   KLTQEQKTKH   0.022       10   TKHCMFSLIS   0.010       2   SKLTQEQKTK   0.002                 V25-HLA-A24-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         3   LFLPCISQKL   66.528       6   PCISQKLKRI   0.150       10   QKLKRIKKGW   0.021       8   ISQKLKRIKK   0.017       4   FLPCISQKLK   0.015       1   IILFLPCISQ   0.015       7   CISQKLKRIK   0.012       9   SQKLKRIKKG   0.011       5   LPCISQKLKR   0.011       2   ILFLPCISQK   0.010                    
     [1199]                       TABLE XVIII                       Start   Subsequence   Score                                    V8-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   KSQFLEEGM   1.000       8   GMGGTIPHV   0.200       7   EGMGGTIPH   0.030       4   FLEEGMGGT   0.030       9   MGGTIPHVS   0.020       5   LEEGMGGTI   0.012       2   SQFLEEGMG   0.010       6   EEGMGGTIP   0.001       3   QFLEEGMGG   0.001                 V13-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNGINGI   0.400       1   SPKSLSETF   0.400       6   SETFLPNGI   0.040       2   PKSLSETFL   0.040       7   ETFLPNGIN   0.030       4   SLSETFLPN   0.020       3   KSLSETFLP   0.010       5   LSETFLPNG   0.003       8   TFLPNGING   0.001                 V14-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   LPLRLFTFW   0.400       7   FTFWRGPVV   0.200       9   FWRGPVVVA   0.150       6   LFTFWRGPV   0.030       8   TFWRGPVVV   0.020       1   NLPLRLFTF   0.020       3   PLRLFTFWR   0.010       5   RLFTFWRGP   0.010       4   LRLFTFWRG   0.001                 V21-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   KTKHCMFSL   4.000       5   QEQKTKHCM   0.100       9   TKHCMFSLI   0.040       4   TQEQKTKHC   0.030       6   EQKTKHCMF   0.020       3   LTQEQKTKH   0.010       1   SKLTQEQKT   0.010       2   KLTQEQKTK   0.010       7   QKTKHCMFS   0.002                 V25-HLA-B7-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   4.000       6   CISQKLKRI   0.400       4   LPCISQKLK   0.200       8   SQKLKRIKK   0.015       1   ILFLPCISQ   0.015       7   ISQKLKRIK   0.010       9   QKLKRIKKG   0.001       2   LFLPCISQK   0.001       5   PCISQKLKR   0.001                    
     [1200]                       TABLE XIX                       Start   Subsequence   Score                                    V8-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         8   EGMGGTIPHV   0.600       5   FLEEGMGGTI   0.120       1   EKSQFLEEGM   0.100       9   GMGGTIPHVS   0.020       10   MGGTIPHVSP   0.015       4   QFLEEGMGGT   0.010       3   SQFLEEGMGG   0.010       2   KSQFLEEGMG   0.010       7   EEGMGGTIPH   0.001       6   LEEGMGGTIP   0.000                 V13-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   SPKSLSETFL   80.000       6   LSETFLPNGI   0.120       9   TFLPNGINGI   0.040       1   GSPKSLSETF   0.020       4   KSLSETFLPN   0.020       10   FLPNGINGIK   0.010       5   SLSETFLPNG   0.010       8   ETFLPNGING   0.010       7   SETFLPNGIN   0.003       3   PKSLSETFLP   0.000                 V14-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         10   FWRGPVVVAI   0.400       6   RLFTFWRGPV   0.300       8   FTFWRGPVVV   0.200       3   LPLRLFTFWR   0.200       2   NLPLRLFTFW   0.020       7   LFTFWRGPVV   0.020       1   ENLPLRLFTF   0.020       9   TFWRGPVVVA   0.015       4   PLRLFTFWRG   0.010       5   LRLFTFWRGP   0.001                 V21-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   KTKHCMFSLI   0.400       8   QKTKHCMFSL   0.400       5   TQEQKTKHCM   0.300       1   LSKLTQEQKT   0.100       4   LTQEQKTKHC   0.100       7   EQKTKHCMFS   0.020       3   KLTQEQKTKH   0.010       10   TKHCMFSLIS   0.002       6   QEQKTKHCMF   0.002       2   SKLTQEQKTK   0.001                 V25-HLA-B7-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         3   LFLPCISQKL   0.400       5   LPCISQKLKR   0.200       6   PCISQKLKRI   0.040       8   ISQKLKRIKK   0.015       1   IILFLPCISQ   0.015       7   CISQKLKRIK   0.010       4   FLPCISQKLK   0.010       9   SQKLKRIKKG   0.010       2   ILFLPCISQK   0.010       10   QKLKRIKKGW   0.002                    
     [1201]                       TABLE XX                       Start   Subsequence   Score                                    V8-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   KSQFLEEGM   20.000       8   GMGGTIPHV   0.200       9   MGGTIPHVS   0.100       4   FLEEGMGGT   0.060       2   SQFLEEGMG   0.015       5   LEEGMGGTI   0.012       7   EGMGGTIPH   0.010       3   QFLEEGMGG   0.003       6   EEGMGGTIP   0.001                 V13-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   60.000       9   FLPNGINGI   0.400       4   SLSETFLPN   0.200       3   KSLSETFLP   0.150       7   ETFLPNGIN   0.100       6   SETFLPNGI   0.040       5   LSETFLPNG   0.015       2   PKSLSETFL   0.010       8   TFLPNGING   0.001                 V14-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 29; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         2   LPLRLFTFW   10.000       1   NLPLRLFTF   1.000       7   FTFWRGPVV   0.200       9   FWRGPVVVA   0.030       6   LFTFWRGPV   0.020       5   RLFTFWRGP   0.020       8   TFWRGPVVV   0.020       3   PLRLFTFWR   0.003       4   LRLFTFWRG   0.001                 V21-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         8   KTKHCMFSL   6.000       6   EQKTKHCMF   3.000       5   QEQKTKHCM   0.200       9   TKHCMFSLI   0.040       2   KLTQEQKTK   0.030       4   TQEQKTKHC   0.030       3   LTQEQKTKH   0.020       7   QKTKHCMFS   0.010       1   SKLTQEQKT   0.010                 V25-HLA-B3501-9mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is 9       amino acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   1.000       6   CISQKLKRI   0.400       4   LPCISQKLK   0.200       7   ISQKLKRIK   0.050       8   SQKLKRIKK   0.030       1   ILFLPCISQ   0.010       9   QKLKRIKKG   0.001       2   LFLPCISQK   0.001       5   PCISQKLKR   0.001                    
     [1202]                       TABLE XXI                       Start   Subsequence   Score                                    V8-HLA-B35-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 17; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   FLEEGMGGTI   0.240       8   EGMGGTIPHV   0.200       1   EKSQFLEEGM   0.200       2   KSQFLEEGMG   0.150       9   GMGGTIPHVS   0.100       4   QFLEEGMGGT   0.020       3   SQFLEEGMGG   0.015       10   MGGTIPHVSP   0.010       7   EEGMGGTIPH   0.001       6   LEEGMGGTIP   0.000                 V13-HLA-B35-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         2   SPKSLSETFL   60.000       1   GSPKSLSETF   5.000       4   KSLSETFLPN   1.000       6   LSETFLPNGI   0.600       9   TFLPNGINGI   0.040       5   SLSETFLPNG   0.020       10   FLPNGINGIK   0.010       7   SETFLPNGIN   0.010       8   ETFLPNGING   0.010       3   PKSLSETFLP   0.000                 V14-HLA-B35-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         1   ENLPLRLFTF   1.000       2   NLPLRLFTFW   0.500       6   RLFTFWRGPV   0.400       8   FTFWRGPVVV   0.200       3   LPLRLFTFWR   0.200       10   FWRGPVVVAI   0.120       7   LFTFWRGPVV   0.020       9   TFWRGPVVVA   0.010       4   PLRLFTFWRG   0.003       5   LRLFTFWRGP   0.001                 V21-HLA-B35-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 43; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         9   KTKHCMFSLI   2.400       1   LSKLTQEQKT   1.500       5   TQEQKTKHCM   0.600       7   EQKTKHCMFS   0.300       4   LTQEQKTKHC   0.200       6   QEQKTKHCMF   0.100       8   QKTKHCMFSL   0.100       3   KLTQEQKTKH   0.020       10   TKHCMFSLIS   0.010       2   SKLTQEQKTK   0.002                 V25-HLA-B35-10mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 51; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the start       position plus nine.                         5   LPCISQKLKR   0.200       3   LFLPCISQKL   0.100       8   ISQKLKRIKK   0.050       10   QKLKRIKKGW   0.050       6   PCISQKLKRI   0.040       9   SQKLKRIKKG   0.030       4   FLPCISQKLK   0.010       7   CISQKLKRIK   0.010       2   ILFLPCISQK   0.010       1   IILFIPCISQ   0.010                    
     [1203]                       TABLE XXII                       Pos   123456789   score                                    V1-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         158   P K DASR Q VY   27       419   F E EEYY R FY   27       405   I S TFHV L IY   26       221   S L ATFF F LY   23       263   A I TLLS L VY   23       392   S F IQST L GY   23       276   L A AAYQ L YY   22       280   Y Q LYYG T KY   21       244   Q S DFYK I PI   19       101   L W DLRH L LV   18       189   P I DLGS L SS   18       198   A R EIEN L PL   18       231   F V RDVI H PY   18       240   A R NQQS D FY   18       275   L L AAAY Q LY   18       311   F F AMVH V AY   18       90   F V AIHR E HY   17       117   S N NMRI N QY   17       327   R S ERYL F LN   17       388   W R EFSF I QS   17       427   Y T PPNF V LA   17       443   I L DLLQ L CR   17       444   L D LLQL C RY   17       46   T I RLIR C GY   16       66   A S EFFP H VV   16       124   Q Y PESN A EY   16       200   E I ENLP L RL   16       330   R Y LFLN M AY   16       352   E E VWRI E MY   16       272   L A GLLA A AY   15       323   L P MRRS E RY   15       351   E E EVWR I EM   15       415   W K RAFE E EY   15       416   K R AFEE E YY   15       13   L S ETCL P NG   14       38   S G DFAK S LT   14       98   Y T SLWD L RH   14       178   V I ELAR Q LN   14       406   S T FHVL I YG   14       94   H R EHYT S LW   13       135   S L FPDS L IV   13       137   F P DSLI V KG   13       251   P I EIVN K TL   13       396   S T LGYV A LL   13                 V2-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         23   L S LPSS W DY   23       36   P C PADF F LY   20       17   F T PFSC L SL   13       28   S W DYRC P PP   12                 V5A-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         7   F T FWRG P VV   9       9   F W RGPV V VA   5                 V5B-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         21   E L EFVF L LT   24       1   W R EFSF I QI   17       17   Q T ELEL E FV   16       13   F A DTQT E LE   15       19   E L ELEF V FL   14                 V6-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         34   F L EEGI G GT   14       28   G W EKSQ F LE   12       35   L E EGIG G TI   12       29   W E KSQF L EE   11       41   G T IPHV S PE   11       1   V L PSIV I LG   9       9   G K IILF L PC   9       19   S R KLKR I KK   9       2   L P SIVI L GK   8       6   V I LGKI I LF   8       16   P C ISRK L KR   8       7   I L GKII L FL   7       37   E G IGGT I PH   7       46   V S PERV T VM   7       3   P S IVIL G KI   6       5   I V ILGK I IL   6       12   I L FLPC I SR   6                 V7A-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   L S ETFL P NG   14       4   S L SETF L PN   12       8   T F LPNG I NG   9       7   E T FLPN G IN   8       3   K S LSET F LP   6                 V7B-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         5   A Y QQST L GY   22       9   S T LGYV A LL   13                 V7C-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         59   W T EEAG A TA   17       90   V T EDDE A QD   17       99   S I DPPE S PD   17       167   K L ETII L SK   17       32   L S EIVL P IE   16       51   S T PPPP A MW   14       154   W S LGEF L GS   14       5   I L DLSV E VL   13       69   A Q ESGI R NK   13       9   S V EVLA S PA   12       38   P I EWQQ D RK   12       60   T E EAGA T AE   12       66   T A EAQE S GI   12       93   D D EAQD S ID   12       104   E S PDRA L KA   12       105   S P DRAL K AA   12       123   H T NGVG P LW   12       130   L W EFLL R LL   12       96   A Q DSID P PE   11       102   P P ESPD R AL   11       128   G P LWEF L LR   11       143   A S GTLS L AF   11       156   L G EFLG S GT   11       42   Q Q DRKI P PL   10       78   S S SSSQ I PV   10       82   S Q IPVV G VV   10       91   T E DDEA Q DS   10       92   E D DEAQ D SI   10       115   S W RNPV L PH   10       176   L T QEQK S KH   10       177   T Q EQKS K HC   10       26   N I LRGG L SE   9       50   L S TPPP P AM   9       79   S S SSQI P VV   9       131   W E FLLR L LK   9       2   S I VILD L SV   8       7   D L SVEV L AS   8       21   K C LGAN I LR   8       31   G L SEIV L PI   8       81   S S QIPV V GV   8       124   T N GVGP L WE   8       132   E F LLRL L KS   8       141   Q A ASGT L SL   8       162   S G TWMK L ET   8       169   E T IILS K LT   8                 V8-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   F L EEGM G GT   14       5   L E EGMG G TI   12       7   E G MGGT I PH   7                 V13-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   L S ETFL P NG   14       4   S L SETF L PN   12       8   T F LPNG I NG   9       7   E T FLPN G IN   8       3   K S LSET F LP   6                 V14-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         7   F T FWRG P VV   9       9   F W RGPV V VA   5                 V21-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         3   L T QEQK T KH   10       4   T Q EQKT K HC   10       1   S K LTQE Q KT   6       8   K T KHCM F SL   6       9   T K HCMF S LI   5                 V25-HLA-A1-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   P C ISQK L KR   10       8   S Q KLKR I KK   9       1   I L FLPC I SQ   6       2   L F LPCI S QK   4       3   F L PCIS Q KL   4       7   I S QKLK R IK   4                    
     [1204]                       TABLE XXIII                       Pos   123456789   score                                    V1-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids, and       the end position for each       peptide is the start       position plus eight.                         365   IMSLG L LSL   29       271   YLAGL L AAA   28       433   VLALV L PSI   28       227   FLYSF V RDV   27       360   YISFG I MSL   27       396   STLGY V ALL   27       17   CLPNG I NGI   26       100   SLWDL R HLL   26       135   SLFPD S LIV   26       203   NLPLR L FTL   26       402   ALLIS T FHV   26       436   LVLPS I VIL   26       128   SNAEY L ASL   25       140   SLIVK G FNV   25       187   FIPID L GSL   25       210   TLWRG P VVV   25       261   IVAIT L LSL   25       403   LLIST F HVL   25       5   SMMGS P KSL   24       264   ITLLS L VYL   24       274   GLLAA A YQL   24       307   LLSFF F AMV   24       369   GLLSL L AVT   24       48   RLIRC G YHV   23       49   LIRCG Y HVV   23       141   LIVKG F NVV   23       313   AMVHV A YSL   23       374   LAVTS I PSV   23       393   FIQST L GYV   23       441   IVILD L LQL   23       106   HLLVG K ILI   22       180   ELARQ L NFI   22       254   IVNKT L PIV   22       258   TLPIV A ITL   22       262   VAITL L SLV   22       265   TLLSL V YLA   22       267   LSLVY L AGL   22       268   SLVYL A GLL   22       333   FLNMA Y QQV   22       378   SIPSV S NAL   22       404   LISTF H VLI   21       435   ALVLP S IVI   21       107   LLVGK I LID   20       108   LVGKI L IDV   20       112   ILIDV S NNM   20       173   QARQQ V IEL   20       184   QLNFI P IDL   20       368   LGLLS L LAV   20       65   FASEF F PHV   19       83   LTKTN I IFV   19       133   LASLF P DSL   19       177   QVIEL A RQL   19       257   KTLPI V AIT   19       306   GLLSF F FAM   19       366   MSLGL L SLL   19       434   LALVL P SIV   19       27   DARKV T VGV   18       196   SSARE I ENL   18       209   FTLWR G PVV   18       259   LPIVA I TLL   18       367   SLGLL S LLA   18       371   LSLLA V TSI   18       397   TLGYV A LLI   18       41   FAKSL T IRL   17       81   DALTK T NII   17       85   KTNII F VAI   17       103   DLRHL L VGK   17       104   LRHLL V GKI   17       153   ALQLG P KDA   17       155   QLGPK D ASR   17       212   WRGPV V VAI   17       250   IPIEI V NKT   17       253   EIVNK T LPI   17       363   FGIMS L GLL   17       370   LLSLL A VTS   17       410   VLIYG W KRA   17       428   TPPNF V LAL   17       438   LPSIV I LDL   17       442   VILDL L QLC   17       25   IKDAR K VTV   16       68   EFFPH V VDV   16       88   IIFVA I HRE   16       93   IHREH Y TSL   16       99   TSLWD L RHL   16       132   YLASL F PDS   16       148   VVSAW A LQL   16       171   NIQAR Q QVI   16       190   IDLGS L SSA   16       200   EIENL P LRL   16       372   SLLAV T SIP   16       12   SLSET C LPN   15       44   SLTIR L IRC   15       50   IRCGY H VVI   15       111   KILID V SNN   15       211   LWRGP V VVA   15       217   VVAIS L ATF   15       221   SLATF F FLY   15       247   FYKIP I EIV   15       249   KIPIE I VNK   15       251   PIEIV N KTL   15       256   NKTLP I VAI   15       270   VYLAG L LAA   15       299   LQCRK Q LGL   15       324   PMRRS E RYL   15       331   YLFLN M AYQ   15       335   NMAYQ Q VHA   15       385   ALNWR E FSF   15       400   YVALL I STF   15       437   VLPSI V ILD   15       23   NGIKD A RKV   14       37   GSGDF A KSL   14       39   GDFAK S LTI   14       42   AKSLT I RLI   14       164   QVYIC S NNI   14       166   YICSN N IQA   14       220   ISLAT F FFL   14       223   ATFFF L YSF   14       266   LLSLV Y LAG   14       275   LLAAA Y QLY   14       278   AAYQL Y YGT   14       300   QCRKQ L GLL   14       309   SFFFA M VHV   14       362   SFGIM S LGL   14       373   LLAVT S IPS   14       395   QSTLG Y VAL   14       411   LIYGW K RAF   14       427   YTPPN F VLA   14       443   ILDLL Q LCR   14                 V2-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   GLQAL S LSL   25       1   SGSPG L QAL   21       8   ALSLS L SSG   18       17   FTPFS C LSL   17       10   SLSLS S GFT   16       3   SPGLQ A LSL   15       12   SLSSG F TPF   14       15   SGFTP F SCL   14       24   SLPSS W DYR   12                 V5A-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         7   FTFWR G PVV   17       1   NLPLR L FTF   16       8   TFWRG P VVV   15       9   FWRGP V VVA   14       5   RLFTF W RGP   13       3   PLRLF T FWR   10       6   LFTFW R GPV   10                 V5B-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         20   LELEF V FLL   21       22   LEFVF L LTL   21       24   FVFLL T LLL   20       19   ELELE F VFL   18       12   SFADT Q TEL   17       17   QTELE L EFV   17       8   QIFCS F ADT   15       6   FIQIF C SFA   14       14   ADTQT E LEL   14       23   EFVFL L TLL   11       21   ELEFV F LLT   10                 V6-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         7   ILGKI I LFL   27       38   GIGGT I PHV   26       10   KIILF L PCI   25       14   FLPCI S RKL   23       34   FLEEG I GGT   23       5   IVILG K IIL   20       17   CISRK L KRI   20       45   HVSPE R VTV   20       4   SIVIL G KII   18       6   VILGK I ILF   18       12   ILFLP C ISR   16       1   VLPSI V ILG   15       27   KGWEK S QFL   15       3   PSIVI L GKI   13       35   LEEGI G GTI   13       41   GTIPH V SPE   13                 V7A-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNG I NGI   27       4   SLSET F LPN   15                 V7B-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         9   STLGY V ALL   27       3   NMAYQ Q STL   21       6   YQQST L GYV   16       8   QSTLG Y VAL   14                 V7C-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         27   ILRGG L SEI   30       4   VILDL S VEV   27       5   ILDLS V EVL   26       31   GLSEI V LPI   26       129   PLWEF L LRL   26       148   SLAFT S WSL   25       2   SIVIL D LSV   24       141   QAASG T LSL   23       155   SLGEF L GSG   21       163   GTWMK L ETI   21       81   SSQIP V VGV   20       82   SQIPV V GVV   20       119   PVLPH T NGV   19       133   FLLRL L KSQ   19       165   WMKLE T IIL   19       24   GANIL R GGL   18       57   AMWTE E AGA   18       112   AANSW R NPV   18       126   GVGPL W EFL   18       12   VLASP A AAW   17       79   SSSSQ I PVV   17       134   LLRLL K SQA   17       167   KLETI I LSK   17       168   LETII L SKL   17       171   IILSK L TQE   17       172   ILSKL T QEQ   17       42   QQDRK I PPL   16       142   AASGT L SLA   16       160   LGSGT W MKL   16       7   DLSVE V LAS   15       17   AAAWK C LGA   15       22   CLGAN I LRG   15       26   NILRG G LSE   15       28   LRGGL S EIV   15       130   LWEFL L RLL   15       136   RLLKS Q AAS   15       137   LLKSQ A ASG   15       159   FLGSG T WMK   15       185   CMFSL I SGS   15       83   QIPVV G VVT   14                 V8-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGT I PHV   26       4   FLEEG M GGT   19       5   LEEGM G GTI   13                 V13-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNG I NGI   27       4   SLSET F LPN   15                 V14-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         7   FTFWR G PVV   17       1   NLPLR L FTF   16       8   TFWRG P VVV   15       9   FWRGP V VVA   14       5   RLFTF W RGP   13       3   PLRLF T FWR   10       6   LFTFW R GPV   10                 V21-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   KTKHC M FSL   16       2   KLTQE Q KTK   11       1   SKLTQ E QKT   10       3   LTQEQ K TKH   10       9   TKHCM F SLI   8                 V25-HLA-A0201-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCI S QKL   23       6   CISQK L KRI   20       1   ILFLP C ISQ   16                    
     [1205]                       TABLE XXIV                       Pos   12345689   score                                    V1-HLA-A0203-9mers-98P4B6       NoResultsFound.       V2-HLA-A0203-9mers-98P4B6       NoResultsFound.       V5A-HLA-A0203-9mers-98P4B6       NoResultsFound.       V5B-HLA-A0203-9mers-98P4B6       NoResultsFound.       V7A-HLA-A0203-9mers-98P4B6       NoResultsFound.       V7B-HLA-A0203-9mers-98P4B6       NoResultsFound.       V7C-HLA-A0203-9mers-98P4B6       NoResultsFound.       V8-HLA-A0203-9mers-98P4B6       NoResultsFound.       V13-HLA-A0203-9mers-98P4B6       NoResultsFound.       V14-HLA-A0203-9mers-98P4B6       NoResultsFound.       V21-HLA-A0203-9mers-98P4B6       NoResultsFound.       V25-HLA-A0203-9mers-98P4B6       NoResultsFound.                    
     [1206]                       TABLE XXV                       Pos   123456789   score                                    V1-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         103   DL R HL LV GK   27       56   VV I GS RN PK   26       249   KI P IE IV NK   26       3   SI S MM GS PK   25       155   QL G PK DA SR   25       263   AI T LL SL VY   25       210   TL W RG PV VV   24       48   RL I RC GY HV   23       142   IV K GF NV VS   23       217   VV A IS LA TF   23       400   YV A LL IS TF   23       177   QV I EL AR QL   22       205   PL R LF TL WR   22       281   QL Y YG TK YR   22       370   LL S LL AV TS   22       441   IV I LD LL QL   22       35   VI G SG DF AK   21       77   TH H ED AL TK   21       148   VV S AW AL QL   21       231   FV R DV IH PY   21       269   LV Y LA GL LA   21       375   AV T SI PS VS   21       385   AL N WR EF SF   21       274   GL L AA AY QL   20       322   CL P MR RS ER   20       409   HV L IY GW KR   20       443   IL D LL QL CR   20       46   TI R LI RC GY   19       87   NI I FV AI HR   19       90   FV A IH RE HY   19       258   TL P IV AI TL   19       261   IV A IT LL SL   19       275   LL A AA YQ LY   19       279   AY Q LY YG TK   19       369   GL L SL LA VT   19       372   SL L AV TS IP   19       411   LI Y GW KR AF   19       436   LV L PS IV IL   19       34   GV I GS GD FA   18       92   AI H RE HY TS   18       140   SL I VK GF NV   18       191   DL G SL SS AR   18       221   SL A TF FF LY   18       435   AL V LP SI VI   18       22   IN G IK DA RK   17       49   LI R CG YH VV   17       82   AL T KT NI IF   17       111   KI L ID VS NN   17       112   IL I DV SN NM   17       135   SL F PD SL IV   17       153   AL Q LG PK DA   17       164   QV Y IC SN NI   17       203   NL P LR LF TL   17       271   YL A GL LA AA   17       304   QL G LL SF FF   17       381   SV S NA LN WR   17       397   TL G YV AL LI   17       403   LL I ST FH VL   17       432   FV L AL VL PS   17       32   TV G VI GS GD   16       107   LL V GK IL ID   16       151   AW A LQ LG PK   16       171   NI Q AR QQ VI   16       189   PI D LG SL SS   16       216   VV V AI SL AT   16       219   AI S LA TF FF   16       234   DV I HP YA RN   16       266   LL S LV YL AG   16       302   RK Q LG LL SF   16       402   AL L IS TF HV   16       12   SL S ET CL PN   15       21   GI N GI KD AR   15       24   GI K DA RK VT   15       30   KV T VG VI GS   15       121   RI N QY PE SN   15       136   LF P DS LI VK   15       179   IE L AR QL NF   15       268   SL V YL AG LL   15       356   RI E MY IS FG   15       367   SL G LL SL LA   15       410   VL I YG WK RA   15       433   VL A LV LP SI   15       25   IK D AR KV TV   14       44   SL T IR LI RC   14       57   VI G SR NP KF   14       61   RN P KF AS EF   14       106   HL L VG KI LI   14       141   LI V KG FN VV   14       180   EL A RQ LN FI   14       207   RL F TL WR GP   14       227   FL Y SF VR DV   14       235   VI H PY AR NQ   14       241   RN Q QS DF YK   14       251   PI E IV NK TL   14       272   LA G LL AA AY   14       294   WL E TW LQ CR   14       303   KQ L FL LS FF   14       307   LL S FF FA MV   14       330   RY L FL NM AY   14       331   YL F LN MA YQ   14       340   QV H AN IE NS   14       353   EV W RI EM YI   14       364   GI M SL GL LS   14       17   CL P NG IN GI   13       18   LP N GI NG IK   13       26   KD A RK VT VG   13       43   KS L TI RL IR   13       55   HV V IG SR NP   13       70   FP H VV DV TH   13       100   SL W DL RH LL   13       113   LI D VS NN MR   13       147   NV V SA WA LQ   13       158   PK D AS RQ VY   13       184   QL N FI PI DL   13       200   EI E NL PL RL   13       211   LW R GP VV VA   13       215   PV V VA IS LA   13       253   EI V NK TL PI   13       260   PI V AI TL LS   13       306   GL L SF FF AM   13       311   FF A MV HV AY   13       314   MV H VA YS LC   13       333   FL N MA YQ QV   13       360   YI S FG IM SL   13       392   SF I QS TL GY   13       408   FH V LI YG WK   13       440   SI V IL DL LQ   13                 V2-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   AL S LS LS SG   19       12   SL S SG FT PF   18       5   GL Q AL SL SL   17       22   CL S LP SS WD   15       24   SL P SS WD YR   15       10   SL S LS SG FT   13       23   LS L PS SW DY   11       33   CP P PC PA DF   11       3   SP G LQ AL SL   10       7   QA L SL SL SS   9       9   LS L SL SS GF   9       11   LS L SS GF TP   9       21   SC L SL PS SW   9       37   CP A DF FL YF   9                 V5A-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NL P LR LF TF   21       3   PL R LF TF WR   19       5   RL F TF WR GP   14       8   TF W RG PV VV   14       9   FW R GP VV VA   13                 V5B-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         19   EL E LE FV FL   15       21   EL E FV FL LT   14       24   FV F LL TL LL   14       8   QI F CS FA DT   13       6   FI Q IF CS FA   12       18   TE L EL EF VF   11       5   SF I QI FC SF   10       9   IF C SF AD TQ   9       2   RE F SF IQ IF   8       16   TQ T EL EL EF   8       22   LE F VF LL TL   7                 V6-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         45   HV S PE RV TV   22       23   KR I KK GW EK   20       12   IL F LP CI SR   19       5   IV I LG KI IL   18       13   LF L PC IS RK   18       6   VI L GK II LF   17       21   KL K RI KK GW   17       2   LP S IV IL GK   15       7   IL G KI IL FL   15       10   KI I LF LP CI   15       18   IS R KL KR IK   15       19   SR K LK RI KK   15       24   RI K KG WE KS   15       34   FL E EG IG GT   14       4   SI V IL GK II   13       11   II L FL PC IS   13       26   KK G WE KS QF   13       42   TI P HV SP ER   13       15   LP C IS RK LK   12       16   PC I SR KL KR   12       17   CI S RK LK RI   12       37   EG I GG TI PH   11       1   VL P SI VI LG   10       14   FL P CI SR KL   10       35   LE E GI GG TI   10       38   GI G GT IP HV   10                 V7A-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   SL S ET FL PN   15       9   FL P NG IN GI   13       1   SP K SL SE TF   10       8   TF L PN GI NG   8                 V7B-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         1   FL N MA YQ QS   13       5   AY Q QS TL GY   12       8   QS T LG YV AL   10       7   QQ S TL GY VA   9       3   NM A YQ QS TL   8       9   ST L GY VA LL   8       4   MA Y QQ ST LG                 V7C-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         167   KL E TI IL SK   28       175   KL T QE QK SK   25       109   AL K AA NS WR   24       3   IV I LD LS VE   23       26   NI L RG GL SE   23       159   FL G SG TW MK   23       27   IL R GG LS EI   22       83   QI P VV GV VT   22       13   LA S PA AA WK   20       35   IV L PI EW QQ   20       134   LL R LL KS QA   20       136   RL L KS QA AS   20       11   EV L AS PA AA   19       137   LL K SQ AA SG   19       170   TI I LS KL TQ   19       12   VL A SP AA AW   18       38   PI E WQ QD RK   18       73   GI R NK SS SS   18       5   IL D LS VE VL   17       9   SV E VL AS PA   17       45   RK I PP LS TP   17       103   PE S PD RA LK   17       133   FL L RL LK SQ   17       171   II L SK LT QE   17       2   SI V IL DL SV   15       4   VI L DL SV EV   15       22   CL G AN IL RG   15       46   KI P PL ST PP   15       69   AQ E SG IR NK   15       99   SI D PP ES PD   15       119   PV L PH TN GV   15       120   VL P HT NG VG   15       131   WE F LL RL LK   15       155   SL G EF LG SG   15       173   LS K LT QE QK   15       7   DL S VE VL AS   14       31   GL S EI VL PI   14       36   VL P IE WQ QD   14       85   PV V GV VT ED   14       129   PL W EF LL RL   14       146   TL S LA FT SW   14       148   SL A FT SW SL   14       25   AN I LR GG LS   13       82   SQ I PV VG VV   13       126   GV G PL WE FL   13                 V8-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         4   FL E EG MG GT   14       5   LE E GM GG TI   10       3   QF L EE GM GG   9       7   EG M GG TI PH   8       6   EE G MG GT IP   6                 V13-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   SL S ET FL PN   15       9   FL P NG IN GI   13       1   SP K SL SE TF   10       8   TF L PN GI NG   8                 V14-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         1   NL P LR LF TF   21       3   PL R LF TF WR   19       5   RL F TF WR GP   14       8   TF W RG PV VV   14       9   FW R GP VV VA   13                 V21-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   KL T QE QK TK   27                 V25-HLA-A3-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   LF L PC IS QK   21       1   IL F LP CI SQ   15       8   SQ K LK RI KK   15       7   IS Q KL KR IK   12       4   LP C IS QK LK   11       3   FL P CI SQ KL   10       5   PC I SQ KL KR   10                    
     [1207]                       TABLE XXVI                       Pos   123456789   score                                    V1-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         352   EEVWRIEMY   29       75   DVTHHEDAL   28       441   IVILDLLQL   28       177   QVIELARQL   26       223   ATFFFLYSF   25       231   FVRDVIHPY   25       400   YVALLISTF   25       200   EIENLPLRL   24       261   IVAITLLSL   24       217   VVAISLATF   23       436   LVLPSIVIL   23       96   EHYTSLWDL   22       234   DVIHPYARN   22       353   EVWRIEMYI   22       390   EFSFIQSTL   22       396   STLGYVALL   21       90   FVAIHREHY   20       148   VVSAWALQL   20       253   EIVNKTLPI   20       264   ITLLSLVYL   20       15   ETCLPNGIN   19       68   EFFPHVVDV   19       115   DVSNNMRIN   19       215   PVVVAISLA   19       296   ETWLQCRKQ   19       31   VTVGVIGSG   18       187   FIPIDLGSL   18       216   VVVAISLAT   18       406   STFHVLIYG   18       439   PSIVILDLL   18       2   ESISMMGSP   17       45   LTIRLIRCG   17       46   TIRLIRCGY   17       108   LVGKILIDV   17       263   AITLLSLVY   17       360   YISFGIMSL   17       363   FGIMSLGLL   17       30   KVTVGVIGS   16       117   SNNMRINQY   16       128   SNAEYLASL   16       259   LPVAITILL   16       355   WRIEMYISF   16       392   SFIQSTLGY   16       405   ISTFHVLIY   16       432   FVLALVLPS   16       32   TVGVIGSGD   15       34   GVIGSGDFA   15       72   HVVDVTHHE   15       147   NVVSAWALQ   15       257   KTLPIVAIT   15       268   SLVYLAGLL   15       329   ERYLFLNMA   15       340   QVHANIENS   15       375   AVTSIPSVS   15       378   SIPSVSNAL   15       381   SVSNALNWR   15       428   TPPNFVLAL   15       55   HVVIGSRNP   14       56   VVIGSRNPK   14       57   VIGSRNPKF   14       83   LTKTNIIFV   14       131   EYLASLFPD   14       138   PDSLIVKGF   14       180   ELARQLNFI   14       214   GPVVVAISL   14       218   VAISLATFF   14       254   IVNKTLPIV   14       302   RKQLGLLSF   14       303   KQLGLLSFF   14       316   HVAYSLCLP   14       365   IMSLGLLSL   14       366   MSLGLLSLL   14       430   PNFVLALVL   14       444   LDLLQLCRY   14                 V2-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         17   FTPFSCLSL   18       1   SGSPGLQAL   15       15   SGFTPFSCL   14       3   SPGLQALSL   11       5   GLQALSLSL   11       9   LSLSLSSGF   11       18   TPFSCLSLP   11       23   LSLPSSWDY   11       12   SLSSGFTPF   10       36   PCPADFFLY   10       37   CPADFFLYF   10       33   CPPPCPADF   9       35   PPCPADFFL   9       30   DYRCPPPCP   8       34   PPPCPADFF   8                 V5A-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   13       7   FTFWRGPVV   13                 V5B-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         23   EFVFLLTLL   27       24   FVFLLTLLL   24       15   DTQTELELE   20       19   ELELEFVFL   18       22   LEFVFLLTL   18       2   REFSFIQIF   17       5   SFIQIFCSF   16       16   TQTELELEF   14       20   LELEFVFLL   14       3   EFSFIQIFC   13                 V6-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         5   IVILGKIIL   23       6   VILGKIILF   18       41   GTIPHVSPE   18       7   ILGKIILFL   15       37   EGIGGTIPH   15       30   EKSQFLEEG   14       3   PSIVILGKI   12       10   KIILFLPCI   12       45   HVSPERVTV   12       4   SIVILGKII   11       14   FLPCISRKL   11       27   KGWEKSQFL   11       36   EEGIGGTIP   11                 V7A-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         7   ETFLPNGIN   23       1   SPKSLSETF   12                 V7B-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         9   STLGYVALL   21       5   AYQQSTLGY   11       3   NMAYQQSTL   10       8   QSTLGYVAL   10                 V7C-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         169   ETIILSKLT   23       34   EIVLPIEWQ   22       11   EVLASPAAA   21       151   FTSWSLGEF   21       179   EQKSKHCMF   21       126   GVGPLWEFL   20       3   IVILDLSVE   19       85   PVVGVVTED   18       168   LETIILSKL   17       125   NGVGPLWEF   16       132   EFLLRLLKS   16       95   EAQDSIDPP   15       129   PLWEFLLRL   15       7   DLSVEVLAS   14       35   IVLPIEWQQ   14       68   EAQESGIRN   14       88   GVVTEDDEA   14       89   VVTEDDEAQ   14       98   DSIDPPESP   14       122   PHTNGVGPL   14       163   GTWMLLETI   14       9   SVEVLASPA   13       42   QQDRKIPPL   13       92   EDDEAQDSI   13       104   ESPDRALKA   13       130   LWEFLLRLL   13       2   SIVILDLSV   12       5   ILDLSVEVL   12       59   WTEEAGATA   12       152   TSWSLGEFL   12       176   LTQEQKSKH   12       8   LSVEVLASP   11       45   RKIPPLSTP   11       51   STPPPPAMW   11       62   EAGATAEAQ   11       65   ATAEAQESG   11       71   ESGIRNKSS   11       82   SQIPVVGVV   11       119   PVLPHTNGV   11       141   QAASGTLSL   11       143   ASGTLSLAF   11       145   GTLSLAFTS   11       158   EFLGSGTWM   11       170   TIILSKLTQ   11       171   IILSKLTQE   11       185   CMFSLISGS   11                 V8-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         6   EEGMGGTIP   11       7   EGMGGTIPH   11       2   SQFLEEGMG   7                 V13-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         7   ETFLPNGIN   23       1   SPKSLSETF   12                 V14-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   13       7   FTFWRGPVV   13                 V21-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         6   EQKTKHCMF   20       8   KTKHCMFSL   17       3   LTQEQKTKH   11                 V25-HLA-A26-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   11       6   CISQKLKRI   9       2   LFLPCISQK   7       5   PCISQKLKR   7       1   ILFLPCISQ   6       9   QKLKRIKKG   5                    
     [1208]                       TABLE XXVII                       Pos   123456789   score                                    V1-HLAB0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         428   TPPNFVLAL   24       438   LPSIVILDL   24       259   LPIVAITLL   21       291   FPPWLETWL   21       125   YPESNAEYL   20       214   GPVVVAISL   20       250   IPIEIVNKT   18       62   NPKFASEFF   17       211   LWRGPVVVA   17       429   PPNFVLALV   17       157   GPKDASRQV   16       326   RRSERYLFL   16       148   VVSAWALQL   15       198   AREIENLPL   15       365   IMSLGLLSL   15       426   FYTPPNFVL   15       93   IHREHYTSL   14       220   ISLATFFFL   14       261   IVAITLLSL   14       287   KYRRFPPWL   14       379   IPSVSNALN   14       396   STLGYVALL   14       5   SMMGSPKSL   13       10   PKSLSETCL   13       137   FPDSLIVKG   13       173   QARQQVIEL   13       200   EIENLPLRL   13       264   ITLLSLVYL   13       289   RRFPPWLET   13       300   QCRKQLGLL   13       315   VHVAYSLCL   13       362   SFGIMSLGL   13       390   EFSFIQSTL   13       395   QSTLGYVAL   13       430   PNFVLALVL   13       436   LVLPSIVIL   13       441   IVILDLLQL   13       18   LPNGINGIK   12       27   DARKVTVGV   12       50   IRCGYHVVI   12       70   FPHVVDVTH   12       105   RHLLVGKIL   12       128   SNAEYLASL   12       133   LASLFPDSL   12       188   IPIDLGSLS   12       202   ENLPLRLFT   12       204   LPLRLFTLW   12       212   WRGPVVVAI   12       219   AISLATFFF   12       256   NKTLPIVAI   12       299   LQCRKQLGL   12       313   AMVHVAYSL   12       324   PMRRSERYL   12       360   YISFGIMSL   12       366   MSLGLLSLL   12       403   LLISTFHVL   12       435   ALVLPSIVI   12       25   IKDARKVTV   11       37   GSGDFAKSL   11       41   FAKSLTIRL   11       68   EFFPHVVDV   11       75   DVTHHEDAL   11       85   KTNIIFVAI   11       96   EHYTSLWDL   11       100   SLWDLRHLL   11       134   ASLFPDSLI   11       146   FNVVSAWAL   11       196   SSAREIENL   11       237   HPYARNQQS   11       253   EIVNKTLPI   11       267   LSLVYLAGL   11       271   YLAGLLAAA   11       274   GLLAAAYQL   11       292   PPWLETWLQ   11       297   TWLQCRKQL   11       323   LPMRRSERY   11       328   SERYLFLNM   11       378   SIPSVSNAL   11       394   IQSTLGYVA   11       425   RFYTPPNFV   11                 V2-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   SPGLQALSL   23       35   PPCPADFFL   22       34   PPPCPADFF   20       37   CPADFFLYF   20       33   CPPPCPADF   18       1   SGSPGLQAL   14       15   SGFTPFSCL   14       5   GLQALSLSL   13       17   FTPFSCLSL   12       25   LPSSWDYRC   12       12   SLSSGFTPF   11       31   YRCPPPCPA   11                 V5A-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         9   FWRGPVVVA   17       2   LPLRLFTFW   13       7   FTFWRGPVV   9       8   TFWRGPVVV   9       6   LFTFWRGPV   8                 V5B-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         19   ELELEFVFL   15       14   ADTQTELEL   14       24   FVFLLTLLL   13       12   SFADTQTEL   12       22   LEFVFLLTL   12       23   EFVFLLTLL   12       20   LELEFVFLL   11       21   ELEFVFLLT   10       10   FCSFADTQT   9       8   QIFCSFADT   8       16   TQTELELEF   8       1   WREFSFIQI   7       2   REFSFIQIF   7       5   SFIQIFCSF   7       6   FIQIFCSFA   7       17   QTELELEFV   7       18   TELELEFVF   7                 V6-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         43   IPHVSPERV   17       7   ILGKIILFL   16       2   LPSIVILGK   14       27   KGWEKSQFL   12       45   HVSPERVTV   12       5   IVILGKIIL   11       15   LPCISRKLK   11       14   FLPCISRKL   10       38   GIGGTIPHV   10       44   PHVSPERVT   10       35   LEEGIGGTI   9       46   VSPERVTVM   9       6   VILGKIILF   8       10   KIILFLPCI   8       17   CISRKLKRI   8       26   KKGWEKSQF   8                 V7A-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   16       2   PKSLSETFL   14                 V7B-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         9   STLGYVALL   14       8   QSTLGYVAL   13       3   NMAYQQSTL   11       7   QQSTLGYVA   10       2   LNMAYQQST   8       6   YQQSTLGYV   6                 V7C-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         102   PPESPDRAL   24       15   SPAAAWKCL   22       52   TPPPPAMWT   20       55   PPAMWTEEA   18       105   SPDRALKAA   18       101   DPPESPDRA   16       113   ANSWRNPVL   16       5   ILDLSVEVL   14       47   IPPLSTPPP   14       84   IPVVGVVTE   14       118   NPVLPHTNG   14       141   QAASGTLSL   14       160   LGSGTWMKL   14       29   RGGLSEIVL   13       42   QQDRKIPPL   13       49   PLSTPPPPA   13       121   LPHTNGVGP   13       126   GVGPLWEFL   13       128   GPLWEFLLR   13       31   GLSEIVLPI   12       48   PPLSTPPPP   12       50   LSTPPPPAM   12       54   PPPAMWTEE   12       61   EEAGATAEA   12       81   SSQIPVVGV   12       122   PHTNGVGPL   12       129   PLWEFLLRL   12       139   KSQAASGTL   12       142   AASGTLSLA   12       143   ASGTLSLAF   12       152   TSWSLGEFL   12       17   AAAWKCLGA   11       24   GANILRGGL   11       27   ILRGGLSEI   11       44   DRKIPPLST   11       53   PPPPAMWTE   11       125   NGVGPLWEF   11       148   SLAFTSWSL   11       158   EFLGSGTWM   11       165   WMKLETIIL   11       181   KSKHCMFSL   11                 V8-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGTIPHV   10       5   LEEGMGGTI   9       1   KSQFLEEGM   7       4   FLEEGMGGT   6       7   EGMGGTIPH   6       6   EEGMGGTIP   4                 V13-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   16       2   PKSLSETFL   14                 V14-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         9   FWRGPVVVA   17       2   LPLRLFTFW   13       7   FTFWRGPVV   9       8   TFWRGPVVV   9       6   LFTFWRGPV   8                 V21-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start       position plus eight.                         8   KTKHCMFSL   11       5   QEQKTKHCM   7       6   EQKTKHCMF   7       9   TKHCMFSLI   7       1   SKLTQEQKT   6                 V25-HLA-B0702-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   10       4   LPCISQKLK   10       6   CISQKLKRI   8       1   ILFLPCISQ   4                    
     [1209]                       TABLE XXVIII                       Pos   123456789   score                                    V1-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         41   FAKSLTIRL   25       203   NLPLRLFTL   25       62   NPKFASEFF   22       173   QARQQVIEL   22       253   EIVNKTLPI   22       57   VIGSRNPKF   20       81   DALTKTNII   20       285   GTKYRRFPP   20       299   LQCRKQLGL   20       326   RRSERYLFL   20       385   ALNWREFSF   20       93   IHREHYTSL   19       140   SLIVKGFNV   19       268   SLVYLAGLL   19       9   SPKSLSETC   18       28   ARKVTVGVI   18       100   SLWDLRHLL   18       171   NIQARQQVI   18       214   GPVVVAISL   18       259   LPIVAITLL   18       428   TPPNFVLAL   18       39   GDFAKSLTI   17       107   LLVGKILID   17       157   GPKDASRQV   17       274   GLLAAAYQL   17       291   FPPWLETWL   17       378   SIPSVSNAL   17       438   LPSIVILDL   17       24   GIKDARKVT   16       44   SLTIRLIRC   16       125   YPESNAEYL   16       155   QLGPKDASR   16       184   QLNFIPIDL   16       200   EIENLPLRL   16       237   HPYARNQQS   16       239   YARNQQSDF   16       251   PIEIVNKTL   16       258   TLPIVAITL   16       283   YYGTKYRRF   16       287   KYRRFPPWL   16       300   QCRKQLGLL   16       324   PMRRSERYL   16       403   LLISTFHVL   16       133   LASLFPDSL   15       159   KDASRQVYI   15       179   IELARQLNF   15       187   FIPIDLGSL   15       322   CLPMRRSER   15       360   YISFGIMSL   15       106   HLLVGKILI   14       128   SNAEYLASL   14       180   ELARQLNFI   14       197   SAREIENLP   14       245   SDFYKIPIE   14       298   WLQCRKQLG   14       323   LPMRRSERY   14       433   VLALVLPSI   14       5   SMMGSPKSL   13       17   CLPNGINGI   13       82   ALTKTNIIF   13       91   VAIHREHYT   13       103   DLRHLLVGK   13       142   IVKGFNVVS   13       146   FNVVSAWAL   13       196   SSAREIENL   13       205   PLRLFTLWR   13       264   ITLLSLVYL   13       304   QLGLLSFFF   13       395   QSTLGYVAL   13       396   STLGYVALL   13       397   TLGYVALLI   13       435   ALVLPSIVI   13       37   GSGDFAKSL   12       60   SRNPKFASE   12       96   EHYTSLWDL   12       105   RHLLVGKIL   12       109   VGKILIDVS   12       177   QVIELARQL   12       247   FYKIPIEIV   12       325   MRRSERYLF   12       362   SFGIMSLGL   12       365   IMSLGLLSL   12       390   EFSFIQSTL   12       414   GWKRAFEEE   12       426   FYTPPNFVL   12       436   LVLPSIVIL   12       441   IVILDLLQL   12                 V2-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   SPGLQALSL   19       5   GLQALSLSL   17       35   PPCPADFFL   16       12   SLSSGFTPF   14       1   SGSPGLQAL   13       15   SGFTPFSCL   12       33   CPPPCPADF   12       34   PPPCPADFF   12       37   CPADFFLYF   12       17   FTPFSCLSL   11       28   SWDYRCPPP   11       10   SLSLSSGFT   9                    
     [1210]                       TABLE XXIX                       Pos   123456789   score                                    V5A-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   21       3   PLRLFTFWR   13                 V5B-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight                         19   ELELEFVFL   20       12   SFADTQTEL   13       20   LELEFVFLL   13       23   EFVFLLTLL   12       24   FVFLLTLLL   12       14   ADTQTELEL   11       22   LEFVFLLTL   11       16   TQTELELEF   9                 V6-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         19   SRKLKRIKK   23       6   VILGKIILF   22       27   KGWEKSQFL   22       17   CISRKLKRI   21       7   ILGKIILFL   18       14   FLPCISRKL   17       21   KLKRIKKGW   17       22   LKRIKKGWE   16       24   RIKKGWEKS   14       4   SIVILGKII   13       5   IVILGKIIL   12       25   IKKGWEKSQ   12       46   VSPERVTVM   12       10   KIILFLPCI   11       23   KRIKKGWEK   11       29   WEKSQFLEE   11                 V7A-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   24       9   FLPNGINGI   14       2   PKSLSETFL   11                 V7B-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         8   QSTLGYVAL   13       9   STLGYVALL   13       3   NMAYQQSTL   11       1   FLNMAYQQS   7                 V7C-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         179   EQKSKHCMF   28       42   QQDRKIPPL   21       73   GIRNKSSSS   21       165   WMKLETIIL   21       27   ILRGGLSEI   20       181   KSKHCMFSL   20       5   ILDLSVEVL   19       15   SPAAAWKCL   19       113   ANSWRNPVL   19       129   PLWEFLLRL   18       148   SLAFTSWSL   18       102   PPESPDRAL   17       109   ALKAANSWR   17       163   GTWMKLETI   17       19   AWKCLGANI   16       31   GLSEIVLPI   16       137   LLKSQAASG   16       24   GANILRGGL   15       171   IILSKLTQE   15       17   AAAWKCLGA   14       141   QAASGTLSL   14       134   LLRLLKSQA   13                 V8-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   FLEEGMGGT   9       5   LEEGMGGTI   6                 V13-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SPKSLSETF   24       9   FLPNGINGI   14       2   PKSLSETFL   11                 V14-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   21       3   PLRLFTFWR   13                 V21-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         6   EQKTKHCMF   28       8   KTKHCMFSL   20       4   TQEQKTKHC   11                 V25-HLA-B08-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   SQKLKRIKK   23       6   CISQKLKRI   21       3   FLPCISQKL   17                 V1-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         93   IHREHYTSL   23       96   EHYTSLWDL   21       105   RHLLVGKIL   20       315   VHVAYSLCL   20       200   EIENLPLRL   15       426   FYTPPNFVL   15       436   LVLPSIVIL   15       54   YHVVIGSRN   14       264   ITLLSLVYL   14       360   YISFGIMSL   14       365   IMSLGLLSL   14       395   QSTLGYVAL   14       77   THHEDALTK   13       99   TSLWDLRHL   13       125   YPESNAEYL   13       173   QARQQVIEL   13       177   QVIELARQL   13       236   IHPYARNQQ   13       261   IVAITLLSL   13       297   TWLQCRKQL   13       390   EFSFIQSTL   13       428   TPPNFVLAL   13       430   PNFVLALVL   13       5   SMMGSPKSL   12       37   GSGDFAKSL   12       41   FAKSLTIRL   12       71   PHVVDVTHH   12       78   HHEDALTKT   12       100   SLWDLRHLL   12       128   SNAEYLASL   12       133   LASLFPDSL   12       146   FNVVSAWAL   12       196   SSAREIENL   12       214   GPVVVAISL   12       220   ISLATFFFL   12       251   PIEIVNKTL   12       258   TLPIVAITL   12       259   LPIVAITLL   12       287   KYRRFPPWL   12       324   PMRRSERYL   12       326   RRSERYLFL   12       396   STLGYVALL   12       403   LLISTFHVL   12       438   LPSIVILDL   12       441   IVILDLLQL   12       10   PKSLSETCL   11       75   DVTHHEDAL   11       148   VVSAWALQL   11       184   QLNFIPIDL   11       198   AREIENLPL   11       201   IENLPLRLF   11       203   NLPLRLFTL   11       267   LSLVYLAGL   11       274   GLLAAAYQL   11       283   YYGTKYRRF   11       300   QCRKQLGLL   11       341   VHANIENSW   11       351   EEEVWRIEM   11       366   MSLGLLSLL   11       378   SIPSVSNAL   11       383   SNALNWREF   11       411   LIYGWKRAF   11       439   PSIVILDLL   11                 V2-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SGSPGLQAL   15       35   PPCPADFFL   12       5   GLQALSLSL   11       15   SGFTPFSCL   11       3   SPGLQALSL   10       17   FTPFSCLSL   10       33   CPPPCPADF   9       12   SLSSGFTPF   8       37   CPADFFLYF   8       34   PPPCPADFF   7                 V5A-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         1   NLPLRLFTF   7       8   TFWRGPVVV   7       9   FWRGPVVVA   7       7   FTFWRGPVV   3                 V5B-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         19   ELELEFVFL   14       12   SFADTQTEL   13       14   ADTQTELEL   12       20   LELEFVFLL   12       22   LEFVFLLTL   12       23   EFVFLLTLL   11       18   TELELEFVF   10       24   FVFLLTLLL   10       16   TQTELELEF   9       2   REFSFIQIF   7       5   SFIQIFCSF   7                 V6-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         44   PHVSPERVT   15       5   IVILGKIIL   14       7   ILGKIILFL   14       14   FLPCISRKL   12       27   KGWEKSQFL   11       46   VSPERVTVM   10       6   VILGKIILF   8       26   KKGWEKSQF   7       45   HVSPERVTV   7                 V7A-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   11       1   SPKSLSETF   7                 V7B-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         8   QSTLGYVAL   14       3   NMAYQQSTL   12       9   STLGYVALL   12                 V7C-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         122   PHTNGVGPL   22       5   ILDLSVEVL   15       102   PPESPDRAL   15       113   ANSWRNPVL   14       126   GVGPLWEFL   13       129   PLWEFLLRL   13       130   LWEFLLRLL   13       24   GANILRGGL   12       29   RGGLSEIVL   12       42   QQDRKIPPL   12       50   LSTPPPPAM   12       141   QAASGTLSL   12       160   LGSGTWMKL   12       15   SPAAAWKCL   11       20   WKCLGANIL   11       139   KSQAASGTL   11       148   SLAFTSWSL   11       152   TSWSLGEFL   11       181   KSKHCMFSL   11       127   VGPLWEFLL   10       165   WMKLETIIL   10       168   LETIILSKL   10       183   KHCMFSLIS   10                 V8-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   KSQFLEEGM   6       4   FLEEGMGGT   4       8   GMGGTIPHV   4       5   LEEGMGGTI   3       7   EGMGGTIPH   3       9   MGGTIPHVS   3       6   EEGMGGT1P   2                 V13-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   11       1   SPKSLSETF   7                 V14-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         1   NLPLRLFTF   7       8   TFWRGPVVV   7       9   FWRGPVVVA   7       7   FTFWRGPVV   3                 V21-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         8   KTKHCMFSL   11       5   QEQKTKHCM   8       6   EQKTKHCMF   7       4   TQEQKTKHC                 V25-HLA-B1510-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   10       7   ISQKLKRIK   6       6   CISQKLKRI   4                    
     [1211]                       TABLE XXX                       Pos   123456789   score                                    V1-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         326   RRSERYLFL   26       424   YRFYTPPNF   26       355   WRIEMYISF   25       198   AREIENLPL   24       240   ARNQQSDFY   22       325   MRRSERYLF   22       47   IRLIRCGYH   21       50   IRCGYHVVI   21       104   LRHLLVGKI   21       289   RRFPPWLET   21       416   KRAFEEEYY   21       212   WRGPVVVAI   20       302   RKQLGLLSF   20       417   RAFEEEYYR   20       28   ARKVTVGVI   19       61   RNPKFASEF   19       182   ARQLNFIPI   19       199   REIENLPLR   19       249   KIPIEIVNK   19       303   KQLGLLSFF   19       53   GYHVVIGSR   18       105   RHLLVGKIL   18       179   IELARQLNF   18       214   GPVVVAISL   18       241   RNQQSDFYK   18       274   GLLAAAYQL   18       282   LYYGTKYRR   18       436   LVLPSIVIL   18       21   GINGIKDAR   17       174   ARQQVIELA   17       223   ATFFFLYSF   17       259   LPIVAITLL   17       264   ITLLSLVYL   17       330   RYLFLNMAY   17       360   YISFGIMSL   17       365   IMSLGLLSL   17       366   MSLGLLSLL   17       400   YVALLISTF   17       430   PNFVLALVL   17       441   IVILDLLQL   17       22   INGIKDARK   16       39   GDFAKSLTI   16       40   DFAKSLTIR   16       43   KSLTIRLIR   16       56   VVIGSRNPK   16       112   ILIDVSNNM   16       175   RQQVIELAR   16       177   QVIELARQL   16       196   SSAREIENL   16       206   LRLFTLWRG   16       218   VAISLATFF   16       225   FFFLYSFVR   16       233   RDVIHPYAR   16       313   AMVHVAYSL   16       319   YSLCLPMRR   16       396   STLGYVALL   16       418   AFEEEYYRF   16       443   ILDLLQLCR   16       37   GSGDFAKSL   15       82   ALTKTNIIF   15       87   NIIFVAIHR   15       93   IHREHYTSL   15       96   EHYTSLWDL   15       155   QLGPKDASR   15       173   QARQQVIEL   15       295   LETWLQCRK   15       297   TWLQCRKQL   15       329   ERYLFLNMA   15       390   EFSFIQSTL   15       401   VALLISTFH   15       409   HVLIYGWKR   15       411   LIYGWKRAF   15       438   LPSIVILDL   15       5   SMMGSPKSL   14       10   PKSLSETCL   14       18   LPNGINGIK   14       33   VGVIGSGDF   14       41   FAKSLTIRL   14       57   VIGSRNPKF   14       60   SRNPKFASE   14       77   THHEDALTK   14       120   MRINQYPES   14       128   SNAEYLASL   14       136   LFPDSLIVK   14       146   FNVVSAWAL   14       162   SRQVYICSN   14       167   ICSNNIQAR   14       193   GSLSSAREI   14       200   EIENLPLRL   14       201   IENLPLRLF   14       217   VVAISLATF   14       258   TLPIVAITL   14       261   IVAITLLSL   14       263   AITLLSLVY   14       267   LSLVYLAGL   14       280   YQLYYGTKY   14       281   QLYYGTKYR   14       299   LQCRKQLGL   14       301   CRKQLGLLS   14       308   LSFFFAMVH   14       318   AYSLCLPMR   14       363   FGIMSLGLL   14       392   SFIQSTLGY   14       395   QSTLGYVAL   14       426   FYTPPNFVL   14       439   PSIVILDLL   14       444   LDLLQLCRY   14       35   VIGSGDFAK   13       98   YTSLWDLRH   13       99   TSLWDLRHL   13       103   DLRHLLVGK   13       113   LIDVSNNMR   13       117   SNNMRINQY   13       124   QYPESNAEY   13       129   NAEYLASLF   13       138   PDSLIVKGF   13       148   VVSAWALQL   13       151   AWALQLGPK   13       191   DLGSLSSAR   13       203   NLPLRLFTL   13       220   ISLATFFFL   13       229   YSFVRDVIH   13       239   YARNQQSDF   13       246   DFYKIPIEI   13       251   PIEIVNKTL   13       268   SLVYLAGLL   13       279   AYQLYYGTK   13       283   YYGTKYRRF   13       287   KYRRFPPWL   13       291   FPPWLETWL   13       300   QCRKQLGLL   13       304   QLGLLSFFF   13       306   GLLSFFFAM   13       315   VHVAYSLCL   13       337   AYQQVHANI   13       348   SWNEEEVWR   13       371   LSLLAVTSI   13       378   SIPSVSNAL   13       388   WREFSFIQS   13       403   LLISTFHVL   13       408   FHVLIYGWK   13       435   ALVLPSIVI   13       17   CLPNGINGI   12       70   FPHVVDVTH   12       71   PHVVDVTHH   12       80   EDALTKTNI   12       86   TNIIFVAIH   12       89   IFVAIHREH   12       106   HLLVGKILI   12       114   IDVSNNMRI   12       133   LASLFPDSL   12       134   ASLFPDSLI   12       164   QVYICSNNI   12       184   QLNFIPIDL   12       187   FIPIDLGSL   12       205   PLRLFTLWR   12       219   AISLATFFF   12       231   FVRDVIHPY   12       232   VRDVIHPYA   12       256   NKTLPIVAI   12       272   LAGLLAAAY   12       288   YRRFPPWLE   12       317   VAYSLCLPM   12       322   CLPMRRSER   12       328   SERYLFLNM   12       349   WNEEEVWRI   12       352   EEVWRIEMY   12       362   SFGIMSLGL   12       381   SVSNALNWR   12       383   SNALNWREF   12       385   ALNWREFSF   12       428   TPPNFVLAL   12                 V2-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   GLQALSLSL   17       9   LSLSLSSGF   15       15   SGFTPFSCL   15       1   SGSPGLQAL   14       3   SPGLQALSL   14       12   SLSSGFTPF   14       23   LSLPSSWDY   14       17   FTPFSCLSL   13       31   YRCPPPCPA   12       33   CPPPCPADF   12       34   PPPCPADFF   12       35   PPCPADFFL   12       24   SLPSSWDYR   11       37   CPADFFLYF   11       2   GSPGLQALS   9       36   PCPADFFLY   8                 V5A-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   LRLFTFWRG   15       1   NLPLRLFTF   13       3   PLRLFTFWR   11       5   RLFTFWRGP   7                 V5B-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   REFSFIQIF   20       1   WREFSFIQI   19       5   SFIQIFCSF   16       22   LEFVFLLTL   16       24   FVFLLTLLL   16       12   SFADTQTEL   15       14   ADTQTELEL   15       18   TELELEFVF   15       23   EFVFLLTLL   15       16   TQTELELEF   14       20   LELEFVFLL   14       19   ELELEFVFL   13                 V6-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         23   KRIKKGWEK   29       19   SRKLKRIKK   25       6   VILGKIILF   19       13   LFLPCISRK   19       5   IVILGKIIL   18       7   ILGKIILFL   18       12   ILFLPCISR   18       16   PCISRKLKR   16       26   KKGWEKSQF   16       2   LPSIVILGK   15       18   ISRKLKRIK   15       27   KGWEKSQFL   15       37   EGIGGTIPH   15       14   FLPCISRKL   14       42   TIPHVSPER   14                 V7A-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   14       1   SPKSLSETF   13       9   FLPNGINGI   12       6   SETFLPNGI   8       7   ETFLPNGIN   6       8   TFLPNGING   6                 V7B-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         9   STLGYVALL   16       3   NMAYQQSTL   14       8   QSTLGYVAL   14       5   AYQQSTLGY   13       4   MAYQQSTLG   7                 V7C-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         21   KCLGANILR   18       29   RGGLSEIVL   18       69   AQESGIRNK   18       167   KLETIILSK   18       175   KLTQEQKSK   18       74   IRNKSSSSS   17       125   NGVGPLWEF   17       128   GPLWEFLLR   17       107   DRALKAANS   16       131   WEFLLRLLK   16       5   ILDLSVEVL   15       20   WKCLGANIL   15       37   LPIEWQQDR   15       42   QQDRKIPPL   15       67   AEAQESGIR   15       100   IDPPESPDR   15       126   GVGPLWEFL   15       129   PLWEFLLRL   15       135   LRLLKSQAA   15       158   EFLGSGTWM   15       160   LGSGTWMKL   15       168   LETIILSKL   15       24   GANILRGGL   14       27   ILRGGLSEI   14       28   LRGGLSEIV   14       38   PIEWQQDRK   14       113   ANSWRNPVL   14       116   WRNPVLPHT   14       139   KSQAASGTL   14       141   QAASGTLSL   14       143   ASGTLSLAF   14       173   LSKLTQEQK   14       13   LASPAAAWK   13       31   GLSEIVLPI   13       44   DRKIPPLST   13       109   ALKAANSWR   13       122   PHTNGVGPL   13       148   SLAFTSWSL   13       151   FTSWSLGEF   13       159   FLGSGTWMK   13       165   WMKLETIIL   13       176   LTQEQKSKH   13       181   KSKHCMFSL   13       39   IEWQQDRKI   12       102   PPESPDRAL   12       103   PESPDRALK   12       130   LWEFLLRLL   12       136   RLLKSQAAS   12       163   GTWMKLETI   12       178   QEQKSKHCM   12       19   AWKCLGANI   11       45   RKIPPLSTP   11       50   LSTPPPPAM   11       108   RALKAANSW   11       115   SWRNPVLPH   11       127   VGPLWEFLL   11       152   TSWSLGEFL   11       157   GEFLGSGTW   11       164   TWMKLETII   11       179   EQKSKHCMF   11       15   SPAAAWKCL   10       30   GGLSEIVLP   10       76   NKSSSSSQI   10       92   EDDEAQDSI   10       75   RNKSSSSSQ   8       85   PVVGVVTED   8       145   GTLSLAFTS   8       171   IILSKLTQE   8       185   CMFSLISGS   8                 V8-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         7   EGMGGTIPH   13       1   KSQFLEEGM   11       5   LEEGMGGTI   9       8   GMGGTIPHV   9                 V13-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   14       1   SPKSLSETF   13       9   FLPNGINGI   12       6   SETFLPNGI   8       7   ETFLPNGIN   6       8   TFLPNGING   6                 V14-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   LRLFTFWRG   15       1   NLPLRLFTF   13       3   PLRLFTFWR   11       5   RLFTFWRGP   7                 V21-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         2   KLTQEQKTK   18       3   LTQEQKTKH   14       8   KTKHCMFSL   13       5   QEQKTKHCM   11       6   EQKTKHCMF   11                 V25-HLA-B2705-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   LFLPCISQK   18       5   PCISQKLKR   16       7   ISQKLKRIK   15       8   SQKLKRIKK   15       3   FLPCISQKL   14       4   LPCISQKLK   13       6   CISQKLKRI   12       9   QKLKRIKKG   9       1   ILFLPCISQ   8                    
     [1212]                       TABLE XXXI                       Pos   123456789   score                                    V1-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         326   RRSERYLFL   25       198   AREIENLPL   22       424   YRFYTPPNF   22       212   WRGPVVVAI   21       28   ARKVTVGVI   20       50   IRCGYHVVI   20       325   MRRSERYLF   20       104   LRHLLVGKI   19       182   ARQLNFIPI   19       355   WRIEMYISF   19       274   GLLAAAYQL   18       289   RRFPPWLET   18       105   RHLLVGKIL   16       193   GSLSSAREI   15       214   GPVVVAISL   15       441   IVILDLLQL   15       37   GSGDFAKSL   14       39   GDFAKSLTI   14       48   RLIRCGYHV   14       264   ITLLSLVYL   14       306   GLLSFFFAM   14       313   AMVHVAYSL   14       425   RFYTPPNFV   14       430   PNFVLALVL   14       436   LVLPSIVIL   14       47   IRLIRCGYH   13       61   RNPKFASEF   13       68   EFFPHVVDV   13       99   TSLWDLRHL   13       135   SLFPDSLIV   13       148   VVSAWALQL   13       177   QVIELARQL   13       179   IELARQLNF   13       206   LRLFTLWRG   13       220   ISLATFFFL   13       287   KYRRFPPWL   13       297   TWLQCRKQL   13       302   RKQLGLLSF   13       396   STLGYVALL   13       41   FAKSLTIRL   12       85   KTNIIFVAI   12       96   EHYTSLWDL   12       114   IDVSNNMRI   12       120   MRINQYPES   12       125   YPESNAEYL   12       146   FNVVSAWAL   12       157   GPKDASRQV   12       159   KDASRQVYI   12       200   EIENLPLRL   12       223   ATFFFLYSF   12       227   FLYSFVRDV   12       232   VRDVIHPYA   12       261   IVAITLLSL   12       267   LSLVYLAGL   12       268   SLVYLAGLL   12       303   KQLGLLSFF   12       315   VHVAYSLCL   12       317   VAYSLCLPM   12       329   ERYLFLNMA   12       365   IMSLGLLSL   12       366   MSLGLLSLL   12       395   QSTLGYVAL   12       403   LLISTFHVL   12       416   KRAFEEEYY   12       426   FYTPPNFVL   12       428   TPPNFVLAL   12       439   PSIVILDLL   12                 V2-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   GLQALSLSL   14       3   SPGLQALSL   12       15   SGFTPFSCL   12       1   SGSPGLQAL   11       9   LSLSLSSGF   11       17   FTPFSCLSL   11       31   YRCPPPCPA   11       35   PPCPADFFL   11       12   SLSSGFTPF   9       33   CPPPCPADF   9       34   PPPCPADFF   9       37   CPADFFLYF   9       32   RCPPPCPAD   6                 V5A-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight                         4   LRLFTFWRG   13       7   FTFWRGPVV   11       6   LFTFWRGPV   9       8   TFWRGPVVV   9       1   NLPLRLFTF   8       5   RLFTFWRGP   6                 V5B-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   WREFSFIQI   19       2   REFSFIQIF   15       14   ADTQTELEL   13       20   LELEFVFLL   13       22   LEFVFLLTL   13       24   FVFLLTLLL   13       19   ELELEFVFL   11       23   EFVFLLTLL   11       5   SFIQIFCSF   10       12   SFADTQTEL   10       16   TQTELELEF   10       18   TELELEFVF   10                 V6-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         7   ILGKIILFL   13       23   KRIKKGWEK   13       5   IVILGKIIL   12       10   KIILFLPCI   12       27   KGWEKSQFL   12       38   GIGGTIPHV   12       14   FLPCISRKL   11       26   KKGWEKSQF   11       3   PSIVILGKI   10       6   VILGKIILF   10       19   SRKLKRIKK   10       31   KSQFLEEGI   10       43   IPHVSPERV   10       45   HVSPERVTV   10       4   SIVILGKII   9       17   CISRKLKRI   9       35   LEEGIGGTI   9       46   VSPERVTVM   9       20   RKLKRIKKG   6       41   GTIPHVSPE   6                 V7A-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   10       1   SPKSLSETF   9       6   SETFLPNGI   9       9   FLPNGINGI   8       3   KSLSETFLP   5       8   TFLPNGING                 V7B-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         9   STLGYVALL   13       8   QSTLGYVAL   12       3   NMAYQQSTL   10       6   YQQSTLGYV   9                 V7C-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         28   LRGGLSEIV   18       29   RGGLSEIVL   14       31   GLSEIVLPI   14       126   GVGPLWEFL   14       24   GANILRGGL   13       5   ILDLSVEVL   12       107   DRALKAANS   12       113   ANSWRNPVL   12       116   WRNPVLPHT   12       122   PHTNGVGPL   12       129   PLWEFLLRL   12       135   LRLLKSQAA   12       139   KSQAASGTL   12       141   QAASGTLSL   12       168   LETIILSKL   12       181   KSKHCMFSL   12       4   VILDLSVEV   11       20   WKCLGANIL   11       42   QQDRKIPPL   11       44   DRKIPPLST   11       50   LSTPPPPAM   11       74   IRNKSSSSS   11       82   SQIPVVGVV   11       102   PPESPDRAL   11       119   PVLPHTNGV   11       152   TSWSLGEFL   11       163   GTWMKLETI   11       2   SIVILDLSV   10       15   SPAAAWKCL   10       19   AWKCLGANI   10       76   NKSSSSSQI   10       79   SSSSQIPVV   10       81   SSQIPVVGV   10       112   AANSWRNPV   10       127   VGPLWEFLL   10       130   LWEFLLRLL   10       143   ASGTLSLAF   10       148   SLAFTSWSL   10       158   EFLGSGTWM   10       160   LGSGTWMKL   10       165   WMKLETIIL   10       27   ILRGGLSEI   9       39   IEWQQDRKI   9       78   SSSSSQIPV   9       125   NGVGPLWEF   9       179   EQKSKHCMF   9       66   TAEAQESGI   8       92   EDDEAQDSI   8       151   FTSWSLGEF   8       164   TWMKLETII   8       178   QEQKSKHCM   8       182   SKHCMFSLI   8                 V8-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         8   GMGGTIPHV   12       1   KSQFLEEGM   10       5   LEEGMGGTI   8                 V13-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   PKSLSETFL   10       1   SPKSLSETF   9       6   SETFLPNGI   9       9   FLPNGINGI   8       3   KSLSETFLP   5       8   TFLPNGING   4                 V14-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         4   LRLFTFWRG   13       7   FTFWRGPVV   11       6   LFTFWRGPV   9       8   TFWRGPVVV   9       1   NLPLRLFTF   8       5   RLFTFWRGP   6                 V21-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         8   KTKHCMFSL   12       5   QEQKTKHCM   8       6   EQKTKHCMF   8       9   TKHCMFSLI   8                 V25-HLA-B2709-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   11       6   CISQKLKRI   9       2   LFLPCISQK   4                    
     [1213]                       TABLE XXXII                       Pos   123456789   score                                    V1-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         352   EEVWRIEMY   26       201   IENLPLRLF   24       179   IELARQLNF   23       14   SETCLPNGI   21       419   FEEEYYRFY   21       357   IEMYISFGI   20       42   AKSLTIRLI   18       436   LVLPSIVIL   18       117   SNNMRINQY   17       144   KGFNVVSAW   17       259   LPIVAITLL   17       441   IVILDLLQL   17       5   SMMGSPKSL   16       138   PDSLIVKGF   16       177   QVIELARQL   16       199   REIENLPLR   16       203   NLPLRLFTL   16       219   AISLATFFF   16       223   ATFFFLYSF   16       256   NKTLPIVAI   16       263   AITLLSLVY   16       290   RFPPWLETW   16       392   SFIQSTLGY   16       403   LLISTFHVL   16       428   TPPNFVLAL   16       439   PSIVILDLL   16       67   SEFFPHVVD   15       79   HEDALTKTN   15       100   SLWDLRHLL   15       130   AEYLASLFP   15       182   ARQLNFIPI   15       196   SSAREIENL   15       200   EIENLPLRL   15       212   WRGPVVVAI   15       231   FVRDVIHPY   15       252   IEIVNKTLP   15       297   TWLQCRKQL   15       363   FGIMSLGLL   15       378   SIPSVSNAL   15       389   REFSFIQST   15       390   EFSFIQSTL   15       396   STLGYVALL   15       400   YVALLISTF   15       421   EEYYRFYTP   15       430   PNFVLALVL   15       438   LPSIVILDL   15       17   CLPNGINGI   14       37   GSGDFAKSL   14       82   ALTKTNIIF   14       85   KTNIIFVAI   14       96   EHYTSLWDL   14       105   RHLLVGKIL   14       148   VVSAWALQL   14       198   AREIENLPL   14       204   LPLRLFTLW   14       218   VAISLATFF   14       221   SLATFFFLY   14       258   TLPIVAITL   14       264   ITLLSLVYL   14       272   LAGLLAAAY   14       303   KQLGLLSFF   14       313   AMVHVAYSL   14       351   EEEVWRIEM   14       355   WRIEMYISF   14       360   YISFGIMSL   14       365   IMSLGLLSL   14       366   MSLGLLSLL   14       383   SNALNWREF   14       385   ALNWREFSF   14       395   QSTLGYVAL   14       411   LIYGWKRAF   14       426   FYTPPNFVL   14       435   ALVLPSIVI   14       28   ARKVTVGVI   13       46   TIRLIRCGY   13       99   TSLWDLRHL   13       126   PESNAEYLA   13       129   NAEYLASLF   13       133   LASLFPDSL   13       134   ASLFPDSLI   13       146   FNVVSAWAL   13       158   PKDASRQVY   13       180   ELARQLNFI   13       184   QLNFIPIDL   13       240   ARNQQSDFY   13       251   PIEIVNKTL   13       253   EIVNKTLPI   13       268   SLVYLAGLL   13       274   GLLAAAYQL   13       286   TKYRRFPPW   13       287   KYRRFPPWL   13       302   RKQLGLLSF   13       311   FFAMVHVAY   13       323   LPMRRSERY   13       326   RRSERYLFL   13       328   SERYLFLNM   13       330   RYLFLNMAY   13       341   VHANIENSW   13       347   NSWNEEEVW   13       380   PSVSNALNW   13       407   TFHVLIYGW   13       418   AFEEEYYRF   13       420   EEEYYRFYT   13       424   YRFYTPPNF   13       444   LDLLQLCRY   13       10   PKSLSETCL   12       39   GDFAKSLTI   12       41   FAKSLTIRL   12       57   VIGSRNPKF   12       61   RNPKFASEF   12       75   DVTHHEDAL   12       81   DALTKTNII   12       94   HREHYTSLW   12       125   YPESNAEYL   12       128   SNAEYLASL   12       173   QARQQVIEL   12       187   FIPIDLGSL   12       214   GPVVVAISL   12       217   VVAISLATF   12       220   ISLATFFFL   12       261   IVAITLLSL   12       267   LSLVYLAGL   12       280   YQLYYGTKY   12       283   YYGTKYRRF   12       299   LQCRKQLGL   12       300   QCRKQLGLL   12       324   PMRRSERYL   12       325   MRRSERYLF   12       350   NEEEVWRIE   12       353   EVWRIEMYI   12       362   SFGIMSLGL   12       404   LISTFHVLI   12       405   ISTFHVLIY   12                 V2-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   SGSPGLQAL   18       15   SGFTPFSCL   15       33   CPPPCPADF   15       3   SPGLQALSL   14       23   LSLPSSWDY   14       12   SLSSGFTPF   13       21   SCLSLPSSW   13       35   PPCPADFFL   13       36   PCPADFFLY   13       37   CPADFFLYF   13       17   FTPFSCLSL   12       34   PPPCPADFF   12       5   GLQALSLSL   11       9   LSLSLSSGF   11                 V5A-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   16       2   LPLRLFTFW   13                 V5B-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         2   REFSFIQIF   25       22   LEFVFLLTL   25       20   LELEFVFLL   23       18   TELELEFVF   22       5   SFIQIFCSF   16       24   FVFLLTLLL   16       19   ELELEFVFL   15       14   ADTQTELEL   14       23   EFVFLLTLL   14       12   SFADTQTEL   12                 V6-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         35   LEEGIGGTI   21       6   VILGKIILF   17       5   IVILGKIIL   15       7   ILGKIILFL   15       21   KLKRIKKGW   15       3   PSIVILGKI   14       10   KIILFLPCI   14       14   FLPCISRKL   14       17   CISRKLKRI   13       26   KKGWEKSQF   12       29   WEKSQFLEE   12       36   EEGIGGTIP   12       4   SIVILGKII   11       27   KGWEKSQFL   11                 V7A-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         6   SETFLPNGI   21       9   FLPNGINGI   14       1   SPKSLSETF   12       2   PKSLSETFL   12                 V7B-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         5   AYQQSTLGY   15       9   STLGYVALL   15       8   QSTLGYVAL   14       3   NMAYQQSTL   12                 V7C-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         33   SEIVLPIEW   26       157   GEFLGSGTW   24       168   LETIILSKL   23       39   IEWQQDRKI   20       143   ASGTLSLAF   17       51   STPPPPAMW   16       70   QESGIRNKS   16       103   PESPDRALK   16       113   ANSWRNPVL   16       131   WEFLLRLLK   16       42   QQDRKIPPL   15       5   ILDLSVEVL   14       61   EEAGATAEA   14       10   VEVLASPAA   13       12   VLASPAAAW   13       15   SPAAAWKCL   13       20   WKCLGANIL   13       29   RGGLSEIVL   13       60   TEEAGATAE   13       67   AEAQESGIR   13       91   TEDDEAQDS   13       102   PPESPDRAL   13       108   RALKAANSW   13       125   NGVGPLWEF   13       126   GVGPLWEFL   13       127   VGPLWEFLL   13       130   LWEFLLRLL   13       146   TLSLAFTSW   13       160   LGSGTWMKL   13       165   WMKLETIIL   13       31   GLSEIVLPI   12       122   PHTNGVGPL   12       123   HTNGVGPLW   12       129   PLWEFLLRL   12       139   KSQAASGTL   12       141   QAASGTLSL   12       151   FTSWSLGEF   12       179   EQKSKHCMF   12                 V8-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   LEEGMGGTI   20       6   EEGMGGTIP   12                 V13-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         6   SETFLPNGI   21       9   FLPNGINGI   14       1   SPKSLSETF   12       2   PKSLSETFL   12                 V14-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         1   NLPLRLFTF   16       2   LPLRLFTFW   13                 V21-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         6   EQKTKHCMF   13       5   QEQKTKHCM   11       8   KTKHCMFSL   11       9   TKHCMFSLI   10                 V25-HLA-B4402-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   FLPCISQKL   13       6   CISQKLKRI   12       2   LFLPCISQK   8       9   QKLKRIKKG   8                    
     [1214]                       TABLE XXXIIII                       Pos   123456789   score                                    V1-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 9 amino acids, and       the end position for each       peptide is the start position       plus eight.                         81   DALTKTNII   29       27   DARKVTVGV   26       65   FASEFFPHV   23       374   LAVTSIPSV   23       434   LALVLPSIV   23       438   LPSIVILDL   22       246   DFYKIPIEI   21       262   VAITLLSLV   21       368   LGLLSLLAV   21       428   TPPNFVLAL   21       429   PPNFVLALV   21       23   NGIKDARKV   20       157   GPKDASRQV   20       214   GPVVVAISL   20       259   LPIVAITLL   20       41   FAKSLTIRL   19       125   YPESNAEYL   19       133   LASLFPDSL   19       173   QARQQVIEL   19       250   IPIEIVNKT   19       291   FPPWLETWL   19       50   IRCGYHVVI   18       228   LYSFVRDVI   17       336   MAYQQVHAN   17       371   LSLLAVTSI   17       28   ARKVTVGVI   16       39   GDFAKSLTI   16       70   FPHVVDVTH   16       104   LRHLLVGKI   16       141   LIVKGFNVV   16       160   DASRQVYIC   16       204   LPLRLFTLW   16       227   FLYSFVRDV   16       237   HPYARNQQS   16       317   VAYSLCLPM   16       52   CGYHVVIGS   15       137   FPDSLIVKG   15       164   QVYICSNNI   15       171   NIQARQQVI   15       193   GSLSSAREI   15       210   TLWRGPVVV   15       212   WRGPVVVAI   15       276   LAAAYQLYY   15       349   WNEEEVWRI   15       363   FGIMSLGLL   15       397   TLGYVALLI   15       425   RFYTPPNFV   15       18   LPNGINGIK   14       25   IKDARKVTV   14       114   IDVSNNMRI   14       152   WALQLGPKD   14       209   FTLWRGPVV   14       222   LATFFFLYS   14       242   NQQSDFYKI   14       258   TLPIVAITL   14       278   AAYQLYYGT   14       379   IPSVSNALN   14       386   LNWREFSFI   14       398   LGYVALLIS   14       401   VALLISTFH   14       404   LISTFHVLI   14       433   VLALVLPSI   14       435   ALVLPSIVI   14                 V2-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         3   SPGLQALSL   18       35   PPCPADFFL   16       15   SGFTPFSCL   15       1   SGSPGLQAL   13       7   QALSLSLSS   13       18   TPFSCLSLP   13       25   LPSSWDYRC   13       37   CPADFFLYF   13       33   CPPPCPADF   12       34   PPPCPADFF   12       17   FTPFSCLSL   10       4   PGLQALSLS   9       5   GLQALSLSL   8                 V5A-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         2   LPLRLFTFW   16       8   TFWRGPVVV   15       7   FTFWRGPVV   13       6   LFTFWRGPV   10       9   FWRGPVVVA   8       4   LRLFTFWRG   7                 V5B-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         20   LELEFVFLL   14       1   WREFSFIQI   13       22   LEFVFLLTL   13       13   FADTQTELE   12       12   SFADTQTEL   9       17   QTELELEFV   9       24   FVFLLTLLL   9       14   ADTQTELEL   8       18   TELELEFVF   8       19   ELELEFVFL   8       23   EFVFLLTLL   8       15   DTQTELELE   6                 V6-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         43   IPHVSPERV   23       2   LPSIVILGK   16       27   KGWEKSQFL   16       35   LEEGIGGTI   15       15   LPCISRKLK   14       17   CISRKLKRI   14       3   PSIVILGKI   13       39   IGGTIPHVS   13       38   GIGGTIPHV   12       4   SIVILGKII   11       7   ILGKIILFL   11       10   KIILFLPCI   11       14   FLPCISRKL   11       45   HVSPERVTV   11                 V7A-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNGINGI   14       1   SPKSLSETF   12       6   SETFLPNGI   12       2   PKSLSETFL                 V7B-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position for       each peptide is the start       position plus eight.                         4   MAYQQSTLG   16       6   YQQSTLGYV   12       9   STLGYVALL   12       3   NMAYQQSTL   9       8   QSTLGYVAL   7                 V7C-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         66   TAEAQESGI   22       101   DPPESPDRA   20       112   AANSWRNPV   19       15   SPAAAWKCL   18       160   LGSGTWMKL   18       29   RGGLSEIVL   17       84   IPVVGVVTE   17       102   PPESPDRAL   17       141   QAASGTLSL   17       24   GANILRGGL   16       39   IEWQQDRKI   16       31   GLSEIVLPI   15       68   EAQESGIRN   15       82   SQIPVVGVV   15       108   RALKAANSW   15       149   LAFTSWSLG   15       163   GTWMKLETI   15       5   ILDLSVEVL   14       27   ILRGGLSEI   14       37   LPIEWQQDR   14       47   IPPLSTPPP   14       48   PPLSTPPPP   14       54   PPPAMWTEE   14       121   LPHTNGVGP   14       127   VGPLWEFLL   14       128   GPLWEFLLR   14       4   VILDLSVEV   13       13   LASPAAAWK   13       18   AAWKCLGAN   13       52   TPPPPAMWT   13       53   PPPPAMWTE   13       62   EAGATAEAQ   13       95   EAQDSIDPP   13       142   AASGTLSLA   13       164   TWMKLETII   13       17   AAAWKCLGA   12       64   GATAEAQES   12       76   NKSSSSSQI   12       79   SSSSQIPVV   12       92   EDDEAQDSI   12       105   SPDRALKAA   12       111   KAANSWRNP   12       118   NPVLPHTNG   12       129   PLWEFLLRL   12       182   SKHCMFSLI   12       16   PAAAWKCLG   11       28   LRGGLSEIV   11       56   PAMWTEEAG   11       81   SSQIPVVGV   11       119   PVLPHTNGV   11       168   LETIILSKL   11       19   AWKCLGANI   10       23   LGANILRGG   10       30   GGLSEIVLP   10       55   PPAMWTEEA   10       78   SSSSSQIPV   10       113   ANSWRNPVL   10       130   LWEFLLRLL   10                 V8-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         5   LEEGMGGTI   16       8   GMGGTIPHV   12       9   MGGTIPHVS   12       7   EGMGGTIPH   8                 V13-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         9   FLPNGINGI   14       1   SPKSLSETF   12       6   SETFLPNGI   12       2   PKSLSETFL   8                 V14-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 9 amino acids,       and the end position for each       peptide is the start position       plus eight.                         2   LPLRLFTFW   16       8   TFWRGPVVV   15       7   FTFWRGPVV   13       6   LFTFWRGPV   10       9   FWRGPVVVA   8       4   LRLFTFWRG   7                 V21-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         9   TKHCMFSLI   13       3   LTQEQKTKH   7       8   KTKHCMFSL   6                 V25-HLA-B5101-9mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 9 amino       acids, and the end position       for each peptide is the start       position plus eight.                         4   LPCISQKLK   14       6   CISQKLKRI   14       3   FLPCISQKL   10       9   QKLKRIKKG   7                    
     [1215]                       TABLE XXXIV                       Pos   1234567890   score                                    V1-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide       is 10 amino acids, and the end       position for each peptide is the       start position plus nine.                         351   E E EVWR I EMY   26       391   F S FIQS T LGY   26       418   A F EEEY Y RFY   26       443   I L DLLQ L CRY   26       220   I S LATF F FLY   24       262   V A ITLL S LVY   23       327   R S ERYL F LNM   23       45   L T IRLI R CGY   22       275   L L AAAY Q LYY   22       404   L I STFH V LIY   22       116   V S NNMR I NQY   20       123   N Q YPES N AEY   20       271   Y L AGLL A AAY   19       279   A Y QLYY G TKY   19       427   Y T PPNF V LAL   19       38   S G DFAK S LTI   18       274   G L LAAA Y QLY   18       101   L W DLRH L LVG   17       157   G P KDAS R QVY   17       178   V I ELAR Q LNF   17       230   S F VRDV I HPY   17       239   Y A RNQQ S DFY   17       396   S T LGYV A LLI   17       66   A S EFFP H VVD   16       89   I F VAIH R EHY   16       94   H R EHYT S LWD   16       129   N A EYLA S LFP   16       310   F F FAMV H VAY   16       322   C L PMRR S ERY   16       329   E R YLFL N MAY   16       350   N E EEVW R IEM   15       414   G W KRAF E EEY   15       415   W K RAFE E EYY   15       13   L S ETCL P NGI   14       125   Y P ESNA E YLA   14       244   Q S DFYK I PIE   14       257   K T LPIV A ITL   14       76   V T HHED A LTK   13       198   A R EIEN L PLR   13       366   M S LGLL S LLA   13       420   E E EYYR F YTP   13       25   I K DARK V TVG   12       135   S L FPDS L IVK   12       137   F P DSLI V KGF   12       200   E I ENLP L RLF   12       221   S L ATFF F LYS   12       251   P I EIVN K TLP   12       268   S L VYLA G LLA   12       419   F E EEYY R FYT   12       439   P S IVIL D LLQ   12                 V2-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         35   P P CPAD F FLY   24       22   C L SLPS S WDY   16       28   S W DYRC P PPC   12       2   G S PGLQ A LSL   11                 V5A-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         8   F T FWRG P VVV   8       1   E N LPLR L FTF   4       2   N L PLRL F TFW   4       4   P L RLFT F WRG   4       10   F W RGPV V VAI   3                 V5B-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         14   F A DTQT E LEL   17       18   Q T ELEL E FVF   17       22   E L EFVF L LTL   17       20   E L ELEF V FLL   14       16   D T QTEL E LEF   12       21   L E LEFV F LLT   11       2   W R EFSF I QIF   10       5   F S FIQI F CSF   8       24   E F VFLL T LLL   8                 V6-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         29   G W EKSQ F LEE   19       35   F L EEGI G GTI   13       36   L E EGIG G TIP   12       1   L V LPSI V ILG   11       19   I S RKLK R IKK   11       42   G T IPHV S PER   10       9   L G KIIL F LPC   9                 V7A-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         6   L S ETFL P NGI   14       4   K S LSET F LPN   13       8   E T FLPN G ING   11                 V7B-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         5   M A YQQS T LGY   21       10   S T LGYV A LLI   17                 V7C-HLA-A1-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 15; each start position is       specified, the length of peptide       is 10 amino acids, and the end       position for each peptide is the       start position plus nine.                         131   L W EFLL R LLK   19       33   L S EIVL P IEW   18       91   V T EDDE A QDS   17       60   W T EEAG A TAE   16       100   S I DPPE S PDR   16       70   A Q ESGI R NKS   14       94   D D EAQD S IDP   14       6   I L DLSV E VLA   13       103   P P ESPD R ALK   13       124   H T NGVG P LWE   13       168   K L ETII L SKL   13       10   S V EVLA S PAA   12       39   P I EWQQ D RKI   12       43   Q Q DRKI P PLS   12       52   S T PPPP A MWT   12       104   P E SPDR A LKA   12       106   S P DRAL K AAN   12       128   V G PLWE F LLR   12       170   E T IILS K LTQ   12       97   A Q DSID P PES   11       115   N S WRNP V LPH   11       154   S W SLGE F LGS   11       2   P S IVIL D LSV   10       61   T E EAGA T AEA   10       67   T A EAQE S GIR   10       92   T E DDEA Q DSI   10       93   E D DEAQ D SID   10       157   L G EFLG S GTW   10       162   G S GTWM K LET   10       178   T Q EQKS K HCM   10       51   L S TPPP P AMW   9       146   G T LSLA F TSW   9       182   K S KHCM F SLI   9                 V8-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         5   F L EEGM G GTI   13       6   L E EGMG G TIP   12                 V13-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         6   L S ETFL P NGI   14       4   K S LSET F LPN   13       8   E T FLPN G ING   11                 V14-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         8   F T FWRG P VVV   8       1   E N LPLR L FTF   4       2   N L PLRL F TFW   4       4   P L RLFT F WRG   4       10   F W RGPV V VAI   3                 V21-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         9   K T KHCM F SLI   11       5   T Q EQKT K HCM   10       1   L S KLTQ E QKT   6       4   L T QEQK T KHC   6       10   T K HCMF S LIS   6                 V25-HLA-A1-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         8   I S QKLK R IKK   11       5   L P CISQ K LKR   8       3   L F LPCI S QKL   6                    
     [1216]                       TABLE XXXV                       Pos   1234567890   score                                    V1-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         373   LLAVT S IPSV   31       266   LLSLV Y LAGL   29       107   LLVGK I LIDV   28       367   SLGLL S LLAV   28       435   ALVLP S IVIL   28       364   GIMSL G LLSL   27       132   YLASL F PDSL   26       370   LLSLL A VTSI   26       437   VLPSI V ILDL   26       82   ALTKT N IIFV   25       100   SLWDL R HLLV   25       140   SLIVK G FNVV   25       263   AITLL S LVYL   25       306   GLLSF F FAMV   25       402   ALLIS T FHVL   25       440   SIVIL D LLQL   25       258   TLPIV A ITLL   24       365   IMSLG L LSLL   24       403   LLIST F HVLI   24       427   YTPPN F VLAL   24       24   GIKDA R KVTV   23       48   RLIRC G YHVV   23       103   DLRHL L VGKI   23       433   VLALV L PSIV   23       92   AIHRE H YTSL   22       260   PIVAI T LLSL   22       261   IVAIT L LSLV   22       298   WLQCR K QLGL   22       432   FVLAL V LPSI   22       207   RLFTL W RGPV   21       210   TLWRG P VVVA   21       257   KTLPI V AITL   21       385   ALNWR E FSFI   21       49   LIRCG Y HVVI   20       98   YTSLW D LRHL   20       172   IQARQ Q VIEL   20       186   NFIPI D LGSL   20       219   AISLA T FFFL   20       227   FLYSF V RDVI   20       249   KIPIE I VNKT   20       253   EIVNK T LPIV   20       12   SLSET C LPNG   19       135   SLFPD S LIVK   19       142   IVKGF N VVSA   19       197   SAREI E NLPL   19       209   FTLWR G PVVV   19       211   LWRGP V VVAI   19       271   YLAGL L AAAY   19       312   FAMVH V AYSL   19       396   STLGY V ALLI   19       16   TCLPN G INGI   18       65   FASEF F PHVV   18       67   SEFFP H VVDV   18       113   LIDVS N NMRI   18       359   MYISF G IMSL   18       392   SFIQS T LGYV   18       106   HLLVG K ILID   17       179   IELAR Q LNFI   17       202   ENLPL R LFTL   17       250   IPIEI V NKTL   17       264   ITLLS L VYLA   17       269   LVYLA G LLAA   17       348   SWNEE E VWRI   17       361   ISFGI M SLGL   17       369   GLLSL L AVTS   17       401   VALLI S TFHV   17       26   KDARK V TVGV   16       41   FAKSL T IRLI   16       111   KILID V SNNM   16       112   ILIDV S NNMR   16       127   ESNAE Y LASL   16       195   LSSAR E IENL   16       223   ATFFF L YSFV   16       226   FFLYS F VRDV   16       268   SLVYL A GLLA   16       299   LQCRK Q LGLL   16       356   RIEMY I SFGI   16       362   SFGIM S LGLL   16       377   TSIPS V SNAL   16       428   TPPNF V LALV   16       434   LALVL P SIVI   16       438   LPSIV I LDLL   16       443   ILDLL Q LCRY   16       27   DARKV T VGVI   15       36   IGSGD F AKSL   15       44   SLTIR L IRCG   15       47   IRLIR C GYHV   15       147   NVVSA W ALQL   15       166   YICSN N IQAR   15       189   PIDLG S LSSA   15       199   REIEN L PLRL   15       221   SLATF F FLYS   15       255   VNKTL P IVAI   15       273   AGLLA A AYQL   15       275   LLAAA Y QLYY   15       314   MVHVA Y SLCL   15       335   NMAYQ Q VHAN   15       336   MAYQQ V HANI   15       345   IENSW N EEEV   15       394   IQSTL G YVAL   15       395   QSTLG Y VALL   15       404   LISTF H VLIY   15       411   LIYGW K RAFE   15                 V2-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         2   GSPGL Q ALSL   16       5   GLQAL S LSLS   15       16   GFTPF S CLSL   15       10   SLSLS S GFTP   14       8   ALSLS L SSGF   13       12   SLSSG F TPFS   13       24   SLPSS W DYRC   13       4   PGLQA L SLSL   12       7   QALSL S LSSG   12       14   SSGFT P FSCL   11       22   CLSLP S SWDY   10       9   LSLSL S SGFT   8       17   FTPFS C LSLP   8       6   LQALS L SLSS   7       34   PPPCP A DFFL   7                 V5A-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         6   RLFTF W RGPV   21       8   FTFWR G PVVV   18       10   FWRGP V VVAI   18       7   LFTFW R GPVV   11       9   TFWRG P VVVA   11       2   NLPLR L FTFW   10                 V5B-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         22   ELEFV F LLTL   22       20   ELELE F VFLL   20       14   FADTQ T ELEL   18       23   LEFVF L LTLL   17       19   TELEL E FVFL   16       17   TQTEL E LEFV   15       12   CSFAD T QTEL   13       9   QIFCS F ADTQ   11       21   LELEF V FLLT   11       1   NWREF S FIQI   10       7   FIQIF C SFAD   10                 V6-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         7   VILGK I ILFL   28       35   FLEEG I GGTI   22       5   SIVIL G KIIL   20       14   LFLPC I SRKL   18       43   TIPHV S PERV   18       2   VLPSI V ILGK   17       13   ILFLP C ISRK   17       3   LPSIV I LGKI   16       8   ILGKI I LFLP   16       10   GKIIL F LPCI   16       38   EGIGG T IPHV   16       1   LVLPS I VILG   14       46   HVSPE R VTVM   14       12   IILFL P CISR   13       34   QFLEE G IGGT   13                 V7A-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         5   SLSET F LPNG   19       9   TFLPN G INGI   18       2   SPKSL S ETFL   11       6   LSETF L PNGI   11       10   FLPNG I NGIK   11                 V7B-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         10   STLGY V ALLI   19       2   FLNMA Y QQST   18       6   AYQQS T LGYV   16       3   LNMAY Q QSTL   15       9   QSTLG Y VALL   15       8   QQSTL G YVAL   13       4   NMAYQ Q STLG   9                 V7C-HLA-A0201-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         5   VILDL S VEVL   26       168   KLETI I LSKL   26       27   NILRG G LSEI   24       28   ILRGG L SEIV   24       130   PLWEF L LRLL   24       160   FLGSG T WMKL   23       4   IVILD L SVEV   22       66   ATAEA Q ESGI   19       81   SSSQI P VVGV   19       156   SLGEF L GSGT   19       6   ILDLS V EVLA   18       32   GLSEI V LPIE   18       112   KAANS W RNPV   18       113   AANSW R NPVL   18       129   GPLWE F LLRL   18       8   DLSVE V LASP   17       19   AAWKC L GANI   17       79   SSSSS Q IPVV   17       127   GVGPL W EFLL   17       134   FLLRL L KSQA   17       135   LLRLL K SQAA   17       141   SQAAS G TLSL   17       31   GGLSE I VLPI   16       42   WQQDR K IPPL   16       58   AMWTE E AGAT   16       82   SSQIP V VGVV   16       84   QIPVV G VVTE   16       122   LPHTN G VGPL   16       137   RLLKS Q AASG   16       138   LLKSQ A ASGT   16       148   LSLAF T SWSL   16       13   VLASP A AAWK   15       23   CLGAN I LRGG   15       24   LGANI L RGGL   15       152   FTSWS L GEFL   15       163   SGTWM K LETI   15       3   SIVIL D LSVE   14       29   LRGGL S EIVL   14       39   PIEWQ Q DRKI   14       121   VLPHT N GVGP   14       139   LKSQA A SGTL   14       142   QAASG T LSLA   14       164   GTWMK L ETII   14       171   TIILS K LTQE   14       172   IILSK L TQEQ   14       18   AAAWK C LGAN   13       50   PLSTP P PPAM   13       100   SIDPP E SPDR   13       149   SLAFT S WSLG   13       2   PSIVI L DLSV   12       20   AWKCL G ANIL   12       47   KIPPL S TPPP   12       52   STPPP P AMWT   12       83   SQIPV V GVVT   12       102   DPPES P DRAL   12       119   NPVLP H TNGV   12       126   NGVGP L WEFL   12       144   ASGTL S LAFT   12       173   ILSKL T QEQK   12       176   KLTQE Q KSKH   12       181   QKSKH C MFSL   12                 V8-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         5   FLEEG M GGTI   22       8   EGMGG T IPHV   15       9   GMGGT I PHVS   12                 V13-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         5   SLSET F LPNG   19       9   TFLPN G INGI   18       2   SPKSL S ETFL   11       6   LSETF L PNGI   11       10   FLPNG I NGIK   11                 V14-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         6   RLFTF W RGPV   21       8   FTFWR G PVVV   18       10   FWRGP V VVAI   18       7   LFTFW R GPVV   11       9   TFWRG P VVVA   11       2   NLPLR L FTFW   10                 V21-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         3   KLTQE Q KTKH   12       9   KTKHC M FSLI   12       8   QKTKH C MFSL   11       1   LSKLT Q EQKT   7       4   LTQEQ K TKHC   7       2   SKLTQ E QKTK   5                 V25-HLA-A0201-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         3   LFLPC I SQKL   18       2   ILFLP C ISQK   17       1   IILFL P CISQ   13       4   FLPCI S QKLK   10       6   PCISQ K LKRI   10       7   CISQK L KRIK   8                    
     [1217]                       TABLE XXXVI                        Pos   1234567890   score                                    V1-HLA-A0203-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         270   V Y LAGL L AAA   27       269   L V YLAG L LAA   19       144   K G FNVV S AWA   18       271   Y L AGLL A AAY   17                 V2-HLA-A0203-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         30   D Y RCPP P CPA   10       31   Y R CPPP C PAD   9       1   S G SPGL Q ALS   8       32   R C PPPC P ADF   8                 V5A-HLA-A0203-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         9   T F WRGP V VVA   10       10   F W RGPV V VAI   9                 V5B-HLA-A0203-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         6   S F IQIF C SFA   10       7   F I QIFC S FAD   9       8   I Q IFCS F ADT   8                 V6-HLA-A0203-10mers-98P4B6       NoResultsFound.       V7A-HLA-A0203-10mers-98P4B6       NoResultsFound.       V7B-HLA-A0203-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         7   Y Q QSTL G YVA   10       8   Q Q STLG Y VAL   9       9   Q S TLGY V ALL   8                 V7C-HLA-A0203-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         11   V E VLAS P AAA   27       10   S V EVLA S PAA   19       105   E S PDRA L KAA   19       135   L L RLLK S QAA   19       57   P A MWTE E AGA   18       59   M W TEEA G ATA   18       61   T E EAGA T AEA   18       12   E V LASP A AAW   17       106   S P DRAL K AAN   17       136   L R LLKS Q AAS   17                 V8-HLA-A0203-10mers-98P4B6       NoResultsFound.       V13-HLA-A0203-10mers-98P4B6       NoResultsFound.       V14-HLA-A0203-10mers-98P4B6                         9   T F WRGP V VVA   10       10   F W RGPV V VAI   9                 V21-HLA-A0203-10mers-98P4B6       NoResultsFound.       V25-HLA-A0203-10mers-98P4B6       NoResultsFound.                    
     [1218]                       TABLE XXXVII                        Pos   1234567890   score                                    V1-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         135   SL F PD SL IVK   28       34   GV I GS GD FAK   26       271   YL A GL LA AAY   26       48   RL I RC GY HVV   24       21   GI N GI KD ARK   23       216   VV V AI SL ATF   23       369   GL L SL LA VTS   23       17   CL P NG IN GIK   22       55   HV V IG SR NPK   22       275   LL A AA YQ LYY   22       278   AA Y QL YY GTK   22       307   LL S FF FA MVH   22       112   IL I DV SN NMR   21       142   IV K GF NV VSA   21       155   QL G PK DA SRQ   21       210   TL W RG PV VVA   21       76   VT H HE DA LTK   20       217   VV A IS LA TFF   20       248   YK I PI EI VNK   20       274   GL L AA AY QLY   20       281   QL Y YG TK YRR   20       294   WL E TW LQ CRK   20       402   AL L IS TF HVL   20       2   ES I SM MG SPK   19       49   LI R CG YH VVI   19       56   VV I GS RN PKF   19       102   WD L RH LL VGK   19       147   NV V SA WA LQL   19       227   FL Y SF VR DVI   19       269   LV Y LA GL LAA   19       375   AV T SI PS VSN   19       443   IL D LL QL CRY   19       24   GI K DA RK VTV   18       140   SL I VK GF NVV   18       333   FL N MA YQ QVH   18       410   VL I YG WK RAF   18       411   LI Y GW KR AFE   18       435   AL V LP SI VIL   18       442   VI L DL LQ LCR   18       46   TI R LI RC GYH   17       92   AI H RE HY TSL   17       164   QV Y IC SN NIQ   17       177   QV I EL AR QLN   17       254   IV N KT LP IVA   17       261   IV A IT LL SLV   17       268   SL V YL AG LLA   17       331   YL F LN MA YQQ   17       400   YV A LL IS TFH   17       403   LL I ST FH VLI   17       404   LI S TF HV LIY   17       30   KV T VG VI GSG   16       123   NQ Y PE SN AEY   16       141   LI V KG FN VVS   16       178   VI E LA RQ LNF   16       207   RL F TL WR GPV   16       234   DV I HP YA RNQ   16       262   VA I TL LS LVY   16       263   AI T LL SL VYL   16       265   TL L SL VY LAG   16       306   GL L SF FF AMV   16       322   CL P MR RS ERY   16       340   QV H AN IE NSW   16       367   SL G LL SL LAV   16       385   AL N WR EF SFI   16       432   FV L AL VL PSI   16       433   VL A LV LP SIV   16       440   SI V IL DL LQL   16       441   IV I LD LL QLC   16       32   TV G VI GS GDF   15       100   SL W DL RH LLV   15       106   HL L VG KI LID   15       121   RI N QY PE SNA   15       153   AL Q LG PK DAS   15       187   FI P ID LG SLS   15       221   SL A TF FF LYS   15       235   VI H PY AR NQQ   15       257   KT L PI VA ITL   15       260   PI V AI TL LSL   15       320   SL C LP MR RSE   15       372   SL L AV TS IPS   15       393   FI Q ST LG YVA   15       436   LV L PS IV ILD   15       60   SR N PK FA SEF   14       88   II F VA IH REH   14       103   DL R HL LV GKI   14       108   LV G KI LI DVS   14       111   KI L ID VS NNM   14       132   YL A SL FP DSL   14       150   SA W AL QL GPK   14       171   NI Q AR QQ VIE   14       180   EL A RQ LN FIP   14       189   PI D LG SL SSA   14       190   ID L GS LS SAR   14       205   PL R LF TL WRG   14       215   PV V VA IS LAT   14       231   FV R DV IH PYA   14       266   LL S LV YL AGL   14       279   AY Q LY YG TKY   14       316   HV A YS LC LPM   14       370   LL S LL AV TSI   14       45   LT I RL IR CGY   13       75   DV T HH ED ALT   13       82   AL T KT NI IFV   13       128   SN A EY LA SLF   13       154   LQ L GP KD ASR   13       157   GP K DA SR QVY   13       166   YI C SN NI QAR   13       191   DL G SL SS ARE   13       200   EI E NL PL RLF   13       204   LP L RL FT LWR   13       240   AR N QQ SD FYK   13       298   WL Q CR KQ LGL   13       304   QL G LL SF FFA   13       310   FF F AM VH VAY   13       314   MV H VA YS LCL   13       321   LC L PM RR SER   13       329   ER Y LF LN MAY   13       353   EV W RI EM YIS   13       364   GI M SL GL LSL   13       373   LL A VT SI PSV   13       397   TL G YV AL LIS   13       399   GY V AL LI STF   13       409   HV L IY GW KRA   13       437   VL P SI VI LDL   13       445   DL L QL CR YPD   13                 V2-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         8   AL S LS LS SGF   21       10   SL S LS SG FTP   19       22   CL S LP SS WDY   17       5   GL Q AL SL SLS   15       32   RC P PP CP ADF   15       12   SL S SG FT PFS   11       24   SL P SS WD YRC   11       2   GS P GL QA LSL   10       33   CP P PC PA DFF   10                 V5A-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         6   RL F TF WR GPV   16       4   PL R LF TF WRG   14       1   EN L PL RL FTF   13       2   NL P LR LF TFW   12       9   TF W RG PV VVA   11       3   LP L RL FT FWR   10       10   FW R GP VV VAI   10       8   FT F WR GP VVV   9       7   LF T FW RG PVV   7                 V5B-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         9   QI F CS FA DTQ   17       22   EL E FV FL LTL   17       18   QT E LE LE FVF   11       20   EL E LE FV FLL   11       7   FI Q IF CS FAD   10       8   IQ I FC SF ADT   8                 V6-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         13   IL F LP CI SRK   26       2   VL P SI VI LGK   23       15   FL P CI SR KLK   21       18   CI S RK LK RIK   21       6   IV I LG KI ILF   20       22   KL K RI KK GWE   19       35   FL E EG IG GTI   19       12   II L FL PC ISR   18       46   HV S PE RV TVM   18       23   LK R IK KG WEK   17       11   KI I LF LP CIS   16       19   IS R KL KR IKK   16       1   LV L PS IV ILG   15       7   VI L GK II LFL   15       25   RI K KG WE KSQ   15       26   IK K GW EK SQF   15       39   GI G GT IP HVS   15       8   IL G KI IL FLP   12                 V7A-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         10   FL P NG IN GIK   22       5   SL S ET FL PNG   12                 V7B-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         5   MA Y QQ ST LGY   13       2   FL N MA YQ QST   12       10   ST L GY VA LLI   11       3   LN M AY QQ STL   9       7   YQ Q ST LG YVA   7       8   QQ S TL GY VAL   7       1   LF L NM AY QQS   6       9   QS T LG YV ALL   6                 V7C-HLA-A3-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         13   VL A SP AA AWK   28       173   IL S KL TQ EQK   25       137   RL L KS QA ASG   24       12   EV L AS PA AAW   21       134   FL L RL LK SQA   21       4   IV I LD LS VEV   20       36   IV L PI EW QQD   20       120   PV L PH TN GVG   20       176   KL T QE QK SKH   20       83   SQ I PV VG VVT   18       84   QI P VV GV VTE   18       156   SL G EF LG SGT   18       167   MK L ET II LSK   18       3   SI V IL DL SVE   17       6   IL D LS VE VLA   17       28   IL R GG LS EIV   17       74   GI R NK SS SSS   17       90   VV T ED DE AQD   17       121   VL P HT NG VGP   17       138   LL K SQ AA SGT   17       27   NI L RG GL SEI   16       100   SI D PP ES PDR   16       110   AL K AA NS WRN   16       168   KL E TI IL SKL   16       171   TI I LS KL TQE   16       5   VI L DL SV EVL   15       8   DL S VE VL ASP   15       26   AN I LR GG LSE   15       37   VL P IE WQ QDR   15       135   LL R LL KS QAA   15       147   TL S LA FT SWS   15       149   SL A FT SW SLG   15       159   EF L GS GT WMK   15       175   SK L TQ EQ KSK   15       38   LP I EW QQ DRK   14       47   KI P PL ST PPP   14       103   PP E SP DR ALK   14       109   RA L KA AN SWR   14       131   LW E FL LR LLK   14       127   GV G PL WE FLL   13       143   AA S GT LS LAF   13                 V8-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         5   FL E EG MG GTI   19                 V13-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         10   FL P NG IN GIK   22       5   SL S ET FL PNG   12                 V14-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         6   RL F TF WR GPV   16       4   PL R LF TF WRG   14       1   EN L PL RL FTF   13       2   NL P LR LF TFW   12       9   TF W RG PV VVA   11       3   LP L RL FT FWR   10       10   FW R GP VV VAI   10       8   FT F WR GP VVV   9       7   LF T FW RG PVV   7                 V21-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start       position plus nine.                         3   KL T QE QK TKH   18       2   SK L TQ EQ KTK   17                 V25-HLA-A3-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         2   IL F LP CI SQK   29       4   FL P CI SQ KLK   20       7   CI S QK LK RIK   18       1   II L FL PC ISQ   14                 V1-HLA-A26-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         216   VVVAISLATF   27       296   ETWLQCRKQL   27       200   EIENLPLRLF   26       147   NVVSAWALQL   25       351   EEEVWRIEMY   25       202   ENLPLRLFTL   24       56   VVIGSRNPKF   23       127   ESNAEYLASL   23       427   YTPPNFVLAL   23       440   SIVILDLLQL   23       45   LTIRLIRCGY   22       234   DVIHPYARNQ   22       253   EIVNKTLPIV   22       260   PIVAITLLSL   22       329   ERYLFLNMAY   21       15   ETCLPNGING   20       32   TVGVIGSGDF   20       98   YTSLWDLRHL   20       353   EVWRIEMYIS   20       68   EFFPHVVDVT   19       75   DVTHHEDALT   19       115   DVSNNMRINQ   19       186   NFIPIDLGSL   19       230   SFVRDVIHPY   19       257   KTLPIVAITL   19       314   MVHVAYSLCL   19       364   GIMSLGLLSL   19       404   LISTFHVLIY   19       217   VVAISLATFF   18       359   MYISFGIMSL   18       399   GYVALLISTF   18       441   IVILDLLQLC   18       2   ESISMMGSPK   17       30   KVTVGVIGSG   17       40   DFAKSLTIRL   17       81   DALTKTNIIF   17       263   AITLLSLVYL   17       406   STFHVLIYGW   17       177   QVIELARQLN   16       215   PVVVAISLAT   16       269   LVYLAGLLAA   16       435   ALVLPSIVIL   16       436   LVLPSIVILD   16       34   GVIGSGDFAK   15       72   HVVDVTHHED   15       116   VSNNMRINQY   15       142   IVKGFNVVSA   15       199   REIENLPLRL   15       250   IPIEIVNKTL   15       261   IVAITLLSLV   15       262   VAITLLSLVY   15       310   FFFAMVHVAY   15       377   TSIPSVSNAL   15       389   REFSFIQSTL   15       391   FSFIQSTLGY   15       432   FVLALVLPSI   15       31   VTVGVIGSGD   14       55   HVVIGSRNPK   14       89   IFVAIHREHY   14       103   DLRHLLVGKI   14       108   LVGKILIDVS   14       148   VVSAWALQLG   14       222   LATFFFLYSF   14       301   CRKQLGLLSF   14       352   EEVWRIEMYI   14       362   SFGIMSLGLL   14       417   RAFEEEYYRF   14       437   VLPSIVILDL   14       443   ILDLLQLCRY   14       27   DARKVTVGVI   13       74   VDVTHHEDAL   13       92   AIHREHYTSL   13       137   FPDSLIVKGF   13       172   IQARQQVIEL   13       176   QQVIELARQL   13       178   VIELARQLNF   13       218   VAISLATFFF   13       223   ATFFFLYSFV   13       258   TLPIVAITLL   13       299   LQCRKQLGLL   13       302   RKQLGLLSFF   13       358   EMYISFGIMS   13       361   ISFGIMSLGL   13       365   IMSLGLLSLL   13       375   AVTSIPSVSN   13       376   VTSIPSVSNA   13       395   QSTLGYVALL   13       410   VLIYGWKRAF   13                    
     [1219]                       TABLE XXXVIII                       Pos   1234567890   score                                    V2-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 3; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         17   FTPFSCLSLP   13       16   GFTPFSCLSL   12       35   PPCPADFFLY   11       2   GSPGLQALSL   10       4   PGLQALSLSL   10       14   SSGFTPFSCL   10       22   CLSLPSSWDY   10       8   ALSLSLSSGF   9       11   LSLSSGFTPF   9       32   RCPPPCPADF   9       33   CPPPCPADFF   9       36   PCPADFFLYF   9       30   DYRCPPPCPA   8       34   PPPCPADFFL   8       7   QALSLSLSSG   7       18   TPFSCLSLPS   7       3   SPGLQALSLS   6                 V5A-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         1   ENLPLRLFTF   24       8   FTFWRGPVVV   12                 V5B-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         16   DTQTELELEF   25       22   ELEFVFLLTL   24       24   EFVFLLTLLL   23       20   ELELEFVFLL   22       18   QTELELEFVF   16       23   LEFVFLLTLL   16       4   EFSFIQIFCS   14       5   FSFIQIFCSF   13       2   WREFSFIQIF   12       12   CSFADTQTEL   12                 V6-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         6   IVILGKIILF   27       5   SIVILGKIIL   18       38   EGIGGTIPHV   18       7   VILGKIILFL   17       1   LVLPSIVILG   16       46   HVSPERVTVM   15       42   GTIPHVSPER   13                 V7A-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         8   ETFLPNGING   24                 V7B-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         9   QSTLGYVALL   13       5   MAYQQSTLGY   11       3   LNMAYQQSTL   10       10   STLGYVALLI   10       8   QQSTLGYVAL   9                 V7C-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         170   ETIILSKLTQ   24       12   EVLASPAAAW   21       35   EIVLPIEWQQ   19       102   DPPESPDRAL   19       127   GVGPLWEFLL   19       5   VILDLSVEVL   17       152   FTSWSLGEFL   17       69   EAQESGIRNK   16       105   ESPDRALKAA   16       89   GVVTEDDEAQ   15       133   EFLLRLLKSQ   15       151   AFTSWSLGEF   15       3   SIVILDLSVE   14       4   IVILDLSVEV   14       45   DRKIPPLSTP   14       86   PVVGVVTEDD   14       90   VVTEDDEAQD   14       99   DSIDPPESPD   14       130   PLWEFLLRLL   14       168   KLETIILSKL   14       171   TIILSKLTQE   14       8   DLSVEVLASP   13       42   WQQDRKIPPL   13       93   EDDEAQDSID   13       122   LPHTNGVGPL   13       125   TNGVGPLWEF   13       129   GPLWEFLLRL   13       10   SVEVLASPAA   12       36   IVLPIEWQQD   12       72   ESGIRNKSSS   12       95   DEAQDSIDPP   12       120   PVLPHTNGVG   12       126   NGVGPLWEFL   12       41   EWQQDRKIPP   11       60   WTEEAGATAE   11       62   EEAGATAEAQ   11       63   EAGATAEAQE   11       66   ATAEAQESGI   11       96   EAQDSIDPPE   11       141   SQAASGTLSL   11       159   EFLGSGTWMK   11       180   EQKSKHCMFS   11                 V8-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         8   EGMGGTIPHV   14       7   EEGMGGTIPH   11       1   EKSQFLEEGM   10       3   SQFLEEGMGG   6                 V13-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         8   ETFLPNGING   24                 V14-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         1   ENLPLRLFTF   24       8   FTFWRGPVVV   12                 V21-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         4   LTQEQKTKHC   10       7   EQKTKHCMFS   10       8   QKTKHCMFSL   10       6   QEQKTKHCMF   9       9   KTKHCMFSLI   9                 V25-HLA-A26-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         2   ILFLPCISQK   10       3   LFLPCISQKL   10       6   PCISQKLKRI   9       1   IILFLPCISQ   6       9   SQKLKRIKKG   6       7   CISQKLKRIK   4                    
     [1220]                       TABLE XXXIX                       Pos   1234567890   score                                    V1-HLA-B0702-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         429   PPNFVLALVL   23       438   LPSIVILDLL   22       9   SPKSLSETCL   21       250   IPIEIVNKTL   21       323   LPMRRSERYL   21       137   FPDSLIVKGF   18       428   TPPNFVLALV   17       125   YPESNAEYLA   16       214   GPVVVAISLA   16       219   AISLATFFFL   16       394   IQSTLGYVAL   16       36   IGSGDFAKSL   15       197   SAREIENLPL   15       325   MRRSERYLFL   15       361   ISFGIMSLGL   15       379   IPSVSNALNW   15       427   YTPPNFVLAL   15       211   LWRGPVVVAI   14       263   AITLLSLVYL   14       402   ALLISTFHVL   14       435   ALVLPSIVIL   14       40   DFAKSLTIRL   13       92   AIHREHYTSL   13       127   ESNAEYLASL   13       172   IQARQQVIEL   13       188   IPIDLGSLSS   13       195   LSSAREIENL   13       199   REIENLPLRL   13       204   LPLRLFTLWR   13       259   LPIVAITLLS   13       260   PIVAITLLSL   13       266   LLSLVYLAGL   13       290   RFPPWLETWL   13       364   GIMSLGLLSL   13       365   IMSLGLLSLL   13       4   ISMMGSPKSL   12       18   LPNGINGIKD   12       70   FPHVVDVTHH   12       98   YTSLWDLRHL   12       142   IVKGFNVVSA   12       147   NVVSAWALQL   12       157   GPKDASRQVY   12       202   ENLPLRLFTL   12       257   KTLPIVAITL   12       273   AGLLAAAYQL   12       292   PPWLETWLQC   12       296   ETWLQCRKQL   12       298   WLQCRKQLGL   12       314   MVHVAYSLCL   12       377   TSIPSVSNAL   12       395   QSTLGYVALL   12       425   RFYTPPNFVL   12       437   VLPSIVILDL   12       440   SIVILDLLQL   12       26   KDARKVTVGV   11       27   DARKVTVGVI   11       49   LIRCGYHVVI   11       62   NPKFASEFFP   11       74   VDVTHHEDAL   11       95   REHYTSLWDL   11       99   TSLWDLRHLL   11       132   YLASLFPDSL   11       145   GFNVVSAWAL   11       183   RQLNFIPIDL   11       186   NFIPIDLGSL   11       201   IENLPLRLFT   11       213   RGPVVVAISL   11       237   HPYARNQQSD   11       252   IEIVNKTLPI   11       258   TLPIVAITLL   11       286   TKYRRFPPWL   11       291   FPPWLETWLQ   11       312   FAMVHVAYSL   11       362   SFGIMSLGLL   11       389   REFSFIQSTL   11                 V2-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         34   PPPCPADFFL   21       33   CPPPCPADFF   18       2   GSPGLQALSL   14       16   GFTPFSCLSL   13       18   TPFSCLSLPS   13       4   PGLQALSLSL   12       14   SSGFTPFSCL   12       25   LPSSWDYRCP   12       35   PPCPADFFLY   12       3   SPGLQALSLS   11       8   ALSLSLSSGF   10       36   PCPADFFLYF   10                 V5A-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         10   FWRGPVVVAI   14       3   LPLRLFTFWR   11       9   TFWRGPVVVA   10       6   RLFTFWRGPV   9       8   FTFWRGPVVV   9       1   ENLPLRLFTF   8       7   LFTFWRGPVV   8                 V5B-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         19   TELELEFVFL   14       24   EFVFLLTLLL   14       14   FADTQTELEL   13       22   ELEFVFLLTL   13       12   CSFADTQTEL   12       20   ELELEFVFLL   12       23   LEFVFLLTLL   11       1   NWREFSFIQI   9       8   IQIFCSFADT   9       21   LELEFVFLLT   9       10   IFCSFADTQT   8       16   DTQTELELEF   8       5   FSFIQIFCSF   7       6   SFIQIFCSFA   7       17   TQTELELEFV   7       18   QTELELEFVF   7       2   WREFSFIQIF   6                 V6-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         3   LPSIVILGKI   18       44   IPHVSPERVT   18       7   VILGKIILFL   15       27   KKGWEKSQFL   13       16   LPCISRKLKR   12       46   HVSPERVTVM   12       14   LFLPCISRKL   11       5   SIVILGKIIL   10       38   EGIGGTIPHV   10       26   IKKGWEKSQF   9       31   EKSQFLEEGI   9       45   PHVSPERVTV   9                 V7A-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         2   SPKSLSETFL   22                 V7B-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         8   QQSTLGYVAL   15       3   LNMAYQQSTL   12       9   QSTLGYVALL   12       10   STLGYVALLI   10       6   AYQQSTLGYV   8       7   YQQSTLGYVA   7                 V7C-HLA-B0702-10mers-98P4B6       Each peptide is a portion SEQ       ID NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         122   LPHTNGVGPL   22       129   GPLWEFLLRL   22       102   DPPESPDRAL   21       49   PPLSTPPPPA   18       55   PPPAMWTEEA   18       119   NPVLPHTNGV   17       141   SQAASGTLSL   15       143   AASGTLSLAF   15       29   LRGGLSEIVL   14       113   AANSWRNPVL   14       15   ASPAAAWKCL   13       48   IPPLSTPPPP   13       85   IPVVGVVTED   13       106   SPDRALKAAN   13       126   NGVGPLWEFL   13       152   FTSWSLGEFL   13       165   TWMKLETIIL   13       181   QKSKHCMFSL   13       1   LPSIVILDLS   12       5   VILDLSVEVL   12       16   SPAAAWKCLG   12       20   AWKCLGANIL   12       24   LGANILRGGL   12       42   WQQDRKIPPL   12       54   PPPPAMWTEE   12       56   PPAMWTEEAG   12       103   PPESPDRALK   12       127   GVGPLWEFLL   12       139   LKSQAASGTL   12       28   ILRGGLSEIV   11       44   QDRKIPPLST   11       53   TPPPPAMWTE   11       81   SSSQIPVVGV   11       104   PESPDRALKA   11       144   ASGTLSLAFT   11       148   LSLAFTSWSL   11       160   FLGSGTWMKL   11       168   KLETIILSKL   11       6   ILDLSVEVLA   10       17   PAAAWKCLGA   10       19   AAWKCLGANI   10       31   GGLSEIVLPI   10       38   LPIEWQQDRK   10       50   PLSTPPPPAM   10       78   KSSSSSQIPV   10       79   SSSSSQIPVV   10       83   SQIPVVGVVT   10       112   KAANSWRNPV   10       130   PLWEFLLRLL   10                 V8-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         8   EGMGGTIPHV   11       1   EKSQFLEEGM   9       4   QFLEEGMGGT   6       5   FLEEGMGGTI   6                 V13-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         2   SPKSLSETFL   22                 V14-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         10   FWRGPVVVAI   14       3   LPLRLFTFWR   11       9   TFWRGPVVVA   10       6   RLFTFWRGPV   9       8   FTFWRGPVVV   9       1   ENLPLRLFTF   8       7   LFTFWRGPVV   8                 V21-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         8   QKTKHCMFSL   11       9   KTKHCMFSLI   8       6   QEQKTKHCMF   7       1   LSKLTQEQKT   6       5   TQEQKTKHCM   6                 V25-HLA-B0702-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position for       each peptide is the start       position plus nine.                         5   LPCISQKLKR   12       3   LFLPCISQKL   11       6   PCISQKLKRI   6                    
     [1221]                       TABLE XL                       Pos   1234567890   score                                    V1-HLA-B08-10mers-98P4B6       NoResultsFound.       V2-HLA-B08-10mers-98P4B6       NoResultsFound.       V5A-HLA-B08-10mers-98P4B6       NoResultsFound.       V5B-HLA-B08-10mers-98P4B6       NoResultsFound.       V6-HLA-B08-10mers-98P4B6       NoResultsFound.       V7A-HLA-B08-10mers-98P4B6       NoResultsFound.       V7B-HLA-B08-10mers-98P4B6       NoResultsFound.       V7C-HLA-B08-10mers-98P4B6       NoResultsFound.       V8-HLA-B08-10mers-98P4B6       NoResultsFound.       V13-HLA-B08-10mers-98P4B6       NoResultsFound.       V14-HLA-B08-10mers-98P4B6       NoResultsFound.       V21-HLA-B08-10mers-98P4B6       NoResultsFound.       V25-HLA-B08-10mers-98P4B6       NoResultsFound.                    
     [1222]                       TABLE XLI                       Pos   1234567890   score                                    V1-HLA-B1510-10mers-98P4B6       NoResultsFound.       V2-HLA-B1510-10mers-98P4B6       NoResultsFound.       V5A-HLA-B1510-10mers-98P4B6       NoResultsFound.       V5B-HLA-B1510-10mers-98P4B6       NoResultsFound.       V6-HLA-B1510-10mers-98P4B6       NoResultsFound.       V7A-HLA-B1510-10mers-98P4B6       NoResultsFound.       V7B-HLA-B1510-10mers-98P4B6       NoResultsFound.       V7C-HLA-B1510-10mers-98P4B6       NoResultsFound.       V8-HLA-B1510-10mers-98P4B6       NoResultsFound.       V13-HLA-B1510-10mers-98P4B6       NoResultsFound.       V14-HLA-B1510-10mers-98P4B6       NoResultsFound.       V21-HLA-B1510-10mers-98P4B6       NoResultsFound.       V25-HLA-B1510-10mers-98P4B6       NoResultsFound.       V1-HLA-B2705-10mers-98P4B6       NoResultsFound.       V2-HLA-B2705-10mers-98P4B6       NoResultsFound.       V5A-HLA-B2705-10mers-98P4B6       NoResultsFound.       V5B-HLA-B2705-10mers-98P4B6       NoResultsFound.       V6-HLA-B2705-10mers-98P4B6       NoResultsFound.       V7A-HLA-B2705-10mers-98P4B6       NoResultsFound.       V7B-HLA-B2705-10mers-98P4B6       NoResultsFound.       V7C-HLA-B2705-10mers-98P4B6       NoResultsFound.       V8-HLA-B2705-10mers-98P4B6       NoResultsFound.       V13-HLA-B2705-10mers-98P4B6       NoResultsFound.       V14-HLA-B2705-10mers-98P4B6       NoResultsFound.       V21-HLA-B2705-10mers-98P4B6       NoResultsFound.       V25-HLA-B2705-10mers-98P4B6       NoResultsFound.       V1-HLA-B2709-10mers-98P4B6       NoResultsFound.       V2-HLA-B2709-10mers-98P4B6       NoResultsFound.       V5A-HLA-B2709-10mers-98P4B6       NoResultsFound.       V5B-HLA-B2709-10mers-98P4B6       NoResultsFound.       V6-HLA-B2709-10mers-98P4B6       NoResultsFound.       V7A-HLA-B2709-10mers-98P4B6       NoResultsFound.       V7B-HLA-B2705-10mers-98P4B6       NoResultsFound.       V7C-HLA-B2709-10mers-98P4B6       NoResultsFound.       V8-HLA-B2709-10mers-98P4B6       NoResultsFound.       V13-HLA-B2709-10mers-98P4B6       NoResultsFound.       V14-HLA-B2709-10mers-98P4B6       NoResultsFound.       V21-HLA-B2709-10mers-98P4B6       NoResultsFound.       V25-HLA-B2709-10mers-98P4B6       NoResultsFound.                    
     [1223]                       TABLE XLIV                       Pos   1234567890   score                                    V1-HLA-B4402-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 3; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         199   REIENLPLRL   25       351   EEEVWRIEMY   25       252   IEIVNKTLPI   23       389   REFSFIQSTL   23       95   REHYTSLWDL   21       179   IELARQLNFI   21       352   EEVWRIEMYI   20       79   HEDALTKTNI   19       377   TSIPSVSNAL   19       186   NFIPIDLGSL   18       202   ENLPLRLFTL   18       257   KTLPIVAITL   18       427   YTPPNFVLAL   18       435   ALVLPSIVIL   18       273   AGLLAAAYQL   17       289   RRFPPWLETW   17       296   ETWLQCRKQL   17       402   ALLISTFHVL   17       16   TCLPNGINGI   16       116   VSNNMRINQY   16       200   EIENLPLRLF   16       219   AISLATFFFL   16       230   SFVRDVIHPY   16       250   IPIEIVNKTL   16       262   VAITLLSLVY   16       263   AITLLSLVYL   16       359   MYISFGIMSL   16       406   STFHVLIYGW   16       410   VLIYGWKRAF   16       36   IGSGDFAKSL   15       45   LTIRLIRCGY   15       56   VVIGSRNPKF   15       60   SRNPKFASEF   15       67   SEFFPHVVDV   15       126   PESNAEYLAS   15       130   AEYLASLFPD   15       203   NLPLRLFTLW   15       255   VNKTLPIVAI   15       258   TLPIVAITLL   15       279   AYQLYYGTKY   15       310   FFFAMVHVAY   15       329   ERYLFLNMAY   15       394   IQSTLGYVAL   15       437   VLPSIVILDL   15       4   ISMMGSPKSL   14       92   AIHREHYTSL   14       98   YTSLWDLRHL   14       99   TSLWDLRHLL   14       123   NQYPESNAEY   14       137   FPDSLIVKGF   14       147   NVVSAWALQL   14       183   RQLNFIPIDL   14       195   LSSAREIENL   14       218   VAISLATFFF   14       271   YLAGLLAAAY   14       290   RFPPWLETWL   14       346   ENSWNEEEVW   14       361   ISFGIMSLGL   14       365   IMSLGLLSLL   14       391   FSFIQSTLGY   14       396   STLGYVALLI   14       399   GYVALLISTF   14       404   LISTFHVLIY   14       418   AFEEEYYRFY   14       420   EEEYYRFYTP   14       440   SIVILDLLQL   14       41   FAKSLTIRLI   13       74   VDVTHHEDAL   13       80   EDALTKTNII   13       81   DALTKTNIIF   13       84   TKTNIIFVAI   13       104   LRHLLVGKIL   13       127   ESNAEYLASL   13       128   SNAEYLASLF   13       143   VKGFNVVSAW   13       145   GFNVVSAWAL   13       157   GPKDASRQVY   13       170   NNIQARQQVI   13       172   IQARQQVIEL   13       176   QQVIELARQL   13       201   IENLPLRLFT   13       211   LWRGPVVVAI   13       213   RGPVVVAISL   13       220   ISLATFFFLY   13       245   SDFYKIPIEI   13       266   LLSLVYLAGL   13       267   LSLVYLAGLL   13       299   LQCRKQLGLL   13       303   KQLGLLSFFF   13       323   LPMRRSERYL   13       324   PMRRSERYLF   13       328   SERYLFLNMA   13       350   NEEEVWRIEM   13       362   SFGIMSLGLL   13       364   GIMSLGLLSL   13       379   IPSVSNALNW   13       384   NALNWREFSF   13       395   QSTLGYVALL   13       403   LLISTFHVLI   13       429   PPNFVLALVL   13       438   LPSIVILDLL   13       443   ILDLLQLCRY   13       38   SGDFAKSLTI   12       40   DFAKSLTIRL   12       93   IHREHYTSLW   12       105   RHLLVGKILI   12       124   QYPESNAEYL   12       178   VIELARQLNF   12       192   LGSLSSAREI   12       197   SAREIENLPL   12       216   VVVAISLATF   12       260   PIVAITLLSL   12       274   GLLAAAYQLY   12       282   LYYGTKYRRF   12       286   TKYRRFPPWL   12       295   LETWLQCRKQ   12       301   CRKQLGLLSF   12       302   RKQLGLLSFF   12       312   FAMVHVAYSL   12       357   IEMYISFGIM   12       385   ALNWREFSFI   12       417   RAFEEEYYRF   12       421   EEYYRFYTPP   12       425   RFYTPPNFVL   12                 V2-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 5; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         8   ALSLSLSSGF   15       32   RCPPPCPADF   15       33   CPPPCPADFF   15       35   PPCPADFFLY   15       2   GSPGLQALSL   14       16   GFTPFSCLSL   14       36   PCPADFFLYF   13       4   PGLQALSLSL   12       11   LSLSSGFTPF   12       14   SSGFTPFSCL   12       20   FSCLSLPSSW   12       22   CLSLPSSWDY   12       34   PPPCPADFFL   11                 V5A-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         1   ENLPLRLFTF   18       2   NLPLRLFTFW   14       10   FWRGPVVVAI   13                 V5B-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 11; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         23   LEFVFLLTLL   24       19   TELELEFVFL   23       20   ELELEFVFLL   15       22   ELEFVFLLTL   15       24   EFVFLLTLLL   15       21   LELEFVFLLT   14       2   WREFSFIQIF   13       3   REFSFIQIFC   13       5   FSFIQIFCSF   13       14   FADTQTELEL   13       1   NWREFSFIQI   12       12   CSFADTQTEL   12       16   DTQTELELEF   12       18   QTELELEFVF   12                 V6-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 13; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         6   IVILGKIILF   19       7   VILGKIILFL   16       14   LFLPCISRKL   16       17   PCISRKLKRI   14       37   EEGIGGTIPH   14       4   PSIVILGKII   13       21   RKLKRIKKGW   13       5   SIVILGKIIL   12       10   GKIILFLPCI   12       26   IKKGWEKSQF   12       3   LPSIVILGKI   11       27   KKGWEKSQFL   11       30   WEKSQFLEEG   11       31   EKSQFLEEGI   11       36   LEEGIGGTIP   11       35   FLEEGIGGTI   9       38   EGIGGTIPHV   9                 V7A-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         9   TFLPNGINGI   16       1   GSPKSLSETF   12       2   SPKSLSETFL   11       6   LSETFLPNGI   11       7   SETFLPNGIN   11                 V7B-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 15; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         8   QQSTLGYVAL   15       10   STLGYVALLI   14       9   QSTLGYVALL   13       3   LNMAYQQSTL   12       5   MAYQQSTLGY   12                 V7C-HLA-B4402-10mers-98P4B6       Each peptide is a portion of SEQ       ID NO: 15; each start position is       specified, the length of peptide is       10 amino acids, and the end       position for each peptide is the       start position plus nine.                         92   TEDDEAQDSI   20       179   QEQKSKHCMF   20       143   AASGTLSLAF   18       34   SEIVLPIEWQ   17       104   PESPDRALKA   17       12   EVLASPAAAW   16       15   ASPAAAWKCL   16       62   EEAGATAEAQ   16       132   WEFLLRLLKS   16       20   AWKCLGANIL   15       5   VILDLSVEVL   14       11   VEVLASPAAA   14       42   WQQDRKIPPL   14       51   LSTPPPPAMW   14       68   AEAQESGIRN   14       71   QESGIRNKSS   14       102   DPPESPDRAL   14       113   AANSWRNPVL   14       127   GVGPLWEFLL   14       151   AFTSWSLGEF   14       168   KLETIILSKL   14       29   LRGGLSEIVL   13       40   IEWQQDRKIP   13       95   DEAQDSIDPP   13       108   DRALKAANSW   13       129   GPLWEFLLRL   13       130   PLWEFLLRLL   13       141   SQAASGTLSL   13       158   GEFLGSGTWM   13       165   TWMKLETIIL   13       169   LETIILSKLT   13       24   LGANILRGGL   12       27   NILRGGLSEI   12       33   LSEIVLPIEW   12       122   LPHTNGVGPL   12       123   PHTNGVGPLW   12       126   NGVGPLWEFL   12       139   LKSQAASGTL   12       146   GTLSLAFTSW   12       19   AAWKCLGANI   11       31   GGLSEIVLPI   11       61   TEEAGATAEA   11       66   ATAEAQESGI   11       125   TNGVGPLWEF   11       148   LSLAFTSWSL   11       152   FTSWSLGEFL   11       157   LGEFLGSGTW   11       160   FLGSGTWMKL   11       163   SGTWMKLETI   11       181   QKSKHCMFSL   11       182   KSKHCMFSLI   11       39   PIEWQQDRKI   10       76   RNKSSSSSQI   9       83   SQIPVVGVVT   9       105   ESPDRALKAA   9                 V8-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 17; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position       plus nine.                         7   EEGMGGTIPH   14       6   LEEGMGGTIP   11       5   FLEEGMGGTI   9       8   EGMGGTIPHV   7                 V13-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 27; each start       position is specified, the       length of peptide is 10 amino       acids, and the end position       for each peptide is the start       position plus nine.                         9   TFLPNGINGI   16       1   GSPKSLSETF   12       2   SPKSLSETFL   11       6   LSETFLPNGI   11       7   SETFLPNGIN   11                 V14-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 29; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         1   ENLPLRLFTF   18       2   NLPLRLFTFW   14       10   FWRGPWVAI   13                 V21-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 43; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         6   QEQKTKHCMF   20       9   KTKHCMFSLI   11       8   QKTKHCMFSL   10                 V25-HLA-B4402-10mers-98P4B6       Each peptide is a portion of       SEQ ID NO: 51; each start       position is specified, the length       of peptide is 10 amino acids,       and the end position for each       peptide is the start position plus nine.                         3   LFLPCISQKL   15       6   PCISQKLKRI   14       10   QKLKRIKKGW   13       9   SQKLKRIKKG   8       2   ILFLPCISQK   7                    
     [1224]                       TABLE XLV                       Pos   1234567890   score                                    V1-HLA-B5101-10mers-98P4B6       NoResultsFound.       V2-HLA-B5101-10mers-98P4B6       NoResultsFound.       V5A-HLA-B5101-10mers-98P4B6       NoResultsFound.       V5B-HLA-B5101-10mers-98P4B6       NoResultsFound.       V6-HLA-B5101-10mers-98P4B6       NoResultsFound.       V7A-HLA-B5101-10mers-98P4B6       NoResultsFound.       V7B-HLA-B5101-10mers-98P4B6       NoResultsFound.       V7C-HLA-B5101-10mers-98P4B6       NoResultsFound.       V8-HLA-B5101-10mers-98P4B6       NoResultsFound.       V13-HLA-B5101-10mers-98P4B6       NoResultsFound.       V14-HLA-B5101-10mers-98P4B6       NoResultsFound.       V21-HLA-B5101-10mers-98P4B6       NoResultsFound.       V25-HLA-B5101-10mers-98P4B6       NoResultsFound.                    
     [1225]                       TABLE XLVI                       Pos   123456789012345   score                                    V1-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       3; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         143   VKGFNVVSAWALQLG   33       266   LLSLVYLAGLLAAAY   33       367   SLGLLSLLAVTSIPS   32       1   MESISMMGSPKSLSE   31       130   AEYLASLFPDSLIVK   30       30   KVTVGVIGSGDFAKS   29       431   NFVLALVLPSIVILD   29       206   LRLFTLWRGPVVVAI   28       215   PVVVAISLATFFFLY   28       370   LLSLLAVTSIPSVSN   28       438   LPSIVILDLLQLCRY   28       101   LWDLRHLLVGKILID   27       185   LNFIPIDLGSLSSAR   27       356   RIEMYISFGIMSLGL   27       360   YISFGIMSLGLLSLL   27       397   TLGYVALLISTFHVL   27       421   EEYYRFYTPPNFVLA   27       38   SGDFAKSLTIRLIRC   26       102   WDLRHLLVGKILIDV   26       122   INQYPESNAEYLASL   26       149   VSAWALQLGPKDASR   26       244   QSDFYKIPIEIVNKT   26       249   KIPIEIVNKTLPIVA   26       256   NKTLPIVAITLLSLV   26       261   IVAITLLSLVYLAGL   26       298   WLQCRKQLGLLSFFF   26       368   LGLLSLLAVTSIPSV   26       109   VGKILIDVSNNMRIN   25       137   FPDSLIVKGFNVVSA   25       145   GFNVVSAWALQLGPK   25       198   AREIENLPLRLFTLW   25       222   LATFFFLYSFVRDVI   25       252   IEIVNKTLPIVAITL   25       264   ITLLSLVYLAGLLAA   25       302   RKQLGLLSFFFAMVH   25       309   SFFFAMVHVAYSLCL   25       354   VWRIEMYISFGIMSL   25       362   SFGIMSLGLLSLLAV   25       365   IMSLGLLSLLAVTSI   25       51   RCGYHVVIGSRNPKF   24       98   YTSLWDLRHLLVGKI   24       106   HLLVGKILIDVSNNM   24       150   SAWALQLGPKDASRQ   24       184   QLNFIPIDLGSLSSA   24       205   PLRLFTLWRGPVVVA   24       229   YSFVRDVIHPYARNQ   24       269   LVYLAGLLAAAYQLY   24       330   RYLFLNMAYQQVHAN   24       335   NMAYQQVHANIENSW   24       388   WREFSFIQSTLGYVA   24       391   FSFIQSTLGYVALLI   24       398   LGYVALLISTFHVLI   24       427   YTPPNFVLALVLPSI   24       430   PNFVLALVLPSIVIL   24       52   CGYHVVIGSRNPKFA   23       55   HVVIGSRNPKFASEF   23       186   NFIPIDLGSLSSARE   23       214   GPVVVAISLATFFFL   23       258   TLPIVAITLLSLVYL   23       351   EEEVWRIEMYISFGI   23       352   EEVWRIEMYISFGIM   23       127   ESNAEYLASLFPDSL   22       178   VIELARQLNFIPIDL   22       189   PIDLGSLSSAREIEN   22       211   LWRGPVVVAISLATF   22       216   VVVAISLATFFFLYS   22       255   VNKTLPIVAITLLSL   22       301   CRKQLGLLSFFFAMV   22       312   FAMVHVAYSLCLPMR   22       359   MYISFGIMSLGLLSL   22       364   GIMSLGLLSLLAVTS   22       395   QSTLGYVALLISTFH   22       432   FVLALVLPSIVILDL   22       435   ALVLPSIVILDLLQL   22       20   NGINGIKDARKVTVG   21       117   SNNMRINQYPESNAE   21       161   ASRQVYICSNNIQAR   21       174   ARQQVIELARQLNFI   21       277   AAAYQLYYGTKYRRF   21       373   LLAVTSIPSVSNALN   21       399   GYVALLISTFHVLIY   21       407   TFHVLIYGWKRAFEE   21       31   VTVGVIGSGDFAKSL   20       142   IVKGFNVVSAWALQL   20       209   FTLWRGPVVVAISLA   20       346   ENSWNEEEVWRIEMY   20       385   ALNWREFSFIQSTLG   20       429   PPNFVLALVLPSIVI   20       45   LTIRLIRCGYHVVIG   19       80   EDALTKTNIIFVAIH   19       95   REHYTSLWDLRHLLV   19       135   SLFPDSLIVKGFNVV   19       139   DSLIVKGFNVVSAWA   19       224   TFFFLYSFVRDVIHP   19       259   LPIVAITLLSLVYLA   19       280   YQLYYGTKYRRFPPW   19       281   QLYYGTKYRRFPPWL   19       288   YRRFPPWLETWLQCR   19       307   LLSFFFAMVHVAYSL   19       322   CLPMRRSERYLFLNM   19       328   SERYLFLNMAYQQVH   19       357   IEMYISFGIMSLGLL   19       400   YVALLISTFHVLIYG   19       424   YRFYTPPNFVLALVL   19       7   MGSPKSLSETCLPNG   18       25   IKDARKVTVGVIGSG   18       27   DARKVTVGVIGSGDF   18       39   GDFAKSLTIRLIRCG   18       47   IRLIRCGYHVVIGSR   18       62   NPKFASEFFPHVVDV   18       129   NAEYLASLFPDSLIV   18       163   RQVYICSNNIQARQQ   18       167   ICSNNIQARQQVIEL   18       179   IELARQLNFIPIDLG   18       190   IDLGSLSSAREIENL   18       236   IHPYARNQQSDFYKI   18       267   LSLVYLAGLLAAAYQ   18       268   SLVYLAGLLAAAYQL   18       285   GTKYRRFPPWLETWL   18       296   ETWLQCRKQLGLLSF   18       299   LQCRKQLGLLSFFFA   18       326   RRSERYLFLNMAYQQ   18       380   PSVSNALNWREFSFI   18       383   SNALNWREFSFIQST   18       390   EFSFIQSTLGYVALL   18       405   ISTFHVLIYGWKRAF   18       410   VLIYGWKRAFEEEYY   18       423   YYRFYTPPNFVLALV   18       433   VLALVLPSIVILDLL   18       22   INGIKDARKVTVGVI   17       29   RKVTVGVIGSGDFAK   17       33   VGVIGSGDFAKSLTI   17       34   GVIGSGDFAKSLTIR   17       44   SLTIRLIRCGYHVVI   17       46   TIRLIRCGYHVVIGS   17       54   YHVVIGSRNPKFASE   17       58   IGSRNPKFASEFFPH   17       77   THHEDALTKTNIIFV   17       87   NIIFVAIHREHYTSL   17       90   FVAIHREHYTSLWDL   17       105   RHLLVGKILIDVSNN   17       119   NMRINQYPESNAEYL   17       138   PDSLIVKGFNVVSAW   17       140   SLIVKGFNVVSAWAL   17       151   AWALQLGPKDASRQV   17       154   LQLGPKDASRQVYIC   17       176   QQVIELARQLNFIPI   17       187   FIPIDLGSLSSAREI   17       195   LSSAREIENLPLRLF   17       217   VVAISLATFFFLYSF   17       226   FFLYSFVRDVIHPYA   17       232   VRDVIHPYARNQQSD   17       251   PIEIVNKTLPIVAIT   17       253   EIVNKTLPIVAITLL   17       270   VYLAGLLAAAYQLYY   17       271   YLAGLLAAAYQLYYG   17       305   LGLLSFFFAMVHVAY   17       316   HVAYSLCLPMRRSER   17       317   VAYSLCLPMRRSERY   17       329   ERYLFLNMAYQQVHA   17       361   ISFGIMSLGLLSLLA   17       363   FGIMSLGLLSLLAVT   17       389   REFSFIQSTLGYVAL   17       392   SFIQSTLGYVALLIS   17       406   STFHVLIYGWKRAFE   17       408   FHVLIYGWKRAFEEE   17       436   LVLPSIVILDLLQLC   17       2   ESISMMGSPKSLSET   16       3   SISMMGSPKSLSETC   16       8   GSPKSLSETCLPNGI   16       11   KSLSETCLPNGINGI   16       16   TCLPNGINGIKDARK   16       24   GIKDARKVTVGVIGS   16       59   GSRNPKFASEFFPHV   16       67   SEFFPHVVDVTHHED   16       71   PHVVDVTHHEDALTK   16       103   DLRHLLVGKILIDVS   16       111   KILIDVSNNMRINQY   16       126   PESNAEYLASLFPDS   16       153   ALQLGPKDASRQVYI   16       166   YICSNNIQARQQVIE   16       171   NIQARQQVIELARQL   16       175   RQQVIELARQLNFIP   16       182   ARQLNFIPIDLGSLS   16       200   EIENLPLRLFTLWRG   16       208   LFTLWRGPVVVAISL   16       219   AISLATFFFLYSFVR   16       225   FFFLYSFVRDVIHPY   16       263   AITLLSLVYLAGLLA   16       265   TLLSLVYLAGLLAAA   16       294   WLETWLQCRKQLGLL   16       304   QLGLLSFFFAMVHVA   16       308   LSFFFAMVHVAYSLC   16       310   FFFAMVHVAYSLCLP   16       314   MVHVAYSLCLPMRRS   16       371   LSLLAVTSIPSVSNA   16       394   IQSTLGYVALLISTF   16       401   VALLISTFHVLIYGW   16       420   EEEYYRFYTPPNFVL   16       428   TPPNFVLALVLPSIV   16       440   SIVILDLLQLCRYPD   16                 V2-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         17   FTPFSCLSLPSSWDY   26       28   SWDYRCPPPCPADFF   26       6   LQALSLSLSSGFTPF   25       8   ALSLSLSSGFTPFSC   25       3   SPGLQALSLSLSSGF   24       10   SLSLSSGFTPFSCLS   22       14   SSGFTPFSCLSLPSS   19       26   PSSWDYRCPPPCPAD   16       31   YRCPPPCPADFFLYF   16       1   SGSPGLQALSLSLSS   15       4   PGLQALSLSLSSGFT   15       20   FSCLSLPSSWDYRCP   15       2   GSPGLQALSLSLSSG   14       7   QALSLSLSSGFTPFS   14       13   LSSGFTPFSCLSLPS   14       16   GFTPFSCLSLPSSWD   14       19   PFSCLSLPSSWDYRC   14       27   SSWDYRCPPPCPADF   14       30   DYRCPPPCPADFFLY   14                 V5A-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       11; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         11   LRLFTFWRGPVVVAI   28        3   AREIENLPLRLFTFW   25       16   FWRGPVVVAISLATF   22       14   FTFWRGPVVVAISLA   20       13   LFTFWRGPVVVAISL   18       5   EIENLPLRLFTFWRG   16       10   PLRLFTFWRGPVVVA   16       12   RLFTFWRGPVVVAIS   15       2   SAREIENLPLRLFTF   14       7   ENLPLRLFTFWRGPV   14       15   TFWRGPVVVAISLAT   14                 V5B-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         7   WREFSFIQJFCSFAD   25       9   EFSFIQIFCSFADTQ   24       4   ALNWREFSFIQIFCS   20       2   SNALNWREFSFIQIF   18       20   ADTQTELELEFVFLL   18       8   REFSFIQIFCSFADT   17       10   FSFIQIFCSFADTQT   17       22   TQTELELEFVFLLTL   17       23   QTELELEFVFLLTLL   17       12   FIQIFCSFADTQTEL   16       16   FCSFADTQTELELEF   16       17   CSFADTQTELELEFV   14                 V6-HL A-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       13; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         1   NFVLALVLPSIVILG   29       8   LPSIVILGKIILFLP   29       46   GGTIPHVSPERVTVM   28       17   IILFLPCISRKLKRI   26       11   IVILGKIILFLPCIS   24       38   SQFLEEGIGGTIPHV   24       39   QFLEEGIGGTIPHVS   24       7   VLPSIVILGKIILFL   23       14   LGKIILFLPCISRKL   23       2   FVLALVLPSIVILGK   22       42   EEGIGGTIPHVSPER   22       13   ILGKIILFLPCISRK   19       3   VLALVLPSIVILGKI   18       6   LVLPSIVILGKIILF   18       9   PSIVILGKIILFLPC   17       15   GKIILFLPCISRKLK   17       5   ALVLPSIVILGKIIL   16       10   SIVILGKIILFLPCI   16       18   ILFLPCISRKLKRIK   15       25   SRKLKRIKKGWEKSQ   15       30   RIKKGWEKSQFLEEG   14       43   EGIGGTIPHVSPERV   14                 V7A-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         12   SETFLPNGINGIKDA   21       5   MGSPKSLSETFLPNG   18       1   SISMMGSPKSLSETF   16       4   MMGSPKSLSETFLPN   16       6   GSPKSLSETFLPNGI   16       9   KSLSETFLPNGINGI   16       14   TFLPNGINGIKDARK   16       2   ISMMGSPKSLSETFL   14       15   FLPNGINGIKDARKV   13       10   SLSETFLPNGINGIK   10                 V7B-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         4   RYLFLNMAYQQSTLG   24       14   QSTLGYVALLISTFH   22       7   FLNMAYQQSTLGYVA   21       2   SERYLFLNMAYQQST   19       9   NMAYQQSTLGYVALL   18       3   ERYLFLNMAYQQSTL   17       11   AYQQSTLGYVALLIS   17       10   MAYQQSTLGYVALLI   16       13   QQSTLGYVALLISTF   16       8   LNMAYQQSTLGYVAL   14                 V7C-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         23   AAAWKCLGANILRGG   36       168   SGTWMKLETIILSKL   35       138   EFLLRLLKSQAASGT   33       13   DLSVEVLASPAAAWK   30       50   DRKIPPLSTPPPPAM   30       28   CLGANILRGGLSEIV   28       62   PAMWTEEAGATAEAQ   27       110   ESPDRALKAANSWRN   26       124   NPVLPHTNGVGPLWE   26       141   LRLLKSQAASGTLSL   25       8   SIVILDLSVEVLASP   24       31   ANILRGGLSEIVLPI   24       42   VLPIEWQQDRKIPPL   24       77   ESGIRNKSSSSSQIP   24       130   TNGVGPLWEFLLRLL   24       137   WEFLLRLLKSQAASG   24       7   PSIVILDLSVEVLAS   23       12   LDLSVEVLASPAAAW   23       150   SGTLSLAFTSWSLGE   23       171   WMKLETIILSKLTQE   23       3   ALVLPSIVILDLSVE   22       53   IPPLSTPPPPAMWTE   22       157   FTSWSLGEFLGSGTW   22       89   QIPVVGVVTEDDEAQ   21       6   LPSIVILDLSVEVLA   20       58   TPPPPAMWTEEAGAT   20       97   TEDDEAQDSIDPPES   20       100   DEAQDSIDPPESPDR   20       134   GPLWEFLLRLLKSQA   19       154   SLAFTSWSLGEFLGS   19       1   VLALVLPSIVILDLS   18       22   PAAAWKCLGANILRG   18       44   PIEWQQDRKIPPLST   18       122   WRNPVLPHTNGVGPL   18       135   PLWEFLLRLLKSQAA   18       140   LLRLLKSQAASGTLS   18       148   AASGTLSLAFTSWSL   18       159   SWSLGEFLGSGTWMK   18       161   SLGEFLGSGTWMKLE   18       169   GTWMKLETIILSKLT   18       176   TIILSKLTQEQKSKH   18       4   LVLPSIVILDLSVEV   17       9   IVILDLSVEVLASPA   17       30   GANILRGGLSEIVLP   17       61   PPAMWTEEAGATAEA   17       67   EEAGATAEAQESGIR   17       94   GVVTEDDEAQDSIDP   17       101   EAQDSIDPPESPDRA   17       107   DPPESPDRALKAANS   17       133   VGPLWEFLLRLLKSQ   17       143   LLKSQAASGTLSLAF   17       162   LGEFLGSGTWMKLET   17       163   GEFLGSGTWMKLETI   17       172   MKLETIILSKLTQEQ   17                 V8-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       17; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         8   SQFLEEGMGGTIPHV   24       9   QFLEEGMGGTIPHVS   24       12   EEGMGGTIPHVSPER   22       13   EGMGGTIPHVSPERV   14       7   KSQFLEEGMGGTIPH   13       2   KKGWEKSQFLEEGMG   12       6   EKSQFLEEGMGGTIP   12                 V13-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         12   SETFLPNGINGIKDA   21       5   MGSPKSLSETFLPNG   18       1   SISMMGSPKSLSETF   16       4   MMGSPKSLSETFLPN   16       6   GSPKSLSETFLPNGI   16       9   KSLSETFLPNGINGI   16       14   TFLPNGINGIKDARK   16       2   ISMMGSPKSLSETFL   14       15   FLPNGINGIKDARKV   13       10   SLSETFLPNGINGIK   10                 V14-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       29; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         10   LRLFTFWRGPVVVAI   28       2   AREIENLPLRLFTFW   25       15   FWRGPVVVAISLATF   22       13   FTFWRGPVVVAISLA   20       12   LFTFWRGPVVVAISL   18       4   EIENLPLRLFTFWRG   16       9   PLRLFTFWRGPVVVA   16       11   RLFTFWRGPVVVAIS   15       1   SAREIENLPLRLFTF   14       6   ENLPLRLFTFWRGPV   14       14   TFWRGPVVVAISLAT   14       8   LPLRLFTFWRGPVVV   12                 V21-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       43; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         3   TIILSKLTQEQKTKH   18       2   ETIILSKLTQEQKTK   14       7   SKLTQEQKTKHCMFS   13       6   LSKLTQEQKTKHCMF   11       11   QEQKTKHCMFSLISG   11       1   LETIILSKLTQEQKT   10       9   LTQEQKTKHCMFSLI   10       10   TQEQKTKHCMFSLIS   9       12   EQKTKHCMFSLISGS   9       5   ILSKLTQEQKTKHCM   8       8   KLTQEQKTKHCMFSL   8                 V25-HLA-DRB1-0101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       51; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         6   IILFLPCISQKLKRI   25       3   LGKIILFLPCISQKL   23       2   ILGKIILFLPCISQK   19       4   GKIILFLPCISQKLK   17       7   ILFLPCISQKLKRIK   15       9   FLPCISQKLKRIKKG   15       14   SQKLKRIKKGWEKSQ   15       15   QKLKRIKKGWEKSQF   13                    
     [1226]                       TABLE XLVII                       Pos   123456789012345   score                                    V1-HLA-DRB1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       3; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         97   HYTSLWDLRHLLVGK   28       176   QQVIELARQLNFIPI   27       228   LYSFVRDVIHPYARN   27       322   CLPMRRSERYLFLNM   27       54   YHVVIGSRNPKFASE   26       296   ETWLQCRKQLGLLSF   26       408   FHVLIYGWKRAFEEE   26       273   AGLLAAAYQLYYGTK   25       439   PSIVILDLLQLCRYP   25       109   VGKILIDVSNNMRIN   24       288   YRRFPPWLETWLQCR   24       87   NIIFVAIHREHYTSL   23       423   YYRFYTPPNFVLALV   23       133   LASLFPDSLIVKGFN   22       185   LNFIPIDLGSLSSAR   22       261   IVAITLLSLVYLAGL   22       272   LAGLLAAAYQLYYGT   22       433   VLALVLPSIVILDLL   22       145   GFNVVSAWALQLGPK   21       214   GPVVVAISLATFFFL   21       269   LVYLAGLLAAAYQLY   21       362   SFGIMSLGLLSLLAV   21       363   FGIMSLGLLSLLAVT   21       175   RQQVIELARQLNFIP   20       198   AREIENLPLRLFTLW   20       258   TLPIVAITLLSLVYL   20       264   ITLLSLVYLAGLLAA   20       376   VTSIPSVSNALNWRE   20       400   YVALLISTFHVLIYG   20       435   ALVLPSIVILDLLQL   20       438   LPSIVILDLLQLCRY   20       440   SIVILDLLQLCRYPD   20       30   KVTVGVIGSGDFAKS   19       53   GYHVVIGSRNPKFAS   19       110   GKILIDVSNNMRINQ   19       130   AEYLASLFPDSLIVK   19       151   AWALQLGPKDASRQV   19       215   PVVVAISLATFFFLY   19       217   VVAISLATFFFLYSF   19       256   NKTLPIVAITLLSLV   19       312   FAMVHVAYSLCLPMR   19       320   SLCLPMRRSERYLFL   19       402   ALLISTFHVLIYGWK   19       3   SISMMGSPKSLSETC   18       22   INGIKDARKVTVGVI   18       34   GVIGSGDFAKSLTIR   18       90   FVAIHREHYTSLWDL   18       119   NMRINQYPESNAEYL   18       139   DSLIVKGFNVVSAWA   18       143   VKGFNVVSAWALQLG   18       162   SRQVYICSNNIQARQ   18       184   QLNFIPIDLGSLSSA   18       195   LSSAREIENLPLRLF   18       233   RDVIHPYARNQQSDF   18       308   LSFFFAMVHVAYSLC   18       331   YLFLNMAYQQVHANI   18       360   YISFGIMSLGLLSLL   18       409   HVLIYGWKRAFEEEY   18       7   MGSPKSLSETCLPNG   17       21   GINGIKDARKVTVGV   17       38   SGDFAKSLTIRLIRC   17       113   LIDVSNNMRINQYPE   17       121   RINQYPESNAEYLAS   17       155   QLGPKDASRQVYICS   17       169   SNNIQARQQVIELAR   17       178   VIELARQLNFIPIDL   17       192   LGSLSSAREIENLPL   17       225   FFFLYSFVRDVIHPY   17       249   KIPIEIVNKTLPIVA   17       292   PPWLETWLQCRKQLG   17       318   AYSLCLPMRRSERYL   17       327   RSERYLFLNMAYQQV   17       338   YQQVHANIENSWNEE   17       379   IPSVSNALNWREFSF   17       416   KRAFEEEYYRFYTPP   17       15   ETCLPNGINGIKDAR   16       72   HVVDVTHHEDALTKT   16       79   HEDALTKTNIIFVAI   16       88   IIFVAIHREHYTSLW   16       111   KILIDVSNNMRINQY   16       205   PLRLFTLWRGPVVVA   16       248   YKIPIEIVNKTLPIV   16       279   AYQLYYGTKYRRFPP   16       342   HANIENSWNEEEVWR   16       382   VSNALNWREFSFIQS   16       413   YGWKRAFEEEYYRFY   16       43   KSLTIRLIRCGYHVV   15       263   AITLLSLVYLAGLLA   15       294   WLETWLQCRKQLGLL   15       321   LCLPMRRSERYLFLN   15       367   SLGLLSLLAVTSIPS   15       387   NWREFSFIQSTLGYV   15       412   IYGWKRAFEEEYYRF   15       73   VVDVTHHEDALTKTN   14       104   LRHLLVGKILIDVSN   14       236   IHPYARNQQSDFYKI   14       267   LSLVYLAGLLAAAYQ   14       304   QLGLLSFFFAMVHVA   14       365   IMSLGLLSLLAVTSI   14       373   LLAVTSIPSVSNALN   14       401   VALLISTFHVLIYGW   14       434   LALVLPSIVILDLLQ   14       1   MESISMMGSPKSLSE   13       4   ISMMGSPKSLSETCL   13       32   TVGVIGSGDFAKSLT   13       33   VGVIGSGDFAKSLTI   13       101   LWDLRHLLVGKILID   13       138   PDSLIVKGFNVVSAW   13       164   QVYICSNNIQARQQV   13       189   PIDLGSLSSAREIEN   13       201   IENLPLRLFTLWRGP   13       213   RGPVVVAISLATFFF   13       266   LLSLVYLAGLLAAAY   13       407   TFHVLIYGWKRAFEE   13                 V2-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         6   LQALSLSLSSGFTPF   20       14   SSGFTPFSCLSLPSS   20       20   FSCLSLPSSWDYRCP   20       24   SLPSSWDYRCPPPCP   16       2   GSPGLQALSLSLSSG   12       3   SPGLQALSLSLSSGF   12       8   ALSLSLSSGFTPFSC   12       9   LSLSLSSGFTPFSCL   12       10   SLSLSSGFTPFSCLS   11       22   CLSLPSSWDYRCPPP   11       30   DYRCPPPCPADFFLY   10       31   YRCPPPCPADFFLYF   10       12   SLSSGFTPFSCLSLP   9       17   FTPFSCLSLPSSWDY   9                 V5A-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       11; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         3   AREIENLPLRLFTFW   20       10   PLRLFTFWRGPVVVA   16       2   SAREIENLPLRLFTF   12       6   IENLPLRLFTFWRGP   12       8   NLPLRLFTFWRGPVV   12       5   EIENLPLRLFTFWRG   11       13   LFTFWRGPVVVAISL   10       4   REIENLPLRLFTFWR   9       11   LRLFTFWRGPVVVAI   9                 V5B-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         15   IFCSFADTQTELELE   24       23   QTELELEFVFLLTLL   20       1   VSNALNWREFSFIQI   16       19   FADTQTELELEFVFL   16       21   DTQTELELEFVFLLT   16       17   CSFADTQTELELEFV   15       22   TQTELELEFVFLLTL   13       2   SNALNWREFSFIQIF   11       10   FSFIQIFCSFADTQT   11                 V6-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       13; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         8   LPSIVILGKIILFLP   26       3   VLALVLPSIVILGKI   22       9   PSIVILGKIILFLPC   22       10   SIVILGKIILFLPCI   21       17   IILFLPCISRKLKRI   20       18   ILFLPCISRKLKRIK   18       25   SRKLKRIKKGWEKSQ   18       21   LPCISRKLKRIKKGW   17       28   LKRIKKGWEKSQFLE   17       29   KRIKKGWEKSQFLEE   16       4   LALVLPSIVILGKII   14       14   LGKIILFLPCISRKL   13       15   GKIILFLPCISRKLK   13       1   NFVLALVLPSIVILG   12       5   ALVLPSIVILGKIIL   12       37   KSQFLEEGIGGTIPH   12                 V7A-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         1   SISMMGSPKSLSETF   18       5   MGSPKSLSETFLPNG   17       13   ETFLPNGINGIKDAR   16       2   ISMMGSPKSLSETFL   13       12   SETFLPNGINGIKDA   13       8   PKSLSETFLPNGING   12       4   MMGSPKSLSETFLPN   9       10   SLSETFLPNGINGIK   8                 V7B-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         5   YLFLNMAYQQSTLGY   18       1   RSERYLFLNMAYQQS   17       6   LFLNMAYQQSTLGYV   14       12   YQQSTLGYVALLIST   12       3   ERYLFLNMAYQQSTL   11       4   RYLFLNMAYQQSTLG   11       7   FLNMAYQQSTLGYVA   11       11   AYQQSTLGYVALLIS   11       14   QSTLGYVALLISTFH   11       8   LNMAYQQSTLGYVAL   10                 V7C-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         93   VGVVTEDDEAQDSID   29       130   TNGVGPLWEFLLRLL   26       7   PSIVILDLSVEVLAS   24       1   VLALVLPSIVILDLS   22       8   SIVILDLSVEVLASP   21       133   VGPLWEFLLRLLKSQ   21       3   ALVLPSIVILDLSVE   20       163   GEFLGSGTWMKLETI   20       9   IVILDLSVEVLASPA   19       123   RNPVLPHTNGVGPLW   19       137   WEFLLRLLKSQAASG   19       154   SLAFTSWSLGEFLGS   19       171   WMKLETIILSKLTQE   19       38   LSEIVLPIEWQQDRK   18       179   LSKLTQEQKSKHCMF   18       40   EIVLPIEWQQDRKIP   17       44   PIEWQQDRKIPPLST   16       90   IPVVGVVTEDDEAQD   16       176   TIILSKLTQEQKSKH   16       15   SVEVLASPAAAWKCL   15       27   KCLGANILRGGLSEI   15       32   NILRGGLSEIVLPIE   15       39   SEIVLPIEWQQDRKI   15       116   LKAANSWRNPVLPHT   15       138   EFLLRLLKSQAASGT   15       175   ETIILSKLTQEQKSK   15       2   LALVLPSIVILDLSV   14                 V8-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       17; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         7   KSQFLEEGMGGTIPH   12       8   SQFLEEGMGGTIPHV   11       12   EEGMGGTIPHVSPER   10       1   IKKGWEKSQFLEEGM   9       4   GWEKSQFLEEGMGGT   7       5   WEKSQFLEEGMGGTI   7                 V13-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         1   SISMMGSPKSLSETF   18       5   MGSPKSLSETFLPNG   17       13   ETFLPNGINGIKDAR   16       2   ISMMGSPKSLSETFL   13       12   SETFLPNGINGIKDA   13       8   PKSLSETFLPNGING   12       4   MMGSPKSLSETFLPN   9       10   SLSETFLPNGINGIK   8                 V14-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       29; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         2   AREIENLPLRLFTFW   20       9   PLRLFTFWRGPVVVA   16       1   SAREIENLPLRLFTF   12       5   IENLPLRLFTFWRGP   12       7   NLPLRLFTFWRGPVV   12       4   EIENLPLRLFTFWRG   11       12   LFTFWRGPVVVAISL   10       3   REIENLPLRLFTFWR   9       10   LRLFTFWRGPVVVAI   9                 V21-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       43; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         6   LSKLTQEQKTKHCMF   18       3   TIILSKLTQEQKTKH   16       2   ETIILSKLTQEQKTK   15       1   LETIILSKLTQEQKT   13       4   IILSKLTQEQKTKHC   10       5   ILSKLTQEQKTKHCM   9       9   LTQEQKTKHCMFSLI   9       11   QEQKTKHCMFSLISG   9                 V25-HLA-DR1-0301-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       51; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         6   IILFLPCISQKLKRI   21       7   ILFLPCISQKLKRIK   18       14   SQKLKRIKKGWEKSQ   18       10   LPCISQKLKRIKKGW   17       3   LGKIILFLPCISQKL   13       4   GKIILFLPCISQKLK   13       5   KIILFLPCISQKLKR   11                    
     [1227]                       TABLE XLVIII                       Pos   123456789012345   score                                    V1-HLA-DR1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       3; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         420   EEEYYRFYTPPNFVL   28       98   YTSLWDLRHLLVGKI   26       109   VGKILIDVSNNMRIN   26       175   RQQVIELARQLNFIP   26       205   PLRLFTLWRGPVVVA   26       213   RGPVVVAISLATFFF   26       225   FFFLYSFVRDVIHPY   26       229   YSFVRDVIHPYARNQ   26       312   FAMVHVAYSLCLPMR   26       370   LLSLLAVTSIPSVSN   26       373   LLAVTSIPSVSNALN   26       376   VTSIPSVSNALNWRE   26       38   SGDFAKSLTIRLIRC   22       51   RCGYHVVIGSRNPKF   22       62   NPKFASEFFPHVVDV   22       87   NIIFVAIHREHYTSL   22       143   VKGFNVVSAWALQLG   22       163   RQVYICSNNIQARQQ   22       184   QLNFIPIDLGSLSSA   22       222   LATFFFLYSFVRDVI   22       244   QSDFYKIPIEIVNKT   22       307   LLSFFFAMVHVAYSL   22       309   SFFFAMVHVAYSLCL   22       328   SERYLFLNMAYQQVH   22       346   ENSWNEEEVWRIEMY   22       357   IEMYISFGIMSLGLL   22       385   ALNWREFSFIQSTLG   22       388   WREFSFIQSTLGYVA   22       405   ISTFHVLIYGWKRAF   22       423   YYRFYTPPNFVLALV   22       429   PPNFVLALVLPSIVI   22       1   MESISMMGSPKSLSE   20       15   ETCLPNGINGIKDAR   20       19   PNGINGIKDARKVTV   20       22   INGIKDARKVTVGVI   20       30   KVTVGVIGSGDFAKS   20       47   IRLIRCGYHVVIGSR   20       53   GYHVVIGSRNPKFAS   20       70   FPHVVDVTHHEDALT   20       71   PHVVDVTHHEDALTK   20       86   TNIIFVAIHREHYTS   20       90   FVAIHREHYTSLWDL   20       101   LWDLRHLLVGKILID   20       106   HLLVGKILIDVSNNM   20       110   GKILIDVSNNMRINQ   20       111   KILIDVSNNMRINQY   20       113   LIDVSNNMRINQYPE   20       130   AEYLASLFPDSLIVK   20       133   LASLFPDSLIVKGFN   20       139   DSLIVKGFNVVSAWA   20       140   SLIVKGFNVVSAWAL   20       145   GFNVVSAWALQLGPK   20       162   SRQVYICSNNIQARQ   20       176   QQVIELARQLNFIPI   20       185   LNFIPIDLGSLSSAR   20       189   PIDLGSLSSAREIEN   20       192   LGSLSSAREIENLPL   20       217   VVAISLATFFFLYSF   20       219   AISLATFFFLYSFVR   20       233   RDVIHPYARNQQSDF   20       247   FYKIPIEIVNKTLPI   20       256   NKTLPIVAITLLSLV   20       258   TLPIVAITLLSLVYL   20       261   IVAITLLSLVYLAGL   20       264   ITLLSLVYLAGLLAA   20       266   LLSLVYLAGLLAAAY   20       267   LSLVYLAGLLAAAYQ   20       273   AGLLAAAYQLYYGTK   20       292   PPWLETWLQCRKQLG   20       302   RKQLGLLSFFFAMVH   20       304   QLGLLSFFFAMVHVA   20       331   YLFLNMAYQQVHANI   20       351   EEEVWRIEMYISFGI   20       354   VWRIEMYISFGIMSL   20       362   SFGIMSLGLLSLLAV   20       365   IMSLGLLSLLAVTSI   20       367   SLGLLSLLAVTSIPS   20       368   LGLLSLLAVTSIPSV   20       379   IPSVSNALNWREFSF   20       395   QSTLGYVALLISTFH   20       398   LGYVALLISTFHVLI   20       401   VALLISTFHVLIYGW   20       430   PNFVLALVLPSIVIL   20       431   NFVLALVLPSIVILD   20       435   ALVLPSIVILDLLQL   20       438   LPSIVILDLLQLCRY   20       440   SIVILDLLQLCRYPD   20       12   SLSETCLPNGINGIK   18       21   GINGIKDARKVTVGV   18       36   IGSGDFAKSLTIRLI   18       76   VTHHEDALTKTNIIF   18       97   HYTSLWDLRHLLVGK   18       142   IVKGFNVVSAWALQL   18       154   LQLGPKDASRQVYIC   18       161   ASRQVYICSNNIQAR   18       168   CSNNIQARQQVIELA   18       186   NFIPIDLGSLSSARE   18       195   LSSAREIENLPLRLF   18       234   DVIHPYARNQQSDFY   18       248   YKIPIEIVNKTLPIV   18       257   KTLPIVAITLLSLVY   18       289   RRFPPWLETWLQCRK   18       339   QQVHANIENSWNEEE   18       348   SWNEEEVWRIEMYIS   18       359   MYISFGIMSLGLLSL   18       364   GIMSLGLLSLLAVTS   18       384   NALNWREFSFIQSTL   18       387   NWREFSFIQSTLGYV   18       399   GYVALLISTFHVLIY   18       432   FVLALVLPSIVILDL   18       66   ASEFFPHVVDVTHHE   16       67   SEFFPHVVDVTHHED   16       95   REHYTSLWDLRHLLV   16       122   INQYPESNAEYLASL   16       129   NAEYLASLFPDSLIV   16       206   LRLFTLWRGPVVVAI   16       209   FTLWRGPVVVAISLA   16       224   TFFFLYSFVRDVIHP   16       226   FFLYSFVRDVIHPYA   16       228   LYSFVRDVIHPYARN   16       236   IHPYARNQQSDFYKI   16       245   SDFYKIPIEIVNKTL   16       268   SLVYLAGLLAAAYQL   16       285   GTKYRRFPPWLETWL   16       288   YRRFPPWLETWLQCR   16       308   LSFFFAMVHVAYSLC   16       330   RYLFLNMAYQQVHAN   16       335   NMAYQQVHANIENSW   16       352   EEVWRIEMYISFGIM   16       360   YISFGIMSLGLLSLL   16       390   EFSFIQSTLGYVALL   16       397   TLGYVALLISTFHVL   16       412   IYGWKRAFEEEYYRF   16       416   KRAFEEEYYRFYTPP   16       424   YRFYTPPNFVLALVL   16       296   ETWLQCRKQLGLLSF   15       3   SISMMGSPKSLSETC   14       4   ISMMGSPKSLSETCL   14       32   TVGVIGSGDFAKSLT   14       33   VGVIGSGDFAKSLTI   14       44   SLTIRLIRCGYHVVI   14       46   TIRLIRCGYHVVIGS   14       54   YHVVIGSRNPKFASE   14       73   VVDVTHHEDALTKTN   14       80   EDALTKTNIIFVAIH   14       85   KTNIIFVAIHREHYT   14       88   IIFVAIHREHYTSLW   14       117   SNNMRINQYPESNAE   14       119   NMRINQYPESNAEYL   14       151   AWALQLGPKDASRQV   14       178   VIELARQLNFIPIDL   14       182   ARQLNFIPIDLGSLS   14       187   FIPIDLGSLSSAREI   14       198   AREIENLPLRLFTLW   14       203   NLPLRLFTLWRGPVV   14       208   LFTLWRGPVVVAISL   14       214   GPVVVAISLATFFFL   14       232   VRDVIHPYARNQQSD   14       249   KIPIEIVNKTLPIVA   14       252   IEIVNKTLPIVAITL   14       259   LPIVAITLLSLVYLA   14       263   AITLLSLVYLAGLLA   14       269   LVYLAGLLAAAYQLY   14       272   LAGLLAAAYQLYYGT   14       305   LGLLSFFFAMVHVAY   14       311   FFAMVHVAYSLCLPM   14       314   MVHVAYSLCLPMRRS   14       318   AYSLCLPMRRSERYL   14       322   CLPMRRSERYLFLNM   14       329   ERYLFLNMAYQQVHA   14       333   FLNMAYQQVHANIEN   14       342   HANIENSWNEEEVWR   14       356   RIEMYISFGIMSLGL   14       363   FGIMSLGLLSLLAVT   14       371   LSLLAVTSIPSVSNA   14       391   FSFIQSTLGYVALLI   14       400   YVALLISTFHVLIYG   14       402   ALLISTFHVLIYGWK   14       407   TFHVLIYGWKRAFEE   14       409   HVLIYGWKRAFEEEY   14       433   VLALVLPSIVILDLL   14       439   PSIVILDLLQLCRYP   14                 V5A-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID       No: 11; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         14   SSGFTPFSCLSLPSS   22       17   FTPFSCLSLPSSWDY   22       3   SPGLQALSLSLSSGF   20       10   SLSLSSGFTPFSCLS   20       2   GSPGLQALSLSLSSG   18       7   QALSLSLSSGFTPFS   18       28   SWDYRCPPPCPADFF   16       6   LQALSLSLSSGFTPF   14       20   FSCLSLPSSWDYRCP   14       4   PGLQALSLSLSSGFT   12       13   LSSGFTPFSCLSLPS   12       16   GFTPFSCLSLPSSWD   12       19   PFSCLSLPSSWDYRC   12       24   SLPSSWDYRCPPPCP   12                 V5B-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         4   ALNWREFSFIQIFCS   22       7   WREFSFIQIFCSFAD   22       9   EFSFIQIFCSFADTQ   22       13   IQIFCSFADTQTELE   22       10   FSFIQIFCSFADTQT   20       23   QTELELEFVFLLTLL   20       3   NALNWREFSFIQIFC   18       15   IFCSFADTQTELELE   18       16   FCSFADTQTELELEF   16       12   FIQIFCSFADTQTEL   14       6   NWREFSFIQIFCSFA   12       14   QIFCSFADTQTELEL   12       20   ADTQTELELEFVFLL   12       22   TQTELELEFVFLLTL   12       24   TELELEFVFLLTLLL   12                 V6-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       13; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         18   ILFLPCISRKLKRIK   26       17   IILFLPCISRKLKRI   22       37   KSQFLEEGIGGTIPH   22       1   NFVLALVLPSIVILG   20       5   ALVLPSIVILGKIIL   20       8   LPSIVILGKIILFLP   20       14   LGKIILFLPCISRKL   20       46   GGTIPHVSPERVTVM   20       2   FVLALVLPSIVILGK   18       22   PCISRKLKRIKKGWE   18       30   RIKKGWEKSQFLEEG   18       3   VLALVLPSIVILGKI   14       11   IVILGKIILFLPCIS   14       15   GKIILFLPCISRKLK   14       16   KIILFLPCISRKLKR   14       25   SRKLKRIKKGWEKSQ   14       28   LKRIKKGWEKSQFLE   14       38   SQFLEEGIGGTIPHV   14       42   EEGIGGTIPHVSPER   14       6   LVLPSIVILGKIILF   12       7   VLPSIVILGKIILFL   12       13   ILGKIILFLPCISRK   12       34   GWEKSQFLEEGIGGT   12       43   EGIGGTIPHVSPERV   12                 V7A-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         13   ETFLPNGINGIKDAR   20       10   SLSETFLPNGINGIK   18       12   SETFLPNGINGIKDA   16       1   SISMMGSPKSLSETF   14       2   ISMMGSPKSLSETFL   14       5   MGSPKSLSETFLPNG   12       7   SPKSLSETFLPNGIN   12       9   KSLSETFLPNGINGI   12                 V7B-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         5   YLFLNMAYQQSTLGY   26       2   SERYLFLNMAYQQST   22       14   QSTLGYVALLISTFH   20       4   RYLFLNMAYQQSTLG   16       9   NMAYQQSTLGYVALL   16       3   ERYLFLNMAYQQSTL   14       7   FLNMAYQQSTLGYVA   14       1   RSERYLFLNMAYQQS   12       6   LFLNMAYQQSTLGYV   12       11   AYQQSTLGYVALLIS   12       15   STLGYVALLISTFHV   12                 V7C-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         134   GPLWEFLLRLLKSQA   28       168   SGTWMKLETIILSKL   28       7   PSIVILDLSVEVLAS   26       13   DLSVEVLASPAAAWK   26       113   DRALKAANSWRNPVL   26       138   EFLLRLLKSQAASGT   26       150   SGTLSLAFTSWSLGE   26       176   TIILSKLTQEQKSKH   26       23   AAAWKCLGANILRGG   22       62   PAMWTEEAGATAEAQ   22       162   LGEFLGSGTWMKLET   22       3   ALVLPSIVILDLSVE   20       8   SIVILDLSVEVLASP   20       31   ANILRGGLSEIVLPI   20       40   EIVLPIEWQQDRKIP   20       50   DRKIPPLSTPPPPAM   20       61   PPAMWTEEAGATAEA   20       89   QIPVVGVVTEDDEAQ   20       92   VVGVVTEDDEAQDSI   20       130   TNGVGPLWEFLLRLL   20       133   VGPLWEFLLRLLKSQ   20       137   WEFLLRLLKSQAASG   20       159   SWSLGEFLGSGTWMK   20       169   GTWMKLETIILSKLT   20       171   WMKLETIILSKLTQE   20       27   KCLGANILRGGLSEI   18       74   EAQESGIRNKSSSSS   18       95   VVTEDDEAQDSIDPP   18       142   RLLKSQAASGTLSLA   18       151   GTLSLAFTSWSLGEF   18       172   MKLETIILSKLTQEQ   18       44   PIEWQQDRKIPPLST   16       119   ANSWRNPVLPHTNGV   16       157   FTSWSLGEFLGSGTW   16       77   ESGIRNKSSSSSQIP   15       175   ETIILSKLTQEQKSK   15       1   VLALVLPSIVILDLS   14       6   LPSIVILDLSVEVLA   14       9   IVILDLSVEVLASPA   14       11   ILDLSVEVLASPAAA   14       16   VEVLASPAAAWKCLG   14       30   GANILRGGLSEIVLP   14       35   RGGLSEIVLPIEWQQ   14       38   LSEIVLPIEWQQDRK   14       39   SEIVLPIEWQQDRKI   14       42   VLPIEWQQDRKIPPL   14       53   IPPLSTPPPPAMWTE   14       87   SSQIPVVGVVTEDDE   14       90   IPVVGVVTEDDEAQD   14       93   VGVVTEDDEAQDSID   14       103   QDSIDPPESPDRALK   14       123   RNPVLPHTNGVGPLW   14       141   LRLLKSQAASGTLSL   14       163   GEFLGSGTWMKLETI   14       179   LSKLTQEQKSKHCMF   14                 V8-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       17; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         7   KSQFLEEGMGGTIPH   22       8   SQFLEEGMGGTIPHV   14       12   EEGMGGTIPHVSPER   14       4   GWEKSQFLEEGMGGT   12       13   EGMGGTIPHVSPERV   12       2   KKGWEKSQFLEEGMG   10                 V13-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         13   ETFLPNGINGIKDAR   20       10   SLSETFLPNGINGIK   18       12   SETFLPNGINGIKDA   16       1   SISMMGSPKSLSETF   14       2   ISMMGSPKSLSETFL   14       5   MGSPKSLSETFLPNG   12       7   SPKSLSETFLPNGIN   12       9   KSLSETFLPNGINGI   12                 V14-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       29; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         9   PLRLFTFWRGPVVVA   26       10   LRLFTFWRGPVVVAI   16       12   LFTFWRGPVVVAISL   16       13   FTFWRGPVVVAISLA   16       2   AREIENLPLRLFTFW   14       7   NLPLRLFTFWRGPVV   14       3   REIENLPLRLFTFWR   12       6   ENLPLRLFTFWRGPV   12       14   TFWRGPVVVAISLAT   12       15   FWRGPVVVAISLATF   12                 V21-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       43; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         3   TIILSKLTQEQKTKH   26       2   ETIILSKLTQEQKTK   15       6   LSKLTQEQKTKHCMF   14       5   ILSKLTQEQKTKHCM   12                 V25-HLA-DRB1-0401-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       51; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         7   ILFLPCISQKLKRIK   26       6   IILFLPCISQKLKRI   22       3   LGKIILFLPCISQKL   20       4   GKIILFLPCISQKLK   20       11   PCISQKLKRIKKGWE   18       5   KIILFLPCISQKLKR   14       14   SQKLKRIKKGWEKSQ   14       2   ILGKIILFLPCISQK   12                    
     [1228]                       TABLE XLIX                          Pos   123456789012345   score                 V1-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       3; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         249   KIPIEIVNKTLPIVA   27       308   LSFFFAMVHVAYSLC   27       229   YSFVRDVIHPYARNQ   26       281   QLYYGTKYRRFPPWL   25       295   LETWLQCRKQLGLLS   25       87   NIIFVAIHREHYTSL   24       388   WREFSFIQSTLGYVA   23       309   SFFFAMVHVAYSLCL   22       3   SISMMGSPKSLSETC   21       71   PHVVDVTHHEDALTK   21       98   YTSLWDLRHLLVGKI   21       175   RQQVIELARQLNFIP   21       205   PLRLFTLWRGPVVVA   21       70   FPHVVDVTHHEDALT   20       95   REHYTSLWDLRHLLV   20       151   AWALQLGPKDASRQV   20       263   AITLLSLVYLAGLLA   20       1   MESISMMGSPKSLSE   19       51   RCGYHVVIGSRNPKF   19       106   HLLVGKILIDVSNNM   19       182   ARQLNFIPIDLGSLS   19       266   LLSLVYLAGLLAAAY   19       351   EEEVWRIEMYISFGI   19       395   QSTLGYVALLISTFH   19       424   YRFYTPPNFVLALVL   19       67   SEFFPHVVDVTHHED   18       222   LATFFFLYSFVRDVI   18       302   RKQLGLLSFFFAMVH   18       307   LLSFFFAMVHVAYSL   18       367   SLGLLSLLAVTSIPS   18       370   LLSLLAVTSIPSVSN   18       28   ARKVTVGVIGSGDFA   17       86   TNIIFVAIHREHYTS   17       99   TSLWDLRHLLVGKIL   17       134   ASLFPDSLIVKGFNV   17       143   VKGFNVVSAWALQLG   17       225   FFFLYSFVRDVIHPY   17       226   FFLYSFVRDVIHPYA   17       244   QSDFYKIPIEIVNKT   17       335   NMAYQQVHANIENSW   17       360   YISFGIMSLGLLSLL   17       405   ISTFHVLIYGWKRAF   17       129   NAEYLASLFPDSLIV   16       136   LFPDSLIVKGFNVVS   16       163   RQVYICSNNIQARQQ   16       184   QLNFIPIDLGSLSSA   16       268   SLVYLAGLLAAAYQL   16       279   AYQLYYGTKYRRFPP   16       282   LYYGTKYRRFPPWLE   16       328   SERYLFLNMAYQQVH   16       330   RYLFLNMAYQQVHAN   16       385   ALNWREFSFIQSTLG   16       397   TLGYVALLISTFHVL   16       429   PPNFVLALVLPSIVI   16       42   AKSLTIRLIRCGYHV   15       47   IRLIRCGYHVVIGSR   15       103   DLRHLLVGKILIDVS   15       142   IVKGFNVVSAWALQL   15       210   TLWRGPVVVAISLAT   15       317   VAYSLCLPMRRSERY   15       318   AYSLCLPMRRSERYL   15       322   CLPMRRSERYLFLNM   15       401   VALLISTFHVLIYGW   15       408   FHVLIYGWKRAFEEE   15       428   TPPNFVLALVLPSIV   15       19   PNGINGIKDARKVTV   14       22   INGIKDARKVTVGVI   14       43   KSLTIRLIRCGYHVV   14       52   CGYHVVIGSRNPKFA   14       53   GYHVVIGSRNPKFAS   14       56   VVIGSRNPKFASEFF   14       66   ASEFFPHVVDVTHHE   14       77   THHEDALTKTNIIFV   14       85   KTNIIFVAIHREHYT   14       89   IFVAIHREHYTSLWD   14       113   LIDVSNNMRINQYPE   14       189   PIDLGSLSSAREIEN   14       198   AREIENLPLRLFTLW   14       203   NLPLRLFTLWRGPVV   14       212   WRGPVVVAISLATFF   14       233   RDVIHPYARNQQSDF   14       261   IVAITLLSLVYLAGL   14       319   YSLCLPMRRSERYLF   14       348   SWNEEEVWRIEMYIS   14       373   LLAVTSIPSVSNALN   14       381   SVSNALNWREFSFIQ   14       407   TFHVLIYGWKRAFEE   14       409   HVLIYGWKRAFEEEY   14       430   PNFVLALVLPSIVIL   14       435   ALVLPSIVILDLLQL   14       30   KVTVGVIGSGDFAKS   14       33   VGVIGSGDFAKSLTI   13       101   LWDLRHLLVGKILID   13       139   DSLIVKGFNVVSAWA   13       146   FNVVSAWALQLGPKD   13       178   VIELARQLNFIPIDL   13       185   LNFIPIDLGSLSSAR   13       206   LRLFTLWRGPVVVAI   13       208   LFTLWRGPVVVAISL   13       223   ATFFFLYSFVRDVIH   13       252   IEIVNKTLPIVAITL   13       256   NKTLPIVAITLLSLV   13       280   YQLYYGTKYRRFPPW   13       311   FFAMVHVAYSLCLPM   13       358   EMYISFGIMSLGLLS   13       364   GIMSLGLLSLLAVTS   13       376   VTSIPSVSNALNWRE   13       391   FSFIQSTLGYVALLI   13       431   NFVLALVLPSIVILD   13                 V2-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 5; each start position is specified,       the length of peptide is 15 amino acids,       and the end position for each peptide is       the start position plus fourteen.                         17   FTPFSCLSLPSSWDY   22       3   SPGLQALSLSLSSGF   19       28   SWDYRCPPPCPADFF   16       24   SLPSSWDYRCPPPCP   14       5   GLQALSLSLSSGFTP   12       8   ALSLSLSSGFTPFSC   12       10   SLSLSSGFTPFSCLS   12       14   SSGFTPFSCLSLPSS   12       26   PSSWDYRCPPPCPAD   10                 V5A-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       11; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         13   LFTFWRGPVVVAISL   17       10   PLRLFTFWRGPVVVA   15       15   TFWRGPVVVAISLAT   15       3   AREIENLPLRLFTFW   14       8   NLPLRLFTFWRGPVV   14       11   LRLFTFWRGPVVVAI   13       14   FTFWRGPVVVAISLA   12       16   FWRGPVVVAISLATF   9       4   REIENLPLRLFTFWR   8                 V5B-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 11; each start position is       specified, the length of peptide is 15       amino acids, and the end position for       each peptide is the start position plus fourteen.                         7   WREFSFIQIFCSFAD   22       9   EFSFIQIFCSFADTQ   22       16   FCSFADTQTELELEF   11       4   ALNWREFSFIQIFCS   10       13   IQIFCSFADTQTELE   10                 V6-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       13; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         8   LPSIVILGKIILFLP   21       18   ILFLPCISRKLKRIK   21       25   SRKLKRIKKGWEKSQ   20       43   EGIGGTIPHVSPERV   20       11   IVILGKIILFLPCIS   19       21   LPCISRKLKRIKKGW   16       22   PCISRKLKRIKKGWE   15       5   ALVLPSIVILGKIIL   14       46   GGTIPHVSPERVTVM   14       1   NFVLALVLPSIVILG   13       4   LALVLPSIVILGKII   13       14   LGKIILFLPCISRKL   13       35   WEKSQFLEEGIGGTI   13       39   QFLEEGIGGTIPHVS   13       42   EEGIGGTIPHVSPER   13       15   GKIILFLPCISRKLK   12       17   IILFLPCISRKLKRI   12       32   KKGWEKSQFLEEGIG   10       37   KSQFLEEGIGGTIPH   10                 V7A-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 15; each start position is       specified, the length of peptide is 15       amino acids, and the end position for       each peptide is the start position plus fourteen.                         1   SISMMGSPKSLSETF   21       8   PKSLSETFLPNGING   12       12   SETFLPNGINGIKDA   10                 V7B-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         4   RYLFLNMAYQQSTLG   22       14   QSTLGYVALLISTFH   19       2   SERYLFLNMAYQQST   16       7   FLNMAYQQSTLGYVA   13       9   NMAYQQSTLGYVALL   10                 V7C-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       15; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         137   WEFLLRLLKSQAASG   26       134   GPLWEFLLRLLKSQA   25       44   PIEWQQDRKIPPLST   24       121   SWRNPVLPHTNGVGP   21       13   DLSVEVLASPAAAWK   19       50   DRKIPPLSTPPPPAM   18       62   PAMWTEEAGATAEAQ   18       138   EFLLRLLKSQAASGT   18       23   AAAWKCLGANILRGG   17       168   SGTWMKLETIILSKL   17       179   LSKLTQEQKSKHCMF   17       157   FTSWSLGEFLGSGTW   16       9   IVILDLSVEVLASPA   15       11   ILDLSVEVLASPAAA   15       19   LASPAAAWKCLGANI   15       35   RGGLSEIVLPIEWQQ   15       43   LPIEWQQDRKIPPLS   15       73   AEAQESGIRNKSSSS   15       3   ALVLPSIVILDLSVE   14       27   KCLGANILRGGLSEI   14       75   AQESGIRNKSSSSSQ   14       89   QIPVVGVVTEDDEAQ   14       135   PLWEFLLRLLKSQAA   14       173   KLETIILSKLTQEQK   14       4   LVLPSIVILDLSVEV   13       6   LPSIVILDLSVEVLA   13       8   SIVILDLSVEVLASP   13       26   WKCLGANILRGGLSE   13       28   CLGANILRGGLSEIV   13       87   SSQIPVVGVVTEDDE   13       90   IPVVGVVTEDDEAQD   13       123   RNPVLPHTNGVGPLW   13       130   TNGVGPLWEFLLRLL   13       152   TLSLAFTSWSLGEFL   13       156   AFTSWSLGEFLGSGT   13       169   GTWMKLETIILSKLT   13       171   WMKLETIILSKLTQE   13       10   VILDLSVEVLASPAA   12       12   LDLSVEVLASPAAAW   12       39   SEIVLPIEWQQDRKI   12       58   TPPPPAMWTEEAGAT   12       74   EAQESGIRNKSSSSS   12       77   ESGIRNKSSSSSQIP   12       100   DEAQDSIDPPESPDR   12       110   ESPDRALKAANSWRN   12       119   ANSWRNPVLPHTNGV   12       124   NPVLPHTNGVGPLWE   12       140   LLRLLKSQAASGTLS   12       150   SGTLSLAFTSWSLGE   12       154   SLAFTSWSLGEFLGS   12       176   TIILSKLTQEQKSKH   12                 V8-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       17; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         13   EGMGGTIPHVSPERV   20       9   QFLEEGMGGTIPHVS   13       12   EEGMGGTIPHVSPER   13       5   WEKSQFLEEGMGGTI   12       2   KKGWEKSQFLEEGMG   10       7   KSQFLEEGMGGTIPH   10                 V13-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID       NO: 27; each start position is       specified, the length of peptide is 15       amino acids, and the end position for       each peptide is the start position plus fourteen.                         1   SISMMGSPKSLSETF   21       8   PKSLSETFLPNGING   12       12   SETFLPNGINGIKDA   10                 V14-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       29; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         12   LFTFWRGPVVVAISL   17       9   PLRLFTFWRGPVVVA   15       14   TFWRGPVVVAISLAT   15       2   AREIENLPLRLFTFW   14       7   NLPLRLFTFWRGPVV   14       10   LRLFTFWRGPVVVAI   13       13   FTFWRGPVVVAISLA   12       15   FWRGPVVVAISLATF   9       3   REIENLPLRLFTFWR   8                 V21-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       43; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         6   LSKLTQEQKTKHCMF   17       3   TIILSKLTQEQKTKH   12       8   KLTQEQKTKHCMFSL   8       9   LTQEQKTKHCMFSLI   8                 V25-HLA-DRB1-1101-15mers-98P4B6       Each peptide is a portion of SEQ ID NO:       51; each start position is specified, the       length of peptide is 15 amino acids, and       the end position for each peptide is the       start position plus fourteen.                         14   SQKLKRIKKGWEKSQ   20       10   LPCISQKLKRIKKGW   16       11   PCISQKLKRIKKGWE   15       3   LGKIILFLPCISQKL   13       7   ILFLPCISQKLKRIK   13       4   GKIILFLPCISQKLK   12       6   IILFLPCISQKLKRI   11       8   LFLPCISQKLKRIKK   9                    
     [1229]               TABLE L                          Properties of 98P4B6                                 Bioinformatic                   Program   URL   Outcome               V.1                   ORF   ORF finder               Protein length           454 aa       Transmembrane region   TM Pred   http://www.ch.embnet.org/   6TM, aa 214-232, 261-286,                   304-325, 359-379,                   393-415, 426-447, N-                   term inside           HMMTop   http://www.enzim.hu/hmmtop/   6TM, aa 215-232 261-279                   306-325 360-379                   396-415 428-447 N-                   term out           Sosui   http://www.genome.ad.jp/SOSui/   6TM, aa 206-228, 255-277,                   304-325, 359-381,                   393-415, 428-450           TMHMM   http://www.cbs.dtu.dk/services/TMHMM   6TM, aa 210-232, 262-284,                   304-323, 360-382,                   392-414, 427-449       Signal Peptide   Signal P   http://www.cbs.dtu.dk/services/SignalP/   none       pI   pI/MW tool   http://www.expasy.ch/tools/   pI 8.74       Molecular weight   pI/MW tool   http://www.expasy.ch/tools/   52.0 kD       Localization   PSORT   http://psort.nibb.ac.jp/   Plasma membrane                   60%, golgi 40%           PSORT II   http://psort.nibb.ac.jp/   Endoplasmic reticulum                   39%, plasma membrane                   34%       Motifs   Pfam   http://www.sanger.ac.uk/Pfam/   no known motifs           Prints   http://www.biochem.ucl.ac.uk/   pyridine nucleotide                   reductase           ProDom   http://prodes.toulouse.inra.f   Dudulin,                   oxidoreductase           Blocks   http://www.blocks.fhcrc.org/   adenosyl-L-                   homocysteine                   hydrolase       V.2       ORF   ORF finder       Protein length            45 aa       Transmembrane region   TM Pred   http://www.ch.embnet.org/   1 TM, aa 5-23, N-term                   inside           HMMTop   http://www.enzim.hu/hmmtop/   no TM           Sosui   http://www.genome.ad.jp/SOSui   souble protein           TMHMM   http://www.cbs.dtu.dk/services/TMHMM   no TM       Signal Peptide   Signal P   http://www.cbs.dtu.dk/services/SignalP/   none       pI   pI/MW tool   http://www.expasy.ch/tools/   pI 4.2       Molecular weight   pI/MW tool   http://www.expasy.ch/tools/   4.84 kD       Localization   PSORT   http://psort.nibb.ac.jp/   Ouside 37%,                   microbody 32%           PSORT II   http://psort.nibb.ac.jp/   Extracellular 33%,                   nuclear 33%       Motifs   Pfam   http://www.sanger.ac.uk/Pfam/   no known motifs           Prints   http://www.biochem.ucl.ac.uk/   no known motifs           Blocks   http://www.blocks.fhcrc.org/   no known motifs       V.5       ORF   ORF finder       Protein length           419 aa       Transmembrane region   TM Pred   http://www.ch.embnet.org/   4TM, aa 214-232, 261-286,                   304-325, 359-379                   N-term inside           HMMTop   http://www.enzim.hu/hmmtop/   4TM, aa 215-232, 259-278,                   305-324, 360-379                   N-term outside           Sosui   http://www.genome.ad.jp/SOSui/   4TM, aa 209-231, 255-277,                   304-325, 356-379           TMHMM   http://www.cbs.dtu.dk/services/TMHMM   4TM, aa 210-232, 262-284,                   304-323, 360-382       Signal Peptide   Signal P   http://www.cbs.dtu.dk/services/SignalP/   none       pI   pI/MW tool   http://www.expasy.ch/tools/   pI 8.1       Molecular weight   pI/MW tool   http://www.expasy.ch/tools/   47.9 kD       Localization   PSORT   http://psort.nibb.ac.jp/   Plasma membrane                   60%, golgi 40%           PSORT II   http://psort.nibb.ac.jp/   Endoplasmic reticulum                   44%, plasma membrane                   22%       Motifs   Pfam   http://www.sanger.ac.uk/Pfam/   no known motifs           Prints   http://www.biochem.ucl.ac.uk/   no known motifs           ProDom   http://prodes.toulouse.inra.f   Dudulin,                   oxidoreductase           Blocks   http://www.blocks.fhcrc.org/   no known motifs       V.6       ORF   ORF finder       Protein length           490 aa       Transmembrane region   TM Pred   http://www.ch.embnet.org/   6TM, aa 214-232, 261-286,                   304-325, 359-379,                   393-415, 432-455           HMMTop   http://www.enzim.hu/hmmtop/   7TM, aa 140-158, 214-232,                   259-280, 305-323,                   361-383, 396-413, 432-455,                   N -term out           Sosui   http://www.genome.ad.jp/SOSui/   6TM, aa 206-228, 255-277,                   304-325, 359-381,                   393-415, 428-450           TMHMM   http://www.cbs.dtu.dk/services/TMHMM   6TM, aa 210-232, 262-284,                   304-323, 360-382,                   392-414, 427-449       Signal Peptide   Signal P   http://www.cbs.dtu.dk/services/SignalP/   none       pI   pI/MW tool   http://www.expasy.ch/tools/   pI 9.2       Molecular weight   pI/MW tool   http://www.expasy.ch/tools/   55.9 kD       Localization   PSORT   http://psort.nibb.ac.jp/   Plasma membrane                   60%, golgi 40%           PSORT II   http://psort.nibb.ac.jp/   Endoplasmic reticulum                   39%, plasma membrane                   34%       Motifs   Pfam   http://www.sanger.ac.uk/Pfam/   no known motifs           Prints   http://www.biochem.ucl.ac.uk/   pyridine nucleotide                   reductase           ProDom   http://prodes.toulouse.inra.f   Dudulin,                   oxidoreductase           Blocks   http://www.blocks.fhcrc.org/   adenosyl-L-                   homocysteine                   hydrolase       V.7       ORF   ORF finder       Protein length           576 aa       Transmembrane region   TM Pred   http://www.ch.embnet.org/   6TM, aa 214-232, 262-280,                   306-322, 331-360,                   371-393, 525-544. N-                   term out           HMMTop   http://www.enzim.hu/hmmtop/   5TM, aa 215-232, 261-279,                   306-325, 342-359,                   378-397 N -term out           Sosui   http://www.genome.ad.jp/SOSui/   5TM, aa 206-228, 255-277,                   304-325, 339-360,                   380-402           TMHMM   http://www.cbs.dtu.dk/services/TMHMM   4TM, aa 210-232,                   262-284, 304-323,                   343-360       Signal Peptide   Signal P   http://www.cbs.dtu.dk/services/SignalP/   none       pI   pI/MW tool   http://www.expasy.ch/tools/   pI 8.5       Molecular weight   pI/MW tool   http://www.expasy.ch/tools/   64.5 kD       Localization   PSORT   http://psort.nibb.ac.jp/   Plasma membrane                   60%, golgi 40%           PSORT II   http://psort.nibb.ac.jp/   Endoplasmic reticulum                   44%, plasma membrane                   22%       Motifs   Pfam   http://www.sanger.ac.uk/Pfam/   no known motifs           Prints   http://www.biochem.ucl.ac.uk/   pyridine nucleotide                   reductase           ProDom   http://prodes.toulouse.inra.f   Dudulin,                   oxidoreductase           Blocks   http://www.blocks.fhbcrc.org/   Ets domain, adenosyl-                   L-homocysteine                   hydrolase                    
     [1230]               TABLE LI                          Exon boundaries of transcript 98P4B6 v.1                                     Exon Number   Start   End   Length                                                 1   23   321   299           2   322   846   525           3   847   1374   528           4   1375   1539   165           5   1540   1687   148           6   1688   2453   766                        
     [1231]               TABLE LII(a)                       Nucleotide sequence (partial, 5′ open) of transcript variant 98P4B6 v.2                                    (SEQ ID NO: 153)                     agtggatccc ccgggctgca ggctctctct ctctctctct cttccgggtt cacgccattc   60               tcctgcctca gcctcccgag tagctgggac tacaggtgcc cgccaccatg cccggctgat   120               ttctttttgt atttttagta cagacggagt ttcaccgtgt tagecaggat ggtctcgatc   180               tcctgacctc gtgatccgcc cgccttggcc tccaaagtgc tgggattaca ggtgtgagct   240               accgcgcccg gcctattatc ttgtactttc taactgagcc ctctattttc tttattttaa   300               taatatttct ccccacttga gaatcacttg ttagttcttg gtaggaattc agttgggcaa   360               tgataacttt tatgggcaaa aacattctat tatagtgaac aaatgaaaat aacagcgtat   420               tttcaatatt ttcttattcc ttaaattcca ctcttttaac actatgctta accacttaat   480               gtgatgaaat attcctaaaa gttaaatgac tattaaagca tatattgttg catgtatata   540               ttaagtagcc gatactctaa ataaaaatac cactgttaca gataaatggg gcctttaaaa   600               atatgaaaaa caaacttgtg aaaatgtata aaagatgcat ctgttgtttc aaatggcact   660               atcttctttt cagtactaca aaaacagaat aattttgaag ttttagaata aatgtaatat   720               atttactata attctaaatg tttaaatgct tttctaaaaa tgcaaaacta tgatgtttag   780               ttgctttatt ttacctctat gtgattattt ttcttaattg ttatttttta taatcattat   840               ttttctgaac cattcttctg gcctcagaag taggactgaa ttctactatt gctaggtgtg   900               agaaagtggt ggtgagaacc ttagagcagt ggagatttgc tacctggtct gtgttttgag   960               aagtgcccct tagaaagtta aaagaatgta gaaaagatac tcagtcttaa tcctatgcaa   1020               aaaaaaaatc aagtaattgt tttcctatga ggaaaataac catgagctgt atcatgctac   1080               ttagctttta tgtaaatatt tcttatgtct cctctattaa gagtatttaa aatcatattt   1140               aaatatgaat ctattcatgc taacattatt tttcaaaaca tacatggaaa tttagcccag   1200               attgtctaca tataaggttt ttatttgaat tgtaaaatat ttaaaagtat gaataaaata   1260               tatttatagg tatttatcag agatgattat tttgtgctac atacaggttg gctaatgagc   1320               tctagtgtta aactacctga ttaatttctt ataaagcagc ataaccttgg cttgattaag   1380               gaattctact ttcaaaaatt aatctgataa tagtaacaag gtatattata ctttcattac   1440               aatcaaatta tagaaattac ttgtgtaaaa gggcttcaag aatatatcca atttttaaat   1500               attttaatat atctcctatc tgataactta attcttctaa attaccactt gccattaagc   1560               tatttcataa taaattctgt acagtttccc ccaaaaaaag agatttattt atgaaatatt   1620               taaagtttct aatgtggtat tttaaataaa gtatcataaa tgtaataagt aaatatttat   1680               ttaggaatac tgtgaacact gaactaatta ttcctgtgtc agtctatgaa atccctgttt   1740               tgaaataagt aaacagccta aaatgtgttg aaattatttt gtaaatccat gacttaaaac   1800               aagatacata catagtataa cacacctcac agtgttaaga tttatattgt gaaatgagac   1860               accctacctt caattgttca tcagtgggta aaacaaattc tgatgtacat tcaggacaaa   1920               tgattagccc taaatgaaac tgtaataatt tcagtggaaa ctcaatctgt ttttaccttt   1980               aaacagtgaa ttttacatga atgaatgggt tcttcacttt ttttttagta tgagaaaatt   2040               atacagtgct taattttcag agattctttc catatgttac taaaaaatgt tttgttcagc   2100               ctaacatact gagttttttt taactttcta aattattgaa tttccatcat gcattcatcc   2160               aaaattaagg cagactgttt ggattcttcc agtggccaga tgagctaaat taaatcacaa   2220               aagcagatgc ttttgtatga tctccaaatt gccaacttta aggaaatatt ctcttgaaat   2280               tgtctttaaa gatcttttgc agctttgcag atacccagac tgagctggaa ctggaatttg   2340               tcttcctatt gactctactt ctttaaaagc ggctgcccat tacattecte agctgtcctt   2400               gcagttaggt gtacatgtga ctgagtgttg gccaqtgaga tgaagtctcc tcaaaggaag   2460               gcagcatgtg tcctttttca tcccttcatc ttgctgctgg gattgtggat ataacaggag   2520               ccctggcagc tgtctccaga ggatcaaagc cacacccaaa gagtaaggca gattagaqac   2580               cagaaagacc ttgactactt ccctacttcc actgcttttt cctgcattta agccattgta   2640               aatctgggtg tgttacatga agtgaaaatt aattctttct gcccttcagt tctttatcct   2700               gataccattt aacactgtct gaattaacta gactgcaata attctttctt ttgaaagctt   2760               ttaaaggata atgtgcaatt cacattaaaa ttgattttcc attgtcaatt agttatactc   2820               attttcctgc cttgatcttt cattagatat tttgtatctg cttggaatat attatcttct   2880               ttttaactgt gtaattggta attactaaaa ctctgtaatc tccaaaatat tgctatcaaa   2940               ttacacacca tgttttctat cattctcata gatctgcctt ataaacattt aaataaaaag   3000               tactatttaa tgatttaaaa aaaaaaaaaa aaaaaaaaaa a  3041                    
     [1232]               TABLE LIII(a)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.2                                    Score = 1429 bits (743), Expect = 0.0 Identities = 750/751 (99%), Gaps = 1/751 (0%)       Strand = Plus/Plus                                         V.1:   1687   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   1746   (SEQ ID NO: 154)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2291   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   2350   (SEQ ID NO: 155)               V.1:   1747   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   1806               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2351   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   2410               V.1:   1807   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   1866               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2411   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   2470               V.1:   1867   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   1926               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2471   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   2530               V.1:   1927   tgtctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   1986               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2531   tgtctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   2590               V.1:   1987   ttgactacttccctacttccactgctttt-cctgcatttaagccattgtaaatctgggtg   2045               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2591   ttgactacttccctacttccactgctttttcctgcatttaagccattgtaaatctgggtg   2650               V.1:   2046   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   2105               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2651   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   2710               V.1:   2106   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   2165               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2711   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   2770               V.1:   2166   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   2225               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2771   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   2830               V.1:   2226   cttgatctttcattagatattttgtatctgcttggaatatattatcttctttttaactgt   2285               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2831   cttgatctttcattagatattttgtatctgcttggaatatattatcttctttttaactgt   2890               V.1:   2286   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   2345               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2891   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   2950               V.1:   2346   tgttttctatcattctcatagatctgccttataaacatttaaataaaaagtactatttaa   2405               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.2:   2951   tgttttctattattctcatagatctgccttataaacatttaaataaaaagtactatttaa   3010               V.1:   2406   tgatttaaaaaaaaaaaaaaaaaaaaaaaaa  2436               |||||||||||||||||||||||||||||||       V.2:   3011   tgatttaaaaaaaaaaaaaaaaaaaaaaaaa  3041                                    
     [1233]               TABLE LIV(a)                       Peptide sequences (partial) of protein coded by 98P4B6 v.2                                        SGSPGLQALS LSLSSGFTPF SCLSLPSSWD YRCPPPCPAD FFLYF 45   (SEQ ID NO: 156)                    
     [1234]               TABLE LV(a)                       Amino acid seguence alignment       of 98P4B6 v.1 and 98P4B6 v.2                  - - - NO SIGNIFICANT HOMOLOGY - - -                    
     [1235]               TABLE LII(b)                       Nucleotide sequence of transcript variant 98P4B6 v.3                                        (SEQ ID NO: 157)                             ttctgctata gagatggaac agtatatgga aagctcccaa gaaagtgaag agaggaaatt   60                   ggaaaattgt gagtggacct tctgatactg ctcctccttg cgtggaaaag gggaaagaac   120               tgcatgcata ttattcagcg tactatatte aaaggatatt cttggtgatc ttggaagtgt   180               ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg aaacttgttt   240               acctaatggc ataaatggta tcaaagatgc aaggaaggtc actgtaggtg tgattggaag   300               tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc atgtggtcat   360               aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag atgtcactca   420               tcatgaagat gctctcacaa aaacaaatat aatatttgtt gctatacaca gagaacatta   480               tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg atgtgagcaa   540               taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggctt cattattccc   600               agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc agttaggacc   660               taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc gacaacaggt   720               tattgaactt gcccgccagt tgaatttcat tcccattgac ttgggatcct tatcatcagc   780               cagagagatt gaaaatttac cectacgact ctttactctc tggagagggc cagtggtggt   840               agctataagc ttggccacat tttttttcct ttattccttt gtcagagatg tgattcatcc   900               atatgctaga aaccaacaga gtgactttta caaaattcct atagagattg tgaataaaac   960               cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc ttctggcagc   1020               tgcttatcaa ctttattacg gcaccaagta taggagattt ccaccttggt tggaaacctg   1080               gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg tccatgttgc   1140               ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca acatggctta   1200               tcagcaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt ggagaattga   1260               aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg cagtcacttc   1320               tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc agtctacact   1380               tggatatgtc gctctgctca taagtacttt ccatgtttta atttatggat ggaaacgagc   1440               ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg ctcttgtttt   1500               gccctcaatt gtaattctgg atcttttgca gctttgcaga tacccagact gagctggaac   1560               tggaatttgt cttcctattg actctacttc tttaaaagcg gctgcccatt acattcctca   1620               gctgtccttg cagttaggtg tacatgtgac tgagtgttgg ccagtgagat gaagtctcct   1680               caaaggaagg cagcatgtgt cctttttcat cccttcatct tgctgctggg attgtggata   1740               taacaggagc cctggcagct gtctccagag gatcaaagcc acacccaaag agtaaggcag   1800               attagagacc agaaagacct tgactacttc cctacttcca ctgctttttc ctgcatttaa   1860               gccattgtaa atctgggtgt gttacatgaa gtgaaaatta attctttctg cccttcagtt   1920               ctttatcctg ataccattta acactgtctg aattaactag actgcaataa ttctttcttt   1980               tgaaagcttt taaaggataa tgtgcaattc acattaaaat tgattttcca ttgtcaatta   2040               gttatactca ttttcctgcc ttgatctttc attagatatt ttgtatctgc ttggaatata   2100               ttatcttctt tttaactgtg taattggtaa ttactaaaac tctgtaatct ccaaaatatt   2160               gctatcaaat tacacaccat gttttctatc attctcatag atctgcctta taaacattta   2220               aataaaaagt actatttaat gatttaactt ctgttttgaa aaaaaaaaaa aaaaaaaaaa   2280                    
     [1236]               Table LIII(b)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.3                                    Score = 4013 bits (2087), Expect = 0.0 Identities = 2116/2128 (99%), Gaps 1/2128 (0%)       Strand = Plus/Plus                                         V.1:   320   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   379   (SEQ ID NO: 158)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   153   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   212   (SEQ ID NO: 159)               V.1:   380   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   439               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   213   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   272               V.1:   440   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   499               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   273   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   332               V.1:   500   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   559               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   333   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   392               V.1:   560   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   619               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   393   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   452               V.1:   620   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   679               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   453   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   512               V.1:   680   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   739               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   513   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   572               V.1:   740   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   799               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   573   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   632               V.1:   800   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   859               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   633   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   692               V.1:   860   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   919               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   693   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   752               V.1:   920   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   979               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   753   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   812               V.1:   980   ttadtctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1039               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   813   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   872               V.1:   1040   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1099               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   873   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   932               V.1:   1100   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1159               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   933   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   992               V.1:   1160   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1219               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   993   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1052               V.1:   1220   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1279               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1053   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1112               V.1:   1200   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1339               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1113   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1172               V.1:   1340   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1399               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1173   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1232               V.1:   1400   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1459               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1233   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1292               V.1:   1460   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1519               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1293   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1352               V.1:   1520   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1579               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1353   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1412               V.1:   1580   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1639               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1413   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1472               V.1:   1640   caccaaactttgttcttgctcttgttttgccctcaattgtaattctggatcttttgcagc   1699               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1473   caccaaactttgttcttgctcttgttttgccctcaattgtaattctggatcttttgcagc   1532               V.1:   1700   tttgcagatacccagactgagctggaactggaatttgtcttcctattgactctacttctt   1759               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1533   tttgcagatacccagactgagctggaactggaatttgtcttcctattgactctacttctt   1592               V.1:   1760   taaaagcggctgcccattacattcctcagctgtccttgcagttaggtgtacatgtgactg   1819               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1593   taaaagcggctgcccattacattcctcagctgtccttgcagttaggtgtacatgtgactg   1652               V.1:   1820   agtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtgtcctttttcatcc   1879               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1653   agtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtgtcctttttcatcc   1712               V.1:   1880   cttcatcttgctgctgggattgtggatataacaggagccctggcagctgtctccagagga   1939               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1713   cttcatcttgctgctgggattgtggatataacaggagccctggcagctgtctccagagga   1772               V.1:   1940   tcaaagccacacccaaagagtaaggcagattagagaccagaaagaccttgactacttccc   1999               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1773   tcaaagccacacccaaagagtaaggcagattagagaccagaaagaccttgactacttccc   1832               V.1:   2000   tacttccactgctttt-cctgcatttaagccattgtaaatctgggtgtgttacatgaagt   2058               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1833   tacttccactgctttttcctgcatttaagccattgtaaatctgggtgtgttacatgaagt   1892               V.1:   2059   gaaaattaattctttctgcccttcagttctttatcctgataccatttaacactgtctgaa   2118               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1893   gaaaattaattctttctgcccttcagttctttatcctgataccatttaacactgtctgaa   1952               V.1:   2119   ttaactagactgcaataattctttcttttgaaagcttttaaaggataatgtgcaattcac   2178               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   1953   ttaactagactgcaataattctttcttttgaaagcttttaaaggataatgtgcaattcac   2012               V.1:   2179   attaaaattgattttccattgtcaattagttatactcattttcctgccttgatctttcat   2238               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   2013   attaaaattgattttccattgtcaattagttatactcattttcctgccttgatctttcat   2072               V.1:   2239   tagatattttgtatctgcttggaatatattatcttctttttaactgtgtaattggtaatt   2298               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   2073   tagatattttgtatctgcttggaatatattatcttctttttaactgtgtaattggtaatt   2132               V.1:   2299   actaaaactctgtaatctccaaaatattgctatcaaattacacaccatgttttctatcat   2358               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   2133   actaaaactctgtaatctccaaaatattgctatcaaattacacaccatgttttctatcat   2192               V.1:   2359   tctcatagatctgccttataaacatttaaataaaaagtactatttaatgatttaaaaaaa   2418               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.3:   2193   tctcatagatctgccttataaacatttaaataaaaagtactatttaatgatttaacttct   2252               V.1:   2419   aaaaaaaaaaaaaaaaaaaaaaaaaaaa  2446               ||||||||||||||||||||||||||||       V.3:   2253   gttttgaaaaaaaaaaaaaaaaaaaaaa  2280                                    
     [1237]               TABLE LV(b)                       Peptide sequences of protein coded 98P4B6 v.3                                    (SEQ ID NO: 160)                     MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKFASEFF PHVVDVTHHE DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFEPLYS FVRDVIHPYA   240               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLFTWLQ   300               CRKQLGLLSF FFANVHVAYS LCLPPRRSFR YLFLNMAYQQ VHANIENSWN EEEVWRIEMY   360               ISFGIMSLGL LSLLAVTSIP SVSNALNWRE FSFIQSTLGY VALLISTFHV LIYGWKRAFE   420               FEYYRFYTPP NFVLALVLPS IVILDLLQLC RYPD  454                    
     [1238]               TABLE LV(b)                       Amino acid sequence alignment of 98P4B6 v.1 and 98P486 v.3                                    Score = 910 bits (2351), Expect = 0.0 Identities 454/454 (100%), Positives = 454/454 (100%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 161)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.3:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 162)               V.1:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIEVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.3:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.3:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFELYSFVRDVIHPYA       V.3:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFPLYSFVRDVIHPYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ       V.3:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY       V.3:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               V.1:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSPIQSTLGYVALLISTFHVLIYGWKRAFE       V.3:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTPHVLIYGWKRAFE   420               V.1:   421   EEYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD  454               EEYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD       V.3:   421   EEYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD  454                    
     [1239]               TABLE LII(c)                       Nucleotide sequence of transcript variant 98P4B6 v.4                                    (SEQ ID NO: 163)                     cccacgcgtc cgcggacgcg tgggcggacg cgtgggttcc tcgggccctc ggcgccacaa   60               gctgtccggg cacgcagccc ctagcggcgc gtcgctgcca agccggcctc cgcgcgcctc   120               cctccttcct tctcccctgg ctgttcgcga tccagcttgg gtaggcgggg aagcagctgg   180               agtgcgaccg ccacggcagc caccctgcaa ccgccagtcg gagagctaag ggcaagtcct   240               gaggttgggc ccaggagaaa gaaggcaagg agacattgtc ccaggatatt cttggtgatc   300               ttggaagtgt ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg   360               aaacttgttt acctaatggc ataaatggta tcaaagatgc aaggaaggtc actgtaggtg   420               tgattggaag tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc   480               atgtggtcat aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag   540               atgtcactca tcatgaagat gctctcacaa aaacaaatat aatatttgtt gctatacaca   600               gagaacatta tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg   660               atgtgagcaa taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggctt   720               cattattccc agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc   780               agttaggacc taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc   840               gacaacaggt tattgaactt gcccgccagt tgaatttcat tcccattgac ttgggatcct   900               tatcatcagc cagagagatt gaaaatttac ccctacgact ctttactctc tggagagggc   960               cagtggtggt agctataagc ttggccacat tttttttcct ttattccttt gtcagagatg   1020               tgattcatcc atatgctaga aaccaacaga gtgactttta caaaattcct atagagattg   1080               tgaataaaac cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc   1140               ttctggcagc tgcttatcaa ctttattacg gcaccaagta taggagattt ccaccttggt   1200               tggaaacctg gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg   1260               tccatgttgc ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca   1320               acatggctta tcagcaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt   1380               ggagaattga aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg   1440               cagtcacttc tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc   1500               agtctacact tggatatgtc gctctgctca taagtacttt ccatgtttta atttatggat   1560               ggaaacgagc ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg   1620               ctcttgtttt gccctcaatt gtaattctgg atcttttgca gctttgcaga tacccagact   1680               gagctggaac tggaatttgt cttcctattg actctacttc tttaaaagcg gctgcccatt   1740               acattcctca gctgtccttg cagttaggtg tacatgtgac tgagtgttgg ccagtgagat   1800               gaagtctcct caaaggaagg cagcatgtgt cctttttcat cccttcatat tgctgctggg   1860               attgtggata taacaggagc cctggcagct gtctccagag gatcaaagcc acacccaaag   1920               agtaaggcag attagagaca agaaagacct tgactacttc cctacttcca ctgcttttcc   1980               tgcatttaag ccattgtaaa tctgggtgtg ttacatgaag tgaaaattaa ttctttctgc   2040               ccttcagttc tttatcctga taccatttaa cactgtctga attaactaga ctgcaataat   2100               tctttctttt gaaagctttt aaaggataat gtgcaattca cattaaaatt gattttccat   2160               tgtcaattag ttatactcat tttcctgcct tgatctttca ttagatattt tgtatctgct   2220               tggaatatat tatcttcttt ttaactgtgt aattggtaat tactaaaact ctgtaatctc   2280               caaaatattg ctatcaaatt acacaccatg ttttctatca ttctcataga tctgccttat   2340               aacatttaa ataaaaagta ctatttaatg attt  2374                    
     [1240]               TABLE LIII(c)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.4                  Score = 404 bits (210),   Expect = e−109 Identities = 210/210 (100%)   Strand = Plus/Plus                                         V.1:   1   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   60   (SEQ ID NO: 164)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   14   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   73   (SEQ ID NO: 165)               V.1:   61   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   120               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   74   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   133               V.1:   121   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcca   180               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   134   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcca   193               V.1:   181   cggcagccaccctgcaaccgccagtcggag  210               ||||||||||||||||||||||||||||||       V.4:   194   cggcagccaccctgcaaccgccagtcggag  223                         Score = 4022 bits (2092), Expect = 0.0   Identities = 2092/2092 (100%) Strand = Plus/Plus                                         V.1:   320   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   379                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   283   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   342               V.1:   380   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   439               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   343   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   402               V.1:   440   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   499               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   403   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   462               V.1:   500   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   559               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   463   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   522               V.1:   560   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   619               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   523   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   582               V.1:   620   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   679               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   583   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   642               V.1:   680   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   739               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   643   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   702               V.1:   740   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   799               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   703   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   762               V.1:   800   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   859               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   763   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   822               V.1:   860   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   919               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   823   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   882               V.1:   920   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   979               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   883   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   942               V.1:   980   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1039               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   943   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1002               V.1:   1040   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1099               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1003   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1062               V.1:   1100   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1159               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1063   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1122               V.1:   1160   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1219               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1123   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1182               V.1:   1220   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1279               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1183   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1242               V.1:   1280   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1339               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1243   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1302               V.1:   1340   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1399               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1303   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1362               V.1:   1400   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1459               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1363   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1422               V.1:   1460   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1519               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1423   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1482               V.1:   1520   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1579               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1483   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1542               V.1:   1580   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1639               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1543   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1602               V.1:   1640   caccaaactttgttcttgctcttgttttgccctcaattgtaattctggatcttttgcagc   1699               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1603   caccaaactttgttcttgctcttgttttgccctcaattgtaattctggatcttttgcagc   1662               V.1:   1700   tttgcagatacccagactgagctggaactggaatttgtcttcctattgactctacttctt   1759               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1663   tttgcagatacccagactgagctggaactggaatttgtcttcctattgactctacttctt   1722               V.1:   1760   taaaagcggctgcccattacattcctcagctgtccttgcagttaggtgtacatgtgactg   1819               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1723   taaaagcggctgcccattacattcctcagctgtccttgcagttaggtgtacatgtgactg   1782               V.1:   1820   agtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtgtcctttttcatcc   1879               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1783   agtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtgtcctttttcatcc   1842               V.1:   1880   cttcatcttgctgctgggattgtggatataacaggagccctggcagctgtctccagagga   1939               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1843   cttcatcttgctgctgggattgtggatataacaggagccctggcagctgtctccagagga   1902               V.1:   1940   tcaaagccacacccaaagagtaaggcagattagagaccagaaagaccttgactacttccc   1999               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1903   tcaaagccacacccaaagagtaaggcagattagagaccagaaagaccttgactacttccc   1962               V.1:   2000   tacttccactgcttttcctgcatttaagccattgtaaatctgggtgtgttacatgaagtg   2059               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   1963   tacttccactgcttttcctgcatttaagccattgtaaatctgggtgtgttacatgaagtg   2022               V.1:   2060   aaaattaattctttctgcccttcagttctttatcctgataccatttaacactgtctgaat   2119               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2023   aaaattaattctttctgcccttcagttctttatcctgataccatttaacactgtctgaat   2082               V.1:   2120   taactagactgcaataattctttcttttgaaagcttttaaaggataatgtgcaattcaca   2179               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2083   taactagactgcaataattctttcttttgaaagcttttaaaggataatgtgcaattcaca   2142               V.1:   2180   ttaaaattgattttccattgtcaattagttatactcattttcctgccttgatctttcatt   2239               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2143   ttaaaattgattttccattgtcaattagttatactcattttcctgccttgatctttcatt   2202               V.1:   2240   agatattttgtatctgcttggaatatattatcttctttttaactgtgtaattggtaatta   2299               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2203   agatattttgtatctgcttggaatatattatcttctttttaactgtgtaattggtaatta   2262               V.1:   2300   ctaaaactctgtaatctccaaaatattgctatcaaattacacaccatgttttctatcatt   2359               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2263   ctaaaactctgtaatctccaaaatattgctatcaaattacacaccatgttttctatcatt   2322               V.1:   2360   ctcatagatctgccttataaacatttaaataaaaagtactatttaatgattt  2411               ||||||||||||||||||||||||||||||||||||||||||||||||||||       V.4:   2323   ctcatagatctgccttataaacatttaaataaaaagtactatttaatgattt  2374                    
     [1241]               TABLE LIV(c)                       Peptide sequences of protein coded by 98P4B6 v.4                                    (SEQ ID NO: 156)                     MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKFASEFF PHVVDVTHHE DALTKTNIIF VAIRREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFFFLYS FVRDVIHPYA   240               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ   300               CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEEVWRTEMY   360               ISEGIMSLGL LSLLAVTSIP SVSNALNWRE FSFIQSTLGY VALLISTFHV LIYGWKRAFE   420               EEYYRFYTPP NFVLALVLPS IVILDLLQLC RYPD  454                    
     [1242]               TABLE LV(c)                       Amino acid sequence alignment of 98P4B6 v.1 and 98P4B6 v.4                  Score = 910 bits (2351), Expect = 0.0 Identities = 454/454 (100%), Positives = 454/454 (100%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 167)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.4:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 168)               V.1:   61   RNPKPASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.4:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.4:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA       V.4:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRPPPWLETWLQ   300               RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ       V.4:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSPFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY       V.4:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               V.1:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE       V.4:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               V.1:   421   EEYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD  454               EEYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD       V.4:   421   EFYYRFYTPPNFVLALVLPSIVILDLLQLCRYPD  454                    
     [1243]               TABLE LII(d)                       Nucleotide sequence of transcript variant 98P4B6 v.5                                    (SEQ ID NO: 169)                     cccacgcgtc cgcggacgcg tgggcggacg cgtgggttcc tcgggccctc ggcgccacaa   60               gctgtccggg cacgcagccc ctagcggcgc gtcgctgcca agccggcctc cgcgcgcctc   120               cctccttcct tctcccctgg ctgttcgcga tccagcttgg gtaggcgggg aagcagctgg   180               agtgcgaccg ctacggcagc caccctgcaa ccgccagtcg gagagctaag ggcaagtcct   240               gaggttgggc ccaggagaaa gaaggcaagg agacattgtc ccaggatatt cttggtgatc   300               ttggaagtgt ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg   360               aaacttgttt acctaatggc ataaatggta tcaaagatgc aaggaaggtc actgtaggtg   420               tgattggaag tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc   480               atgtggtcat aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag   540               atgtcactca tcatgaagat gctctcacaa aaacaaatat aatatttgtt gctatacaca   600               gagaacatta tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg   660               atgtgagcaa taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggctt   720               cattattccc agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc   780               agttaggacc taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc   840               gacaacaggt tattgaactt gcccgccagt tgaatttcat tcccattgac ttgggatcct   900               tatcatcagc cagagagatt gaaaatttac ccctacgact ctttactttc tggagagggc   960               cagtggtggt agctataagc ttggccacat tttttttcct ttattccttt gtcagagatg   1020               tgattcatcc atatgctaga aaccaacaga gtgactttta caaaattcct atagagattg   1080               tgaataaaac cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc   1140               ttctggcagc tgcttatcaa ctttattacg gcaccaagta taggagattt ccaccttggt   1200               tggaaacctg gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg   1260               tccatgttgc ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca   1320               acatggctta tcagcaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt   1380               ggagaattga aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg   1440               cagtcacttc tatcccttcg gtgagcaatg ctttaaactg gagagaattc agttttattc   1500               agatcttttg cagctttgca gatacccaga ctgagctgga actggaattt gtcttcctat   1560               tgactctact tctttaaaag cggctgccca ttacattcct cagctgtcct tgcagttagg   1620               tgtacatgtg actgagtgtt ggccagtgag atgaagtctc ctcaaaggaa ggcagcatgt   1680               gtcctttttc atcccttcat cttgctgctg ggattgtgga tataacagga gccctggcag   1740               ctgctccaga ggatcaaagc cacacccaaa gagtaaggca gattagagac cagaaagacc   1800               ttgactactt ccctacttcc actgcttttt cctgcattta agccattgta aatctgggtg   1860               tgttacatga agtgaaaatt aattctttct gcccttcagt tctttatcct gataccattt   1920               aacactgtct gaattaacta gactgcaata attctttctt ttgaaagctt ttaaaggata   1980               atgtgcaatt cacattaaaa ttgattttcc attgtcaatt agttatactc attttcctgc   2040               cttgatcttt cattagatat tttgtatctg cttggaatat attatcttct ttttaactgt   2100               gtaattggta attactaaaa ctctgtaatc tccaaaatat tgctatcaaa ttacacacca   2160               tgttttctat cattctcata gatctgcctt ataaacattt aaataaaaag tactatttac   2220               caaaaaaaaa aaaaaaaaaa aaaaaaaaa  2249                    
     [1244]               TABLE LIII(d)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.5                  Score = 398 bits (207),   Expect = e−107 Identities = 209/210 (99%)   Strand = Plus/Plus                                         V.1:   1   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   60   (SEQ ID NO: 170)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   14   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   73   (SEQ ID NO: 171)               V.1:   61   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   120               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   74   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   133               V.1:   121   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcca   180               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   134   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcta   193               V.1:   181   cggcagccaccctgcaaccgccagtcggag  210               ||||||||||||||||||||||||||||||       V.5:   194   cggcagccaccctgcaaccgccagtcggag  223                         Score = 2334 bits (1214), Expect = 0.0   Identities = 1218/1220 (99%) Strand = Plus/Plus                                         V.1:   320   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   379                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   283   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   342               V.1:   380   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   439               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   343   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   402               V.1:   440   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   499               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   403   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   462               V.1:   500   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   559               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   463   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   522               V.1:   560   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   619               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   523   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   582               V.1:   620   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   679               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   583   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   642               V.1:   680   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   739               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   643   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   702               V.1:   740   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   799               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   703   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   762               V.1:   800   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   859               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   763   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   822               V.1:   860   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   919               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   823   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   882               V.1:   920   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   979               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   883   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   942               V.1:   980   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1039               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   943   ttactttctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1002               V.1:   1040   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1099               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1003   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1062               V.1:   1100   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1159               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1063   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1122               V.1:   1160   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1219               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1123   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1182               V.1:   1220   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1279               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1183   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1242               V.1:   1280   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1339               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1243   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1302               V.1:   1340   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1399               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1303   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1362               V.1:   1400   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1459               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1363   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1422               V.1:   1460   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1519               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1423   gcttactttccctcctggcagtcacttctatcccttcggtgagcaatgctttaaactgga   1482               V.1:   1520   gagaattcagttttattcag  1539               ||||||||||||||||||||       V.5:   1483   gagaattcagttttattcag  1502                         Score = 1375 bits (715),  Expect = 0.0   Identities = 741/749 (98%),  Gaps = 2/749 (0%)       Strand = Plus/Plus                                         V.1:   1687   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   1746                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1502   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   1561               V.1:   1747   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   1806               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1562   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   1621               V.1:   1807   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   1866               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1622   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   1681               V.1:   1867   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   1926               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1682   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   1741               V.1:   1927   tgtctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   1986               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1742   tg-ctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   1800               V.1:   1987   ttgactacttccctacttccactgctttt-cctgcatttaagccattgtaaatctgggtg   2045               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1801   ttgactacttccctacttccactgctttttcctgcatttaagccattgtaaatctgggtg   1860               V.1:   2046   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   2105               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1861   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   1920               V.1:   2106   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   2165               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1921   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   1980               V.1:   2166   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   2225               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   1981   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   2040               V.1:   2226   cttgatctttcattagatattttgtatctgcttggaatatattatcttctttttaactgt   2285               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   2041   cttgatctttcattagatattttgtatctgcttggaatatattatcttctttttaactgt   2100               V.1:   2286   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   2345               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   2101   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   2160               V.1:   2346   tgttttctatcattctcatagatctgccttataaacatttaaataaaaagtactatttaa   2405               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.5:   2161   tgttttctatcattctcatagatctgccttataaacatttaaataaaaagtactatttac   2220               V.1:   2406   tgatttaaaaaaaaaaaaaaaaaaaaaaa  2434               |||||||||||||||||||||||||||||       V.5:   2221   caaaaaaaaaaaaaaaaaaaaaaaaaaaa  2249                                    
     [1245]               TABLE LIV(d)                       Peptide sequences of protein coded by 98P4B6 v.5                                        (SEQ ID NO: 172)                         MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKFASEFF PHVVDVTHHF DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT EWRGPVVVAI SLATFFFLYS FVRDVIHPYA   240               RNQQSDFYKT PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ   300               CRKQLGLLSF FEAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEFVWRIEMY   360               ISFGIMSLGL LSLLAVTSIP SVSNALNWRE ESFIQIFCSF ADTQTELELE FVFLLTLLL   419                    
     [1246]               TABLE LV(d)                       Amino acid sequence alignment of 98P4B6 v.1 and 98P4B6 v.5                  Score = 788 bits (2036), Expect = 0.0 Identities = 394/395 (99%), Positives = 394/395 (99%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVTGS   60   (SEQ ID NO: 173)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.5:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 174)               V.1:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.5:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.5:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA       V.5:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTFWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLFTWLQ       V.5:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY       V.5:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               V.1:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQ  395               ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQ       V.5:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQ  395                                    
     [1247]               TABLE LII(e)                       Nucleotide sequence of transcript variant 98P4B6 v.6                                    (SEQ ID NO: 175)                     cccacgcgtc cgcggacgcg tgggcggacg cgtgggttcc tcgggccctc ggcgccacaa   60               gctgtccggg cacgcagccc ctagcggcgc gtcgctgcca agccggcctc cgcgcgcctc   120               cctccttcct tctcccctgg ctgttcgcga tccagcttgg gtaggcgggg aagcagctgg   180               agtgcgaccg ccacggcagc caccctgcaa ccgccagtcg gagagctaag ggcaagtcct   240               gaggttgggc ccaggagaaa gaaggcaagg agacattgtc ccaggatatt cttggtgatc   300               ttggaagtgt ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg   360               aaacttgttt acctaatggc ataaatggta tcaaagatgc aaggaaggtc actgtaggtg   420               tgattggaag tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc   480               atgtggtcat aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag   540               atgtcactca tcatgaagat gctctcacaa aaacaaatat aatatttgtt gctatacaca   600               gagaacatta tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg   660               atgtgagcaa taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggctt   720               cattattccc agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc   780               agttaggacc taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc   840               gacaacaggt tattgaactt gcccgccagt tgaatttcat tcccattgac ttgggatcct   900               tatcatcagc cagagagatt gaaaatttac ccctacgact ctttactctc tggagagggc   960               cagtggtggt agctataagc ttggccacat tttttttcct ttattccttt gtcagagatg   1020               tgattcatcc atatgctaga aaccaacaga gtgactttta caaaattcct atagagattg   1080               tgaataaaac cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc   1140               ttctggcagc tgcttatcaa ctttattacg gcaccaagta taggagattt ccaccttggt   1200               tggaaacctg gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg   1260               tccatgttgc ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca   1320               acatggctta tcagcaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt   1380               ggagaattga aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg   1440               cagtcacttc tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc   1500               agtctacact tggatatgtc gctctgctca taagtacttt ccatgtttta atttatggat   1560               ggaaacgagc ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg   1620               ctcttgtttt gccctcaatt gtaattctgg gtaagattat tttattcctt ccatgtataa   1680               gccgaaagct aaaacgaatt aaaaaaggct gggaaaagag ccaatttctg gaagaaggta   1740               ttggaggaac aattcctcat gtctccccgg agagggtcac agtaatgtga tgataaatgg   1800               tgttcacagc tgccatataa agttctactc atgccattat ttttatgact tctacgttca   1860               gttacaagta tgctgtcaaa ttatcgtggg ttgaaacttg ttaaatgaga tttcaactga   1920               cttagtgata gagttttctt caagttaatt ttcacaaatg tcatgtttgc caatatgaat   1980               ttttctagtc aacatattat tgtaatttag gtatgttttg ttttgttttg cacaactgta   2040               accctgttgt tactttatat ttcataatca gacaaaaata cttacagtta ataatataga   2100               tataatgtta aaaacaattt gcaaaccagc agaattttaa gcttttaaaa taattcaatg   2160               gatatacatt tttttctgaa gattaagatt ttaattattc aacttaaaaa gtagaaatgc   2220               attattatac atttttttaa gaaaggacac gttatgttag catctaggta aggctgcatg   2280               atagcattcc tatatttctc tcataaaata ggatttgaag gatgaaatta attgtatgaa   2340               gcaatgtgat tatatgaaga gacacaaatt aaaaagacaa attaaacctg aaattatatt   2400               taaaatatat ttgagacatg aaatacatac tgataataca tacctcatga aagattttat   2460               tctttattgt gttacagagc agtttcattt tcatattaat atactgatca ggaagaggat   2520               tcagtaacat ttggcttcca aaactgctat ctctaatacg gtaccaatcc taggaactgt   2580               atactagttc ctacttagaa caaaagtatc aagtttgcac acaagtaatc tgccagctga   2640               cctttgtcgc accttaacca gtcaccactt gctatggtat aggattatac tgatgttctt   2700               tgagggattc tgatgtgcta ggcatggttc taagtacttt acttgtatta tcccatttaa   2760               tacttagaac aaccccgtga gataagtagt tattatcctc attttacaca tgagggaccg   2820               aaggatagaa aagttatttt tcaaaggtct tgcagttaat aaatggcaga gtgagcattc   2880               aagtccaggt agtcatattc cagaggccac ggttttaacc actaggctct agagctcccg   2940               ccgcgcccct atgcattatg ttcacaatgc caatctagat gcttcctctt ttgtataaag   3000               tcactgacat tctttagagt gggttgggtg catccaaaaa tgtataaaaa tattattata   3060               ataaacttat tactgcttgt agggtaattc acagttactt accctattct tgcttggaac   3120               atgagcctgg agacccatgg cagtccatat gcctccctat gcagtgaagg gccctagcag   3180               tgttaacaaa ttgctgagat cccacggagt ctttcaaaaa tctctgtaga gttagtcttc   3240               tccttttctc ttcctgagaa gttctcctgc ctgcataacc attcattagg gagtacttta   3300               caagcatgaa ggatattagg gtaagtggct aattataaat ctactctaga gacatataat   3360               catacagatt attcataaaa tttttcagtg ctgtccttcc acatttaatt gcattttgct   3420               caaactgtag aatgccctac attcccccca ccccaatttg ctatttcctt attaaaatag   3480               aaaattatag gcaagataca attatatgcg ttcctcttcc tgaaattata acatttctaa   3540               acttacccac gtagggacta ctgaatccaa ctgccaacaa taaaaagact tttatttagt   3600               agaggctacc tttcccccca gtgactcttt ttctacaact gccttgtcag tttggtaatt   3660               cacttatgat tttctaatgt tctcttggtg aattttatta tcttggaccc tctttttttt   3720               ttttttaaa gacagagtct tgctctgtca ccca  3754                    
     [1248]               TABLE LIII(e)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.6                  Score = 404 bits (210),   Expect = e−109 Identities = 210/210 (100%)   Strand = Plus/Plus                                         V.1:   1   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   60   (SEQ ID NO: 176)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   14   ggacgcgtgggcggacgcgtgggttcctcgggccctcggcgccacaagctgtccgggcac   73   (SEQ ID NO: 177)               V.1:   61   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   120               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   74   gcagcccctagcggcgcgtcgctgccaagccggcctccgcgcgcctccctccttccttct   133               V.1:   121   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcca   180               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   134   cccctggctgttcgcgatccagcttgggtaggcggggaagcagctggagtgcgaccgcca   193               V.1:   181   cggcagccaccctgcaaccgccagtcggag  210               ||||||||||||||||||||||||||||||       V.6:   194   cggcagccaccctgcaaccgccagtcggag  223                         Score = 2630 bits (1368), Expect = 0.0   Identities = 1368/1368 (100%) Strand = Plus/Plus                                         V.1:   320   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   379                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   283   aggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaa   342               V.1:   380   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   439               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   343   gccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaa   402               V.1:   440   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   499               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   403   ggaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgac   462               V.1:   500   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   559               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   463   ttattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaat   522               V.1:   560   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   619               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   523   tttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataa   582               V.1:   620   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   679               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   583   tatttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttg   642               V.1:   680   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   739               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   643   tgggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatcca   702               V.1:   740   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   799               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   703   atgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttg   762               V.1:   800   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   859               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   763   tctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgca   822               V.1:   860   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   919               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   823   gcaacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattc   882               V.1:   920   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   979               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   883   ccattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactct   942               V.1:   980   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1039               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   943   ttactctctggagagggccagtggtggtagctataagcttggccacattttttttccttt   1002               V.1:   1040   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1099               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1003   attcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttaca   1062               V.1:   1100   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1159               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1063   aaattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccc   1122               V.1:   1160   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1219               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1123   tagtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtata   1182               V.1:   1220   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1279               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1183   ggagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaa   1242               V.1:   1280   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1339               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1243   gttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcag   1302               V.1:   1340   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1399               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1303   agagatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactctt   1362               V.1:   1400   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1459               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1363   ggaatgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttg   1422               V.1:   1460   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1519               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1423   gcttactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactgga   1482               V.1:   1520   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1579               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1483   gagaattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttcc   1542               V.1:   1580   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1639               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1543   atgttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacac   1602               V.1:   1640   caccaaactttgttcttgctcttgttttgccctcaattgtaattctgg  1687               ||||||||||||||||||||||||||||||||||||||||||||||||       V.6:   1603   caccaaactttgttcttgctcttgttttgccctcaattgtaattctgg  1650                    
     [1249]               TABLE LIV(e)                       Peptide sequences of protein coded by 98P4B6 v.6                                        (SEQ ID NO: 178)                         MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKFASEFF PHVVDVTHHE DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFFFLYS FVRDVIHPYA   240               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ   300               CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEEVWRIEMY   360               ISFGIMSLGL LSLLAVTSIP SVSNALNWRE FSFIQSTLGY VALLISTFHV LIYGWKRAFE   420               EEYYRFYTPP NFVLALVLPS IVILGKIILF LPCISRKLKR IKKGWEKSQF LEEGIGGTIP   480                    
     [1250]               TABLE LV(e)                       Amino acid sequence alignment of 98P4B6 v.1 and 98P4B6 v.6                                    Score = 888 bits (2294), Expect = 0.0 Identities = 444/444 (100%), Positives = 444/444 (100%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 179)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.6:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSCDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 180)               V.1:   61   RNPKFASEFFPHVVDVTHHEDALTKTNTIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.6:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.6:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATEFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA       V.6:   181   LARQLNEIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               RNQQSDFYKISIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ       V.6:   241   RNQQSDEYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFEAMVHVAYSLCLPMRRSERYLELNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY       V.6:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               V.1:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREESEIQSTLGYVALLISTFHVLIYGWKRAEE   420               ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE       V.6:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               V.1:   421   EEYYRFYTPPNFVLALVLPSIVIL  444               EEYYRFYTPPNFVLALVLPSIVIL       V.6:   421   EEYYRFYTPPNFVLALVLPSIVIL  444                    
     [1251]               TABLE LII(f)                       Nucleotide sequence of transcript variant 98P4B6 v.7                                        (SEQ ID NO: 181)                             ggagaaaatt tacagaaacc cagagccaaa ggtgctctca ggggatcccc tgaaacattc   60                   aaagccattg cggccccaga agcttgggta ggcggggaag cagctggagt gcgaccgccg   120               cggcagacac cctgcaaccg ccagtcggag gtgcagtccg taggccctgg cccccgggtg   180               ggcccttggg gagtcggcgc cgctcccggg gagctgcaag gctcgcccct gcccggcgtg   240               gagggcgcgg ggggcgcgga ggatattctt ggtgatcttg gaagtgtccg tatcatggaa   300               tcaatctcta tgatgggaag ccctaagagc cttagtgaaa cttttttacc taatggcata   360               aatggtatca aagatgcaag gaaggtcact gtaggtgtga ttggaagtgg agattttgcc   420               aaatccttga ccattcgact tattagatgc ggctatcatg tggtcatagg aagtagaaat   480               cctaagtttg cttctgaatt ttttcctcat gtggtagatg tcactcatca tgaagatgct   540               ctcacaaaaa caaatataat atttgttgct atacacagag aacattatac ctccctgtgg   600               gacctgagac atctgcttgt gggtaaaatc ctgattgatg tgagcaataa catgaggata   660               aaccagtacc cagaatccaa tgctgaatat ttggcttcat tattcccaga ttctttgatt   720               gtcaaaggat ttaatgttgt ctcagcttgg gcacttcagt taggacctaa ggatgccagc   840               cgccagttga atttcattcc cattgacttg ggatccttat catcagccag agagattgaa   900               aatttacccc tacgactctt tactctctgg agagggccag tggtggtagc tataagcttg   960               gccacatttt ttttccttta ttcctttgtc agagatgtga ttcatccata tgctagaaac   1020               caacagagtg acttttacaa aattcctata gagattgtga ataaaacctt acctatagtt   1080               gccattactt tgctctccct agtatacctc gcaggtcttc tggcagctgc ttatcaactt   1140               tattacggca ccaagtatag gagatttcca ccttggttgg aaacctggtt acagtgtaga   1200               aaacagcttg gattactaag ttttttcttc gctatggtcc atgttgccta cagcctctgc   1260               ttaccgatga gaaggtcaga gagatatttg tttctcaaca tggcttatca gcagtctaca   1320               cttggatatg tcgctctgct cataagtact ttccatgttt taatttatgg atggaaacga   1380               gcttttgagg aagagtacta cagattttat acaccaccaa actttgttct tgctcttgtt   1440               ttgccctcaa ttgtaattct ggatctgtct gtggaggttc tggcttcccc agctgctgcc   1500               tggaaatgct taggtgctaa tatcctgaga ggaggattgt cagagatagt actccccata   1560               gagtggcagc aggacaggaa gateccecca ctctccaccc cgccgccacc ggccatgtgg   1620               acagaggaag ccggggcgac cgccgaggcc caggaatccg gcatcaggaa caagtctagc   1680               agttccagtc aaatcccggt ggttggggtg gtgacggagg acgatgaggc ggaggattcc   1740               attgatcccc cagagagccc tgatcgtgcc ttaaaagccg cgaattcctg gaggaaccct   1800               gtcctgcctc acactaatgg tgtggggcca ctgtgggaat tcctgttgag gcttctcaaa   1860               tctcaggctg cgtcaggaac cctgtctctt gcgttcacat cctggagcct tggagagttc   1920               cttgggagtg ggacatggat gaagctggaa accataattc tcagcaaact aacacaggaa   1980               cagaaatcca aacactgcat gttctcactg ataagtggga gttgaacaat gagaacacat   2040               ggacacaggg aggggaacgt cacacaccag ggcctgtcgg gggtgggagg cctagcaatt   2100               cattagaatt acctgtgaag cttttaaaat gtaaggtttg gatggaatgc tcagacccta   2160               ccttagaccc aattaagccc acagctttga gg  2192                    
     [1252]               TABLE LIII(f)                       Nucleotide sequence alignment of 98P4B6 v.1 and 98P4B6 v.7                                    Score = 2350 bits (1222), Expect = 0.0 Identities = 1230/1234 (99%) Strand = Plus/Plus                                         V.1:   141   agcttgggtaggcggggaagcagctggagtgcgaccgccacggcagccaccctgcaaccg   200   (SEQ ID NO: 182)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   81   agcttgggtaggcggggaagcagctggagtgcgaccgccgcggcagccaccctgcaaccg   140   (SEQ ID NO: 183)               V.1:   201   ccagtcggaggtgcagtccgtaggccctggcccccgggtgggcccttggggagtcggcgc   260               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   141   ccagtcggaggtgcagtccgtaggccctggcccccgggtgggcccttggggagtcggcgc   200               V.1:   261   cgctcccgaggagctgcaaggctcgcccctgcccggcgtggagggcgcggggggcgcgga   320               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   201   cgctcccggggagctgcaaggctcgcccctgcccggcgtggagggcgcggggggcgcgga   260               V.1:   321   ggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaag   380               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   261   ggatattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaag   320               V.1:   381   ccctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaag   440               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   321   ccctaagagccttagtgaaacttttttacctaatggcataaatggtatcaaagatgcaag   380               V.1:   441   gaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgact   500               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   381   gaaggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgact   440               V.1:   501   tattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaatt   560               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   441   tattagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaatt   500               V.1:   561   ttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataat   620               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   501   ttttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataat   560               V.1:   621   atttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttgt   680               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   561   atttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttgt   620               V.1:   681   gggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatccaa   740               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   621   gggtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatccaa   680               V.1:   741   tgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttgt   800               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   681   tgctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttgt   740               V.1:   801   ctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgcag   860               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   741   ctcagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgcag   800               V.1:   861   caacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattcc   920               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   801   caacaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattcc   860               V.1:   921   cattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactctt   980               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   861   cattgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactctt   920               V.1:   981   tactctctggagagggccagtggtggtagctataagcttggccacattttttttccttta   1040               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   921   tactctctggagagggccagtggtggtagctataagcttggccacattttttttccttta   980               V.1:   1041   ttcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttacaa   1100               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   981   ttcctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttacaa   1040               V.1:   1101   aattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccct   1160               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1041   aattcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccct   1100               V.1:   1161   agtataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtatag   1220               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1101   agtatacctcgcaggtcttctggcagctgcttatcaactttattacggcaccaagtatag   1160               V.1:   1221   gagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaag   1280               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1161   gagatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaag   1220               V.1:   1281   ttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcaga   1340               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1221   ttttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcaga   1280               V.1:   1341   gagatatttgtttctcaacatggcttatcagcag  1374               ||||||||||||||||||||||||||||||||||       V.7:   1281   gagatatttgtttctcaacatggcttatcagcag  1314                         Score = 298 bits (155), Expect = 2e−77 Identities = 155/155 (100%) Strand = Plus/Plus                                         V.1:   1537   cagtctacacttggatatgtcgctctgctcataagtactttccatgttttaatttatgga   1596                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1312   cagtctacacttggatatgtcgctctgctcataagtactttccatgttttaatttatgga   1371               V.1:   1597   tggaaacgagcttttgaggaagagtactacagattttatacaccaccaaactttgttctt   1656               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.7:   1372   tggaaacgagcttttgaggaagagtactacagattttatacaccaccaaactttgttctt   1431               V.1:   1657   gctcttgttttgccctcaattgtaattctggatct  1691               |||||||||||||||||||||||||||||||||||       V.7:   1432   gctcttgttttgccctcaattgtaattctggatct  1466                    
     [1253]               TABLE LIV(f)                       Peptide seguences of protein coded by 98P4B6 v.7                                        (SEQ ID NO: 184)                         MESISMMGSP KSLSETFLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKFASEFF PHVVDVTHHE DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGFNVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFEFLYS FVRDVIHPYA   240               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ   300               CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ STLGYVALLI STFHVLIYGW   360               KRAFEEEYYR FYTPPNFVLA LVLPSIVILD LSVEVLASPA AAWKCLGANI LRGGLSEIVL   420               PIEWQQDRKI PPLSTPPPPA MWTEEAGATA EAQESGIRNK SSSSSQIPVV GVVTEDDEAQ   480               DSIDPPESPD RALKAANSWR NPVLPHTNGV GPLWEFLLRL LKSQAASGTL SLAFTSWSLG   540               EFLGSGTWMK LETIILSKLT QEQKSKHCMF SLISGS  576                    
     [1254]               TABLE LV(f)                       Amino acid sequence alignment of 98P4B6 v.1 and 98P4B6 v.7                                    Score = 753 bits (1944), Expect = 0.0 Identities = 390/446 (87%),       Positives = 390/446 (87%), Gaps = 55/446 (12%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 185)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.7:   1   MESISMMGSPKSLSETFLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 186)               V.1:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.7:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLEPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   130               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.7:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   101   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYA       V.7:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHRYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRPPPWLETWLQ   300               RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ       V.7:   241   RNQQSDFYKIPIFIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQ       V.7:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQ--------------------   340               V.1:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420                                                  STLGYVALLISTFHVLIYGWKRAFE       V.7:   341   -----------------------------------STLGYVALLISTFHVLIYGWKRAFE   365               V.1:   421   EEYYRFYTPPNFVLALVLPSIVILDL  446               EEYYRFYTPPNFVLALVLPSIVILDL       V.7:   366   EEYYRFYTPPNFVLALVLPSIVILDL  391                    
     [1255]               TABLE LII(g)                       Nucleotide seguence of transcript variant 98P486 v.8                                    (SEQ ID NO: 187)                     gccccctccg agctccccga ctcctccccg cgctccacgg ctcttcccga ctccagtcag   60               cgttcctcgg gccctcggcg ccacaagctg tccgggcacg cagcccctag cggcgcgtcg   120               ctgccaagcc ggcctccgcg cgcctccctc cttccttctc ccctggctgt tcgcgatcca   180               gcttgggtag gcggggaagc agctggagtg cgaccgccac ggcagccacc ctgcaaccgc   240               cagtcggagg tgcagtccgt aggccctggc ccccgggtgg gcccttgggg agtcggcgcc   300               gctcccgagg agctgcaagg ctcgcccctg cccggcgtgg agggcgcggg gggcgcggag   360               gatattcttg gtgatcttgg aagtgtccgt atcatggaat caatctctat gatgggaagc   420               cctaagagcc ttagtgaaac ttgtttacct aatggcataa atggtatcaa agatgcaagg   480               aaggtcactg taggtgtgat tggaagtgga gattttgcca aatccttgac cattcgactt   540               attagatgcg gctatcatgt ggtcatagga agtagaaatc ctaagtttgc ttctgaattt   600               tttcctcatg tggtagatgt cactcatcat gaagatgctc tcacaaaaac aaatataata   660               tttgttgcta tacacagaga acattatacc tccctgtggg acctgagaca tctgcttgtg   720               ggtaaaatcc tgattgatgt gagcaataac atgaggataa accagtaccc agaatccaat   780               gctgaatatt tggcttcatt attcccagat tctttgattg tcaaaggatt taatgttgtc   840               tcagcttggg cacttcagtt aggacctaag gatgccagcc ggcaggttta tatatgcagc   900               aacaatattc aagcgcgaca acaggttatt gaacttgccc gccagttgaa tttcattccc   960               attgacttgg gatccttatc atcagccaga gagattgaaa atttacccct acgactcttt   1020               actctctgga gagggccagt ggtggtagct ataagcttgg ccacattttt tttcctttat   1080               tcctttgtca gagatgtgat tcatacatat gctagaaacc aacagagtga cttttacaaa   1140               attcctatag agattgtgaa taaaacctta cctatagttg ccattacttt gctctcccta   1200               gtataccttg caggtcttct ggcagctgct tatcaacttt attacggcac caagtatagg   1260               agatttccac cttggttgga aacctggtta cagtgtagaa aacagcttgg attactaagt   1320               tttttcttcg ctatggtcca tgttgcctac agcctctgct taccgatgag aaggtcagag   1380               agatatttgt ttctcaacat ggcttatcag caggttcatg caaatattga aaactcttgg   1440               aatgaggaag aagtttggag aattgaaatg tatatctcct ttggcataat gagccttggc   1500               ttactttccc tcctggcagt cacttctatc ccttcagtga gcaatgcttt aaactggaga   1560               gaattcagtt ttattcagtc tacacttgga tatgtcgctc tgctcataag tactttccat   1620               gttttaattt atggatggaa acgagctttt gaggaagagt actacagatt ttatacacca   1680               ccaaactttg ttcttgctct tgttttgccc tcaattgtaa ttctgggtaa gattatttta   1740               ttccttccat gtataagccg aaagctaaaa cgaattaaaa aaggctggga aaagagccaa   1800               tttctggaag aaggtatggg aggaacaatt cctcatgtct ccccggagag ggtcacagta   1860               atgtgatgac aaatggtgtt cacagctgcc atataaagtt ctactcatgc cattattttt   1920               atgacttcta cgttcagtta caagtatgct gtcaaattat cgtgggttga aacttgttaa   1980               atgagatttc aactgactta gtgatagagt tttcttcaag ttaattttca caaatgtcat   2040               gtttgccaat atgaattttt ctagtcaaca tattattgta atttaggtat gttttgtttt   2100               gttttgcaca actgtaaccc tgttgttact ttatatttca taatcaggca aaaatactta   2160               cagttaataa tatagatata atgttaaaaa caatttgcaa accagcagaa ttttaagctt   2220               ttaaaataat tcaatggata tacatttttt tctgaagatt aagattttaa ttattcaact   2280               taaaaagtag aaatgcatta ttatacattt ttttaagaaa ggacacgtta tgttagcatc   2340               taggtaaggc tgcatgatag cattcctata tttctctcat aaaataggat ttgaaggatg   2400               aaattaattg tatgaagcaa tgtgattata tgaagagaca caaattaaaa agacaaatta   2460               aacctgaaat tatatttaaa atatatttga gacatgaaat acatactgat aatacatacc   2520               tcatgaaaga ttttattctt tattgtgtta cagagcagtt tcattttcat attaatatac   2580               tgatcaggaa gaggatteag taacatttgg cttccaaaac tgctatctct aatacggtac   2640               caatcctagg aactgtatac tagttcctac ttagaacaaa agtatcaagt ttgcacacaa   2700               gtaatctgcc agctgacctt tgtcgcacct taaccagtca ccacttgcta tggtatagga   2760               ttatactgat gttctttgag ggattctgat gtgctaggca tggttctaag tactttactt   2820               gtattatccc atttaatact tagaacaacc ccgtgagata agtagttatt atcctcattt   2880               tacacatgag ggaccgaagg atagaaaagt tatttttcaa aggtcttgca gttaataaat   2940               ggcagagtga gcattcaagt ccaggtagtc atattccagg ggccacggtt ttaaccacta   3000               ggctctagag ctcccgccgc gcccctatgc attatgttca caatgccaat ctagatgctt   3060               cctcttttgt ataaagtcac tgacattctt tagagtgggt tgggtgcatc caaaaatgta   3120               taaaaatatt attataataa acttattact gcttgtaggg taattcacag ttacttaccc   3180               tattcttgct tggaacatga gcctggagac ccatggcagt ccatatgcct ccctatgcag   3240               tgaagggccc tagcagtgtt aacaaattgc tgagatccca cggagtcttt caaaaatctc   3300               tgtagagtta gtcttctcct tttctcttcc tgagaagttc tcctgcctgc ataaccattc   3360               attagggagt actttacaag catgaaggat attagggtaa gtggctaatt ataaatctac   3420               tctagagaca tataatcata cagattattc ataaaatttt tcagtgctgt ccttccacat   3480               ttaattgcat tttgctcaaa ctgtagaatg ccctacattc cccccacccc aatttgctat   3540               ttccttatta aaatagaaaa ttataggcaa gatacaatta tatgcgttcc tcttcctgaa   3600               attataacat ttctaaactt acccacgtag gtactactga atccaactgc caacaataaa   3660               aagactttta tttagtagag gctacctttc ccaccagtga ctctttttct acaactgcct   3720               tgtcagtttg gtaattcact tatgattttc taatgttctc ttggtgaatt ttattatctt   3780               gtaccctctt tttttttttt ttttttttta aagacagagt cttgctctgt cacccaggct   3840               ggagtgcagt ggcacgatct cggctcactg caagctctgc ctcccgggtt cacgccattc   3900               tcctgcctca gcctcccgag tagctgggac tacaggtgcc cgccaccatg cccggctgat   3960               ttctttttgt atttttagta gagacggagt ttcaccgtgt tagccaggat ggtctcgatc   4020               tcctgacctc gtgatccgcc cgccttggcc tccaaagtgc tgggattaca ggtgtgagct   4080               accgcgcccg gcctattatc ttgtactttc taactgagcc ctctattttc tttattttaa   4140               taatatttct ccccacttga gaatcacttg ttagttcttg gtaggaattc agttgggcaa   4200               tgataacttt tatgggcaaa aacattctat tatagtgaac taatgaaaat aacagcgtat   4260               tttcaatatt ttcttattcc ttaaattcca ctcttttaac actatgctta accacttaat   4320               gtgatgaaat attcctaaaa gttaaatgac tattaaagca tatattgttg catgtatata   4380               ttaagtagcc gatactctaa ataaaaatac cactgttaca gataaatggg gcctttaaaa   4440               atatgaaaaa caaacttgtg aaaatgtata aaagatgcat ctgttgtttc aaatggcact   4500               atcttctttt cagtactaca aaaacagaat aattttgaag ttttagaata aatgtaatat   4560               atttactata attctaaatg tttaaatgct tttctaaaaa tgcaaaacta tgatgtttag   4620               ttgctttatt ttacctctat gtgattattt ttcttaattg ttatttttta taatcattat   4680               ttttctgaac cattcttctg gcctcagaag taggactgaa ttctactatt gctaggtgtg   4740               agaaagtggt ggtgagaacc ttagagcagt ggagatttgc tacctggtct gtgttttgag   4800               aagtgcccct tagaaagtta aaagaatgta gaaaagatac tcagtcttaa tcctatgcaa   4860               aaaaaaaaat caagtaattg ttttcctatg aggaaaataa ccatgagctg tatcatgcta   4920               cttagctttt atgtaaatat ttcttatgtc tcctctatta agagtattta aaatcatatt   4980               taaatatgaa tctattcatg ctaacattat ttttcaaaac atacatggaa atttagccca   5040               gattgtctac atataaggtt tttatttgaa ttgtaaaata tttaaaagta tgaataaaat   5100               atatttatag gtatttatca gagatgatta ttttgtgcta catacaggtt ggctaatgag   5160               ctctagtgtt aaactacctg attaatttct tataaagcag cataaccttg gcttgattaa   5220               ggaattctac tttcaaaaat taatctgata atagtaacaa ggtatattat actttcatta   5280               caatcaaatt atagaaatta cttgtgtaaa agggcttcaa gaatatatcc aatttttaaa   5340               tattttaata tatctcctat ctgataactt aattcttcta aattaccact tgccattaag   5400               ctatttcata ataaattctg tacagtttcc ccccaaaaaa gagatttatt tatgaaatat   5460               ttaaagtttc taatgtggta ttttaaataa agtatcataa atgtaataag taaatattta   5520               tttaggaata ctgtgaacac tgaactaatt attcctgtgt cagtctatga aatccctgtt   5580               ttgaaatacg taaacagcct aaaatgtgtt gaaattattt tgtaaatcca tgacttaaaa   5640               caagatacat acatagtata acacacctca cagtgttaag atttatattg tgaaatgaga   5700               caccctacct tcaattgttc atcagtgggt aaaacaaatt ctgatgtaca ttcaggacaa   5760               atgattagcc ctaaatgaaa ctgtaataat ttcagtggaa actcaatctg tttttacctt   5820               taaacagtga attttacatg aatgaatggg ttcttcactt tttttttagt atgagaaaat   5880               tatacagtgc ttaattttca gagattcttt ccatatgtta ctaaaaaatg ttttgttcag   5940               cctaacatac tgagtttttt ttaactttct aaattattga atttccatca tgcattcatc   6000               caaaattaag gcagactgtt tggattcttc cagtggccag atgagctaaa ttaaatcaca   6060               aaagcagatg cttttgtatg atctccaaat tgccaacttt aaggaaatat tctcttgaaa   6120               ttgtctttaa agatcttttg cagctttgca gatacccaga ctgagctgga actggaattt   6180               gtcttcctat tgactctact tctttaaaag cggctgccca ttacattcct cagctgtcct   6240               tgcagttagg tgtacatgtg actgagtgtt ggccagtgag atgaagtctc ctcaaaggaa   6300               ggcagcatgt gtcctttttc atcccttcat cttgctgctg ggattgtgga tataacagga   6360               gccctggcag ctgtctccag aggatcaaag ccacacccaa agagtaaggc agattagaga   6420               ccagaaagac cttgactact tccctacttc cactgctttt tcctgcattt aagccattgt   6480               aaatctgggt gtgttacatg aagtgaaaat taattctttc tgcccttcag ttctttatcc   6540               tgataccatt taacactgtc tgaattaact agactgcaat aattctttct tttgaaagct   6600               tttaaaggat aatgtgcaat tcacattaaa attgattttc cattgtcaat tagttatact   6660               cattttcctg ccttgatctt tcattagata ttttgtatct gcttggaata tattatcttc   6720               tttttaactg tgtaattggt aattactaaa actctgtaat ctccaaaata ttgctatcaa   6780               attacacacc atgttttcta tcattctcat agatctgcct tataaacatt taaaataaaa   6840               gtactattta atgattt  6857                    
     [1256]               TABLE LIII(g)                       Nucleotide seguence alignment of 98P4B6 v.1 and 98P4B6 v.8                                    Score = 3201 bits (1665), Expect = 0.0 Identities = 1665/1665 (100%) Strand = Plus/Plus                                         V.1:   23   gttcctcgggccctcggcgccacaagctgtccgggcacgcagcccctagcggcgcgtcgc   82   (SEQ ID NO: 188)               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   62   gttcctcgggccctcggcgccacaagctgtccgggcacgcagcccctagcggcgcgtcgc   121   (SEQ ID NO: 189)               V.1:   83   tgccaagccggcctccgcgcgcctccctccttccttctcccctggctgttcgcgatccag   142               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   122   tgccaagccggcctccgcgcgcctccctccttccttctcccctggctgttcgcgatccag   181               V.1:   143   cttgggtaggcggggaagcagctggagtgcgaccgccacggcagccaccctgcaaccgcc   202               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   182   cttgggtaggcggggaagcagctggagtgcgaccgccacggcagccaccctgcaaccgcc   241               V.1:   203   agtcggaggtgcagtccgtaggccctggcccccgggtgggcccttggggagtcggcgccg   262               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   242   agtcggaggtgcagtccgtaggccctggcccccgggtgggcccttggggagtcggcgccg   301               V.1:   263   ctcccgaggagctgcaaggctcgcccctgcccggcgtggagggcgcggggggcgcggagg   322               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   302   ctcccgaggagctgcaaggctcgcccctgcccggcgtggagggcgcggggggcgcggagg   361               V.1:   323   atattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaagcc   382               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   362   atattcttggtgatcttggaagtgtccgtatcatggaatcaatctctatgatgggaagcc   421               V.1:   383   ctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaagga   442               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   422   ctaagagccttagtgaaacttgtttacctaatggcataaatggtatcaaagatgcaagga   481               V.1:   443   aggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgactta   502               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   482   aggtcactgtaggtgtgattggaagtggagattttgccaaatccttgaccattcgactta   541               V.1:   503   ttagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaatttt   562               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   542   ttagatgcggctatcatgtggtcataggaagtagaaatcctaagtttgcttctgaatttt   601               V.1:   563   ttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataatat   622               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   602   ttcctcatgtggtagatgtcactcatcatgaagatgctctcacaaaaacaaatataatat   661               V.1:   623   ttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttgtgg   682               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   662   ttgttgctatacacagagaacattatacctccctgtgggacctgagacatctgcttgtgg   721               V.1:   683   gtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatccaatg   742               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   722   gtaaaatcctgattgatgtgagcaataacatgaggataaaccagtacccagaatccaatg   781               V.1:   743   ctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttgtct   802               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   782   ctgaatatttggcttcattattcccagattctttgattgtcaaaggatttaatgttgtct   841               V.1:   803   cagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgcagca   862               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   842   cagcttgggcacttcagttaggacctaaggatgccagccggcaggtttatatatgcagca   901               V.1:   863   acaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattccca   922               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   902   acaatattcaagcgcgacaacaggttattgaacttgcccgccagttgaatttcattccca   961               V.1:   923   ttgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactcttta   982               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   962   ttgacttgggatccttatcatcagccagagagattgaaaatttacccctacgactcttta   1021               V.1:   983   ctctctggagagggccagtggtggtagctataagcttggccacattttttttcctttatt   1042               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1022   ctctctggagagggccagtggtggtagctataagcttggccacattttttttcctttatt   1081               V.1:   1043   cctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttacaaaa   1102               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1082   cctttgtcagagatgtgattcatccatatgctagaaaccaacagagtgacttttacaaaa   1141               V.1:   1103   ttcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccctag   1162               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1142   ttcctatagagattgtgaataaaaccttacctatagttgccattactttgctctccctag   1201               V.1:   1163   tataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtatagga   1222               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1202   tataccttgcaggtcttctggcagctgcttatcaactttattacggcaccaagtatagga   1261               V.1:   1223   gatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaagtt   1282               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1262   gatttccaccttggttggaaacctggttacagtgtagaaaacagcttggattactaagtt   1321               V.1:   1283   ttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcagaga   1342               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1322   ttttcttcgctatggtccatgttgcctacagcctctgcttaccgatgagaaggtcagaga   1381               V.1:   1343   gatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactcttgga   1402               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1382   gatatttgtttctcaacatggcttatcagcaggttcatgcaaatattgaaaactcttgga   1441               V.1:   1403   atgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttggct   1462               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1442   atgaggaagaagtttggagaattgaaatgtatatctcctttggcataatgagccttggct   1501               V.1:   1463   tactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactggagag   1522               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1502   tactttccctcctggcagtcacttctatcccttcagtgagcaatgctttaaactggagag   1561               V.1:   1523   aattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttccatg   1582               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1562   aattcagttttattcagtctacacttggatatgtcgctctgctcataagtactttccatg   1621               V.1:   1583   ttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacaccac   1642               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   1622   ttttaatttatggatggaaacgagcttttgaggaagagtactacagattttatacaccac   1681               V.1:   1643   caaactttgttcttgctcttgttttgccctcaattgtaattctgg  1687               |||||||||||||||||||||||||||||||||||||||||||||       V.8:   1682   caaactttgttcttgctcttgttttgccctcaattgtaattctgg  1726                         Score = 1381 bits (718), Expect = 0.0 Identities = 725|726 (99%), Gaps = 1/726 (0%)       Strand = Plus/Plus                                         V.1:   1687   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   1746                   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6132   gatcttttgcagctttgcagatacccagactgagctggaactggaatttgtcttcctatt   6191               V.1:   1747   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   1806               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6192   gactctacttctttaaaagcggctgcccattacattcctcagctgtccttgcagttaggt   6251               V.1:   1807   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   1866               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6252   gtacatgtgactgagtgttggccagtgagatgaagtctcctcaaaggaaggcagcatgtg   6311               V.1:   1867   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   1926               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6312   tcctttttcatcccttcatcttgctgctgggattgtggatataacaggagccctggcagc   6371               V.1:   1927   tgtctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   1986               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6372   tgtctccagaggatcaaagccacacccaaagagtaaggcagattagagaccagaaagacc   6431               V.1:   1987   ttgactacttccctacttccactgctttt-cctgcatttaagccattgtaaatctgggtg   2045               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6432   ttgactacttccctacttccactgctttttcctgcatttaagccattgtaaatctgggtg   6491               V.1:   2046   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   2105               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6492   tgttacatgaagtgaaaattaattctttctgcccttcagttctttatcctgataccattt   6551               V.1:   2106   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   2165               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6552   aacactgtctgaattaactagactgcaataattctttcttttgaaagcttttaaaggata   6611               V.1:   2166   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   2225               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6612   atgtgcaattcacattaaaattgattttccattgtcaattagttatactcattttcctgc   6671               V.1:   2226   cttgatctttcattagatattltgtatctgcttggaatatattatcttctttttaactgt   2285               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6672   cttgatctttcattagatattttgtatctgcttggaatatattatcttctttttaactgt   6731               V.1:   2286   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   2345               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6732   gtaattggtaattactaaaactctgtaatctccaaaatattgctatcaaattacacacca   6791               V.1:   2346   tgttttctatcattctcatagatctgccttataaacatttaaataaaaagtactatttaa   2405               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       V.8:   6792   tgttttctatcattctcatagatctgccttataaacatttaaataaaaagtactatttaa   6851               V.1:   2406   tgattt  2411               ||||||       V.8:   6852   tgattt  6857                    
     [1257]               TABLE LIV(g)                       Peptide seguences of protein coded by 98P4B6 v.8                                    (SEQ ID NO: 190)                     MESISMMGSP KSLSETCLPN GINGIKDARK VTVGVIGSGD FAKSLTIRLI RCGYHVVIGS   60               RNPKKASEFF PHVVDVTHHE DALTKTNIIF VAIHREHYTS LWDLRHLLVG KILIDVSNNM   120               RINQYPESNA EYLASLFPDS LIVKGENVVS AWALQLGPKD ASRQVYICSN NIQARQQVIE   180               LARQLNFIPI DLGSLSSARE IENLPLRLFT LWRGPVVVAI SLATFFFLYS FVRDVIHPYA   240               RNQQSDFYKI PIEIVNKTLP IVAITLLSLV YLAGLLAAAY QLYYGTKYRR FPPWLETWLQ   300               CRKQLGLLSF FFAMVHVAYS LCLPMRRSER YLFLNMAYQQ VHANIENSWN EEEVWRIEMY   360               ISFGIMSLGL LSLLAVTSIP SVSNALNWRE FSPIQSTLGY VALLISTFHV LIYGWKRAFE   420               EEYYRFYTPP NFVLALVLPS IVILGKIILP LPCISRKLKR IKKGWEKSQF LEEGMGGTIP   480               HVSPERVTVM  490                    
     [1258]               TABLE LV(g)                       Amino acid seguence alignment of 98P4B6 v.1 and 98P4B6 v.8                                    Score = 888 bits (2294), Expect = 0.0 Identities = 444/444 (100%),       Positives = 444/444 (100%)                                         V.1:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 191)               MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS       V.8:   1   MESISMMGSPKSLSETCLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGS   60   (SEQ ID NO: 192)               V.1:   61   RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM   120               RNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNM       V.8:   61   RNPKEASEEEPHVVDVTHHEDALTKTNIIEVAIRREHYTSLWDLRHLLVGKILIDVSNNM   120               V.1:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE       V.8:   121   RINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIE   180               V.1:   181   LARQLNFIPIDLGSLSSAREIENLPLRLETLWRGPVVVAISLATFFFLYSFVRDVIHPYA   240               LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFEFLYSFVRDVIHPYA       V.8:   181   LARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATEFFLYSFVRDVIHPYA   240               V.1:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ   300               RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQ       V.8:   241   RNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRREPPWLETWLQ   300               V.1:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLELNMAYQQVHANIENSWNEEEVWRIEMY   360               CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLELNMAYQQVHANIENSWNEEEVWRIEMY       V.8:   301   CRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMY   360               V.1:   361   ISEGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE       V.8:   361   ISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFE   420               V.1:   421   EEYYREYTPPNFVLALVLPSIVIL  444               EEYYRFYTPPNFVLALVLPSIVIL       V.8:   421   EEYYRFYTPPNEVLALVLPSIVIL  444                    
     [1259] 
    
     
       
         0 
         
           
               
            
               
                   
               
               
                   
               
               
                 SEQUENCE LISTING 
               
            
           
           
               
            
               
                 The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO 
               
               
                 web site (http://seqdata.uspto.gov/sequence.html?DocID=20040048798). An electronic copy of the “Sequence Listing” will also be available from the 
               
               
                 USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).